FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Spangler, M Hawley, H Barnes, N Saxena, S AF Spangler, Mikayla Hawley, Heather Barnes, Nicole Saxena, Shailendra TI A Review of Guidelines and Pharmacologic Options for Asthma Treatment, With a Focus on Exercise-Induced Bronchoconstriction SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE asthma; treatment; quick relief; long-term control; exacerbation; exercise-induced asthma ID ACTING BETA-AGONISTS; METAANALYSIS AB Asthma affects millions of individuals worldwide. Exercise-induced bronchoconstriction is common in patients diagnosed with asthma, but may also occur in patients without chronic asthma. Patients with isolated exercise-induced bronchoconstriction may require pretreatment with inhaled short-acting beta-agonists prior to exercise. Patients diagnosed with asthma can achieve good control of the symptoms of exercise-induced bronchoconstriction with appropriate treatment of underlying chronic asthma. Current guidelines suggest staging patients with asthma based on severity of symptoms and initiating therapy according to their stage. Pharmacotherapy for asthma management consists of both quick-relief medications (short-acting beta-agonists) as well as maintenance, or long-term control, medications (inhaled corticosteroids, long-acting beta-agonists, leukotriene receptor antagonists, cromolyn, and theophylline). C1 [Spangler, Mikayla] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA. [Spangler, Mikayla] Creighton Univ, Sch Med, Dept Family Practice, Omaha, NE 68178 USA. [Hawley, Heather] William S Middleton Mem Vet Adm Med Ctr, PGY Ambulatory Care Pharm Resident 2, Madison, WI USA. [Barnes, Nicole] San Antonio Mil Med Ctr, San Antonio, TX USA. [Saxena, Shailendra] Creighton Univ, Sch Med, Dept Family Practice, Omaha, NE USA. RP Spangler, M (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA. NR 18 TC 4 Z9 4 U1 0 U2 3 PU JTE MULTIMEDIA PI WEST CONSHOHOCKEN PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD SEP PY 2013 VL 41 IS 3 BP 50 EP 57 DI 10.3810/psm.2013.09.2024 PG 8 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA AR2FA UT WOS:000343397800005 PM 24113702 ER PT J AU Schunemann, HJ Tugwell, P Reeves, BC Akl, EA Santesso, N Spencer, FA Shea, B Wells, G Helfand, M AF Schuenemann, Holger J. Tugwell, Peter Reeves, Barnaby C. Akl, Elie A. Santesso, Nancy Spencer, Frederick A. Shea, Beverley Wells, George Helfand, Mark TI Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions (vol 4, pg 49, 2013) SO RESEARCH SYNTHESIS METHODS LA English DT Correction C1 [Schuenemann, Holger J.; Akl, Elie A.; Santesso, Nancy] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada. [Schuenemann, Holger J.; Spencer, Frederick A.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada. [Tugwell, Peter; Shea, Beverley] Ottawa Hosp, Ottawa Hosp Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada. [Tugwell, Peter; Wells, George] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Tugwell, Peter] Ctr Global Hlth, Inst Populat Hlth, Ottawa, ON, Canada. [Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England. [Akl, Elie A.] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Wells, George] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada. RP Schunemann, HJ (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Sci Ctr, Room 2C10B,1280 Main St West, Hamilton, ON L8S 4K1, Canada. EM schuneh@mcmaster.ca NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-2879 EI 1759-2887 J9 RES SYNTH METHODS JI Res. Synth. Methods PD SEP PY 2013 VL 4 IS 3 BP 289 EP 289 PG 1 WC Mathematical & Computational Biology; Multidisciplinary Sciences SC Mathematical & Computational Biology; Science & Technology - Other Topics GA V38ZP UT WOS:000209381600011 ER PT J AU Wang, HE Wells, JM Rizk, DV AF Wang, Henry E. Wells, James M. Rizk, Dana V. TI Bullous Lesions After Use of a Commercial Therapeutic Hypothermia Temperature Management System: A Possible Burn Injury? SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT LA English DT Article AB Therapeutic hypothermia (TH) is a novel technique for improving the likelihood of survival with good neurologic outcome after cardiopulmonary arrest. While commercial temperature management systems (TMS) are intended to facilitate cooling of the body during TH, their operation also involves body exposure to heat. We describe the case of a 72-year-old female postarrest patient who underwent TH using a commercial water-circulating TMS and concurrent continuous renal replacement therapy. The patient developed bullous lesions on the thigh and torso suspected to constitute a scald burn injury from the TMS. Clinicians must be aware of this important adverse event when providing TH, especially in the setting of concurrent hemodialysis therapy. C1 [Wang, Henry E.] Univ Alabama Birmingham, Dept Emergency Med, Sch Med, Birmingham, AL 35249 USA. [Wells, James M.] Univ Alabama Birmingham, Dept Med, Sch Med, Div Pulm & Crit Care Med, Birmingham, AL 35249 USA. [Wells, James M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Rizk, Dana V.] Univ Alabama Birmingham, Dept Med, Sch Med, Div Nephrol, Birmingham, AL 35249 USA. RP Wang, HE (reprint author), Univ Alabama Birmingham, Dept Emergency Med, 619 19th St South OHB 251, Birmingham, AL 35249 USA. EM hwang@uabmc.edu NR 22 TC 3 Z9 3 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-7658 EI 2153-7933 J9 THER HYPOTHERMIA TEM JI Ther. Hypothermia Temp. Manag. PD SEP 1 PY 2013 VL 3 IS 3 BP 147 EP 150 DI 10.1089/ther.2013.0013 PG 4 WC Critical Care Medicine SC General & Internal Medicine GA V38PI UT WOS:000209354900010 ER PT J AU Paintlia, AS Paintlia, MK Singh, AK Singh, I AF Paintlia, Ajaib S. Paintlia, Manjeet K. Singh, Avtar K. Singh, Inderjit TI Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR--dependent mechanism SO GLIA LA English DT Article DE lovastatin; EAE; MS; oligodendrocyte progenitors; PPAR-; RhoA-ROCK; survival; differentiation ID CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; COA REDUCTASE INHIBITOR; N-ACETYL CYSTEINE; ENDOTHELIAL-CELLS; IN-VITRO; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); DEMYELINATING DISEASES AB We earlier documented that lovastatin (LOV)-mediated inhibition of small Rho GTPases activity protects vulnerable oligodendrocytes (OLs) in mixed glial cell cultures stimulated with Th1 cytokines and in a murine model of multiple sclerosis (MS). However, the precise mechanism of OL protection remains unclear. We here employed genetic and biochemical approaches to elucidate the underlying mechanism that protects LOV treated OLs from Th1 (tumor necrosis factor-alpha) and Th17 (interleukin-17) cytokines toxicity in in vitro. Cytokines enhanced the reactive oxygen species (ROS) generation and mitochondrial membrane depolarization with corresponding lowering of glutathione (reduced) level in OLs and that were reverted by LOV. In addition, the expression of ROS detoxifying enzymes (catalase and superoxide-dismutase 2) and the transactivation of peroxisome proliferators-activated receptor (PPAR)-alpha/-beta/-gamma including PPAR-gamma coactivator-1 alpha were enhanced by LOV in similarly treated OLs. Interestingly, LOV-mediated inhibition of small Rho GTPases, i.e., RhoA and cdc42, and Rho-associated kinase (ROCK) activity enhanced the levels of PPAR ligands in OLs via extracellular signal regulated kinase (1/2)/p38 mitogen-activated protein kinase/cytoplasmic phospholipase 2/cyclooxygenase-2 signaling cascade activation. Small hairpin RNA transfection-based studies established that LOV mainly enhances PPAR-alpha and less so of PPAR-beta and PPAR-gamma transactivation that enhances ROS detoxifying defense in OLs. In support of this, the observed LOV-mediated protection was lacking in PPAR-alpha-deficient OLs exposed to cytokines. Collectively, these data provide unprecedented evidence that LOV-mediated inhibition of the Rho-ROCK signaling pathway boosts ROS detoxifying defense in OLs via PPAR-alpha-dependent mechanism that has implication in neurodegenerative disorders including MS. C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU National Institutes of Health [NS-22576, NS-37766, C06 RR018823]; Department of Veterans Affairs [VA-1BX001072, VA-BX001999] FX Grant sponsor: National Institutes of Health; Grant numbers: NS-22576, NS-37766, and C06 RR018823; Grant sponsor: Department of Veterans Affairs; Grant numbers: VA-1BX001072 and VA-BX001999. NR 67 TC 10 Z9 10 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 J9 GLIA JI Glia PD SEP PY 2013 VL 61 IS 9 BP 1500 EP 1517 DI 10.1002/glia.22537 PG 18 WC Neurosciences SC Neurosciences & Neurology GA 190ID UT WOS:000322331700009 PM 23839981 ER PT J AU Prather, AA Epel, ES Cohen, BE Neylan, TC Whooley, MA AF Prather, Aric A. Epel, Elissa S. Cohen, Beth E. Neylan, Thomas C. Whooley, Mary A. TI Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: Findings from the Heart and Soul Study SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Sleep; Inflammation; Gender; Coronary heart disease ID C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; RISK-FACTOR; TESTOSTERONE REPLACEMENT; HYPOGONADAL MEN; WHITEHALL-II; OLDER-ADULTS; DURATION; HEALTH; WOMEN AB Systemic inflammation is proposed as a putative mechanism underlying the link between poor sleep and cardiovascular disease. The aim of present study was to investigate the cross-sectional and prospective associations of self-reported sleep quality with biomarkers of inflammation and coagulation implicated in coronary heart disease (CHD) and to explore whether these associations differed between men and women. To this end, measures of sleep quality and markers of inflammation, including circulating levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (CRP), and fibrinogen were assessed at baseline in 980 participants with established CHD and 626 at 5-year follow-up. In the sample as a whole, subjective sleep quality was unrelated to inflammatory markers in cross-sectional and prospective analyses. However, in gender stratified analyses, adjusting for age, ethnicity, education, body mass index, and regular snoring, poorer subjective sleep quality at baseline was prospectively associated with 5-year increases in IL-6 (b = 0.14, SE = 0.05, p = 0.003), CRP (b = 0.21, SE = 0.09, p = 0.02), and fibrinogen (b = 18.02, SE = 7.62, p = 0.02) in women but not men. These associations remained independent of lifestyle/psychosocial factors, medical comorbidities, medication use, and cardiac function. Women who reported baseline sleep disturbances characterized by a tendency to wake up too early in the morning also showed significant 5-year increases in circulating IL-6 that withstood covariate adjustment. Further research is necessary to elucidate the pathways that underlie gender-specific associations between subjective sleep quality and markers of inflammation and coagulation as this may help clarify gender disparities in CHD. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Prather, Aric A.; Epel, Elissa S.; Cohen, Beth E.; Neylan, Thomas C.; Whooley, Mary A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94118 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cohen, Beth E.; Neylan, Thomas C.; Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Prather, AA (reprint author), Univ Calif San Francisco, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94118 USA. EM prathera@chc.ucsf.edu FU NIH/NHLBI [K08 HL112961]; Robert Wood Johnson Foundation Health and Society Scholars fellowship; Department of Veterans Affairs, Washington DC; National Heart, Lung and Blood Institute, Bethesda, MD [R01 HL079235]; American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY; Robert Wood Johnson Foundation, Princeton, NJ; Ischemia Research and Education Foundation, South San Francisco, CA FX This research was supported in part by NIH/NHLBI Grant K08 HL112961 and a Robert Wood Johnson Foundation Health and Society Scholars fellowship to Dr. Prather. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington DC, the National Heart, Lung and Blood Institute (R01 HL079235), Bethesda, MD, the American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY, the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ, and the Ischemia Research and Education Foundation, South San Francisco, CA. NR 57 TC 21 Z9 21 U1 2 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD SEP PY 2013 VL 47 IS 9 BP 1228 EP 1235 DI 10.1016/j.psychires.2013.05.004 PG 8 WC Psychiatry SC Psychiatry GA 191LF UT WOS:000322413800015 PM 23746737 ER PT J AU Weathington, NM Mallampalli, RK AF Weathington, Nathaniel M. Mallampalli, Rama K. TI New insights on the function of SCF ubiquitin E3 ligases in the lung SO CELLULAR SIGNALLING LA English DT Review DE Protein degradation; Proteolysis; Lung; Inflammation ID F-BOX PROTEINS; NF-KAPPA-B; ALLOSTERIC INHIBITOR; MULTIPLE-MYELOMA; MITOTIC ARREST; BETA-TRCP; K-ATPASE; DEGRADATION; CANCER; PROTEASOME AB Recent developments in pulmonary cell biology have shown that the maintenance of protein concentrations, proteostasis, is an integral process of all biologic systems. The balance of available protein is the sum total of three key elements of cell metabolism: production by transcription and translation, compartmentalization through processing and sorting, and proteolytic degradation of proteins at any stage of their life-span. Considerable advances are constantly made in each of these three essential fields, and our appreciation for the diversity of mechanisms of protein degradation has expanded greatly in the last decade. The ubiquitin proteasome system (UPS) has emerged as the predominant protein degradation pathway in eukaryotes, with the large cullin-RING family of E3 ligases responsible for ubiquitination of a broad array of proteins to be degraded. The Skip-Cullin-F-box (SCF) ubiquitin E3 ligase superfamily is the largest family of cullin-RING ligases, with interchangeable F-box proteins orchestrating the trafficking proteins for ubiquitination and degradation. We will discuss the best characterized and most recent developments in the role of this intriguing family of proteins in normal physiology and disorders of the lungs. (c) 2013 Elsevier Inc. All rights reserved. C1 [Weathington, Nathaniel M.; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU BLRD VA [I01 BX002200]; NHLBI NIH HHS [R01 HL068135, R01 HL098174, R01 HL081784, R01 HL096376, R01 HL097376] NR 43 TC 3 Z9 3 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD SEP PY 2013 VL 25 IS 9 BP 1792 EP 1798 DI 10.1016/j.cellsig.2013.05.003 PG 7 WC Cell Biology SC Cell Biology GA 189WK UT WOS:000322298800008 PM 23680451 ER PT J AU Wright, JL Plymate, S D'Oria-Cameron, A Bain, C Haugk, K Xiao, LR Lin, DW Stanford, JL McTiernan, A AF Wright, Jonathan L. Plymate, Stephen D'Oria-Cameron, Andrea Bain, Carolyn Haugk, Kathy Xiao, Liren Lin, Daniel W. Stanford, Janet L. McTiernan, Anne TI A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: A randomized controlled trial SO PROSTATE LA English DT Article DE obesity; prostate cancer; diet; randomized ID IGF-BINDING PROTEIN-3; DIABETES PREVENTION PROGRAM; BODY-MASS INDEX; WEIGHT-LOSS; RADICAL PROSTATECTOMY; LIFE-STYLE; CLINICAL-TRIAL; GROWTH-FACTORS; UNITED-STATES; RISK-FACTOR AB INTRODUCTION. Obese men have an increased risk of prostate cancer (PCa)-specific mortality. Potential mechanisms include insulin and related proteins. We investigate whether a short-term caloric restriction diet in overweight/obese men with newly diagnosed PCa can lead to measurable changes in patient anthropometrics and insulin-related proteins. METHODS. Overweight and obese PCa patients choosing active surveillance or radical prostatectomy were randomized to a 6-week, caloric-restricted diet or to continue their current diet. Changes from baseline to end of study in anthropometrics, dietary constituents and serum proteins (insulin, c-peptide, IGF-1, adiponectin, IGF-BP3) were compared between the intervention and control groups using a Generalized Estimating Equation model. RESULTS. Nineteen patients were randomized to the intervention (N=10) or control (N=9) group. Men in the intervention group had a 1.7% (3.7lbs) mean decline in weight versus 1.0% (2.0lbs) in controls (P<0.05), and a reduced intake of calories, total and saturated fat, protein and starch (all P<0.1 compared to controls). There was a significant difference (P=0.002) in mean serum IGFBP-3 between the intervention (+2.8%) and control group (-6.9%). Other biomarkers changed with the diet intervention to a degree similar to previous weight loss studies but were not statistically significant compared with controls. CONCLUSION. In this small pilot study, a 6-week caloric restricted diet in men with newly diagnosed PCa produced changes in weight, diet and serum proteins possibly related to prognosis. These results support larger-scale trials testing longer-term weight loss effects on potential PCa progression biomarkers. Prostate 73: 1345-1351, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Wright, Jonathan L.; Lin, Daniel W.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Wright, Jonathan L.; D'Oria-Cameron, Andrea; Bain, Carolyn; Xiao, Liren; Lin, Daniel W.; Stanford, Janet L.; McTiernan, Anne] Fred Hutchison Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Wright, Jonathan L.; Lin, Daniel W.] VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. [Plymate, Stephen] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Plymate, Stephen; Haugk, Kathy] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Plymate, Stephen; Haugk, Kathy] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Stanford, Janet L.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP Wright, JL (reprint author), Fred Hutchison Canc Res Ctr, 1100 Fairview Ave North,M4-B874, Seattle, WA 98109 USA. EM jlwright@u.washington.edu FU NIH; National Cancer Institute [P50CA097186]; Fred Hutchinson Cancer Research Center FX Grant sponsor: NIH; Grant sponsor: National Cancer Institute; Grant number: P50CA097186; Grant sponsor: Fred Hutchinson Cancer Research Center. NR 40 TC 5 Z9 6 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 J9 PROSTATE JI Prostate PD SEP PY 2013 VL 73 IS 12 BP 1345 EP 1351 DI 10.1002/pros.22682 PG 7 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 186AH UT WOS:000322013100010 PM 23775525 ER PT J AU Long, TJ Takeno, M Sprenger, CC Plymate, SR Ratner, BD AF Long, Thomas J. Takeno, Marc Sprenger, Cynthia C. Plymate, Stephen R. Ratner, Buddy D. TI Capillary Force Seeding of Sphere-Templated Hydrogels for Tissue-Engineered Prostate Cancer Xenografts SO TISSUE ENGINEERING PART C-METHODS LA English DT Article ID SCAFFOLDS; PROLIFERATION AB Biomaterial-based tissue-engineered tumor models are now widely used in cancer biology studies. However, specific methods for efficient and reliable cell seeding into these and tissue-engineering constructs used for regenerative medicine often remain poorly defined. Here, we describe a capillary force-based method for seeding the human prostate cancer cell lines M12 and LNCaP C4-2 into sphere-templated poly(2-hydroxyethyl methacrylate) hydrogels. The capillary force seeding method improved the cell number and distribution within the porous scaffolds compared to well-established protocols such as static and centrifugation seeding. Seeding efficiency was found to be strongly dependent on the rounded cell diameter relative to the pore diameter and pore interconnect size, parameters that can be controllably modulated during scaffold fabrication. Cell seeding efficiency was evaluated quantitatively using a PicoGreen DNA assay, which demonstrated some variation in cell retention using the capillary force method. When cultured within the porous hydrogels, both cell lines attached and proliferated within the network, but histology showed the formation of a necrotic zone by 7 days likely due to oxygen and nutrient diffusional limitations. The necrotic zone thickness was decreased by dynamically culturing cells in an orbital shaker. Proliferation analysis showed that despite a variable seeding efficiency, by 7 days in culture, scaffolds contained a roughly consistent number of cells as they proliferated to fill the pores of the scaffold. These studies demonstrate that sphere-templated polymeric scaffolds have the potential to serve as an adaptable cell culture substrate for engineering a three-dimensional prostate cancer model. C1 [Long, Thomas J.; Takeno, Marc; Ratner, Buddy D.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Sprenger, Cynthia C.; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Ratner, BD (reprint author), Univ Washington, Dept Bioengn, Box 355061,3720 15th Ave NE, Seattle, WA 98195 USA. EM ratner@uweb.engr.washington.edu FU Nanotechnology and Physical Science in Cancer Research Training Program NIH [T32CA138312, TMEN-U54CA126540, PO1 CA085859]; Veterans Affairs Research Service FX This work was supported by the Nanotechnology and Physical Science in Cancer Research Training Program NIH T32CA138312 (T.J.L. and B. D. R.), TMEN-U54CA126540 (S. R. P.), PO1 CA085859 (S. R. P.), and the Veterans Affairs Research Service (S.R.P.). NR 22 TC 5 Z9 5 U1 1 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3384 J9 TISSUE ENG PART C-ME JI Tissue Eng. Part C-Methods PD SEP PY 2013 VL 19 IS 9 BP 738 EP 744 DI 10.1089/ten.tec.2012.0388 PG 7 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 187KS UT WOS:000322117900008 PM 23373788 ER PT J AU Taylor, DJ Bramoweth, AD Grieser, EA Tatum, JI Roane, BM AF Taylor, Daniel J. Bramoweth, Adam D. Grieser, Emily A. Tatum, Jolyn I. Roane, Brandy M. TI Epidemiology of Insomnia in College Students: Relationship With Mental Health, Quality of Life, and Substance Use Difficulties SO BEHAVIOR THERAPY LA English DT Article DE insomnia; college; psychosocial; hypnotic; stimulant ID MOTOR-VEHICLE ACCIDENTS; INDIRECT COSTS; SLEEP; POPULATION; DEPRESSION; INVENTORY; INSTRUMENT; DISORDERS; PATTERNS; CRITERIA AB The purpose of this study was to evaluate the prevalence and correlates of insomnia using rigorous diagnostic criteria and a comprehensive assessment battery. In a large sample (N=1,074) of college students (mean age 20.39 years), participants were asked to complete a week-long sleep diary and comprehensive questionnaire packet assessing recommended daytime functioning domains (i.e., fatigue, quality of life, depression, anxiety, stress, academic performance, substance use) during the academic year. A significant portion of this sample of college students met proposed DSM-5 criteria for chronic insomnia (9.5%). The chronic insomnia group reported significantly worse sleep, fatigue, depression, anxiety, stress, and quality of life, and greater hypnotic and stimulant use for sleep problems. There were no differences between groups on excessive daytime sleepiness, academic performance, or substance use. This was a rigorous and comprehensive assessment of the prevalence and psychosocial correlates of insomnia. Insomnia is a significant problem in college students and should be regularly assessed. More research is also needed to guide treatment in this population. C1 [Taylor, Daniel J.] Univ N Texas, Denton, TX 76203 USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Roane, Brandy M.] Univ N Texas, Hlth Sci Ctr, Denton, TX 76203 USA. RP Taylor, DJ (reprint author), Univ N Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. EM djtaylor@unt.edu FU PHS HHS [A1085558] NR 49 TC 31 Z9 31 U1 11 U2 91 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD SEP PY 2013 VL 44 IS 3 BP 339 EP 348 PG 10 WC Psychology, Clinical SC Psychology GA 176PR UT WOS:000321317100001 PM 23768662 ER PT J AU Bonner, LM Lanto, AB Bolkan, C Watson, GS Campbell, DG Chaney, EF Zivin, K Rubenstein, LV AF Bonner, Laura M. Lanto, Andy B. Bolkan, Cory Watson, G. Stennis Campbell, Duncan G. Chaney, Edmund F. Zivin, Kara Rubenstein, Lisa V. TI Help-Seeking from Clergy and Spiritual Counselors Among Veterans with Depression and PTSD in Primary Care SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Depression; PTSD; Clergy ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROFESSIONALS; SOCIAL SUPPORT; QUALITY IMPROVEMENT; COLLABORATION; SETTINGS; SYMPTOMS; SUICIDE; NEED AB Little is known about the prevalence or predictors of seeking help for depression and PTSD from spiritual counselors and clergy. We describe openness to and actual help-seeking from spiritual counselors among primary care patients with depression. We screened consecutive VA primary care patients for depression; 761 Veterans with probable major depression participated in telephone surveys (at baseline, 7 months, and 18 months). Participants were asked about (1) openness to seeking help for emotional problems from spiritual counselors/clergy and (2) actual contact with spiritual counselors/clergy in the past 6 months. At baseline, almost half of the participants, 359 (47.2 %), endorsed being "very" or "somewhat likely" to seek help for emotional problems from spiritual counselors; 498 (65.4 %) were open to a primary care provider, 486 (63.9 %) to a psychiatrist, and 409 (66.5 %) to another type of mental health provider. Ninety-one participants (12 %) reported actual spiritual counselor/clergy consultation. Ninety-five (10.3 %) participants reported that their VA providers had recently asked them about spiritual support; the majority of these found this discussion helpful. Participants with current PTSD symptoms, and those with a mental health visit in the past 6 months, were more likely to report openness to and actual help-seeking from clergy. Veterans with depression and PTSD are amenable to receiving help from spiritual counselors/clergy and other providers. Integration of spiritual counselors/clergy into care teams may be helpful to Veterans with PTSD. Training of such providers to address PTSD specifically may also be desirable. C1 [Bonner, Laura M.] Educ & Clin Ctr GRECC, VA Puget Sound Geriatr Res, Seattle, WA 98018 USA. [Bonner, Laura M.] Hlth Serv Res & Dev HSR&D, Seattle, WA 98018 USA. [Bonner, Laura M.; Watson, G. Stennis; Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lanto, Andy B.; Chaney, Edmund F.; Rubenstein, Lisa V.] VA Greater Los Angeles, Los Angeles, CA USA. [Bolkan, Cory] Washington State Univ, Vancouver, WA USA. [Watson, G. Stennis] Univ Washington, Seattle, WA 98195 USA. [Campbell, Duncan G.] Univ Montana, Missoula, MT 59812 USA. [Zivin, Kara] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Corp, Los Angeles, CA USA. RP Bonner, LM (reprint author), Educ & Clin Ctr GRECC, VA Puget Sound Geriatr Res, GRECC S 182,1660 S Columbian Way, Seattle, WA 98018 USA. EM Laura.bonner@va.gov NR 28 TC 9 Z9 9 U1 1 U2 21 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 J9 J RELIG HEALTH JI J. Relig. Health PD SEP PY 2013 VL 52 IS 3 BP 707 EP 718 DI 10.1007/s10943-012-9671-0 PG 12 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 174DC UT WOS:000321132600002 PM 23297184 ER PT J AU Tian, HJ Bi, XD Li, CS Zhao, KW Brochmann, EJ Montgomery, SR Aghdasi, B Chen, DY Daubs, MD Wang, JC Murray, SS AF Tian, Haijun Bi, Xiaoda Li, Chen-Shuang Zhao, Ke-Wei Brochmann, Elsa J. Montgomery, Scott R. Aghdasi, Bayan Chen, Deyu Daubs, Michael D. Wang, Jeffrey C. Murray, Samuel S. TI Secreted Phosphoprotein 24 kD (Spp24) and Spp14 Affect TGF-beta Induced Bone Formation Differently SO PLOS ONE LA English DT Article ID GROWTH-FACTOR-BETA; MORPHOGENETIC PROTEIN-2; LIGAND-BINDING; TRANSFORMING GROWTH-FACTOR-BETA-1; CRYSTAL-STRUCTURE; RECEPTOR; MATRIX; ANTAGONISTS; MUTAGENESIS; EXPRESSION AB Transforming growth factor-beta (TGF-beta) and bone morphogenetic proteins (BMPs) have opposing but complementary functions in directing bone growth, repair, and turnover. Both are found in the bone matrix. Proteins that bind to and affect the activity of these growth factors will determine the relative abundance of the growth factors and, therefore, regulate bone formation. Secreted phosphoprotein 24 kD (Spp24) is a bone matrix protein that has been demonstrated to bind to and affect the activity of BMPs. The arginine-rich carboxy terminus of Spp24 is proteolytically processed to produce three other predictable truncation products (Spp18.1, Spp16.0, and Spp14.5). In this work, we report that kinetic data obtained by surface plasmon resonance demonstrate that Spp24 and the three C-terminal truncation products all bind to TGF-beta 1 and TGF-beta 2 with a similar but somewhat less affinity than they bind BMP-2; that, as in the case of BMP-2, the full-length (FL) form of Spp24 binds TGF-beta with greater affinity than do the truncation products; that FL-Spp24 inhibits TGF-beta 2 induced bone formation in vivo, but Spp14.5 does not; and that co-administration of FL-Spp24 or Spp14.5 with TGF-beta 2 in vivo is associated with a reduction in the amount of cartilage, relative to new bone, present at the site of injection. This finding is consistent with the observation that low-dose TGF-beta administration in vivo is associated with greater bone formation than high-dose TGF-beta administration, and suggests that one function of Spp24 and its truncation products is to down-regulate local TGF-beta activity or availability during bone growth and development. The similarities and differences of the interactions between Spp24 proteins and TGF-beta compared to the interaction of the Spp24 proteins and BMPs have significant implications with respect to the regulation of bone metabolism and with respect to engineering therapeutic proteins for skeletal disorders. C1 [Tian, Haijun; Chen, Deyu] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China. [Bi, Xiaoda] 309th Hosp PLA, Dept Ophthalmol, Beijing, Peoples R China. [Li, Chen-Shuang] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing 100871, Peoples R China. [Zhao, Ke-Wei; Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Los Angeles Healthcare Syst, Res Serv, Educ & Clin Ctr, North Hills, CA USA. [Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Geriatr Res, North Hills, CA USA. [Brochmann, Elsa J.; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Bi, Xiaoda] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Montgomery, Scott R.; Daubs, Michael D.; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA. [Aghdasi, Bayan] Methodist Hosp Syst, Dept Orthopaed Surg, Houston, TX USA. RP Tian, HJ (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China. EM haijuntianmd@gmail.com FU Department of Veterans Affairs Biomedical Laboratory Research; Development and Rehabilitation Research and Development Services [1I01BX000511, 1I0RX000383] FX This work was supported by the Department of Veterans Affairs Biomedical Laboratory Research (http://www.research.va.gov/services/blrd/#.UW8XKqV9FFg) and Development and Rehabilitation Research and Development Services (http://www.research.va.gov/services/rrd.cfm#.UW8XV6V9FFg) (1I01BX000511 and 1I0RX000383). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 9 Z9 9 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 26 PY 2013 VL 8 IS 8 AR e72645 DI 10.1371/journal.pone.0072645 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 215RU UT WOS:000324228800081 PM 23991133 ER PT J AU Ghosh-Choudhury, N Mandal, CC Das, F Ganapathy, S Ahuja, S Choudhury, GG AF Ghosh-Choudhury, Nandini Mandal, Chandi C. Das, Falguni Ganapathy, Suthakar Ahuja, Seema Choudhury, Goutam Ghosh TI c-Abl-dependent Molecular Circuitry Involving Smad5 and Phosphatidylinositol 3-Kinase Regulates Bone Morphogenetic Protein-2-induced Osteogenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BMP-2 GENE-TRANSCRIPTION; TGF-BETA; TYROSINE KINASE; OSTEOBLAST DIFFERENTIATION; SIGNAL-TRANSDUCTION; IMATINIB MESYLATE; CELL-DIFFERENTIATION; PRECURSOR CELLS AB Skeletal remodeling consists of timely formation and resorption of bone by osteoblasts and osteoclasts in a quantitative manner. Patients with chronic myeloid leukemia receiving inhibitors of c-Abl tyrosine kinase often show reduced bone remodeling due to impaired osteoblast and osteoclast function. BMP-2 plays a significant role in bone generation and resorption by contributing to the formation of mature osteoblasts and osteoclasts. The effects of c-Abl on BMP-2-induced bone remodeling and the underlying mechanisms are not well studied. Using a pharmacological inhibitor and expression of a dominant negative mutant of c-Abl, we show an essential role of this tyrosine kinase in the development of bone nodules containing mature osteoblasts and formation of multinucleated osteoclasts in response to BMP-2. Calvarial osteoblasts prepared from c-Abl null mice showed the absolute requirement of this tyrosine kinase in maturation of osteoblasts and osteoclasts. Activation of phosphatidylinositol 3-kinase (PI 3-kinase)/Akt signaling by BMP-2 leads to osteoblast differentiation. Remarkably, inhibition of c-Abl significantly suppressed BMP-2-stimulated PI 3-kinase activity and its downstream Akt phosphorylation. Interestingly, c-Abl regulated BMP-2-induced osteoclastogenic CSF-1 expression. More importantly, we identified the requirements of c-Abl in BMP-2 autoregulation and the expressions of alkaline phosphatase and osterix that are necessary for osteoblast differentiation. c-Abl contributed to BMP receptor-specific Smad-dependent transcription of CSF-1, osterix, and BMP-2. Finally, c-Abl associates with BMP receptor IA and regulates phosphorylation of Smad in response to BMP-2. We propose that activation of c-Abl is an important step, which induces into two signaling pathways involving noncanonical PI 3-kinase and canonical Smads to integrate BMP-2-induced osteogenesis. C1 [Ghosh-Choudhury, Nandini; Ahuja, Seema; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Mandal, Chandi C.; Ganapathy, Suthakar] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Das, Falguni; Ahuja, Seema; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Ghosh-Choudhury, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. EM choudhury@uthscsa.edu FU National Institutes of Health [RO1 AR52425, RO1 DK50190]; Veterans Affairs Merit Review grant; CTRC P30 Cancer Center Support Grant [CA 054174]; Veterans Affairs Merit Review grants; Cancer Prevention Research Institute of Texas; Veterans Affairs Senior Research Career Scientist Award FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 AR52425 (to N. G. C.) and RO1 DK50190 (to G. G. C.). This work was also supported by Veterans Affairs Merit Review grant and CTRC P30 Cancer Center Support Grant CA 054174 (to N. G. C.) and in part by Veterans Affairs Merit Review grants (to G. G. C.).; Recipient of a fellowship from the Cancer Prevention Research Institute of Texas.; Recipient of Veterans Affairs Senior Research Career Scientist Award. NR 78 TC 10 Z9 10 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 23 PY 2013 VL 288 IS 34 BP 24503 EP 24517 DI 10.1074/jbc.M113.455733 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302NW UT WOS:000330612300019 PM 23821550 ER PT J AU Rosenbaum, L Shrank, WH AF Rosenbaum, Lisa Shrank, William H. TI Taking Our Medicine - Improving Adherence in the Accountability Era SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID MEDICATION AB

Many U.S. patients do not adhere to prescribed medication regimens, ultimately costing the United States $100 billion to $290 billion annually. As physician payment is increasingly tied to patient outcomes, nonadherence poses new challenges and opportunities.

A new patient with an abnormal electrocardiogram comes to your office. He is 53, smokes, and has hypertension and hyperlipidemia. Though he comes for preoperative risk evaluation, he needs more than medical clearance he needs a primary doctor. Given his risk factors and hesitance to change his lifestyle, you recommend aspirin, a statin, and an antihypertensive. When he doesn't show up for his stress test, you call him, and he says he doesn't understand what the fuss is all about he feels fine. Why don't you wait until something is wrong with me to give me these medications? ... C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Shrank, William H.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. [Shrank, William H.] Harvard Univ, Sch Med, Boston, MA USA. RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 5 TC 13 Z9 13 U1 0 U2 9 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 22 PY 2013 VL 369 IS 8 BP 694 EP 695 DI 10.1056/NEJMp1307084 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 204FA UT WOS:000323349300004 PM 23964931 ER PT J AU Parchman, ML Noel, PH Culler, SD Lanham, HJ Leykum, LK Romero, RL Palmer, RF AF Parchman, Michael L. Noel, Polly H. Culler, Steven D. Lanham, Holly J. Leykum, Luci K. Romero, Raquel L. Palmer, Raymond F. TI A randomized trial of practice facilitation to improve the delivery of chronic illness care in primary care: initial and sustained effects SO IMPLEMENTATION SCIENCE LA English DT Article ID HEALTH-CARE; INTERVENTIONS; QUALITY; MODEL; DESIGN AB Background: Practice facilitation (PF) is an implementation strategy now commonly used in primary care settings for improvement initiatives. PF occurs when a trained external facilitator engages and supports the practice in its change efforts. The purpose of this group-randomized trial is to assess PF as an intervention to improve the delivery of chronic illness care in primary care. Methods: A randomized trial of 40 small primary care practices who were randomized to an initial or a delayed intervention (control) group. Trained practice facilitators worked with each practice for one year to implement tailored changes to improve delivery of diabetes care within the Chronic Care Model framework. The Assessment of Chronic Illness Care (ACIC) survey was administered at baseline and at one-year intervals to clinicians and staff in both groups of practices. Repeated-measures analyses of variance were used to assess the main effects (mean differences between groups) and the within-group change over time. Results: There was significant improvement in ACIC scores (p < 0.05) within initial intervention practices, from 5.58 (SD 1.89) to 6.33 (SD 1.50), compared to the delayed intervention (control) practices where there was a small decline, from 5.56 (SD 1.54) to 5.27 (SD 1.62). The increase in ACIC scores was sustained one year after withdrawal of the PF intervention in the initial intervention group, from 6.33 (SD 1.50) to 6.60 (SD 1.94), and improved in the delayed intervention (control) practices during their one year of PF intervention, from 5.27 (SD 1.62) to 5.99 (SD 1.75). Conclusions: Practice facilitation resulted in a significant and sustained improvement in delivery of care consistent with the CCM as reported by those involved in direct patient care in small primary care practices. The impact of the observed change on clinical outcomes remains uncertain. Trial registration: This protocol followed the CONSORT guidelines and is registered per ICMJE guidelines: Clinical Trial Registration Number: NCT00482768. C1 [Parchman, Michael L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, MacColl Ctr Healthcare Innovat, Seattle, WA USA. [Noel, Polly H.; Lanham, Holly J.; Leykum, Luci K.] South Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Program, San Antonio, TX USA. [Noel, Polly H.; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Culler, Steven D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Lanham, Holly J.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Romero, Raquel L.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. RP Parchman, ML (reprint author), Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, MacColl Ctr Healthcare Innovat, 1730 Minor Ave Suite 1600, Seattle, WA USA. EM parchman.m@ghc.org OI Parchman, Michael/0000-0001-7129-2889 FU National Institute of Diabetes, Digestive, and Kidney Disorders [R18 DK 075692] FX This study was funded by a grant from the National Institute of Diabetes, Digestive, and Kidney Disorders (R18 DK 075692), follows the Consolidated Standards of Reporting Trials guidelines, and is registered per International Committee of Medical Journal Editors guidelines (Clinical Trial Registration Number NCT00482768). This work was also supported with resources and the use of facilities at the Audie L. Murphy Veterans Hospital, Veterans Health Administration, Department of Veterans Affairs. This study received approval for human subjects research from the institutional review board of the University of Texas Health Science Center at San Antonio. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. We would like to express our appreciation to the physicians and offices staff in the South Texas Ambulatory Research Network (STARNet) for their participation in this study. NR 27 TC 21 Z9 21 U1 1 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD AUG 22 PY 2013 VL 8 AR 93 DI 10.1186/1748-5908-8-93 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 210QO UT WOS:000323849700001 PM 23965255 ER PT J AU Clark, KB AF Clark, Kevin B. TI Ciliates learn to diagnose and correct classical error syndromes in mating strategies SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE courtship and dominance displays; evolutionary psychology; intracellular calcium; mate selection; mating pathways; pheromones; social decision making; soft-matter physics ID SPIROSTOMUM-AMBIGUUM; MATHEMATICAL-THEORY; EUPLOTES-RAIKOVI; SOCIAL-BEHAVIOR; SEX-PHEROMONE; IN-VIVO; COMMUNICATION; HABITUATION; EVOLUTION; CALCIUM AB Preconjugal ciliates learn classical repetition error-correction codes to safeguard mating messages and replies from corruption by "rivals" and local ambient noise. Because individual cells behave as memory channels with Szilard engine attributes, these coding schemes also might be used to limit, diagnose, and correct mating-signal errors due to noisy intracellular information processing. The present study, therefore, assessed whether heterotrich ciliates effect fault-tolerant signal planning and execution by modifying engine performance, and consequently entropy content of codes, during mock cell cell communication. Socially meaningful serial vibrations emitted from an ambiguous artificial source initiated ciliate behavioral signaling performances known to advertise mating fitness with varying courtship strategies. Microbes, employing calcium-dependent Hebbian-like decision making, learned to diagnose then correct error syndromes by recursively matching Boltzmann entropies between signal planning and execution stages via "power" or "refrigeration" cycles. All eight serial contraction and reversal strategies incurred errors in entropy magnitude by the execution stage of processing. Absolute errors, however, subtended expected threshold values for single bit-flip errors in three-bit replies, indicating coding schemes protected information content throughout signal production. Ciliate preparedness for vibrations selectively and significantly affected the magnitude and valence of Szilard engine performance during modal and non-modal strategy corrective cycles. But entropy fidelity for all replies mainly improved across learning trials as refinements in engine efficiency. Fidelity neared maximum levels for only modal signals coded in resilient three-bit repetition error-correction sequences. Together, these findings demonstrate microbes can elevate survival/reproductive success by learning to implement classical fault-tolerant information processing in social contexts. C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA USA. RP Clark, KB (reprint author), 4229 SE Harney St, Portland, OR 97206 USA. EM kbclarkphd@yahoo.com NR 97 TC 5 Z9 5 U1 1 U2 2 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD AUG 19 PY 2013 VL 4 AR 229 DI 10.3389/fmicb.2013.00229 PG 22 WC Microbiology SC Microbiology GA AA9EQ UT WOS:000331397000001 PM 23966987 ER PT J AU Liu, YH Qi, WB Richardson, A Van Remmen, H Ikeno, Y Salmon, AB AF Liu, Yuhong Qi, Wenbo Richardson, Arlan Van Remmen, Holly Ikeno, Yuji Salmon, Adam B. TI Oxidative damage associated with obesity is prevented by overexpression of CuZn- or Mn-superoxide dismutase SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Diabetes; Mitochondria; F-2-isoprostane; Oxidative stress ID INSULIN-RESISTANCE; DIABETES-MELLITUS; STRESS; MITOCHONDRIA; DEFICIENCY; MICE; DNA AB The development of insulin resistance is the primary step in the etiology of type 2 diabetes mellitus. There are several risk factors associated with insulin resistance, yet the basic biological mechanisms that promote its development are still unclear. There is growing literature that suggests mitochondrial dysfunction and/or oxidative stress play prominent roles in defects in glucose metabolism. Here, we tested whether increased expression of CuZn-superoxide dismutase (Sod1) or Mn-superoxide dismutase (Sod2) prevented obesity-induced changes in oxidative stress and metabolism. Both Sod1 and Sod2 overexpressing mice were protected from high fat diet-induced glucose intolerance. Lipid oxidation (F-2-isoprostanes) was significantly increased in muscle and adipose with high fat feeding. Mice with increased expression of either Sod1 or Sod2 showed a significant reduction in this oxidative damage. Surprisingly, mitochondria from the muscle of high fat diet-fed mice showed no significant alteration in function. Together, our data suggest that targeting reduced oxidative damage in general may be a more applicable therapeutic target to prevent insulin resistance than is improving mitochondrial function. Published by Elsevier Inc. C1 [Richardson, Arlan; Van Remmen, Holly; Ikeno, Yuji; Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Liu, Yuhong; Qi, Wenbo; Richardson, Arlan; Van Remmen, Holly; Ikeno, Yuji; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. RP Salmon, AB (reprint author), 15355 Lambda Dr, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu FU Geriatric Research Education and Clinical Center of the South Texas Veterans Health Care System; Biomedical Laboratory Research & Development Service of the Veteran's Affairs Office of Research and Development by [VA Merit Review Grants] [1I01BX001023, 1I01BX000547]; American Federation for Aging Research; Glenn Foundation FX Mitochondria and F2-isoprostane measurements were performed by the Mitochondrial Function and Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. This work was supported by the Geriatric Research Education and Clinical Center of the South Texas Veterans Health Care System, and grants from the Biomedical Laboratory Research & Development Service of the Veteran's Affairs Office of Research and Development by [VA Merit Review Grants 1I01BX001023 (Y.I.) and 1I01BX000547 (A.R.)], the American Federation for Aging Research (Y.I.) and the Glenn Foundation (Y.I.). NR 23 TC 16 Z9 17 U1 0 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 16 PY 2013 VL 438 IS 1 BP 78 EP 83 DI 10.1016/j.bbrc.2013.07.029 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 205TG UT WOS:000323467100014 PM 23872067 ER PT J AU Wei, R Bhattacharya, A Hamilton, RT Jernigan, AL Chaudhuri, AR AF Wei, Rochelle Bhattacharya, Arunabh Hamilton, Ryan T. Jernigan, Amanda L. Chaudhuri, Asish R. TI Differential effects of mutant SOD1 on protein structure of skeletal muscle and spinal cord of familial amyotrophic lateral sclerosis: Role of chaperone network SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Heat shock proteins; Familial ALS; BisANS; Protein conformation; Mutant SOD1; Surface hydrophobicity ID DELAYS DISEASE PROGRESSION; MOTOR-NEURON DEGENERATION; HEAT-SHOCK PROTEINS; MOUSE MODEL; RESTRICTED EXPRESSION; EXTENDING SURVIVAL; MOTONEURON DISEASE; CELL-DEATH; ALS; MICE AB Protein misfolding is considered to be a potential contributing factor for motor neuron and muscle loss in diseases like Amyotrophic lateral sclerosis (ALS). Several independent studies have demonstrated using over-expressed mutated Cu/Zn-superoxide dismutase (mSOD1) transgenic mouse models which mimic familial ALS (f-ALS), that both muscle and motor neurons undergo degeneration during disease progression. However, it is unknown whether protein conformation of skeletal muscle and spinal cord is equally or differentially affected by mSOD1-induced toxicity. It is also unclear whether heat shock proteins (Hsp's) differentially modulate skeletal muscle and spinal cord protein structure during ALS disease progression. We report three intriguing observations utilizing the f-ALS mouse model and cell-free in vitro system; (i) muscle proteins are equally sensitive to misfolding as spinal cord proteins despite the presence of low level of soluble and absence of insoluble G93A protein aggregate, unlike in spinal cord, (ii) Hsp's levels are lower in muscle compared to spinal cord at any stage of the disease, and (iii) G93ASOD1 enzyme-induced toxicity selectively affects muscle protein conformation over spinal cord proteins. Together, these findings strongly suggest that differential chaperone levels between skeletal muscle and spinal cord may be a critical determinant for G93A-induced protein misfolding in ALS. Published by Elsevier Inc. C1 [Wei, Rochelle; Bhattacharya, Arunabh; Hamilton, Ryan T.; Jernigan, Amanda L.; Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chaudhuri, Asish R.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM chaudhuria@uthscsa.edu FU VA-Merit Grant FX This work was supported by VA-Merit Grant (to A.R.C.). We like to thank Dr. Holly Van Remmen for providing wild-type and G93A mouse tissues and to Dr. John Hart for providing purified recombinant G93ASOD1 enzyme. NR 27 TC 3 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 16 PY 2013 VL 438 IS 1 BP 218 EP 223 DI 10.1016/j.bbrc.2013.07.060 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 205TG UT WOS:000323467100037 PM 23886956 ER PT J AU Kim, S Beyer, BA Lewis, C Nadel, JA AF Kim, Suil Beyer, Brittney A. Lewis, Courtney Nadel, Jay A. TI Normal CFTR Inhibits Epidermal Growth Factor Receptor-Dependent Pro-Inflammatory Chemokine Production in Human Airway Epithelial Cells SO PLOS ONE LA English DT Article ID NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; TRANSMEMBRANE CONDUCTANCE REGULATOR; PSEUDOMONAS-AERUGINOSA INFECTION; CYSTIC-FIBROSIS AIRWAYS; INTERLEUKIN-8 PRODUCTION; TNF-ALPHA; CYTOKINE SECRETION; SIGNALING CASCADE; IL-8 EXPRESSION AB Mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein cause cystic fibrosis, a disease characterized by exaggerated airway epithelial production of the neutrophil chemokine interleukin (IL)-8, which results in exuberant neutrophilic inflammation. Because activation of an epidermal growth factor receptor (EGFR) signaling cascade induces airway epithelial IL-8 production, we hypothesized that normal CFTR suppresses EGFR-dependent IL-8 production and that loss of CFTR at the surface exaggerates IL-8 production via activation of a pro-inflammatory EGFR cascade. We examined this hypothesis in human airway epithelial (NCI-H292) cells and in normal human bronchial epithelial (NHBE) cells containing normal CFTR treated with a CFTR-selective inhibitor (CFTR-172), and in human airway epithelial (IB3) cells containing mutant CFTR versus isogenic (C38) cells containing wild-type CFTR. In NCI-H292 cells, CFTR-172 induced IL-8 production EGFR-dependently. Pretreatment with an EGFR neutralizing antibody or the metalloprotease TACE inhibitor TAPI-1, or TACE siRNA knockdown prevented CFTR-172-induced EGFR phosphorylation (EGFR-P) and IL-8 production, implicating TACE-dependent EGFR pro-ligand cleavage in these responses. Pretreatment with neutralizing antibodies to I-L1R or to IL-1alpha, but not to IL-1beta, markedly suppressed CFTR-172-induced EGFR-P and IL-8 production, suggesting that binding of IL-1alpha to IL-1R stimulates a TACE-EGFR-IL-8 cascade. Similarly, in NHBE cells, CFTR-172 increased IL-8 production EGFR-, TACE-, and IL-1alpha/IL-1R-dependently. In IB3 cells, constitutive IL-8 production was markedly increased compared to C38 cells. EGFR-P was increased in IB3 cells compared to C38 cells, and exaggerated IL-8 production in the IB3 cells was EGFR-dependent. Activation of TACE and binding of IL-1alpha to IL-1R contributed to EGFR-P and IL-8 production in IB3 cells but not in C38 cells. Thus, we conclude that normal CFTR suppresses airway epithelial IL-8 production that occurs via a stimulatory EGFR cascade, and that loss of normal CFTR activity exaggerates IL-8 production via activation of a pro-inflammatory EGFR cascade. C1 [Kim, Suil; Beyer, Brittney A.] Oregon Hlth & Sci Univ, Dept Med, Portland Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Kim, Suil] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [Lewis, Courtney; Nadel, Jay A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Lewis, Courtney; Nadel, Jay A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Nadel, Jay A.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA. RP Kim, S (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97201 USA. EM kimsui@ohsu.edu FU Cystic Fibrosis Foundation Pilot Research Award; Portland VA Research Foundation; Cardiovascular Research Institute FX This work was supported by a Cystic Fibrosis Foundation Pilot Research Award (www.cff.org) and Portland VA Research Foundation (www.pvarf.org) grant to SK, and by Cardiovascular Research Institute funding to JN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 12 Z9 12 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 16 PY 2013 VL 8 IS 8 AR e72981 DI 10.1371/journal.pone.0072981 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 207BA UT WOS:000323570200094 PM 23977375 ER PT J AU Zhang, ZR Chu, WF Song, BL Gooz, M Zhang, JN Yu, CJ Jiang, S Baldys, A Gooz, P Steele, S Owsianik, G Nilius, B Komlosi, P Bell, PD AF Zhang, Zhi-Ren Chu, Wen-Feng Song, Binlin Gooz, Monika Zhang, Jia-Ning Yu, Chang-Jiang Jiang, Shuai Baldys, Aleksander Gooz, Pal Steele, Stacy Owsianik, Grzegorz Nilius, Bernd Komlosi, Peter Bell, P. Darwin TI TRPP2 and TRPV4 Form an EGF-Activated Calcium Permeable Channel at the Apical Membrane of Renal Collecting Duct Cells SO PLOS ONE LA English DT Article ID POLYCYSTIC KIDNEY-DISEASE; NONSELECTIVE CATION CHANNEL; GROWTH-FACTOR RECEPTOR; PORE PROPERTIES; MUTANT MICE; PROTEIN; PKD2; INHIBITION; PERMEATION; RESTORES AB Objective: Regulation of apical calcium entry is important for the function of principal cells of the collecting duct. However, the molecular identity and the regulators of the transporter/channel, which is responsible for apical calcium entry and what factors regulate the calcium conduction remain unclear. Methods and Results: We report that endogenous TRPP2 and TRPV4 assemble to form a 23-pS divalent cation-permeable non-selective ion channel at the apical membrane of renal principal cells of the collecting duct. TRPP2\TRPV4 channel complex was identified by patch-clamp, immunofluorescence and co-immunprecipitation studies in both principal cells that either possess normal cilia (cilia (+)) or in which cilia are absent (cilia (-)). This channel has distinct biophysical and pharmacological and regulatory profiles compared to either TRPP2 or TRPV4 channels. The rate of occurrence detected by patch clamp was higher in cilia (-) compared to cilia (+) cells. In addition, shRNA knockdown of TRPP2 increased the prevalence of TRPV4 channel activity while knockdown of TRPV4 resulted in TRPP2 activity and knockdown of both proteins vastly decreased the 23-pS channel activity. Epidermal growth factor (EGF) stimulated TRPP2\TRPV4 channel through the EGF receptor (EGFR) tyrosine kinase-dependent signaling. With loss of cilia, apical EGF treatment resulted in 64-fold increase in channel activity in cilia (-) but not cilia (+) cells. In addition EGF increased cell proliferation in cilia (-) cell that was dependent upon TRPP2\TRPV4 channel mediated increase in intracellular calcium. Conclusion: We conclude that in the absence of cilia, an EGF activated TRPP2\TRPV4 channel may play an important role in increased cell proliferation and cystogenesis. C1 [Bell, P. Darwin] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zhang, Zhi-Ren; Chu, Wen-Feng; Song, Binlin; Gooz, Monika; Baldys, Aleksander; Gooz, Pal; Steele, Stacy; Komlosi, Peter; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Zhang, Zhi-Ren; Chu, Wen-Feng; Song, Binlin; Zhang, Jia-Ning; Yu, Chang-Jiang; Jiang, Shuai] Harbin Med Univ, Educ Minist Myocardial Ischemia & Treatment, Affiliated Hosp 2, Dept Pharm,Key Labs,Dept Pharmacol, Harbin, Peoples R China. [Zhang, Zhi-Ren; Chu, Wen-Feng; Song, Binlin; Zhang, Jia-Ning; Yu, Chang-Jiang; Jiang, Shuai] Harbin Med Univ, Educ Minist Myocardial Ischemia & Treatment, Affiliated Hosp 2, Dept Cardiol,Key Labs,Dept Pharmacol, Harbin, Peoples R China. [Owsianik, Grzegorz; Nilius, Bernd] Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Ion Channel Res, Louvain, Belgium. RP Zhang, ZR (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM zhirenz@yahoo.com; Bellpd@musc.edu OI Komlosi, Peter/0000-0002-5284-8877 FU Key Project of Chinese National Program for Fundamental Research and Development (973 Program) [2012CB517803]; National Natural Science Foundation, China [81070217, 30871007]; Key Project National Science Foundation of Heilongjiang, China [ZD200807-01]; Heilongjiang Educational Committee, China [1154HZ11]; Veterans Affairs Merit Grant; National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD) [DK074038]; NIH/NIDDK [RO1 DK32032]; Dialysis Clinic, Inc. (DCI) [C-2618A] FX This work was supported by Key Project of Chinese National Program for Fundamental Research and Development (973 Program, 2012CB517803) National Natural Science Foundation, China (# 81070217 & # 30871007), Key Project National Science Foundation of Heilongjiang, China (# ZD200807-01) and Grant from Heilongjiang Educational Committee, China (# 1154HZ11) to ZRZ and by Veterans Affairs Merit Grant, National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD) DK074038, NIH/NIDDK RO1 DK32032 and a Grant from the Dialysis Clinic, Inc. (DCI) # C-2618A to PDB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 19 Z9 19 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 16 PY 2013 VL 8 IS 8 AR UNSP e73424 DI 10.1371/journal.pone.0073424 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 207BA UT WOS:000323570200095 PM 23977387 ER PT J AU Chiao, EY Hartman, CM El-Serag, HB Giordano, TP AF Chiao, Elizabeth Y. Hartman, Christine M. El-Serag, Hashem B. Giordano, Thomas P. TI The Impact of HIV Viral Control on the Incidence of HIV-Associated Anal Cancer SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE anal cancer; HIV; epidemiology; combined antiretroviral therapy ID SQUAMOUS INTRAEPITHELIAL LESIONS; ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY; UNITED-STATES; POSITIVE MEN; INFECTION; HAART; EPIDEMIOLOGY; PROGRESSION; NEOPLASIA AB Background: Recent studies have shown that the incidence of squamous cell cancer of the anus (SCCA) has increased in the combined antiretroviral therapy (cART) era. The effect of undetectable HIV viral loads as a result of successful cART has not been evaluated. Methods: We performed a retrospective cohort study among male US veterans diagnosed with HIV and followed between 1985 and 2009 using the Veterans Affairs Immunologic Case Registry (VA-ICR). We calculated age-adjusted incidence rates and rate ratios for SCCA. We conducted Cox proportional hazards ratios of SCCA in a multivariable model including time-varying covariates of nadir CD4 count and overall percentage of time with an undetectable HIV viral load. Results: The age-adjusted SCCA incidence rate among the group who ever received cART was 146.8/100,000 person-years (95% confidence interval, 124.1 to 172.6) and was not significantly higher than the SCCA rate of those who never received cART (134.3/100,000 person-years; 95% confidence interval, 112.5 to 159.0). In a multivariable model limited to veterans who had ever received cART (adjusted for demographic variables, nadir, and most recent CD4 counts) individuals who had 61%-80% or 81%-100% of follow-up time with undetectable HIV viral loads had significantly decreased SCCA risk compared with those who had undetectable HIV viral loads <20% of the time (odds ratio, 0.56; P = 0.040 and odds ratio, 0.55; P = 0.0004, respectively). Conclusions: HIV control as measured by the percent of time with undetectable HIV viral load seems to decrease the risk of SCCA. Optimizing cART adherence and HIV viral load control may decrease the risk of subsequent SCCA. C1 [Chiao, Elizabeth Y.; Hartman, Christine M.; El-Serag, Hashem B.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Chiao, Elizabeth Y.; Hartman, Christine M.; El-Serag, Hashem B.; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Chiao, Elizabeth Y.; Hartman, Christine M.; El-Serag, Hashem B.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Chiao, EY (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM echiao@bcm.edu FU Houston Health Services Research and Development Center of Excellence [FP90-020]; Michael E. DeBakey Veterans Affairs Medical Center; Baylor College of Medicine; National Cancer Institute [K23CA124318, R01CA163103, K24DK078154, P30DK58338] FX Supported with resources and the use of facilities at the Houston Health Services Research and Development Center of Excellence (FP90-020), Michael E. DeBakey Veterans Affairs Medical Center, and by a seed fund grant from the Baylor College of Medicine. E.Y.C. (K23CA124318 and R01CA163103) and H.B.E.-S. (K24DK078154 and P30DK58338) received support from the National Cancer Institute. NR 26 TC 18 Z9 18 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2013 VL 63 IS 5 BP 631 EP 638 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300FN UT WOS:000330449900023 PM 23614995 ER PT J AU Ding, YN Li, J Wu, Q Yang, P Luo, B Xie, ST Druey, KM Zajac, AJ Hsu, HC Mountz, JD AF Ding, Yanna Li, Jun Wu, Qi Yang, Pingar Luo, Bao Xie, Shutao Druey, Kirk M. Zajac, Allan J. Hsu, Hui-Chen Mountz, John D. TI IL-17RA Is Essential for Optimal Localization of Follicular Th Cells in the Germinal Center Light Zone To Promote Autoantibody-Producing B Cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HELPER-CELLS; BXD2 MICE; CENTER SELECTION; AUTOIMMUNITY; DIFFERENTIATION; RECEPTOR; IL-21; INTERLEUKIN-21; PATHWAY AB Germinal centers (GCs) provide a microenvironment that promotes and regulates the interactions of B cells with follicular Th (T-FH) cells. In this study, we show that there are significantly higher frequencies of CXCR5(+)ICOS(+) T-FH cells in autoimmune BXD2 mice, and these cells express both IL-21R and IL-17RA. Although IL-17 and IL-21 are both important for the formation of spontaneous GCs and development of pathogenic autoantibodies, IL-21, but not IL-17, is required for the proper development of T-FH cells in BXD2 mice. The total numbers of T-FH cells and their ability to induce B cell responses in vitro were not affected by a deficiency of IL-17RA in BXD2-Il17ra(-/-) mice, the majority of CXCR5(+) T-FH cells from BXD2-Il17ra(-/-) mice were, however, not localized in the GC light zone (LZ). Interruption of IL-17 signaling, either acutely by AdIL-17R:Fc or chronically by Il17ra(-/-), disrupted T-FH-B interactions and abrogated the generation of autoantibody-forming B cells in BXD2 mice. IL-17 upregulated the expression of regulator of G-protein signaling 16 (RGS16) to promote the ability of T-FH to form conjugates with B cells, which was abolished in T-FH cells from BXD2-Rgs16(-/-) mice. The results suggests that IL-17 is an extrinsic stop signal that it acts on postdifferentiated IL-17RA(+) T-FH to enable its interaction with responder B cells in the LZ niche. These data suggest a novel concept that T-FH differentiation and its stabilization in the LZ are two separate checkpoints and that IL-21 and IL-17 act at each checkpoint to enable pathogenic GC development. C1 [Ding, Yanna; Li, Jun; Wu, Qi; Yang, Pingar; Luo, Bao; Xie, Shutao; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Ding, Yanna] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Druey, Kirk M.] NIAID, NIH, Bethesda, MD 20892 USA. [Zajac, Allan J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Hsu, HC (reprint author), Univ Alabama Birmingham, Dept Med, Room 311 Shelby Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA. EM rheu078@uab.edu; jdmountz@uab.edu FU Veterans Affairs Merit Review Grant [1I01BX000600-01]; National Institutes of Health/National Institute of Allergy and Infectious Diseases [1AI 071110, ARRA 3RO1AI71110-02S1, 1RO1 AI083705, U01 AI082966, P30 AI027767]; American College of Rheumatology-Within-Our-Reach, the Rheumatology Research Foundation; Alliance for Lupus Research; Arthritis Foundation; Lupus Research Institute; National Institute of Allergy and Infectious Diseases, National Institutes of Health; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS] [P30 AR048311]; University of Alabama at Birmingham Analytic Imaging and Immunoreagents Core (NIAMS) [P30 AR048311] FX This work was supported by Veterans Affairs Merit Review Grant 1I01BX000600-01; the National Institutes of Health/National Institute of Allergy and Infectious Diseases Grants 1AI 071110, ARRA 3RO1AI71110-02S1, 1RO1 AI083705, and U01 AI082966; American College of Rheumatology-Within-Our-Reach, the Rheumatology Research Foundation; the Alliance for Lupus Research; the Arthritis Foundation; the Lupus Research Institute; and in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Flow cytometry and confocal imaging data acquisition were carried out at the University of Alabama at Birmingham Comprehensive Flow Cytometry Core (supported by National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS] Grant P30 AR048311 and National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant P30 AI027767) and University of Alabama at Birmingham Analytic Imaging and Immunoreagents Core (NIAMS Grant P30 AR048311), respectively. NR 49 TC 24 Z9 25 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 15 PY 2013 VL 191 IS 4 BP 1614 EP 1624 DI 10.4049/jimmunol.1300479 PG 11 WC Immunology SC Immunology GA 194KT UT WOS:000322632900012 PM 23858031 ER PT J AU Li, XH Redus, L Chen, C Martinez, PA Strong, R Li, SL O'Connor, JC AF Li, Xiuhua Redus, Laney Chen, Cang Martinez, Paul A. Strong, Randy Li, Senlin O'Connor, Jason C. TI Cognitive Dysfunction Precedes the Onset of Motor Symptoms in the MitoPark Mouse Model of Parkinson's Disease SO PLOS ONE LA English DT Article ID DEPRESSIVE-LIKE BEHAVIOR; NONMOTOR SYMPTOMS; TREATED PATIENTS; CALMETTE-GUERIN; MICE; IMPAIRMENT; INDUCTION; DOPAMINE; DEMENTIA; MEMORY AB Parkinson's disease (PD) is a neurodegenerative disorder primarily characterized by progressive loss of dopamine neurons, leading to loss of motor coordination. However, PD is associated with a high rate of non-motor neuropsychiatric comorbities that often develop before the onset of movement symptoms. The MitoPark transgenic mouse model is the first to recapitulate the cardinal clinical features, namely progressive neurodegeneration and death of neurons, loss of motor function and therapeutic response to L-DOPA. To investigate whether MitoPark mice exhibit early onset of cognitive impairment, a non-motor neuropsychiatric comorbidity, we measured performance on a spatial learning and memory task before (similar to 8 weeks) or after (similar to 20 weeks) the onset of locomotor decline in MitoPark mice or in littermate controls. Consistent with previous studies, we established that a progressive loss of spontaneous locomotor activity began at 12 weeks of age, which was followed by progressive loss of body weight beginning at 16-20 weeks. Spatial learning and memory was measured using the Barnes Maze. By 20 weeks of age, MitoPark mice displayed a substantial reduction in overall locomotor activity that impaired their ability to perform the task. However, in the 8-week-old mice, locomotor activity was no different between genotypes, yet MitoPark mice took longer, traveled further and committed more errors than same age control mice, while learning to successfully navigate the maze. The modest between-day learning deficit of MitoPark mice was characterized by impaired within-day learning during the first two days of testing. No difference was observed between genotypes during probe trials conducted one or twelve days after the final acquisition test. Additionally, 8-week-old MitoPark mice exhibited impaired novel object recognition when compared to control mice. Together, these data establish that mild cognitive impairment precedes the loss of motor function in a novel rodent model of PD, which may provide unique opportunities for therapeutic development. C1 [Li, Xiuhua; Redus, Laney; Chen, Cang; Martinez, Paul A.; Strong, Randy; Li, Senlin; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Li, Xiuhua; Chen, Cang; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Martinez, Paul A.; Strong, Randy; Li, Senlin; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA. [O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Mood Disorders Translat Res Core, San Antonio, TX 78229 USA. [Strong, Randy; Li, Senlin] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Strong, Randy; Li, Senlin] Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Li, Xiuhua] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurol, Jinan 250100, Peoples R China. RP Li, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. EM lis1@uthscsa.edu; oconnorj@uthscsa.edu FU Owen's Medical research Foundation; [R01-MH090127]; [P30-MH089868]; [NIA-1P30-AG13319]; [VA-BX001641]; [VA-BX000737]; [NIH-UL1-TR0000149] FX This research was supported by grants R01-MH090127 and P30-MH089868 (to JO); NIA-1P30-AG13319 and VA-BX001641 (to RS); and VA-BX000737, NIH-UL1-TR0000149 Pilot Project grant and an Owen's Medical research Foundation Award (to SL). The content is the sole the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health or the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 14 Z9 14 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 15 PY 2013 VL 8 IS 8 AR e71341 DI 10.1371/journal.pone.0071341 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 204OU UT WOS:000323378000043 PM 23977020 ER PT J AU Agostoni, P Swenson, ER Fumagalli, R Salvioni, E Cattadori, G Farina, S Bussotti, M Tamplenizza, M Lombardi, C Bonacina, D Brioschi, M Caravita, S Modesti, P Revera, M Giuliano, A Meriggi, P Faini, A Bilo, G Banfi, C Parati, G AF Agostoni, Piergiuseppe Swenson, Erik R. Fumagalli, Roberto Salvioni, Elisabetta Cattadori, Gaia Farina, Stefania Bussotti, Maurizio Tamplenizza, Margherita Lombardi, Carolina Bonacina, Daniele Brioschi, Maura Caravita, Sergio Modesti, Pietro Revera, Miriam Giuliano, Andrea Meriggi, Paolo Faini, Andrea Bilo, Grzegorz Banfi, Cristina Parati, Gianfranco TI Acute high-altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE Gas exchange; Surfactant derived proteins; Pulmonary edema; Hypoxia ID ACUTE MOUNTAIN-SICKNESS; INTERSTITIAL PULMONARY-EDEMA; CHRONIC HEART-FAILURE; SURFACTANT PROTEIN-B; RECREATIONAL CLIMBERS; CARBON-MONOXIDE; GAS-EXCHANGE; EXERCISE; CAPACITY; PLASMA AB The causes and development of lung fluid, as well as the integrity of the alveolar-capillary membrane at high altitude, are undefined. This study was conceived to see whether fluid accumulates within the lung with acute high altitude exposure, and whether this is associated with alveolar capillary membrane damage. We studied lung carbon monoxide diffusion (DLCO), its components membrane diffusion (D-M) and capillary volume (V-C) and alveolar volume (V-A) measured in 43 healthy subjects in Milan (122 m) and after 1 and 3 days at Capanna Regina Margherita (4559 m). DLCO measurement was adjusted for hemoglobin and inspired oxygen. We also measured plasma surfactant derived protein B (SPB) and Receptor of Advanced Glycation End-products (RAGE) as markers of alveolar-capillary membrane damage, and ultrasound lung comets as a marker of extravascular lung water. 21 subjects received acetazolamide and 22 placebo. DLCO was lower at Capanna Regina Margherita (day 1: 24.3 +/- 4.7 and day 3: 23.6 +/- 5.4 mL/mmHg/min), than in Milan (25.8 +/- 5.5; p < 0.001 vs. day 1 and 3) due to D-M reduction (Milan: 50.5 +/- 14.6 mL/mmHg/min, Capanna Regina Margherita day 1: 45.1 +/- 11.5 mL/mmHg/min, day 3: 43.2 +/- 13.9 mL/mmHg/min; p < 0.05 Milan vs. day 3) with a partially compensatory V-C increase (Milan: 96 +/- 37 mL, Capanna Regina Margherita day 1: 152 66 mL, day 3: 153 59 mL; p < 0.001 Milan vs. day 1 and day 3). Acetazolamide did not prevent the fall in DLCO albeit, between day 1 and 3, such a trend was observed. Regardless of treatment lung comets increased from 0 to 7.2 +/- 3.6 (p < 0.0001). SPB and RAGE were unchanged. Lung fluid increased at high altitude without evidence from plasma measurements, supporting alveolar-capillary damage. (C) 2013 Elsevier B.V. All rights reserved. C1 [Agostoni, Piergiuseppe; Salvioni, Elisabetta; Cattadori, Gaia; Farina, Stefania; Brioschi, Maura; Banfi, Cristina] IRCCS, Ctr Cardiol Monzino, I-20138 Milan, Italy. [Agostoni, Piergiuseppe] Univ Washington, Div Pulm Crit Care & Med, Dept Med, VA Med Ctr, Seattle, WA 98108 USA. [Agostoni, Piergiuseppe] Dept Clin Sci & Community Hlth, I-20138 Milan, Italy. [Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care & Med, Dept Med, VA Puget Sound Hlth Care Syst,VA Med Ctr, Seattle, WA 98108 USA. [Fumagalli, Roberto; Bonacina, Daniele] Univ Milano Bicocca, Dipartimento Med Sperimentale, Osped S Gerardo Monza, Unita Operat Anestesia & Rianimaz 1, Milan, Italy. [Bussotti, Maurizio] IRCCS, Fdn S Maugeri, Milan, Italy. [Tamplenizza, Margherita] Univ Milan, CIMAINA, Milan, Italy. [Lombardi, Carolina; Caravita, Sergio; Revera, Miriam; Giuliano, Andrea; Faini, Andrea; Bilo, Grzegorz; Parati, Gianfranco] S Luca Hosp, Ist Auxol Italian, Dept Cardiol, I-20131 Milan, Italy. [Lombardi, Carolina; Revera, Miriam; Parati, Gianfranco] Univ Milano Bicocca, Dept Clin Med & Prevent, I-20149 Milan, Italy. [Modesti, Pietro] Univ Florence, Dipartimento Area Crit Med Chirurg, I-50134 Florence, Italy. [Meriggi, Paolo] Fdn Don Carlo Gnocchi, Biomed Technol Dept, I-20148 Milan, Italy. RP Agostoni, P (reprint author), Ctr Cardiol Monzino, Via Parea 4, I-20138 Milan, Italy. EM piergiuseppe.agostoni@unimi.it RI Modesti, Pietro Amedeo/B-2638-2012; Bilo, Grzegorz/J-8694-2016 OI Modesti, Pietro Amedeo/0000-0002-9511-2173; Bilo, Grzegorz/0000-0002-5104-9176; Revera, Miriam/0000-0002-3388-1858; caravita, sergio/0000-0002-3003-6499; Parati, Gianfranco/0000-0001-9402-7439; Faini, Andrea/0000-0002-8924-8234 NR 40 TC 13 Z9 14 U1 3 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD AUG 15 PY 2013 VL 188 IS 2 BP 223 EP 228 DI 10.1016/j.resp.2013.04.005 PG 6 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 204YU UT WOS:000323408000018 PM 23619193 ER PT J AU Baldwin, LM Andrilla, CHA Porter, MP Rosenblatt, RA Patel, S Doescher, MP AF Baldwin, Laura-Mae Andrilla, C. Holly A. Porter, Michael P. Rosenblatt, Roger A. Patel, Shilpen Doescher, Mark P. TI Treatment of early-stage prostate cancer among rural and urban patients SO CANCER LA English DT Article DE prostatic neoplasms; rural population; health care quality; access; and evaluation; SEER Program ID BREAST-CANCER; RADIATION-THERAPY; TRAVEL DISTANCE; TREATMENT CHOICES; RADIOTHERAPY; MASTECTOMY; OUTCOMES; RECEIPT; CARCINOMA; SURVIVAL AB BACKGROUND: Geographic barriers and limited availability of cancer specialists may influence early prostate cancer treatment options for rural men. This study compares receipt of different early prostate cancer treatments between rural and urban patients. METHODS: Using 2004-2006 SEER Limited-Use Data, 51,982 early prostate cancer patients were identified (T1c, T2a, T2b, T2c, T2NOS; no metastases) who were most likely to benefit from definitive treatment (<75 years old, Gleason score<8, PSA <= 20). Definitive treatment included radical prostatectomy, daily external beam radiation for 5 to 8 weeks, brachytherapy, or combination external beam radiation/brachytherapy. Adjusted definitive treatment rates were calculated by rural-urban residence overall, and for different sociodemographic and cancer characteristics, and different states based on logistic regression analyses, using general estimating equation methods to account for clustering by county. RESULTS: Adjusted definitive treatment rates were lower for rural (83.7%) than urban (87.1%) patients with early-stage prostate cancer (P <= .01). Rural men were more likely than urban men to receive non-definitive surgical treatment and no initial treatment. The lowest definitive treatment rates were among rural subgroups: 70 to 74 years (73.9%), African Americans (75.6%), American Indians/Alaska Natives (77.8%), single/separated/divorced (76.8%), living in New Mexico (69.3%), and living in counties with persistent poverty (79.6%). CONCLUSIONS: Between 2004 and 2006, this adjusted analysis found that men who were living in rural areas were less likely to receive definitive treatment for their early-stage prostate cancer than those living in urban areas. Certain rural patient groups with prostate cancer need particular attention to ensure their access to appropriate treatment. Rural providerss, rural health care systems, and cancer advocacy and support organizations should ensure resources are in place so that the most vulnerable rural groups (men between 60 and 74 years of age; African American men; men who are single, separated, or divorced; and men living in rural New Mexico) can make informed prostate cancer treatment choices based on their preferences. Cancer 2013; 119: 3067-75. (C) 2013 American Cancer Society. C1 [Baldwin, Laura-Mae; Andrilla, C. Holly A.; Rosenblatt, Roger A.] Univ Washington, Dept Family Med, WWAMI Rural Hlth Res Ctr, Seattle, WA 98195 USA. [Porter, Michael P.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Porter, Michael P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Patel, Shilpen] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. [Doescher, Mark P.] Univ Oklahoma, Hlth Serv Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA. [Doescher, Mark P.] Univ Oklahoma, Hlth Serv Ctr, Dept Family Med, Oklahoma City, OK USA. RP Baldwin, LM (reprint author), Univ Washington, Dept Family Med, Box 354982, Seattle, WA 98195 USA. EM lmb@uw.edu FU federal Office of Rural Health Policy, Health Resources and Services Administration, Department of Health and Human Services FX This University of Washington Rural Health Research Center study was supported by the federal Office of Rural Health Policy, Health Resources and Services Administration, Department of Health and Human Services. This article is the result of work supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 31 TC 10 Z9 10 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD AUG 15 PY 2013 VL 119 IS 16 BP 3067 EP 3075 DI 10.1002/cncr.28037 PG 9 WC Oncology SC Oncology GA 194KQ UT WOS:000322632400020 PM 23765584 ER PT J AU Vick, A Estrada, CA Rodriguez, JM AF Vick, Amanda Estrada, Carlos A. Rodriguez, J. Martin TI Clinical Reasoning for the Infectious Disease Specialist: A Primer to Recognize Cognitive Biases SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE cognitive biases; clinical reasoning; histoplasmosis; granulomatosis with polyangiitis ID DIAGNOSTIC ERROR; EDUCATIONAL-STRATEGIES; MEDICINE; MODEL AB Infectious disease specialists are frequently consulted for diagnostic and therapeutic advice on challenging cases. When evaluating patients, the infectious disease specialist is well positioned to offer an appropriate diagnostic approach but is also at risk of not recognizing the correct diagnosis for a variety of reasons. We believe it is important to provide infectious disease specialists and trainees with a fundamental understanding of diagnostic errors, clinical reasoning, and cognitive biases. We present 2 cases demonstrating common cognitive biases leading to diagnostic errors, and we reflect on strategies that may aid in their prevention. We hope to provide knowledge and tools that may help prevent diagnostic errors in the future. C1 [Vick, Amanda] Tinsley Harrison Internal Med Residency Program, Birmingham, AL USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA. [Rodriguez, J. Martin] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA. RP Rodriguez, JM (reprint author), Univ Alabama Birmingham, Div Infect Dis, THT 229 Tinsley Harrison Tower,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mrodri2@uab.edu FU Merck Co, Inc. FX J. M. R. has received research support from Merck & Co, Inc. All other authors report no potential conflicts. NR 24 TC 3 Z9 3 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2013 VL 57 IS 4 BP 573 EP 578 DI 10.1093/cid/cit248 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 190LV UT WOS:000322342500022 PM 23595833 ER PT J AU Korvatska, O Strand, NS Berndt, JD Strovas, T Chen, DH Leverenz, JB Kiianitsa, K Mata, IF Karakoc, E Greenup, JL Bonkowski, E Chuang, J Moon, RT Eichler, EE Nickerson, DA Zabetian, CP Kraemer, BC Bird, TD Raskind, WH AF Korvatska, Olena Strand, Nicholas S. Berndt, Jason D. Strovas, Tim Chen, Dong-Hui Leverenz, James B. Kiianitsa, Konstantin Mata, Ignacio F. Karakoc, Emre Greenup, J. Lynne Bonkowski, Emily Chuang, Joseph Moon, Randall T. Eichler, Evan E. Nickerson, Deborah A. Zabetian, Cyrus P. Kraemer, Brian C. Bird, Thomas D. Raskind, Wendy H. TI Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS) SO HUMAN MOLECULAR GENETICS LA English DT Article ID H+-ATPASE; (PRO)RENIN RECEPTOR; MENTAL-RETARDATION; PRORENIN RECEPTOR; MUTATIONS; REPEATS; PROTEIN; BAFILOMYCIN-A1; ACIDIFICATION; INHIBITOR AB We report a novel gene for a parkinsonian disorder. X-linked parkinsonism with spasticity (XPDS) presents either as typical adult onset Parkinsons disease or earlier onset spasticity followed by parkinsonism. We previously mapped the XPDS gene to a 28 Mb region on Xp11.2X13.3. Exome sequencing of one affected individual identified five rare variants in this region, of which none was missense, nonsense or frame shift. Using patient-derived cells, we tested the effect of these variants on expression/splicing of the relevant genes. A synonymous variant in ATP6AP2, c.345CT (p.S115S), markedly increased exon 4 skipping, resulting in the overexpression of a minor splice isoform that produces a protein with internal deletion of 32 amino acids in up to 50 of the total pool, with concomitant reduction of isoforms containing exon 4. ATP6AP2 is an essential accessory component of the vacuolar ATPase required for lysosomal degradative functions and autophagy, a pathway frequently affected in Parkinsons disease. Reduction of the full-size ATP6AP2 transcript in XPDS cells and decreased level of ATP6AP2 protein in XPDS brain may compromise V-ATPase function, as seen with siRNA knockdown in HEK293 cells, and may ultimately be responsible for the pathology. Another synonymous mutation in the same exon, c.321CT (p.D107D), has a similar molecular defect of exon inclusion and causes X-linked mental retardation Hedera type (MRXSH). Mutations in XPDS and MRXSH alter binding sites for different splicing factors, which may explain the marked differences in age of onset and manifestations. C1 [Korvatska, Olena; Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Strand, Nicholas S.; Berndt, Jason D.; Moon, Randall T.; Kraemer, Brian C.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Chen, Dong-Hui; Leverenz, James B.; Mata, Ignacio F.; Bonkowski, Emily; Zabetian, Cyrus P.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Kiianitsa, Konstantin] Univ Washington, Dept Immunol, Seattle, WA 98195 USA. [Karakoc, Emre; Eichler, Evan E.; Nickerson, Deborah A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Chuang, Joseph; Bird, Thomas D.; Raskind, Wendy H.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA. [Kraemer, Brian C.] Univ Washington, Dept Med, Gerontol Div, Seattle, WA 98195 USA. [Strovas, Tim; Leverenz, James B.; Mata, Ignacio F.; Greenup, J. Lynne; Zabetian, Cyrus P.; Kraemer, Brian C.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Leverenz, James B.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Leverenz, James B.; Raskind, Wendy H.] Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr VISN 20, Seattle, WA 98108 USA. [Moon, Randall T.; Eichler, Evan E.] Howard Hughes Med Inst, Seattle, WA USA. RP Korvatska, O (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM ok5@u.washington.edu; wendyrun@uw.edu RI Berndt, Jason/M-3681-2013; Moon, Randall/B-1743-2014 OI Berndt, Jason/0000-0002-7388-6792; Moon, Randall/0000-0002-9352-1408; Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veteran Affairs (VISN-20 MIRECC VA Puget Sound Health Care System); Department of Veteran Affairs (VA Merit Award) [1I01BX000531]; Department of Veteran Affairs (GRECC); Department of Veteran Affairs (PADRECC VA Puget Sound Health Care System, VA Merit Award) [I01BX000877]; American Recovery and Reinvestment Act funds, National Institutes of Health [RC2HG005608]; National Institutes of Health [T32 GM00727, P01 GM081619, R01NS069719, R01NS064131, R01 NS065070]; National Heart, Lung and Blood Institute [HL 1029230, HL 102924, HL-102925, HL 102926, HL-103010] FX This work was supported by the Department of Veteran Affairs (VISN-20 MIRECC VA Puget Sound Health Care System and VA Merit Award for T. D. B. and W. H. R., GRECC and PADRECC VA Puget Sound Health Care System, VA Merit Award I01BX000877 for B. C. K. and VA Merit Award 1I01BX000531 for C.P.Z.), the American Recovery and Reinvestment Act funds [through RC2HG005608 from the National Institutes of Health to D.A.N. and W. H. R.] and the National Institutes of Health (T32 GM00727 and P01 GM081619 to N.S.S., R01NS069719 to W. H. R., R01NS064131 to B. C. K. and R01 NS065070 to C.P.Z.). We would also like to recognize the following ongoing studies that produced and provided exome variant calls for comparison: the National Heart, Lung and Blood Institute [Lung GO Cohort Sequencing Project (HL 1029230) and the Women's Health Initiative Sequencing Project (HL 102924)], the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL 102926) and the Heart GO Sequencing Project (HL-103010). NR 34 TC 24 Z9 25 U1 3 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD AUG 15 PY 2013 VL 22 IS 16 BP 3259 EP 3268 DI 10.1093/hmg/ddt180 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 190LK UT WOS:000322341300008 PM 23595882 ER PT J AU Morrison, VA Oxman, MN Levin, MJ Schmader, KE Guatelli, JC Betts, RF Gelb, LD Pachucki, CT Keay, SK Menzies, B Griffin, MR Kauffman, CA Marques, AR Toney, JF Simberkoff, MS Serrao, R Arbeit, RD Gnann, JW Greenberg, RN Holodniy, M Keitel, WA Yeh, SS Davis, LE Crawford, GE Neuzil, KM Johnson, GR Zhang, JH Harbecke, R Chan, ISF Keller, PM Williams, HM Boardman, KD Silber, JL Annunziato, PW AF Morrison, Vicki A. Oxman, Michael N. Levin, Myron J. Schmader, Kenneth E. Guatelli, John C. Betts, Robert F. Gelb, Larry D. Pachucki, Constance T. Keay, Susan K. Menzies, Barbara Griffin, Marie R. Kauffman, Carol A. Marques, Adriana R. Toney, John F. Simberkoff, Michael S. Serrao, Richard Arbeit, Robert D. Gnann, John W. Greenberg, Richard N. Holodniy, Mark Keitel, Wendy A. Yeh, Shingshing S. Davis, Larry E. Crawford, George E. Neuzil, Kathy M. Johnson, Gary R. Zhang, Jane H. Harbecke, Rith Chan, Ivan S. F. Keller, Paul M. Williams, Heather M. Boardman, Kathy D. Silber, Jeffrey L. Annunziato, Paula W. CA Shingles Prevention Study Grp TI Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE zoster vaccine; herpes zoster; zoster vaccine safety; zoster vaccine in elderly persons; ACIP recommendations ID IMMUNE-RESPONSES; VIRUS; TRIAL AB After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). Methods. A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. Results. The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was <5 years for approximately 80% of recipients. The proportion of vaccinated SPS placebo recipients with prior HZ who developed >= 1 SAE (0.95%) was not significantly different from that of vaccinated SPS placebo recipients with no prior history of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable. Conclusions. These results demonstrate that the general safety of zoster vaccine in older persons is not altered by a recent history of documented HZ, supporting the safety aspect of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendation to administer zoster vaccine to all persons >= 60 years of age with no contraindications, regardless of a prior history of HZ. C1 [Morrison, Vicki A.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Morrison, Vicki A.] Univ Minnesota, Minneapolis, MN USA. [Oxman, Michael N.; Guatelli, John C.; Harbecke, Rith; Williams, Heather M.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Oxman, Michael N.; Guatelli, John C.; Harbecke, Rith; Williams, Heather M.] Univ Calif San Diego, San Diego, CA 92103 USA. [Levin, Myron J.] Univ Colorado Denver, Denver, CO USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, GRECC, Durham, NC USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Durham, NC USA. [Betts, Robert F.] Univ Rochester, New York, NY USA. [Gelb, Larry D.] Vet Affairs Med Ctr, St Louis, MO USA. [Pachucki, Constance T.] Hines Vet Affairs Med Ctr, Hines, IL USA. [Keay, Susan K.] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD USA. [Keay, Susan K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Menzies, Barbara; Neuzil, Kathy M.] Vet Affairs Med Ctr Puget Sound, Seattle, WA USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kauffman, Carol A.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Marques, Adriana R.] NIAID, Bethesda, MD 20892 USA. [Toney, John F.] Vet Affairs Med Ctr, Tampa, FL USA. [Simberkoff, Michael S.] VA New York Harbor Healthcare Syst, New York, NY USA. [Simberkoff, Michael S.] NYU, Sch Med, New York, NY USA. [Serrao, Richard; Arbeit, Robert D.] Boston Univ, Boston, MA 02215 USA. [Gnann, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Gnann, John W.] Univ Alabama Birmingham, Birmingham, AL USA. [Greenberg, Richard N.] Univ Kentucky, Sch Med, Lexington, KY 40506 USA. [Holodniy, Mark] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Keitel, Wendy A.] Baylor Coll Med, Houston, TX 77030 USA. [Yeh, Shingshing S.] Northport Vet Affairs Med Ctr, Northport, NY USA. [Davis, Larry E.] Vet Affairs Med Ctr, Albuquerque, NM USA. [Crawford, George E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Johnson, Gary R.; Zhang, Jane H.] Dept Vet Affairs, Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA. [Chan, Ivan S. F.; Keller, Paul M.; Silber, Jeffrey L.; Annunziato, Paula W.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA. [Boardman, Kathy D.] Dept Vet Affairs, Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA. RP Morrison, VA (reprint author), VAMC, Hematol Oncol Sect, 111E,1 Vet Dr, Minneapolis, MN 55417 USA. EM morri002@umn.edu RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431; Serrao, Richard/0000-0002-7440-8645 FU James R. and Jesse V. Scott Fund for Shingles Research FX The study was conducted by the Cooperative Studies Program, Department of Veterans Affairs, Office of Research and Development. Additional support was provided by Merck Sharp & Dohme, by the James R. and Jesse V. Scott Fund for Shingles Research, and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Data management and analysis support was provided at West Haven CSPCC by Karen Dellert and Kathy Newvine. NR 9 TC 18 Z9 18 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2013 VL 208 IS 4 BP 559 EP 563 DI 10.1093/infdis/jit182 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 191KO UT WOS:000322412100005 PM 23633406 ER PT J AU French, AL Evans, CT Agniel, DM Cohen, MH Peters, M Landay, AL Desai, SN AF French, Audrey L. Evans, Charlesnika T. Agniel, Denis M. Cohen, Mardge H. Peters, Marion Landay, Alan L. Desai, Seema N. TI Microbial Translocation and Liver Disease Progression in Women Coinfected With HIV and Hepatitis C Virus SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; hepatitis C; microbial translocation; fibrosis; liver disease progression; soluble CD14 ID HUMAN-IMMUNODEFICIENCY-VIRUS; PLATELET RATIO INDEX; GASTROINTESTINAL-TRACT; INFECTION; FIBROSIS; LIPOPOLYSACCHARIDE; THERAPY; FAILURE; PERFORMANCE; PREDICTION AB Background. Microbial translocation has been implicated in the pathogenesis of liver fibrosis and cirrhosis. We sought to determine whether markers of microbial translocation are associated with liver disease progression during coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Methods. We measured serial plasma lipopolysaccharide (LPS), endotoxin core antibody, intestinal fatty acid-binding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), interleukin 10, and tumor necrosis factor a (TNF-alpha) levels over a 5-year period in 44 HIV/HCV-coinfected women, 21 of whom experienced liver disease progression and 23 were nonprogressors. Results. While LPS levels did not differ significantly over time between progressors and nonprogressors (P = .60), progressors had significantly higher plasma levels of sCD14, a marker of monocyte activation by LPS, at the first time point measured (P = .03) and throughout the study period (P = .001); progressors also had higher IL-6 and I-FABP levels over the 5-year study period (P = .02 and .03, respectively). The associations between progression and sCD14, I-FABP, and IL-6 levels were unchanged in models controlling for HIV RNA and CD4(+) T-cell count. Conclusions. Although LPS levels did not differ between liver disease progressors and nonprogressors, the association of sCD14, I-FABP, and IL-6 levels with liver disease progression suggests that impairment of gut epithelial integrity and consequent microbial translocation may play a role in the complex interaction of HIV and HCV pathogenesis. C1 [French, Audrey L.; Agniel, Denis M.; Cohen, Mardge H.] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Dept Med, Chicago, IL 60612 USA. [French, Audrey L.; Cohen, Mardge H.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Landay, Alan L.; Desai, Seema N.] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA. [Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Evans, Charlesnika T.] US Dept Vet Affairs, Hines, IL USA. [Peters, Marion] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP French, AL (reprint author), John H Stroger Jr Hosp Cook Cty, Div Infect Dis, 1900 W Polk St,Rm 1243, Chicago, IL 60612 USA. EM audrey_French@rush.edu FU Chicago Consortium of the Women's Interagency HIV Study; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [MO1-RR-00071, MO1-RR-00079, MO1-RR-00083]; Chicago Developmental Center for AIDS Research [P30 AI-082151] FX This work was supported by the Chicago Consortium of the Women's Interagency HIV Study, which is funded by the National Institute of Allergy and Infectious Diseases (grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and the National Institute of Child Health and Human Development (grant UO1-HD-32632); the National Cancer Institute; the National Institute on Drug Abuse; the National Institute on Deafness and Other Communication Disorders; the National Center for Research Resources (grants MO1-RR-00071, MO1-RR-00079, and MO1-RR-00083); and the Chicago Developmental Center for AIDS Research (grant P30 AI-082151 to A. L. F.). NR 43 TC 21 Z9 21 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2013 VL 208 IS 4 BP 679 EP 689 DI 10.1093/infdis/jit225 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 191KO UT WOS:000322412100018 PM 23687224 ER PT J AU London, MJ Schwartz, GG Henderson, WG AF London, Martin J. Schwartz, Gregory G. Henderson, William G. TI Mortality After Perioperative beta-Blocker Use in Noncardiac Surgery Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [London, Martin J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Schwartz, Gregory G.] Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA. [Henderson, William G.] Colorado Sch Publ Hlth, Hlth Outcomes Program, Aurora, CO USA. RP London, MJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM londonm@anesthe-sia.ucsf.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 14 PY 2013 VL 310 IS 6 BP 645 EP 645 DI 10.1001/jama.2013.8522 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 200HI UT WOS:000323058400026 PM 23942690 ER PT J AU Dhaliwal, G Detsky, AS AF Dhaliwal, Gurpreet Detsky, Allan S. TI The Evolution of the Master Diagnostician SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PHYSICIANS C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Detsky, Allan S.] Univ Toronto, Dept Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada. [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada. RP Detsky, AS (reprint author), Mt Sinai Hosp, 600 Univ Ave,Room 429, Toronto, ON M5G 1X5, Canada. EM adetsky@mtsinai.on.ca NR 9 TC 4 Z9 4 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 14 PY 2013 VL 310 IS 6 BP 579 EP 580 DI 10.1001/jama.2013.7572 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 200HI UT WOS:000323058400009 PM 23942674 ER PT J AU Murray, CJL Abraham, J Ali, MK Alvarado, M Atkinson, C Baddour, LM Bartels, DH Benjamin, EJ Bhalla, K Birbeck, G Bolliger, I Burstein, R Carnahan, E Chen, HL Chou, D Chugh, SS Cohen, A Colson, KE Cooper, LT Couser, W Criqui, MH Dabhadkar, KC Dahodwala, N Danaei, G Dellavalle, RP Des Jarlais, DC Dicker, D Ding, EL Dorsey, R Duber, H Ebel, BE Engell, RE Ezzati, M Felson, DT Finucane, MM Flaxman, S Flaxman, AD Fleming, T Forouzanfar, MH Freedman, G Freeman, MK Gabriel, SE Gakidou, E Gillum, RF Gonzalez-Medina, D Gosselin, R Grant, B Gutierrez, HR Hagan, H Havmoeller, R Hoffman, H Jacobsen, KH James, SL Jasrasaria, R Jayaraman, S Johns, N Kassebaum, N Khatibzadeh, S Knowlton, LM Lan, Q Leasher, JL Lim, S Lin, JK Lipshultz, SE London, S Lozano, R Lu, Y MacIntyre, MF Mallinger, L McDermott, MM Meltzer, M Mensah, GA Michaud, C Miller, TR Mock, C Moffitt, TE Mokdad, AA Mokdad, AH Moran, AE Mozaffarian, D Murphy, T Naghavi, M Narayan, KMV Nelson, RG Olives, C Omer, SB Ortblad, K Ostro, B Pelizzari, PM Phillips, D Pope, CA Raju, M Ranganathan, D Razavi, H Ritz, B Rivara, FP Roberts, T Sacco, RL Salomon, JA Sampson, U Sanman, E Sapkota, A Schwebel, DC Shahraz, S Shibuya, K Shivakoti, R Silberberg, D Singh, GM Singh, D Singh, JA Sleet, DA Steenland, K Tavakkoli, M Taylor, JA Thurston, GD Towbin, JA Vavilala, MS Vos, T Wagner, GR Weinstock, MA Weisskopf, MG Wilkinson, JD Wulf, S Zabetian, A Lopez, AD AF Murray, Christopher J. L. Abraham, Jerry Ali, Mohammed K. Alvarado, Miriam Atkinson, Charles Baddour, Larry M. Bartels, David H. Benjamin, Emelia J. Bhalla, Kavi Birbeck, Gretchen Bolliger, Ian Burstein, Roy Carnahan, Emily Chen, Honglei Chou, David Chugh, Sumeet S. Cohen, Aaron Colson, K. Ellicott Cooper, Leslie T. Couser, William Criqui, Michael H. Dabhadkar, Kaustubh C. Dahodwala, Nabila Danaei, Goodarz Dellavalle, Robert P. Des Jarlais, Don C. Dicker, Daniel Ding, Eric L. Dorsey, Ray Duber, Herbert Ebel, Beth E. Engell, Rebecca E. Ezzati, Majid Felson, David T. Finucane, Mariel M. Flaxman, Seth Flaxman, Abraham D. Fleming, Thomas Forouzanfar, Mohammad H. Freedman, Greg Freeman, Michael K. Gabriel, Sherine E. Gakidou, Emmanuela Gillum, Richard F. Gonzalez-Medina, Diego Gosselin, Richard Grant, Bridget Gutierrez, Hialy R. Hagan, Holly Havmoeller, Rasmus Hoffman, Howard Jacobsen, Kathryn H. James, Spencer L. Jasrasaria, Rashmi Jayaraman, Sudha Johns, Nicole Kassebaum, Nicholas Khatibzadeh, Shahab Knowlton, Lisa Marie Lan, Qing Leasher, Janet L. Lim, Stephen Lin, John Kent Lipshultz, Steven E. London, Stephanie Lozano, Rafael Lu, Yuan MacIntyre, Michael F. Mallinger, Leslie McDermott, Mary M. Meltzer, Michele Mensah, George A. Michaud, Catherine Miller, Ted R. Mock, Charles Moffitt, Terrie E. Mokdad, Ali A. Mokdad, Ali H. Moran, Andrew E. Mozaffarian, Dariush Murphy, Tasha Naghavi, Mohsen Narayan, K. M. Venkat Nelson, Robert G. Olives, Casey Omer, Saad B. Ortblad, Katrina Ostro, Bart Pelizzari, Pamela M. Phillips, David Pope, C. Arden, III Raju, Murugesan Ranganathan, Dharani Razavi, Homie Ritz, Beate Rivara, Frederick P. Roberts, Thomas Sacco, Ralph L. Salomon, Joshua A. Sampson, Uchechukwu Sanman, Ella Sapkota, Amir Schwebel, David C. Shahraz, Saeid Shibuya, Kenji Shivakoti, Rupak Silberberg, Donald Singh, Gitanjali M. Singh, David Singh, Jasvinder A. Sleet, David A. Steenland, Kyle Tavakkoli, Mohammad Taylor, Jennifer A. Thurston, George D. Towbin, Jeffrey A. Vavilala, Monica S. Vos, Theo Wagner, Gregory R. Weinstock, Martin A. Weisskopf, Marc G. Wilkinson, James D. Wulf, Sarah Zabetian, Azadeh Lopez, Alan D. CA Us Burden Dis Collaborators TI The State of US Health, 1990-2010 Burden of Diseases, Injuries, and Risk Factors SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; ADJUSTED LIFE YEARS; GLOBAL BURDEN; SYSTEMATIC ANALYSIS; UNITED-STATES; PUBLIC-HEALTH; CARDIOVASCULAR-DISEASE; BUILT ENVIRONMENT; PHYSICAL-ACTIVITY; BLOOD-PRESSURE AB IMPORTANCE Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy. OBJECTIVES To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries. DESIGN We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries. Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age. Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health. Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs. Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs. Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages. RESULTS US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years. The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury. Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls. The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders. As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs. The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use. Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th. CONCLUSIONS AND RELEVANCE From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable. However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations. C1 [Murray, Christopher J. L.; Alvarado, Miriam; Atkinson, Charles; Bolliger, Ian; Burstein, Roy; Carnahan, Emily; Chou, David; Colson, K. Ellicott; Dicker, Daniel; Duber, Herbert; Engell, Rebecca E.; Flaxman, Abraham D.; Gakidou, Emmanuela; Gonzalez-Medina, Diego; James, Spencer L.; Jasrasaria, Rashmi; Johns, Nicole; Lim, Stephen; MacIntyre, Michael F.; Mallinger, Leslie; Mokdad, Ali A.; Mokdad, Ali H.; Murphy, Tasha; Naghavi, Mohsen; Ortblad, Katrina; Phillips, David; Ranganathan, Dharani; Roberts, Thomas; Sanman, Ella; Vos, Theo; Wulf, Sarah] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Couser, William; Ebel, Beth E.; Kassebaum, Nicholas; Mock, Charles; Olives, Casey; Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Seattle, WA 98195 USA. [Abraham, Jerry] Univ Texas San Antonio, Sch Med, San Antonio, TX USA. [Omer, Saad B.; Steenland, Kyle] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ali, Mohammed K.; Dabhadkar, Kaustubh C.; Narayan, K. M. Venkat; Zabetian, Azadeh] Emory Univ, Atlanta, GA 30322 USA. [Baddour, Larry M.; Gabriel, Sherine E.] Mayo Clin, Rochester, MN USA. [Danaei, Goodarz; Ding, Eric L.; Finucane, Mariel M.; Khatibzadeh, Shahab; Knowlton, Lisa Marie; Lin, John Kent; Lu, Yuan; Singh, Gitanjali M.; Tavakkoli, Mohammad; Weisskopf, Marc G.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Bartels, David H.; Jayaraman, Sudha; Mozaffarian, Dariush] Harvard Univ, Sch Med, Boston, MA USA. [Bhalla, Kavi] Harvard Univ, Boston, MA 02115 USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Felson, David T.] Boston Univ, Boston, MA 02215 USA. [Birbeck, Gretchen] Michigan State Univ, E Lansing, MI USA. [Chen, Honglei; London, Stephanie] NIEHS, Res Triangle Pk, NC 27709 USA. [Lan, Qing] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Grant, Bridget; Hoffman, Howard; Mensah, George A.] NIH, Bethesda, MD 20892 USA. [Nelson, Robert G.] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA. [Wagner, Gregory R.] NIOSH, Baltimore, MD USA. [Chugh, Sumeet S.; Havmoeller, Rasmus] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Havmoeller, Rasmus] Karolinska Inst, Stockholm, Sweden. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Cooper, Leslie T.] Loyola Univ, Sch Med, Chicago, IL 60611 USA. [Criqui, Michael H.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Dahodwala, Nabila; Silberberg, Donald] Univ Penn, Philadelphia, PA 19104 USA. [Dellavalle, Robert P.] Denver VA Med Ctr, Denver, CO USA. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Dorsey, Ray; Shivakoti, Rupak] Johns Hopkins Univ, Baltimore, MD USA. [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostatist, MRC HPA Ctr Environm & Hlth, London, England. [Flaxman, Seth] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Gillum, Richard F.] Howard Univ, Coll Med, Washington, DC USA. [Gosselin, Richard] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gutierrez, Hialy R.] Mailman Sch Publ Hlth, New York, NY USA. [Moran, Andrew E.] Columbia Univ, New York, NY USA. [Hagan, Holly; Thurston, George D.] NYU, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Lipshultz, Steven E.; Sacco, Ralph L.; Wilkinson, James D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Lopez, Alan D.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Lozano, Rafael] Inst Nacl Salud Publ, Ctr Invest Sistemas Salud, Cuernavaca, Morelos, Mexico. [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Michaud, Catherine] China Med Board, Boston, MA USA. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Moffitt, Terrie E.] Duke Univ, Durham, NC USA. [Mozaffarian, Dariush] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ostro, Bart] Calif Environm Protect Agcy, Sacramento, CA USA. [Pelizzari, Pamela M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Pope, C. Arden, III] Brigham Young Univ, Provo, UT 84602 USA. [Raju, Murugesan] Univ Missouri, Mason Eye Inst, Columbia, MO 65211 USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Ritz, Beate] Univ Calif Los Angeles, Los Angeles, CA USA. [Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN 37235 USA. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Shahraz, Saeid] Brandeis Univ, Waltham, MA USA. [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Tokyo, Japan. [Singh, David] Queens Med Ctr, Honolulu, HI USA. [Sleet, David A.] Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Taylor, Jennifer A.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Towbin, Jeffrey A.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Weinstock, Martin A.] Brown Univ, Providence, RI 02912 USA. RP Murray, CJL (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Ste 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI ; Lopez, Alan D/F-1487-2010; Salomon, Joshua/D-3898-2009; Dellavalle, Robert/L-2020-2013; Moffitt, Terrie/D-5295-2011; Narayan, K.M. Venkat /J-9819-2012; Ritz, Beate/E-3043-2015; Sapkota, Amir/A-5968-2011; Bolliger, Ian/C-4207-2016; Jacobsen, Kathryn/B-5857-2008 OI London, Stephanie/0000-0003-4911-5290; Lopez, Alan D/0000-0001-5818-6512; Mock, Charles/0000-0002-0564-568X; Ding, Eric/0000-0002-5881-8097; singh, jasvinder/0000-0003-3485-0006; Johns, Nicole/0000-0003-4513-4582; Mensah, George/0000-0002-0387-5326; Benjamin, Emelia/0000-0003-4076-2336; Miller, Ted/0000-0002-0958-2639; Chen, Honglei/0000-0003-3446-7779; Salomon, Joshua/0000-0003-3929-5515; Dellavalle, Robert/0000-0001-8132-088X; Moffitt, Terrie/0000-0002-8589-6760; Narayan, K.M. Venkat /0000-0001-8621-5405; Pelizzari, Pamela/0000-0002-6992-9462; Ranganathan, Dharani/0000-0001-6506-2825; Bolliger, Ian/0000-0001-8055-297X; Jacobsen, Kathryn/0000-0002-4198-6246 FU National Institutes of Health, the National Institute of Environmental Health Sciences; Bill and Melinda Gates Foundation FX This study is supported in part by the Intramural Program of the National Institutes of Health, the National Institute of Environmental Health Sciences, and in part by the Bill and Melinda Gates Foundation. NR 81 TC 564 Z9 569 U1 39 U2 250 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 14 PY 2013 VL 310 IS 6 BP 591 EP 608 DI 10.1001/jama.2013.13805 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 200HI UT WOS:000323058400015 PM 23842577 ER PT J AU Gross, R Bellamy, SL Strom, BL AF Gross, Robert Bellamy, Scarlett L. Strom, Brian L. TI Does Managed Problem Solving Work and in What Setting? Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Gross, Robert; Bellamy, Scarlett L.; Strom, Brian L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gross, Robert; Bellamy, Scarlett L.; Strom, Brian L.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gross, Robert] Univ Penn, Div Infect Dis, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Gross, R (reprint author), Univ Penn, Dept Med, Div Infect Dis, Ctr Clin Epidemiol & Biostat,Perelman Sch Med, 423 Guardian Dr,804 Blockley Hall, Philadelphia, PA 19104 USA. EM grossr@mail.med.upenn.edu FU NIMH NIH HHS [R01 MH067498] NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG 12 PY 2013 VL 173 IS 15 BP 1475 EP 1476 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 218NY UT WOS:000324440400029 PM 23939524 ER PT J AU Makam, AN Lanham, HJ Batchelor, K Samal, L Moran, B Howell-Stampley, T Kirk, L Cherukuri, M Santini, N Leykum, LK Halm, EA AF Makam, Anil N. Lanham, Holly J. Batchelor, Kim Samal, Lipika Moran, Brett Howell-Stampley, Temple Kirk, Lynne Cherukuri, Manjula Santini, Noel Leykum, Luci K. Halm, Ethan A. TI Use and satisfaction with key functions of a common commercial electronic health record: a survey of primary care providers SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article DE Electronic health record (EHR); Attitude of health personnel; Attitude to computers; Primary care; Efficiency; Quality of care; Medical informatics/utilization ID DECISION-SUPPORT-SYSTEMS; INFORMATION-TECHNOLOGY; AMBULATORY-CARE; STATEWIDE-SURVEY; QUALITY; PHYSICIANS; IMPACT; DOCUMENTATION; EFFICIENCY AB Background: Despite considerable financial incentives for adoption, there is little evidence available about providers' use and satisfaction with key functions of electronic health records (EHRs) that meet "meaningful use" criteria. Methods: We surveyed primary care providers (PCPs) in 11 general internal medicine and family medicine practices affiliated with 3 health systems in Texas about their use and satisfaction with performing common tasks (documentation, medication prescribing, preventive services, problem list) in the Epic EHR, a common commercial system. Most practices had greater than 5 years of experience with the Epic EHR. We used multivariate logistic regression to model predictors of being a structured documenter, defined as using electronic templates or prepopulated dot phrases to document at least two of the three note sections (history, physical, assessment and plan). Results: 146 PCPs responded (70%). The majority used free text to document the history (51%) and assessment and plan (54%) and electronic templates to document the physical exam (57%). Half of PCPs were structured documenters (55%) with family medicine specialty (adjusted OR 3.3, 95% CI, 1.4-7.8) and years since graduation (nonlinear relationship with youngest and oldest having lowest probabilities) being significant predictors. Nearly half (43%) reported spending at least one extra hour beyond each scheduled half-day clinic completing EHR documentation. Three-quarters were satisfied with documenting completion of pneumococcal vaccinations and half were satisfied with documenting cancer screening (57% for breast, 45% for colorectal, and 46% for cervical). Fewer were satisfied with reminders for overdue pneumococcal vaccination (48%) and cancer screening (38% for breast, 37% for colorectal, and 31% for cervical). While most believed the problem list was helpful (70%) and kept an up-to-date list for their patients (68%), half thought they were unreliable and inaccurate (51%). Conclusions: Dissatisfaction with and suboptimal use of key functions of the EHR may mitigate the potential for EHR use to improve preventive health and chronic disease management. Future work should optimize use of key functions and improve providers' time efficiency. C1 [Makam, Anil N.; Batchelor, Kim; Moran, Brett; Howell-Stampley, Temple; Kirk, Lynne; Santini, Noel; Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Lanham, Holly J.; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. [Lanham, Holly J.; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Samal, Lipika] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02120 USA. [Cherukuri, Manjula] Univ North Texas Hlth Sci Ctr, Dept Family & Community Med, Ft Worth, TX 76105 USA. [Santini, Noel] Parkland Hlth & Hosp Syst, Community Med Div, Dallas, TX 75235 USA. RP Makam, AN (reprint author), Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM anil.makam@utsouthwestern.edu OI Makam, Anil/0000-0001-7072-9946 FU University of Texas Chancellors Fellow for Health Information Technology program; NRSA training grant [T32HP19025-07-00] FX We would like to thank the primary care physicians who participated in this study. This study was supported by a grant from the University of Texas Chancellors Fellow for Health Information Technology program (PI, Halm). Much of Dr. Makam's work on this project was completed while he was a Primary Care Research Fellow at the University of California San Francisco, funded by an NRSA training grant (T32HP19025-07-00). Preliminary results of this study were presented at the Society of General Internal Medicine (SGIM) annual meeting in Orlando, Florida, in 2012. NR 26 TC 11 Z9 11 U1 3 U2 31 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD AUG 9 PY 2013 VL 13 AR 86 DI 10.1186/1472-6947-13-86 PG 7 WC Medical Informatics SC Medical Informatics GA 200HH UT WOS:000323058300001 PM 24070335 ER PT J AU Della Beffa, C Slansky, E Pommerenke, C Klawonn, F Li, JL Dai, L Schumacher, HR Pessler, F AF Della Beffa, Cristina Slansky, Elisabeth Pommerenke, Claudia Klawonn, Frank Li, Jialiang Dai, Lie Schumacher, H. Ralph, Jr. Pessler, Frank TI The Relative Composition of the Inflammatory Infiltrate as an Additional Tool for Synovial Tissue Classification SO PLOS ONE LA English DT Article ID WAR-VETERANS-ILLNESS; JOINT PAIN; ARTHRITIS; ARTHROPATHIES; BIOMARKER; SCORE AB Objectives: Traditionally, differences in absolute numbers of cells expressing a certain marker (e. g., positive staining cells per mm(2)) have been used in immunohistological synovial tissue classification. We have begun to evaluate the relative composition of the inflammatory infiltrates, i.e. percentages of inflammatory cell types in inflammatory infiltrates, as an alternate classification tool that may potentially improve tissue diagnostics, subgrouping in clinical trials, and understanding of pathogenesis of inflammatory and noninflammatory arthropathies. Methods: Synovial tissue specimens (normal synovium, n=15; orthopedic arthropathies, n=6; osteoarthritis, n=26; early undifferentiated arthritis, n=10; rheumatoid arthritis, n=26; chronic septic arthritis, n=11) were stained for CD15, CD68, CD3, CD20, and CD38. Densities of cells expressing a given marker were determined in the superficial subintima. Binary and multicategory receiver operating characteristic (ROC) analysis and naive Bayes classifier were used to compare the abilities of (1) the absolute densities of cells expressing a given marker (absolute method) with (2) the percentages of these cells in the inflammatory cell population (relative method) to differentiate among the six tissue classes. Results: The inflammatory infiltrates in normal synovium and the orthopedic arthropathies consisted almost exclusively of CD68+ and CD3+ cells. Notable fractions of CD20+ and CD38+ cells appeared in a subset of osteoarthritis samples, and increased further in early, rheumatoid and chronic septic arthritis. ROC analyses and naive Bayes classifier ranked the absolute method above the relative method in terms of overall discriminatory ability. The relative method became slightly superior when the samples were also stratified according to the total number of inflammatory cells/mm(2). Conclusions: This exploratory investigation featuring a variety of joint disorders revealed that measuring the relative proportions of inflammatory cell types may aid in synovial tissue classification if the samples are also stratified according to the intensity of inflammation. C1 [Della Beffa, Cristina; Klawonn, Frank] Helmholtz Ctr Infect Res, Dept Cellular Prote, Braunschweig, Germany. [Pommerenke, Claudia] Helmholtz Ctr Infect Res, Dept Infect Genet, Braunschweig, Germany. [Klawonn, Frank] Ostfalia Univ Appl Sci, Dept Comp Sci, Wolfenbuttel, Germany. [Slansky, Elisabeth; Li, Jialiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore. [Dai, Lie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou 510275, Guangdong, Peoples R China. [Schumacher, H. Ralph, Jr.] Philadelphia Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Pessler, Frank] TWINCORE Ctr Expt & Clin Infect Res, Res Grp Biomarkers Infect Dis, Hannover, Germany. RP Pessler, F (reprint author), TWINCORE Ctr Expt & Clin Infect Res, Res Grp Biomarkers Infect Dis, Hannover, Germany. EM frank.pessler@twincore.de RI Li, Jialiang/B-9132-2014 OI Li, Jialiang/0000-0002-9704-4135 FU International Collaboration Seed from the German Federal Ministry for Education and Science (International Office) [SGP 08/A01, SGP 09/1AP] FX Support is gratefully acknowledged from International Collaboration Seed Grant SGP 08/A01 and grant SGP 09/1AP "German-Singaporean Network for Rheumatology Research" from the German Federal Ministry for Education and Science (International Office). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 18 TC 2 Z9 2 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 8 PY 2013 VL 8 IS 8 AR e72494 DI 10.1371/journal.pone.0072494 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 201ER UT WOS:000323124000085 PM 23951325 ER PT J AU Cadenhead, KS Addington, J Cannon, TD Cornblatt, BA de la Fuente-Sandoval, C Mathalon, DH Perkins, DO Seidman, LJ Tsuang, M Walker, EF Woods, SW Bachman, P Belger, A Carrion, RE Donkers, FCL Duncan, E Johannesen, J Leon-Ortiz, P Light, G Mondragon, A Niznikiewicz, M Nunag, J Roach, BJ Solis-Vivanco, R AF Cadenhead, Kristin S. Addington, Jean Cannon, Tyrone D. Cornblatt, Barbara A. de la Fuente-Sandoval, Camilo Mathalon, Dan H. Perkins, Diana O. Seidman, Larry J. Tsuang, Ming Walker, Elaine F. Woods, Scott W. Bachman, Peter Belger, Ayse Carrion, Ricardo E. Donkers, Franc C. L. Duncan, Erica Johannesen, Jason Leon-Ortiz, Pablo Light, Gregory Mondragon, Alejandra Niznikiewicz, Margaret Nunag, Jason Roach, Brian J. Solis-Vivanco, Rodolfo CA North Amer Prodromal Longitudinal TI Between-site reliability of startle prepulse inhibition across two early psychosis consortia SO NEUROREPORT LA English DT Article DE endophenotype; prepulse inhibition; reliability; startle ID TEST-RETEST RELIABILITY; ACOUSTIC STARTLE; SCHIZOPHRENIA; REFLEX; HABITUATION; GENETICS; HERITABILITY; POPULATION; MULTISITE AB Prepulse inhibition (PPI) and reactivity of the acoustic startle response are widely used biobehavioral markers in psychopathology research. Previous studies have demonstrated that PPI and startle reactivity exhibit substantial within-site stability; however, between-site stability has not been established. In two separate consortia investigating biomarkers of early psychosis, traveling participants studies were carried out as a part of quality assurance procedures to assess the fidelity of data across sites. In the North American Prodromal Longitudinal Studies (NAPLS) consortium, eight normal participants traveled to each of the eight NAPLS sites and were tested twice at each site on the startle PPI paradigm. In preparation for a binational study, 10 healthy participants were assessed twice in both San Diego and Mexico City. Intraclass correlations between and within sites were significant for PPI and startle response parameters, confirming the reliability of startle measures across sites in both consortia. There were between-site differences in startle magnitude in the NAPLS study that did not appear to be related to methods or equipment. In planning multisite studies, it is essential to institute quality assurance procedures early and establish between-site reliability to assure comparable data across sites. NeuroReport 24:626-630 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Cadenhead, Kristin S.; Tsuang, Ming; Light, Gregory; Nunag, Jason] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Cadenhead, Kristin S.; Light, Gregory] Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA. [Mathalon, Dan H.; Roach, Brian J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Dan H.; Roach, Brian J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bachman, Peter] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Cannon, Tyrone D.; Johannesen, Jason] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Woods, Scott W.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Cornblatt, Barbara A.; Carrion, Ricardo E.] Zucker Hillside Hosp, Dept Psychiat, New York, NY USA. [Cornblatt, Barbara A.; Carrion, Ricardo E.] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA. [Cornblatt, Barbara A.; Carrion, Ricardo E.] Hofstra North Shore LIJ Sch Med, Dept Psychiat & Mol Med, New York, NY USA. [Perkins, Diana O.; Belger, Ayse; Donkers, Franc C. L.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Seidman, Larry J.; Niznikiewicz, Margaret] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Walker, Elaine F.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Duncan, Erica] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Duncan, Erica] Emory Univ, Dept Atlanta Vet Affairs, Atlanta, GA 30322 USA. [Addington, Jean] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [de la Fuente-Sandoval, Camilo; Leon-Ortiz, Pablo; Mondragon, Alejandra; Solis-Vivanco, Rodolfo] INNN, Dept Psychiat, Mexico City, DF, Mexico. RP Cadenhead, KS (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM kcadenhead@ucsd.edu RI Duncan, Erica/B-1671-2016; Donkers, Franc/H-2391-2013 OI Donkers, Franc/0000-0002-8252-0426; Roach, Brian/0000-0002-3264-1465; Belger, Aysenil/0000-0003-2687-1966; Mathalon, Daniel/0000-0001-6090-4974; Carrion, Ricardo/0000-0002-6393-392X; de la Fuente-Sandoval, Camilo/0000-0003-0773-1642 FU UCMEXUS-CONACYT; National Institutes of Health (NIH) [U01 MH081944, U01 MH082022, U01MH081984, U01 MH081902, UO1 MH081857, U01MH082004, U01 MH081928, U01MH081988] FX This research was supported by a collaborative grant from UCMEXUS-CONACYT (K. S. C. and C.d.l.F.-S., co-PIs), National Institutes of Health (NIH)-supported grants U01 MH081944 to K. S. C., U01 MH082022 to S. W. W., U01MH081984 to J.A., U01 MH081902 to T. D. C., UO1 MH081857 to B. A. C., U01MH082004 to D.O.P., U01 MH081928 to L. J. S., and U01MH081988 to E.F.W. NR 22 TC 0 Z9 0 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 EI 1473-558X J9 NEUROREPORT JI Neuroreport PD AUG 7 PY 2013 VL 24 IS 11 BP 626 EP 630 DI 10.1097/WNR.0b013e3283637845 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 299DJ UT WOS:000330375000009 PM 23799460 ER PT J AU LeardMann, CA Powell, TM Smith, TC Bell, MR Smith, B Boyko, EJ Hooper, TI Gackstetter, GD Ghamsary, M Hoge, CW AF LeardMann, Cynthia A. Powell, Teresa M. Smith, Tyler C. Bell, Michael R. Smith, Besa Boyko, Edward J. Hooper, Tomoko I. Gackstetter, Gary D. Ghamsary, Mark Hoge, Charles W. TI Risk Factors Associated With Suicide in Current and Former US Military Personnel SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-DEATH-INDEX; MILLENNIUM COHORT; SERVICE MEMBERS; PRIMARY-CARE; VITAL STATUS; FOLLOW-UP; PRIME-MD; HEALTH; POPULATION AB IMPORTANCE Beginning in 2005, the incidence of suicide deaths in the US military began to sharply increase. Unique stressors, such as combat deployments, have been assumed to underlie the increasing incidence. Previous military suicide studies, however, have relied on case series and cross-sectional investigations and have not linked data during service with postservice periods. OBJECTIVE To prospectively identify and quantify risk factors associated with suicide in current and former US military personnel including demographic, military, mental health, behavioral, and deployment characteristics. DESIGN, SETTING, AND PARTICIPANTS Prospective longitudinal study with accrual and assessment of participants in 2001, 2004, and 2007. Questionnaire data were linked with the National Death Index and the Department of Defense Medical Mortality Registry through December 31, 2008. Participants were current and former US military personnel from all service branches, including active and Reserve/National Guard, who were included in the Millennium Cohort Study (N = 151 560). MAIN OUTCOMES AND MEASURES Death by suicide captured by the National Death Index and the Department of Defense Medical Mortality Registry. RESULTS Through the end of 2008, findings were 83 suicides in 707 493 person-years of follow-up (11.73/100 000 person-years [95% CI, 9.21-14.26]). In Cox models adjusted for age and sex, factors significantly associated with increased risk of suicide included male sex, depression, manic-depressive disorder, heavy or binge drinking, and alcohol-related problems. None of the deployment-related factors (combat experience, cumulative days deployed, or number of deployments) were associated with increased suicide risk in any of the models. In multivariable Cox models, individuals with increased risk for suicide were men (hazard ratio [HR], 2.14; 95% CI, 1.17-3.92; P = .01; attributable risk [AR], 3.5 cases/10 000 persons), and those with depression (HR, 1.96; 95% CI, 1.05-3.64; P = .03; AR, 6.9/10 000 persons), manic-depressive disorder (HR, 4.35; 95% CI, 1.56-12.09; P = .005; AR, 35.6/10 000 persons), or alcohol-related problems (HR, 2.56; 95% CI, 1.56-4.18; P < .001; AR, 7.7/10 000 persons). A nested, matched case-control analysis using 20: 1 control participants per case confirmed these findings. CONCLUSIONS AND RELEVANCE In this sample of current and former military personnel observed July 1, 2001-December 31, 2008, suicide risk was independently associated with male sex and mental disorders but not with military-specific variables. These findings may inform approaches to mitigating suicide risk in this population. C1 [LeardMann, Cynthia A.; Powell, Teresa M.; Smith, Tyler C.; Smith, Besa] Naval Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Smith, Tyler C.] Natl Univ, Sch Hlth & Human Serv, San Diego, CA USA. [Smith, Besa] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Bell, Michael R.; Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Gackstetter, Gary D.] Analyt Serv Inc, Arlington, VA USA. [Ghamsary, Mark] Loma Linda Univ, Sch Publ Hlth, Loma Linda, CA 92350 USA. [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA. RP LeardMann, CA (reprint author), Naval Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM cynthia.leardmann@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X FU Department of Defense [12-53, 60002]; Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland; VA Puget Sound Health Care System FX This work represents report 12-53, supported by the Department of Defense, under work unit no. 60002. The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland. Dr Boyko's effort in this project was supported by VA Puget Sound Health Care System. NR 38 TC 110 Z9 110 U1 4 U2 34 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 7 PY 2013 VL 310 IS 5 BP 496 EP 506 DI 10.1001/jama.2013.65164 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 196OZ UT WOS:000322786400022 PM 23925620 ER PT J AU Namjou, B Kim-Howard, X Sun, CL Adler, A Chung, SA Kaufman, KM Kelly, JA Glenn, SB Guthridge, JM Scofield, RH Kimberly, RP Brown, EE Alarcon, GS Edberg, JC Kim, JH Choi, J Ramsey-Goldman, R Petri, MA Reveille, JD Vila, LM Boackle, SA Freedman, BI Tsao, BP Langefeld, CD Vyse, TJ Jacob, CO Pons-Estel, B Niewold, TB Sivils, KLM Merrill, JT Anaya, JM Gilkeson, GS Gaffney, PM Bae, SC Alarcon-Riquelme, ME Harley, JB Criswell, LA James, JA Nath, SK AF Namjou, Bahram Kim-Howard, Xana Sun, Celi Adler, Adam Chung, Sharon A. Kaufman, Kenneth M. Kelly, Jennifer A. Glenn, Stuart B. Guthridge, Joel M. Scofield, Robert H. Kimberly, Robert P. Brown, Elizabeth E. Alarcon, Graciela S. Edberg, Jeffrey C. Kim, Jae-Hoon Choi, Jiyoung Ramsey-Goldman, Rosalind Petri, Michelle A. Reveille, John D. Vila, Luis M. Boackle, Susan A. Freedman, Barry I. Tsao, Betty P. Langefeld, Carl D. Vyse, Timothy J. Jacob, Chaim O. Pons-Estel, Bernardo Niewold, Timothy B. Sivils, Kathy L. Moser Merrill, Joan T. Anaya, Juan-Manuel Gilkeson, Gary S. Gaffney, Patrick M. Bae, Sang-Cheol Alarcon-Riquelme, Marta E. Harley, John B. Criswell, Lindsey A. James, Judith A. Nath, Swapan K. CA Argentine Collaborative Grp BIOLUPUS GENLES Networks TI PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes SO PLOS ONE LA English DT Article ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISM; LYMPHOID TYROSINE PHOSPHATASE; OF-FUNCTION VARIANT; AUTOIMMUNE-DISEASE; RHEUMATOID-ARTHRITIS; R620W POLYMORPHISM; C1858T POLYMORPHISM; GENETIC ASSOCIATION; SUSCEPTIBILITY LOCI AB Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is a negative regulator of T-cell activation associated with several autoimmune diseases, including systemic lupus erythematosus (SLE). Missense rs2476601 is associated with SLE in individuals with European ancestry. Since the rs2476601 risk allele frequency differs dramatically across ethnicities, we assessed robustness of PTPN22 association with SLE and its clinical sub-phenotypes across four ethnically diverse populations. Ten SNPs were genotyped in 8220 SLE cases and 7369 controls from in European-Americans (EA), African-Americans (AA), Asians (AS), and Hispanics (HS). We performed imputation-based association followed by conditional analysis to identify independent associations. Significantly associated SNPs were tested for association with SLE clinical sub-phenotypes, including autoantibody profiles. Multiple testing was accounted for by using false discovery rate. We successfully imputed and tested allelic association for 107 SNPs within the PTPN22 region and detected evidence of ethnic-specific associations from EA and HS. In EA, the strongest association was at rs2476601 (P = 4.7 x 10(-9), OR = 1.40 (95% CI = 1.25-1.56)). Independent association with rs1217414 was also observed in EA, and both SNPs are correlated with increased European ancestry. For HS imputed intronic SNP, rs3765598, predicted to be a cis-eQTL, was associated (P = 0.007, OR = 0.79 and 95% CI = 0.67-0.94). No significant associations were observed in AA or AS. Case-only analysis using lupus-related clinical criteria revealed differences between EA SLE patients positive for moderate to high titers of IgG anti-cardiolipin (aCL IgG >20) versus negative aCL IgG at rs2476601 (P = 0.012, OR = 1.65). Association was reinforced when these cases were compared to controls (P = 2.7 x 10(-5), OR = 2.11). Our results validate that rs2476601 is the most significantly associated SNP in individuals with European ancestry. Additionally, rs1217414 and rs3765598 may be associated with SLE. Further studies are required to confirm the involvement of rs2476601 with aCL IgG. C1 [Namjou, Bahram; Kim-Howard, Xana; Sun, Celi; Adler, Adam; Kelly, Jennifer A.; Glenn, Stuart B.; Guthridge, Joel M.; Scofield, Robert H.; Sivils, Kathy L. Moser; Gaffney, Patrick M.; Alarcon-Riquelme, Marta E.; James, Judith A.; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Namjou, Bahram; Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Chung, Sharon A.; Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, Dept Med, San Francisco, CA 94143 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Scofield, Robert H.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Kimberly, Robert P.; Brown, Elizabeth E.; Alarcon, Graciela S.; Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kim, Jae-Hoon; Choi, Jiyoung; Bae, Sang-Cheol] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA. [Vila, Luis M.] Univ Puerto Rico Med Sci Campus, Dept Med, San Juan, PR USA. [Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. [Freedman, Barry I.] Wake Forest Univ Hlth Sci, Ctr Publ Hlth Genom, Wake Forest, NC USA. [Freedman, Barry I.; Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Wake Forest, NC USA. [Tsao, Betty P.] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med, London, England. [Vyse, Timothy J.] Kings Coll London, Div Immunol, London, England. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Pons-Estel, Bernardo] Sanatorio Parque, Dept Med, Rosario, Santa Fe, Argentina. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Alarcon-Riquelme, Marta E.] Pfizer Univ Granada Junta Andalucia, Ctr Genom & Invest Oncol GENYO, Granada, Spain. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Swapan-nath@omrf.org RI D'Alfonso, Sandra/K-7295-2014; Witte, Torsten/B-5783-2016; Anaya, Juan-Manuel/J-1960-2016 OI D'Alfonso, Sandra/0000-0002-3983-9925; Anaya, Juan-Manuel/0000-0002-6444-1249; Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Silva, Berta/0000-0001-6579-5068; Frostegard, Johan/0000-0002-3569-3367 FU US National Institutes of Health [AR060366, AR053483, AR43814, AR049084, AR002138, AR030692, AR053308, AR057172, AI094377, AI101934, AI082714, AI070304, AI078004, AI063274, GM103510, GM103456, RR025741, RR020143]; National Center for Advancing Translational Research of the National Institutes of Health [UL1TR00165, UL1TR000004, UL1RR024131]; Alliance for Lupus Research; Kirkland Scholar Award; Korea Healthcare Technology RD Project; Ministry for Health and Welfare, Republic of Korea [A120404]; European Union; European Science Foundation FX This work was supported by grants from the US National Institutes of Health (AR060366, AR053483, AR43814, AR049084, AR002138, AR030692, AR053308, AR057172, AI094377, AI101934, AI082714, AI063274, AI070304, AI078004, AI063274, AI083194, AI078004, GM103510, GM103456, RR025741, and RR020143); National Center for Advancing Translational Research of the National Institutes of Health (UL1TR00165, UL1TR000004, and UL1RR024131); the Alliance for Lupus Research, Kirkland Scholar Award, the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A120404). Instituto de Salud Carlos III partly financed through FEDER funds from the European Union; the BIOLUPUS Research Network is supported by funding from the European Science Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 64 TC 19 Z9 19 U1 0 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 7 PY 2013 VL 8 IS 8 AR e69404 DI 10.1371/journal.pone.0069404 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 200ZE UT WOS:000323109700017 PM 23950893 ER PT J AU Hong, CH Falvey, C Harris, TB Simonsick, EM Satterfield, S Ferrucci, L Metti, AL Patel, KV Yaffe, K AF Hong, Chang Hyung Falvey, Cherie Harris, Tamara B. Simonsick, Eleanor M. Satterfield, Suzanne Ferrucci, Luigi Metti, Andrea L. Patel, Kushang V. Yaffe, Kristine TI Anemia and risk of dementia in older adults Findings from the Health ABC study SO NEUROLOGY LA English DT Article ID ALZHEIMER-DISEASE; HEMOGLOBIN CONCENTRATION; CARDIOVASCULAR HEALTH; COGNITIVE IMPAIRMENT; ERYTHROPOIETIN; MORTALITY; PREVALENCE; OUTCOMES; DECLINE; COHORT AB Objective: To determine whether anemia is associated with incident dementia in older adults. Methods: We studied 2,552 older adults (mean age 76.1 years; 38.9% black; 51.8% female) participating in the Health, Aging, and Body Composition study and free of dementia at baseline. We defined anemia using WHO criteria (hemoglobin concentration <13 g/dL for men and <12 g/dL for women). Dementia diagnosis was determined by dementia medication use, hospital records, or a change in Modified Mini-Mental State (3MS) score of more than 1.5 SD from mean. Discrete time Cox proportional hazard regression models were used to examine the hazard for developing dementia associated with anemia. Results: Of 2,552 participants, 392 (15.4%) older adults had anemia at baseline. Over 11 years of follow-up, 455 (17.8%) participants developed dementia. In the unadjusted model, those with baseline anemia had an increased risk of dementia (23% vs 17%, hazard ratio = 1.64; 95% confidence interval 1.30, 2.07) compared to those without anemia. The association remained significant after adjusting for demographics, APOE epsilon 4, baseline 3MS score, comorbidities, and renal function. Additional adjustment for other anemia measures (mean corpuscular volume, red cell distribution width), erythropoietin, and C-reactive protein did not appreciably change the results. There was no interaction by sex and race on risk of developing dementia. Conclusion: Among older adults, anemia is associated with an increased risk of developing dementia. Findings suggest that further study of anemia as a risk factor for dementia and a target for intervention for cognitive health is warranted. C1 [Hong, Chang Hyung] Ajou Univ Sch Med, Dept Psychiat, Suwon, South Korea. [Hong, Chang Hyung] Ajou Univ Sch Med, Inst Aging, Suwon, South Korea. [Falvey, Cherie; Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. [Falvey, Cherie; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Baltimore, MD 21224 USA. [Simonsick, Eleanor M.; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Satterfield, Suzanne] Univ Tennessee Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Metti, Andrea L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. EM kristine.yaffe@ucsf.edu FU NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIH; National Institute of Aging; National Institute of Aging [K24AG031155]; American Health Assistance Foundation [A201-0029] FX NIA contract numbers: N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106. NIA grant numbers: R01-AG028050, NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH and National Institute of Aging. Dr. Yaffe is supported in part by a National Institute of Aging Grant (K24AG031155) and a grant from the American Health Assistance Foundation (A201-0029). NR 34 TC 28 Z9 28 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD AUG 6 PY 2013 VL 81 IS 6 BP 528 EP 533 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 304JH UT WOS:000330742400007 PM 23902706 ER PT J AU Webster, CM Hokari, M McManus, A Tang, XN Ma, HL Kacimi, R Yenari, MA AF Webster, Corey M. Hokari, Masaaki McManus, April Tang, Xian Nan Ma, Hualong Kacimi, Rachid Yenari, Midori A. TI Microglial P2Y(12) Deficiency/Inhibition Protects against Brain Ischemia SO PLOS ONE LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PREVENTS ATP EXCITOTOXICITY; EXPERIMENTAL STROKE; ANTITHROMBOTIC DRUGS; THERAPEUTIC TARGETS; CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; NERVE INJURY; RAT-BRAIN; RECEPTOR AB Objective: Microglia are among the first immune cells to respond to ischemic insults. Triggering of this inflammatory response may involve the microglial purinergic GPCR, P2Y(12), activation via extracellular release of nucleotides from injured cells. It is also the inhibitory target of the widely used antiplatelet drug, clopidogrel. Thus, inhibiting this GPCR in microglia should inhibit microglial mediated neurotoxicity following ischemic brain injury. Methods: Experimental cerebral ischemia was induced, in vitro with oxygen-glucose deprivation (OGD), or in vivo via bilateral common carotid artery occlusion (BCCAO). Genetic knock-down in vitro via siRNA, or in vivo P2Y(12) transgenic mice (P2Y(12)-/- or P2Y(12)+/-), or in vivo treatment with clopidogrel, were used to manipulate the receptor. Neuron death, microglial activation, and microglial migration were assessed. Results: The addition of microglia to neuron-astrocyte cultures increases neurotoxicity following OGD, which is mitigated by microglial P2Y(12) deficiency (P < 0.05). Wildtype microglia form clusters around these neurons following injury, which is also prevented in P2Y(12) deficient microglia (P < 0.01). P2Y(12) knock-out microglia migrated less than WT controls in response to OGD-conditioned neuronal supernatant. P2Y(12) (+/-) or clopidogrel treated mice subjected to global cerebral ischemia suffered less neuronal injury (P < 0.01, P < 0.001) compared to wild-type littermates or placebo treated controls. There were also fewer microglia surrounding areas of injury, and less activation of the pro-inflammatory transcription factor, nuclear factor Kappa B (NFkB). Interpretation: P2Y(12) participates in ischemia related inflammation by mediating microglial migration and potentiation of neurotoxicity. These data also suggest an additional anti-inflammatory, neuroprotective benefit of clopidogrel. C1 [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM yenari@alum.mit.edu FU National Institutes of Health [NS40516]; Veteran's Merit Award FX This work was supported by grants from the National Institutes of Health (NS40516) and the Veteran's Merit Award to MAY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 28 Z9 28 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2013 VL 8 IS 8 AR e70927 DI 10.1371/journal.pone.0070927 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218XC UT WOS:000324465000158 PM 23940669 ER PT J AU Ross, JS Hu, W Rosen, B Snider, AJ Obeid, LM Cowart, LA AF Ross, Jessica S. Hu, Wei Rosen, Bess Snider, Ashley J. Obeid, Lina M. Cowart, L. Ashley TI Sphingosine Kinase 1 Is Regulated by Peroxisome Proliferator-activated Receptor alpha in Response to Free Fatty Acids and Is Essential for Skeletal Muscle Interleukin-6 Production and Signaling in Diet-induced Obesity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-NECROSIS-FACTOR; INDUCED INSULIN-RESISTANCE; FACTOR-KAPPA-B; ADIPOSE-TISSUE; MYOGENIC DIFFERENTIATION; CERAMIDE BIOSYNTHESIS; METABOLIC SYNDROME; DEPENDENT ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION AB We previously demonstrated that sphingosine kinase 1 (Sphk1) expression and activity are up-regulated by exogenous palmitate (PAL) in a skeletal muscle model system and in diet-induced obesity in mice; however, potential functions and in vivo relevance of this have not been addressed. Here, we aimed to determine the mechanism by which PAL regulates SphK1 in muscle, and to determine potential roles for its product, sphingosine-1-phosphate (S1P), in muscle biology in the context of obesity. Cloning and analysis of the mouse Sphk1 promoter revealed a peroxisome proliferator-activated receptor (PPAR) alpha cis-element that mediated activation of a reporter under control of the Sphk1 promoter; direct interaction of PPAR alpha was demonstrated by chromatin immunoprecipitation. PAL treatment induced the proinflammatory cytokine interleukin (IL)-6 in a manner dependent on SphK1, and this was attenuated by inhibition of the sphingosine-1-phosphate receptor 3 (S1PR3). Diet-induced obesity in mice demonstrated that IL-6 expression in muscle, but not adipose tissue, increased in obesity, but this was attenuated in Sphk1(-/-)mice. Moreover, plasma IL-6 levels were significantly decreased in obese Sphk1(-/-) mice relative to obese wild type mice, and muscle, but not adipose tissue IL-6 signaling was activated. These data indicate that PPAR alpha regulates Sphk1 expression in the context of fatty acid oversupply and links PAL to muscle IL-6 production. Moreover, this function of SphK1 in diet-induced obesity suggests a potential role for SphK1 in obesity-associated pathological outcomes. C1 [Ross, Jessica S.; Hu, Wei; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Ross, Jessica S.] Med Univ S Carolina, Dept Mol & Cellular Biol, Charleston, SC 29425 USA. [Ross, Jessica S.] Med Univ S Carolina, Pathobiol Program, Charleston, SC 29425 USA. [Snider, Ashley J.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Rosen, Bess] Boston Univ, Sch Med, Ctr Regenerat Med, Boston, MA 02118 USA. [Obeid, Lina M.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11790 USA. [Obeid, Lina M.] Northport Vet Affairs Med Ctr, Northpoint, NY 11768 USA. [Snider, Ashley J.; Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC509, Charleston, SC 29425 USA. EM cowartl@musc.edu FU National Institutes of Health COBREaward [P20 RR017677]; Veterans Affairs Merit award; GAANN fellowship in Lipidomics and Systems Biology; Office of the Director of the National Institutes of Health [C06 RR018823]; National Center for Research Resources; Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina Grant [P30 CA138313]; Lipidomics Core in the South Carolina Lipidomics and Pathobiology COBRE Grant [P20 RR017677] FX This work was supported, in whole or in part, by National Institutes of Health COBREaward P20 RR017677 (to L. A. C.), a Veterans Affairs Merit award, and a GAANN fellowship in Lipidomics and Systems Biology (to J. S. R.). Lipidomic analysis was performed by the Medical University of South Carolina Lipidomic Core supported by the National Center for Research Resources and the Office of the Director of the National Institutes of Health through Grant C06 RR018823. Research was supported in part by the Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina Grant P30 CA138313, and the Lipidomics Core in the South Carolina Lipidomics and Pathobiology COBRE Grant P20 RR017677. NR 100 TC 10 Z9 10 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 2 PY 2013 VL 288 IS 31 BP 22193 EP 2206 DI 10.1074/jbc.M113.477786 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302HY UT WOS:000330596300002 PM 23766515 ER PT J AU Wu, Y Collier, L Qin, WP Creasey, G Bauman, WA Jarvis, J Cardozo, C AF Wu, Yong Collier, Lauren Qin, Weiping Creasey, Graham Bauman, William A. Jarvis, Jonathan Cardozo, Christopher TI Electrical stimulation modulates Wnt signaling and regulates genes for the motor endplate and calcium binding in muscle of rats with spinal cord transection SO BMC NEUROSCIENCE LA English DT Article DE Spinal cord injury; Paralysis; Electrical stimulation; Exercise; Gene expression ID ANKYRIN REPEAT PROTEIN; SKELETAL-MUSCLE; RESISTANCE EXERCISE; INJURED INDIVIDUALS; MOLECULAR RESPONSES; BETA-CATENIN; FIBER-TYPE; EXPRESSION; GROWTH; HYPERTROPHY AB Background: Spinal cord injury (SCI) results in muscle atrophy and a shift of slow oxidative to fast glycolytic fibers. Electrical stimulation (ES) at least partially restores muscle mass and fiber type distribution. The objective of this study was to was to characterize the early molecular adaptations that occur in rat soleus muscle after initiating isometric resistance exercise by ES for one hour per day for 1, 3 or 7 days when ES was begun 16 weeks after SCI. Additionally, changes in mRNA levels after ES were compared with those induced in soleus at the same time points after gastrocnemius tenotomy (GA). Results: ES increased expression of Hey1 and Pitx2 suggesting increased Notch and Wnt signaling, respectively, but did not normalize RCAN1.4, a measure of calcineurin/NFAT signaling, or PGC-1 beta mRNA levels. ES increased PGC-1 alpha expression but not that of slow myofibrillar genes. Microarray analysis showed that after ES, genes coding for calcium binding proteins and nicotinic acetylcholine receptors were increased, and the expression of genes involved in blood vessel formation and morphogenesis was altered. Of the 165 genes altered by ES only 16 were also differentially expressed after GA, of which 12 were altered in the same direction by ES and GA. In contrast to ES, GA induced expression of genes related to oxidative phosphorylation. Conclusions: Notch and Wnt signaling may be involved in ES-induced increases in the mass of paralyzed muscle. Molecular adaptations of paralyzed soleus to resistance exercise are delayed or defective compared to normally innervated muscle. C1 [Wu, Yong; Collier, Lauren; Qin, Weiping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Creasey, Graham] Stanford Univ, VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Jarvis, Jonathan] Univ Liverpool, Sch Biomed Sci, Liverpool L69 3BX, Merseyside, England. RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B9212C, B4055X, B3347K]; European Commission Project [RISE QLG5-CT-2001-02191] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (grants B9212C to WAB and B4055X and B3347K to CC) and European Commission Project RISE QLG5-CT-2001-02191 to JCJ. NR 63 TC 6 Z9 6 U1 0 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2202 J9 BMC NEUROSCI JI BMC Neurosci. PD AUG 2 PY 2013 VL 14 AR 81 DI 10.1186/1471-2202-14-81 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 196OP UT WOS:000322785300001 PM 23914941 ER PT J AU Kirkwood, CM Ciuchta, J Ikonomovic, MD Fish, KN Abrahamson, EE Murray, PS Klunk, WE Sweet, RA AF Kirkwood, Caitlin M. Ciuchta, Jennifer Ikonomovic, Milos D. Fish, Kenneth N. Abrahamson, Eric E. Murray, Patrick S. Klunk, William E. Sweet, Robert A. TI Dendritic Spine Density, Morphology, and Fibrillar Actin Content Surrounding Amyloid-beta Plaques in a Mouse Model of Amyloid-beta Deposition SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; Amyloid-beta; Dendritic spine; Genetic mouse models; Phalloidin; X-34 ID LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; TRANSGENIC MICE; SYNAPSE LOSS; PRECURSOR-PROTEIN; OLIGOMERS; ABNORMALITIES; PRESENILIN-1; DEPRESSION AB Dendritic spines are the site of most excitatory synapses, the loss of which correlates with cognitive impairment in patients with Alzheimer disease. Substantial evidence indicates that amyloid-beta (A beta) peptide, either insoluble fibrillar A beta deposited into plaques or soluble nonfibrillar A beta species, can cause spine loss but the concurrent contributions of fibrillar A beta and nonfibrillar A beta to spine loss has not been previously assessed. We used multiple-label immunohistochemistry to measure spine density, size, and F-actin content surrounding plaques in the cerebral cortex in the PSAPP mouse model of A beta deposition. Our approach allowed us to measure fibrillar A beta plaque content and an index of nonfibrillar A beta species concurrently. We found that spine density was reduced within 6 Km of the plaque perimeter, remaining spines were more compact, and F-actin content per spine was increased. Measures of fibrillar A beta plaque content were associated with reduced spine density near plaques, whereas measures of nonfibrillar A beta species were associated with reduced spine density and size but not altered F-actin content. These findings suggest that strategies to preserve dendritic spines in AD patients may need to address both nonfibrillar and fibrillar forms of A beta and that nonfibrillar A beta may exert spine toxicity through pathways not mediated by depolymerization of F-actin. C1 [Kirkwood, Caitlin M.; Ciuchta, Jennifer; Ikonomovic, Milos D.; Fish, Kenneth N.; Murray, Patrick S.; Klunk, William E.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA. [Klunk, William E.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), 3811 OHara St,BST W1645, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Klunk, William/0000-0001-5512-0251 FU National Institutes of Health [AG027224, AG14449, AG044070] FX This work was supported by Grants AG027224, AG14449, and AG044070 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. There are no actual or potential conflicts of interest. NR 49 TC 15 Z9 15 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD AUG PY 2013 VL 72 IS 8 BP 791 EP 800 PG 10 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 299GI UT WOS:000330383600008 PM 23860033 ER PT J AU Jessup, JA Wang, H MacNamara, LM Presley, TD Kim-Shapiro, DB Zhang, LL Chen, AF Groban, L AF Jessup, Jewell A. Wang, Hao MacNamara, Lindsay M. Presley, Tennille D. Kim-Shapiro, Daniel B. Zhang, Lili Chen, Alex F. Groban, Leanne TI Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Cardiac biopterins; Diastolic dysfunction; Estrogen timing; Left ventricular remodeling; Menopause; Nitrite ID VENTRICULAR DIASTOLIC DYSFUNCTION; HYPERTENSIVE POSTMENOPAUSAL WOMEN; NITRIC-OXIDE SYNTHASE; HEART-FAILURE; CARDIOVASCULAR-DISEASE; EJECTION FRACTION; SYSTOLIC FUNCTION; HORMONE-THERAPY; 17-BETA-ESTRADIOL ANTAGONIZES; CARDIOMYOCYTE HYPERTROPHY AB Objective: mRen2.Lewis rats exhibit exacerbated increases in blood pressure, left ventricular (LV) remodeling, and diastolic impairment after the loss of estrogens. In this same model, depletion of estrogens has marked effects on the cardiac biopterin profile concomitant with suppressed nitric oxide release. With respect to the establishment of overt systolic hypertension after oophorectomy (OVX), we assessed the effects of timing long-term 17 beta-estradiol (E-2) therapy on myocardial function, myocardial structure, and the cardiac nitric oxide system. Methods: OVX (n = 24) or sham operation (Sham; n = 13) was performed in 4-week-old female mRen2.Lewis rats. After randomization, OVX rats received E-2 immediately (OVX + E-2-early; n = 7), E-2 at 11 weeks of age (OVX + E-2-late; n = 8), or no E-2 at all (OVX; n = 9). Results: E-2-early was associated with lower body weight, less hypertension-related cardiac remodeling, and decreased LV filling pressure compared with OVX rats without E-2 supplementation. E-2-late similarly attenuated the adverse effects of ovarian hormone loss on tissue Doppler-derived LV filling pressures and perivascular fibrosis, and significantly improved myocardial relaxation or mitral annular velocity (e'). Early and late exposures to E-2 decreased dihydrobiopterin, but only E-2-late yielded significant increases in cardiac nitrite concentrations. Conclusions: Although there are some similarities between E-2-early and E-2-late treatments in relation to preservation of diastolic function and cardiac structure after OVX, the lusitropic potential of E-2 is most consistent with late supplementation. The cardioprotective effects of E-2-late are independent of blood pressure and may have occurred through regulation of cardiac biopterins and nitric oxide production. C1 [Jessup, Jewell A.; Groban, Leanne] Wake Forest Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA. [Wang, Hao; MacNamara, Lindsay M.; Groban, Leanne] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA. [Presley, Tennille D.] Winston Salem State Univ, Dept Chem, Winston Salem, NC USA. [Presley, Tennille D.; Kim-Shapiro, Daniel B.; Groban, Leanne] Wake Forest Univ, Translat Sci Ctr, Winston Salem, NC 27109 USA. [Kim-Shapiro, Daniel B.] Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA. [Zhang, Lili; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA. [Groban, Leanne] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA. RP Groban, L (reprint author), Wake Forest Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM lgroban@wakehealth.edu FU National Institutes of Health [R01-AG033727, HL058091, R01 GM077352]; American Heart Association [0855601GH] FX This work was supported, in part, by grants from the National Institutes of Health (R01-AG033727 to L. G., HL058091 to D.B.K.-S., and R01 GM077352 to A. F. C.) and the American Heart Association Grant-in-Aid (0855601GH to A.F.C.). NR 61 TC 10 Z9 10 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD AUG PY 2013 VL 20 IS 8 BP 860 EP 868 DI 10.1097/gme.0b013e318280589a PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300KN UT WOS:000330462900012 PM 23481117 ER PT J AU Massof, RW Stelmack, JA AF Massof, Robert W. Stelmack, Joan A. TI Interpretation of Low-Vision Rehabilitation Outcome Measures SO OPTOMETRY AND VISION SCIENCE LA English DT Article DE low-vision rehabilitation; patient-reported outcome measure; visual function questionnaire; differential item functioning; Rasch analysis; item response theory ID QUALITY-OF-LIFE; RATING-SCALE QUESTIONNAIRES; VISUAL FUNCTIONING QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL; MACULAR DEGENERATION; SYSTEMS-MODEL; SERVICE; RASCH; EFFICACY; IMPACT AB Purpose. This article presents a theoretical interpretation of patient-reported outcomes of low-vision rehabilitation (LVR) using rating scale questionnaires and uses previously published results of LVR outcome studies to illustrate theoretical points and validate assumptions. Theory. Patients' judgments of the difficulty they have performing tasks are interpreted as magnitude estimates of their functional reserve for each task, which is the difference between their visual ability and the visual ability demanded by the task. We assume that improvements in functional reserve can occur by increasing the patient's visual ability with medical, surgical, or refractive interventions or decreasing the visual ability demanded by the item with activity-specific vision assistive equipment, adaptations, and environmental modifications. Activity-specific interventions cause differential item functioning (intervention-related DIF). Intervention-related DIF makes the measured size of the treatment effect dependent on the item content and the mix of responsive and unresponsive items to intervention. Conclusions. Because intervention-related DIF depends on the choice of items, the outcome measure selected should be appropriate to the aims of the intervention and the impairment level of the sample to demonstrate the full effects of an intervention. Items that are given extreme positive ratings at preintervention baseline (e. g., "not difficult'') have no room for improvement. These items must also be filtered out because they will dilute the measured effect of the activity-specific interventions of LVR. C1 [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA. [Stelmack, Joan A.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Blind Rehabil Ctr, Hines, IL 60141 USA. [Stelmack, Joan A.] Univ Illinois, Sch Med, UIC Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL USA. [Stelmack, Joan A.] Illinois Coll Optometry, Chicago, IL USA. RP Massof, RW (reprint author), Wilmer B43 Johns Hopkins Hosp, 600 N Wolfe St, Baltimore, MD 21287 USA. EM bmassof@jhmi.edu FU National Eye Institute [EY022322]; Department of Veterans Affairs Rehabilitation Research and Development Service [C3457] FX This study was supported by grants from the National Eye Institute (EY022322) and the Department of Veterans Affairs Rehabilitation Research and Development Service (C3457). NR 37 TC 9 Z9 9 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-5488 EI 1538-9235 J9 OPTOMETRY VISION SCI JI Optom. Vis. Sci. PD AUG PY 2013 VL 90 IS 8 BP 788 EP 798 PG 11 WC Ophthalmology SC Ophthalmology GA 298SP UT WOS:000330345000010 PM 23873035 ER PT J AU Hu, XM Li, PY Chen, J AF Hu, Xiaoming Li, Peiying Chen, Jun TI PRO: Regulatory T Cells Are Protective in Ischemic Stroke SO STROKE LA English DT Editorial Material DE regulatory T cells; stroke C1 [Hu, Xiaoming; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15261 USA. [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, Med Ctr, Pittsburgh, PA 15260 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS36736, NS43802, NS45048] NR 8 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD AUG PY 2013 VL 44 IS 8 BP E85 EP E86 DI 10.1161/STROKEAHA.113.001267 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 293OO UT WOS:000329982400002 PM 23821231 ER PT J AU Kapa, S Epstein, AE Callans, DJ Garcia, FC Lin, D Bala, R Riley, MP Hutchinson, MD Gerstenfeld, EP Tzou, W Marchlinski, FE Frankel, DS Cooper, JM Supple, G Deo, R Verdino, RJ Patel, VV Dixit, S AF Kapa, Suraj Epstein, Andrew E. Callans, David J. Garcia, Fermin C. Lin, David Bala, Rupa Riley, Michael P. Hutchinson, Mathew D. Gerstenfeld, Edward P. Tzou, Wendy Marchlinski, Francis E. Frankel, David S. Cooper, Joshua M. Supple, Gregory Deo, Rajat Verdino, Ralph J. Patel, Vickas V. Dixit, Sanjay TI Assessing Arrhythmia Burden After Catheter Ablation of Atrial Fibrillation Using an Implantable Loop Recorder: The ABACUS Study SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE antiarrhythmic drugs; atrial fibrillation; catheter ablation; implantable loop recorder; monitoring; pulmonary vein isolation ID RADIOFREQUENCY ABLATION; FOLLOW-UP; MONITOR; RECURRENCES; PERFORMANCE; MANAGEMENT; SYNCOPE; TRIAL AB Assessing Arrhythmia Burden After Ablation IntroductionArrhythmia monitoring in patients undergoing atrial fibrillation (AF) ablation is challenging. Transtelephonic monitors (TTMs) are cumbersome to use and provide limited temporal assessment. Implantable loop recorders (ILRs) may overcome these limitations. We sought to evaluate the utility of ILRs versus conventional monitoring (CM) in patients undergoing AF ablation. Methods and ResultsForty-four patients undergoing AF ablation received ILRs and CM (30-day TTM at discharge and months 5 and 11 postablation). Over the initial 6 months, clinical decisions were made based on CM. Subjects were then randomized for the remaining 6 months to arrhythmia assessment and management by ILR versus CM. The primary endpoint was arrhythmia recurrence. The secondary endpoint was actionable clinical events (change of antiarrhythmic drugs [AADs], anticoagulation, non-AF arrhythmia events, etc.) due to either monitoring strategy. Over the study period, 6 patients withdrew. In the first 6 months, AF recurred in 18 patients (7 noted by CM, 18 by ILR; P = 0.002). Five patients in the CM (28%) and 5 in the ILR arm (25%; P = NS) had AF recurrence during the latter 6 months. AF was falsely diagnosed frequently by ILR (730 of 1,421 episodes; 51%). In more patients in the ILR compared with the CM arm, rate control agents (60% vs 39%, P = 0.02) and AADs (71% vs 44%, P = 0.04) were discontinued. ConclusionIn AF ablation patients, ILR can detect more arrhythmias than CM. However, false detection remains a challenge. With adequate oversight, ILRs may be useful in monitoring these patients after ablation. C1 [Kapa, Suraj; Epstein, Andrew E.; Callans, David J.; Garcia, Fermin C.; Lin, David; Bala, Rupa; Riley, Michael P.; Hutchinson, Mathew D.; Marchlinski, Francis E.; Frankel, David S.; Cooper, Joshua M.; Supple, Gregory; Deo, Rajat; Verdino, Ralph J.; Patel, Vickas V.; Dixit, Sanjay] Hosp Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. [Epstein, Andrew E.; Dixit, Sanjay] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Gerstenfeld, Edward P.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Tzou, Wendy] Univ Colorado, Dept Med, Div Cardiol, Aurora, CO USA. RP Dixit, S (reprint author), Hosp Univ Penn, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM sanjay.dixit@uphs.upenn.edu OI Marchlinski, Francis/0000-0001-7962-9423; Hutchinson, Mathew/0000-0002-8286-0113 FU Medtronic, Inc.; Medtronic FX The study was supported by an unrestricted grant from Medtronic, Inc., who had no role in the administration of the study, in the interpretation of data and writing of the manuscript.; A.E.E., D.J.C., R.B., M.D.H., E.P.G., F.E.M., D.F., J.M.C., R.J.C., and S.D. received honoraria from Medtronic. A.E.E., E.P.G., F.E.M., and S.D. received research support from Medtronic. M.D.H. and F.E.M. served on advisory boards for Medtronic and D.J.C. received consulting fees. Other authors: No disclosures. NR 23 TC 22 Z9 22 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD AUG PY 2013 VL 24 IS 8 BP 875 EP 881 DI 10.1111/jce.12141 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 283AW UT WOS:000329217500009 PM 23577826 ER PT J AU Hsieh, CL Kim, CC Ryba, BE Niemi, EC Bando, JK Locksley, RM Liu, JL Nakamura, MC Seaman, WE AF Hsieh, Christine L. Kim, Charles C. Ryba, Bryan E. Niemi, Erene C. Bando, Jennifer K. Locksley, Richard M. Liu, Jialing Nakamura, Mary C. Seaman, William E. TI Traumatic brain injury induces macrophage subsets in the brain SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Alternative activation; Inflammation; Macrophage; Traumatic brain injury ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; ALTERNATIVE ACTIVATION; MICROGLIAL ACTIVATION; MICE; INFLAMMATION; RECRUITMENT; RECOVERY; HETEROGENEITY AB Traumatic brain injury (TBI) elicits innate inflammatory responses that can lead to secondary brain injury. To better understand the mechanisms involved in TBI-induced inflammation, we examined the nature of macrophages responding to TBI in mice. In this model, brain macrophages were increased >20-fold the day after injury and >77-fold 4 days after injury in the ipsilateral hemisphere compared with sham controls. TBI macrophage subsets were identified by using a reporter mouse strain (YARG) that expresses eYFP from an internal ribosome entry site (IRES) inserted at the 3 end of the gene for arginase-1 (Arg1), a hallmark of alternatively activated (M2) macrophages. One day after TBI, 21 +/- 1.5% of ipsilateral brain macrophages expressed relatively high levels of Arg1 as detected by yellow fluorescent protein, and this subpopulation declined thereafter. Arg1(+) cells localized with macrophages near the TBI lesion. Gene expression analysis of sorted Arg1(+) and Arg1(-) brain macrophages revealed that both populations had profiles that included features of conventional M2 macrophages and classically activated (M1) macrophages. The Arg1(+) cells differed from Arg1(-) cells in multiple aspects, most notably in their chemokine repertoires. Thus, the macrophage response to TBI initially involves heterogeneous polarization toward at least two major subsets. C1 [Hsieh, Christine L.; Ryba, Bryan E.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hsieh, Christine L.; Kim, Charles C.; Niemi, Erene C.; Bando, Jennifer K.; Locksley, Richard M.; Nakamura, Mary C.; Seaman, William E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Hsieh, Christine L.; Liu, Jialing; Nakamura, Mary C.; Seaman, William E.] Northern Calif Inst Res & Educ, San Francisco, CA USA. RP Hsieh, CL (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111R, San Francisco, CA 94121 USA. EM christine.hsieh@ucsf.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382; Kim, Charles/0000-0001-6474-8227 FU NIH/NCRR UCSF-CTSI [UL1 RR024131]; Department of Veterans Affairs; Department of Defense FX The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Dr. David Erle, Andrea Barczak, Rebecca Barbeau, and Joshua Pollack at the Sandler Asthma Basic Research (SABRE) Center Functional Genomics Core Facility (NIH/NCRR UCSF-CTSI grant number UL1 RR024131), and Ivy Hsieh of the San Francisco VA Cell Imaging core for their contributions. This work was supported by the Department of Veterans Affairs and by grants from the Department of Defense to WES and CLH, which were administered by the Northern California Institute for Research and Education. NR 53 TC 33 Z9 34 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD AUG PY 2013 VL 43 IS 8 BP 2010 EP 2022 DI 10.1002/eji.201243084 PG 13 WC Immunology SC Immunology GA 277SN UT WOS:000328839700006 PM 23630120 ER PT J AU Daubenmier, J Sze, J Kerr, CE Kemeny, ME Mehling, W AF Daubenmier, Jennifer Sze, Jocelyn Kerr, Catherine E. Kemeny, Margaret E. Mehling, Wolf TI Follow your breath: Respiratory interoceptive accuracy in experienced meditators SO PSYCHOPHYSIOLOGY LA English DT Article DE Meditation; Interoceptive awareness; Interoceptive accuracy; Respiration; Anxiety; Mindfulness ID INSPIRATORY RESISTIVE LOADS; PERCEPTUAL DECISION-MAKING; EVOKED-POTENTIALS; STRESS REDUCTION; EMOTIONAL EXPERIENCE; MINDFULNESS PRACTICE; RELAPSE PREVENTION; ANTERIOR INSULA; BODY AWARENESS; ELASTIC LOADS AB Attention to internal bodily sensations is a core feature of mindfulness meditation. Previous studies have not detected differences in interoceptive accuracy between meditators and nonmeditators on heartbeat detection and perception tasks. We compared differences in respiratory interoceptive accuracy between meditators and nonmeditators in the ability to detect and discriminate respiratory resistive loads and sustain accurate perception of respiratory tidal volume during nondistracted and distracted conditions. Groups did not differ in overall performance on the detection and discrimination tasks; however, meditators were more accurate in discriminating the resistive load with the lowest ceiling effect. Meditators were also more accurate during the nondistracted tracking task at a lag time of 1s following the breath. Results provide initial support for the notion that meditators have greater respiratory interoceptive accuracy compared to nonmeditators. C1 [Daubenmier, Jennifer] Univ Calif San Francisco, Dept Med, Osher Ctr Integrat Med, San Francisco, CA USA. [Sze, Jocelyn] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Kerr, Catherine E.] Brown Univ, Allpert Sch Med, Dept Family Med, Providence, RI 02912 USA. [Kemeny, Margaret E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mehling, Wolf] Univ Calif San Francisco, Dept Family & Community Med, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. RP Mehling, W (reprint author), Osher Ctr Integrat Med, 1545 Divisadero St,4th Floor, San Francisco, CA 94115 USA. EM jjdaubenmier@yahoo.com; MehlingW@ocim.ucsf.edu FU Mt. Zion Health Fund; National Institutes of Health (NIH) from the National Center for Complementary & Alternative Medicine (NCCAM) [K01AT004199, K01AT003459, K23-AT002298] FX We are grateful to David Goldman, Anthony Maes, Derek Ramsey, Kevin Chan, Viranjini Gopisetty, and Elizabeth Bartmess for their work on this project. We thank Cynthia Price, Paul Davenport, David Anderson, and two anonymous reviewers for valuable comments on earlier versions of this manuscript, and Paul Davenport and Paul Grossman for initial consultations on the task design. This research was supported by the Mt. Zion Health Fund; and National Institutes of Health (NIH) grants K01AT004199 awarded to JD, K01AT003459 awarded to CK, and K23-AT002298 awarded to WM from the National Center for Complementary & Alternative Medicine (NCCAM). The content is solely the responsibility of the authors and does not necessarily represent the official views of NCCAM or NIH. NR 74 TC 23 Z9 23 U1 7 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD AUG PY 2013 VL 50 IS 8 BP 777 EP 789 DI 10.1111/psyp.12057 PG 13 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 279EL UT WOS:000328943100011 PM 23692525 ER PT J AU Evans, MC Paquet, AC Huang, W Napolitano, L Frantzell, A Toma, J Stawiski, EW Goetz, MB Petropoulos, CJ Whitcomb, J Coakley, E Haddad, M AF Evans, Mark C. Paquet, Agnes C. Huang, Wei Napolitano, Laura Frantzell, Arne Toma, Jonathan Stawiski, Eric W. Goetz, Matthew Bidwell Petropoulos, Christos J. Whitcomb, Jeannette Coakley, Eoin Haddad, Mojgan TI A CASE-BASED REASONING SYSTEM FOR GENOTYPIC PREDICTION OF HIV-1 CO-RECEPTOR TROPISM SO JOURNAL OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY LA English DT Article DE Tropism prediction; genotypic algorithm; HIV-1 co-receptor; V3 ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIDDEN MARKOV-MODELS; PHENOTYPE PREDICTION; CLINICAL MANAGEMENT; USAGE; INFECTION; SEQUENCE; DISEASE; ASSAY AB Accurate co-receptor tropism (CRT) determination is critical for making treatment decisions in HIV management. We created a genotypic tropism prediction tool by utilizing the case-based reasoning (CBR) technique that attempts to solve new problems through applying the solution from similar past problems. V3 loop sequences from 732 clinical samples with diverse characteristics were used to build a case library. Additional sequence and molecular properties of the V3 loop were examined and used for similarity assessment. A similarity metric was defined based on each attribute's frequency in the CXCR4-using viruses. We implemented three other genotype-based tropism predictors, support vector machines (SVM), position specific scoring matrices (PSSM), and the 11/25 rule, and evaluated their performance as the ability to predict CRT compared to Monogram's enhanced sensitivity Trofile (R) assay (ESTA). Overall concordance of the CBR based tropism prediction algorithm was 81%, as compared to ESTA. Sensitivity to detect CXCR4 usage was 90% and specificity was at 73%. In comparison, sensitivity of the SVM, PSSM, and the 11/25 rule were 85%, 81%, and 36% respectively while achieving a specificity of 90% by SVM, 75% by PSSM, and 97% by the 11/25 rule. When we evaluated these predictors in an unseen dataset, higher sensitivity was achieved by the CBR algorithm (87%), compared to SVM (82%), PSSM (76%), and the 11/25 rule (33%), while maintaining similar level of specificity. Overall this study suggests that CBR can be utilized as a genotypic tropism prediction tool, and can achieve improved performance in independent datasets compared to model or rule based methods. C1 [Evans, Mark C.; Paquet, Agnes C.; Stawiski, Eric W.; Haddad, Mojgan] Monogram Biosci Inc, Bioinformat Biostat, San Francisco, CA 94080 USA. [Huang, Wei; Frantzell, Arne; Toma, Jonathan; Petropoulos, Christos J.] Monogram Biosci Inc, Res & Dev, San Francisco, CA 94080 USA. [Napolitano, Laura; Coakley, Eoin] Monogram Biosci Inc, Clin Res, San Francisco, CA 94080 USA. [Whitcomb, Jeannette] Monogram Biosci Inc, Operat, San Francisco, CA 94080 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Haddad, M (reprint author), Monogram Biosci Inc, Bioinformat Biostat, San Francisco, CA 94080 USA. EM mhaddad@monogrambio.com OI Goetz, Matthew/0000-0003-4542-992X FU National Institutes of Health [U01 AI-42170, U01 AI-46362, U01 AI-68641] FX The authors would like to acknowledge the Monogram Biosciences clinical reference and R&D laboratories for performance of all phenotype and genotype assays. The CPCRA and INSIGHT networks are funded by the National Institutes of Health (U01 AI-42170, U01 AI-46362, U01 AI-68641). NR 32 TC 1 Z9 1 U1 0 U2 3 PU IMPERIAL COLLEGE PRESS PI LONDON PA 57 SHELTON ST, COVENT GARDEN, LONDON WC2H 9HE, ENGLAND SN 0219-7200 EI 1757-6334 J9 J BIOINF COMPUT BIOL JI J. Bioinform. Comput. Biol. PD AUG PY 2013 VL 11 IS 4 AR 1350006 DI 10.1142/S0219720013500066 PG 17 WC Biochemical Research Methods; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Computer Science; Mathematical & Computational Biology GA 268IO UT WOS:000328163800004 PM 23859270 ER PT J AU Ahmed, FA Kamnaksh, A Kovesdi, E Long, JB Agoston, DV AF Ahmed, Farid A. Kamnaksh, Alaa Kovesdi, Erzsebet Long, Joseph B. Agoston, Denes V. TI Long-term consequences of single and multiple mild blast exposure on select physiological parameters and blood-based biomarkers SO ELECTROPHORESIS LA English DT Article DE Animal models; Brain trauma; Experimental; Physiology; Proteomics ID TRAUMATIC BRAIN-INJURY; CONCUSSION; RATS AB Mild traumatic brain injury (mTBI), especially when it is repeated (rmTBI), can lead to progressive degenerative diseases and lasting neuropsychiatric abnormalities. To better understand the long-term pathobiological changes in mTBI and rmTBI, we exposed rats to single or repeated (5 total; administered on consecutive days) mild blast overpressure, monitored changes in physiological parameters, and determined the plasma levels of select biomarkers at 42 days post injury by proteomics. We unexpectedly found comparable changes in arterial oxygen saturation levels and heart rates of single-injured (SI) and multiple-injured (MI) rats throughout the observation period. Our analyses indicated lasting oxidative stress, vascular abnormalities, and neuronal and glial cell loss in both injured groups. However, MI rats exhibited a relatively more pronounced increase in the plasma levels of most of the tested markers-particularly those associated with inflammation-albeit the differences between the two injured groups were not statistically significant. Our findings indicate that the frequency of blast exposures is an important determinant of the resulting cumulative damage in rmTBI. C1 [Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA. [Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA. [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA. [Long, Joseph B.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA. RP Agoston, DV (reprint author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM vagoston@usuhs.edu FU Center for Neuroscience and Regenerative Medicine [G1703F] FX We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. The authors have no financial disclosures. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. NR 18 TC 15 Z9 16 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0173-0835 EI 1522-2683 J9 ELECTROPHORESIS JI Electrophoresis PD AUG PY 2013 VL 34 IS 15 BP 2229 EP 2233 DI 10.1002/elps.201300077 PG 5 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 261KJ UT WOS:000327663600012 PM 23712899 ER PT J AU Buttenheim, AM Cherng, ST Asch, DA AF Buttenheim, Alison M. Cherng, Sarah T. Asch, David A. TI Provider dismissal policies and clustering of vaccine-hesitant families An agent-based modeling approach SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE vaccination; immunization; immunization schedule; decision-making; parents ID DISEASE OUTBREAKS; REFUSES VACCINES; DYNAMICS; BEHAVIOR; IMMUNIZATION; EPIDEMIOLOGY; EXPERIENCE; NETWORKS; CHILDREN; HEALTH AB Many pediatric practices have adopted vaccine policies that require parents who refuse to vaccinate according to the ACIP schedule to find another health care provider. Such policies may inadvertently cluster unvaccinated patients into practices that tolerate non-vaccination or alternative schedules, turning them into risky pockets of low herd immunity. The objective of this study was to assess the effect of provider zero-tolerance vaccination policies on the clustering of intentionally unvaccinated children. We developed an agent-based model of parental vaccine hesitancy, provider non-vaccination tolerance, and selection of patients into pediatric practices. We ran 84 experiments across a range of parental hesitancy and provider tolerance scenarios. When the model is initialized, all providers accommodate refusals and intentionally unvaccinated children are evenly distributed across providers. As provider tolerance decreases, hesitant children become more clustered in a smaller number of practices and eventually are not able to find a practice that will accept them. Each of these effects becomes more pronounced as the level of hesitancy in the population rises. Heterogeneity in practice tolerance to vaccine-hesitant parents has the unintended result of concentrating susceptible individuals within a small number of tolerant practices, while providing little if any compensatory protection to adherent individuals. These externalities suggest an agenda for stricter policy regulation of individual practice decisions. C1 [Buttenheim, Alison M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA. [Buttenheim, Alison M.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Cherng, Sarah T.] Univ Michigan, Ctr Studies Complex Syst, Ann Arbor, MI 48109 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Buttenheim, AM (reprint author), Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA. EM abutt@nursing.upenn.edu OI Asch, David/0000-0002-7970-286X FU Robert Wood Johnson Foundation Health and Society Scholars Program at the University of Pennsylvania; National Cancer Institute [1KM1CA156715-01] FX This research was supported by the Robert Wood Johnson Foundation Health and Society Scholars Program at the University of Pennsylvania and by the National Cancer Institute (1KM1CA156715-01). NR 33 TC 7 Z9 7 U1 2 U2 11 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD AUG 1 PY 2013 VL 9 IS 8 BP 1819 EP 1824 DI 10.4161/hv.25635 PG 6 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 259SY UT WOS:000327547800035 PM 23831786 ER PT J AU Strickland, LR Guo, FJ Lok, K Garvey, WT AF Strickland, Leah R. Guo, Fangjian Lok, Kerry Garvey, W. Timothy TI Type 2 Diabetes With Partial Lipodystrophy of the Limbs A new lipodystrophy phenotype SO DIABETES CARE LA English DT Article ID FAMILIAL PARTIAL LIPODYSTROPHY; LEPTIN-REPLACEMENT THERAPY; FATTY-ACID-METABOLISM; INSULIN-RESISTANCE; INHERITED LIPODYSTROPHIES; ADIPOSE-TISSUE; GLUCOSE-UPTAKE; BODY-FAT; MACROPHAGES; MICE AB OBJECTIVELipodystrophies are categorized by the extent of fat loss (generalized vs. partial) and by inheritance (congenital vs. acquired). We examined whether a group of patients with partial lipodystrophy of the limbs (PLL), type 2 diabetes mellitus (T2DM), and an absence of a family history of lipodystrophy constitute a new clinical subtype.RESEARCH DESIGN AND METHODSTen women with T2DM and PLL were identified in academic diabetes clinics and were matched by age, sex, BMI, ethnicity, and diabetes status with 10 women with control T2DM without lipodystrophy. All patients were characterized by clinical evaluation and hyperinsulinemic clamp.RESULTSPatients with T2DM and PLL exhibited symmetrical loss of subcutaneous fat in forearms, or forearms plus calves, and acanthosis nigricans. Maximally stimulated glucose disposal rates were markedly reduced by 56% in the T2DM with PLL group compared with the control T2DM patients, whether normalized by body weight or surface area. Most PLL patients exhibited little or no insulin-mediated glucose uptake after subtraction of non-insulin-mediated glucose uptake. The T2DM with PLL group also had greater elevations in hepatic transaminases and triglycerides and earlier onset of diabetes compared with control T2DM.CONCLUSIONST2DM with PLL represents a previously unrecognized phenotype of lipodystrophy and of T2DM. These T2DM patients exhibit symmetrical lipodystrophy of the distal limbs, acanthosis nigricans, marked insulin resistance with little insulin-mediated glucose uptake, hypertriglyceridemia, and hepatic transaminase elevations, which are greater in severity than observed in patients with common T2DM. C1 [Strickland, Leah R.; Guo, Fangjian; Lok, Kerry; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Strickland, Leah R.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM garveyt@uab.edu RI Guo, Fangjian/B-7705-2015 OI Guo, Fangjian/0000-0003-3729-2724 FU National Institutes of Health [DK-083562, DK-038764]; Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases [P60-DK-079626]; Amylin Pharmaceuticals, Inc.; Merck Co.; UAB Obesity Training Program [T32 DK-062710] FX This work was supported by grants from the National Institutes of Health (DK-083562, DK-038764) to W.T.G, and the Merit Review program of the Department of Veterans Affairs to W.T.G. L.R.S. was supported by a Summer Research Fellowship for Medical Students provided by National Institute of Diabetes and Digestive and Kidney Diseases to the University of Alabama (UAB) Diabetes Research and Training Center (P60-DK-079626) and administered by the UAB Obesity Training Program (T32 DK-062710).; W.T.G. has received speaker honoraria from Merck & Co.; has served on advisory boards for Vivus, Daiichi-Sankyo, LipoScience, Janssen, and Alkermes; and has received research support from Amylin Pharmaceuticals, Inc. and Merck & Co. No other potential conflicts of interest relevant to this article were reported. NR 28 TC 8 Z9 10 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2013 VL 36 IS 8 BP 2247 EP 2253 DI 10.2337/dc12-1529 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255PP UT WOS:000327252600037 PM 23423695 ER PT J AU Lopes-Virella, MF Baker, NL Hunt, KJ Cleary, PA Klein, R Virella, G AF Lopes-Virella, Maria F. Baker, Nathaniel L. Hunt, Kelly J. Cleary, Patricia A. Klein, Richard Virella, Gabriel CA DCCT EDIC Res Grp TI Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects SO DIABETES CARE LA English DT Article ID EURODIAB PROSPECTIVE COMPLICATIONS; TNF RECEPTORS 1; RISK-FACTORS; MICROVASCULAR COMPLICATIONS; MACROVASCULAR COMPLICATIONS; ENDOTHELIAL DYSFUNCTION; VASCULAR-DISEASE; DCCT/EDIC COHORT; FOLLOW-UP; NEPHROPATHY AB OBJECTIVEThe current study aimed to determine in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications cohort whether or not abnormal levels of markers of inflammation and endothelial dysfunction measured in samples collected at DCCT baseline were able to predict the development of macroalbuminuria.RESEARCH DESIGN AND METHODSLevels of inflammation and endothelial cell dysfunction biomarkers were measured in 1,237 of 1,441 patients enrolled in the DCCT study who were both free of albuminuria and cardiovascular disease at baseline. To test the association of log-transformed biomarkers with albuminuria, generalized logistic regression models were used to quantify the association of increased levels of biomarkers and development of abnormal albuminuria. Normal, micro-, and macroalbuminuria were the outcomes of interest.RESULTSIn the logistic regression models adjusted by DCCT treatment assignment, baseline albumin excretion rate, and use of ACE/angiotensin receptor blocker drugs, one unit increase in the standardized levels of soluble E-selectin (sE-selectin) was associated with an 87% increase in the odds to develop macroalbuminuria and one unit increase in the levels of interleukin-6 (IL-6), plasminogen activator inhibitor 1 (PAI-1; total and active), and soluble tumor necrosis factor receptors (TNFR)-1 and -2 lead to a 30-50% increase in the odds to develop macroalbuminuria. Following adjustment for DCCT baseline retinopathy status, age, sex, HbA(1c), and duration of diabetes, significant associations remained for sE-selectin and TNFR-1 and -2 but not for IL-6 or PAI-1.CONCLUSIONSOur study indicates that high levels of inflammatory markers, mainly E-selectin and sTNRF-1 and -2, are important predictors of macroalbuminuria in patients with type 1 diabetes. C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.; Klein, Richard] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA. [Cleary, Patricia A.] George Washington Univ, Ctr Biostat, Washington, DC USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. EM virellam@musc.edu FU National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center; Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the National Institutes of Health; National Center for Research Resources through the General Clinical Research Centers program; Genentech, Inc.; [R01-DK-081352] FX This work was supported by the Grant R01-DK-081352 funded by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and by the Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center.; The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the National Institutes of Health. Additional support was provided by the National Center for Research Resources through the General Clinical Research Centers program and by Genentech, Inc., through a Cooperative Research and Development Agreement with the NIDDK. No other potential conflicts of interest relevant to this article were reported. NR 27 TC 27 Z9 27 U1 1 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2013 VL 36 IS 8 BP 2317 EP 2323 DI 10.2337/dc12-2521 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255PP UT WOS:000327252600047 PM 23514730 ER PT J AU Chirinos, JA Segers, P Gillebert, TC Buyzere, ML Van Daele, CM Khan, ZA Khawar, U Bacquer, D Rietzschel, ER AF Chirinos, Julio A. Segers, Patrick Gillebert, Thierry C. De Buyzere, Marc L. Van Daele, Caroline M. Khan, Zubair A. Khawar, Umair De Bacquer, Dirk Rietzschel, Ernst R. CA Asklepios Investigators TI Central Pulse Pressure and Its Hemodynamic Determinants in Middle-Aged Adults With Impaired Fasting Glucose and Diabetes SO DIABETES CARE LA English DT Article ID AORTIC ROOT DILATATION; CARDIOVASCULAR RISK-FACTORS; BODY-SURFACE AREA; ARTERIAL STIFFNESS; NONINVASIVE EVALUATION; ESSENTIAL-HYPERTENSION; WAVE REFLECTIONS; PLASMA-GLUCOSE; ORGAN DAMAGE; OLDER-ADULTS AB OBJECTIVEPulse pressure (PP), a strong predictor of cardiovascular events in type 2 diabetes, is a composite measure affected by several hemodynamic factors. Little is known about the hemodynamic determinants of central PP in type 2 diabetes or whether abnormalities in central pulsatile hemodynamics are already present in individuals with impaired fasting glucose (IFG). In a population-based study, we aimed to compare central PP and its hemodynamic determinants among adults with normal fasting glucose (n = 1654), IFG (n = 240), and type 2 diabetes (n = 33).RESEARCH DESIGN AND METHODSWe measured carotid pressure, left ventricular outflow, aortic root diameter, carotid artery flow, and distension in order to measure various structural and hemodynamic arterial parameters.RESULTSIFG was associated with a greater mean arterial pressure (MAP) but was not associated with intrinsic aortic stiffening or abnormal aortic pulsatile indices after adjustment for MAP. After adjustment for age, sex, and MAP, type 2 diabetes was associated with a higher aortic root characteristic impedance (Zc), aortic root elastance-thickness product (Eh), and aortic root pulse wave velocity (but not aortic root diameter), a greater carotid-femoral pulse wave velocity, and lower total arterial compliance and wave reflection magnitude. Carotid size, Zc, distensibility, or Eh did not significantly differ between the groups.CONCLUSIONSType 2 diabetes, but not IFG, is associated with greater large artery stiffness, without abnormalities in aortic root diameter or carotid stiffness. Subjects with type 2 diabetes demonstrate a decreased reflection magnitude, which may indicate an increased penetration of pulsatile energy to distal vascular beds. C1 [Chirinos, Julio A.; Khan, Zubair A.; Khawar, Umair] Univ Penn, Sch Med, Hosp Univ Penn, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Segers, Patrick] Univ Ghent, Inst Biomed Technol, B-9000 Ghent, Belgium. [Gillebert, Thierry C.; De Buyzere, Marc L.; Van Daele, Caroline M.; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium. [De Bacquer, Dirk; Rietzschel, Ernst R.] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium. RP Chirinos, JA (reprint author), Univ Penn, Sch Med, Hosp Univ Penn, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu OI Khan, Zubair/0000-0002-0451-9155; Gillebert, Thierry/0000-0002-3832-919X FU Fonds voor Wetenschappelijk Onderzoek Vlaanderen Grant [G.0.838.10]; American Heart Association [0885031N]; National Institutes of Health; Atcor Medical; Cardiodynamics; APC Cardiovascular Ltd. FX This study was supported by Fonds voor Wetenschappelijk Onderzoek Vlaanderen Grant G.0.838.10 and the American Heart Association Research Award 0885031N. J.A.C. received significant (>$10,000) grants from the National Institutes of Health and the American Heart Association for research studies related to arterial hemodynamics and has received minor support (equipment loans) from Atcor Medical, Cardiodynamics, and APC Cardiovascular Ltd. No other potential conflicts of interest relevant to this article were reported. NR 41 TC 17 Z9 19 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2013 VL 36 IS 8 BP 2359 EP 2365 DI 10.2337/dc12-1463 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255PP UT WOS:000327252600053 PM 23610081 ER PT J AU Hill, JO Galloway, JM Goley, A Marrero, DG Minners, R Montgomery, B Peterson, GE Ratner, RE Sanchez, E Aroda, VR AF Hill, James O. Galloway, James M. Goley, April Marrero, David G. Minners, Regan Montgomery, Brenda Peterson, Gregory E. Ratner, Robert E. Sanchez, Eduardo Aroda, Vanita R. TI Scientific Statement: Socioecological Determinants of Prediabetes and Type 2 Diabetes SO DIABETES CARE LA English DT Article ID POSTCHALLENGE PLASMA-GLUCOSE; SUGAR-SWEETENED BEVERAGES; SCHOOL-BASED INTERVENTION; TELEVISION VIEWING TIME; LIFE-STYLE INTERVENTION; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; SEDENTARY TIME; SITTING TIME C1 [Hill, James O.] Univ Colorado, Sch Med, Denver, CO USA. [Galloway, James M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Goley, April] Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC USA. [Marrero, David G.] Indiana Univ, Indianapolis, IN 46204 USA. [Minners, Regan; Ratner, Robert E.] Amer Diabet Assoc, Sci & Med Div, Alexandria, VA USA. [Montgomery, Brenda] Univ Washington, Seattle, WA 98195 USA. [Montgomery, Brenda] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Peterson, Gregory E.] Des Moines Univ, Des Moines, IA USA. [Sanchez, Eduardo] Amer Heart Assoc, Natl Ctr, Dallas, TX USA. [Aroda, Vanita R.] Georgetown Univ, Sch Med, MedStar Hlth Res Inst, Washington, DC USA. RP Ratner, RE (reprint author), Amer Diabet Assoc, Sci & Med Div, Alexandria, VA USA. EM rratner@diabetes.org NR 121 TC 28 Z9 28 U1 7 U2 20 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2013 VL 36 IS 8 BP 2430 EP 2439 DI 10.2337/dc13-1161 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255PP UT WOS:000327252600063 PM 23788649 ER PT J AU Oliva, EM Bowe, T Harris, AHS Trafton, JA AF Oliva, Elizabeth M. Bowe, Thomas Harris, Alex H. S. Trafton, Jodie A. TI Datapoints False Starts in Psychotherapy for Substance Use Disorders and PTSD in the VHA SO PSYCHIATRIC SERVICES LA English DT Editorial Material C1 [Oliva, Elizabeth M.; Bowe, Thomas; Harris, Alex H. S.; Trafton, Jodie A.] US Dept Vet Affairs, Program Evaluat & Resource Ctr, Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA. RP Oliva, EM (reprint author), US Dept Vet Affairs, Program Evaluat & Resource Ctr, Palo Alto Hlth Care Syst, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. EM elizabeth.oliva@va.gov NR 1 TC 2 Z9 2 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD AUG PY 2013 VL 64 IS 8 BP 722 EP 722 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255YN UT WOS:000327276100006 PM 23903602 ER PT J AU Gomez, CA Singh, N AF Gomez, Carlos A. Singh, Nina TI Donor-derived filamentous fungal infections in solid organ transplant recipients SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE aspergillosis; donor-derived infection; mold infections; mucormycosis; solid-organ transplantation; transplant infections ID COMMERCIAL RENAL-TRANSPLANTATION; KIDNEY-TRANSPLANTATION; INVASIVE ASPERGILLOSIS; MUCORMYCOSIS; ALLOGRAFT; RUPTURE; TOURISM; GRAFT; TRANSMISSION; MULTICENTER AB Purpose of reviewFilamentous fungal infections due to rare opportunistic moulds can be transmitted with an allograft. However, epidemiologic and clinical characteristics of donor-derived filamentous fungal infections (DDFFIs) in transplant recipients are poorly understood. Hence, the aim of this article is to describe donor-related risk factors, clinical presentation, graft and recipient outcomes associated with DDFFIs.Recent findingsTo date, 23 cases of donor-derived opportunistic filamentous fungal infections have been reported; a majority (91%) occurred in kidney transplant recipients. Aspergillus spp. was the most common organism (71%). Risk factors for DDFFIs include immunosuppressive state of the donor (transplant recipients serving as organ donors), near-drowning events, and transplant-tourism practices. DDFFIs manifested as vascular complications related to graft vasculature (65%), allograft dysfunction (43%) and unexplained febrile illness (39%) in the recipient. Rates of graft loss and overall mortality were 83 and 17%, respectively.SummaryDonor-transmitted filamentous mycoses have a unique spectrum of illness and clinical settings under which transmission occurs. Prompt recognition, early surgical intervention and specific antifungal therapy are necessary for achieving optimal graft and recipient outcomes. C1 [Gomez, Carlos A.] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA. [Singh, Nina] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu NR 49 TC 8 Z9 9 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD AUG PY 2013 VL 26 IS 4 BP 309 EP 316 DI 10.1097/QCO.0b013e3283630e4d PG 8 WC Infectious Diseases SC Infectious Diseases GA 248VL UT WOS:000326733200003 PM 23806894 ER PT J AU Rogus-Pulia, N Robbins, J AF Rogus-Pulia, Nicole Robbins, JoAnne TI Approaches to the Rehabilitation of Dysphagia in Acute Poststroke Patients SO SEMINARS IN SPEECH AND LANGUAGE LA English DT Article DE Dysphagia; stroke; acute; rehabilitation; evidence ID NEUROMUSCULAR ELECTRICAL-STIMULATION; ACUTE STROKE PATIENTS; RANDOMIZED CONTROLLED-TRIAL; ACUTE ISCHEMIC-STROKE; OROPHARYNGEAL DYSPHAGIA; SWALLOWING DISORDERS; PHARYNGEAL DYSPHAGIA; ASPIRATION PNEUMONIA; NEUROGENIC DYSPHAGIA; EMERGENCY-DEPARTMENT AB Dysphagia occurs frequently following stroke and may result in serious health consequences including pneumonia, malnutrition, dehydration, and mortality. Prevention of these negative health outcomes requires early identification and treatment of dysphagia. The speech-language pathologist, as part of a multidisciplinary team, holds the primary responsibility for selection of an effective dysphagia rehabilitation program for these patients. Because much research has focused on patients with chronic dysphagia, this review will focus on treatment of patients within the acute phase of recovery poststroke. Although some acute patients may experience transient dysphagia that resolves spontaneously, many will go on to develop chronic dysphagia that may be prevented with provision of early and intensive treatment. An overview of dysphagia following stroke will be provided with information regarding incidence, complications, evaluation, and causes of dysphagia. A thorough discussion of evidence supporting varying approaches to dysphagia rehabilitation will follow with inclusion of several current, novel, and experimental techniques. The importance of the multidisciplinary team and regular reevaluation will be emphasized as well. C1 [Rogus-Pulia, Nicole; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Gastroenterol & Hepatol, Madison, WI USA. RP Rogus-Pulia, N (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Madison GRECC 11G,Room D521, Madison, WI 53705 USA. EM nicolepulia@gmail.com NR 126 TC 5 Z9 6 U1 2 U2 21 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0734-0478 EI 1098-9056 J9 SEMIN SPEECH LANG JI Semin. Speech Lang. PD AUG PY 2013 VL 34 IS 3 BP 154 EP 169 DI 10.1055/s-0033-1358368 PG 16 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 242IF UT WOS:000326231800004 PM 24166190 ER PT J AU Potter, WB Basu, T O'Riordan, KJ Kirchner, A Rutecki, P Burger, C Roopra, A AF Potter, Wyatt B. Basu, Trina O'Riordan, Kenneth J. Kirchner, Allison Rutecki, Paul Burger, Corinna Roopra, Avtar TI Reduced Juvenile Long-Term Depression in Tuberous Sclerosis Complex Is Mitigated in Adults by Compensatory Recruitment of mGluR5 and Erk Signaling SO PLOS BIOLOGY LA English DT Article ID METABOTROPIC GLUTAMATE RECEPTORS; TEMPORAL-LOBE EPILEPSY; FRAGILE-X-SYNDROME; TUMOR-SUPPRESSOR COMPLEX; INITIATION-FACTOR 4E; MAMMALIAN TARGET; MOUSE MODEL; PROTEIN-SYNTHESIS; 3-KINASE/AKT PATHWAY; SYNAPTIC PLASTICITY AB Tuberous sclerosis complex (TSC) is a multisystem genetic disease that manifests with mental retardation, tumor formation, autism, and epilepsy. Heightened signaling through the mammalian target of rapamycin (mTOR) pathway is involved in TSC pathology, however it remains unclear how other signaling pathways are perturbed and contribute to disease symptoms. Reduced long-term depression (LTD) was recently reported in TSC mutant mice. We find that although reduced LTD is a feature of the juvenile mutant hippocampus, heightened expression of metabotropic glutamate receptor 5 and constitutively activated Erk signaling in the adult hippocampus drives wild-type levels of LTD. Increased mGluR5 and Erk results in a novel mTOR-independent LTD in CA1 hippocampus of adult mice, and contributes to the development of epileptiform bursting activity in the TSC2(+/-) CA3 region of the hippocampus. Inhibition of mGluR5 or Erk signaling restores appropriate mTOR-dependence to LTD, and significantly reduces epileptiform bursting in TSC2(+/-) hippocampal slices. We also report that adult TSC2(+/-) mice exhibit a subtle perseverative behavioral phenotype that is eliminated by mGluR5 antagonism. These findings highlight the potential of modulating the mGluR5-Erk pathway in a developmental stage-specific manner to treat TSC. C1 [Potter, Wyatt B.; Basu, Trina; Kirchner, Allison; Roopra, Avtar] Univ Wisconsin, Med Sci Ctr, Dept Neurosci, Madison, WI USA. [Potter, Wyatt B.; Basu, Trina] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [O'Riordan, Kenneth J.; Rutecki, Paul; Burger, Corinna] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Neurol, Madison, WI USA. [O'Riordan, Kenneth J.; Rutecki, Paul; Burger, Corinna] Univ Wisconsin, Madison, WI USA. RP Potter, WB (reprint author), Univ Wisconsin, Med Sci Ctr, Dept Neurosci, Madison, WI USA. EM asroopra@wisc.edu OI Burger, Corinna/0000-0002-9432-0114; O'Riordan, Kenneth J/0000-0003-0081-6010 FU Neuroscience Training Program [NIH/NIGMS T32GM007507]; Epilepsy Foundation individual pre-doctoral fellowship; CURE Multidisciplinary Award; NIH/NINDS [RO1NS065067] FX Neuroscience Training Program grant NIH/NIGMS T32GM007507. WBP was supported by an Epilepsy Foundation individual pre-doctoral fellowship. CURE Multidisciplinary Award to AR, CB, and PR. NIH/NINDS RO1NS065067 to AR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 9 Z9 10 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1545-7885 J9 PLOS BIOL JI PLoS. Biol. PD AUG PY 2013 VL 11 IS 8 AR e1001627 DI 10.1371/journal.pbio.1001627 PG 12 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 209PR UT WOS:000323771900008 PM 23966835 ER PT J AU Chiyomaru, T Yamamura, S Fukuhara, S Yoshino, H Kinoshita, T Majid, S Saini, S Chang, I Tanaka, Y Enokida, H Seki, N Nakagawa, M Dahiya, R AF Chiyomaru, Takeshi Yamamura, Soichiro Fukuhara, Shinichiro Yoshino, Hirofumi Kinoshita, Takashi Majid, Shahana Saini, Sharanjot Chang, Inik Tanaka, Yuichiro Enokida, Hideki Seki, Naohiko Nakagawa, Masayuki Dahiya, Rajvir TI Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR SO PLOS ONE LA English DT Article ID LONG NONCODING RNA; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAYS; EXPRESSION; BETA; MICRORNA-27A; PROGRESSION; SOX17; RISK AB Objective: Genistein is a soy isoflavone that has antitumor activity both in vitro and in vivo. It has been shown that genistein inhibits many type of cancers including prostate cancer (PCa) by regulating several cell signaling pathways and microRNAs (miRNAs). Recent studies suggest that the long non-coding RNAs (lncRNAs) are also involved in many cellular processes. At present there are no reports about the relationship between gensitein, miRNAs and lncRNAs. In this study, we focused on miRNAs, lncRNA that are regulated by genistein and investigated their functional role in PCa. Method: Microarray (SurePrint G3 Human GE 8x60K) was used for expression profiling of genistein treated and control PCa cells (PC3 and DU145). Functional assay (cell proliferation, migration, invasion, apoptosis and cell cycle assays) were performed with the PCa cell lines, PC3 and DU145. Both in vitro and in vivo (nude mouse) models were used for growth assays. Luciferase reporter assays were used for binding of miR-34a to HOTAIR. Results: LncRNA profiling showed that HOTAIR was highly regulated by genistein and its expression was higher in castration-resistant PCa cell lines than in normal prostate cells. Knockdown (siRNA) of HOTAIR decreased PCa cell proliferation, migration and invasion and induced apoptosis and cell cycle arrest. miR-34a was also up-regulated by genistein and may directly target HOTAIR in both PC3 and DU145 PCa cells. Conclusions: Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa. C1 [Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yoshino, Hirofumi; Enokida, Hideki] Kagoshima Univ, Dept Urol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan. [Kinoshita, Takashi; Seki, Naohiko; Nakagawa, Masayuki] Chiba Univ, Dept Funct Genom, Grad Sch Med, Chiba, Japan. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU National Center for Research Resources of the National Institutes of Health [R01CA160079, R01CA138642, T32DK007790]; VA Merit Review and VA Program Project FX This research was supported by the National Center for Research Resources of the National Institutes of Health through Grant Number R01CA160079, R01CA138642, T32DK007790 and VA Merit Review and VA Program Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 67 Z9 72 U1 1 U2 24 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 1 PY 2013 VL 8 IS 8 AR e70372 DI 10.1371/journal.pone.0070372 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 219PB UT WOS:000324518400062 PM 23936419 ER PT J AU Welzel, TM Graubard, BI Quraishi, S Zeuzem, S Davila, JA El-Serag, HB McGlynn, KA AF Welzel, Tania M. Graubard, Barry I. Quraishi, Sabah Zeuzem, Stefan Davila, Jessica A. El-Serag, Hashem B. McGlynn, Katherine A. TI Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PRIMARY LIVER-CANCER; C VIRUS-INFECTION; NONALCOHOLIC STEATOHEPATITIS; DIABETES-MELLITUS; HEPATITIS-B; ALCOHOL; DISEASE; COHORT; EPIDEMIOLOGY; ASSOCIATION AB OBJECTIVES: Risk factors for hepatocellular carcinoma (HCC) include hepatitis B and C viruses (HBV, HCV), excessive alcohol consumption, rare genetic disorders and diabetes/obesity. The population attributable fractions (PAF) of these factors, however, have not been investigated in population-based studies in the United States. METHODS: Persons >= 68 years diagnosed with HCC (n = 6,991) between 1994 and 2007 were identified in the SEER-Medicare database. A 5 % random sample (n = 255,702) of persons residing in SEER locations were selected for comparison. For each risk factor, odds ratios (ORs), 95 % confidence intervals (95 % CI) and PAFs were calculated. RESULTS: As anticipated, the risk of HCC was increased in relationship to each factor: HCV (OR 39.89, 95 % CI: 36.29-43.84), HBV (OR 11.17, 95 % CI: 9.18-13.59), alcohol-related disorders (OR 4.06, 95 % CI: 3.82-4.32), rare metabolic disorders (OR 3.45, 95 % CI: 2.97-4.02), and diabetes and/or obesity (OR 2.47, 95 % CI: 2.34-2.61). The PAF of all factors combined was 64.5 % (males 65.6 %; females 62.2 %). The PAF was highest among Asians (70.1 %) and lowest among black persons (52.4 %). Among individual factors, diabetes/obesity had the greatest PAF (36.6 %), followed by alcohol-related disorders (23.5%), HCV (22.4%), HBV (6.3%) and rare genetic disorders (3.2%). While diabetes/obesity had the greatest PAF among both males (36.4%) and females (36.7%), alcohol-related disorders had the second greatest PAF among males (27.8%) and HCV the second greatest among females (28.1%). Diabetes/obesity had the greatest PAF among whites (38.9%) and Hispanics (38.1%), while HCV had the greatest PAF among Asians (35.4%) and blacks (34.9%). The second greatest PAF was alcohol-related disorders in whites (25.6%), Hispanics (30.1%) and blacks (and 18.5%) and HBV in Asians (28.5%). CONCLUSIONS: The dominant risk factors for HCC in the United States among persons = 68 years differ by sex and race/ethnicity. Overall, eliminating diabetes/obesity could reduce the incidence of HCC more than the elimination of any other factor. C1 [Welzel, Tania M.; Zeuzem, Stefan] Johann Wolfgang Goethe Univ Hosp, Frankfurt, Germany. [Graubard, Barry I.; Quraishi, Sabah; McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD 20852 USA. [Davila, Jessica A.; El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Houston, TX USA. [Davila, Jessica A.; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. RP McGlynn, KA (reprint author), NCI, DCEG, NIH, EPS 5022,6120 Execut Blvd, Rockville, MD 20852 USA. EM mcglynnk@mail.nih.gov FU Intramural Research Program of the National Cancer Institute, National Institutes of Health FX This work was funded by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. NR 32 TC 76 Z9 76 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD AUG PY 2013 VL 108 IS 8 BP 1314 EP 1321 DI 10.1038/ajg.2013.160 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 222BM UT WOS:000324704800013 PM 23752878 ER PT J AU Dominitz, JA Robertson, DJ AF Dominitz, Jason A. Robertson, Douglas J. TI Interval Cancers: Learning from the Past as We Build for the Future SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID SERVICES TASK-FORCE; COLORECTAL-CANCER; SCREENING COLONOSCOPY; ASYMPTOMATIC ADULTS; COST-EFFECTIVENESS; MISS RATE; RISK; PREDICTORS; RATIONALE; MORTALITY AB While colonoscopy is the gold standard for the evaluation of the colon, research on post-colonoscopy colorectal cancers has increased our awareness of its limitations. In this issue of the Journal, Erichsen et al. provide evidence to suggest that post-colonoscopy colorectal cancers are most likely due to missed cancers at the time of the index colonoscopy, rather than due to aggressive tumor biology. Ultimately, studies demonstrating the shortcomings of colonoscopy are a call to action for the gastroenterology community to develop strategies and new technologies to improve the effectiveness of colonoscopy. C1 [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, White River Junct VA Med Ctr, White River Junction, VA USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 111 Gastro, Seattle, WA 98108 USA. EM jason.dominitz@va.gov OI Dominitz, Jason/0000-0002-8070-7086 NR 32 TC 2 Z9 2 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD AUG PY 2013 VL 108 IS 8 BP 1341 EP 1343 DI 10.1038/ajg.2013.177 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 222BM UT WOS:000324704800016 PM 23912407 ER PT J AU Friedlander, AH Aghazadehsanai, N Chang, TI Harada, N Garrett, NR AF Friedlander, A. H. Aghazadehsanai, N. Chang, T. I. Harada, N. Garrett, N. R. TI Prevalence of calcified carotid artery atheromas on panoramic images of individuals with primary hyperparathyroidism SO DENTOMAXILLOFACIAL RADIOLOGY LA English DT Article DE primary hyperparathyroidism; atherosclerosis; carotid artery; panoramic images ID PARATHYROID-HORMONE; CARDIOVASCULAR RISK; RADIOGRAPHY; MORTALITY; POPULATION; DISEASE AB Objectives: Primary hyperparathyroidism (PHPT), affecting 1% of the population, is associated with increased cardiovascular morbidity and mortality. The presence of calcified carotid artery plaque (CCAP) on panoramic images is a validated risk indicator of future adverse cardiovascular events. We hypothesized that military veterans aged 50 years or older diagnosed with PHPT by increased parathyroid hormone and calcium levels would frequently have CCAP on their images. Methods: We determined the prevalence rates of CCAP on the images of patients diagnosed with PHPT and evaluated their atherogenic risk profiles, including hypertension, dyslipidaemia, diabetes and obesity. Comparisons of atherogenic risk factors were made between subjects with and without observed CCAP on their panoramic images. Results: Of the 60 patients (86.7% males and 13.3% females, mean age 73.2 +/- 11.3 years) with PHPT, 40% had atheromas. There were no significant differences between CCAP+ and CCAP- groups in gender or race (p > 0.05). The atherogenic profile (age, body mass index, hypertension, diabetes, hyperlipidaemia) in the CCAP+ and CCAP- groups was not significantly different (p > 0.05). Conclusions: Calcified carotid artery atheromas are often seen on the panoramic images of patients with PHPT. Thus, dentists must be uniquely vigilant for these lesions when evaluating these studies. C1 [Friedlander, A. H.; Aghazadehsanai, N.; Chang, T. I.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, A. H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. [Friedlander, A. H.; Chang, T. I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Aghazadehsanai, N.; Chang, T. I.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Harada, N.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Member Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Harada, N.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Garrett, N. R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 26 TC 1 Z9 2 U1 0 U2 2 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0250-832X J9 DENTOMAXILLOFAC RAD JI Dentomaxillofac. Radiol. PD AUG PY 2013 VL 42 IS 8 AR 20130118 DI 10.1259/dmfr.20130118 PG 4 WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging GA 223FA UT WOS:000324788900003 PM 23775925 ER PT J AU Lam, DY O'Hare, AM Vig, EK AF Lam, Daniel Y. O'Hare, Ann M. Vig, Elizabeth K. TI Decisions About Dialysis Initiation in the Elderly SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; STARTING DIALYSIS; UNITED-STATES; END; PREVALENCE; LIFE; HEMODIALYSIS; MANAGEMENT; SURVIVAL C1 [Lam, Daniel Y.; O'Hare, Ann M.; Vig, Elizabeth K.] Univ Washington, Seattle, WA 98195 USA. [O'Hare, Ann M.; Vig, Elizabeth K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lam, DY (reprint author), Univ Washington, Med Ctr, Div Nephrol, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA. EM dlam34@u.washington.edu NR 20 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD AUG PY 2013 VL 46 IS 2 BP 298 EP 302 DI 10.1016/j.jpainsymman.2013.05.014 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 213AU UT WOS:000324026100019 PM 23938186 ER PT J AU Yoo, JW Nakagawa, S Kim, S AF Yoo, Ji Won Nakagawa, Shunichi Kim, Sulgi TI Relationships among advance directives, principal diagnoses, and discharge outcomes in critically ill older adults SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Critical care; Health services for the aged; Advance directives; Diagnosis-related groups ID LENGTH-OF-STAY; SEVERE SEPSIS; CARE-UNIT; RESOURCE USE; SURVIVORS; ADMISSION; MEDICARE; MEDICINE; HOSPICE; STATES AB Objective: The purpose of this study was to determine the relationships among advance directive status, principal diagnoses, and the discharge outcomes in community-dwelling, critically ill older adults. Method: Using administrative and clinical data (n = 1673), multinomial logit regressions were used to examine the relationships among advance directive status, principal diagnoses, and discharge outcomes (in-hospital deaths, hospice discharges, and transition to institutions). Results: In the overall sample, the adjusted probability of in-hospital deaths with advance directives (12%) was lower than that without advance directives (17%; odds ratio [OR] 0.56; p = 0.007) and the adjusted probability of hospice discharges with advance directives (11%) was higher than that without advance directives (7%; OR = 1.96; p = 0.03). Subgroup analysis showed that the magnitude of the abovementioned changes was aggregated when their principal diagnoses were a group of diseases with more difficult prognostication (circulatory and respiratory diseases) and more potential for reversibility (infectious diseases). By contrast, the magnitude of the abovementioned findings was diminished with other principal diagnoses. On the other hand, the presence of advance directives did not make a contribution to transition from communities to institutions. Significance of results: Significantly fewer in-hospital deaths in addition to higher hospice discharges were observed with any advance directives in community-dwelling, critically ill older adults. The magnitude of these findings was aggregated when their principal diagnoses were a group of diseases with more difficult prognostication (circulatory and respiratory diseases) and more potential for reversibility (infectious diseases). By contrast, the magnitude of these findings was diminished with other principal diagnoses. C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Educ & Clin Ctr, Bronx, NY USA. [Kim, Sulgi] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Yoo, Ji Won] Korea Univ, Dept Internal Med, Seoul, South Korea. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org NR 37 TC 1 Z9 1 U1 3 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD AUG PY 2013 VL 11 IS 4 BP 315 EP 322 DI 10.1017/S1478951512000259 PG 8 WC Health Policy & Services SC Health Care Sciences & Services GA 219XL UT WOS:000324544900005 PM 22892195 ER PT J AU Stiens, SA Fawber, HL Yuhas, SA AF Stiens, Steven A. Fawber, Heidi L. Yuhas, Steven A. TI The Person with a Spinal Cord Injury An Evolving Prototype for Life Care Planning SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Spinal cord injury; Life care plan; Problem list; Patient-centered care; Cost of care; Outcome; Prevention ID QUALITY-OF-LIFE; NEUROGENIC BOWEL; MEDICINE; ADJUSTMENT; EMPLOYMENT; PEOPLE AB The sequela of spinal cord injury (SCI) can provide a prototype for life care planning because the segmental design of the vertebrate body allows assessments to be quantitative, repeatable, and predictive of the injured person's impairments, self-care capabilities, and required assistance. Life care planning for patients with SCI uses a standard method that is comparable between planner, yet individualizes assessment and seeks resources that meet unique patient-centered needs in their communities of choice. Clinical care and rehabilitation needs organized with an SCI problem list promotes collaboration by the interdisciplinary team, caregivers, and family in efficient achievement of patient-centered goals and completion of daily care plans. C1 [Stiens, Steven A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Stiens, Steven A.] Univ Washington, Seattle, WA 98195 USA. [Stiens, Steven A.] Univ Hosp, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Fawber, Heidi L.; Yuhas, Steven A.] Int Assoc Rehabil Profess, Int Acad Life Care Planners Sect, Glenview, IL 60025 USA. [Yuhas, Steven A.] Direct Grp Inc, Mt Pleasant, SC 29464 USA. RP Stiens, SA (reprint author), Univ Hosp, VA Puget Sound Hlth Care Syst, POB 356490,Hlth Sci Bldg,1959 North East Pacific, Seattle, WA 98195 USA. EM Steven.Stiens@va.gov FU Lou and Virginia Muhlhofer, Cincinnati, OH, USA FX Lou and Virginia Muhlhofer, Cincinnati, OH, USA. NR 51 TC 1 Z9 1 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD AUG PY 2013 VL 24 IS 3 BP 419 EP + DI 10.1016/j.pmr.2013.03.006 PG 27 WC Rehabilitation SC Rehabilitation GA 214QG UT WOS:000324149800004 PM 23910484 ER PT J AU Chen, BB Glasser, JR Coon, TA Mallampalli, RK AF Chen, B. B. Glasser, J. R. Coon, T. A. Mallampalli, R. K. TI Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis SO CELL DEATH & DISEASE LA English DT Article DE ubiquitin; tumor; proteolysis; drug; small molecule ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SPINDLE ASSEMBLY CHECKPOINT; HISTONE H3 PHOSPHORYLATION; KINASE INHIBITOR; KINETOCHORE ORIENTATION; CHROMOSOME CONDENSATION; MITOTIC PROGRESSION; REGULATORY ENZYME; HUMAN-CELLS; PROTEIN AB Aurora B kinase is an integral regulator of cytokinesis, as it stabilizes the intercellular canal within the midbody to ensure proper chromosomal segregation during cell division. Here we identified that the ubiquitin E3 ligase complex SCFFBXL2 mediates Aurora B ubiquitination and degradation within the midbody, which is sufficient to induce mitotic arrest and apoptosis. Three molecular acceptor sites (K-102, K-103 and K-207) within Aurora B protein were identified as important sites for its ubiquitination. A triple Lys mutant of Aurora B (K-102/103/207R) exhibited optimal resistance to SCFFBXL2-directed polyubiquitination, and overexpression of this variant resulted in a significant delay in anaphase onset, resulting in apoptosis. A unique small molecule F-box/LRR-repeat protein 2 (FBXL2) activator, BC-1258, stabilized and increased levels of FBXL2 protein that promoted Aurora B degradation, resulting in tetraploidy, mitotic arrest and apoptosis of tumorigenic cells, and profoundly inhibiting tumor formation in athymic nude mice. These findings uncover a new proteolytic mechanism targeting a key regulator of cell replication that may serve as a basis for chemotherapeutic intervention in neoplasia. C1 [Chen, B. B.; Glasser, J. R.; Coon, T. A.; Mallampalli, R. K.] Univ Pittsburgh, Dept Med Pulm Allergy & Crit Care Med, UPMC Montefiore, Pittsburgh, PA 15213 USA. [Chen, B. B.] Univ Pittsburgh, Dept Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, R. K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Chen, BB (reprint author), Univ Pittsburgh, Dept Med Pulm Allergy & Crit Care Med, UPMC Montefiore, 3459 5th Ave,NW 628, Pittsburgh, PA 15213 USA. EM chenb@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL116472, HL096376, HL097376, HL098174] FX We thank DW Gerlich for providing pH2B-mCherry-IRES-puro2 and pMyrPalm-mEGFP plasmids. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL116472 (to BBC), HL096376, HL097376 and HL098174 (to RKM). NR 49 TC 15 Z9 15 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD AUG PY 2013 VL 4 AR e759 DI 10.1038/cddis.2013.271 PG 10 WC Cell Biology SC Cell Biology GA 214PK UT WOS:000324146000016 PM 23928698 ER PT J AU Clark, KB Eisenstein, EM AF Clark, Kevin B. Eisenstein, E. M. TI Targeting Host Store-Operated Ca2+ Release to Attenuate Viral Infections SO CURRENT TOPICS IN MEDICINAL CHEMISTRY LA English DT Review DE diarrhea; intracellular Ca2+ signaling; IP3 pathway and receptors; protein-protein allostery; T cells; viral replication; virus-associated dementia; virus-induced cytotoxicity ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; EPSTEIN-BARR-VIRUS; ENDOPLASMIC-RETICULUM MEMBRANE; CEREBELLAR PURKINJE-CELLS; POLYAMINE-SENSITIVE-SITE; LONG-TERM POTENTIATION; NA+/H+ EXCHANGER NHE3; D-ASPARTATE RECEPTOR; LIGAND-BINDING SITE; TRISPHOSPHATE RECEPTOR AB Viruses coopt host intracellular Ca2+ signaling pathways to optimize timing and effectiveness of infection stages against barriers to invasion, pathogenesis, replication, and release. Virus-induced changes in free cytosolic Ca2+ levels facilitate virus adsorption, uncoating, catalysis, toxin production, structural assembly and stabilization, trafficking, and fusion and budding. Ca2+-associated alterations in virus status also selectively precipitate host cytopathologies through, among other events, retardation or induction of apoptosis, elevation of metabolic stress and reactive oxygen species production, and promotion of proinflammatory cytokine and chemokine synthesis and release. Viral particles and proteins tune spatiotemporal dynamics of host free cytosolic Ca2+ concentrations by modulating Ca2+ entry from the extracellular environment, upstream first or second messengers, ion-and ATP-dependent Ca2+ pumps that sequester or extrude free cytosolic Ca2+, store-operated Ca2+ mobilization and leakage, and viral capsid/envelope and downstream host Ca2+ binding proteins and sensors. Each of these major viral mechanisms, briefly reviewed in this article, presents a suitable drug target capable of mitigating the severity and incidence of viral infections. Given its pivotal role in cellular response regulation, bioenergetics, posttranslational protein and lipid modification and transport, homeostasis, cell motility and morphogenesis, and T lymphocyte proliferation, targeting virally stimulated inositol 1,4,5-trisphoshate (IP3)-mediated store-operated Ca2+ release especially offers unique, predictable benefits for augmenting immunoprotection in vertebrate clinical populations. We appraise possibilities of modulating this system with experimental proteins that gate activation kinetics of endoplasmic-reticulum-localized Ca2+-conducting IP3 receptors via allosteric protein-protein interactions. Such compounds are expected to be valuable in treating primary disease symptoms and sequelae, including virus-associated dementia. C1 [Eisenstein, E. M.] Vet Affairs Greater Los Angeles Hlth Care Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. RP Clark, KB (reprint author), 4229 SE Harney St, Portland, OR 97206 USA. EM kbclarkphd@yahoo.com NR 220 TC 3 Z9 3 U1 4 U2 8 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0266 J9 CURR TOP MED CHEM JI Curr. Top. Med. Chem. PD AUG PY 2013 VL 13 IS 16 BP 1916 EP 1932 PG 17 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 214WH UT WOS:000324167500003 PM 23895094 ER PT J AU Rosenberg, PB Lanctot, KL Drye, LT Herrmann, N Scherer, RW Bachman, DL Mintzer, JE AF Rosenberg, Paul B. Lanctot, Krista L. Drye, Lea T. Herrmann, Nathan Scherer, Roberta W. Bachman, David L. Mintzer, Jacobo E. CA ADMET Investigators TI Safety and Efficacy of Methylphenidate for Apathy in Alzheimer's Disease: A Randomized, Placebo-Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DEXTROAMPHETAMINE CHALLENGE; NEUROPSYCHIATRIC SYMPTOMS; DEMENTIA; DEPRESSION; RELIABILITY; SERTRALINE; DOPAMINE; VALIDITY; DESIGN; CARE AB Objective: In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method: Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer's disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December 2011. Primary outcomes were change in Apathy Evaluation Scale (AES) score and modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGI-C). Secondary outcomes included change in Neuropsychiatric Inventory (NPI) apathy score, Mini-Mental State Examination (MMSE) score, and safety. Results: 60 participants were randomly assigned (29 methylphenidate, 31 placebo). At baseline, mean (SD) age = 76 (8) years, MMSE score = 20 (5), AES score = 51 (12), NPI total score = 16 (8), and 62% of the participants (n=37) were female. After 6 weeks' treatment, mean (SD) change in AES score was -1.9 (1.5) for methylphenidate and 0.6 (1.4) for placebo (P = .23). Odds ratio for improvement in ADCS-CGI-C was 3.7 (95% CI, 1.3 to 10.8) (P = .02), with 21% of methylphenidate versus 3% of placebo rated as moderately or markedly improved. NPI apathy score improvement was 1.8 points (95% CI, 0.3 to 3.4) greater on methylphenidate than on placebo (P = .02). MMSE trended toward improvement on methylphenidate (P = .06). There were trends toward greater anxiety and weight loss >2% in the methylphenidate-treated group. Conclusions: Methylphenidate treatment of apathy in Alzheimer's disease was associated with significant improvement in 2 of 3 efficacy outcomes and a trend toward improved global cognition with minimal adverse events, supporting the safety and efficacy of methylphenidate treatment for apathy in Alzheimer's disease. Trial Registration: ClinicalTrials.gov identifier: NCT01117181 (C) Copyright 2013 Physicians Postgraduate Press, Inc. C1 [Rosenberg, Paul B.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Drye, Lea T.; Scherer, Roberta W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Sunnybrook Res Inst, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Sunnybrook Res Inst, Brain Sci Res Program, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Dept Pharmacol Toxicol, Toronto, ON M5S 1A1, Canada. [Bachman, David L.; Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Alzheimers Res Program, Charleston, SC 29425 USA. [Bachman, David L.; Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Alzheimers Clin Program, Charleston, SC 29425 USA. [Bachman, David L.; Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Mintzer, JE (reprint author), Alzheimers Res Program, 5900 Core Rd,Ste 203, Charleston, SC 29406 USA. EM mintzerj@musc.edu OI Drye, Lea/0000-0002-2964-1878 FU National Institute on Aging [R01 AG033032-01, 1 K08 AG029157-01A1] FX National Institute on Aging (R01 AG033032-01 and 1 K08 AG029157-01A1). NR 27 TC 34 Z9 38 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD AUG PY 2013 VL 74 IS 8 BP 810 EP 816 DI 10.4088/JCP.12m08099 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 212NI UT WOS:000323989700004 PM 24021498 ER PT J AU Teo, AR Du, YB Escobar, JI AF Teo, Alan R. Du, Ye B. Escobar, Javier I. TI How can we better manage difficult patient encounters? SO JOURNAL OF FAMILY PRACTICE LA English DT Editorial Material ID CARE; OUTCOMES; HEALTH C1 [Teo, Alan R.] Portland VA Med Ctr, Portland, OR USA. [Teo, Alan R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Du, Ye B.] Columbia Univ, Dept Psychiat, New York, NY USA. [Escobar, Javier I.] Rutgers Robert Wood Johnson Med Sch, Dept Psychiat & Family Med, New Brunswick, NJ USA. RP Teo, AR (reprint author), 3710 SW US Vet Hosp Rd,R&D66, Portland, OR 97239 USA. EM alan.teo@va.gov NR 19 TC 5 Z9 5 U1 1 U2 4 PU DOWDEN HEALTH MEDIA PI MONTVALE PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD AUG PY 2013 VL 62 IS 8 BP 414 EP 421 PG 6 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 218WW UT WOS:000324464300005 PM 24143334 ER PT J AU Jafari, S Etminan, M Aminzadeh, F Samii, A AF Jafari, Siavash Etminan, Mahyar Aminzadeh, Farhad Samii, Ali TI Head injury and risk of Parkinson disease: A systematic review and meta-analysis SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; head injury; head trauma; traumatic brain injury; inflammation; meta-analysis; systematic review ID TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL-FACTORS; YOUNG-ONSET; POPULATION; EPIDEMIOLOGY; HISTORY; LIFE AB Head trauma has been implicated in the etiopathogenesis of Parkinson's disease (PD). We performed a meta-analysis to investigate the association between head trauma and the risk of developing PD. We included observational studies if they (1) clearly defined PD, (2) defined head trauma leading to concussion, and (3) presented odds ratios (ORs) and 95% confidence intervals (CIs) or provided data to compute these statistics. Random effect model was used to estimate the pooled, adjusted OR. Heterogeneity between studies was evaluated with the Q test and the I-2 statistic. We conducted a sensitivity analysis to assess the influence of each study and repeated the analysis by excluding the studies with the largest weights. We used funnel plot to assess the presence of publication bias. After reviewing more than 636 article titles, 34 articles were selected for full review. In total, 22 studies (19 case-control studies, 2 nested case-control studies, and 1 cohort study) were included in the meta-analysis. The pooled OR for the association of PD and head trauma was 1.57 (95% CI, 1.35-1.83). The results of our meta-analysis indicate that a history of head trauma that results in concussion is associated with a higher risk of developing PD. (c) 2013 Movement Disorder Society C1 [Jafari, Siavash] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Etminan, Mahyar] Univ British Columbia, Fac Med, Prov Hlth Serv, Therapeut Evaluat Unit, Vancouver, BC, Canada. [Aminzadeh, Farhad] St Georges Univ, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England. [Samii, Ali] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Seattle Parkinson Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Samii, A (reprint author), Univ Washington, Vet Affairs Puget Hlth Care Syst, Seattle Parkinson Dis Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM asamii@u.washington.edu NR 52 TC 32 Z9 33 U1 0 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD AUG PY 2013 VL 28 IS 9 BP 1222 EP 1229 DI 10.1002/mds.25458 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 210KA UT WOS:000323830100015 PM 23609436 ER PT J AU Sung, VW Nicholas, AP AF Sung, Victor W. Nicholas, Anthony P. TI Nonmotor Symptoms in Parkinson's Disease Expanding the View of Parkinson's Disease Beyond a Pure Motor, Pure Dopaminergic Problem SO NEUROLOGIC CLINICS LA English DT Article DE Parkinson's disease; Nonmotor symptoms; Motor symptoms; Dopaminergic ID QUALITY STANDARDS SUBCOMMITTEE; SLEEP BEHAVIOR DISORDER; L-DOPA; AMERICAN-ACADEMY; PRACTICE PARAMETER; RATING-SCALES; REM-SLEEP; QUESTIONNAIRE; DEPRESSION; RECOMMENDATIONS AB Nonmotor symptoms (NMS) of Parkinson's disease (PD) are critical to identify and treat because of their impact on quality of life. Despite growing evidence of the importance of NMS on patients' quality of life, gaps remain in their recognition and treatment. The result is a need for increased information and understanding of specific NMS and the clinical approaches for their assessment and management in the context of PD as a whole. This article discusses the NMS of PD, their relationship to the pathologic basis of PD, and how NMS can be best managed. C1 [Sung, Victor W.; Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Sung, Victor W.; Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Sung, VW (reprint author), Univ Alabama Birmingham, Dept Neurol, SC 360C,1720 7th Ave South, Birmingham, AL 35294 USA. EM vsung@uab.edu OI Sung, Victor/0000-0003-1024-3404 NR 78 TC 14 Z9 15 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD AUG PY 2013 VL 31 IS 3 SU S BP S1 EP + DI 10.1016/j.ncl.2013.04.013 PG 17 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 218PV UT WOS:000324445500002 PM 23931951 ER PT J AU Pongas, G Dasgupta, SK Thiagarajan, P AF Pongas, Georgios Dasgupta, Swapan Kumar Thiagarajan, Perumal TI Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia SO THROMBOSIS RESEARCH LA English DT Article ID HEPARIN-INDUCED THROMBOCYTOPENIA; DEEP-VEIN THROMBOSIS; CHLAMYDIA-PNEUMONIAE; PLATELET ACTIVATION; IGG-SEROPOSITIVITY; SPONTANEOUS HIT; PLATELET-FACTOR-4; BINDING; COMPLICATIONS; PURIFICATION AB Heparin-induced thrombocytopenia (HIT) is an antibody-mediated syndrome of thrombocytopenia and prothrombotic state that follows exposure to heparin. However, spontaneous HIT has been described in the setting of infection, without evidence of previous heparin administration. Since PF4 binds to lipid A portion of lipopolysaccharide, we tested for the presence of antiPF4/heparin antibodies in patients with gram-negative bacteremia. Patients with bacteremia had higher titers of antiPF4/heparin antibodies compared to normal controls 26.3 +/- SD 34 units, N = 32 versus 6.3 +/- SD 2.38 units, N = 10, P = 0.001. FITC-labeled PF4 interacted with lipopolysaccharide in a concentration-dependent manner as determined by quenching of the emission spectrum following excitation at lambda 488. In addition, immunoaffinity purified antiPF4/Heparin antibodies from 3 patients with HIT cross-reacted with PF4/heparin complex. These results show that PF4/LPS complex is immunogenic and can elicit cross-reacting antibodies against PF4/Heparin, providing an explanation for the presence of these antibodies in individuals, who were never been exposed to heparin before. These antibodies may also be at least partly responsible for the thrombocytopenia associated with infection. Published by Elsevier Ltd. C1 [Pongas, Georgios; Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Dasgupta, Swapan Kumar] Baylor Coll Med, Dept Pathol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Thiagarajan, P (reprint author), Michael E DeBakey VA Med Ctr, Mail Stop 113,2002 Holcombe Blvd, Houston, TX 77030 USA. EM perumalt@bcm.edu OI Thiagarajan, Perumal/0000-0003-2186-7036 FU Department of Veterans Affairs; National Blood Foundation FX GP and PT designed and perform the experiments and wrote the paper. SKG isolated the PF4 and performed fluorescence measurements. This study was supported in part by grants from the Department of Veterans Affairs (to PT) and by a grant from the National Blood Foundation (to SKD). NR 26 TC 6 Z9 6 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD AUG PY 2013 VL 132 IS 2 BP 217 EP 220 DI 10.1016/j.thromres.2013.06.013 PG 4 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 213LV UT WOS:000324059600028 PM 23830968 ER PT J AU Aston-Mourney, K Subramanian, SL Zraika, S Samarasekera, T Meier, DT Goldstein, LC Hull, RL AF Aston-Mourney, Kathryn Subramanian, Shoba L. Zraika, Sakeneh Samarasekera, Thanya Meier, Daniel T. Goldstein, Lynn C. Hull, Rebecca L. TI One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE DPP-4 inhibitor; IAPP; beta-cell mass; amyloid; exocrine pancreas pathology ID ENDOPLASMIC-RETICULUM STRESS; TRANSGENIC MOUSE; DIPEPTIDYL PEPTIDASE-4; GLYCEMIC CONTROL; DIABETES-MELLITUS; INCRETIN THERAPY; DPP-4 INHIBITOR; RODENT MODEL; POLYPEPTIDE; METFORMIN AB The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin is an attractive therapy for diabetes, as it increases insulin release and may preserve beta-cell mass. However, sitagliptin also increases beta-cell release of human islet amyloid polypeptide (hIAPP), the peptide component of islet amyloid, which is cosecreted with insulin. Thus, sitagliptin treatment may promote islet amyloid formation and its associated beta-cell toxicity. Conversely, metformin treatment decreases islet amyloid formation by decreasing beta-cell secretory demand and could therefore offset sitagliptin's potential proamyloidogenic effects. Sitagliptin treatment has also been reported to be detrimental to the exocrine pancreas. We investigated whether long-term sitagliptin treatment, alone or with metformin, increased islet amyloid deposition and beta-cell toxicity and induced pancreatic ductal proliferation, pancreatitis, and/or pancreatic metaplasia/neoplasia. hIAPP transgenic and nontransgenic littermates were followed for 1 yr on no treatment, sitagliptin, metformin, or the combination. Islet amyloid deposition, beta-cell mass, insulin release, and measures of exocrine pancreas pathology were determined. Relative to untreated mice, sitagliptin treatment did not increase amyloid deposition, despite increasing hIAPP release, and prevented amyloid-induced beta-cell loss. Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice. Ductal proliferation was not altered among treatment groups, and no evidence of pancreatitis, ductal metaplasia, or neoplasia were observed. Therefore, long-term sitagliptin treatment stimulates beta-cell secretion without increasing amyloid formation and protects against amyloid-induced beta-cell loss. This suggests a novel effect of sitagliptin to protect the beta-cell in type 2 diabetes that appears to occur without adverse effects on the exocrine pancreas. C1 [Aston-Mourney, Kathryn; Subramanian, Shoba L.; Zraika, Sakeneh; Samarasekera, Thanya; Meier, Daniel T.; Hull, Rebecca L.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Aston-Mourney, Kathryn; Subramanian, Shoba L.; Zraika, Sakeneh; Samarasekera, Thanya; Meier, Daniel T.; Hull, Rebecca L.] Univ Washington, Seattle, WA 98195 USA. [Aston-Mourney, Kathryn] Deakin Univ, Sch Med, Metab Res Unit, Geelong, Vic 3217, Australia. [Goldstein, Lynn C.] PhenoPath Labs, Seattle, WA USA. RP Hull, RL (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@uw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K99-DK-080945, T32-DK-007247, P30-DK-017047]; University of Washington McAbee Fellowship; American Diabetes Association Mentor Award; Department of Veterans Affairs FX This work was supported by the Department of Veterans Affairs and National Institute of Diabetes and Digestive and Kidney Diseases grants, K99-DK-080945 (S. Zraika), T32-DK-007247, and P30-DK-017047 (Cellular and Molecular Imaging Core of the University of Washington Diabetes Research Center). K. Aston-Mourney was supported by the University of Washington McAbee Fellowship and an American Diabetes Association Mentor Award (to Dr. S. E. Kahn). NR 47 TC 19 Z9 20 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD AUG PY 2013 VL 305 IS 4 BP E475 EP E484 DI 10.1152/ajpendo.00025.2013 PG 10 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 205GT UT WOS:000323432000002 PM 23736544 ER PT J AU Ibrahim, MK Barnes, JL Anstead, GM Jimenez, F Travi, BL Peniche, AG Osorio, EY Ahuja, SS Melby, PC AF Ibrahim, Marwa K. Barnes, Jeffrey L. Anstead, Gregory M. Jimenez, Fabio Travi, Bruno L. Peniche, Alex G. Osorio, E. Yaneth Ahuja, Seema S. Melby, Peter C. TI The Malnutrition-Related Increase in Early Visceralization of Leishmania donovani Is Associated with a Reduced Number of Lymph Node Phagocytes and Altered Conduit System Flow SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID PROTEIN-ENERGY MALNUTRITION; BONE-MARROW-CELLS; IMMUNE-RESPONSE; MALNOURISHED RATS; DENDRITIC CELLS; SOUTHERN SUDAN; RISK-FACTOR; KALA-AZAR; INFECTION; NUTRITION AB In a murine model of moderate childhood malnutrition we found that polynutrient deficiency led to a 4-5-fold increase in early visceralization of L. donovani (3 days post-infection) following cutaneous infection and a 16-fold decrease in lymph node barrier function (p<0.04 for all). To begin to understand the mechanistic basis for this malnutrition-related parasite dissemination we analyzed the cellularity, architecture, and function of the skin-draining lymph node. There was no difference in the localization of multiple cell populations in the lymph node of polynutrient deficient (PND) mice, but there was reduced cellularity with fewer CD11c(+) dendritic cells (DCs), fibroblastic reticular cells (FRCs), MOMA-2(+) macrophages, and CD169(+) subcapsular sinus macrophage (p<0.05 for all) compared to the well-nourished (WN) mice. The parasites were equally co-localized with DCs associated with the lymph node conduit network in the WN and PND mice, and were found in the high endothelial venule into which the conduits drain. When a fluorescent low molecular weight (10 kD) dextran was delivered in the skin, there was greater efflux of the marker from the lymph node conduit system to the spleens of PND mice (p<0.04), indicating that flow through the conduit system was altered. There was no evidence of disruption of the conduit or subcapsular sinus architecture, indicating that the movement of parasites into the subcortical conduit region was due to an active process and not from passive movement through a leaking barrier. These results indicate that the impaired capacity of the lymph node to act as a barrier to dissemination of L. donovani infection is associated with a reduced number of lymph node phagocytes, which most likely leads to reduced capture of parasites as they transit through the sinuses and conduit system. C1 [Ibrahim, Marwa K.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Ibrahim, Marwa K.; Barnes, Jeffrey L.; Anstead, Gregory M.; Jimenez, Fabio; Ahuja, Seema S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Barnes, Jeffrey L.; Anstead, Gregory M.; Jimenez, Fabio; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Travi, Bruno L.; Peniche, Alex G.; Osorio, E. Yaneth; Melby, Peter C.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA. [Travi, Bruno L.; Melby, Peter C.] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA. [Travi, Bruno L.; Melby, Peter C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA. [Travi, Bruno L.; Melby, Peter C.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. RP Ibrahim, MK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. EM pcmelby@utmb.edu OI Ibrahim, Marwa/0000-0002-2603-8280 NR 67 TC 5 Z9 5 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD AUG PY 2013 VL 7 IS 8 AR e2329 DI 10.1371/journal.pntd.0002329 PG 16 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 211WE UT WOS:000323941500008 PM 23967356 ER PT J AU Amato, RJ Felts, AS Rodriguez, AL Venable, DF Morrison, RD Byers, FW Daniels, JS Niswender, CM Conn, PJ Lindsley, CW Jones, CK Emmitte, KA AF Amato, Russell J. Felts, Andrew S. Rodriguez, Alice L. Venable, Daryl F. Morrison, Ryan D. Byers, Frank W. Daniels, J. Scott Niswender, Colleen M. Conn, P. Jeffrey Lindsley, Craig W. Jones, Carrie K. Emmitte, Kyle A. TI Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu(5): Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of Cocaine Addiction SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE mGlu(5); negative allosteric modulator; noncompetitive antagonist; CNS; cocaine; addiction ID METABOTROPIC GLUTAMATE RECEPTORS; MGLUR5 ANTAGONIST MPEP; 2-METHYL-6-(PHENYLETHYNYL)-PYRIDINE MPEP; SQUIRREL-MONKEYS; DRUG DISCOVERY; CNS EXPOSURE; PHARMACOLOGY; SEEKING; REWARD; POTENT AB Cocaine is a powerful and highly addictive stimulant that disrupts the normal reward circuitry in the central nervous system (CNS), producing euphoric effects. Cocaine use can lead to acute and life threatening emergencies, and abuse is associated with increased risk for contracting infectious diseases. Though certain types of behavioral therapy have proven effective for treatment of cocaine addiction, relapse remains high, and there are currently no approved medications for the treatment of cocaine abuse. Evidence has continued to accumulate that indicates a critical role for the metabotropic glutamate receptor subtype 5 (mGlu(5)) in the modulation of neural circuitry associated with the addictive properties of cocaine. While the small molecule mGlu(5) negative allosteric modulator (NAM) field is relatively advanced, investigation into the potential of small molecule mGlu(5) NAMs for the treatment of cocaine addiction remains an area of high interest. Herein we describe the discovery and characterization of a potent and selective compound 29 (VU0463841) with good CNS exposure in rats. The utility of 29 (VU0463841) was demonstrated by its ability to attenuate drug seeking behaviors in relevant rat models of cocaine addiction. C1 [Amato, Russell J.; Felts, Andrew S.; Rodriguez, Alice L.; Venable, Daryl F.; Morrison, Ryan D.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Conn, P. Jeffrey; Lindsley, Craig W.; Jones, Carrie K.; Emmitte, Kyle A.] Vanderbilt Univ Sch Med, Dept Pharmacol, Nashville, TN 37232 USA. [Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ Sch Med, Dept Chem, Nashville, TN 37232 USA. [Amato, Russell J.; Felts, Andrew S.; Rodriguez, Alice L.; Venable, Daryl F.; Morrison, Ryan D.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Conn, P. Jeffrey; Lindsley, Craig W.; Jones, Carrie K.; Emmitte, Kyle A.] Vanderbilt Univ Sch Med, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Jones, CK (reprint author), Vanderbilt Univ Sch Med, Vanderbilt Ctr Neurosci Drug Discovery, 1205 Light Hall, Nashville, TN 37232 USA. EM carrie.jones@vanderbilt.edu; kyle.a.emmitte@vanderbilt.edu FU NIH; NIMH; NIDA [R01 DA023947]; Alzheimer's Association; Bristol-Myers Squibb; AstraZeneca; Tennessee Valley Healthcare System (U.S. Dept. of Veteran's Affairs); NINDS; Seaside Therapeutics [VUMC33842] FX C.W.L. receives funding from NIH, NIMH, NIDA, the Alzheimer's Association, Bristol-Myers Squibb, and AstraZeneca. C.K.J. receives funding from NIMH and Tennessee Valley Healthcare System (U.S. Dept. of Veteran's Affairs), Bristol-Myers Squibb, and AstraZeneca. C.M.N. receives funding from NINDS, Bristol-Myers Squibb, and AstraZeneca. P.J.C. receives funding from NIH, NIMH, NINDS, Bristol-Myers Squibb, and AstraZeneca. K.A.E. receives funding from NIMH. The authors thank NIDA (R01 DA023947) and Seaside Therapeutics (VUMC33842) for their support of our programs in the development of mGlu5 NAMs. NR 58 TC 8 Z9 8 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD AUG PY 2013 VL 4 IS 8 BP 1217 EP 1228 DI 10.1021/cn400070k PG 12 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA 206PZ UT WOS:000323535900010 PM 23682684 ER PT J AU Rifkin, DE Katz, R Chonchol, M Shlipak, MG Sarnak, MJ Fried, LF Newman, AB Siscovick, DS Peralta, CA AF Rifkin, Dena E. Katz, Ronit Chonchol, Michel Shlipak, Michael G. Sarnak, Mark J. Fried, Linda F. Newman, Anne B. Siscovick, David S. Peralta, Carmen A. TI Blood Pressure Components and Decline in Kidney Function in Community-Living Older Adults: The Cardiovascular Health Study SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; cystatin C; diastolic blood pressure; elderly; hypertension; kidney function; systolic blood pressure ID ISOLATED SYSTOLIC HYPERTENSION; STAGE RENAL-DISEASE; CYSTATIN-C; UNITED-STATES; RISK; MORTALITY; ASSOCIATION; PREVALENCE; CREATININE AB BACKGROUND Although hypertension contributes to kidney dysfunction in the general population, the contributions of elevated systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) to kidney function decline in community-dwelling older adults are unknown. METHODS We used linear and logistic regression to examine the separate and combined associations of SBP, DBP, and PP at baseline with kidney function decline among 4,365 older adults in the Cardiovascular Health Study. We used cystatin C to estimate glomerular filtration rate on 3 occasions over 7 years of follow-up. We defined rapid decline >= 3 ml/min/year. RESULTS Average age was 72.2 and mean (standard deviation) SBP, DBP, and PP were 135 (21), 71 (11), and 65 (18) mm Hg, respectively. SBP and PP, rather than DBP, were most significantly associated with kidney function decline. In adjusted linear models, each 10-mm Hg increment in SBP and PP was associated with 0.13 ml/min/year (-0.19, -0.08, P < 0.001) and 0.15-ml/min/year faster decline (-0.21, -0.09, P < 0.001), respectively. Each 10-mm Hg increment in DBP was associated with a nonsignificant 0.10-ml/min/year faster decline (95% confidence interval, -0.20, 0.01). In adjusted logistic models, SBP had the strongest associations with rapid decline, with 14% increased hazard of rapid decline (95% confidence interval, 10% to 17%, P < 0.01) per 10 mm Hg. In models combining BP components, only SBP consistently had independent associations with rapid decline. CONCLUSIONS Our findings suggest that elevated BP, particularly SBP, contributes to declining kidney function in older adults. C1 [Rifkin, Dena E.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Rifkin, Dena E.] Univ Calif San Diego, Div Family & Prevent Med, San Diego, CA 92103 USA. [Rifkin, Dena E.] Vet Affairs Med Ctr, San Diego, CA 92161 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Sch Med, Div Geriatr Med, Pittsburgh, PA 15261 USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. RP Rifkin, DE (reprint author), Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. EM drifkin@ucsd.edu OI Newman, Anne B./0000-0002-0106-1150 FU NHLBI [HHSN268201200036C, N01-HC-85239, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, HL080295]; NIA [AG-023629, AG-15928, AG-20098, AG-027058] FX This work was supported by NHLBI contracts HHSN268201200036C, N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and NHLBI grant HL080295, with additional contribution from NINDS. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also http://www.chs-nhlbi.org/pi.htm. NR 23 TC 10 Z9 12 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD AUG PY 2013 VL 26 IS 8 BP 1037 EP 1044 DI 10.1093/ajh/hpt067 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 182CO UT WOS:000321718300014 PM 23709568 ER PT J AU Perkins, PS Slane, JD Klump, KL AF Perkins, Patrick Scott Slane, Jennifer D. Klump, Kelly L. TI Personality clusters and family relationships in women with disordered eating symptoms SO EATING BEHAVIORS LA English DT Article DE Personality clusters; Family relationships; Disordered eating ID PARENTAL-BONDING INSTRUMENT; BEHAVIORAL RISK-FACTORS; ANOREXIA-NERVOSA; BULIMIA-NERVOSA; STRUCTURAL-ANALYSIS; ADOLESCENT GIRLS; SOCIAL-ADJUSTMENT; SELF-REPORT; DSM-IV; SUBTYPES AB Personality clusters in women with eating disorders predict important clinical variables (e.g., social functioning) better than eating disorder diagnoses. However, it is unknown whether these findings generalize to samples with subclinical pathology. Further, little is known about associations between personality clusters and family relationships. This study sought to address these limitations by replicating personality clusters in a college sample of women with disordered eating symptoms Based on reported symptoms, women were divided into a restricting, binging and purging, or control (i.e., symptom free) group. Participants completed measures of personality, social functioning, and family relationships. Cluster analyses suggested three personality groups (i.e., Adaptive, Rigid, Dysregulated) which corresponded to those identified previously in clinical samples. Personality clusters, and not disordered eating groups, significantly predicted social functioning, and these clusters were differentially associated with family conflict type. Meaningful personality clusters are present in subclinical populations and have clinical utility in predicting social functioning and family relationships. Published by Elsevier Ltd. C1 [Perkins, Patrick Scott] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Slane, Jennifer D.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Klump, Kelly L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. RP Slane, JD (reprint author), 7180 Highland Dr,Suite 201N,Bldg 4,2nd Floor, Pittsburgh, PA 15206 USA. EM jennifer.slane@va.gov NR 71 TC 4 Z9 5 U1 1 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1471-0153 EI 1873-7358 J9 EAT BEHAV JI Eat. Behav. PD AUG PY 2013 VL 14 IS 3 BP 299 EP 308 DI 10.1016/j.eatbeh.2013.05.007 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 207GK UT WOS:000323586700012 PM 23910771 ER PT J AU Hanson, AJ Bayer-Carter, JL Green, PS Montine, TJ Wilkinson, CW Baker, LD Watson, S Bonner, LM Callaghan, M Leverenz, JB Tsai, E Postupna, N Zhang, J Lampe, J Craft, S AF Hanson, Angela J. Bayer-Carter, Jennifer L. Green, Pattie S. Montine, Thomas J. Wilkinson, Charles W. Baker, Laura D. Watson, Stennis Bonner, Laura M. Callaghan, Maureen Leverenz, James B. Tsai, Elaine Postupna, Nadia Zhang, Jing Lampe, Johanna Craft, Suzanne TI Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides Randomized Clinical Trial SO JAMA NEUROLOGY LA English DT Article ID A-BETA OLIGOMERS; SPORADIC ALZHEIMERS-DISEASE; MILD COGNITIVE IMPAIRMENT; HIGH-DENSITY-LIPOPROTEIN; TRANSGENIC MOUSE MODEL; CEREBROSPINAL-FLUID; INSULIN-RESISTANCE; BRAIN INSULIN; DIABETES-MELLITUS; PRECURSOR PROTEIN AB IMPORTANCE Sporadic Alzheimer disease (AD) is caused in part by decreased clearance of the beta-amyloid (A beta) peptide breakdown products. Lipid-depleted (LD) apolipoproteins are less effective at binding and clearing A beta, and LD A beta peptides are more toxic to neurons. However, not much is known about the lipid states of these proteins in human cerebrospinal fluid. OBJECTIVE To characterize the lipidation states of A beta peptides and apolipoprotein E in the cerebrospinal fluid in adults with respect to cognitive diagnosis and APOE epsilon 4 allele carrier status and after a dietary intervention. DESIGN Randomized clinical trial. SETTING Veterans Affairs Medical Center clinical research unit. PARTICIPANTS Twenty older adults with normal cognition (mean [SD] age, 69 [7] years) and 27 with amnestic mild cognitive impairment (67 [6] years). INTERVENTIONS Randomization to a diet high in saturated fat content and with a high glycemic index (High diet; 45% of energy from fat [>25% saturated fat], 35%-40% from carbohydrates with a mean glycemic index >70, and 15%-20% from protein) or a diet low in saturated fat content and with a low glycemic index (Low diet; 25% of energy from fat [<7% saturated fat], 55%-60% from carbohydrates with a mean glycemic index <55, and 15%-20% from protein). MAIN OUTCOMES AND MEASURES Lipid-depleted A beta 42 and A beta 40 and apolipoprotein E in cerebrospinal fluid. RESULTS Baseline levels of LD A beta were greater for adults with mild cognitive impairment compared with adults with normal cognition (LD A beta 42, P =.05; LD A beta 40, P = .01). These findings were magnified in adults with mild cognitive impairment and the epsilon 4 allele, who had higher LD apolipoprotein E levels irrespective of cognitive diagnosis (P < .001). The Low diet tended to decrease LD A beta levels, whereas the High diet increased these fractions (LD A beta 42, P = .01; LD A beta 40, P = .15). Changes in LD A beta levels with the Low diet negatively correlated with changes in cerebrospinal fluid levels of insulin (LD A beta 42 and insulin, r = -0.68 [P = .01]; LD A beta 40 and insulin, r = -0.78 [P = .002]). CONCLUSIONS AND RELEVANCE The lipidation states of apolipoproteins and A beta peptides in the brain differ depending on APOE genotype and cognitive diagnosis. Concentrations can be modulated by diet. These findings may provide insight into the mechanisms through which apolipoprotein E4 and unhealthy diets impart risk for developing AD. C1 [Hanson, Angela J.; Bayer-Carter, Jennifer L.; Green, Pattie S.; Wilkinson, Charles W.; Baker, Laura D.; Watson, Stennis; Bonner, Laura M.; Callaghan, Maureen; Craft, Suzanne] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr,Dept Neurol, Seattle, WA USA. [Hanson, Angela J.; Green, Pattie S.; Tsai, Elaine] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Bayer-Carter, Jennifer L.; Wilkinson, Charles W.; Baker, Laura D.; Watson, Stennis; Bonner, Laura M.; Postupna, Nadia; Zhang, Jing; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.; Lampe, Johanna] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Craft, S (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM suzcraft@wakehealth.edu FU Hartford Center of Excellence scholarship; National Institute on Aging [R37-AG-10880, P50 AG-05136]; Nancy and Buster Alvord Endowment; Department of Veterans Affairs; [T32 AG-000258-13] FX This study was supported by grant T32 AG-000258-13 and a Hartford Center of Excellence scholarship (Dr Hanson); by grants R37-AG-10880 (Dr Craft) and P50 AG-05136 (Dr Montine) from the National Institute on Aging; by the Nancy and Buster Alvord Endowment; and by the Department of Veterans Affairs. NR 67 TC 22 Z9 23 U1 0 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD AUG PY 2013 VL 70 IS 8 BP 972 EP 980 DI 10.1001/jamaneurol.2013.396 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 206ZO UT WOS:000323565900004 PM 23779114 ER PT J AU Hasham, A Zhang, WJ Lotay, V Haggerty, S Stefan, M Concepcion, E Dieterich, DT Tomer, Y AF Hasham, Alia Zhang, Weijia Lotay, Vaneet Haggerty, Shannon Stefan, Mihaela Concepcion, Erlinda Dieterich, Douglas T. Tomer, Yaron TI Genetic analysis of interferon induced thyroiditis (IIT): Evidence for a key role for MHC and apoptosis related genes and pathways SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Interferon; Thyroiditis; Autoimmunity; Thyroid ID CHRONIC HEPATITIS-C; GRAVES-DISEASE; AUTOIMMUNITY; ALPHA; ASSOCIATION; POPULATION; CELLS; TAP1; PML; POLYMORPHISMS AB Autoimmune thyroid diseases (AITD) have become increasingly recognized as a complication of interferon-alpha (IFN alpha) therapy in patients with chronic Hepatitis C virus (HCV) infection. Interferon-induced thyroiditis (IIT) can manifest as clinical thyroiditis in approximately 15% of HCV patients receiving IFN alpha and subclinical thyroiditis in up to 40% of patients, possibly resulting in either dose reduction or discontinuation of IFN alpha treatment. However, the exact mechanisms that lead to the development of IIT are unknown and may include IFN alpha-mediated immune-recruitment as well as direct toxic effects on thyroid follicular cells. We hypothesized that IIT develops in genetically predisposed individuals whose threshold for developing thyroiditis is lowered by IFN alpha. Therefore, our aim was to identify the susceptibility genes for IIT. We used a genomic convergence approach combining genetic association data with transcriptome analysis of genes upregulated by IFN alpha. Integrating results of genetic association, transcriptome data, pathway, and haplotype analyses enabled the identification of 3 putative loci, SP100/110/140 (2q37.1), HLA (6p21.3), and TAP1 (6p21.3) that may be involved in the pathogenesis of IIT. Immune-regulation and apoptosis emerged as the predominant mechanisms underlying the etiology of IIT. (C) Published by Elsevier Ltd. C1 [Hasham, Alia; Stefan, Mihaela; Concepcion, Erlinda; Tomer, Yaron] Mt Sinai Sch Med, Dept Med, Div Endocrinol, New York, NY USA. [Hasham, Alia; Stefan, Mihaela; Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA. [Zhang, Weijia; Lotay, Vaneet] Mt Sinai Sch Med, Dept Med Bioinformat Core, New York, NY USA. [Haggerty, Shannon] Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH USA. [Dieterich, Douglas T.] Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu FU VA Merit award from Department of Veterans Affairs [1I01BX002031]; NIDDK [DK61659, DK073681] FX This work was supported in part by a VA Merit award 1I01BX002031 from the Department of Veterans Affairs, and by grants DK61659, and DK073681 from NIDDK (to YT). We thank Dr. David A. Greenberg (Battelle Center for Mathematical Medicine and Department of Neurology, Nationwide Children's Hospital, Columbus, Ohio) for his suggestions and expert review of this manuscript. NR 39 TC 7 Z9 10 U1 3 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 J9 J AUTOIMMUN JI J. Autoimmun. PD AUG PY 2013 VL 44 BP 61 EP 70 DI 10.1016/j.jaut.2013.04.002 PG 10 WC Immunology SC Immunology GA 208PJ UT WOS:000323691300008 PM 23683877 ER PT J AU Richardson, A AF Richardson, Arlan TI Rapamycin, anti-aging, and avoiding the fate of Tithonus SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID EXTENDS LIFE-SPAN; GENETICALLY HETEROGENEOUS MICE; MAMMALIAN TARGET; MTOR; INHIBITION AB The discovery that rapamycin increased the lifespan of mice was recognized by Science as one of the top 10 scientific breakthroughs of 2009. In addition to increasing lifespan, Neff and colleagues show that while rapamycin improves several functions/pathologies that change with age, it has little effect on the majority of the physiological and structural parameters they evaluated. What do these data tell us about the ability of rapamycin to delay aging and improve quality of life, i.e., prevent the fate of Tithonus? C1 [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Richardson, Arlan] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Richardson, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM richardsona@uthscsa.edu FU NIA NIH HHS [RC2 AG036613] NR 23 TC 12 Z9 12 U1 0 U2 3 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD AUG PY 2013 VL 123 IS 8 BP 3204 EP 3206 DI 10.1172/JCI70800 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 196CH UT WOS:000322750500005 PM 24063054 ER PT J AU Gabrielian, S Yuan, A Rubenstein, L Andersen, RM Gelberg, L AF Gabrielian, Sonya Yuan, Anita Rubenstein, Lisa Andersen, Ronald M. Gelberg, Lillian TI Serving homeless Veterans in the VA Desert Pacific Healthcare Network: A needs assessment to inform quality improvement endeavors SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Homeless people; Veterans; quality improvement; needs assessment ID SERIOUS MENTAL-ILLNESS; MEDICAL-CARE; ADULTS AB This report describes a needs assessment of VA programs for homeless Veterans in Southern California and Nevada, the geographic region with the most homeless Veterans in the nation. The assessment was formulated through key informant interviews. Current service provisions are discussed, along with salient unmet needs for this vulnerable population. C1 [Gabrielian, Sonya; Gelberg, Lillian] Vet Adm Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. [Yuan, Anita] VA GLA, Dept Primary Care, Los Angeles, CA USA. [Rubenstein, Lisa] VA GLA, Hlth Serv Res & Dev Ctr Excellence Study Healthca, Los Angeles, CA USA. [Rubenstein, Lisa] RAND Corp, Santa Monica, CA 90406 USA. [Andersen, Ronald M.; Gelberg, Lillian] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. RP Gabrielian, S (reprint author), VA Greater Los Angeles WLA, 11301 Wilshire Blvd,Bldg 210A, Los Angeles, CA 90073 USA. EM sonya.gabrielian@va.gov FU Intramural VA [VA999999]; NIDA NIH HHS [R01 DA022445, DA 022445]; NIMHD NIH HHS [P20 MD000182, P20MD000148/P20MD000182, P20 MD000148] NR 18 TC 0 Z9 0 U1 0 U2 8 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD AUG PY 2013 VL 24 IS 3 BP 1344 EP 1352 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 206OR UT WOS:000323532500033 PM 23974403 ER PT J AU Bhargava, P Robinson, TJ Lyer, RS Seyal, AR Munsell, A Moshiri, M Dighe, MK Richardson, ML Weinberger, E AF Bhargava, Puneet Robinson, Tracy J. Lyer, Ramesh S. Seyal, Adeel R. Munsell, Andrew Moshiri, Mariam Dighe, Manjiri K. Richardson, Michael L. Weinberger, Edward TI Sharing a Collection of Radiology Educational Websites as Bookmarks Among Radiologists SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID RESOURCES; INTERNET; FUTURE C1 [Bhargava, Puneet; Robinson, Tracy J.; Lyer, Ramesh S.; Munsell, Andrew; Moshiri, Mariam; Dighe, Manjiri K.; Richardson, Michael L.; Weinberger, Edward] Univ Washington, Sch Med, Dept Radiol, Seattle, WA USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lyer, Ramesh S.; Munsell, Andrew; Weinberger, Edward] Seattle Childrens Hosp, Seattle, WA USA. [Seyal, Adeel R.] Harrison Med Ctr, Bremerton, WA USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, Dept Radiol, 1660 S Columbian Way,Mailbox 358280,S-114-Radiol, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 8 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD AUG PY 2013 VL 10 IS 8 BP 627 EP 632 DI 10.1016/j.jacr.2012.12.015 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 204UP UT WOS:000323397000017 PM 23453725 ER PT J AU Quinn, DI Tangen, CM Hussain, M Lara, PN Goldkorn, A Moinpour, CM Garzotto, MG Mack, PC Carducci, MA Monk, JP Twardowski, PW Van Veldhuizen, PJ Agarwal, N Higano, CS Vogelzang, NJ Thompson, IM AF Quinn, David I. Tangen, Catherine M. Hussain, Maha Lara, Primo N., Jr. Goldkorn, Amir Moinpour, Carol M. Garzotto, Mark G. Mack, Philip C. Carducci, Michael A. Monk, J. Paul Twardowski, Przemyslaw W. Van Veldhuizen, Peter J. Agarwal, Neeraj Higano, Celestia S. Vogelzang, Nicholas J. Thompson, Ian M., Jr. TI Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial SO LANCET ONCOLOGY LA English DT Article ID BONE METASTASES; DOUBLE-BLIND; III TRIAL; COMPARING DOCETAXEL; ENDOTHELIN RECEPTOR; INCREASED SURVIVAL; PLUS PREDNISONE; PAIN; CHEMOTHERAPY; MITOXANTRONE AB Background The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer. Atrasentan, an endothelin receptor antagonist, has shown activity in prostate cancer. We therefore assessed its effect on survival in patients with castration-resistant prostate cancer with bone metastases. Methods In a double-blind phase 3 trial, men with metastatic castration-resistant prostate cancer, stratified for progression type (prostate-specific antigen or radiological), baseline pain, extraskeletal metastases, and bisphosphonate use, were randomly assigned in a 1:1 ratio to docetaxel (75 mg/m(2) every 21 days, intravenously) with atrasentan (10 mg/day, orally) or placebo for up to 12 cycles and treated until disease progression or unacceptable toxicity. Patients who did not progress on treatment were permitted to continue atrasentan or placebo for up to 52 weeks. Coprimary endpoints were progression-free survival (PFS) and overall survival. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00134056. Findings 498 patients were randomly assigned to the atrasentan group and 496 to the placebo group. The trial was halted early for futility in April, 2011, after a planned interim analysis. Median PFS was 9.2 months (95% CI 8.5-9.9) in the atrasentan group and 9.1 months (8.4-10.2) in the placebo group (hazard ratio 1.02, 0.89-1.16; p=0.81). Median overall survival was 17.8 months (16.4-19.8) in the atrasentan group versus 17.6 months (16.4-20.1) in the placebo group (1.04, 0.90-1.19; p=0.64). 278 (57%) of 492 patients in the atrasentan group had grade 3 and greater toxicity compared with 294 (60%) of 486 in the placebo group (p=0.22). Three deaths in the atrasentan group and seven in the placebo group were judged to be possibly or probably due to protocol treatment. Interpretation Atrasentan, when added to docetaxel, does not improve overall survival or PFS in men with castration-resistant prostate cancer and bone metastases; therefore, single-agent docetaxel should remain as one of the standard treatments. C1 [Quinn, David I.; Goldkorn, Amir] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Tangen, Catherine M.; Moinpour, Carol M.] SWOG Stat Ctr, Seattle, WA USA. [Hussain, Maha] Univ Michigan, Ann Arbor, MI 48109 USA. [Lara, Primo N., Jr.; Mack, Philip C.] Univ Calif Davis, Sacramento, CA 95817 USA. [Garzotto, Mark G.] Portland VA Med Ctr, Portland, OR USA. [Carducci, Michael A.] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. [Monk, J. Paul] Ohio State Univ, Columbus, OH 43210 USA. [Twardowski, Przemyslaw W.] City Hope Natl Med Ctr, Med Ctr, Duarte, CA USA. [Van Veldhuizen, Peter J.] Univ Kansas, Kansas City, KS USA. [Agarwal, Neeraj] Univ Utah, Salt Lake City, UT USA. [Higano, Celestia S.] Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA USA. [Higano, Celestia S.] Univ Washington, Seattle, WA 98195 USA. [Vogelzang, Nicholas J.] US Oncol Res, Ctr Comprehens Canc, Las Vegas, NV USA. [Thompson, Ian M., Jr.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Quinn, DI (reprint author), Univ So Calif, Norris Comprehens Canc Ctr, 1441 Eastlake Ave,Suite 3440, Los Angeles, CA 90033 USA. EM diquinn@med.usc.edu RI Quinn, David/F-4343-2015 OI Quinn, David/0000-0002-1411-0417 FU Public Health Service; National Cancer Institute, Department of Health and Human Services [CA32102, CA38926, CA46368, CA46441, CA58882, CA58861, CA12644, CA22433, CA46282, CA27057, CA58416, CA45807, CA45808, CA45450, CA42777, CA35281, CA20319, CA35090, CA76429, CA14028, CA67575, CA45377, CA68183, CA63848, CA74647, CA16385, CA35192, CA63844, CA11083, CA63845, CA76447]; Sanofi-Aventis; Abbott Laboratories FX The investigation was supported, partly, by the following Public Health Service Cooperative Agreement grant numbers awarded by the National Cancer Institute, Department of Health and Human Services: CA32102, CA38926, CA46368, CA46441, CA58882, CA58861, CA12644, CA22433, CA46282, CA27057, CA58416, CA45807, CA45808, CA45450, CA42777, CA35281, CA20319, CA35090, CA76429, CA14028, CA67575, CA45377, CA68183, CA63848, CA74647, CA16385, CA35192, CA63844, CA11083, CA63845, CA76447, CA35128, CA13612, CA35431, CA76448, CA35178, CA35176, CA35119, CA35421, CA128567, CA04919, CA68183, CA45560, CA37981, CA58723, CA21115, CA16116, and CA31949; and, partly, by Sanofi-Aventis and Abbott Laboratories. The authors report on behalf of a large team and would like to acknowledge the contribution of clinicians, research teams, patients, and their families through ECOG, CALGB, and the Clinical Trials Support Unit in completing SWOG S0421. NR 33 TC 60 Z9 66 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD AUG PY 2013 VL 14 IS 9 BP 893 EP 900 DI 10.1016/S1470-2045(13)70294-8 PG 8 WC Oncology SC Oncology GA 205DZ UT WOS:000323423400046 PM 23871417 ER PT J AU Schulz, CF Davis, TT Fung, DA AF Schulz, Carolyn F. Davis, Timothy T. Fung, Daniel A. TI Epidural Lipomatosis as a Cause for High Impedance Values During a Spinal Cord Stimulator Trial SO PM&R LA English DT Article ID MECHANISMS C1 [Schulz, Carolyn F.] Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA. [Davis, Timothy T.; Fung, Daniel A.] Ctr Spine & Joint Restorat, Santa Monica, CA 90043 USA. RP Fung, DA (reprint author), Ctr Spine & Joint Restorat, 2811 Wilshire Blvd,Suite 850, Santa Monica, CA 90043 USA. EM DFUNGMD@gmail.com FU Medtronic FX Disclosures outside this publication: board membership (no money), ABNM; consultancy, Medtronic; payment for lectures including service on speakers bureaus, Medtronic; payment for development of educational presentations, Medtronic; travel/accommodations/meeting expenses, Medtronic NR 9 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD AUG PY 2013 VL 5 IS 8 BP 729 EP 731 DI 10.1016/j.pmrj.2013.04.021 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 207JK UT WOS:000323594500019 PM 23643840 ER PT J AU Gabayan, GZ Asch, SM Hsia, RY Zingmond, D Liang, LJ Han, WJ McCreath, H Weiss, RE Sun, BC AF Gabayan, Gelareh Z. Asch, Steven M. Hsia, Renee Y. Zingmond, David Liang, Li-Jung Han, Weijuan McCreath, Heather Weiss, Robert E. Sun, Benjamin C. TI Factors Associated With Short-Term Bounce-Back Admissions After Emergency Department Discharge SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID ADVERSE HEALTH OUTCOMES; PUBLIC HOSPITAL EMERGENCY; DEATH AFTER-DISCHARGE; ELDERLY-PATIENTS; UNSCHEDULED RETURNS; MEDICAL ADVICE; OLDER PATIENTS; RISK-FACTORS; VISITS; CARE AB Study objective: Hospitalizations that occur shortly after emergency department (ED) discharge may reveal opportunities to improve ED or follow-up care. There currently is limited, population-level information about such events. We identify hospital- and visit-level predictors of bounce-back admissions, defined as 7-day unscheduled hospital admissions after ED discharge. Methods: Using the California Office of Statewide Health Planning and Development files, we conducted a retrospective cohort analysis of adult (aged >18 years) ED visits resulting in discharge in 2007. Candidate predictors included index hospital structural characteristics such as ownership, teaching affiliation, trauma status, and index ED size, along with index visit patient characteristics of demographic information, day of service, against medical advice or eloped disposition, insurance, and ED primary discharge diagnosis. We fit a nnultivariable, hierarchic logistic regression to account for clustering of ED visits by hospitals. Results: The study cohort contained a total of 5,035,833 visits to 288 facilities in 2007. Bounce-back admission within 7 days occurred in 130,526 (2.6%) visits and was associated with Medicaid (odds ratio [OR] 1.42; 95% confidence interval [CI] 1.40 to 1.45) or Medicare insurance (OR 1.53; 95% CI 1.50 to 1.55) and a disposition of leaving against medical advice or before the evaluation was complete (OR 1.90; 95% CI 1.89 to 2.0). The 3 most common age-adjusted index ED discharge diagnoses associated with a bounce-back admission were chronic renal disease, not end stage (OR 3.3; 95% CI 2.8 to 3.8), end-stage renal disease (OR 2.9; 95% CI 2.4 to 3.6), and congestive heart failure (OR 2.5; 95% CI 2.3 to 2.6). Hospital characteristics associated with a higher bounce-back admission rate were for-profit status (OR 1.2; 95% CI 1.1 to 1.3) and teaching affiliation (OR 1.2; 95% CI 1.0 to 1.3). Conclusion: We found 2.6% of discharged patients from California EDs to have a bounce-back admission within 7 days. We identified vulnerable populations, such as the very old and the use of Medicaid insurance, and chronic or end-stage renal disease as being especially at risk. Our findings suggest that quality improvement efforts focus on high-risk individuals and that the disposition plan of patients consider vulnerable populations. C1 [Gabayan, Gelareh Z.; Zingmond, David; Liang, Li-Jung] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Gabayan, Gelareh Z.] Greater Los Angeles Vet Affairs Healthcare Syst, Div Emergency Med, Los Angeles, CA USA. [Gabayan, Gelareh Z.] Ronald Reagan UCLA, Ctr Emergency Med, Los Angeles, CA USA. [Asch, Steven M.] Vet Affairs Palo Alto Healthcare Syst, Div Gen Med Disciplines, Palo Alto, CA USA. [Asch, Steven M.] Stanford Sch Med, Palo Alto, CA USA. [Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Han, Weijuan; McCreath, Heather; Weiss, Robert E.] UCLA Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. EM gelareh@gabayan.com FU Emergency Medicine Foundation; Agency for Healthcare Research and Quality [R03 HS18098]; UCLA Older American Independence Center NIH/National Institute on Aging (NIA) grant; NIH/NCRR/OD UCSF-CTSI grant [KL2RR024130]; Robert Wood Johnson Foundation Physician Faculty Scholars; NIH/NCRR/NCATS UCLA CTSI [KL2TR000122] FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This research was supported by the Emergency Medicine Foundation (Dr. Sun), the Agency for Healthcare Research and Quality (Dr. Sun, R03 HS18098), the UCLA Older American Independence Center NIH/National Institute on Aging (NIA) grant (Dr. McCreath, Mrs. Han), the NIH/NCRR/OD UCSF-CTSI grant (Dr. Hsia, KL2RR024130), and the Robert Wood Johnson Foundation Physician Faculty Scholars (Dr. Hsia). Dr. Gabayan receives support from the NIH/NCRR/NCATS UCLA CTSI (grant KL2TR000122). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the NIA. The funding organizations did not have a role in the design and conduct of the study; management, analysis, and interpretation of the data; and preparation, review, or approval of the article. NR 42 TC 12 Z9 12 U1 0 U2 14 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD AUG PY 2013 VL 62 IS 2 BP 136 EP 144 DI 10.1016/j.annemergmed.2013.01.017 PG 9 WC Emergency Medicine SC Emergency Medicine GA 199SC UT WOS:000323014800008 PM 23465554 ER PT J AU Doran, KM Raven, MC Rosenheck, RA AF Doran, Kelly M. Raven, Maria C. Rosenheck, Robert A. TI What Drives Frequent Emergency Department Use in an Integrated Health System? National Data From the Veterans Health Administration SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID UTILIZATION PATTERNS; MENTAL-DISORDERS; RANDOMIZED-TRIAL; CASE-MANAGEMENT; MEDICAL-CARE; RISK-FACTORS; SERVICES; OUTCOMES; DEFINITIONS; POPULATION AB Study objective: There is widespread concern about patients with frequent emergency department (ED) use. We identify sociodemographic and clinical factors most strongly associated with frequent ED use within the Veterans Health Administration (VHA) nationally. Methods: We conducted a cross-sectional analysis of national VHA databases (N=5,531,379) in 2010. The primary outcome measure was the number of VHA ED visits categorized into 6 frequency levels. Results: In 2010, 4,600,667 (83.2%) VHA patients had no ED visit, whereas 493,391 (8.9%) had 1 visit, 356,258 (6.4%) had 2 to 4 visits, 70,741 (1.3%) had 5 to 10 visits, 9,705 (0.2%) had 11 to 25 visits, and 617 (0.01%) had greater than 25 visits. Increasing ED use frequency was associated with homelessness, medical diagnoses, substance abuse and psychiatric diagnoses, receipt of psychotropic and opioid prescriptions, and more frequent use of outpatient medical and mental health services. In multivariable analyses, factors most strongly associated with all levels of ED use were schizophrenia (odds ratio [OR] range 1.44 [95% confidence interval {Cl} 1.41 to 1.47] to 6.86 [95% Cl 5.55 to 8.48] across categories of increasing ED use), homelessness (OR range 1.41 [95% CI 1.38 to 1.43] to 6.60 [95% Cl 5.36 to 8.12]), opioid prescriptions filled (OR range 2.09 [95% Cl 2.07 to 2.10] to 5.08 [95% Cl 4.16 to 6.19]), and heart failure (OR range 1.64 [95% Cl 1.63 to 1.66] to 3.53 [95% Cl 2.64 to 4.72]). Conclusion: Frequent ED use occurs even in a coordinated health care system that provides ready access to outpatient care. Frequent ED users are characterized by traits that represent high levels of psychosocial and medical needs. The correlates we identified for frequent ED use were consistent across multiple distinct levels of ED use. C1 [Doran, Kelly M.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA. [Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT USA. [Doran, Kelly M.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Raven, Maria C.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Rosenheck, Robert A.] VA New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. RP Doran, KM (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA. EM kelly.doran@yale.edu FU VA New England Mental Illness Research and Education Center FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Support was provided by the VA New England Mental Illness Research and Education Center. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the article. NR 44 TC 35 Z9 35 U1 2 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD AUG PY 2013 VL 62 IS 2 BP 151 EP 159 DI 10.1016/j.annemergmed.2013.02.016 PG 9 WC Emergency Medicine SC Emergency Medicine GA 199SC UT WOS:000323014800011 PM 23582617 ER PT J AU Bekris, LM Lutz, F Montine, TJ Yu, CE Tsuang, D Peskind, ER Leverenz, JB AF Bekris, Lynn M. Lutz, Franziska Montine, Thomas J. Yu, Chang En Tsuang, Debby Peskind, Elaine R. Leverenz, James B. TI MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma SO BIOMARKERS LA English DT Article DE Amyloid; biomarker; braak stage; miR-15a; miR-370; miR-328; miR-138; miR-132; plaque ID ENDOGENOUS CONTROL GENES; NEUROPATHOLOGIC ASSESSMENT; PROSTATE-CANCER; NEURONAL LOSS; EXPRESSION; IDENTIFICATION; DEMENTIA; MIRNA; BIOMARKERS; DIAGNOSIS AB MicroRNA (miRNA) may be potential biomarkers of Alzheimer's disease (AD). The objective of this investigation was to demonstrate that miRNAs in human brain or biofluids are differentially expressed according to disease status, tissue type, neuritic plaque score or Braak stage. Post-mortem brain (PMB) miRNA were profiled using arrays and validated using quantitative RT-PCR (qRT-PCR). Five gRT-PCR-validated miRNAs were measured in an independent sample of PMB, cerebrospinal fluid and plasma from the same subjects. Plasma miR-15a was found to be associated with plaque score in the independent sample. In conclusion, miRNA present in human biofluids may offer utility as biomarkers of AD. C1 [Bekris, Lynn M.; Lutz, Franziska; Yu, Chang En; Tsuang, Debby; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Geriatr GRECC, Res Ctr, Seattle, WA USA. [Bekris, Lynn M.; Lutz, Franziska; Yu, Chang En; Tsuang, Debby; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Geriatr GRECC, Educ Ctr, Seattle, WA USA. [Bekris, Lynn M.; Lutz, Franziska; Yu, Chang En; Tsuang, Debby; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Geriatr GRECC, Ctr Clin, Seattle, WA USA. [Bekris, Lynn M.; Lutz, Franziska; Yu, Chang En] Univ Washington, Dept Med, Seattle, WA 98108 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98108 USA. [Tsuang, Debby; Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Mental Illness MIRECC, Res Ctr, Seattle, WA USA. [Tsuang, Debby; Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Mental Illness MIRECC, Educ Ctr, Seattle, WA USA. [Tsuang, Debby; Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Mental Illness MIRECC, Ctr Clin, Seattle, WA USA. [Tsuang, Debby; Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Parkinsons Dis PADRECC, Res Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Parkinsons Dis PADRECC, Educ Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Dept Parkinsons Dis PADRECC, Ctr Clin, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98108 USA. RP Bekris, LM (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Box 358280 VAPSHCS GRECC S182,1660 South Columbia, Seattle, WA 98108 USA. EM lbekris@uw.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program; Biomedical Laboratory Research Program; NIH [P50AG005136-27, P50NS062684-01A1, P50 NS062684, K99AG034214-02/R00AG034214-03] FX This work is supported, in part, by the U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program, the Biomedical Laboratory Research Program and NIH Grants: P50AG005136-27, P50NS062684-01A1, P50 NS062684 and K99AG034214-02/R00AG034214-03. NR 79 TC 32 Z9 35 U1 1 U2 37 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1354-750X J9 BIOMARKERS JI Biomarkers PD AUG PY 2013 VL 18 IS 5 BP 455 EP 466 DI 10.3109/1354750X.2013.814073 PG 12 WC Biotechnology & Applied Microbiology; Toxicology SC Biotechnology & Applied Microbiology; Toxicology GA 200RF UT WOS:000323085900012 PM 23822153 ER PT J AU Lerman, MA Burnham, JM Chang, PY Daniel, E Foster, CS Hennessy, S Jabs, DA Joffe, MM Kacmaz, RO Levy-Clarke, GA Mills, MD Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Kempen, JH AF Lerman, Melissa A. Burnham, Jon M. Chang, Peter Y. Daniel, Ebenezer Foster, C. Stephen Hennessy, Sean Jabs, Douglas A. Joffe, Marshall M. Kacmaz, R. Oktay Levy-Clarke, Grace A. Mills, Monte D. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Kempen, John H. TI Response of Pediatric Uveitis to Tumor Necrosis Factor-alpha Inhibitors SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE UVEITIS; TUMOR NECROSIS FACTOR ANTAGONIST; JUVENILE IDIOPATHIC ARTHRITIS ID JUVENILE IDIOPATHIC ARTHRITIS; CHRONIC NONINFECTIOUS UVEITIS; REFRACTORY CHILDHOOD UVEITIS; OCULAR INFLAMMATORY DISEASES; TERM-FOLLOW-UP; RHEUMATOID-ARTHRITIS; INFLIXIMAB THERAPY; RISK-FACTORS; CASE SERIES; CHILDREN AB Objective. To evaluate the outcome of tumor necrosis factor-alpha inhibition (anti-TNF) for pediatric uveitis. Methods. We retrospectively assessed children (age <= 18 yrs) with noninfectious uveitis receiving anti-TNF at 5 uveitis centers and 1 pediatric rheumatology center. Incident treatment success was defined as minimal or no uveitis activity at >= 2 consecutive ophthalmological examinations L 28 days apart while taking no oral and <= 2 eyedrops/day of corticosteroids. Eligible children had active uveitis and/or were taking higher corticosteroid doses. Results. Among 56 eligible children followed over 33.73 person-years, 52% had juvenile idiopathic arthritis (JIA) and 75% had anterior uveitis (AU). The Kaplan-Meier estimated proportion achieving treatment success within 12 months was 75% (95% CI 62%-87%). Complete absence of inflammatory signs with discontinuation of all corticosteroids was observed in an estimated 64% by 12 months (95% CI 51%-76%). Diagnoses of JIA or AU were associated with greater likelihood of success, as was the oligoarticular subtype among JIA cases. In a multivariable model, compared to those with JIA-associated AU, those with neither or with JIA or AU alone had a 75%-80% lower rate of achieving quiescence under anti-TNF, independent of the number of immunomodulators previously or concomitantly prescribed. Uveitis reactivated within 12 months of achieving quiescence in 14% of those continuing anti-TNF (95% CI 6%-31%). The incidence of discontinuation for adverse effects was 8%/year (95% CI 1%-43%). Conclusion. Treatment with anti-TNF was successful and sustained in a majority of children with noninfectious uveitis, and treatment-limiting toxicity was infrequent. JIA-associated AU may be especially responsive to anti-TNF. C1 Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA. Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Ctr Clin Epidemiol & Biostat,Dept Epidemiol & Bio, Philadelphia, PA 19104 USA. Univ Penn, Perelman Sch Med SOM, Philadelphia, PA 19104 USA. Ocular Immunol & Uveitis Fdn, Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Chang, Peter Y.] New York Eye & Ear Infirm, New York, NY 10003 USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Boston, MA USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21218 USA. [Kacmaz, R. Oktay] Allergan Pharmaceut Inc, Irvine, CA 92715 USA. [Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.] Johnson & Johnson Vis Care, Jacksonville, FL USA. Childrens Hosp Philadelphia, Div Ophthalmol, Philadelphia, PA 19104 USA. Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR USA. Oregon Hlth & Sci Univ, Div Rheumatol, Dept Internal Med, Portland, OR USA. Portland VA Med Ctr, Dept Ophthalmol, Portland, OR USA. RP Lerman, MA (reprint author), Childrens Hosp Philadelphia, Div Rheumatol, Abramson Res Ctr, Suite 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM lermanm@email.chop.edu FU Rheumatology Research Foundation Scientist Development Award; Autoimmunity Centers of Excellence, National Institute of Allergy and Infectious Diseases; National Eye Institute (NEI), US National Institutes of Health (NIH) [R01 EY014943]; National Institute on Aging [AG025152, AG035751]; NEI [U10 EY08052]; NIH [U10 EY08052]; Johns Hopkins University Bloomberg School of Public Health [U10 EY08057]; University of Wisconsin [U10 EY08067]; US Department of Veterans Affairs; Abbott; LuxBio Genentech; Bristol Myers Squibb; Novartis; EyeGate; RPB Sybil B. Harrington Special Scholars Award; Research to Prevent Blindness; Paul and Evanina Mackall Foundation FX Supported by a Rheumatology Research Foundation Scientist Development Award (Dr. Lerman); Autoimmunity Centers of Excellence, National Institute of Allergy and Infectious Diseases (Dr. Burnham); R01 EY014943 National Eye Institute (NEI), US National Institutes of Health (NIH; Drs. Daniel, Rosenbaum, Suhler, Thorne, and Kempen); grants AG025152 and AG035751 from the National Institute on Aging (Dr. Hennessy); cooperative agreements from the NEI and the NIH to the Mount Sinai School of Medicine (U10 EY08052), the Johns Hopkins University Bloomberg School of Public Health, (U10 EY08057), and the University of Wisconsin (U10 EY08067; Dr. Jabs); intramural funding from the NEI (Dr. Levy-Clarke, and previously, Dr. Nussenblatt); The US Department of Veterans Affairs (Dr. Suhler); research grants from Abbott, LuxBio Genentech, Bristol Myers Squibb, Novartis, EyeGate, and the RPB Sybil B. Harrington Special Scholars Award (Dr. Thorne); and Research to Prevent Blindness, and the Paul and Evanina Mackall Foundation (Dr. Kempen). NR 50 TC 17 Z9 17 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD AUG PY 2013 VL 40 IS 8 BP 1394 EP 1403 DI 10.3899/jrheum.121180 PG 10 WC Rheumatology SC Rheumatology GA 202CY UT WOS:000323192300025 PM 23818712 ER PT J AU Cohen, ME Ko, CY Bilimoria, KY Zhou, L Huffman, K Wang, X Liu, YM Kraemer, K Meng, XJ Merkow, R Chow, W Matel, B Richards, K Hart, AJ Dimick, JB Hall, BL AF Cohen, Mark E. Ko, Clifford Y. Bilimoria, Karl Y. Zhou, Lynn Huffman, Kristopher Wang, Xue Liu, Yaoming Kraemer, Kari Meng, Xiangju Merkow, Ryan Chow, Warren Matel, Brian Richards, Karen Hart, Amy J. Dimick, Justin B. Hall, Bruce L. TI Optimizing ACS NSQIP Modeling for Evaluation of Surgical Quality and Risk: Patient Risk Adjustment, Procedure Mix Adjustment, Shrinkage Adjustment, and Surgical Focus SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID SUPPORT VECTOR MACHINE; IMPROVEMENT PROGRAM; HOSPITAL OUTCOMES; PREDICTION MODELS; MORTALITY-RATE; REPORT CARDS; ROC CURVE; SURGERY; PERFORMANCE; REGRESSION AB The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) collects detailed clinical data from participating hospitals using standardized data definitions, analyzes these data, and provides participating hospitals with reports that permit risk-adjusted comparisons with a surgical quality standard. Since its inception, the ACS NSQIP has worked to refine surgical outcomes measurements and enhance statistical methods to improve the reliability and validity of this hospital profiling. From an original focus on controlling for between-hospital differences in patient risk factors with logistic regression, ACS NSQIP has added a variable to better adjust for the complexity and risk profile of surgical procedures (procedure mix adjustment) and stabilized estimates derived from small samples by using a hierarchical model with shrinkage adjustment. New models have been developed focusing on specific surgical procedures (eg, "Procedure Targeted" models), which provide opportunities to incorporate indication and other procedure-specific variables and outcomes to improve risk adjustment. In addition, comparative benchmark reports given to participating hospitals have been expanded considerably to allow more detailed evaluations of performance. Finally, procedures have been developed to estimate surgical risk for individual patients. This article describes the development of, and justification for, these new statistical methods and reporting strategies in ACS NSQIP. (C) 2013 by the American College of Surgeons C1 [Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.; Zhou, Lynn; Huffman, Kristopher; Wang, Xue; Liu, Yaoming; Kraemer, Kari; Meng, Xiangju; Merkow, Ryan; Chow, Warren; Matel, Brian; Richards, Karen; Hart, Amy J.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Surg Outcomes & Qual Improvement Ctr, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dimick, Justin B.] Univ Michigan, Dept Surg, Michigan Surg Collaborat Outcomes Res & Evaluat, Ann Arbor, MI 48109 USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, BJC Healthcare, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. RP Cohen, ME (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM markcohen@facs.org NR 47 TC 140 Z9 141 U1 3 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD AUG PY 2013 VL 217 IS 2 BP 336 EP + DI 10.1016/j.jamcollsurg.2013.02.027 PG 12 WC Surgery SC Surgery GA 201TX UT WOS:000323167000022 PM 23628227 ER PT J AU Hanlon, JT Schmader, KE Semla, TP AF Hanlon, Joseph T. Schmader, Kenneth E. Semla, Todd P. TI Update of Studies on Drug-Related Problems in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aged; drug utilization; adverse drug event ID HOSPITALIZATIONS C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Semla, Todd P.] Pharm Benefits Management, Dept Vet Affairs, Hines, IL USA. [Semla, Todd P.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufman Med Bldg,Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU Agency for Healthcare Research and Quality [R01 HS018721, K12 HS019461]; National Institute of Aging [P30AG024827, T32 AG021885, K07AG033174, R01A G027017, R01 AG037451] FX The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper. Dr. Semla serves on the Omnicare Pharmacy and Therapeutics Committee (long-term care). He is an author and editor for LexiComp, Inc; his spouse is an employee of Abbott Labs. Dr. Hanlon is supported by Agency for Healthcare Research and Quality Grants R01 HS018721, and K12 HS019461 and National Institute of Aging Grants P30AG024827, T32 AG021885, K07AG033174, R01A G027017, and R01 AG037451. NR 13 TC 9 Z9 10 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2013 VL 61 IS 8 BP 1365 EP 1368 DI 10.1111/jgs.12354 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 198ZY UT WOS:000322964500016 PM 23731022 ER PT J AU Plagge, JM Lu, MW Lovejoy, TI Karl, AI Dobscha, SK AF Plagge, Jane M. Lu, Mary W. Lovejoy, Travis I. Karl, Andrea I. Dobscha, Steven K. TI Treatment of Comorbid Pain and PTSD in Returning Veterans: A Collaborative Approach Utilizing Behavioral Activation SO PAIN MEDICINE LA English DT Article DE Pain; Posttraumatic Stress Disorder; Veterans; Behavioral Activation; Collaborative Care ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH TREATMENT; MUSCULOSKELETAL PAIN; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; DEPRESSION; AFGHANISTAN; SCALE; IRAQ; INTERVENTION AB Objective. We explore preliminary clinical effectiveness and feasibility of an intervention utilizing collaborative care components and behavioral activation (BA) to treat comorbid chronic pain and posttraumatic stress disorder (PTSD). Design. Descriptive, including pre- and posttreatment assessment results. Setting. Portland Veterans Affairs Medical Center. Participants. Fifty-eight Iraq and Afghanistan veterans with chronic pain and PTSD symptoms. Interventions. Veterans participated in a biopsychosocial evaluation and up to eight BA sessions using a collaborative approach involving primary care, mental health, and other clinicians. A physiatrist assisted the psychologist in providing recommendations to primary care providers. Outcome Measures. Participants were administered pre-and posttreatment measures of PTSD, pain severity, pain interference, mental health, quality of life, satisfaction, and global ratings of change with the purpose of assessing progress and improving quality. Results. Of the 58 participants, 30 completed treatment. Common recommendations included physical therapy and exercise programs, pain medication or pain medication adjustments, and additional diagnostic workups, such as imaging. Participants who completed the program showed significant improvements on measures of PTSD, pain severity, and pain interference. Improvements were also evident on measures of mental health and quality of life. Overall, participants were satisfied with the program, and on average reported feeling "somewhat better." Conclusions. These findings suggest that a collaborative approach that includes BA is feasible and a potentially effective treatment for comorbid chronic pain and PTSD. C1 [Plagge, Jane M.; Lu, Mary W.; Lovejoy, Travis I.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Karl, Andrea I.] Portland VA Med Ctr, Dept Rehabil Med, Portland, OR 97239 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. [Plagge, Jane M.; Lu, Mary W.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Mental Hlth & Neurosci Div, 3710 SW US Vet Hosp Rd,POB 1034,P3MHADM, Portland, OR 97239 USA. EM steven.dobscha@va.gov FU Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC); VA Mental Health Services FX No author reports having any financial or other potential conflict of interest with this study. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. This work was supported by the Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC) and VA Mental Health Services. The authors acknowledge Alex Linke, BS, for assistance with utilization data extraction, and Amy Wagner, PhD, for assistance in implementing behavioral activation and for reviewing the manuscript. NR 44 TC 6 Z9 6 U1 3 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD AUG PY 2013 VL 14 IS 8 BP 1164 EP 1172 DI 10.1111/pme.12155 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 202FP UT WOS:000323199400008 PM 23746043 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Medical Comorbidity is Associated with Persistent Index Hip Pain after Total Hip Arthroplasty SO PAIN MEDICINE LA English DT Article DE Pain; Function; Functional Limitation; Total Hip Replacement; Primary; Arthroplasty; Joint Replacement; Outcomes; Patient-Reported Outcomes ID QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; KNEE ARTHROPLASTY; RHEUMATOID-ARTHRITIS; FUNCTIONAL STATUS; REVISION HIP; OUTCOMES; REPLACEMENT; HEALTH; RISK AB Objective. To characterize whether medical comorbidity predicts persistent moderate-severe pain after total hip arthroplasty (THA). Methods. We analyzed the prospectively collected data from the Mayo Clinic Total Joint Registry for patients who underwent primary or revision THA between 1993 and 2005. Using multivariable-adjusted logistic regression analyses, we examined whether certain medical comorbidities were associated with persistent moderate-severe hip pain 2 or 5 years after primary or revision THA. Odds ratios (ORs), along with 95% confidence intervals (CIs) and P value, are presented. Results. The primary THA cohort consisted of 5,707 THAs and 3,289 THAs at 2 and 5 years, and revision THA, 2,687 and 1,627 THAs, respectively. In multivariable-adjusted logistic regression models, in the primary THA cohort, renal disease was associated with lower odds of moderate-severe hip pain (OR 0.6; 95% CI 0.3, 1.0) at 2 years. None of the comorbidities were significantly associated at 5 years. In the revision THA cohort, heart disease was significantly associated with higher risk (OR 1.7; 95% CI 1.1, 2.6) at 2 years and connective tissue disease with lower risk (OR 0.5; 95% CI 0.3, 0.9) of moderate-severe hip pain at 5-year follow-up. Conclusion. This study identified new correlates of moderate-severe hip pain after primary or revision THA, a much-feared outcome of hip arthroplasty. Patients with these comorbidities should be informed regarding the risk of moderate-severe index hip pain, so that they can have a fully informed consent and realistic expectations. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Aging and National Cancer Institute FX This material is the result of work supported with research grants from the Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Aging and National Cancer Institute. NR 35 TC 8 Z9 8 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD AUG PY 2013 VL 14 IS 8 BP 1222 EP 1229 DI 10.1111/pme.12153 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 202FP UT WOS:000323199400014 PM 23742141 ER PT J AU Huang, LW Choi, SY Chacon-Heszele, M Ryu, YK McKenna, S Zuo, XF Kuruvilla, R Lipschutz, J AF Huang, Liwei Choi, Soo Young Chacon-Heszele, Maria Ryu, Yun Kyoung McKenna, Sarah Zuo, Xiaofeng Kuruvilla, Rejji Lipschutz, Josh TI The Role of Wnt5a in Pronephric and Metanephric Kidney Development SO PEDIATRIC NEPHROLOGY LA English DT Meeting Abstract C1 [Huang, Liwei; Choi, Soo Young; Chacon-Heszele, Maria; McKenna, Sarah; Zuo, Xiaofeng; Lipschutz, Josh] Univ Penn, Philadelphia, PA 19104 USA. [Ryu, Yun Kyoung; Kuruvilla, Rejji] Johns Hopkins Univ, Baltimore, MD USA. [Lipschutz, Josh] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0931-041X J9 PEDIATR NEPHROL JI Pediatr. Nephrol. PD AUG PY 2013 VL 28 IS 8 BP 1348 EP 1348 PG 1 WC Pediatrics; Urology & Nephrology SC Pediatrics; Urology & Nephrology GA 177PJ UT WOS:000321387201012 ER PT J AU Siever, L AF Siever, Larry TI Paranoid case vignette SO PERSONALITY AND MENTAL HEALTH LA English DT Editorial Material C1 [Siever, Larry] Icahn Sch Med Mt Sinai, New York, NY USA. [Siever, Larry] James J Peters VA Med Ctr, Psychiat Program, Bronx, NY USA. RP Siever, L (reprint author), James J Peters VA Med Ctr, Psychiat Program, Bronx, NY USA. EM larry.siever@mssm.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-8621 J9 PERSONAL MENT HEALTH JI Personal. Ment. Health PD AUG PY 2013 VL 7 IS 3 BP 262 EP 263 DI 10.1002/pmh.1243 PG 2 WC Psychiatry; Psychology, Social SC Psychiatry; Psychology GA 201OS UT WOS:000323151900010 PM 24343970 ER PT J AU Kosten, TA Shen, XY O'Malley, PW Kinsey, BM Lykissa, ED Orson, FM Kosten, TR AF Kosten, Therese A. Shen, Xiaoyun Y. O'Malley, Patrick W. Kinsey, Berma M. Lykissa, Ernest D. Orson, Frank M. Kosten, Thomas R. TI A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Article DE Antinociception; Conditioned place preference; Heroin metabolites; Immunotherapy; Opioid dependence ID SERUM-ALBUMIN; HEROIN; METHADONE; PHARMACOTHERAPY; METABOLITES; ANTIBODIES; DEPENDENCE; ADDICTION; EFFICACY; COCAINE AB Vaccines for opioid dependence may provide a treatment that would reduce or slow the distribution of the drug to brain, thus reducing the drug's reinforcing effects. We tested whether a conjugate vaccine against morphine (keyhole limpet hemocyanin-6-succinylmorphine; KLH-6-SM) administered to rats would produce antibodies and show specificity for morphine or other heroin metabolites. The functional effects of the vaccine were tested with antinociceptive and conditioned place preference (CPP) tests. Rats were either vaccinated with KLH-6-SM and received two boosts 3 and 16 weeks later or served as controls and received KLH alone. Anti-morphine antibodies were produced in vaccinated rats; levels increased and were sustained at moderate levels through 24 weeks. Antibody binding was inhibited by free morphine and other heroin metabolites as demonstrated by competitive inhibition ELISA. Vaccinated rats showed reduced morphine CPP, tested during weeks 4 to 6, and decreased antinociceptive responses to morphine, tested at week 7. Brain morphine levels, assessed using gas-chromatography coupled to mass spectrometry (GC-MS) on samples obtained at 26 weeks, were significantly lower in vaccinated rats. This suggests that morphine entry into the brain was reduced or slowed. These results provide support for KLH-6-SM as a candidate vaccine for opioid dependence. (C) 2013 Elsevier Inc. All rights reserved. C1 [Shen, Xiaoyun Y.; O'Malley, Patrick W.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kosten, Therese A.; Shen, Xiaoyun Y.; Kinsey, Berma M.; Orson, Frank M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Orson, Frank M.; Kosten, Thomas R.] Michael E Debakey Vet Med Affairs Ctr, Houston, TX USA. [Lykissa, Ernest D.] ExperTox, Houston, TX USA. RP Kosten, TA (reprint author), Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tkosten@bcm.edu FU National Institute on Drug Abuse [DA026859]; VA Merit Review Program FX Financial support was provided by a grant from the National Institute on Drug Abuse, DA026859, and by a grant from the VA Merit Review Program. The authors gratefully acknowledge the excellent technical assistance provided by A. Lopez and Y. Wu and thank Dr. Reetakshi Arora for her valuable input. NR 34 TC 10 Z9 10 U1 1 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD AUG 1 PY 2013 VL 45 BP 223 EP 229 DI 10.1016/j.pnpbp.2013.05.012 PG 7 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 202RW UT WOS:000323238300030 PM 23739535 ER PT J AU Carmody, TP Duncan, CL Huggins, J Solkowitz, SN Lee, SK Reyes, N Mozgai, S Simon, JA AF Carmody, Timothy P. Duncan, Carol L. Huggins, Joy Solkowitz, Sharon N. Lee, Sharon K. Reyes, Norma Mozgai, Sharon Simon, Joel A. TI Telephone-Delivered Cognitive-Behavioral Therapy for Pain Management Among Older Military Veterans: A Randomized Trial SO PSYCHOLOGICAL SERVICES LA English DT Article DE pain; chronic pain; cognitive-behavioral therapy; pain management; telemen health ID LOW-BACK-PAIN; LUMBAR INSTRUMENTED FUSION; PRIMARY-CARE; PSYCHOLOGICAL INTERVENTIONS; ADMINISTERED PSYCHOTHERAPY; PSYCHOMETRIC PROPERTIES; DEPRESSION TREATMENT; COST-EFFECTIVENESS; CLINICAL-TRIAL; HEALTH-CARE AB This study investigated the effectiveness of telephone-delivered cognitive-behavioral therapy (T-CBT) in the management of chronic pain with older military veterans enrolled in VA primary-care clinics. We conducted a randomized clinical trial comparing T-CBT with telephone-delivered pain education (T-EDU). A total of 98 military veterans with chronic pain were enrolled in the study and randomized into one of two treatment conditions. Study participants were recruited from primary-care clinics at an urban VA medical center and affiliated VA community-based outpatient clinics (CBOCs). Pain management outcomes were measured at midtreatment (10 weeks), posttreatment (20 weeks), 3-month follow-up (32 weeks), and 6-month follow-up (46 weeks). No significant differences were found between the two treatment groups on any of the outcome measures. Both treatment groups reported small but significant increases in level of physical and mental health, and reductions in pain and depressive symptoms. Improvements in all primary outcome measures were mediated by reductions in catastrophizing. Telephone-delivered CBT and EDU warrant further study as easily accessible interventions for rural-living older individuals with chronic pain. C1 [Carmody, Timothy P.; Duncan, Carol L.; Huggins, Joy; Solkowitz, Sharon N.; Lee, Sharon K.; Reyes, Norma; Mozgai, Sharon; Simon, Joel A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Carmody, Timothy P.; Duncan, Carol L.; Huggins, Joy; Solkowitz, Sharon N.; Lee, Sharon K.; Reyes, Norma; Mozgai, Sharon] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Simon, Joel A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Simon, Joel A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Carmody, TP (reprint author), VA Med Ctr, 116B,4150 Clement St, San Francisco, CA 94121 USA. EM timothy.carmody@va.gov NR 57 TC 8 Z9 8 U1 3 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2013 VL 10 IS 3 SI SI BP 265 EP 275 DI 10.1037/a0030944 PG 11 WC Psychology, Clinical SC Psychology GA 198HX UT WOS:000322914400001 PM 23244028 ER PT J AU Santa Ana, EJ Stallings, DL Rounsaville, BJ Martino, S AF Santa Ana, Elizabeth J. Stallings, Deidre L. Rounsaville, Bruce J. Martino, Steve TI Development of an In-Home Telehealth Program for Outpatient Veterans With Substance Use Disorders SO PSYCHOLOGICAL SERVICES LA English DT Article DE telepsychiatry; home telehealth; care coordination home telehealth; substance abuse treatment; treatment barriers ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; ALCOHOL DEPENDENCE; CARE; TELEPSYCHIATRY; INTERVENTION; TECHNOLOGY; MANAGEMENT; ADDICTION AB A variety of obstacles (e.g., lack of transportation, less availability of treatment in rural districts) contribute to underutilization of treatment among patients with substance use disorders, warranting the need to develop innovative strategies for enhancing access to treatment for these patients. The telehealth in-home-messaging-device is a small message-delivering and monitoring device connected via landline phone to a secure server that provides assessment and disease self-management education to patients in their homes. We describe the development of a Substance Use Disorder telehealth management program (SUD program) for use on this device and a feasibility pilot of the program with six outpatient veterans with substance use disorders referred by their primary medical care providers. These patients indicated that the SUD program was acceptable, easy to use, and helpful toward addressing their substance use problems. Home telehealth technology may be an innovative and feasible approach for providing substance abuse evidence-based treatment either as an adjunct to specialty treatment for substance use disorders or as a stand-alone intervention within primary care for a larger number of patients who may otherwise not access traditional treatment services. C1 [Santa Ana, Elizabeth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Neurosci, Charleston, SC 29401 USA. [Santa Ana, Elizabeth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Stallings, Deidre L.] VHA Off Telehlth Serv, Sunshine Training Ctr 08A, Lake City, FL USA. Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. VA CT Healthcare Syst, West Haven, CT USA. RP Santa Ana, EJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 109 Bee St, Charleston, SC 29401 USA. EM santaana@musc.edu NR 36 TC 2 Z9 2 U1 1 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2013 VL 10 IS 3 SI SI BP 304 EP 314 DI 10.1037/a0026511 PG 11 WC Psychology, Clinical SC Psychology GA 198HX UT WOS:000322914400007 PM 23937090 ER PT J AU Baker, RR AF Baker, Rodney R. TI The History of the Division of Psychologists in Public Service (1946-2006) SO PSYCHOLOGICAL SERVICES LA English DT Article DE public service psychology; history of Division 18; history of APA; history of psychology AB The 60-year history of the American Psychological Association (APA) Division of Psychologists in Public Service (Division 18) is described. Included are relevant events in the history of the APA that led to the establishment of the division and later events within the APA that influenced the development and activities of the division. C1 [Baker, Rodney R.] Dept Vet Affairs, San Antonio, TX USA. RP Baker, RR (reprint author), 10710 Old Blue Lane, San Antonio, TX 78230 USA. EM rodbaker@att.net NR 7 TC 0 Z9 0 U1 1 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2013 VL 10 IS 3 SI SI BP 353 EP 358 DI 10.1037/a0031598 PG 6 WC Psychology, Clinical SC Psychology GA 198HX UT WOS:000322914400013 PM 23398088 ER PT J AU Pape, TLB Guernon, A Lundgren, S Patil, V Herrold, AA Smith, B Blahnik, M Picon, LM Harton, B Peterson, M Mallinson, T Hoffmann, M AF Pape, Theresa Louise-Bender Guernon, Ann Lundgren, Sandra Patil, Vijaya Herrold, Amy A. Smith, Bridget Blahnik, Melanie Picon, Linda M. Harton, Brett Peterson, Michelle Mallinson, Trudy Hoffmann, Michael TI Predicting Levels of Independence With Expressing Needs and Ideas 1 Year After Severe Brain Injury SO REHABILITATION PSYCHOLOGY LA English DT Article DE prognoses; communication; coma; vegetative state; minimally conscious state ID SEVERE HEAD-INJURY; VEGETATIVE STATE; MEDICAL REHABILITATION; CONSCIOUSNESS SCALE; FAMILY CAREGIVERS; SUPPORT NEEDS; DISORDERS; RECOVERY; COMA; PROGNOSIS AB Purpose/Objective: Severe brain injury (BI) is a catastrophic event often evolving into a complex chronic and severely disabling condition making activity participation possible only with sustained caregiving. One aspect of building sustainable caregiving is early provision of information about expected outcomes germane to patients and their caregivers. An analysis was conducted to determine whether 2 levels of independence with expressing needs and ideas 1-year after severe BI could be predicted using variables available early after injury. Method: The authors examined a subsample (n = 79) of participants of an outcome study who received repeated neurobehavioral evaluations with the Disorders of Consciousness Scale (DOCS) and who were assessed 1 year after injury with the Functional Independence Measures (FM). Explanatory variables included DOCS measures, patient characteristics, coexisting conditions, and interventions. The outcome is measured with the FIM Expression item. Optimal data analysis was used to construct multivariate classification tree models. Results: The 2nd (p = .004) DOCS visual measure and seizure (p = .004) entered the final model providing 79% accuracy in classifying more or less independence with expressing needs and ideas at 1 year. The model will correctly identify 78% of future severe BI survivors who will have more independence and 82% of persons who will have less independence. Conclusions: For persons incurring severe BI, it is possible to predict, early after injury, C1 [Pape, Theresa Louise-Bender; Herrold, Amy A.; Smith, Bridget; Harton, Brett] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Pape, Theresa Louise-Bender; Herrold, Amy A.; Harton, Brett] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care Ctr Excellence, Hines, IL 60141 USA. [Pape, Theresa Louise-Bender] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Evanston, IL 60208 USA. [Guernon, Ann] Marianjoy Rehabil Hosp, Res Dept, Wheaton, IL USA. [Lundgren, Sandra] Minneapolis VA Hlth Care Syst, Psychol Serv, Minneapolis, MN USA. [Patil, Vijaya; Hoffmann, Michael] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. [Patil, Vijaya; Smith, Bridget] Loyola Univ Chicago, Stritch Sch Med, Dept Neurol, Chicago, IL USA. [Picon, Linda M.] James A Haley Vet Hosp, Audiol & Speech Pathol Serv, Tampa, FL 33612 USA. [Picon, Linda M.] Univ S Florida, Dept Commun Sci & Disorders, Tampa, FL 33620 USA. [Mallinson, Trudy] Univ So Calif, Div Occupat Sci & Occupat Therapy, Los Angeles, CA 90089 USA. RP Pape, TLB (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, POB 5000,M-C 151H, Hines, IL 60141 USA. EM theresa.pape@va.gov OI Pape, Theresa/0000-0001-7738-5963; Mallinson, Trudy/0000-0002-4888-5579 NR 51 TC 3 Z9 3 U1 0 U2 2 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD AUG PY 2013 VL 58 IS 3 BP 253 EP 262 DI 10.1037/a0032610 PG 10 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 204ZB UT WOS:000323408700004 PM 23978083 ER PT J AU Byrne, T Montgomery, AE Dichter, ME AF Byrne, Thomas Montgomery, Ann Elizabeth Dichter, Melissa E. TI Homelessness Among Female Veterans: A Systematic Review of the Literature SO WOMEN & HEALTH LA English DT Review DE homelessness; women; veterans; systematic review ID HEALTH-CARE UTILIZATION; WOMEN VETERANS; GENDER-DIFFERENCES; MENTAL-HEALTH; CLINICAL-OUTCOMES; SUBSTANCE-ABUSERS; PREDICTORS; PROGRAM; ILLNESS; DETERMINANTS AB The authors conducted a systematic, critical review of the literature to assess and summarize existing research on homelessness among female veterans. They searched seven electronic databases (ERIC, Proquest Dissertations and Theses, PsycINFO, PubMed, Social Services Abstracts, Social Science Citation Index, and Sociological Abstracts), websites of several government and research organizations, and reference lists of prior studies. They abstracted data on study design, funding source, and topic from studies meeting inclusion criteria and classified each study into one of the following categories: epidemiology, health and other services utilization, and interventions. The authors included both experimental and observational studies of interventions in the review and performed a narrative synthesis for each of the 26 studies identified. No studies were experimental, 20 were observational, and the remainder were either qualitative or descriptive. Of the 26 identified studies, 14 were epidemiologic, 7 focused on the health and additional service utilization, and 5 were intervention studies. Findings provided important baseline epidemiologic information about homelessness among female veterans and indicated that female veterans were at an increased risk of homelessness relative to their male veteran and female non-veteran counterparts. Additional research is needed to develop and implement effective, evidence-based programs to prevent and end homelessness among women veterans. C1 [Byrne, Thomas; Montgomery, Ann Elizabeth] Natl Ctr Homelessness Vet, Philadelphia, PA 19104 USA. [Byrne, Thomas] Univ Penn, Philadelphia, PA 19104 USA. [Dichter, Melissa E.] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. RP Byrne, T (reprint author), Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM byrnet@sp2.upenn.edu NR 56 TC 5 Z9 5 U1 3 U2 22 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0363-0242 J9 WOMEN HEALTH JI Women Health PD AUG 1 PY 2013 VL 53 IS 6 BP 572 EP 596 DI 10.1080/03630242.2013.817504 PG 25 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 199WF UT WOS:000323025500003 PM 23937730 ER PT J AU Pompili, M Serafini, G Innamorati, M Venturini, P Fusar-Poli, P Sher, L Amore, M Girardi, P AF Pompili, Maurizio Serafini, Gianluca Innamorati, Marco Venturini, Paola Fusar-Poli, Paolo Sher, Leo Amore, Mario Girardi, Paolo TI Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY LA English DT Review DE Agomelatine; antidepressant drugs; efficacy; tolerability; neuroplasticity ID MAJOR DEPRESSIVE DISORDER; 5HT(2C) RECEPTORS ANTAGONIST; PLACEBO-CONTROLLED-TRIAL; DOUBLE-BLIND; MELATONIN RECEPTORS; NEUROTROPHIC FACTOR; MESSENGER-RNA; HIPPOCAMPAL NEUROGENESIS; NEURONAL PLASTICITY; CELLULAR RESILIENCE AB Objectives. The treatment of major affective disorders, commonly associated with high disability and elevated social costs may be still considered unsatisfactory. Among all antidepressant drugs, predominantly acting through monoaminergic mechanisms, agomelatine is of particular interest due to another alternative mechanism of action. Targeting melatonergic receptors, agomelatine play a crucial role in synchronizing circadian rhythms, known to be altered in depressed subjects. Methods. A critical review of the literature focusing on efficacy, safety and tolerability of agomelatine in major affective disorders was performed. Additionally, we focused on the potential of agomelatine in enhancing neuroplasticity mechanisms and promote neurogenesis. A total of 136 articles from peer-reviewed journals were identified, of which 50 were assessed for eligibility and 21 were included. Results. Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be effective as antidepressant drug. Studies confirmed not only clinical efficacy but also safety and tolerability of agomelatine. Also, it enhances neuroplasticity mechanisms and adult neurogenesis in brain areas such as hippocampus and prefrontal cortex. Conclusions. Agomelatine actually represents an intriguing option in the treatment of affective disorders. C1 [Pompili, Maurizio; Serafini, Gianluca; Innamorati, Marco; Venturini, Paola; Girardi, Paolo] Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Organs, St Andrea Hosp, I-00189 Rome, Italy. [Fusar-Poli, Paolo] Inst Psychiat, Dept Psychosis Studies, London, England. [Sher, Leo] Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, Dept Psychiat, Bronx, NY USA. [Amore, Mario] Univ Genoa, Sect Psychiat, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy. RP Pompili, M (reprint author), Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Organs, St Andrea Hosp, Suicide Prevent Ctr, Via Grottarossa 1035-1039, I-00189 Rome, Italy. EM maurizio.pompili@uniroma1.it; gianluca.serafini@uniroma1.it OI Innamorati, Marco/0000-0003-1389-2290; Pompili, Maurizio/0000-0003-1886-4977 NR 101 TC 26 Z9 27 U1 2 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1562-2975 J9 WORLD J BIOL PSYCHIA JI World J. Biol. Psychiatry PD AUG PY 2013 VL 14 IS 6 BP 412 EP 431 DI 10.3109/15622975.2013.765593 PG 20 WC Psychiatry SC Psychiatry GA 206CM UT WOS:000323494100002 PM 23530731 ER PT J AU Gabayan, GZ Sun, BC Asch, SM Timmermans, S Sarkisian, C Yiu, S Lancaster, EM Poon, KT Kellermann, AL Ryan, G Miniel, NJ Flansbaum, D Hoffman, JR Derose, SF AF Gabayan, Gelareh Z. Sun, Benjamin C. Asch, Steven M. Timmermans, Stefan Sarkisian, Catherine Yiu, Sau Lancaster, Elizabeth M. Poon, K. Trudy Kellermann, Arthur L. Ryan, Gery Miniel, Nicholas J. Flansbaum, Drew Hoffman, Jerome R. Derose, Stephen F. TI Qualitative Factors in Patients Who Die Shortly After Emergency Department Discharge SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID DEATH AFTER-DISCHARGE; MEDICAL LITERATURE; USERS GUIDES; HEALTH-CARE; HOME; XXIII; FALLS; TIME AB Objectives Early death after emergency department (ED) discharge may signal opportunities to improve care. Prior studies are limited by incomplete mortality ascertainment and lack of clinically important information in administrative data. The goal in this hypothesis-generating study was to identify patient and process of care themes that may provide possible explanations for early postdischarge mortality. Methods This was a qualitative analysis of medical records of adult patients who visited the ED of any of six hospitals in an integrated health system (Kaiser Permanente Southern California [KPSC]) and died within 7days of discharge in 2007 and 2008. Nonmembers, visits to non-health plan hospitals, patients receiving or referred to hospice care, and patients with do not attempt resuscitation or do not intubate orders (DNAR/DNI) were excluded. Under the guidance of two qualitative research scientists, a team of three emergency physicians used grounded theory techniques to identify patient clinical presentations and processes of care that serve as potential explanations for poor outcome after discharge. Results The source population consisted of a total of 290,092 members with 446,120 discharges from six KPSC EDs in 2007 and 2008. A total of 203 deaths occurred within 7days of ED discharge (0.05%). Sixty-one randomly chosen cases were reviewed. Patient-level themes that emerged included an unexplained persistent acute change in mental status, recent fall, abnormal vital signs, ill-appearing presentation, malfunctioning indwelling device, and presenting symptoms remaining at discharge. Process-of-care factors included a discrepancy in history of present illness, incomplete physical examination, and change of discharge plan by a third party, such as a consulting or admitting physician. Conclusions In this hypothesis-generating study, qualitative research techniques were used to identify clinical and process-of-care factors in patients who died withindays after discharge from an ED. These potential predictors will be formally tested in a future quantitative study. (C) 2013 by the Society for Academic Emergency Medicine C1 [Gabayan, Gelareh Z.; Sarkisian, Catherine] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Timmermans, Stefan] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA. [Gabayan, Gelareh Z.; Sarkisian, Catherine] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA. [Gabayan, Gelareh Z.; Lancaster, Elizabeth M.; Flansbaum, Drew; Hoffman, Jerome R.] Ronald Reagan UCLA, Ctr Emergency Med, Los Angeles, CA USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. [Asch, Steven M.] Stanford Sch Med, Dept Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Yiu, Sau; Lancaster, Elizabeth M.; Poon, K. Trudy; Derose, Stephen F.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Kellermann, Arthur L.; Ryan, Gery] RAND Hlth, Santa Monica, CA USA. [Miniel, Nicholas J.; Flansbaum, Drew] Olive View UCLA Emergency Med Ctr, Sylmar, CA USA. RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. EM Gelareh@gabayan.com FU Kaiser Permanente Southern California; Emergency Medicine Foundation Career Development Award [59668]; UCLA Oppenheimer Foundation; UCLA Older Americans Independence Center (NIH/NIA K) [P30-AG028748]; National Center for Advancing Translational Sciences [KL2TR000122] FX This research was supported by Kaiser Permanente Southern California. During the initial phase of the project, Dr. Gabayan received support from the Emergency Medicine Foundation Career Development Award (59668 G. Gabayan) and the UCLA Oppenheimer Foundation, and Dr. Sun received support from the UCLA Older Americans Independence Center (NIH/NIA K grant P30-AG028748). Continued support was obtained for Dr. Gabayan from the National Center for Advancing Translational Sciences, grant KL2TR000122. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NIA. NR 25 TC 6 Z9 6 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD AUG PY 2013 VL 20 IS 8 BP 778 EP 785 DI 10.1111/acem.12181 PG 8 WC Emergency Medicine SC Emergency Medicine GA 201IQ UT WOS:000323134300005 PM 24033620 ER PT J AU Peralta, CA Vittinghoff, E Bansal, N Jacobs, D Muntner, P Kestenbaum, B Lewis, C Siscovick, D Kramer, H Shlipak, M Bibbins-Domingo, K AF Peralta, Carmen A. Vittinghoff, Eric Bansal, Nisha Jacobs, David, Jr. Muntner, Paul Kestenbaum, Bryan Lewis, Cora Siscovick, David Kramer, Holly Shlipak, Michael Bibbins-Domingo, Kirsten TI Trajectories of Kidney Function Decline in Young Black and White Adults With Preserved GFR: Results From the Coronary Artery Risk Development in Young Adults (CARDIA) Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Trajectories; race; decline; kidney ID STAGE RENAL-DISEASE; SERUM CYSTATIN-C; SERIAL MEASUREMENTS; RACIAL-DIFFERENCES; UNITED-STATES; CREATININE; PROGRESSION; MORTALITY AB Background: Strong racial discrepancies in end-stage renal disease exist. Whether there are race differences in kidney function loss in younger healthy persons is not well established. Study Design: Longitudinal. Setting & Participants: 3,348 black and white adults with at least 2 measurements of cystatin C-based estimated glomerular filtration rate (eGFR(cys)) at scheduled Coronary Artery Risk Development in Young Adults (CARDIA) examinations (years 10, 15, and 20). Predictor: Race. Outcomes & Measurements: We used linear mixed models to examine race differences in annualized rates of eGFR(cys) decline, adjusting for age, sex, lifetime exposure to systolic blood pressure >120 mm Hg, diabetes, and albumin-creatinine ratio. We used Poisson regression to compare racial differences in rapid decline (eGFR(cys) decline >3% per year) by study period (10-15 years after baseline examination [defining period 1] and >15-20 years after baseline examination [defining period 2]). Results: Mean age was 35 +/- 3.6 (SD) years, and mean eGFR(cys) was 110 +/- 20 mL/min/1.73 m(2) for blacks and 104 +/- 17 mL/min/1.73 m(2) for whites at baseline. For both blacks and whites, eGFR(cys) decline was minimal at younger ages (<35 years) and eGFR(cys) loss accelerated at older ages. However, acceleration of eGFR(cys) decline occurred at earlier ages for blacks than whites. Blacks had somewhat faster annualized rates of decline compared with whites, but differences were attenuated after adjustment in period 1 (0.13 mL/min/1.73 m(2) per year faster; P = 0.2). In contrast, during period 2, blacks had significantly faster annualized rates of decline, even after adjustment (0.32 mL/min/1.73 m(2) per year faster; P = 0.003). The prevalence of rapid decline was significantly higher for blacks versus whites, with prevalence rate ratios of 1.31 (95% CI, 1.04-1.63) for period 1 and 1.24 (95% CI, 1.09-1.41) for period 2. Differences were attenuated after full adjustment: adjusted prevalence rate ratios were 1.20 (95% CI, 0.95-1.49) for period 1 and 1.10 (95% CI, 0.96-1.26) for period 2. Limitations: No measured GFR. Conclusions: eGFR(cys) decline differs by race at early ages, with faster annualized rates of decline for blacks. Future studies are required to explain the observed differences. (c) 2013 by the National Kidney Foundation, Inc. C1 [Peralta, Carmen A.; Vittinghoff, Eric; Bansal, Nisha; Shlipak, Michael; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Peralta, Carmen A.; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [Jacobs, David, Jr.] Univ Minnesota, Minneapolis, MN USA. [Muntner, Paul] Univ Alabama Birmingham, Birmingham, AL USA. [Kestenbaum, Bryan; Siscovick, David] Univ Washington, Washington, DC USA. [Kramer, Holly] Loyola Univ, Chicago, IL 60611 USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu OI Kramer, Holly/0000-0002-6374-837X FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K23DK082793-01, R01DK078124]; Robert Wood Johnson Harold Amos Program; National Heart, Lung and Blood Institute (NHLBI) [N01HC48050]; National Institute on Minority Health and Health Disparities (NIMHD), Comprehensive Centers of Excellence [1P60MD006902]; NIDDK [P30-DK092924] FX Dr Peralta is funded by grant 1K23DK082793-01 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Robert Wood Johnson Harold Amos Program. Dr Bibbins-Domingo was in part supported by grant R01DK078124 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), grant N01HC48050 from the National Heart, Lung and Blood Institute (NHLBI), from grant 1P60MD006902 from the National Institute on Minority Health and Health Disparities (NIMHD), Comprehensive Centers of Excellence and from grant P30-DK092924 from the NIDDK. NR 17 TC 16 Z9 16 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2013 VL 62 IS 2 BP 261 EP 266 DI 10.1053/j.ajkd.2013.01.012 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 196OK UT WOS:000322784700012 PM 23473985 ER PT J AU Paintlia, AS Paintlia, MK Mohan, S Singh, AK Singh, I AF Paintlia, Ajaib S. Paintlia, Manjeet K. Mohan, Sarumathi Singh, Avtar K. Singh, Inderjit TI AMP-Activated Protein Kinase Signaling Protects Oligodendrocytes that Restore Central Nervous System Functions in an Experimental Autoimmune Encephalomyelitis Model SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; MULTIPLE-SCLEROSIS; DEMYELINATING DISEASES; COMBINATION THERAPY; AXON DEGENERATION; OXIDATIVE STRESS; INTERFERON-GAMMA; PROGENITOR CELLS; NAD(P)H OXIDASE; ENERGY-BALANCE AB AMP-activated protein kinase (AMPK) signaling is reported to protect neurons under pathologic conditions; however, its effect on oligodendrocytes (OLs) remains to be elucidated. We investigated whether AMPK signaling protects OLs to restore central nervous system (CNS) functions in an experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. Increased inflammation and demyelination in the CNS and peripheral immune responses were consistent with the observed clinical impairments in EAE animals, which were attenuated by treatment with metformin compared with vehicle. In addition, expressions of neurotrophic factors and of signatory genes of OL lineages were increased in the CNS of metformin-treated EAE animals. Likewise, metformin attenuated inflammatory response and enhanced expressions of neurotrophic factors, thereby protecting OLs via AMPK activation in mixed glial cultures stimulated with lipopolysaccharide/interferon gamma in vitro, as evidenced by analysis of the expression of signatory genes of 01(+)/MBP+ OLs and their cellular populations. Metformin also attenuated oxidative stress and malondialdehyde-containing protein levels, with corresponding induction of anti-oxidative defenses in OLs exposed to cytokines via AMPK activation. These effects of metformin were evident in the CNS of EAE animals. These data provide evidence that AMPK signaling is crucial to protect OLs and, thus, CNS functions in EAE animals. We conclude that AMPK activators, including metformin, have the potential to limit neurologic deficits in multiple sclerosis and related neurodegenerative disorders. C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Mohan, Sarumathi; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU NIH [VA-1BX001072, VA-BX001999, NS-22576, NS-37766, C06-RR018823] FX Supported by NIH grants VA-1BX001072, VA-BX001999, NS-22576, NS-37766, and C06-RR018823. NR 65 TC 13 Z9 15 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD AUG PY 2013 VL 183 IS 2 BP 526 EP 541 DI 10.1016/j.ajpath.2013.04.030 PG 16 WC Pathology SC Pathology GA 194DR UT WOS:000322611700021 PM 23759513 ER PT J AU Woodbury, ML Velozo, CA Richards, LG Duncan, PW AF Woodbury, Michelle L. Velozo, Craig A. Richards, Lorie G. Duncan, Pamela W. TI Rasch Analysis Staging Methodology to Classify Upper Extremity Movement Impairment After Stroke SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Rehabilitation; Stroke; Upper extremity ID FUGL-MEYER ASSESSMENT; COMPUTERIZED ADAPTIVE TEST; UPPER-LIMB; CLINICAL INTERPRETATION; OUTCOME MEASURES; MOTOR DEFICITS; HEMIPARESIS; REHABILITATION; RECOVERY; VALIDITY AB Objectives: To define Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) cutoff scores that demarcate 1 level of upper extremity (UE) impairment from another, and describe motor behaviors for each category in terms of expected FMA-UE item performance. Design: Analysis of existing FMA-UE data. Setting: University research laboratory. Participants: Persons (N=512) 0 to 145 days poststroke, 42 to 90 years of age. Intervention: Not applicable. Main Outcome Measures: An item response Rasch analysis staging method was used to calculate cutoff scores, which were defined as the RaschAndrich threshold values of 2 criterion FMA-UE items derived from an analysis of this sample. The analysis enabled conversion of cutoff scores, in logit units, to FMA-UE points assessed on 30 FMA-UE voluntary movement items (60 possible points). Results: The boundary between severe and moderate impairment was defined as -1.59 +/-.27 logits or 19 +/- 2 points; and between moderate and mild impairment was defined as 2.44 +/-.27 logits or 47 +/- 2 points. A description of expected performance in each impairment level shows that patients with severe impairment exhibited some distal movements, and patients with mild impairment had difficulties with some proximal movements. Conclusions: The cutoff scores, which link to a description of specific movements a patient can, can partially, and cannot perform, may enable formation of heterogeneous patient groups, advance efforts to identify specific movement therapy targets, and define treatment response in terms of specific movement that changed or did not change with therapy. Archives of Physical Medicine and Rehabilitation 2013;94:1527-33 (C) 2013 by the American Congress of Rehabilitation Medicine C1 [Woodbury, Michelle L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Woodbury, Michelle L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Velozo, Craig A.] Malcom Randall VA Med Ctr, Gainesville, FL USA. [Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, Gainesville, FL USA. [Richards, Lorie G.] Univ Utah, Dept Occupat Therapy, Salt Lake City, UT USA. [Duncan, Pamela W.] Wake Forest Baptist Hlth, Dept Neurol, Winston Salem, NC USA. RP Woodbury, ML (reprint author), Med Univ S Carolina, Coll Hlth Profess, 77 President St, Charleston, SC 29425 USA. EM WoodbuML@musc.edu FU Ralph H. Johnson Veterans Affairs Medical Center; Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award [B-6332W]; National Institute on Aging, Claude D. Pepper Center [5P60AG14635] FX Supported by the Ralph H. Johnson Veterans Affairs Medical Center and the Office of Research and Development, Rehabilitation Research and Development, Department of Veterans Affairs, Career Development-2 Award (grant no. B-6332W); and the National Institute on Aging, Claude D. Pepper Center (grant no. 5P60AG14635). NR 51 TC 13 Z9 13 U1 0 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2013 VL 94 IS 8 BP 1527 EP 1533 DI 10.1016/j.apmr.2013.03.007 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 196TZ UT WOS:000322801600013 PM 23529144 ER PT J AU Cameron, MH Asano, M Bourdette, D Finlayson, ML AF Cameron, Michelle H. Asano, Miho Bourdette, Dennis Finlayson, Marcia L. TI People With Multiple Sclerosis Use Many Fall Prevention Strategies but Still Fall Frequently SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Accidental falls; Activities of daily living; Multiple sclerosis; Rehabilitation; Self care ID OLDER-PEOPLE; RISK-FACTORS; ADULTS; METAANALYSIS; COMMUNITY; PROGRAM; BALANCE; TRIAL; DRUGS; WOMEN AB Objective: To compare the use of fall prevention strategies by people with multiple sclerosis (MS) who do or do not fall. Design: Prospective cohort. All assessments were completed between January 2011 and December 2011. Data used in this analysis were collected as part of an observational study that included baseline assessment followed by prospective counting of falls using fall calendars. Setting: Veterans Affairs and university medical centers. Participants: People with MS (N=58) of any subtype, aged 18 to 50 years, with Expanded Disability Status Scale score <6.0, recruited from MS clinics at the Portland VA Medical Center and Oregon Health and Science University and from the surrounding areas. Interventions: Not applicable. Main Outcome Measures: Measures included the occurrence of falls over 3 months and scores on the Fall Prevention Strategy Survey (FPSS) and the relations between fall prevention strategy use reported on the FPSS and falls. Results: A total of 52 subjects completed the study. Of these, 33 (63%) subjects fell at least once in the 3-month period, and 19 (36%) subjects did not fall. The mean total FPSS score for the fallers was significantly higher than the nonfallers (mean +/- SD, 8.1 +/- 6.4 vs 4.0 +/- 4.1; range, 0-20 vs 0-15; P=.007), and FPSS scores correlated with monthly fall rates (rho=.49, P=.01). A higher proportion of fallers than nonfallers used the strategies of turning on lights at home, asking others for help, and talking to a health care professional about fall prevention. However, both groups rarely talked to a health care professional about fall prevention or asked a provider to check whether any medications might increase fall risk. Conclusions: People with MS who fall use more fall prevention strategies than those who do not fall. Archives of Physical Medicine and Rehabilitation 2013;94:1562-6 (C) 2013 by the American Congress of Rehabilitation Medicine C1 [Cameron, Michelle H.; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Cameron, Michelle H.; Bourdette, Dennis] Portland VA Med Ctr, Portland, OR USA. [Asano, Miho; Finlayson, Marcia L.] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada. RP Cameron, MH (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, L226,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM cameromi@ohsu.edu RI Finlayson, Marcia /G-2654-2014 OI Finlayson, Marcia /0000-0002-1774-4810 FU Department of Veterans Affairs, Rehabilitation Research and Development [E7244W] FX Supported by the Department of Veterans Affairs, Rehabilitation Research and Development (grant no. E7244W). NR 26 TC 3 Z9 4 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2013 VL 94 IS 8 BP 1562 EP 1566 DI 10.1016/j.apmr.2013.01.021 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 196TZ UT WOS:000322801600018 PM 23391522 ER PT J AU Pompili, M Gonda, X Serafini, G Innamorati, M Sher, L Amore, M Rihmer, Z Girardi, P AF Pompili, Maurizio Gonda, Xenia Serafini, Gianluca Innamorati, Marco Sher, Leo Amore, Mario Rihmer, Zoltan Girardi, Paolo TI Epidemiology of suicide in bipolar disorders: a systematic review of the literature SO BIPOLAR DISORDERS LA English DT Review DE adults; bipolar disorder; completed suicides; risk factors; suicide rates ID MAJOR DEPRESSION; RISK-FACTORS; FOLLOW-UP; COMPLETED SUICIDE; ANXIETY DISORDERS; MIXED-STATE; STEP-BD; LITHIUM; BEHAVIOR; PREVALENCE AB Objective: Suicidal behavior is a major public health problem worldwide, and its prediction and prevention represent a challenge for everyone, including clinicians. The aim of the present paper is to provide a systematic review of the existing literature on the epidemiology of completed suicides in adult patients with bipolar disorder (BD). Methods: We performed a Pubmed/Medline, Scopus, PsycLit, PsycInfo, and Cochrane database search to identify all relevant papers published between 1980 and 2011. A total of 34 articles meeting our inclusion criteria were included in the present review. Results: Several prospective follow-up contributions, many retrospective analyses, and a few psychological autopsy studies and review articles investigated the epidemiology of completed suicides in patients with BD. The main finding of the present review was that the risk for suicide among BD patients was up to 20-30 times greater than that for the general population. Conclusion: Special attention should be given to the characteristics of suicides in patients with BD. Better insight and understanding of suicide and suicidal risk in this very disabling illness should ultimately help clinicians to adequately detect, and thus prevent, suicidal acts in patients with BD. C1 [Pompili, Maurizio; Serafini, Gianluca; Innamorati, Marco; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00189 Rome, Italy. [Gonda, Xenia; Rihmer, Zoltan] Semmelweis Univ, Dept Clin & Theoret Mental Hlth, Kutvolgyi Clin Ctr, H-1085 Budapest, Hungary. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Amore, Mario] Univ Genoa, Sect Psychiat, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy. [Girardi, Paolo] Villa Rosa Med Res Ctr, Viterbo, Italy. RP Pompili, M (reprint author), Univ Roma La Sapienza, St Andrea Hosp, Dept Psychiat, 1035-1039 Via Grottarossa, I-00189 Rome, Italy. EM maurizio.pompili@uniroma1.it OI Innamorati, Marco/0000-0003-1389-2290; Pompili, Maurizio/0000-0003-1886-4977 NR 73 TC 57 Z9 58 U1 7 U2 35 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD AUG PY 2013 VL 15 IS 5 SI SI BP 457 EP 490 DI 10.1111/bdi.12087 PG 34 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 196KV UT WOS:000322774700002 PM 23755739 ER PT J AU Yerevanian, BI Choi, YM AF Yerevanian, Boghos I. Choi, Young Mee TI Impact of psychotropic drugs on suicide and suicidal behaviors SO BIPOLAR DISORDERS LA English DT Review DE anticonvulsants; antidepressants; antipsychotics; bipolar disorder; lithium; mood disorder; psychotropic drugs; sedatives and hypnotics; suicide ID BIPOLAR-I DISORDER; PLACEBO-CONTROLLED TRIAL; LITHIUM MAINTENANCE TREATMENT; TREATMENT ENHANCEMENT PROGRAM; TERM ANTIDEPRESSANT TREATMENT; MAJOR AFFECTIVE-DISORDERS; CONTROLLED 18-MONTH TRIAL; STEP-BD; DOUBLE-BLIND; ANTIEPILEPTIC DRUGS AB Objective: To examine the impact of psychotropic drugs on suicide and suicidal behaviors in bipolar disorders. Methods: A Medline search of articles published from January 1960 to January 2013 was performed using relevant keywords to identify studies examining the relationship of psychotropic drugs to suicidal behaviors. The publications were further reviewed for relevant references and information. Additionally, the US Food and Drug Administration Center for Drug Evaluation Research website was searched. Results: The available studies used differing methodologies, making interpretation of the findings difficult. Studies suggest that antidepressants may increase suicidal risk in bipolar disorder, this possibly being related to the induction of broadly defined mixed states. There is no evidence that antiepileptic drugs as a class increase suicidal risk in patients with bipolar disorder. Only lithium provides convincing data that it reduces the risk of suicide over the long term. There is little known regarding the effects of antipsychotics, as well as anti-anxiety and hypnotic drugs, on suicidal behavior. Conclusions: The available evidence for the impact of psychotropics on suicidal risk in patients with bipolar disorder is largely methodologically flawed and, except for a few instances, clinically not useful at this point. Adequately powered, prospective randomized controlled studies are needed to assess the impact of each class of psychotropic and each psychotropic as well as common combination therapies. Until such studies have been carried out, clinicians are urged to exercise caution in using these drugs and rely on the traditional means of carefully assessing and monitoring patients with bipolar disorder who are at high risk for suicide. C1 [Yerevanian, Boghos I.; Choi, Young Mee] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA. [Yerevanian, Boghos I.; Choi, Young Mee] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Yerevanian, BI (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Sepulveda Ambulatory Care Ctr, 16111 Plummer St Bldg 10,MC 116A3, North Hills, CA 91343 USA. EM byerevan@ucla.edu NR 137 TC 18 Z9 20 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD AUG PY 2013 VL 15 IS 5 SI SI BP 594 EP 621 DI 10.1111/bdi.12098 PG 28 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 196KV UT WOS:000322774700011 PM 23869907 ER PT J AU Janzen, DM Rosales, MA Paik, DY Lee, DS Smith, DA Witte, ON Iruela-Arispe, ML Memarzadeh, S AF Janzen, Deanna M. Rosales, Miguel A. Paik, Daniel Y. Lee, Daniel S. Smith, Daniel A. Witte, Owen N. Iruela-Arispe, M. Luisa Memarzadeh, Sanaz TI Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy SO CANCER RESEARCH LA English DT Article ID UTERINE EPITHELIUM; ANDROGEN RECEPTOR; PROSTATE-CANCER; BREAST-CANCER; ESTROGEN; CARCINOMA; HYPERPLASIA; EXPRESSION; MOUSE; ADENOCARCINOMA AB Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. The clinical use of progesterone is limited because of the lack of biomarkers that predict hormone sensitivity. Despite its efficacy in cancer therapy, mechanisms and site of action for progesterone remain unknown. Using an in vivo endometrial cancer mouse model driven by clinically relevant genetic changes but dichotomous responses to hormonal therapy, we show that signaling through stromal PR is necessary and sufficient for progesterone antitumor effects. Endometrial cancers resulting from epithelial loss of PTEN (PTENKO) were hormone sensitive and had abundant expression of stromal PR. Stromal deletion of PR as a single genetic change in these tumors induced progesterone resistance indicating that paracrine signaling through the stroma is essential for the progesterone therapeutic effects. A hormone-refractory endometrial tumor with low levels of stromal PR developed when activation of KRAS was coupled with PTEN-loss (PTENKO/Kras). The innate progesterone resistance in PTENKO/Kras tumors stemmed from methylation of PR in the tumor microenvironment. Add-back of stromal PR expressed from a constitutively active promoter sensitized these tumors to progesterone therapy. Results show that signaling through stromal PR is sufficient for inducing hormone responsiveness. Our findings suggest that epigenetic derepression of stromal PR could be a potential therapeutic target for sensitizing hormone-refractory endometrial tumors to progesterone therapy. On the basis of these results, stromal expression of PR may emerge as a reliable biomarker in predicting response to hormonal therapy. (C)2013 AACR. C1 [Janzen, Deanna M.; Rosales, Miguel A.; Paik, Daniel Y.; Lee, Daniel S.; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Iruela-Arispe, M. Luisa] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA. [Smith, Daniel A.; Witte, Owen N.; Iruela-Arispe, M. Luisa] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA. [Witte, Owen N.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Smith, Daniel A.; Witte, Owen N.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, 555 Westwood Plaza,Level B,Box 957243,1015 Terasa, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu FU VA CDA-2 Award; Scholars in Translational Medicine Program; Mary Kay Award; CDU/UCLA NIH/NCI [U54-CA-143931]; Sidney Kimmel Foundation; UCLA Cancer Research Coordinating Committee; Concern foundation FX S. Memarzadeh is supported by a VA CDA-2 Award, Scholars in Translational Medicine Program, Mary Kay Award, the CDU/UCLA NIH/NCI Grant #U54-CA-143931 award, a Sidney Kimmel Foundation award, the UCLA Cancer Research Coordinating Committee grant, and the Concern foundation. NR 49 TC 12 Z9 15 U1 1 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2013 VL 73 IS 15 BP 4697 EP 4710 DI 10.1158/0008-5472.CAN-13-0930 PG 14 WC Oncology SC Oncology GA 194HC UT WOS:000322620800012 PM 23744837 ER PT J AU Maw, TT Fried, L AF Maw, Thin Thin Fried, Linda TI Chronic Kidney Disease in the Elderly SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Elderly; Geriatric; Chronic kidney disease; Renal function; Dialysis ID GLOMERULAR-FILTRATION-RATE; CHRONIC RENAL-INSUFFICIENCY; BONE-MINERAL DENSITY; BLOOD-PRESSURE; CYSTATIN-C; CARDIOVASCULAR OUTCOMES; SERUM CREATININE; UNITED-STATES; OLDER INDIVIDUALS; GLUCOSE CONTROL AB Chronic kidney disease (CKD) is increasingly being recognized as a disease of elderly individuals. In recent years the definition and categorization of kidney disease has been standardized. There are concerns that this standardization has led to an increase in the number of older individuals labeled as having CKD. This article addresses the definitions of CKD, recently published revised CKD stages with risk stratifications, and limitations of using formulas to assess renal function in the elderly. Also discussed are management of common risk factors of progression CKD, nonrenal-related outcomes, prognosis of CKD in older individuals, and criteria for referral to nephrology. C1 [Maw, Thin Thin; Fried, Linda] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. RP Fried, L (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA. EM linda.fried@va.gov NR 57 TC 6 Z9 6 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD AUG PY 2013 VL 29 IS 3 BP 611 EP + DI 10.1016/j.cger.2013.05.003 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 198MY UT WOS:000322928200006 PM 23849011 ER PT J AU Nguyen, HM Graber, CJ AF Nguyen, Hien M. Graber, Christopher J. TI Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on? SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Cephalothin; Antibiotics; Susceptibility; MIC; Urinary tract infection ID ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; CEPHALEXIN; CEFADROXIL; CEFPODOXIME; MECHANISMS; CEFAZOLIN; CEFACLOR AB Based on current epidemiologic and resistance trends, we propose reconsideration of the use of cephalothin susceptibility to predict susceptibility to oral narrow-spectrum cephalosporins among Enterobacteriaceae, particularly in predicting cephalexin susceptibility for urinary tract isolates. (c) 2013 Elsevier Inc. All rights reserved. C1 [Nguyen, Hien M.] Dept Infect Dis, Portland, OR USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90095 USA. RP Nguyen, HM (reprint author), Dept Infect Dis, Portland, OR USA. EM hien.m.nguyen@kp.org NR 18 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD AUG PY 2013 VL 76 IS 4 BP 483 EP 485 DI 10.1016/j.diagmicrobio.2013.03.022 PG 3 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 195FK UT WOS:000322687500015 PM 23680238 ER PT J AU Saxon, AJ AF Saxon, Andrew J. TI Donald A. Calsyn, Ph.D.: 1949-2013 SO DRUG AND ALCOHOL DEPENDENCE LA English DT Biographical-Item C1 VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Saxon, Andrew J.] Univ Washington, Seattle, WA 98195 USA. RP Saxon, AJ (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. EM Andrew.Saxon@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD AUG 1 PY 2013 VL 131 IS 3 BP 324 EP 324 DI 10.1016/j.drugalcdep.2013.04.011 PG 1 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 197MP UT WOS:000322855600020 ER PT J AU Zhou, T Hasty, P Walter, CA Bishop, AJR Scott, LM Rebel, VI AF Zhou, Ting Hasty, Paul Walter, Christi A. Bishop, Alexander J. R. Scott, Linda M. Rebel, Vivienne I. TI Myelodysplastic syndrome: An inability to appropriately respond to damaged DNA? SO EXPERIMENTAL HEMATOLOGY LA English DT Review ID HEMATOPOIETIC STEM-CELLS; BASE EXCISION-REPAIR; ROTHMUND-THOMSON SYNDROME; FLUDARABINE COMBINATION CHEMOTHERAPY; BONE-MARROW FAILURE; FANCONI-ANEMIA; MYELOID-LEUKEMIA; MISMATCH REPAIR; MOUSE MODEL; CHROMOSOMAL INSTABILITY AB Myelodysplastic syndrome (MDS) is considered a hematopoietic stem cell disease that is characterized by abnormal hematopoietic differentiation and a high propensity to develop acute myeloid leukemia. It is mostly associated with advanced age, but also with prior cancer therapy and inherited syndromes related to abnormalities in DNA repair. Recent technologic advances have led to the identification of a myriad of frequently occurring genomic perturbations associated with MDS. These observations suggest that MDS and its progression to acute myeloid leukemia is a genomic instability disorder, resulting from a stepwise accumulation of genetic abnormalities. The notion is now emerging that the underlying mechanism of this disease could be a defect in one or more pathways that are involved in responding to or repairing damaged DNA. In this review, we discuss these pathways in relationship to a large number of studies performed with MDS patient samples and MDS mouse models. Moreover, in view of our current understanding of how DNA damage response and repair pathways are affected by age in hematopoietic stem cells, we also explore how this might relate to MDS development. (c) 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [Zhou, Ting; Bishop, Alexander J. R.; Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Zhou, Ting; Walter, Christi A.; Bishop, Alexander J. R.; Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Hasty, Paul] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Hasty, Paul; Walter, Christi A.; Bishop, Alexander J. R.; Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy Res Ctr, San Antonio, TX 78229 USA. [Hasty, Paul; Walter, Christi A.; Bishop, Alexander J. R.; Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] South Texas Vet Hlth Care Syst, Audie Murphy Hosp, San Antonio, TX USA. [Scott, Linda M.] Univ Queensland, Fac Hlth Sci, Diamantina Inst, Brisbane, Qld, Australia. [Scott, Linda M.] Univ Queensland, Fac Hlth Sci, Sch Med, Brisbane, Qld, Australia. RP Rebel, VI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM rebel@uthscsa.edu RI Scott, Linda/D-9777-2012 OI Scott, Linda/0000-0003-0334-1479 FU National Institute of Aging [5R21AG033339]; National Institute of Environmental Health Sciences [1RO1ES022054]; Hyundai Hope on Wheels FX This work was supported by the National Institute of Aging (grant 5R21AG033339 to V.I.R. and C.A.W.), the National Institute of Environmental Health Sciences (grant 1RO1ES022054 to P.E.H. and V.I.R.), and Hyundai Hope on Wheels (to A.J.R.B. and V.I.R.). NR 108 TC 13 Z9 13 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD AUG PY 2013 VL 41 IS 8 BP 665 EP 674 DI 10.1016/j.exphem.2013.04.008 PG 10 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 199VX UT WOS:000323024700001 PM 23643835 ER PT J AU Psaltis, AJ Schlosser, RJ Yawn, JR Henriquez, O Mulligan, JK AF Psaltis, Alkis J. Schlosser, Rodney J. Yawn, James R. Henriquez, Oswaldo Mulligan, Jennifer K. TI Characterization of B-cell subpopulations in patients with chronic rhinosinusitis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE Chronic rhino sinusitis; B lymphocytes; B cells; plasma cells; Nasal polyps; chronic inflammation; sinusitis ID NASAL POLYPS AB Background: Recent research suggest that B and plasma cells may play an important role in the pathogenesis of chronic rhinosinusitis with nasal polyposis (CRSwNP). The purpose of this study was to subcharacterize the B cell response in the sinus mucosa of control and CRS patients. Methods: Representative tissue samples and peripheral blood samples were obtained from controls, CRS without nasal polyps (CRSsNP) and CRSwNP. Using single-cell suspension flow cytometry these samples were analyzed for overall and stage-specific B and plasma cell percentages. Results: Both atopic and nonatopic CRSwNP patients showed an increase in local numbers of naive, active, and memory B cells compared to controls. CRSsNP patients only showed local elevations of naive B cells. Plasma cells were only significantly elevated in the sinus tissue of atopic CRSwNP patients. These local tissue increases did not correlate with increased numbers of circulating B cells. Conclusion: This study provides further evidence of an important role of B cells in CRSwNP patients. The local increase appears to be independent of a systemic response. (C) 2013 ARS-AAOA, LLC. C1 [Psaltis, Alkis J.; Schlosser, Rodney J.; Yawn, James R.; Henriquez, Oswaldo; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Psaltis, AJ (reprint author), Stanford Univ, Stanford Sch Med, Dept Otolaryngol Head & Neck Surg, 801 Welch Rd, Palo Alto, CA 94303 USA. EM alkispsaltis@gmail.com FU American Academy of Otolaryngic Allergy; Garnett Passe and Rodney Williams Memorial Foundation; Department of Veterans Affairs; Flight Attendant Medical Research Institutes FX Funding sources for the study: American Academy of Otolaryngic Allergy (to A.J.P.); Garnett Passe and Rodney Williams Memorial Foundation (to A.J.P.); Department of Veterans Affairs (to R.J.S.); Flight Attendant Medical Research Institutes (to J.K.M. and R.J.S.). NR 23 TC 9 Z9 9 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD AUG PY 2013 VL 3 IS 8 BP 621 EP 629 DI 10.1002/alr.21173 PG 9 WC Otorhinolaryngology SC Otorhinolaryngology GA 201WE UT WOS:000323172900004 PM 23640795 ER PT J AU CorveraTindel, T Doering, LV AF CorveraTindel, Teresita Doering, Lynn V. TI Social Connections and Depressive Symptoms in Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 17th Annual Scientific Meeting of the Heart-Failure-Society-of-America (HFSA) CY SEP 22-25, 2013 CL Orlando, FL SP Heart Failure Soc Amer (HFSA) C1 [CorveraTindel, Teresita] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Doering, Lynn V.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2013 VL 19 IS 8 SU 1 MA 014 BP S6 EP S6 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 201LG UT WOS:000323142500015 ER PT J AU Kashyap, A Dezellem, S Vardeny, O AF Kashyap, Anita Dezellem, Sheryl Vardeny, Orly TI A Retrospective Evaluation of Spironolactone Versus Eplerenone on Potassium Homeostasis and Renal Function SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 17th Annual Scientific Meeting of the Heart-Failure-Society-of-America (HFSA) CY SEP 22-25, 2013 CL Orlando, FL SP Heart Failure Soc Amer (HFSA) C1 [Kashyap, Anita; Dezellem, Sheryl] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Vardeny, Orly] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2013 VL 19 IS 8 SU 1 MA 077 BP S28 EP S28 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 201LG UT WOS:000323142500077 ER PT J AU Jovanovich, A Buzkova, P Chonchol, M Robbins, J Fink, HA de Boer, IH Kestenbaum, B Katz, R Carbone, L Lee, J Laughlin, GA Mukamal, KJ Fried, LF Shlipak, MG Ix, JH AF Jovanovich, Anna Buzkova, Petra Chonchol, Michel Robbins, John Fink, Howard A. de Boer, Ian H. Kestenbaum, Bryan Katz, Ronit Carbone, Laura Lee, Jennifer Laughlin, Gail A. Mukamal, Kenneth J. Fried, Linda F. Shlipak, Michael G. Ix, Joachim H. TI Fibroblast Growth Factor 23, Bone Mineral Density, and Risk of Hip Fracture Among Older Adults: The Cardiovascular Health Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CHRONIC KIDNEY-DISEASE; PHOSPHATE HOMEOSTASIS; CYSTATIN-C; FGF-23; FIBROBLAST-GROWTH-FACTOR-23; OSTEOMALACIA; OSTEOPOROSIS; HEMODIALYSIS; ASSOCIATION; MORTALITY AB Context: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that also inhibits calcitriol synthesis. Objective: Our objective was to evaluate the relationships of plasma FGF23 concentrations with bone mineral density (BMD) and hip fracture in community-dwelling older adults. Design and Setting: Linear regression and Cox proportional hazard models were used to examine the associations of plasma FGF23 concentrations with BMD and incident hip fracture, respectively. Analyses were also stratified by chronic kidney disease. Participants: Participants included 2008 women and 1329 men >= 65 years from the 1996 to 1997 Cardiovascular Health Study visit. Main Outcome Measures: Dual x-ray absorptiometry measured total hip (TH) and lumbar spine (LS) BMD in 1291 participants. Hip fracture incidence was assessed prospectively through June 30, 2008 by hospitalization records in all participants. Results: Women had higher plasma FGF23 concentrations than men (75 [56-107] vs 66 [interquartile range = 52-92] relative units/mL; P < .001). After adjustment, higher FGF23 concentrations were associated with greater total hip and lumbar spine BMD in men only (beta per doubling of FGF23 = 0.02, with 95% confidence interval [CI] = 0.001-0.04 g/cm(2), and 0.03 with 95% CI = 0.01-0.06 g/cm(2)). During 9.6 +/- 5.1-11.0 years of follow-up, 328 hip fractures occurred. Higher FGF23 concentrations were not associated with hip fracture risk in women or men(adjusted hazard ratio = 0.95, with 95% CI = 0.78-1.15, and 1.09 with 95% CI = 0.82-1.46 per doubling of FGF23). Results did not differ by chronic kidney disease status (P > .4 for interactions). Conclusions: In this large prospective cohort of community-dwelling older adults, higher FGF23 concentrations were weakly associated with greater lumbar spine and total hip BMD but not with hip fracture risk. C1 [Jovanovich, Anna; Chonchol, Michel] Univ Colorado, Sch Med, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. [Buzkova, Petra; Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98105 USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98105 USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98105 USA. [Robbins, John] Univ Calif Davis, Sacramento, CA 95817 USA. [Fink, Howard A.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN 55417 USA. [Carbone, Laura] Dept Vet Affairs Med Ctr, Memphis, TN 38104 USA. [Lee, Jennifer] Calif Pacific Med Ctr, San Francisco Coordinating Ctr, Res Inst, San Francisco, CA 94115 USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Vet Adm Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92161 USA. [Laughlin, Gail A.] Univ Calif San Diego, Div Epidemiol, Dept Family & Prevent Med, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent, Dept Family & Prevent Med, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent, Dept Med, San Diego, CA 92093 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu FU National Heart, Lung, and Blood Institute (NHLBI) [R01HL096851]; American Heart Association [0575021N]; NHLBI [U01 HL080295]; [HHSN268201200036C]; [N01 HC-85079]; [N01HC-85086]; [N01-HC-35129]; [N01 HC-15103]; [N01 HC-55222]; [N01 HC-75150]; [N01 HC-54133]; [N01-HC-80007] FX This work was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (R01HL096851) and American Heart Association (0575021N) to J.H.I. Additionally, this paper was supported in part with resources of the Veterans Affairs San Diego Healthcare System. The Cardiovascular Health Study was supported by contract numbers HHSN268201200036C, N01 HC-85079 through N01HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01 HC-75150, N01 HC-54133, and N01-HC-80007 and Grant U01 HL080295 from the NHLBI, with additional contributions from the National Institute of Neurological Disorders and Stroke. NR 31 TC 11 Z9 11 U1 0 U2 24 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD AUG PY 2013 VL 98 IS 8 BP 3323 EP 3331 DI 10.1210/jc.2013-1152 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 196NC UT WOS:000322781300050 PM 23771921 ER PT J AU Cross, DJ Anzai, Y Petrie, EC Martin, N Richards, TL Maravilla, KR Peskind, ER Minoshima, S AF Cross, Donna J. Anzai, Yoshimi Petrie, Eric C. Martin, Nathalie Richards, Todd L. Maravilla, Kenneth R. Peskind, Elaine R. Minoshima, Satoshi TI Loss of Olfactory Tract Integrity Affects Cortical Metabolism in the Brain and Olfactory Regions in Aging and Mild Cognitive Impairment SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE olfactory tract; Alzheimer's disease; fiber tract integrity; glucose metabolism; F-18-FDG PET; DTI ID TRAUMATIC AXONAL INJURY; ALZHEIMERS-DISEASE; TAU PATHOLOGY; IN-VIVO; DYSFUNCTION; MRI; EPSILON-4; BULB; PET AB Olfactory dysfunction is an early feature of Alzheimer disease. This study used multimodal imaging of PET and F-18-FDG combined with diffusion tensor imaging (DTI) to investigate the association of fiber tract integrity in the olfactory tract with cortical glucose metabolism in subjects with mild cognitive impairment (MCI) and normal controls. We hypothesized that MCI subjects would show loss of olfactory tract integrity and may have altered associations with glucose metabolism. Methods: Subjects diagnosed with amnestic MCI (n = 12) and normal controls (n = 23) received standard brain F-18-FDG PET and DTI with 32 gradient directions on a 3-T MR imaging scanner. Fractional anisotropy (FA) maps were generated. Voxelwise correlation analysis of olfactory tract FA values with F-18-FDG PET images was performed. Results: Integrated analysis over all subjects indicated a positive correlation between white matter integrity in the olfactory tract and metabolic activity in olfactory processing structures, including the rostral prefrontal cortex, dorsomedial thalamus, hypothalamus, orbitofrontal cortex, and uncus, and in the superior temporal gyrus, insula, and anterior cingulate cortex. Subjects with MCI, compared with normal controls, showed differential associations of olfactory tract integrity with medial temporal lobe and posterior cortical structures. Conclusion: These findings indicate that impairment of axonal integrity or neuronal loss may be linked to functional metabolic changes and that disease-specific neurodegeneration may affect this relationship. Multimodal imaging using F-18-FDG PET and DTI may provide better insights into aging and neurodegenerative processes. C1 [Cross, Donna J.; Anzai, Yoshimi; Petrie, Eric C.; Martin, Nathalie; Richards, Todd L.; Maravilla, Kenneth R.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Petrie, Eric C.; Peskind, Elaine R.] MIRECC, VA Puget Sound, Seattle, WA USA. RP Cross, DJ (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM dcross@uw.edu FU NIH [R01 NS045254]; NIA [P50AG005136]; VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC) FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was supported by NIH R01 NS045254, NIA grant P50AG005136, and the VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC). No other potential conflict of interest relevant to this article was reported. NR 31 TC 13 Z9 14 U1 0 U2 4 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD AUG PY 2013 VL 54 IS 8 BP 1278 EP 1284 DI 10.2967/jnumed.112.116558 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 195HH UT WOS:000322692400035 PM 23804325 ER PT J AU Lloyd, S Buscariollo, DL Gross, CP Makarov, DV Yu, JB AF Lloyd, Shane Buscariollo, Daniela L. Gross, Cary P. Makarov, Danil V. Yu, James B. TI Determinants of Enrollment in Cancer Clinical Trials: The Relationship Between the Current State of Knowledge, Societal Disease Burden, and Randomized Clinical Trial Enrollment SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID RECOMMENDATIONS AB Whether clinical cancer research currently focuses on gaps in the evidentiary basis for clinical guidelines and/or on cancers that impose greater societal burden is unclear. This study assessed the relationship between cancer research efforts in terms of planned randomized controlled trial (RCT) enrollment, objective measures of evidence quality, and a cancer's burden on society. The authors calculated the planned RCT enrollment listed on ClinicalTrials.gov for the 17 most prevalent solid cancers. Using cancer type as the unit of analysis, linear regression was used to examine the association between planned enrollment in RCTs and 1) evidence quality, as measured by the absolute number and percent of highest quality category (category 1 [C1]) recommendations in the NCCN Clinical Practice Guidelines in Oncology for each cancer, and 2) measures of burden on society, including prevalence, incidence, person-years of life lost (PYLL), and disability-adjusted life years (DALY). Non-normal distributions were log transformed when appropriate. Overall, 15% of the NCCN recommendations were based on the highest quality evidence. Results produced 1260 RCTs. Planned RCT enrollment ranged from 2270 (testis) to 492,876 (breast) and was correlated neither with absolute number nor percent of C1 recommendations for that cancer. Planned RCT enrollment was positively correlated with a cancer's prevalence (P=.01), incidence (P<.01), PYLL (P<.01), and DALY (P<0.01). In multivariate analysis, prevalence (P<.01) and PYLL (P<.01) had the strongest association with planned RCT enrollment. Findings showed, therefore, that planned cancer RCT enrollment is associated with higher societal disease burden, not the quality of a cancer's clinical guidelines. C1 [Lloyd, Shane; Yu, James B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. [Buscariollo, Daniela L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Makarov, Danil V.] NYU, Sch Med, Dept Urol, US Dept Vet Affairs, New York, NY 10003 USA. [Makarov, Danil V.] NYU, Sch Med, US Dept Vet Affairs, Dept Populat Hlth & Canc, New York, NY 10003 USA. RP Yu, JB (reprint author), Yale Univ, Sch Med, Dept Therapeut Radiol, LL 516 Smilow,POB 208040, New Haven, CT 06510 USA. EM james.b.yu@yale.edu FU Medtronic FX Drs. Lloyd, Buscariollo, Makarov, and Yu have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Gross has disclosed that he receives a research grant from Medtronic and is on the advisory board for Fair Health Inc. NR 18 TC 0 Z9 0 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD AUG PY 2013 VL 11 IS 8 BP 928 EP 936 PG 9 WC Oncology SC Oncology GA 201QE UT WOS:000323156900004 PM 23946172 ER PT J AU Goodson, JT Lefkowitz, CM Helstrom, AW Gawrysiak, MJ AF Goodson, Jason T. Lefkowitz, Carin M. Helstrom, Amy W. Gawrysiak, Michael J. TI Outcomes of Prolonged Exposure Therapy for Veterans With Posttraumatic Stress Disorder SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PSYCHOLOGICAL TREATMENTS; COMPENSATION-SEEKING; PTSD; IRAQ; WAR; PSYCHOTHERAPY; METAANALYSIS; TRIAL; MOOD; PAIN AB Prolonged Exposure (PE) is an evidenced-based psychotherapy for posttraumatic stress disorder (PTSD) that is being disseminated nationally within the U.S. Department of Veterans Affairs (VA) with promising initial results. Empirical evidence, however, regarding the effectiveness of PE for treatment of PTSD in military veterans is limited. Building on previous treatment outcome research, the current study investigated the effectiveness of PE in a diverse veteran sample. One-hundred fifteen veterans were enrolled in PE at an urban VA medical center and its surrounding outpatient clinics. PTSD and depression symptoms as well as quality of life were measured before and after treatment. Several baseline patient characteristics were examined as predictors of treatment response. Eighty-four participants completed treatment. Participants experienced a 42% reduction in PTSD symptoms, a 31% reduction in depression symptoms, and an increase in quality of life following PE. Veterans not prescribed psychotropic medication reported greater PTSD symptom reduction than veterans prescribed such medication. The implications of these results for treatment programs targeting PTSD in veterans are discussed. C1 [Goodson, Jason T.; Lefkowitz, Carin M.; Helstrom, Amy W.; Gawrysiak, Michael J.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Goodson, Jason T.; Lefkowitz, Carin M.; Helstrom, Amy W.; Gawrysiak, Michael J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Goodson, JT (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Jason.Goodson@va.gov NR 40 TC 21 Z9 21 U1 0 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2013 VL 26 IS 4 BP 419 EP 425 DI 10.1002/jts.21830 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 198CD UT WOS:000322898400001 PM 23934939 ER PT J AU Kearney, DJ Malte, CA McManus, C Martinez, ME Felleman, B Simpson, TL AF Kearney, David J. Malte, Carol A. McManus, Carolyn Martinez, Michelle E. Felleman, Ben Simpson, Tracy L. TI Loving-Kindness Meditation for Posttraumatic Stress Disorder: A Pilot Study SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID ADMINISTERED PTSD SCALE; ALTERNATIVE MEDICINE; MILITARY VETERANS; SELF-COMPASSION; MINDFULNESS; COMPLEMENTARY; CLINICIAN; SYMPTOMS; THERAPY; PSYCHOTHERAPY AB Loving-kindness meditation is a practice designed to enhance feelings of kindness and compassion for self and others. Loving-kindness meditation involves repetition of phrases of positive intention for self and others. We undertook an open pilot trial of loving-kindness meditation for veterans with posttraumatic stress disorder (PTSD). Measures of PTSD, depression, self-compassion, and mindfulness were obtained at baseline, after a 12-week loving-kindness meditation course, and 3 months later. Effect sizes were calculated from baseline to each follow-up point, and self-compassion was assessed as a mediator. Attendance was high; 74% attended 9-12 classes. Self-compassion increased with large effect sizes and mindfulness increased with medium to large effect sizes. A large effect size was found for PTSD symptoms at 3-month follow-up (d = -0.89), and a medium effect size was found for depression at 3-month follow-up (d = -0.49). There was evidence of mediation of reductions in PTSD symptoms and depression by enhanced self-compassion. Overall, loving-kindness meditation appeared safe and acceptable and was associated with reduced symptoms of PTSD and depression. Additional study of loving-kindness meditation for PTSD is warranted to determine whether the changes seen are due to the loving-kindness meditation intervention versus other influences, including concurrent receipt of other treatments. C1 [Kearney, David J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Kearney, David J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Malte, Carol A.; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [McManus, Carolyn] Swedish Med Ctr, Dept Phys Therapy, Seattle, WA USA. [Martinez, Michelle E.; Felleman, Ben] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov NR 40 TC 35 Z9 35 U1 6 U2 52 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2013 VL 26 IS 4 BP 426 EP 434 DI 10.1002/jts.21832 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 198CD UT WOS:000322898400002 PM 23893519 ER PT J AU Talbot, LS Maguen, S Epel, ES Metzler, TJ Neylan, TC AF Talbot, Lisa S. Maguen, Shira Epel, Elissa S. Metzler, Thomas J. Neylan, Thomas C. TI Posttraumatic Stress Disorder Is Associated With Emotional Eating SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID ADMINISTERED PTSD SCALE; ABDOMINAL OBESITY; FOOD; SYSTEM; WOMEN AB The present study investigated the relationship between posttraumatic stress disorder (PTSD) and emotional eating in a sample of medically healthy and medication-free adults. Participants with PTSD (n= 44) and control participants free of lifetime psychiatric history (n= 49) completed a measure of emotional eating. Emotional eating is the tendency to eat or overeat in response to negative emotions. PTSD participants exhibited greater emotional eating than control participants ((2)= .20) and emotional eating increased with higher PTSD symptom severity (R-2= .11). Results supported the stress-eating-obesity model whereby emotional eating is a maladaptive response to stressors. Over time, this could lead to weight gain, particularly abdominal stores, and contribute to higher risk for comorbid medical disorders. Findings suggest the importance of future longitudinal research to understand whether emotional eating contributes to the high rates of obesity, diabetes, and heart disease in PTSD. C1 [Talbot, Lisa S.; Maguen, Shira; Metzler, Thomas J.; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Talbot, Lisa S.; Maguen, Shira; Epel, Elissa S.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Talbot, LS (reprint author), San Francisco VA Med Ctr 116H, 4150 Clement St, San Francisco, CA 94121 USA. EM lisa.talbot@gmail.com FU NIMH NIH HHS [5R01MH073978-04, 5R34MH077667-03, R01 MH073978, R34 MH077667] NR 23 TC 19 Z9 19 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2013 VL 26 IS 4 BP 521 EP 525 DI 10.1002/jts.21824 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 198CD UT WOS:000322898400014 PM 23893425 ER PT J AU Kaiser, NC Lee, GJ Lu, PH Mather, MJ Shapira, J Jimenez, E Thompson, PM Mendez, MF AF Kaiser, Natalie C. Lee, Grace J. Lu, Po H. Mather, Michelle J. Shapira, Jill Jimenez, Elvira Thompson, Paul M. Mendez, Mario F. TI What dementia reveals about proverb interpretation and its neuroanatomical correlates SO NEUROPSYCHOLOGIA LA English DT Article DE Frontotemporal dementia; Alzheimer's disease; MRI; Tensor based morphometry; Proverbs; Executive functioning ID ONSET ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; BEHAVIORAL VARIANT; COGNITIVE DEFICITS; CLINICAL-DIAGNOSIS; RIGHT-HEMISPHERE; FRONTAL VARIANT; LANGUAGE; BRAIN; COMPREHENSION AB Objective: Neuropsychologists frequently include proverb interpretation as a measure of executive abilities. A concrete interpretation of proverbs, however, may reflect semantic impairments from anterior temporal lobes, rather than executive dysfunction from frontal lobes. The investigation of proverb interpretation among patients with different dementias with varying degrees of temporal and frontal dysfunction may clarify the underlying brain-behavior mechanisms for abstraction from proverbs. We propose that patients with behavioral variant frontotemporal dementia (bvFTD), who are characteristically more impaired on proverb interpretation than those with Alzheimer's disease (AD), are disproportionately impaired because of anterior temporal-mediated semantic deficits. Methods: Eleven patients with bvFTD and 10 with AD completed the Delis-Kaplan Executive Function System (D-KEFS) Proverbs Test and a series of neuropsychological measures of executive and semantic functions. The analysis included both raw and age-adjusted normed data for multiple choice responses on the D-KEFS Proverbs Test using independent samples t-tests. Tensor-based morphometry (TBM) applied to 3D T1-weighted MRI scans mapped the association between regional brain volume and proverb performance. Computations of mean Jacobian values within select regions of interest provided a numeric summary of regional volume, and voxel-wise regression yielded 3D statistical maps of the association between tissue volume and proverb scores. Results: The patients with bvFTD were significantly worse than those with AD in proverb interpretation. The worse performance of the bvFTD patients involved a greater number of concrete responses to common, familiar proverbs, but not to uncommon, unfamiliar ones. These concrete responses to common proverbs correlated with semantic measures, whereas concrete responses to uncommon proverbs correlated with executive functions. After controlling for dementia diagnosis, TBM analyses indicated significant correlations between impaired proverb interpretation and the anterior temporal lobe region (left > right). Conclusions: Among two dementia groups, those with bvFTD, demonstrated a greater number of concrete responses to common proverbs compared to those with AD, and this performance correlated with semantic deficits and the volume of the left anterior lobe, the hub of semantic knowledge. The findings of this study suggest that common proverb interpretation is greatly influenced by semantic dysfunction and that the use of proverbs for testing executive functions needs to include the interpretation of unfamiliar proverbs. Published by Elsevier Ltd. C1 [Kaiser, Natalie C.; Mather, Michelle J.; Shapira, Jill; Jimenez, Elvira; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Lee, Grace J.; Lu, Po H.; Shapira, Jill; Jimenez, Elvira; Thompson, Paul M.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Kaiser, NC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 401 Room A235, Los Angeles, CA USA. EM Natalie.Kaiser@va.gov FU National Institute of Health [R01AG034499-3]; GRECC Advanced Geriatric Fellowship Award FX Research supported by National Institute of Health Grant #R01AG034499-3 (M. Mendez PI); GRECC Advanced Geriatric Fellowship Award to N. Kaiser NR 56 TC 6 Z9 6 U1 1 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD AUG PY 2013 VL 51 IS 9 BP 1726 EP 1733 DI 10.1016/j.neuropsychologia.2013.05.021 PG 8 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 199TM UT WOS:000323018400008 PM 23747602 ER PT J AU Conwell, WD Josephson, SA Li, H Saint, S Janssen, WJ AF Conwell, Walter D. Josephson, S. Andrew Li, Howard Saint, Sanjay Janssen, William J. TI Weak in the Knees SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EATON MYASTHENIC SYNDROME AB A 61-year-old woman presented to her primary care physician with a 4-week history of progressive leg weakness, bilateral leg pain, and difficulty walking. The weakness was symmetric and did not fluctuate during the course of the day. Foreword In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information, sharing his or her reasoning with the reader (regular type). The authors' commentary follows. Stage A 61-year-old woman presented to her primary care physician with a 4-week history of progressive bilateral leg weakness, bilateral leg pain, and difficulty walking. The weakness was symmetric, without exacerbating or ameliorating factors, and did not fluctuate during the course of the day. The patient also reported depression, anxiety, memory problems, and intermittent headaches that had begun several months earlier. She had a dry mouth but no difficulty swallowing. Previously very active, she had become homebound over a period of several months because of the leg weakness. ResponseWeakness is a common symptom and can result from dysfunction of either the central nervous system (brain or spinal cord) or the peripheral nervous system (anterior horn cell, nerve, neuromuscular junction, or muscle). Bilateral symmetric weakness of the legs can also result from problems with either the central ... C1 [Conwell, Walter D.; Li, Howard; Janssen, William J.] Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO USA. [Li, Howard] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Janssen, William J.] Natl Jewish Hlth, Dept Med, Div Pulm Med, Denver, CO 80206 USA. [Josephson, S. Andrew] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Saint, Sanjay] Univ Michigan, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48109 USA. [Saint, Sanjay] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Janssen, WJ (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. EM janssenw@njhealth.org NR 10 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 1 PY 2013 VL 369 IS 5 BP 459 EP 464 DI 10.1056/NEJMcps1210293 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 193GQ UT WOS:000322547400013 PM 23902486 ER PT J AU Schumacher, HR Pullman-Mooar, S Gupta, SR Dinnella, JE Kim, R McHugh, MP AF Schumacher, H. R. Pullman-Mooar, S. Gupta, S. R. Dinnella, J. E. Kim, R. McHugh, M. P. TI Randomized double-blind crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis (OA) of the knee SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE WOMAC; C-reactive protein; Inflammation; Placebo ID CONTROLLED-TRIAL; CLINICAL-TRIAL; PLACEBO; PAIN; ANTHOCYANINS; INFLAMMATION; CONSUMPTION; HIP; METHYLSULFONYLMETHANE; GLUCOSAMINE AB Objective: To assess the efficacy of tart cherry juice in treating pain and other features of knee osteoarthritis (OA). Methods: 58 non-diabetic patients with Kellgren grade 2-3 OA were randomized to begin treatment with cherry juice or placebo. Two 8 oz bottles of tart cherry juice or placebo were consumed daily for 6 weeks with a 1 week washout period before switching treatments (crossover design). Western Ontario McMaster Osteoarthritis Index (WOMAC) scores and walking times were recorded prior to and after each treatment period. Additionally, plasma urate, creatinine and high sensitivity C-reactive protein (hsCRP) were recorded at baseline, after the first treatment period and after the second treatment period. Acetaminophen was allowed as a rescue drug and self reported after each treatment period. Treatment effect was examined with repeated measures analysis of variance (ANOVA) using an intention-to-treat (ITT) analysis. Results: There were five withdrawals during the cherry juice treatment (four adverse events (AEs)) and seven withdrawals during the placebo treatment (three AEs). WOMAC scores decreased significantly (P < 0.01) after the cherry juice treatment but not after the placebo treatment (P = 0.46); differences between treatments were not significant (P = 0.16). hsCRP declined during the cherry juice treatment vs placebo (P < 0.01). The decline in hsCRP was associated with WOMAC improvement (P < 0.01). Walking time, acetaminophen use, plasma urate and creatinine were unaffected by treatments. Conclusions: Tart cherry juice provided symptom relief for patients with mild to moderate knee OA, but this effect was not significantly greater than placebo. Tart cherry juice lowered hsCRP levels and this effect was associated with improved WOMAC scores. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Schumacher, H. R.; Pullman-Mooar, S.; Gupta, S. R.; Dinnella, J. E.; Kim, R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Schumacher, H. R.; Pullman-Mooar, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kim, R.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [McHugh, M. P.] Lenox Hill Hosp, Nicholas Inst Sports Med & Athlet Trauma, New York, NY 10075 USA. RP McHugh, MP (reprint author), Lenox Hill Hosp, Nicholas Inst Sports Med & Athlet Trauma, 100 E 77 ST, New York, NY 10075 USA. EM schumacr@mail.med.upenn.edu; sally.pullman-mooar@va.gov; Smita.Gupta@uphs.upenn.edu; jdinnell@mail.med.upenn.edu; rosakim330@gmail.com; mchugh@nismat.org FU CherryPharm, Inc., Geneva, NY FX Funding and cherry juice were provided by CherryPharm, Inc., Geneva, NY. NR 38 TC 9 Z9 9 U1 1 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD AUG PY 2013 VL 21 IS 8 BP 1035 EP 1041 DI 10.1016/j.joca.2013.05.009 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 196VU UT WOS:000322806300003 PM 23727631 ER PT J AU Goodman, JD McKay, JR DePhilippis, D AF Goodman, Jessica D. McKay, James R. DePhilippis, Dominick TI Progress Monitoring in Mental Health and Addiction Treatment: A Means of Improving Care SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE psychotherapy outcome; progress monitoring; outcome monitoring; substance abuse services; research synthesis ID TREATMENT OUTCOME PACKAGE; CLINICAL SUPPORT TOOLS; PSYCHOMETRIC PROPERTIES; CLIENT FEEDBACK; CONTINUING CARE; COCAINE DEPENDENCE; 24-MONTH OUTCOMES; BRIEF INSTRUMENT; STEPPED-CARE; CORE-OM AB Although monitoring of treatment response is standard practice for many medical conditions, practitioners in mental health treatments, and substance abuse treatment in particular, have been slow to adopt these practices. Progress monitoring (PM), consisting of measurement and feedback, has the potential to significantly improve treatment outcomes. This paper reviews the existing literature on the effects of PM in mental health and substance use disorder (SUD) treatment. Whereas previous reviews have examined aspects of PM in mental health treatment, this is the first such review to cover monitoring efforts in substance abuse treatment, conceptualized here as diverse forms of measurement-based care. To address drug use, monitoring in SUD treatment has typically relied on treatment attendance and urine screens as indicators of treatment progress. However, some research has shown that other means of PM can significantly improve SUD treatment effectiveness. Previous meta-analyses show that PM significantly improves outcomes in mental health treatment. More extensive research on three particular measures, demonstrate the effectiveness of PM in mental health treatment. With the growing focus on quality improvement in medical care, there is need for further research and adoption of progress monitoring methods in mental health and SUD treatment. C1 [Goodman, Jessica D.; McKay, James R.; DePhilippis, Dominick] Philadelphia Vet Affairs Med Ctr, CESATE, Philadelphia, PA USA. [DePhilippis, Dominick] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP McKay, JR (reprint author), Univ Penn, Ctr Continuum Care, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM jimrache@mail.med.upenn.edu NR 78 TC 11 Z9 11 U1 5 U2 23 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD AUG PY 2013 VL 44 IS 4 BP 231 EP 246 DI 10.1037/a0032605 PG 16 WC Psychology, Multidisciplinary SC Psychology GA 198GI UT WOS:000322909900006 ER PT J AU Zhang, XY Chen, DC Xiu, MH Haile, CN He, SC Luo, X Zuo, L Rosenheck, R Kosten, TA Kosten, TR AF Zhang, X. Y. Chen, D. C. Xiu, M. H. Haile, C. N. He, S. C. Luo, X. Zuo, L. Rosenheck, R. Kosten, T. A. Kosten, T. R. TI Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Cognition; first episode; nicotine; psychopathology; schizophrenia; smoking ID NICOTINIC ACETYLCHOLINE-RECEPTOR; TOBACCO SMOKING; WORKING-MEMORY; PSYCHOSIS; DEPENDENCE; DEFICITS; ONSET; METAANALYSIS; ASSOCIATION; ABSTINENCE AB Background. Although patients with chronic schizophrenia have substantially higher smoking rates than either the general population or patients with other mental illnesses, drug-naive patients with a first episode of schizophrenia have received little systemic study. This study examined smoking rates, the association between smoking and symptom severity and cognitive function in Chinese first-episode schizophrenia (FES) patients using cross-sectional and case-control designs. Method. Two hundred and forty-four drug-naive FES patients and 256 healthy controls matched for gender, age and education completed the Fagerstrom Test for Nicotine Dependence (FTND) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Patients were also rated on the Positive and Negative Symptom Scale (PANSS). Results. The rate and quantity of smoking were not significantly higher among FES patients compared to the general population. Among patients, smokers scored higher than non-smokers on the total PANSS and the positive symptom subscale scores. There were no significant associations between cognitive function and smoking in either FES patients or healthy controls. Conclusions. In contrast to studies in patients with chronic schizophrenia, drug-naive FES patients did not smoke more frequently than the general population. Furthermore, patients with psychotic disorders who smoked did not exhibit significant cognitive differences compared with those who did not smoke. However, smoking may have other detrimental effects on physical and mental health, for example on positive symptoms. C1 [Zhang, X. Y.; Haile, C. N.; Kosten, T. A.; Kosten, T. R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, X. Y.; Haile, C. N.; Kosten, T. A.; Kosten, T. R.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Zhang, X. Y.; Chen, D. C.; Xiu, M. H.] Peking Univ, Beijing HuiLongGuan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China. [He, S. C.] Peking Univ, Dept Psychol, Beijing 100871, Peoples R China. [Luo, X.; Zuo, L.; Rosenheck, R.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU National Natural Science Foundation of China [81000509]; Beijing Municipal Excellent Talents Foundation [2010 D003034000032]; United States National Institute of Health [U01-MH79639, K05-DA0454, P50-DA18827]; Stanley Medical Research Institute [03T-459, 05T-726] FX This study was funded by the National Natural Science Foundation of China (81000509), the Beijing Municipal Excellent Talents Foundation (2010 D003034000032), the United States National Institute of Health (U01-MH79639, K05-DA0454 and P50-DA18827) and the Stanley Medical Research Institute (03T-459 and 05T-726). NR 52 TC 8 Z9 9 U1 1 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD AUG PY 2013 VL 43 IS 8 BP 1651 EP 1660 DI 10.1017/S0033291712002590 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 187MJ UT WOS:000322122900007 PM 23149169 ER PT J AU Aversa, LH Stoddard, JA Doran, NM Au, S Chow, B McFall, M Saxon, AJ Baker, DG AF Aversa, Laura H. Stoddard, Jill A. Doran, Neal M. Au, Selwyn Chow, Bruce McFall, Miles Saxon, Andrew J. Baker, Dewleen G. TI Longitudinal analysis of the relationship between PTSD symptom clusters, cigarette use, and physical health-related quality of life SO QUALITY OF LIFE RESEARCH LA English DT Article DE Health-related quality of life; PTSD; Smoking; Tobacco; SF-36; Longitudinal ID POSTTRAUMATIC-STRESS-DISORDER; SMOKING-CESSATION; ANXIETY DISORDERS; MAJOR DEPRESSION; VIETNAM VETERANS; CONTROLLED-TRIAL; MORTALITY; PREDICTOR; DISEASE; RISK AB Posttraumatic stress disorder (PTSD) symptoms, particularly numbing and hyperarousal symptoms, are related to poor physical health-related quality of life (HRQoL). Tobacco dependence is also associated with poor HRQoL, and individuals with PTSD may smoke at higher rates than the general population. Our study aimed to examine the impact of quitting smoking and changes in PTSD symptoms over time on changes in physical HRQoL. The study used archival data from enrollees (N = 943) in a smoking cessation clinical trial for veterans with PTSD (VA Cooperative study #519). Two of the physical HRQoL domains were sensitive to changes in PTSD symptoms over time: General Health and Vitality. Our findings suggest that particular physical HRQoL domains may be subject to improvement if PTSD symptoms decrease over time. C1 [Aversa, Laura H.; Baker, Dewleen G.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. [Aversa, Laura H.; Stoddard, Jill A.] Alliant Int Univ, Calif Sch Profess Psychol, San Diego, CA USA. [Doran, Neal M.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Au, Selwyn; Chow, Bruce] Vet Affairs Palo Alto Hlth Care Syst, Cooperat Studies Program, Mountain View, CA USA. [McFall, Miles; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. RP Aversa, LH (reprint author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr 151, San Diego, CA 92161 USA. EM laura.h.aversa@gmail.com FU Cooperative Studies Program of the Clinical Science Research and Development Service, U.S. Department of Veterans Affairs (DVA; CSP) [519, NCT00118534]; Tobacco-Related Disease Research Program [19DT-0003]; Department of Defense [CDMRP PTO 090738]; DVA [HSRD SDR09-128]; VA Center of Excellence for Stress and Mental Health; VA Merit [821]; NIAAA [1 P20 AA017839-01]; NIDA [5 U10 DA013714-08]; VA HSRD [1 IO1 HX000616-01]; Department of Defense (Navy BUMED) FX Funding was provided by the Cooperative Studies Program of the Clinical Science Research and Development Service, U.S. Department of Veterans Affairs (DVA; CSP #519, NCT00118534) and the Tobacco-Related Disease Research Program 19DT-0003. Dr. Baker receives research support from the Department of Defense (Navy BUMED and CDMRP PTO 090738) and the DVA (HSR&D SDR09-128) and is supported in part by the VA Center of Excellence for Stress and Mental Health. Dr. McFall receives research support from VA Merit #821 and DVA. Dr. Saxon receives research support from NIAAA (1 P20 AA017839-01), NIDA (5 U10 DA013714-08), and from VA HSR&D (1 IO1 HX000616-01). The views expressed herein are those of the authors and not necessarily those of the U.S. Department of Veterans Affairs. The authors report no financial relationships with commercial interests. NR 55 TC 3 Z9 3 U1 4 U2 10 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD AUG PY 2013 VL 22 IS 6 BP 1381 EP 1389 DI 10.1007/s11136-012-0280-x PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 195XA UT WOS:000322735700023 PM 23054494 ER PT J AU Borrero, S Zhao, X Mor, MK Schwarz, EB Good, CB Gellad, WF AF Borrero, Sonya Zhao, Xinhua Mor, Maria K. Schwarz, Eleanor B. Good, Chester B. Gellad, Walid F. TI Adherence to hormonal contraception among women veterans: differences by race/ethnicity and contraceptive supply SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE adherence; contraception; female veterans; race/ethnicity; unintended pregnancy ID RANDOMIZED-CONTROLLED-TRIAL; 2002 NATIONAL-SURVEY; UNINTENDED PREGNANCY; UNITED-STATES; HEALTH-CARE; FAMILY GROWTH; PROJECT; CONTINUATION; DISPARITIES; FAILURE AB OBJECTIVE: The objective of the study was to assess the adherence to hormonal contraception (pill, patch, ring, or injectable) among women veterans and examine the relationships between race/ethnicity and the months of contraceptive supply dispensed with contraceptive adherence. STUDY DESIGN: We conducted a retrospective analysis of the Department of Veterans Affairs (VA) national databases to examine the adherence to hormonal contraception over 12 months among women aged 18-45 years who had hormonal contraceptive coverage during the first week of fiscal year 2008. We examined several adherence indicators including gaps between refills and months of contraceptive coverage. Descriptive statistics and multivariable models were used to examine the associations between race/ethnicity and contraceptive supply dispensed with adherence. RESULTS: Our cohort included 6946 women: 47% were white, 6% were Hispanic, 22% were black, and 25% were other race or had missing race information. Most women (83%) received a 3 month supply of contraception at each fill. More than 64% of women had at least 1 gap in coverage of 7 days or longer. Only 22% of women received a full 12 months of contraception without any gaps (perfect adherence). Compared with whites, Hispanics were significantly more likely to experience gaps (64% vs 70%; P = .02), and Hispanics and blacks received fewer months of contraceptive coverage (9.3 vs 8.9 and 9.0, P < .001). Compared with women receiving 3 month supplies, those receiving 1 month supplies had a higher likelihood of a gap (63% vs 72%, P < .001), fewer months of coverage (9.3 vs 6.9, P < .001), and a lower likelihood of perfect adherence (22% vs 11%, P < .001). CONCLUSION: Adherence to hormonal contraception among women veterans is poor. Efforts to improve contraceptive adherence and lower risk of unintended pregnancy are needed; dispensing more months of supply for hormonal contraception may be a promising strategy. C1 [Borrero, Sonya; Zhao, Xinhua; Mor, Maria K.; Good, Chester B.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Borrero, Sonya; Zhao, Xinhua; Schwarz, Eleanor B.; Good, Chester B.; Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. [Schwarz, Eleanor B.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Good, Chester B.] Vet Affairs Ctr Medicat Safety, Hines, IL USA. RP Borrero, S (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM borrerosp@upmc.edu OI Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU Office of Research and Development, Veterans Health Administration, Department of Veterans Affairs, VISN 4 CHERP Pilot Project Award FX This study was supported by the Office of Research and Development, Veterans Health Administration, Department of Veterans Affairs, VISN 4 CHERP Pilot Project Award (principal investigator, Sonya Borrero). NR 45 TC 3 Z9 3 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD AUG PY 2013 VL 209 IS 2 AR 103.e1 DI 10.1016/j.ajog.2013.03.024 PG 11 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 194UA UT WOS:000322657000008 PM 23524170 ER PT J AU Fatemi, G Fang, MA AF Fatemi, Gita Fang, Meika A. TI IgG4-related pharyngitis-an addition to the nomenclature of IgG4-related disease: comment on the article by Stone et al SO ARTHRITIS AND RHEUMATISM LA English DT Letter C1 [Fatemi, Gita] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Fatemi, G (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 3 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD AUG PY 2013 VL 65 IS 8 BP 2217 EP 2218 DI 10.1002/art.37999 PG 2 WC Rheumatology SC Rheumatology GA 190HD UT WOS:000322329100036 PM 23666890 ER PT J AU Raab, PA Mackintosh, MA Gros, DF Morland, LA AF Raab, Phillip A. Mackintosh, Margaret-Anne Gros, Daniel F. Morland, Leslie A. TI Influence of Depression on State and Trait Anger in Veterans with Posttraumatic Stress Disorder SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE Posttraumatic stress disorder; Anger; Major depressive disorder; Numbing; Dysphoria ID ADMINISTERED PTSD SCALE; COMBAT VETERANS; AGGRESSION; SYMPTOMS; HOSTILITY; SPECIFICITY; COMORBIDITY; THERAPY; ANXIETY; TRIAL AB Anger is one of the most important symptoms of posttraumatic stress disorder (PTSD), and is associated with many of the adverse correlates of PTSD. Researchers have proposed theories to explain the relationship between anger and PTSD, but no study to date has examined the mediating role of depression. The purpose of this study was to explore the mediating effects of current major depression disorder (MDD), as well as PTSD numbing and dysphoria symptom clusters (King et al. 1998; Simms et al. 2002) on the relationship between PTSD and anger. There were 98 participants in the study, and all were male veterans with combat-related PTSD taking part in a clinical trial. Results indicated that MDD partially mediated the relationship between PTSD and state anger, while numbing and dysphoria clusters partially mediated the relationships between other PTSD symptom clusters and trait anger. Implications for the treatment of anger in veterans with PTSD are discussed. C1 [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Honolulu, HI 96819 USA. [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Pacific Hlth Res & Educ Inst, Honolulu, HI USA. [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Charleston, SC 29425 USA. [Morland, Leslie A.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA. RP Raab, PA (reprint author), Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, 3375 Koapaka,Suite I-560, Honolulu, HI 96819 USA. EM drewraab@gmail.com OI Mackintosh, Margaret-Anne/0000-0002-2725-3177 NR 39 TC 2 Z9 2 U1 2 U2 10 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD AUG PY 2013 VL 37 IS 4 BP 673 EP 679 DI 10.1007/s10608-012-9506-z PG 7 WC Psychology, Clinical SC Psychology GA 189MU UT WOS:000322272100002 ER PT J AU Kaunitz, JD Akiba, Y AF Kaunitz, Jonathan D. Akiba, Yasutada TI Wireless Telemetry and Cystic Fibrosis: Just the pHacts SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material ID PH C1 [Kaunitz, Jonathan D.; Akiba, Yasutada] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] West Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221] NR 6 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD AUG PY 2013 VL 58 IS 8 BP 2129 EP 2130 DI 10.1007/s10620-013-2714-x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 194RR UT WOS:000322650900002 PM 23748712 ER PT J AU Pugh, MJV Marcum, ZA Copeland, LA Mortensen, EM Zeber, JE Noel, PH Berlowitz, DR Downs, JR Good, CB Alvarez, C Amuan, ME Hanlon, JT AF Pugh, Mary Jo V. Marcum, Zachary A. Copeland, Laurel A. Mortensen, Eric M. Zeber, John E. Noel, Polly H. Berlowitz, Dan R. Downs, John R. Good, Chester B. Alvarez, Carlos Amuan, Megan E. Hanlon, Joseph T. TI The Quality of Quality Measures: HEDISA (R) Quality Measures for Medication Management in the Elderly and Outcomes Associated with New Exposure SO DRUGS & AGING LA English DT Article ID LONGITUDINAL DATA-ANALYSIS; ADVERSE DRUG EVENTS; OLDER-ADULTS; HEALTH OUTCOMES; BEERS CRITERIA; EXPLICIT CRITERIA; VETERANS; RISK; CARE; HOSPITALIZATIONS AB Clinical validation studies of the Healthcare Effectiveness Data and Information Set (HEDISA (R)) measures of inappropriate prescribing in the elderly are limited. The objective of this study was to examine associations of new exposure to high-risk medication in the elderly (HRME) and drug-disease interaction (Rx-DIS) with mortality, hospital admission, and emergency care. A retrospective database study was conducted examining new use of HRME and Rx-DIS in fiscal year 2006 (Oct 2005-Sep 2006; FY06), with index date being the date of first HRME/Rx-DIS exposure, or first day of FY07 if no HRME/Rx-DIS exposure. Outcomes were assessed 1 year after the index date. The participants were veterans who were a parts per thousand yen65 years old in FY06 and received Veterans Health Administration (VA) care in FY05-06. A history of falls/hip fracture, chronic renal failure, and/or dementia per diagnosis codes defined the Rx-DIS subsample. The variables included a number of new unique HRME drug exposures and new unique Rx-DIS drug exposure (0, 1, > 1) in FY06, and outcomes (i.e., 1-year mortality, hospital admission, and emergency care) up to 1 year after exposure. Descriptive statistics summarized variables for the overall HRME cohort and the Rx-DIS subset. Multivariable statistical analyses using generalized estimating equations (GEE) models with a logit link accounted for nesting of patients within facilities. For these latter analyses, we controlled for demographic characteristics, chronic disease states, and indicators of disease burden the previous year (e.g., number of prescriptions, emergency/hospital care). Among the 1,807,404 veterans who met inclusion criteria, 5.2 % had new HRME exposure. Of the 256,388 in the Rx-DIS cohort, 3.6 % had new Rx-DIS exposure. Multivariable analyses found that HRME was significantly associated with mortality [1: adjusted odds ratio (AOR) = 1.62, 95 % CI 1.56-1.68; > 1: AOR = 1.80, 95 % CI 1.45-2.23], hospital admission (1: AOR = 2.31, 95 % CI 2.22-2.40; > 1: AOR = 3.44, 95 % CI 3.06-3.87), and emergency care (1: AOR = 2.59, 95 % CI 2.49-2.70; > 1: AOR = 4.18, 95 % CI 3.71-4.71). Rx-DIS exposure was significantly associated with mortality (1: AOR = 1.60, 95 % CI 1.51-1.71; > 1: AOR = 2.00, 95 % CI 1.38-2.91), hospital admission for one exposure (1: AOR = 1.12, 95 % CI 1.03-1.27; > 1: AOR = 1.18, 95 % CI 0.71-1.95), and emergency care for two or more exposures (1: AOR = 1.06, 95 % CI 0.97-1.15; > 1: AOR = 2.0, 95 % CI 1.35-3.10). Analyses support the link between HRME/Rx-DIS exposure and clinically significant outcomes in older veterans. Now is the time to begin incorporating input from both patients who receive these medications and providers who prescribe to develop approaches to reduce exposure to these agents. C1 [Pugh, Mary Jo V.; Noel, Polly H.; Downs, John R.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Noel, Polly H.; Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Marcum, Zachary A.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Copeland, Laurel A.; Zeber, John E.] Cent Texas Vet Healthcare Syst, Temple, TX USA. [Copeland, Laurel A.; Zeber, John E.] Cent Texas Vet Hlth Care Syst, Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Mortensen, Eric M.; Alvarez, Carlos] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Berlowitz, Dan R.; Amuan, Megan E.] Edith Nourse Rogers Mem Vet Hosp, CHQOER, Bedford, MA USA. [Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA USA. [Good, Chester B.] Pharm Benefits Management Serv, Dept Vet Affairs, Hines, IL USA. [Alvarez, Carlos] Texas Tech Univ, Hlth Sci Ctr, Dallas, TX USA. RP Pugh, MJV (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, Vet Evidence Based Res Disseminat Implementat Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM PughM@uthscsa.edu FU VA Health Services Research and Development Service [IIR 06-062]; South Texas Veterans Healthcare System/Audie L. Murphy Division; VERDICT research program; Central Texas Veterans Healthcare System; Center for Applied Health Research FX This study was funded by VA Health Services Research and Development Service, IIR 06-062 (Dr. Pugh PI). The funding agency had no role in data collection, analysis, or manuscript development. No conflict of interest is reported for any co-authors. We also acknowledge assistance with manuscript preparation by Jeffrey Tabares, Margaret Wells, and Kathleen Franklin. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the VERDICT research program, and from the Central Texas Veterans Healthcare System, Center for Applied Health Research. Data from this paper was presented at the VA Health Services Research and Development Annual Research Meeting, National Harbor, MD, July 2012. NR 49 TC 10 Z9 10 U1 0 U2 7 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X EI 1179-1969 J9 DRUG AGING JI Drugs Aging PD AUG PY 2013 VL 30 IS 8 BP 645 EP 654 DI 10.1007/s40266-013-0086-8 PG 10 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 186AW UT WOS:000322014600007 PM 23645530 ER PT J AU Wang, FC Scoville, D He, XC Mahe, MM Box, A Perry, JM Smith, NR Lei, NY Davies, PS Fuller, MK Haug, JS McClain, M Gracz, AD Ding, S Stelzner, M Dunn, JCY Magness, ST Wong, MH Martin, MG Helmrath, M Li, LH AF Wang, Fengchao Scoville, David He, Xi C. Mahe, Maxime M. Box, Andrew Perry, John M. Smith, Nicholas R. Lei, Nan Ye Davies, Paige S. Fuller, Megan K. Haug, Jeffrey S. McClain, Melainia Gracz, Adam D. Ding, Sheng Stelzner, Matthias Dunn, James C. Y. Magness, Scott T. Wong, Melissa H. Martin, Martin G. Helmrath, Michael Li, Linheng TI Isolation and Characterization of Intestinal Stem Cells Based on Surface Marker Combinations and Colony-Formation Assay SO GASTROENTEROLOGY LA English DT Article DE Stemness; Differentiation; Single-Cell Sorting; Flow Cytometry Analysis ID MOUSE SMALL-INTESTINE; SELF-RENEWAL; IN-VITRO; EXPRESSION MARKS; EPITHELIAL-CELLS; LGR5; POPULATIONS; EXPANSION; IDENTIFICATION; ORGANOIDS AB BACKGROUND & AIMS: Identification of intestinal stem cells (ISCs) has relied heavily on the use of transgenic reporters in mice, but this approach is limited by mosaic expression patterns and difficult to directly apply to human tissues. We sought to identify reliable surface markers of ISCs and establish a robust functional assay to characterize ISCs from mouse and human tissues. METHODS: We used immunohistochemistry, real-time reverse-transcription polymerase chain reaction, and fluorescence-activated cell sorting (FACS) to analyze intestinal epithelial cells isolated from mouse and human intestinal tissues. We compared different combinations of surface markers among ISCs isolated based on expression of Lgr5-green fluorescent protein. We developed a culture protocol to facilitate the identification of functional ISCs from mice and then tested the assay with human intestinal crypts and putative ISCs. RESULTS: CD44(+)CD24(lo)CD166(+) cells, isolated by FACS from mouse small intestine and colon, expressed high levels of stem cell-associated genes. Transit-amplifying cells and progenitor cells were then excluded based on expression of GRP78 or c-Kit. CD44(+)CD24(lo)CD166(+) GRP78(lo/-) putative stem cells from mouse small intestine included Lgr5-GFP(hi) and Lgr5-GFP(med/lo) cells. Incubation of these cells with the GSK inhibitor CHIR99021 and the E-cadherin stabilizer Thiazovivin resulted in colony formation by 25% to 30% of single-sorted ISCs. CONCLUSIONS: We developed a culture protocol to identify putative ISCs from mouse and human tissues based on cell surface markers. CD44(+)CD24(lo)CD166(+) , GRP78(lo/-), and c-Kit L facilitated identification of putative stem cells from the mouse small intestine and colon, respectively. CD44(+)CD24(-/lo)CD166(+) also identified putative human ISCs. These findings will facilitate functional studies of mouse and human ISCs. C1 [Wang, Fengchao; He, Xi C.; Box, Andrew; Perry, John M.; Haug, Jeffrey S.; McClain, Melainia; Li, Linheng] Stowers Inst Med Res, Kansas City, MO 64110 USA. [Scoville, David; Li, Linheng] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66103 USA. [Mahe, Maxime M.; Fuller, Megan K.; Helmrath, Michael] Cincinnati Childrens Hosp Med Res Ctr, Cincinnati, OH USA. [Smith, Nicholas R.; Davies, Paige S.; Wong, Melissa H.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. [Lei, Nan Ye; Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol, Los Angeles, CA 90024 USA. [Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Fuller, Megan K.; Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol Cell Biol & Physiol &, Chapel Hill, NC USA. [Fuller, Megan K.; Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Surg, Chapel Hill, NC USA. [Ding, Sheng] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA. [Stelzner, Matthias] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Magness, Scott T.; Wong, Melissa H.; Martin, Martin G.; Li, Linheng] Intestinal Stem Cell Consortium, Duarte, CA USA. RP Li, LH (reprint author), Stowers Inst Med Res, 1000 East 50th St, Kansas City, MO 64110 USA. EM lil@stowers.org RI Mahe, Maxime/G-5552-2017 OI Mahe, Maxime/0000-0003-2560-193X FU Intestinal Stem Cell Consortium [U01DK085507, U01DK85525, U01DK85535, U01DK085547, U01DK85532]; Stowers Institute for Medical Research FX This research was performed as a project of the Intestinal Stem Cell Consortium, L. Li (U01DK085507), M. H. Wong (U01DK85525), M. Martin (U01DK85535), S. T. Magness (U01DK085547: SJH/STM), and the Coordinating Center J. Niland (U01DK85532). L. Li is supported in part by Stowers Institute for Medical Research. NR 36 TC 53 Z9 54 U1 1 U2 33 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD AUG PY 2013 VL 145 IS 2 BP 383 EP + DI 10.1053/j.gastro.2013.04.050 PG 34 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 194KC UT WOS:000322630600028 PM 23644405 ER PT J AU Burks, ML Kundrotas, L AF Burks, Margaret L. Kundrotas, Leon TI Unusual Colon Biopsy SO GASTROENTEROLOGY LA English DT Editorial Material ID SPIROCHETOSIS C1 [Burks, Margaret L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kundrotas, Leon] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Gastroenterol, San Antonio, TX USA. RP Burks, ML (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD AUG PY 2013 VL 145 IS 2 BP E10 EP E11 DI 10.1053/j.gastro.2013.04.054 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 194KC UT WOS:000322630600005 PM 23810345 ER PT J AU Fogel, BL Vickrey, BG Walton-Wetzel, J Lieber, E Browner, CH AF Fogel, Brent L. Vickrey, Barbara G. Walton-Wetzel, Jenny Lieber, Eli Browner, Carole H. TI Utilization of Genetic Testing Prior to Subspecialist Referral for Cerebellar Ataxia SO GENETIC TESTING AND MOLECULAR BIOMARKERS LA English DT Article ID LATE-ONSET CEREBELLAR; CLINICAL-FEATURES; CARE; NEUROLOGISTS; INVOLVEMENT AB Objective: To evaluate the utilization of laboratory testing in the diagnosis of cerebellar ataxia, including the completeness of initial standard testing for acquired causes, the early use of genetic testing, and associated clinical and nonclinical factors, among a cohort referred for subspecialty consultation. Methods: Data were abstracted from records of 95 consecutive ataxia patients referred to one neurogenetics subspecialist from 2006-2010 and linked to publicly available data on characteristics of referral clinicians. Multivariable logistic and linear regression models were used to analyze unique associations of clinical and nonclinical factors with laboratory investigation of acquired causes and with early genetic testing prior to referral. Results: At referral, 27 of 95 patients lacked evidence of any of 14 laboratory studies suggested for initial work-up of an acquired cause for ataxia (average number of tests = 4.5). In contrast, 92% of patients had undergone brain magnetic resonance imaging prior to referral. Overall, 41.1% (n = 39) had genetic testing prior to referral; there was no association between family history of ataxia and obtaining genetic testing prior to referral (p = 0.39). The level of early genetic testing was 31.6%, primarily due to genetic testing despite an incomplete laboratory evaluation for acquired causes and no family history. A positive family history was consistently associated with less extensive laboratory testing (p = 0.004), and referral by a neurologist was associated with higher levels of early genetic testing. Conclusions: Among consecutive referrals to a single center, a substantial proportion of sporadic cases had genetic testing without evidence of a work-up for acquired causes. Better strategies to guide decision making and subspecialty referrals in rare neurologic disorders are needed, given the cost and consequences of genetic testing. C1 [Fogel, Brent L.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Walton-Wetzel, Jenny; Browner, Carole H.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA. [Lieber, Eli; Browner, Carole H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. RP Browner, CH (reprint author), UCLA Psychiat & Biobehav Sci Anthropol, David Geffen Sch Med, Box 951553,347 Haines Hall, Los Angeles, CA 90095 USA. EM browner@ucla.edu FU NIMH [K08MH86297]; UCLA Committee on Research Faculty Research Grant FX The authors acknowledge the contribution of the following individuals: Stefanie D. Vassar, MS for assistance with statistical analysis, and Jacob Foreman and Kelly Hitch for assistance with data collection. Support provided by NIMH K08MH86297 (B. L. F.), UCLA Committee on Research Faculty Research Grant (C. H. B.). NR 20 TC 4 Z9 4 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1945-0265 J9 GENET TEST MOL BIOMA JI Genet. Test. Mol. Biomark. PD AUG PY 2013 VL 17 IS 8 BP 588 EP 594 DI 10.1089/gtmb.2013.0005 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 194IH UT WOS:000322624500003 PM 23725007 ER PT J AU Lindenauer, PK Grosso, LM Wang, CQ Wang, Y Krishnan, JA Lee, TA Au, DH Mularski, RA Bernheim, SM Drye, EE AF Lindenauer, Peter K. Grosso, Laura M. Wang, Changqin Wang, Yun Krishnan, Jerry A. Lee, Todd A. Au, David H. Mularski, Richard A. Bernheim, Susannah M. Drye, Elizabeth E. TI Development, validation, and results of a risk-standardized measure of hospital 30-day mortality for patients with exacerbation of chronic obstructive pulmonary disease SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID QUALITY-OF-CARE; HEART-FAILURE; PERFORMANCE; OUTCOMES; COPD; MODELS; DEATH; RATES AB BACKGROUND: Despite its large clinical and economic significance, measuring and improving the outcomes of patients hospitalized for chronic obstructive pulmonary disease (COPD) is only beginning to emerge as a national priority for policy makers and payers. OBJECTIVE: To facilitate the public reporting of hospital outcomes, we developed a risk-standardized measure of hospital 30-day mortality for patients admitted with exacerbation of COPD. DESIGN: Hierarchical logistic regression model. SETTING/PATIENTS: Medicare Part A and Part B claims in a random sample of half of all admissions for patients admitted to acute care hospitals in 2008 (development cohort) and remaining 2008 admissions (validation cohort). We also assessed model performance and predictive ability in 2007 and 2009 data. MEASUREMENTS: Hospital risk-standardized 30-day mortality rates. RESULTS: The model development sample consisted of 150,035 admissions at 4537 nonfederal acute care US hospitals, with a mean unadjusted hospital 30-day mortality rate of 8.6%. The mean risk-standardized mortality rate was 8.6% and ranged from 5.9% to 13.5%. The development and validation models had good discrimination (areas under the receiver operating characteristic curve 0.72 and 0.72, respectively) and predictive ability (predicted mortality at the 1st and 10th deciles 1.5%, 23.7%, and 1.6%, 23.8%, respectively) and showed no evidence of over-fitting. CONCLUSIONS: A 30-day mortality model based on administrative claims had similar discrimination to other public reporting models and can be used to compare riskadjusted outcomes for patients with exacerbations of COPD and to track changes in outcomes over time. The high mortality and variation in rates across institutions suggest opportunities to improve quality of care. Journal of Hospital Medicine 2013; 8: 428-435. (C) 2013 Society of Hospital Medicine C1 [Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA 01199 USA. [Lindenauer, Peter K.] Baystate Med Ctr, Div Gen Internal Med, Springfield, MA 01199 USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Grosso, Laura M.; Wang, Changqin; Wang, Yun; Bernheim, Susannah M.; Drye, Elizabeth E.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Wang, Changqin; Wang, Yun] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Krishnan, Jerry A.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL USA. [Krishnan, Jerry A.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Adm, Chicago, IL USA. [Au, David H.] VA Puget Sound HealthCare Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Mularski, Richard A.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Mularski, Richard A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bernheim, Susannah M.] Yale Univ, Sch Med, Dept Internal Med, Sect Gen Internal Med, New Haven, CT 06510 USA. [Drye, Elizabeth E.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. RP Lindenauer, PK (reprint author), Baystate Med Ctr, Ctr Qual Care Res, 759 Chestnut St, Springfield, MA 01199 USA. EM peter.lindenauer@bhs.org FU MIDS [HHSM-500-2008-0025I/HHSM-500-T0001]; NIH, Department of Veterans Affairs, AHRQ, and Gilead Sciences; CMS FX Peter K. Lindenauer, MD, MSc, is the guarantor of this article, taking responsibility for the integrity of the work as a whole, from inception to published article, and takes responsibility for the content of the manuscript, including the data and data analysis. All authors have made substantial contributions to the conception and design, or acquisition of data, or analysis and interpretation of data; have drafted the submitted article or revised it critically for important intellectual content; and have provided final approval of the version to be published. Preparation of this manuscript was completed under Contract Number: HHSM-500-2008-0025I/HHSM-500-T0001, Modification No. 000007, Option Year 2 Measure Instrument Development and Support (MIDS). Sponsors did not contribute to the development of the research or manuscript. Dr. Au reports being an unpaid research consultant for Bosch Inc. He receives research funding from the NIH, Department of Veterans Affairs, AHRQ, and Gilead Sciences. The views of the this manuscript represent the authors and do not necessarily represent those of the Department of Veterans Affairs. Drs. Drye and Bernheim report receiving contract funding from CMS to develop and maintain quality measures. NR 27 TC 4 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD AUG PY 2013 VL 8 IS 8 BP 428 EP 435 DI 10.1002/jhm.2066 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 196QU UT WOS:000322791400002 PM 23913593 ER PT J AU Burke, RE Donze, J Schnipper, JL AF Burke, Robert E. Donze, Jacques Schnipper, Jeffrey L. TI Contribution of psychiatric illness and substance abuse to 30-day readmission risk SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HOSPITAL READMISSION; MENTAL-ILLNESS; CARE; DISORDERS; MORTALITY; LITERACY; QUALITY AB BACKGROUND: Little is known about the contribution of psychiatric illness to medical 30-day readmission risk. OBJECTIVE: To determine the independent contribution of psychiatric illness and substance abuse to all-cause and potentially avoidable 30-day readmissions in medical patients. DESIGN: Retrospective cohort study. SETTING: Patients discharged from the medicine services at a large teaching hospital from July 1, 2009 to June 30, 2010. MEASUREMENTS: The main outcome of interest was 30-day all-cause and potentially avoidable readmissions; the latter determined by a validated algorithm (SQLape) in both bivariate and multivariate analysis. Readmissions were captured at 3 hospitals where the majority of these patients are readmitted. RESULTS: Of 6987 discharged patients, 1260 were readmitted within 30 days (18.0%); 388 readmissions were potentially avoidable (5.6%). In multivariate analysis, 2 or more prescribed outpatient psychiatric medications (odds ratio [OR]: 1.1, 95% confidence interval [CI]: 1.01-1.20) or any prescription of anxiolytics (OR: 1.16, 95% CI: 1.001.35) were associated with increased all-cause readmissions, whereas discharge diagnoses of anxiety (OR: 0.82, 95% CI: 0.68-0.99) or substance abuse (OR: 0.80, 96% CI: 0.65-0.99) were associated with fewer all-cause readmissions. These findings were not replicated as predictors of potentially avoidable readmissions; rather, patients with discharge diagnoses of depression (OR: 1.49, 95% CI: 1.09-2.04) and schizophrenia (OR: 2.63, 95% CI: 1.13-6.13) were at highest risk. CONCLUSIONS: Our data suggest that patients treated during a hospitalization for depression and for schizophrenia are at higher risk for potentially avoidable 30-day readmissions, whereas those prescribed more psychiatric medications as outpatients are at increased risk for all-cause readmissions. These populations may represent fruitful targets for interventions to reduce readmission risk. (C) 2013 Society of Hospital Medicine C1 [Burke, Robert E.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Hosp Med Sect, Denver, CO USA. [Burke, Robert E.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Denver, CO USA. [Donze, Jacques; Schnipper, Jeffrey L.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA. [Donze, Jacques; Schnipper, Jeffrey L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Schnipper, Jeffrey L.] Brigham & Womens Hosp BWH Hospitalist Serv, Boston, MA USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Med Serv 111, 1055 Clermont St, Denver, CO 80220 USA. EM Robert.Burke5@va.gov FU Swiss National Science Foundation; Swiss Foundation for Medical-Biological Scholarships FX Dr. Donze was supported by the Swiss National Science Foundation and the Swiss Foundation for Medical-Biological Scholarships. The authors otherwise have no conflicts of interest to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US Department of Veterans Affairs. NR 26 TC 11 Z9 11 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD AUG PY 2013 VL 8 IS 8 BP 450 EP 455 DI 10.1002/jhm.2044 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 196QU UT WOS:000322791400005 PM 23589474 ER PT J AU Khateeb, R Gandhi, T Dhaliwal, G AF Khateeb, Rafina Gandhi, Tejal Dhaliwal, Gurpreet TI A raw deal SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID Q-FEVER; INFECTIONS; CLUSTER C1 [Khateeb, Rafina] Univ Michigan Hlth Syst, Dept Internal Med, Div Gen Med, Ann Arbor, MI USA. [Gandhi, Tejal] Univ Michigan Hlth Syst, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Khateeb, R (reprint author), 3119 Taubman Ctr,1500 E Med Ctr Dr,SPC 5376, Ann Arbor, MI 48109 USA. EM rafina@umich.edu NR 9 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD AUG PY 2013 VL 8 IS 8 BP 464 EP 467 DI 10.1002/jhm.2055 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 196QU UT WOS:000322791400007 PM 23878111 ER PT J AU Wallace, GC Haar, CP Vandergrift, WA Giglio, P Dixon-Mah, YN Varma, AK Ray, SK Patel, SJ Banik, NL Das, A AF Wallace, Gerald C. Haar, Catherine P. Vandergrift, W. Alex, III Giglio, Pierre Dixon-Mah, Yaenette N. Varma, Abhay K. Ray, Swapan K. Patel, Sunil J. Banik, Naren L. Das, Arabinda TI Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Glioblastoma; Diallyl trisulfide; p53; Mitosis; Histone deacetylase ID PROSTATE-CANCER CELLS; MOLECULAR-MECHANISMS; GARLIC COMPOUNDS; IN-VIVO; HISTONE ACETYLATION; DIALLYL DISULFIDE; INDUCTION; NEUROBLASTOMA; LIVER; MODEL AB Glioblastoma, the most lethal brain tumor, remains incurable despite aggressive chemotherapy and surgical interventions. New chemotherapeutics for glioblastoma have been explored in preclinical models and some agents have reached the clinical setting. However, success rates are not significant. Previous investigations involving diallyl trisulfide (DATS), a garlic compound, indicated significant anti-cancer effects in glioblastoma in vitro. DATS has also been shown to inhibit histone deacetylase activity and impede glioblastoma tumor progression. We hypothesized that DATS would block ectopic U87MG tumor by multiple pro-apoptotic pathways via inhibiting histone deacetylase (HDAC). To prove this, we developed ectopic U87MG tumors in SCID mice and treated them daily with intraperitoneal injections of DATS for 7 days. Results indicated that DATS (10 mu g/kg-10 mg/kg) dose-dependently reduced tumor mass and number of mitotic cells within tumors. Histological and biochemical assays demonstrated that DATS reduced mitosis in tumors, decreased HDAC activity, increased acetylation of H3 and H4, inhibited cell cycle progression, decreased pro-tumor markers (e.g., survivin, Bcl-2, c-Myc, mTOR, EGFR, VEGF), promoted apoptotic factors (e.g., bax, mcalpian, active caspase-3), and induced DNA fragmentation. Our data also demonstrated an increase in p21Waf1 expression, which correlated with increased p53 expression and MDM2 degradation following DATS treatment. Finally, histological assessment and enzyme assays showed that even the highest dose of DATS did not negatively impact hepatic function. Collectively, our results clearly demonstrated that DATS could be an effective therapeutic agent in preventing tumor progression and inducing apoptosis in human glioblastoma in vivo, without impairing hepatic function. C1 [Wallace, Gerald C.; Haar, Catherine P.; Vandergrift, W. Alex, III; Giglio, Pierre; Dixon-Mah, Yaenette N.; Varma, Abhay K.; Patel, Sunil J.; Banik, Naren L.; Das, Arabinda] Med Univ S Carolina, Dept Neurosci Neurol & Neurooncol, Charleston, SC 29425 USA. [Wallace, Gerald C.; Haar, Catherine P.; Vandergrift, W. Alex, III; Giglio, Pierre; Dixon-Mah, Yaenette N.; Varma, Abhay K.; Patel, Sunil J.; Banik, Naren L.; Das, Arabinda] Med Univ S Carolina, MUSC Brain & Spine Tumor Program, Charleston, SC 29425 USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurosci Neurol & Neurooncol, Charleston, SC 29425 USA. EM dasa@musc.edu FU Veteran Administration Research Program [NS-38146, NS-41088, 101BX001262]; Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation; [SC SCIRF-11-002] FX Completion of this investigation was made possible in part by these Grants (NS-38146, NS-41088, 101BX001262 [Veteran Administration Research Program], and SC SCIRF-11-002) and Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation. NR 28 TC 14 Z9 14 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD AUG PY 2013 VL 114 IS 1 BP 43 EP 50 DI 10.1007/s11060-013-1165-8 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 191EH UT WOS:000322395200005 PM 23754639 ER PT J AU Miller, RS Brenner, L Churchill, S Bahraini, N Price, R Skiba, V Caviness, J Mooney, S Weaver, L AF Miller, R. Scott Brenner, Lisa Churchill, Susan Bahraini, Nazanin Price, Robert Skiba, Virginia Caviness, James Mooney, Scott Weaver, Lindell TI A PHASE II, RANDOMIZED, SHAM-CONTROLLED TRIAL HYPERBARIC OXYGEN FOR POST-CONCUSSION SYNDROME: IMPACT OF INTERVENTION ON SYMPTOMS AND WELL BEING SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 31st Annual National Neurotrauma Symposium CY AUG 04-07, 2013 CL Nashville, TN DE hyperbaric oxygen; post-concussion syndrome; sham-controlled randomized trial C1 [Miller, R. Scott] US Army Med Mat Dev Act, Ft Carson, CO USA. [Brenner, Lisa; Bahraini, Nazanin] Denver VA Med Ctr, Ft Carson, CO USA. [Churchill, Susan; Weaver, Lindell] LDS Hosp, Ft Carson, CO USA. [Price, Robert] Evans Army Community Hosp, Ft Carson, CO USA. [Mooney, Scott] Eisenhower Army Med Ctr, Ft Gordon, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD AUG PY 2013 VL 30 IS 15 BP A56 EP A56 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 191WY UT WOS:000322446800103 ER PT J AU Ritchie, CS Zulman, DM AF Ritchie, Christine S. Zulman, Donna M. TI Research Priorities in Geriatric Palliative Care: Multimorbidity SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID MULTIPLE CHRONIC CONDITIONS; RANDOMIZED CONTROLLED-TRIALS; CHRONIC HEART-FAILURE; QUALITY-OF-LIFE; PATIENT COMPLEXITY; CHRONIC DISEASES; DIABETES CARE; COMORBIDITY; IMPACT; HEALTH AB With global aging and scientific advances extending survival, the number of adults experiencing multiple chronic conditions has grown substantially and is projected to increase by another third between 2000 and 2030. Among the many challenges posed by multimorbidity, some of the most pressing include how to characterize and measure comorbid conditions, understand symptoms and illness burden, and provide person-centered care in the context of competing health care priorities and increasing complexity. In this white paper emanating from a National Institute on Aging supported conference to discuss research gaps at the geriatrics-palliative care interface, the authors review common definitions of multimorbidity; describe the association between multimorbidity and quality of life, functional status, quality of care, and health care utilization; note content and methodological gaps in multimorbidity evidence; and make recommendations regarding research priorities in this area of expanding public health impact. C1 [Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Ritchie, Christine S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ritchie, Christine S.] Jewish Home San Francisco, San Francisco, CA USA. [Zulman, Donna M.] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA. [Zulman, Donna M.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. RP Ritchie, CS (reprint author), Univ Calif San Francisco, Sch Med, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM christine.ritchie@ucsf.edu FU National Institute on Aging Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741]; Advanced Illness and Multimorbidity Geriatric Academic Leadership Award [K07AG31779]; National Institute for Nursing Research; Commonwealth Fund; Retirement Research Foundation; Stephen D. Bechtel Foundation through the Program for the Aging Century; career development award through Veterans Affairs Health Services Research Development [CDA 12-173] FX This work was supported by the National Institute on Aging Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai (5P30AG028741). Dr. Ritchie is supported by the Advanced Illness and Multimorbidity Geriatric Academic Leadership Award (K07AG31779); and by the National Institute for Nursing Research, the Commonwealth Fund, the Retirement Research Foundation, and the Stephen D. Bechtel Foundation through the Program for the Aging Century. Dr. Zulman is supported by a career development award through Veterans Affairs Health Services Research & Development (CDA 12-173). NR 44 TC 4 Z9 4 U1 6 U2 20 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD AUG PY 2013 VL 16 IS 8 BP 843 EP 847 DI 10.1089/jpm.2013.9491 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 187JT UT WOS:000322114600012 PM 23777331 ER PT J AU Foering, K Chang, AY Piette, EW Cucchiara, A Okawa, J Werth, VP AF Foering, Kristen Chang, Aileen Y. Piette, Evan W. Cucchiara, Andrew Okawa, Joyce Werth, Victoria P. TI Characterization of clinical photosensitivity in cutaneous lupus erythematosus SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article; Proceedings Paper CT Dermatology Research agenda conference CY JUN 22-23, 2012 CL Washington, DC DE cutaneous lupus erythematosus; dendritic cells; immunohistochemistry; photosensitivity; polymorphic light eruption; systemic lupus erythematosus ID POLYMORPHOUS LIGHT ERUPTION; QUALITY-OF-LIFE; TERM-FOLLOW-UP; DISEASE-ACTIVITY; SEVERITY INDEX; T-CELLS; SKIN; MANIFESTATIONS; RESIDENT; LESIONS AB Background: Photosensitivity (PS) in lupus erythematosus (LE) is frequently determined by patient report. Objective: We sought to characterize self-reported PS in cutaneous LE (CLE). Methods: The PS survey was used to classify subject responses into 5 phenotypes: direct sun-induced CLE flare (directCLE); general exacerbation of CLE (genCLE); polymorphic light eruption-like reactions (genSkin); general pruritus/paresthesias (genRxn); and sun-induced systemic symptoms (genSys). In all, 91 subjects with CLE alone or with CLE and systemic LE were interviewed. Results: In all, 81% ascribed to 1 or more PS phenotypes. CLE-specific reactions (direct sun-induced CLE flare or general exacerbation of CLE) were reported by 86% of photosensitive subjects. Higher CLE disease activity (measured by CLE Disease Area and Severity Index activity scores) was suggestive of direct sun-induced CLE flare reactions (P = .09). In all, 60% of photosensitive subjects described CLE-nonspecific reactions: polymorphic light eruption-like rash and general pruritus/paresthesias. These phenotypes often co-occurred with CLE-specific reactions and were predicted by more systemic disease activity as measured by Physicians Global Assessment (PGA) scores in regression analyses (genSkin, P = .02) and (genRxn, P = .05). In all, 36% of subjects reported systemic reactions and higher PGA scores were predictive of the sun-induced systemic symptoms phenotype (P = .02); a diagnosis of systemic LE was not (P = .14). Limitations: PS was inferred from patient report and not directly observed. Conclusions: Characterization of self-reported PS in LE reveals that patients experience combinations of CLE-specific, CLE-nonspecific, and systemic reactions to sunlight. Sun-induced CLE flares are associated with more active CLE disease. Polymorphic light eruption-like, generalized pruritus/paresthesias, and systemic reactions are associated with more active systemic disease. Recognition of PS phenotypes will permit improved definitions of clinical PS and allow for more precise investigation into its pathophysiology. C1 [Foering, Kristen; Chang, Aileen Y.; Piette, Evan W.; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Vet Affairs Med Ctr, Philadelphia Dept, Philadelphia, PA 19104 USA. [Foering, Kristen; Chang, Aileen Y.; Piette, Evan W.; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Foering, Kristen; Cucchiara, Andrew] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU National Institutes of Health [NIH K24-AR 18 02207]; National Center for Advancing Translational Research [TL1RR024133]; National Center for Advancing Translational Science [TL1TR00138]; Department of Veterans Affairs, Veteran Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX This material is based upon work supported by the National Institutes of Health, including NIH K24-AR 18 02207 (Dr Werth); National Center for Advancing Translational Research TL1RR024133, which is now National Center for Advancing Translational Science TL1TR00138 (Drs Foering and Cucchiara); and Department of Veterans Affairs, Veteran Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 31 TC 10 Z9 10 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD AUG PY 2013 VL 69 IS 2 BP 205 EP 213 DI 10.1016/j.jaad.2013.03.015 PG 9 WC Dermatology SC Dermatology GA 186TK UT WOS:000322068100027 PM 23648190 ER PT J AU Steele, JW Ju, S Lachenmayer, ML Liken, J Stock, A Kim, SH Delgado, LM Alfaro, IE Bernales, S Verdile, G Bharadwaj, P Gupta, V Barr, R Friss, A Dolios, G Wang, R Ringe, D Protter, AA Martins, RN Ehrlich, ME Yue, Z Petsko, GA Gandy, S AF Steele, J. W. Ju, S. Lachenmayer, M. L. Liken, J. Stock, A. Kim, S. H. Delgado, L. M. Alfaro, I. E. Bernales, S. Verdile, G. Bharadwaj, P. Gupta, V. Barr, R. Friss, A. Dolios, G. Wang, R. Ringe, D. Protter, A. A. Martins, R. N. Ehrlich, M. E. Yue, Z. Petsko, G. A. Gandy, S. TI Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain SO MOLECULAR PSYCHIATRY LA English DT Article DE autophagy; proteotoxicity; alpha-synuclein; therapeutics ID ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; IN-VIVO; DIMEBON; YEAST; COGNITION; TOXICITY; BETA; PROTEINOPATHY; AGGREGATION AB Latrepirdine (Dimebon; dimebolin) is a neuroactive compound that was associated with enhanced cognition, neuroprotection and neurogenesis in laboratory animals, and has entered phase II clinical trials for both Alzheimer's disease and Huntington's disease (HD). Based on recent indications that latrepirdine protects cells against cytotoxicity associated with expression of aggregatable neurodegeneration-related proteins, including A beta 42 and gamma-synuclein, we sought to determine whether latrepirdine offers protection to Saccharomyces cerevisiae. We utilized separate and parallel expression in yeast of several neurodegeneration-related proteins, including alpha-synuclein (alpha-syn), the amyotrophic lateral sclerosis-associated genes TDP43 and FUS, and the HD-associated protein huntingtin with a 103 copy-polyglutamine expansion (HTT gene; htt-103Q). Latrepirdine effects on alpha-syn clearance and toxicity were also measured following treatment of SH-SY5Y cells or chronic treatment of wildtype mice. Latrepirdine only protected yeast against the cytotoxicity associated with alpha-syn, and this appeared to occur via induction of autophagy. We further report that latrepirdine stimulated the degradation of alpha-syn in differentiated SH-SY5Y neurons, and in mouse brain following chronic administration, in parallel with elevation of the levels of markers of autophagic activity. Ongoing experiments will determine the utility of latrepirdine to abrogate alpha-syn accumulation in transgenic mouse models of alpha-syn neuropathology. We propose that latrepirdine may represent a novel scaffold for discovery of robust proautophagic/anti-neurodegeneration compounds, which might yield clinical benefit for synucleinopathies including Parkinson's disease, Lewy body dementia, rapid eye movement (REM) sleep disorder and/or multiple system atrophy, following optimization of its pro-autophagic and pro-neurogenic activities. C1 [Steele, J. W.; Lachenmayer, M. L.; Stock, A.; Kim, S. H.; Ehrlich, M. E.; Yue, Z.; Gandy, S.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Steele, J. W.; Stock, A.; Kim, S. H.; Gandy, S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Steele, J. W.; Stock, A.; Kim, S. H.; Gandy, S.] Mt Sinai Sch Med, Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Steele, J. W.] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA. [Ju, S.; Liken, J.; Ringe, D.; Petsko, G. A.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem, Waltham, MA 02254 USA. [Ju, S.; Liken, J.; Ringe, D.; Petsko, G. A.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Chem, Waltham, MA 02254 USA. [Lachenmayer, M. L.] Univ Bonn, Dept Neurol, Bonn, Germany. [Delgado, L. M.] Univ Andres Bello, Fac Ciencias Biol, Santiago, Chile. [Alfaro, I. E.; Bernales, S.] Fdn Ciencia & Vida, Santiago, Chile. [Bernales, S.; Protter, A. A.] Medivation Inc, San Francisco, CA USA. [Verdile, G.; Bharadwaj, P.; Gupta, V.; Barr, R.; Martins, R. N.] Edith Cowan Univ, Sch Med Sci, Ctr Excellence Alzheimers Dis Res & Care, Churchlands, WA 6018, Australia. [Friss, A.; Dolios, G.; Wang, R.; Ehrlich, M. E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Martins, R. N.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Crawley, WA, Australia. [Martins, R. N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA, Australia. [Ehrlich, M. E.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. [Yue, Z.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Petsko, G. A.] Cornell Univ, Dept Neurol & Neurosci, Weill Med Coll, New York, NY 10021 USA. [Gandy, S.] James J Peters VA Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM samuel.gandy@mssm.edu RI Wang, Rong/A-8721-2009 FU National Institute of General Medical Sciences [T32GM062754]; Deutsche Forschungsgemeinschaft; NHMRC [APP1009295]; McCusker Alzheimer's Research Foundation [PFB-16]; Fidelity Biosciences Research Initiative; Cure Alzheimer's Fund; US Department of Veterans Affairs; NIH [P01AG10491, P50AG05138, P30 NS061777, S10 RR022415, R01NS060123, U54RR022220] FX The work in this manuscript was used in a dissertation by JWS as partial requirement for the fulfillment of the PhD degree. JWS is a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32GM062754 from the National Institute of General Medical Sciences. MLL was supported by the Deutsche Forschungsgemeinschaft. SG is a member of the Oligomer Research Consortium of the Cure Alzheimer's Fund. We acknowledge the generous support of the NH&MRC (APP1009295 to RM, GV, SG), McCusker Alzheimer's Research Foundation (RM, GV), Conicyt (PFB-16 to SB), Fidelity Biosciences Research Initiative (SJ, JL, DR, GAP), Cure Alzheimer's Fund (SG), the US Department of Veterans Affairs (SG), and the NIH (P01AG10491 to SG; P50AG05138 to Mary Sano; P30 NS061777 and S10 RR022415 to RW; R01NS060123 and U54RR022220 to ZY). We would like to thank Rosilyn Kazanjian for her gift in memory of Powel Kazanjian. We would also like to thank Loren E Khan and Justine Bonet for technical assistance in animal colony management and Dr Yun Zhong for technical support, and Dr Kostas Vekrellis (Foundation for Biomedical Research of the Academy of Athens, Athens, Greece) for generously providing the tet-off inducible alpha-syn overexpressing SH-SY5Y neuro-blastoma cell line. NR 35 TC 29 Z9 30 U1 5 U2 35 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD AUG PY 2013 VL 18 IS 8 BP 882 EP 888 DI 10.1038/mp.2012.115 PG 7 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 191XM UT WOS:000322448400009 PM 22869031 ER PT J AU Steele, JW Lachenmayer, ML Ju, S Stock, A Liken, J Kim, SH Delgado, LM Alfaro, IE Bernales, S Verdile, G Bharadwaj, P Gupta, V Barr, R Friss, A Dolios, G Wang, R Ringe, D Fraser, P Westaway, D St George-Hyslop, PH Szabo, P Relkin, NR Buxbaum, JD Glabe, CG Protter, AA Martins, RN Ehrlich, ME Petsko, GA Yue, Z Gandy, S AF Steele, J. W. Lachenmayer, M. L. Ju, S. Stock, A. Liken, J. Kim, S. H. Delgado, L. M. Alfaro, I. E. Bernales, S. Verdile, G. Bharadwaj, P. Gupta, V. Barr, R. Friss, A. Dolios, G. Wang, R. Ringe, D. Fraser, P. Westaway, D. St George-Hyslop, P. H. Szabo, P. Relkin, N. R. Buxbaum, J. D. Glabe, C. G. Protter, A. A. Martins, R. N. Ehrlich, M. E. Petsko, G. A. Yue, Z. Gandy, S. TI Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model SO MOLECULAR PSYCHIATRY LA English DT Article DE Alzheimer's disease; amyloid; autophagy; therapeutics ID AMYLOID-BETA LEVELS; HUNTINGTONS-DISEASE; DIMEBON; DEFICITS; AUTOPHAGY; MTOR; INHIBITION; DISCOVERY; RAT AB Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer's disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States. We sought to determine whether latrepirdine (LAT)-stimulated amyloid precursor protein (APP) catabolism is at least partially attributable to regulation of macroautophagy, a highly conserved protein catabolism pathway that is known to be impaired in brains of patients with Alzheimer's disease (AD). We utilized several mammalian cellular models to determine whether LAT regulates mammalian target of rapamycin (mTOR) and Atg5-dependent autophagy. Male TgCRND8 mice were chronically administered LAT prior to behavior analysis in the cued and contextual fear conditioning paradigm, as well as immunohistological and biochemical analysis of AD-related neuropathology. Treatment of cultured mammalian cells with LAT led to enhanced mTOR-and Atg5-dependent autophagy. Latrepirdine treatment of TgCRND8 transgenic mice was associated with improved learning behavior and with a reduction in accumulation of A beta 42 and alpha-synuclein. We conclude that LAT possesses pro-autophagic properties in addition to the previously reported pro-neurogenic properties, both of which are potentially relevant to the treatment and/or prevention of neurodegenerative diseases. We suggest that elucidation of the molecular mechanism(s) underlying LAT effects on neurogenesis, autophagy and behavior might warranty the further study of LAT as a potentially viable lead compound that might yield more consistent clinical benefit following the optimization of its pro-neurogenic, pro-autophagic and/or pro-cognitive activities. C1 [Steele, J. W.; Lachenmayer, M. L.; Stock, A.; Kim, S. H.; Ehrlich, M. E.; Yue, Z.; Gandy, S.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Steele, J. W.; Kim, S. H.; Buxbaum, J. D.; Gandy, S.] Dept Psychiat, New York, NY USA. [Steele, J. W.; Kim, S. H.; Buxbaum, J. D.; Gandy, S.] Mt Sinai Alzheimers Dis Res Ctr, New York, NY USA. [Steele, J. W.] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA. [Lachenmayer, M. L.] Univ Bonn, Dept Neurol, Bonn, Germany. [Ju, S.; Liken, J.; Ringe, D.; Petsko, G. A.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem, Waltham, MA 02254 USA. [Ju, S.; Liken, J.; Ringe, D.; Petsko, G. A.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Chem, Waltham, MA 02254 USA. [Delgado, L. M.] Univ Andres Bello, Fac Ciencias Biol, Santiago, Chile. [Alfaro, I. E.; Bernales, S.] Fdn Ciencia & Vida, Santiago, Chile. [Bernales, S.; Protter, A. A.] Medivation Inc, San Francisco, CA USA. [Verdile, G.; Bharadwaj, P.; Gupta, V.; Barr, R.; Martins, R. N.] Edith Cowan Univ, Sch Med Sci, Ctr Excellence Alzheimers Dis Res & Care, Perth, WA, Australia. [Friss, A.; Dolios, G.; Wang, R.; Buxbaum, J. D.; Ehrlich, M. E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Fraser, P.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada. [Fraser, P.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Westaway, D.; St George-Hyslop, P. H.] Univ Alberta, Ctr Prions & Prot Folding Dis, Edmonton, AB, Canada. [Szabo, P.; Relkin, N. R.; Petsko, G. A.] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA. [Buxbaum, J. D.] Mt Sinai Sch Med, Dept Psychiat, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. [Buxbaum, J. D.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY 10029 USA. [Glabe, C. G.] Univ Calif Irvine, Dept Neurol, Sch Med, Irvine, CA 92717 USA. [Martins, R. N.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Crawley, WA, Australia. [Martins, R. N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA, Australia. [Ehrlich, M. E.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. [Yue, Z.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Gandy, S.] James J Peters VA Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM samuel.gandy@mssm.edu RI Wang, Rong/A-8721-2009 OI Buxbaum, Joseph/0000-0001-8898-8313 FU National Institute of General Medical Sciences [T32GM062754]; Deutsche Forschungsgemeinschaft; Oligomer Research Consortium of the Cure Alzheimer's Fund; McCusker Alzheimer's Research Foundation; Conicyt [PFB-16]; Fidelity Biosciences Research Initiative; Cure Alzheimer's Fund; US Department of Veterans Affairs; NIH [P01AG10491, U01AG01483, NS045283, R01NS060123, U54RR022220, P30 NS061777, S10 RR022415, P50AG05138]; Canadian Institutes of Health Research and Alzheimer Society of Ontario; Baxter Healthcare FX The work in this manuscript was used in a dissertation by JWS as partial requirement for the fulfillment of the PhD degree. JWS is a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32GM062754 from the National Institute of General Medical Sciences. MLL was supported by the Deutsche Forschungsgemeinschaft. SG and CGG are members of the Oligomer Research Consortium of the Cure Alzheimer's Fund. We acknowledge the generous support of the NH&MRC (APP1009295 to RNM, GV, SG), the McCusker Alzheimer's Research Foundation (RNM, GV), Conicyt (PFB-16 to SB), the Fidelity Biosciences Research Initiative (SJ, JL, DR, GAP), Cure Alzheimer's Fund (SG; CGG), the US Department of Veterans Affairs (SG), the NIH (P01AG10491 to SG; U01AG01483 to PS; NS045283 to CGG, R01NS060123; U54RR022220 to ZY; P30 NS061777 and S10 RR022415 to RW; and P50AG05138 to Mary Sano), the Canadian Institutes of Health Research and Alzheimer Society of Ontario (PF), and Baxter Healthcare (PS and NRR). We would also like to thank Rosilyn Kazanjian for the gift in memory of Powel Kazanjian that supported the purchase of the Luminex xMAP100/200 system. We would like to thank Loren E Khan and Justine Bonet for technical assistance in animal colony management and Dr Yun Zhong for technical support. NR 35 TC 34 Z9 35 U1 2 U2 18 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD AUG PY 2013 VL 18 IS 8 BP 889 EP 897 DI 10.1038/mp.2012.106 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 191XM UT WOS:000322448400010 PM 22850627 ER PT J AU Crabbe, JC Spence, SE Huang, LC Cameron, AJ Schlumbohm, JP Barkley-Levenson, AM Metten, P AF Crabbe, John C. Spence, Stephanie E. Huang, Lawrence C. Cameron, Andy J. Schlumbohm, Jason P. Barkley-Levenson, Amanda M. Metten, Pamela TI Ethanol drinking in Withdrawal Seizure-Prone and -Resistant selected mouse lines SO ALCOHOL LA English DT Article DE Ethanol withdrawal; Selective breeding; Ethanol preference; Drinking in the dark; Mouse; Genetics ID ACUTE ALCOHOL-WITHDRAWAL; QUANTITATIVE TRAIT LOCI; STRAIN DIFFERENCES; MUS-MUSCULUS; INBRED MICE; RAT LINES; SEVERITY; PREFERENCE; SUSCEPTIBILITY; INTOXICATION AB Withdrawal Seizure-Prone (WSP) and Withdrawal Seizure-Resistant (WSR) mouse lines were bidirectionally selectively bred, respectively, to have severe or mild ethanol withdrawal handling-induced convulsions (HICs) after cessation of 3 days of ethanol vapor inhalation. Murine genotypes with severe withdrawal have been found to show low ethanol consumption, and high consumers show low withdrawal. An early drinking study with WSP and WSR mice showed modest evidence consistent with this genetic correlation, but there were several limitations to that experiment. We therefore conducted a thorough assessment of two bottle ethanol preference drinking in both replicate pairs of WSP/WSR selected lines in mice of both sexes. Greater preference drinking of WSR-2 than WSP-2 female mice confirmed the earlier report. However, in the parallel set of selected lines, the WSP-1 mice drank more than the WSR-1s. Naive mice tested for preference for sucrose, saccharin and quinine did not differ markedly for any tastant Finally, in a test of binge-like drinking, Drinking in the Dark (DID), WSP mice drank more than WSR mice and attained significantly higher (but still modest) blood ethanol concentrations. Tests of acute withdrawal after DID showed a mild, but significant elevation in handling-induced convulsions in the WSP line. These results provide further evidence that 2-bottle ethanol preference and DID are genetically distinguishable traits. Published by Elsevier Inc. C1 [Crabbe, John C.; Spence, Stephanie E.; Huang, Lawrence C.; Cameron, Andy J.; Schlumbohm, Jason P.; Barkley-Levenson, Amanda M.; Metten, Pamela] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Crabbe, John C.; Spence, Stephanie E.; Huang, Lawrence C.; Cameron, Andy J.; Schlumbohm, Jason P.; Barkley-Levenson, Amanda M.; Metten, Pamela] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Crabbe, JC (reprint author), Portland VA Med Ctr, Res R&D 12,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM crabbe@ohsu.edu FU NIH-NIAAA [AA10760, AA13519, AA20245, AA007468]; Department of Veterans Affairs; Department of the Army/DoD-TATRC grant [10245005.05]; Achievement Rewards for College Scientists Foundation; OHSU Graduate Research Scholar fellowship FX These studies were supported by Grants AA10760, AA13519, and AA20245 from the NIH-NIAAA; by the Department of Veterans Affairs; and by the Department of the Army/DoD-TATRC grant 10245005.05. AMB-L was supported by NIH-NIAAA grant AA007468, the Achievement Rewards for College Scientists Foundation, and an OHSU Graduate Research Scholar fellowship. NR 29 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD AUG PY 2013 VL 47 IS 5 BP 381 EP 389 DI 10.1016/j.alcohol.2013.05.002 PG 9 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 187EH UT WOS:000322099200004 PM 23809872 ER PT J AU McCarthy, MJ Fernandes, M Kranzler, HR Covault, JM Welsh, DK AF McCarthy, Michael J. Fernandes, Malcolm Kranzler, Henry R. Covault, Jonathan M. Welsh, David K. TI Circadian Clock Period Inversely Correlates with Illness Severity in Cells from Patients with Alcohol Use Disorders SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Circadian Rhythm; Genetics; Alcohol ID GENE-EXPRESSION; ACTIVITY RHYTHMS; BETA-ENDORPHIN; FAMILY-HISTORY; SLEEP PROBLEMS; CONSUMPTION; ETHANOL; DEPENDENCE; RELAPSE; RATS AB Background: Clinical and genetic studies suggest circadian clock genes may contribute to biological mechanisms underlying alcohol use disorders (AUD). In particular, the Per2 gene regulates alcohol consumption in mutant animals, and in humans with AUD, the 10870 variant in PER2 has been associated with alcohol consumption. However, with respect to function, the molecular clock remains largely uncharacterized in AUD patients. Methods: In skin fibroblast cultures from well-characterized human AUD patients (n = 19) and controls (n = 13), we used a bioluminescent reporter gene (Per2:: luc) to measure circadian rhythms in gene expression at high sampling density for 5 days. Cells were genotyped for the PER2 10870 variant. The rhythm parameters period and amplitude were then analyzed using a case-control design and by genetic and clinical characteristics of the AUD subjects. Results: There were no differences between AUD cases and controls in rhythm parameters. However, period was inversely correlated with illness severity (defined as the number of alcohol dependence criteria met). The PER2 variant 10870 was not associated with differences in rhythm parameters. Conclusions: Our data suggest that differences in the cellular circadian clock are not pronounced in fibroblasts from AUD cases and controls. However, we found evidence that the circadian clock may be associated with an altered trajectory of AUD, possibly related to illness severity. Future work will be required to determine the mechanistic basis of this association. C1 [McCarthy, Michael J.; Fernandes, Malcolm; Welsh, David K.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. [McCarthy, Michael J.; Fernandes, Malcolm; Welsh, David K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [McCarthy, Michael J.; Fernandes, Malcolm; Welsh, David K.] Univ Calif San Diego, Ctr Chronobiol, San Diego, CA 92103 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Covault, Jonathan M.] Univ Connecticut, Sch Med, Alcohol Res Ctr, Farmington, CT USA. RP McCarthy, MJ (reprint author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr MC 116A, San Diego, CA 92161 USA. EM mmccarthy@ucsd.edu OI McCarthy, Michael/0000-0001-6219-4945 FU Veterans Affairs Career Development Award [1IK2BX001275]; NIH [R21AA017584, R01AA021164]; Veterans Affairs Merit Award [1I01BX001146]; NIMH [R01 MH082945]; NARSAD Young Investigator Award FX MJM is supported by a Veterans Affairs Career Development Award (1IK2BX001275). JMC receives support from NIH (R21AA017584). HRK receives support from NIH (R01AA021164). DKW receives support from a Veterans Affairs Merit Award (1I01BX001146), NIMH (R01 MH082945), and a NARSAD Young Investigator Award. The funders had no role in the analysis, decision to publish, or preparation of the manuscript. NR 40 TC 9 Z9 9 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD AUG PY 2013 VL 37 IS 8 BP 1304 EP 1310 DI 10.1111/acer.12106 PG 7 WC Substance Abuse SC Substance Abuse GA 190GV UT WOS:000322328300008 PM 23550834 ER PT J AU Rubinsky, AD Dawson, DA Williams, EC Kivlahan, DR Bradley, KA AF Rubinsky, Anna D. Dawson, Deborah A. Williams, Emily C. Kivlahan, Daniel R. Bradley, Katharine A. TI AUDIT-C Scores as a Scaled Marker of Mean Daily Drinking, Alcohol Use Disorder Severity, and Probability of Alcohol Dependence in a US General Population Sample of Drinkers SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE AUDIT-C; Alcohol Screening; Mean Daily Drinking; Alcohol Misuse Severity; Alcohol Dependence ID NATIONAL EPIDEMIOLOGIC SURVEY; PRIMARY-CARE PATIENTS; RISK DRINKING; CONSUMPTION QUESTIONS; IDENTIFICATION TEST; UNITED-STATES; METAANALYSIS; INTERVENTION; VALIDITY; IV AB Background: Brief alcohol screening questionnaires are increasingly used to identify alcohol misuse in routine care, but clinicians also need to assess the level of consumption and the severity of misuse so that appropriate intervention can be offered. Information provided by a patient's alcohol screening score might provide a practical tool for assessing the level of consumption and severity of misuse. Methods: This post hoc analysis of data from the 2001 to 2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) included 26,546 U. S. adults who reported drinking in the past year and answered additional questions about their consumption, including Alcohol Use Disorders Identification Test-Consumption questionnaire (AUDIT-C) alcohol screening. Linear or logistic regression models and postestimation methods were used to estimate mean daily drinking, the number of endorsed alcohol use disorder (AUD) criteria ("AUD severity"), and the probability of alcohol dependence associated with each individual AUDIT-C score (1 to 12), after testing for effect modification by gender and age. Results: Among eligible past-year drinkers, mean daily drinking, AUD severity, and the probability of alcohol dependence increased exponentially across increasing AUDIT-C scores. Mean daily drinking ranged from < 0.1 to 18.0 drinks/d, AUD severity ranged from < 0.1 to 5.1 endorsed AUD criteria, and probability of alcohol dependence ranged from < 1 to 65% across scores 1 to 12. AUD severity increased more steeply across AUDIT-C scores among women than men. Both AUD severity and mean daily drinking increased more steeply across AUDIT-C scores among younger versus older age groups. Conclusions: Results of this study could be used to estimate patient-specific consumption and severity based on age, gender, and alcohol screening score. This information could be integrated into electronic decision support systems to help providers estimate and provide feedback about patient-specific risks and identify those patients most likely to benefit from further diagnostic assessment. C1 [Rubinsky, Anna D.; Williams, Emily C.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Rubinsky, Anna D.; Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Dawson, Deborah A.] NIAAA, Lab Epidemiol & Biometry, Div Clin & Biol Res, NIH, Bethesda, MD USA. [Dawson, Deborah A.] Kelly Govt Serv Inc, Bethesda, MD USA. [Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Rubinsky, AD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM anna.rubinsky@va.gov FU U.S. Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development; Substance Use Disorders Quality Enhancement Research Initiative; Agency for Healthcare Research and Quality (AHRQ) National Research Services Award (NRSA) at the University of Washington [T32 HS013853] FX The research reported here was supported by the U.S. Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development, and the Substance Use Disorders Quality Enhancement Research Initiative. ADR was also supported by an Agency for Healthcare Research and Quality (AHRQ) National Research Services Award (NRSA) at the University of Washington (T32 HS013853). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States Government, or any of the authors' institutions. NR 49 TC 36 Z9 36 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD AUG PY 2013 VL 37 IS 8 BP 1380 EP 1390 DI 10.1111/acer.12092 PG 11 WC Substance Abuse SC Substance Abuse GA 190GV UT WOS:000322328300017 PM 23906469 ER PT J AU Teng, E Leone-Friedman, J Lee, GJ Woo, S Apostolova, LG Harrell, S Ringman, JM Lu, PH AF Teng, Edmond Leone-Friedman, Judith Lee, Grace J. Woo, Stephanie Apostolova, Liana G. Harrell, Shelly Ringman, John M. Lu, Po H. TI Similar Verbal Fluency Patterns in Amnestic Mild Cognitive Impairment and Alzheimer's Disease SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Mild cognitive impairment; Alzheimer's disease; Verbal fluency; Dementia; Assessment; Cognition ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; OLDER-ADULTS; DEMENTIA; SUBTYPES; CONVERSION; AGE; EDUCATION; MCI; VARIABILITY; DISCREPANCY AB Disproportionately greater deficits in semantic relative to phonemic verbal fluency are seen in Alzheimer's disease (AD) and have been attributed to neurodegenerative changes in the temporal lobe. Amnestic (AMN) mild cognitive impairment (MCI), which often represents incipient AD, is also characterized by early temporal lobe neuropathology, but previous comparisons of verbal fluency between AD and AMN MCI have yielded mixed results. We examined semantic and phonemic verbal fluency performance in 399 individuals (78 AD, 138 AMN MCI, 72 non-amnestic MCI, and 111 cognitively normal controls). Similar verbal fluency patterns were seen in AMN MCI and AD; both groups exhibited disproportionately poorer performance on semantic verbal fluency relative to normal controls. However, relative verbal fluency indices performed more poorly than individual semantic or phonemic verbal fluency indices for discriminating AMN MCI or AD participants from normal controls, suggesting that they are unlikely to provide additional utility for predicting progression from MCI to AD. C1 [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Teng, Edmond; Leone-Friedman, Judith; Apostolova, Liana G.; Ringman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA. [Teng, Edmond; Leone-Friedman, Judith; Apostolova, Liana G.; Ringman, John M.; Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Lee, Grace J.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92350 USA. [Woo, Stephanie; Harrell, Shelly] Pepperdine Univ, Grad Sch Educ & Psychol, Los Angeles, CA USA. RP Lu, PH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, RNRC, 710 Westwood Plaza,Room 2-258, Los Angeles, CA 90095 USA. EM plu@mednet.ucla.edu FU NIH from the National Institute on Aging [P50 AG 16570, K23 AG 028727, K08 AG 34628]; National Institute on Aging; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation; Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers at UCLA FX This research was supported by NIH grants from the National Institute on Aging (P50 AG 16570, K23 AG 028727 to PL and K08 AG 34628 to ET; jointly sponsored by the National Institute on Aging, American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor), the Alzheimer's Disease Research Centers of California, the Sidell-Kagan Foundation, and the Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers at UCLA. NR 43 TC 5 Z9 5 U1 1 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD AUG PY 2013 VL 28 IS 5 BP 400 EP 410 DI 10.1093/arclin/act039 PG 11 WC Psychology, Clinical; Psychology SC Psychology GA 186CN UT WOS:000322019600002 PM 23752677 ER PT J AU Bae, ON Wang, JM Baek, SH Wang, Q Yuan, H Chen, AF AF Bae, Ok-Nam Wang, Jie-Mei Baek, Seung-Hoon Wang, Qingde Yuan, Hong Chen, Alex F. TI Oxidative Stress-Mediated Thrombospondin-2 Upregulation Impairs Bone Marrow-Derived Angiogenic Cell Function in Diabetes Mellitus SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE angiogenesis inhibitors; diabetes; oxidative stress; stem cells; thrombospondin-2; human ID ENDOTHELIAL PROGENITOR CELLS; MANGANESE SUPEROXIDE-DISMUTASE; CORONARY-ARTERY-DISEASE; NITRIC-OXIDE SYNTHASE; MICRORNA EXPRESSION; TUMOR ANGIOGENESIS; PROLIFERATION; PATHOPHYSIOLOGY; MECHANISMS; PHENOTYPE AB Objective Circulating angiogenic cells play an essential role in angiogenesis but are dysfunctional in diabetes mellitus characterized by excessive oxidative stress. We hypothesize that oxidative stress-mediated upregulation of thrombospondin-2 (TSP-2), a potent antiangiogenic protein, contributes to diabetic bone marrow-derived angiogenic cell (BMAC) dysfunction. Approach and Results BMACs were isolated from adult male type 2 diabetic db/db mice and control db/+ (C57BLKS/J) mice. In Matrigel tube formation assay, angiogenic function was impaired in diabetic BMACs, accompanied by increased oxidative stress and nicotinamide adenine dinucleotide phosphate oxidase activity. BMAC angiogenic function was restored by overexpression of dominant negative Rac1 or by overexpression of manganese superoxide dismutase. TSP-2 mRNA and protein were both significantly upregulated in diabetic BMACs, mediated by increased oxidative stress as shown by a decrease in TSP-2 level after overexpression of dominant negative Rac1 or manganese superoxide dismutase. Silencing TSP-2 by its small interfering RNA in diabetic BMACs improved BMAC function in tube formation, adhesion, and migration assays. Notably, the upregulation of TSP-2 was also found in BMACs from streptozotocin-induced type 1 diabetic mice, and normal BMACs with high glucose treatment. let-7f, a microRNA which has been related to endothelial angiogenic function, is found to play key role in TSP-2 increase, but let-7f did not directly interact with TSP-2 mRNA. Conclusions The upregulation of TSP-2 mediated by increased oxidative stress contributes to angiogenesis dysfunction in diabetic BMACs. C1 [Wang, Jie-Mei; Wang, Qingde; Yuan, Hong; Chen, Alex F.] Cent S Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Dept Cardiol, Changsha 410013, Hunan, Peoples R China. [Wang, Jie-Mei; Wang, Qingde; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Wang, Jie-Mei; Wang, Qingde; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bae, Ok-Nam; Baek, Seung-Hoon] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA. [Bae, Ok-Nam] Hanyang Univ, Coll Pharm, Ansan, South Korea. [Baek, Seung-Hoon] Ajou Univ, Coll Pharm, Suwon 441749, Gyeonggido, South Korea. RP Chen, AF (reprint author), Cent S Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Dept Cardiol, 138 Tong Zi Bo Rd, Changsha 410013, Hunan, Peoples R China. EM afychen@yahoo.com RI WANG, JIEMEI/G-9805-2017 OI WANG, JIEMEI/0000-0002-8723-4410 FU National Institutes of Health (NIH)/National Institute of General Medical Sciences [R01 GM077352]; United States Department of Veterans Affairs Rehabilitation Research & Development Merit Awards [I01RX000244, 1I01RX000652]; American Diabetes Association [7-11-BS-23]; National Science Foundation of China Key Research Project [81130004]; NIH [1R21CA158650]; Korea Research Foundation [2012R1A1A3013240]; American Heart Association [0920110G]; China Oversea Scholarship [20070320] FX This work was supported in part by National Institutes of Health (NIH)/National Institute of General Medical Sciences R01 GM077352 (to A.F. Chen), United States Department of Veterans Affairs Rehabilitation Research & Development Merit Awards I01RX000244 and 1I01RX000652 (to Dr Chen), American Diabetes Association Research Award 7-11-BS-23 (to Dr Chen), the National Science Foundation of China Key Research Project 81130004 (to Dr Chen) and NIH 1R21CA158650 (to Q. Wang). Dr Bae is the receipt of a research fund from the Korea Research Foundation (2012R1A1A3013240). J.-M. Wang the receipt of the American Heart Association Postdoctoral Fellowship 0920110G and the China Oversea Scholarship 20070320. NR 40 TC 13 Z9 14 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD AUG PY 2013 VL 33 IS 8 BP 1920 EP 1927 DI 10.1161/ATVBAHA.113.301609 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 188IW UT WOS:000322187600028 PM 23723366 ER PT J AU Joo, MJ Sharp, LK Au, DH Lee, TA Fitzgibbon, ML AF Joo, Min J. Sharp, Lisa K. Au, David H. Lee, Todd A. Fitzgibbon, Marian L. TI Use of Spirometry in the Diagnosis of COPD: A Qualitative Study in Primary Care SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE chronic disease; diagnosis; pulmonary diseases; qualitative research ID OBSTRUCTIVE PULMONARY-DISEASE; GENERAL-PRACTICE; OFFICE SPIROMETRY; CONTROLLED-TRIAL; MANAGEMENT; ASTHMA; ACCURACY; HISTORY; RISK AB Guidelines that recommend spirometry to confirm airflow obstruction among patients with suspected COPD are not routinely followed. We conducted a qualitative study to identify attitudes and barriers of primary care physicians to performing spirometry for patients with possible COPD. We conducted four focus groups, each with three primary care physicians (PCPs) who practice in an urban, academic medical center. In general, PCPs believed that spirometry was not necessary to confirm the diagnosis of COPD. Compared to other co-morbid conditions, in a patient with a diagnosis of COPD without self-reported symptoms, COPD was not a priority during a clinic visit. This was in part due to the belief that there was lack of evidence that medication used in COPD lead to improved outcomes and that there was no point of care measure for COPD compared to other co-morbid conditions such as diabetes mellitus or hypertension. Health system barriers specific to spirometry use was not identified. In conclusion, in our sample of PCPs, there was skepticism that spirometry is warranted to diagnose and manage COPD. Availability of spirometry was not a perceived barrier. Our results explain, in part, why previous interventions to improve access to spirometry and diagnosis of COPD in primary care settings have been difficult to conduct and/or have had marginal success. Our findings strongly suggest that a first step toward increasing the use of spirometry among primary care physicians is to have them believe in its utility in the diagnosis of COPD. C1 [Joo, Min J.] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL 60612 USA. [Joo, Min J.; Sharp, Lisa K.; Fitzgibbon, Marian L.] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Sect Hlth Promot Res, Chicago, IL 60612 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Lee, Todd A.] Univ Illinois Hosp & Hlth Sci Syst, Dept Pharm Practice, Ctr Pharmacoecon Res, Chicago, IL 60612 USA. RP Joo, MJ (reprint author), Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Sect Pulm Crit Care Sleep & Allergy, 840 S Wood St,M-C 719, Chicago, IL 60612 USA. EM joo@uic.edu FU Bosch Inc.; Gilead Sciences; NHLBI [K23HL094461]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [UL1RR029879]; Department of Veterans Affairs FX Min Joo has no conflicts of interest to disclose. Lisa Sharp has no conflicts of interest to disclose. David Au has received funding as a research consultant for Bosch Inc. and research funding from Gilead Sciences in the past three years. Todd Lee has no conflicts of interest to disclose. Marian Fitzgibbon has no conflicts of interest to disclose.; The project described was supported by Award Number K23HL094461 from the NHLBI and also supported, in part, by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1RR029879. Dr. Au was supported by the Department of Veterans Affairs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute, the National Institutes of Health or the Department of Veterans Affairs. NR 23 TC 8 Z9 8 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD AUG PY 2013 VL 10 IS 4 BP 444 EP 449 DI 10.3109/15412555.2013.766683 PG 6 WC Respiratory System SC Respiratory System GA 186TX UT WOS:000322069500007 PM 23537230 ER PT J AU Sonnenberg, A Boardman, CR AF Sonnenberg, Amnon Boardman, Charles R. TI How to review SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD AUG PY 2013 VL 78 IS 2 BP 343 EP 345 DI 10.1016/j.gie.2013.01.031 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 183OC UT WOS:000321825200020 PM 23867375 ER PT J AU Larson, ER Feldman, MD Valvano, JW Pearce, JA AF Larson, Erik R. Feldman, Marc D. Valvano, Jonathan W. Pearce, John A. TI Analysis of the Spatial Sensitivity of Conductance/Admittance Catheter Ventricular Volume Estimation SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Conductivity; conductance catheter; permittivity; sensitivity; tetrapolar ID PARALLEL CONDUCTANCE; DIELECTRIC-PROPERTIES; SYSTEM AB Conductance catheters are known to have a nonuniform spatial sensitivity due to the distribution of the electric field. The Geselowitz relation is applied to murine and multisegment conductance catheters using finite element models to determine the spatial sensitivity in a uniform medium and simplified left ventricle models. A new formulation is proposed that allows determination of the spatial sensitivity to admittance. Analysis of FEM numerical modeling results using the Geselowitz relation provides a true measure of parallel conductance in simplified left ventricle models for assessment of the admittance method and hypertonic saline techniques. The spatial sensitivity of blood conductance (G(b)) is determined throughout the cardiac cycle. G(b) is converted to volume using Wei's equation to determine if the presence of myocardium alters the nonlinear relationship through changes to the electric field. Results show that muscle conductance (G(m)) from the admittance method matches results from the Geselowitz relation and that the relationship between G(b) and volume is accurately fit using Wei's equation. Single-segment admittance measurements in large animals result in a more evenly distributed sensitivity to the LV blood pool. The hypertonic saline method overestimates parallel conductance throughout the cardiac cycle in both murine and multisegment conductance catheters. C1 [Larson, Erik R.; Valvano, Jonathan W.; Pearce, John A.] Univ Texas Austin, Dept Elect & Comp Engn, Austin, TX 78712 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Larson, ER (reprint author), Windmill Cardiovasc Syst, Austin, TX 78752 USA. EM Larson@ece.utexas.edu; feldmanm@uthscsa.edu; valvano@mail.utexas.edu; jpearce@mail.utexas.edu FU TLL Temple Foundation; South Texas Veterans Health Care System, San Antonio, TX, USA; Scisense Systems Inc., London, ON, Canada; Admittance Technologies, Inc. FX This work was supported in part by the TLL Temple Foundation, in part by the South Texas Veterans Health Care System, San Antonio, TX, USA, and in part by Scisense Systems Inc., London, ON, Canada. The work of Dr. M. D. Feldman, Dr. J. W. Valvano, and Dr. J. A. Pearce was supported by Admittance Technologies, Inc. Asterisk indicates corresponding author. NR 17 TC 0 Z9 0 U1 1 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD AUG PY 2013 VL 60 IS 8 BP 2316 EP 2324 DI 10.1109/TBME.2013.2256134 PG 9 WC Engineering, Biomedical SC Engineering GA 186ER UT WOS:000322025300029 PM 23559022 ER PT J AU Rigg, KK Murphy, JW AF Rigg, Khary K. Murphy, John W. TI Storylines as a Neglected Tool for Mental Health Service Providers and Researchers SO INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION LA English DT Article DE Mental health practice and research; Etiology; Storylines; Community-based approach; Risk and protective factors ID PARTICIPATORY RESEARCH; SOCIAL-INDICATORS; RISK-FACTORS; MODEL; DEPRESSION; RELEVANCE; ILLNESS AB Mental health service providers and researchers usually explain psychological/behavioral problems in terms of risk and protective factors. Although such an approach may seem empirical, and thus accurate, the manner in which patients interpret these factors is often overlooked. The result is that practitioners and researchers draw conclusions and make possible causal attributions that do not take into account the perspective of those who are studied or in care. Storylines, however, are a promising strategy to understanding mental health problems that is sensitive to the experiences and situations of people, and can bring into view more relevant details of patients' lives. This paper provides a theoretically grounded justification for the use of storylines in both mental health practice and research. Storylines are defined, while suggestions are provided for how this framework might be put into practice. A discussion is offered on how storylines might improve the design and implementation of health interventions by requiring these services to become more attuned to the lived experience of patients and the meanings they attach to common risk factors. C1 [Rigg, Khary K.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Rigg, Khary K.] Univ Penn, Penn Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Murphy, John W.] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA. RP Rigg, KK (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 4100 Chester Ave,Suite 202, Philadelphia, PA USA. EM kharyrigg@gmail.com FU Veterans Affairs Advanced Fellowship Program in Health Services Research Development FX Manuscript preparation was supported, in part, by funding received through the Veterans Affairs Advanced Fellowship Program in Health Services Research & Development. NR 49 TC 4 Z9 4 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1874 J9 INT J MENT HEALTH AD JI Int. J. Mental Health Addict. PD AUG PY 2013 VL 11 IS 4 BP 431 EP 440 DI 10.1007/s11469-012-9426-x PG 10 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 189DJ UT WOS:000322247000003 ER PT J AU Basile, JN Bloch, MJ AF Basile, Jan N. Bloch, Michael J. TI Analysis of Recent Papers in Hypertension Initial Combination Therapy Provides More Prompt Blood Pressure Control and Reduces Cardiovascular Events But Remains Underutilized SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID RISK C1 [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med Geriatr, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Vasc Div, Renown Inst Heart & Vasc Hlth, Reno, NV 89557 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA. RP Bloch, MJ (reprint author), Univ Hlth Syst, 1500 East 2nd St,Suite 302, Reno, NV 89502 USA. EM michael@bluesprucemed.com NR 7 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD AUG PY 2013 VL 15 IS 8 BP 523 EP 525 DI 10.1111/jch.12124 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 188JG UT WOS:000322188700001 PM 23889711 ER PT J AU Sands-Lincoln, M Grandner, M Whinnery, J Keenan, BT Jackson, N Gurubhagavatula, I AF Sands-Lincoln, Megan Grandner, Michael Whinnery, Julia Keenan, Brendan T. Jackson, Nick Gurubhagavatula, Indira TI The Association Between Obstructive Sleep Apnea and Hypertension by Race/Ethnicity in a Nationally Representative Sample SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID POSITIVE AIRWAY PRESSURE; RISK-FACTOR; BLOOD-PRESSURE; HEART HEALTH; CARDIOVASCULAR-DISEASE; CLINICAL PRESENTATION; ADULTS; MEN; POPULATION; PREVALENCE AB The association between obstructive sleep apnea (OSA) and hypertension by race/ethnicity has not been well characterized in a national sample. Adult participants in the 2007-2008 National Health and Nutrition Examination Survey were reviewed by self-report of sleep apnea diagnosis, snorting, gasping or stopping breathing during sleep, and snoring to derive whether OSA was probable (pOSA). Multivariable logistic regression determined whether pOSA predicted hypertension in the overall cohort, and by body mass index (BMI) group and ethno-racial strata. pOSA predicted hypertension in several groups: (1) Within BMI strata, there was a significant association among overweight individuals [odds ratio [OR], 1.82; 95% confidence interval [CI], 1.26-2.62); (2) In race/ethnicity subgroups, the association was significant among Hispanic/Latinos (OR, 1.69; 95% CI, 1.13-2.53) and whites (OR, 1.40; 95% CI, 1.07-1.84); (3) In models stratified by both race/ethnicity and BMI, pOSA predicted hypertension among overweight black/African Americans (OR, 4.74; 95% CI, 1.86-12.03), overweight whites (OR, 1.65; 95% CI, 1.06-2.57), and obese Hispanic/Latino participants (OR, 2.01; 95% CI, 1.16-3.49). A simple, self-report tool for OSA was strongly associated with hypertension, and may serve as a potential future opportunity for OSA diagnosis. (C)2013 Wiley Periodicals, Inc. C1 [Sands-Lincoln, Megan; Grandner, Michael; Keenan, Brendan T.; Gurubhagavatula, Indira] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Sands-Lincoln, Megan] Elsevier, Ctr Evidence Based Med, Philadelphia, PA USA. [Whinnery, Julia] Einstein Med Ctr, Div Cardiol, Philadelphia, PA USA. [Jackson, Nick] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care Sleep Sect, Philadelphia, PA USA. RP Sands-Lincoln, M (reprint author), Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM megsands@mail.med.upenn.edu FU NIH [T32HL07713-19]; American Heart Association [12SDG9180007]; National Heart, Lung, and Blood Institute [K23HL110216]; National Institute for Environmental Health Sciences [R21ES022931]; Institute for Translational Medicine and Therapeutics; Penn CTSA [UL1RR024134]; [RO1-OH009149] FX The authors report no specific funding in relation to this research and no conflicts of interest to disclose. With regards to grant funding, Dr Sands-Lincoln is supported by NIH grant T32HL07713-19; Dr Grandner was supported by the American Heart Association (12SDG9180007), the National Heart, Lung, and Blood Institute (K23HL110216), the National Institute for Environmental Health Sciences (R21ES022931), and a fellowship from the Institute for Translational Medicine and Therapeutics, funded by UL1RR024134 (Penn CTSA); and Dr Gurubhagavatula is funded by RO1-OH009149. NR 40 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD AUG PY 2013 VL 15 IS 8 BP 593 EP 599 DI 10.1111/jch.12144 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 188JG UT WOS:000322188700013 PM 23889723 ER PT J AU Li, C Shu, ZJ Lee, S Gupta, MB Jansson, T Nathanielsz, PW Kamat, A AF Li, Cun Shu, Zhen-Ju Lee, Shuko Gupta, Madhulika B. Jansson, Thomas Nathanielsz, Peter W. Kamat, Amrita TI Effects of maternal nutrient restriction, intrauterine growth restriction, and glucocorticoid exposure on phosphoenolpyruvate carboxykinase-1 expression in fetal baboon hepatocytes in vitro SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE dexamethasone; diabetes non-human primate; liver ID GENE-EXPRESSION; DEVELOPMENTAL ORIGINS; EXPERIMENTAL-MODELS; METABOLIC SYNDROME; PAPIO-HAMADRYAS; SMALL-INTESTINE; BLOOD-PRESSURE; LATE-GESTATION; RHESUS FETUS; LINKAGE MAP AB Background The objective of this study was to develop a cell culture system for fetal baboon hepatocytes and to test the hypotheses that (i) expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase-1 (PEPCK-1) is upregulated in hepatocytes isolated from fetuses of nutrient-restricted mothers (MNR) compared with ad libitum-fed controls (CTR), and (ii) glucocorticoids stimulate PEPCK-1 expression. Methods Hepatocytes from 0.9G CTR and MNR fetuses were isolated and cultured. PEPCK-1 protein and mRNA levels in hepatocytes were determined by Western blot and quantitative PCR, respectively. Results Fetuses of MNR mothers were intrauterine growth restricted (IUGR). Feasibility of culturing 0.9G fetal baboon hepatocytes was demonstrated. PEPCK-1 protein levels were increased in hepatocytes isolated from IUGR fetuses, and PEPCK-1 mRNA expression was stimulated by glucocorticoids in fetal hepatocytes. Conclusions Cultured fetal baboon hepatocytes that retain their in vivo phenotype provide powerful in vitro tools to investigate mechanisms that regulate normal and programmed hepatic function. C1 [Li, Cun; Jansson, Thomas; Nathanielsz, Peter W.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA. [Li, Cun; Jansson, Thomas; Nathanielsz, Peter W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA. [Shu, Zhen-Ju; Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Shu, Zhen-Ju; Kamat, Amrita] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA. [Lee, Shuko; Kamat, Amrita] South Texas Vet Hlth Care Syst, Res Serv, Audie L Murphy Div, San Antonio, TX USA. [Gupta, Madhulika B.] Univ Western Ontario, Dept Pediat, London, ON N6A 3K7, Canada. [Gupta, Madhulika B.] Univ Western Ontario, Dept Biochem, London, ON, Canada. RP Kamat, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA. EM kamat@uthscsa.edu OI Nathanielsz, Peter/0000-0001-8410-6280 FU NIH [HD 21350]; American Heart Association; Kronos Longevity Research Institute; CTSA [UL1RR025767] FX We would like to acknowledge grant support from NIH grant HD 21350 (PWN), Grant-in-Aid American Heart Association Award (AK), Kronos Longevity Research Institute grant (AK) and CTSA grant UL1RR025767 (AK). NR 59 TC 6 Z9 7 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2013 VL 42 IS 4 BP 211 EP 219 DI 10.1111/jmp.12048 PG 9 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 190VI UT WOS:000322369600006 PM 23600855 ER PT J AU Pierre, JF Heneghan, AF Meudt, JM Shea, MP Krueger, CG Reed, JD Kudsk, KA Shanmuganayagam, D AF Pierre, Joseph F. Heneghan, Aaron F. Meudt, Jennifer M. Shea, Michael P. Krueger, Christian G. Reed, Jess D. Kudsk, Kenneth A. Shanmuganayagam, Dhanansayan TI Parenteral nutrition increases susceptibility of ileum to invasion by E coli SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Parenteral nutrition; Enteroinvasion; Extra-intestinal pathogens; Escherichia coli; Secretory phospholipase A2; Paneth cells; Ex vivo; Polarized in vitro organ culture ID INDUCED BACTERIAL TRANSLOCATION; HUMAN INTESTINAL-MUCOSA; GUT-DERIVED SEPSIS; PHOSPHOLIPASE A(2); PSEUDOMONAS-AERUGINOSA; SEPTIC COMPLICATIONS; SURGICAL-PATIENTS; LYMPHOID-TISSUE; PANETH CELL; DEFENSINS AB Background: Parenteral nutrition (PN), with the lack of enteral feeding, compromises mucosal immune function and increases the risk of infections. We developed an ex vivo intestinal segment culture (EVISC) model to study the ex vivo effects of PN on susceptibility of the ileum to invasion by extra-intestinal pathogenic Escherichia coli (ExPEC) and on ileal secretion of antimicrobial secretory phospholipase A(2) (sPLA(2)) in response to the pathogen. Materials and methods: Study 1: Using mouse (n = 7) ileal tissue, we examined the effects of ileal region (proximal versus distal) and varying ExPEC inoculum concentrations on ex vivo susceptibility to ExPEC invasion and sPLA(2) secretion. Study 2: Ten mice were randomized to oral chow or intravenous PN feeding for 5 d (n = 5/group). Using the EVISC model, we compared the susceptibility of ileal tissue to invasion by ExPEC and sPLA(2) secretion in response to the pathogen. Results: Study 1: The proximal ileum was more susceptible to invasion (P < 0.0001) and secreted lower amounts of sPLA(2) (P = 0.0002) than the distal ileum. Study 2: Ileal tissue from PN-fed animals was more susceptible (approximately 4-fold, P = 0.018) to invasion than those from chow-fed animals. Ileal tissue from PN-fed animals secreted less sPLA(2) (P < 0.02) than those from chow-fed animals. Conclusions: The data illustrate EVISC as a reproducible model for studying host-pathogen interactions and the effects of diet on susceptibility to infections. Specifically, the findings support our hypothesis that PN with the lack of enteral feeding decreases mucosal responsiveness to pathogen exposure and provides a plausible mechanism by which PN is associated with increased risk of infectious complication. (c) 2013 Elsevier Inc. All rights reserved. C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Res Serv, Madison, WI USA. [Pierre, Joseph F.; Meudt, Jennifer M.; Shea, Michael P.; Krueger, Christian G.; Reed, Jess D.; Shanmuganayagam, Dhanansayan] Univ Wisconsin, Reed Res Grp, Dept Anim Sci, Madison, WI 53706 USA. [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. RP Shanmuganayagam, D (reprint author), Univ Wisconsin, Reed Res Grp, 1675 Observ Dr,Rm 1146, Madison, WI 53706 USA. EM dshanmug@wisc.edu FU Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX001672]; National Institute of Health (NIH) Grant [R01 GM53439]; Reed Research Group Multi-donor Fund FX We would like to thank Kristin M. Kohlmann for her technical assistance with bacterial culturing and preparations, and Joseph A. Heintz for his technical assistance with electron microscopy. We would also like to thank Dr. Walter J. Hopkins (Department of Urology, University of Wisconsin School of Medicine and Public Health) for providing the ExPEC Strain-5011 that was used in our studies. This project was supported by Award Number I01BX001672 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development.; This research was also supported by National Institute of Health (NIH) Grant R01 GM53439 and the Reed Research Group Multi-donor Fund. The contents of this article do not represent the views of the Veterans Affairs or the United States Government. NR 39 TC 10 Z9 10 U1 2 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD AUG PY 2013 VL 183 IS 2 BP 583 EP 591 DI 10.1016/j.jss.2013.01.054 PG 9 WC Surgery SC Surgery GA 182JH UT WOS:000321737300020 PM 23481564 ER PT J AU Paulson, EC Fu, XY Epstein, AJ AF Paulson, Emily Carter Fu, Xiaoying Epstein, Andrew J. TI Location and timing of care for colon cancer patients in the VA Health System SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Colonic neoplasms; Coordination of care; Veteran's Health Administration; Cancer treatment ID ADJUVANT CHEMOTHERAPY; VETERANS-AFFAIRS; BREAST-CANCER; SURVIVAL; SURGERY; QUALITY; DELAY; TIME AB Background: We sought to identify colon cancer patients within the Veterans Affairs (VA) system who experienced lengthy wait times for surgery or chemotherapy. We looked specifically at the relationship between location of treatment and timing of care. Methods: We performed a retrospective cohort study of 4635 patients diagnosed with colon cancer in the VA Health System during 2002-2010 and treated with surgery followed by chemotherapy. We used VA administrative databases, including the VA Outpatient Clinic, Patient Treatment, and Fee Basis inpatient and outpatient files. Time from diagnosis to surgery and time from surgery to initiation of chemotherapy were the primary outcome measures. Results: Patients who required referral to a hospital different from their home VA facility for surgery experienced delays in surgical intervention compared with patients treated at their home VA medical center. For patients referred outside of the VA system, this delay was almost 2 wk (13.5 d, P < 0.001). When these patients then went to another hospital for chemotherapy, they experienced further delays in care. Patients treated surgically outside the VA system who returned to the VA system for chemotherapy were more likely to initiate chemo >8 wk following surgery (OR 1.69, P = 0.01). The average adjusted time from surgery to chemotherapy for these patients compared with those treated wholly within the VA system was 11.4 d (P = 0.003). Conclusions: VA patients who require treatment at multiple hospitals for colon cancer, especially those who require surgery outside of the VA system, are more likely to experience delays in care compared with patients treated at a single hospital. Published by Elsevier Inc. C1 [Paulson, Emily Carter; Fu, Xiaoying; Epstein, Andrew J.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Paulson, Emily Carter] Univ Penn, Dept Surg, Div Colon & Rectal Surg Philadelphia, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Paulson, EC (reprint author), Univ Penn, Vet Affairs Med Ctr, Dept Surg Educ, 3900 Woodland Ave PVAMC,5th Floor, Philadelphia, PA 19104 USA. EM ecp6z@yahoo.com FU Center for Health Equity Research and Promotion (CHERP), VA Pittsburgh Healthcare System/Philadelphia VA Medical Center, VISN4 VA Healthcare Network FX This research was funded by a pilot grant from the Center for Health Equity Research and Promotion (CHERP), VA Pittsburgh Healthcare System/Philadelphia VA Medical Center, VISN4 VA Healthcare Network. NR 20 TC 3 Z9 3 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD AUG PY 2013 VL 183 IS 2 BP 639 EP 644 DI 10.1016/j.jss.2013.02.049 PG 6 WC Surgery SC Surgery GA 182JH UT WOS:000321737300027 PM 23522460 ER PT J AU Shlipak, MG Day, EC AF Shlipak, Michael G. Day, Erica C. TI Biomarkers for incident CKD: a new framework for interpreting the literature SO NATURE REVIEWS NEPHROLOGY LA English DT Review ID CHRONIC KIDNEY-DISEASE; ATHEROSCLEROSIS MESA; PREDICTION MODELS; TREFOIL FACTOR-3; FUNCTION DECLINE; URINARY LEVELS; RISK; APOL1; NEPHROPATHY; VARIANTS AB Biomarkers are a useful tool for the investigation of chronic kidney disease (CKD), although the design, analytical tools and outcomes used in many biomarker studies are suboptimal. In part, this situation might reflect a lack of appreciation of the nature of different biomarkers. A particular biomarker could, for example, be implicated in the pathogenesis of CKD because it is a physiological risk factor for declining kidney function, an indicator of impaired kidney function, or a marker of ongoing injury within the kidney. Such risk factors enable us to understand the process of disease and to identify treatment targets. By contrast, risk markers enable us to distinguish persons who will or will not develop CKD, even though the markers themselves are not required to be modifiable by (or directly involved in) the disease process. Accurate prediction of CKD risk will probably require a combination of biomarkers of several types, however. This Review offers a conceptual framework for interpreting the results of studies evaluating biomarkers of declining kidney function and incident CKD. C1 [Shlipak, Michael G.; Day, Erica C.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Shlipak, MG (reprint author), San Francisco Vet Adm Med Ctr, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institutes of Health, Bethesda, MD, USA [5R01AG034853-04, 5R01AG027002-07, 5R01DK087961-02] FX The authors acknowledge research grant support (M. G. Shlipak as principal investigator) from the National Institutes of Health, Bethesda, MD, USA (5R01AG034853-04; 5R01AG027002-07; 5R01DK087961-02). NR 33 TC 7 Z9 7 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD AUG PY 2013 VL 9 IS 8 BP 478 EP 483 DI 10.1038/nrneph.2013.108 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 190EL UT WOS:000322321700009 PM 23752888 ER PT J AU Loftis, JM Huckans, M AF Loftis, Jennifer M. Huckans, Marilyn TI Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE Addiction; Drug discovery; Inflammation; Psychoneuroimmunology; Substance use disorders; Treatment strategies ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-DEPENDENT PATIENTS; PITUITARY-ADRENAL AXIS; TUMOR-NECROSIS-FACTOR; KILLER-CELL-ACTIVITY; HEPATITIS-C VIRUS; ETHANOL EXPOSURE; DRUG-ABUSE; METHAMPHETAMINE DEPENDENCE AB An estimated 76.4 million people worldwide meet criteria for alcohol use disorders, and 15.3 million meet criteria for drug use disorders. Given the high rates of addiction and the associated health, economic, and social costs, it is essential to develop a thorough understanding of the impact of substance abuse on mental and physical health outcomes and to identify new treatment approaches for substance use disorders (SUDs). Psychoneuroimmunology is a rapidly expanding, multidisciplinary area of research that may be of particular importance to addiction medicine, as its focus is on the dynamic and complex interactions among behavioral factors, the central nervous system, and the endocrine and immune systems (Ader, 2001). This review, therefore, focuses on: 1) the psychoneuroimmunologic effects of SUDs by substance type and use pattern, and 2) the current and future treatment strategies, including barriers that can impede successful recovery outcomes. Evidence-based psychosocial and pharmacotherapeutic treatments are reviewed. Psychological factors and central nervous system correlates that impact treatment adherence and response are discussed. Several novel therapeutic approaches that are currently under investigation are introduced; translational data from animal and human studies is presented, highlighting immunotherapy as a promising new direction for addiction medicine. Published by Elsevier Inc. C1 [Loftis, Jennifer M.; Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA. [Loftis, Jennifer M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM loftisj@ohsu.edu; Jennifer.loftis2@va.gov FU NIDA/NIH [DA018165] FX This work was in part supported by NIDA/NIH grant DA018165 to the Methamphetamine Abuse Research Center (MARC) in Portland, Oregon. This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center and Oregon Health 82 Sciences University. NR 158 TC 8 Z9 8 U1 0 U2 30 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD AUG PY 2013 VL 139 IS 2 BP 289 EP 300 DI 10.1016/j.pharmthera.2013.04.011 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 187DX UT WOS:000322098200009 PM 23631821 ER PT J AU Sonnenberg, A AF Sonnenberg, A. TI Review article: historic changes of Helicobacter pylori-associated diseases SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Review ID GASTROESOPHAGEAL-REFLUX DISEASE; PERFORATED PEPTIC-ULCER; COLORECTAL-CANCER; DUODENAL-ULCER; UNITED-STATES; TIME TRENDS; BIRTH-COHORT; HOSPITAL ADMISSIONS; GASTRIC-CANCER; ESOPHAGEAL ADENOCARCINOMA AB BackgroundThe long-term time trends of multiple gastrointestinal diseases are characterised by a striking rise and fall. These temporal changes provide important clues about disease aetiology. AimTo highlight the importance of Helicobacter pylori infection in shaping the temporal trends of many common gastrointestinal diseases. MethodsLiterature review of the time trends associated with common digestive diseases. ResultsThe general trends of gastric ulcer, duodenal ulcer, gastric cancer, colon cancer, rectum cancer have all been shaped by a similar underlying birth-cohort phenomenon. Mortality associated with these diagnoses increased in all generations born during the nineteenth century. It peaked among generations born shortly before the turn of the century and then decreased in all subsequent generations born throughout the twentieth century. These patterns can be observed in the incidence, hospitalisation and mortality data from many different countries. They reflect similar rising and falling trends of H. pylori infection in the general population. Diseases that are inversely associated with H. pylori, such as reflux disease, erosive oesophagitis, Barrett's oesophagus, and oesophageal adenocarcinoma, have seen a striking rise during the recent decline of H. pylori infection. ConclusionThe temporal variations of H. pylori infection have affected the occurrence of gastroenterology's most common disorders. C1 [Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 105 TC 18 Z9 18 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD AUG PY 2013 VL 38 IS 4 BP 329 EP 342 DI 10.1111/apt.12380 PG 14 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 182VU UT WOS:000321773700001 PM 23786250 ER PT J AU de Groot, NL van Haalen, HGM Spiegel, BMR Laine, L Lanas, A Focks, JJ Siersema, PD van Oijen, MGH AF de Groot, N. L. van Haalen, H. G. M. Spiegel, B. M. R. Laine, L. Lanas, A. Focks, J. Jaspers Siersema, P. D. van Oijen, M. G. H. TI Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance SO CARDIOVASCULAR DRUGS AND THERAPY LA English DT Article DE Cost-effectiveness; QALY; Aspirin; Proton pump inhibitor; Dyspepsia; Gastrointestinal bleeding; Compliance ID PROTON PUMP INHIBITORS; CORONARY-ARTERY-DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ST-SEGMENT ELEVATION; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIALS; ISCHEMIC-HEART-DISEASE; LONG-TERM ADHERENCE; ESOMEPRAZOLE 20 MG; ACETYLSALICYLIC-ACID AB Low-dose aspirin (ASA) increases the risk of upper gastrointestinal (GI) complications. Proton pump inhibitors (PPIs) reduce these upper GI side effects, yet patient compliance to PPIs is low. We determined the cost-effectiveness of gastroprotective strategies in low-dose ASA users considering ASA and PPI compliance. Using a Markov model we compared four strategies: no medication, ASA monotherapy, ASA+PPI co-therapy and a fixed combination of ASA and PPI for primary and secondary prevention of ACS. The risk of acute coronary syndrome (ACS), upper GI bleeding and dyspepsia was modeled as a function of compliance and the relative risk of developing these events while using medication. Costs, quality adjusted life years and number of ACS events were evaluated, applying a variable risk of upper GI bleeding. Probabilistic sensitivity analyses were performed. For our base case patients using ASA for primary prevention of ACS no medication was superior to ASA monotherapy. PPI co-therapy was cost-effective (incremental cost-effectiveness ratio [ICER] a,not sign10,314) compared to no medication. In secondary prevention, PPI co-therapy was cost-effective (ICER a,not sign563) while the fixed combination yielded an ICER < a,not sign20,000 only in a population with elevated risk for upper GI bleeding or moderate PPI compliance. PPI co-therapy had the highest probability to be cost-effective in all scenarios. PPI use lowered the overall number of ACS. Considering compliance, PPI co-therapy is likely to be cost-effective in patients taking low dose ASA for primary and secondary prevention of ACS, given low PPI prices. In secondary prevention, a fixed combination seems cost-effective in patients with elevated risk for upper GI bleeding or in those with moderate PPI compliance. Both strategies reduced the number of ACS compared to ASA monotherapy. C1 [de Groot, N. L.; van Haalen, H. G. M.; Siersema, P. D.; van Oijen, M. G. H.] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, NL-3508 GA Utrecht, Netherlands. [Spiegel, B. M. R.] Vet Affairs Greater Los Angeles Hlth Care Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. [Spiegel, B. M. R.; van Oijen, M. G. H.] Univ Calif Los Angeles, Vet Affairs Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [Laine, L.] Univ So Calif, Keck Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA. [Lanas, A.] Univ Zaragoza, Sch Med, Aragon Hlth Res Inst IIS Aragon, CIBERehd, Zaragoza, Spain. [Focks, J. Jaspers] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, NL-6525 ED Nijmegen, Netherlands. RP de Groot, NL (reprint author), Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, POB 85500 Internal Code F02-618, NL-3508 GA Utrecht, Netherlands. EM n.l.degroot-3@umcutrecht.nl FU AstraZeneca FX This study was sponsored by an unrestricted educational grant from AstraZeneca. NR 68 TC 6 Z9 6 U1 1 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-3206 J9 CARDIOVASC DRUG THER JI Cardiovasc. Drugs Ther. PD AUG PY 2013 VL 27 IS 4 BP 341 EP 357 DI 10.1007/s10557-013-6448-y PG 17 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 183AS UT WOS:000321786600010 PM 23417566 ER PT J AU Hauer, KE Soni, K Cornett, P Kohlwes, J Hollander, H Ranji, SR ten Cate, O Widera, E Calton, B O'Sullivan, PS AF Hauer, Karen E. Soni, Krishan Cornett, Patricia Kohlwes, Jeff Hollander, Harry Ranji, Sumant R. ten Cate, Olle Widera, Eric Calton, Brook O'Sullivan, Patricia S. TI Developing Entrustable Professional Activities as the Basis for Assessment of Competence in an Internal Medicine Residency: A Feasibility Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE clinical competence; assessment; education; medical; graduate medical education ID CARE; ENVIRONMENT; INPATIENT; EDUCATION AB Graduate medical education programs assess trainees' performance to determine readiness for unsupervised practice. Entrustable professional activities (EPAs) are a novel approach for assessing performance of core professional tasks. To describe a pilot and feasibility evaluation of two EPAs for competency-based assessment in internal medicine (IM) residency. Post-graduate year-1 interns (PGY-1s) and attendings at a large internal medicine (IM) residency program. Two Entrustable professional activities (EPA) assessments (Discharge, Family Meeting) were piloted. Twenty-eight out of 43 (65.1 %) PGY-1 s and 32/43 (74.4 %) attendings completed surveys about the Discharge EPA experience. Most who completed the EPA assessment (10/12, 83.8 %, PGY-1s; 9/11, 83.3 %, attendings) agreed it facilitated useful feedback discussions. For the Family Meeting EPA, 16/26 (61.5 %) PGY-1s completed surveys, and most who participated (9/12 PGY1s, 75 %) reported it improved attention to family meeting education, although only half recommended continuing the EPA assessment. From piloting two EPA assessments in a large IM residency, we recognized our reminder systems and time dedicated for completing EPA requirements as inadequate. Collaboration around patient safety and palliative care with relevant clinical services has enhanced implementation and buy-in. We will evaluate how well EPA-based assessment serves the intended purpose of capturing trainees' trustworthiness to conduct activities unsupervised. (C) Society of General Internal Medicine 2013 C1 [Hauer, Karen E.; Soni, Krishan; Hollander, Harry; Ranji, Sumant R.; ten Cate, Olle; Calton, Brook; O'Sullivan, Patricia S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Cornett, Patricia; Kohlwes, Jeff; Widera, Eric] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [ten Cate, Olle] Univ Utrecht, Dept Med, Utrecht, Netherlands. RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM Karen.hauer@ucsf.edu OI O'Sullivan, Patricia/0000-0002-8706-4095; ten Cate, Olle/0000-0002-6379-8780 FU American Board of Internal Medicine FX Dr. Hauer received support from the American Board of Internal Medicine. There was no additional funding specific to this project. NR 19 TC 17 Z9 17 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2013 VL 28 IS 8 BP 1110 EP 1114 DI 10.1007/s11606-013-2372-x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184DZ UT WOS:000321869000022 PM 23595926 ER PT J AU Jambunathan, K Watson, DS Najvar, LK Wiederhold, NP Kirkpatrick, WR Patterson, TF Askew, DS Kodukula, K Galande, AK AF Jambunathan, Kalyani Watson, Douglas S. Najvar, Laura K. Wiederhold, Nathan P. Kirkpatrick, William R. Patterson, Thomas F. Askew, David S. Kodukula, Krishna Galande, Amit K. TI Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis SO MEDICAL MYCOLOGY LA English DT Article DE fluorogenic probes; invasive aspergillosis; proteolytic enzymes; combinatorial library; broncheoalveolar lavage fluid ID NEUTROPENIC PATIENTS; FUNGAL-INFECTIONS; FUMIGATUS; ENZYME; GALACTOMANNAN; IDENTIFICATION; IMMUNOASSAY; MANAGEMENT; SUBSTRATE; PROTEASES AB Improved diagnostics are needed to detect invasive pulmonary aspergillosis, a life-threatening infection caused by the pathogenic fungus Aspergillus fumigatus. We are investigating secreted fungal proteases as novel biomarkers for the diagnosis of this disease. Although the A. fumigatus genome encodes a multitude of secreted proteases, few have been experimentally characterized. Here, we employed an unbiased combinatorial library of internally quenched fluorogenic probes to detect infection-associated proteolysis in the lungs of guinea pigs experimentally infected with A. fumigatus. Comparative protease activity profiling revealed a prolyl endopeptidase activity that is reproducibly induced during infection but is not observed in healthy animals. This proteolytic activity was found in four independent animal experiments involving two A. fumigatus isolates. We synthesized a small, focused fluorogenic probe library to define the substrate specificity of the prolyl endopeptidase substrate motif and to identify optimal Probe sequences. These efforts resulted in the identification of a panel of six individual substrate-based fluorescent probes capable of detecting infection in guinea pigs with high statistical significance (P < 0.005 in most cases). Receiver operating characteristic analyses demonstrated that this fluorogenic assay could detect A. fumigatus infection-associated proteolysis with comparable sensitivity and specificity as existing diagnostic procedures, suggesting that further optimization of the methodology may lead to improved diagnostics options for invasive pulmonary aspergillosis. C1 [Jambunathan, Kalyani; Watson, Douglas S.; Kodukula, Krishna; Galande, Amit K.] SRI Int, Biosci Div, Harrisonburg, VA 22802 USA. [Najvar, Laura K.; Wiederhold, Nathan P.; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Askew, David S.] Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. [Najvar, Laura K.; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX USA. RP Galande, AK (reprint author), SRI Int, Biosci Div, 140 Res Dr, Harrisonburg, VA 22802 USA. EM amit.galande@sri.com OI Wiederhold, Nathan/0000-0002-2225-5122 FU National Institute of Allergy and Infectious Diseases (NIAID) [R21AI08502, N01AI30041, HHSN2722010000381]; Commonwealth of Virginia FX The authors wish to acknowledge the encouragement and guidance of Dr Joe Perrone, Director of Diagnostics at SRI Biosciences, and Dr Walter Moos, Vice President of SRI Biosciences. This work was supported by grant R21AI08502 and contract N01AI30041 and HHSN2722010000381 from the National Institute of Allergy and Infectious Diseases (NIAID). SRI International's Center for Advanced Drug Research was established through funding support from the Commonwealth of Virginia. NR 43 TC 3 Z9 4 U1 0 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD AUG PY 2013 VL 51 IS 6 BP 592 EP 602 DI 10.3109/13693786.2012.761360 PG 11 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 183CG UT WOS:000321790600006 PM 23356446 ER PT J AU A-Gonzalez, N Guillen, JA Gallardo, G Diaz, M de la Rosa, JV Hernandez, IH Casanova-Acebes, M Lopez, F Tabraue, C Beceiro, S Hong, C Lara, PC Andujar, M Arai, S Miyazaki, T Li, SL Corbi, AL Tontonoz, P Hidalgo, A Castrillo, A AF A-Gonzalez, Noelia Guillen, Jose A. Gallardo, German Diaz, Mercedes de la Rosa, Juan V. Hernandez, Irene H. Casanova-Acebes, Maria Lopez, Felix Tabraue, Carlos Beceiro, Susana Hong, Cynthia Lara, Pedro C. Andujar, Miguel Arai, Satoko Miyazaki, Toru Li, Senlin Corbi, Angel L. Tontonoz, Peter Hidalgo, Andres Castrillo, Antonio TI The nuclear receptor LXR alpha controls the functional specialization of splenic macrophages SO NATURE IMMUNOLOGY LA English DT Article ID LIVER-X-RECEPTORS; DENDRITIC CELLS; MARGINAL-ZONE; IMMUNE-RESPONSE; GENE-EXPRESSION; MYELOID CELLS; B-CELLS; MONOCYTES; SPLEEN; INFLAMMATION AB Macrophages are professional phagocytic cells that orchestrate innate immune responses and have considerable phenotypic diversity at different anatomical locations. However, the mechanisms that control the heterogeneity of tissue macrophages are not well characterized. Here we found that the nuclear receptor LXR alpha was essential for the differentiation of macrophages in the marginal zone (MZ) of the spleen. LXR-deficient mice were defective in the generation of MZ and metallophilic macrophages, which resulted in abnormal responses to blood-borne antigens. Myeloid-specific expression of LXR alpha or adoptive transfer of wild-type monocytes restored the MZ microenvironment in LXR alpha-deficient mice. Our results demonstrate that signaling via LXR alpha in myeloid cells is crucial for the generation of splenic MZ macrophages and identify an unprecedented role for a nuclear receptor in the generation of specialized macrophage subsets. C1 [A-Gonzalez, Noelia; Guillen, Jose A.; Diaz, Mercedes; Hernandez, Irene H.; Beceiro, Susana; Castrillo, Antonio] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols Madrid, Madrid, Spain. [A-Gonzalez, Noelia; Guillen, Jose A.; Gallardo, German; Diaz, Mercedes; de la Rosa, Juan V.; Hernandez, Irene H.; Lopez, Felix; Tabraue, Carlos; Beceiro, Susana; Castrillo, Antonio] Univ Las Palmas Gran Canaria, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols Madrid, Unidad Asociada Biomed, Las Palmas Gran Canaria, Spain. [Casanova-Acebes, Maria; Hidalgo, Andres] Ctr Nacl Invest Cardiovasc, Dept Epidemiol Atherothrombosis & Imaging, Madrid, Spain. [Hong, Cynthia; Tontonoz, Peter] Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA. [Lara, Pedro C.] Hosp Univ Gran Canaria Dr Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Spain. [Andujar, Miguel] Hosp Univ Materno Infantil Las Palmas, Serv Patol, Las Palmas Gran Canaria, Spain. [Arai, Satoko; Miyazaki, Toru] Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Lab Mol Biomed Pathogenesis, Tokyo 113, Japan. [Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Li, Senlin] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Corbi, Angel L.] CSIC, Ctr Invest Biol, Madrid, Spain. RP Castrillo, A (reprint author), Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols Madrid, Madrid, Spain. EM acastrillo@iib.uam.es RI Tabraue, Carlos/D-7126-2015; Alonso Gonzalez , Noelia/H-4488-2015; Hidalgo, Andres/L-5643-2014; Corbi, Angel/B-7194-2011 OI Tabraue, Carlos/0000-0001-9920-8116; Alonso Gonzalez , Noelia/0000-0003-0533-5216; Hidalgo, Andres/0000-0001-5513-555X; Corbi, Angel/0000-0003-1980-5733 FU Spanish Ministry of Research and Innovation [SAF2008-00057]; Ministry of Economy and Competitiveness [SAF2011-29244, SAF2009-11037]; European Union [IRG246655]; Howard Hughes Medical Institute; US National Institutes of Health [HL-066088, HL-030568]; Subprograma Ramon y Cajal [RYC-2007-00697]; Formacion de Personal Investigador [BES-2010-032828, BES-2009-012191]; Universidad Las Palmas de Gran Canaria FX We thank D. Mangelsdorf (University of Texas Southwestern Medical Center) for LXR alpha- and LXR beta-sufficient wild-type (Nr1h3+/+ Nr1h2+/+) mice, LXR alpha-deficient (Nr1h3-/-) mice, LXR alpha-deficient (Nr1h2-/-) mice and LXR-deficient (Nr1h3-/-Nr1h2-/-) mice; the Institut Clinique de la Souris for Nr1h3fl/fl mice; D. Kioussis (Medical Research Council) and S. Gonzalez (Centro Nacional de Investigaciones Cardiovasculares) for Vav-Cre mice; S. Gordon and M. Stacey (University of Oxford) for antibody to F4/80 (anti-F4/80) and anti-CD169; G. Randolph (Washington University St. Louis) for discussions and anti-TREML4 from the R. Steinman laboratory (Rockefeller University); M. Kosco-Vilbois (NovImmune) for anti-FDC-M1 and anti-FDC-M2; J. Collins and T. Willson (GlaxoSmithKline) for the synthetic ligands of LXR (GW3965) and retinoid X receptor (LG268); N. Ruddle, C. Glass, N. Spann, A. Chawla, G. Lemke, D. Hume, L. Hedrick, A. Lazarus and L. Bosca for comments; and Servicio Microscopia Electronica (University of Las Palmas de Gran Canaria) for electron microscopy. Supported by the Spanish Ministry of Research and Innovation (SAF2008-00057 to A.C.), the Ministry of Economy and Competitiveness (SAF2011-29244 to A.C. and SAF2009-11037 to A.H.), Framework Programme 7 of the European Union (International Reintegration Grant IRG246655 to A. H.), the Howard Hughes Medical Institute (P.T.), the US National Institutes of Health (HL-066088 and HL-030568 to P.T.), Subprograma Ramon y Cajal (RYC-2007-00697 to A. H.), Formacion de Personal Investigador (BES-2010-032828 to M. C.-A. and BES-2009-012191 to I.H.H.) and Universidad Las Palmas de Gran Canaria (J.V.d.l.R.). NR 47 TC 32 Z9 34 U1 2 U2 20 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD AUG PY 2013 VL 14 IS 8 BP 831 EP + DI 10.1038/ni.2622 PG 11 WC Immunology SC Immunology GA 185ZN UT WOS:000322010600012 PM 23770640 ER PT J AU Pugh, TD Conklin, MW Evans, TD Polewski, MA Barbian, HJ Pass, R Anderson, BD Colman, RJ Eliceiri, KW Keely, PJ Weindruch, R Beasley, TM Anderson, RM AF Pugh, Thomas D. Conklin, Matthew W. Evans, Trent D. Polewski, Michael A. Barbian, Hannah J. Pass, Rachelle Anderson, Bradley D. Colman, Ricki J. Eliceiri, Kevin W. Keely, Patricia J. Weindruch, Richard Beasley, T. Mark Anderson, Rozalyn M. TI A shift in energy metabolism anticipates the onset of sarcopenia in rhesus monkeys SO AGING CELL LA English DT Article DE aging; metabolism; mitochondria; NAD; PGC-1; skeletal muscle; rhesus monkeys ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; SKELETAL-MUSCLE; FLUORESCENCE MICROSCOPY; CALORIE RESTRICTION; BODY-COMPOSITION; IN-VIVO; AGE; SIRT1; ADAPTATION; BIOLOGY AB Age-associated skeletal muscle mass loss curtails quality of life and may contribute to defects in metabolic homeostasis in older persons. The onset of sarcopenia occurs in middle age in rhesusmacaques although the trigger has yet to be identified. Here, we show that a shift in metabolism occurs in advance of the onset of sarcopenia in rhesus vastuslateralis. Multiphoton laser-scanning microscopy detects a shift in the kinetics of photon emission from autofluorescent metabolic cofactors NADH and FAD. Lifetime of both fluorophores is shortened at mid-age, and this is observed in both free and bound constituent pools. Levels of FAD and free NADH are increased and the NAD/NADH redox ratio is lower. Concomitant with this, expression of fiber-type myosin isoforms is altered resulting in a shift in fiber-type distribution, activity of cytochrome c oxidase involved in mitochondrial oxidative phosphorylation is significantly lower, and the subcellular organization of mitochondria in oxidative fibers is compromised. A regulatory switch involving the transcriptional coactivator PGC-1 directs metabolic fuel utilization and governs the expression of structural proteins. Age did not significantly impact total levels of PGC-1; however, its subcellular localization was disrupted, suggesting that PGC-1 activities may be compromised. Consistent with this, intracellular lipid storage is altered and there is shift to larger lipid droplet size that likely reflects a decline in lipid turnover or a loss in efficiency of lipid metabolism. We suggest that changes in energy metabolism contribute directly to skeletal muscle aging in rhesus monkeys. C1 [Pugh, Thomas D.; Evans, Trent D.; Polewski, Michael A.; Barbian, Hannah J.; Pass, Rachelle; Anderson, Bradley D.; Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Conklin, Matthew W.; Eliceiri, Kevin W.] Univ Wisconsin, Lab Opti& Computat Instrumen, Madison, WI 53706 USA. [Colman, Ricki J.; Anderson, Rozalyn M.] Univ Wisconsin, Natl Primate Res Ctr, Madison, WI 53715 USA. [Keely, Patricia J.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53706 USA. [Weindruch, Richard; Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. RP Anderson, RM (reprint author), VA Hosp, GRECC D5214,2500 Overlook Terrace, Madison, WI 53705 USA. EM rmanderson@medicine.wisc.edu OI Eliceiri, Kevin/0000-0001-8678-670X FU NIA [P01AG011915]; NIH [UL1RR025011, R01CA13659, R01AG037000]; Department of Medicine, School of Medicine and Public Health, UW Madison FX We would like to acknowledge Scott Baum and Susan McKiernan for assistance with sample procurement. We also thank staff at LOCI for assistance with imaging instrumentation. Funding for this study was provided by NIA grant P01AG011915, NIH UL1RR025011, NIH R01CA13659, NIH R01AG037000, and the Department of Medicine, School of Medicine and Public Health, UW Madison. The study was conducted with the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison WI. NR 48 TC 14 Z9 14 U1 3 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD AUG PY 2013 VL 12 IS 4 BP 672 EP 681 DI 10.1111/acel.12091 PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 182WP UT WOS:000321775800015 PM 23607901 ER PT J AU Clark, DJ Kautz, SA Bauer, AR Chen, YT Christou, EA AF Clark, David J. Kautz, Steven A. Bauer, Andrew R. Chen, Yen-Ting Christou, Evangelos A. TI Synchronous EMG Activity in the Piper Frequency Band Reveals the Corticospinal Demand of Walking Tasks SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE Walking; Electromyography; Motor control; Nervous system; Locomotion ID EVOKED MOTOR-RESPONSES; CORTICOMUSCULAR COHERENCE; HUMAN GAIT; DEPENDENT MODULATION; MUSCLE-ACTIVITY; SURFACE EMG; EEG-EMG; CORTEX; OSCILLATIONS; DRIVE AB Evidence indicates that the frequency-domain characteristics of surface electromyogram (EMG) signals are modulated according to the contributing sources of neural drive. Modulation of inter-muscular EMG synchrony within the Piper frequency band (30-60 Hz) during movement tasks has been linked to drive from the corticospinal tract. However, it is not known whether EMG synchrony is sufficiently sensitive to detect task-dependent differences in the corticospinal contribution to leg muscle activation during walking. We investigated this question in seventeen healthy older men and women. It was hypothesized that, relative to typical steady state walking, Piper band EMG synchrony of the triceps surae muscle group would be reduced for dual-task walking (because of competition for cortical resources), similar for fast walking (because walking speed is directed by an indirect locomotor pathway rather than by the corticospinal tract), and increased when taking a long step (because voluntary gait pattern modifications are directed by the corticospinal tract). Each of these hypotheses was confirmed. These findings support the use of frequency-domain analysis of EMG in future investigations into the corticospinal contribution to control of healthy and disordered human walking. C1 [Clark, David J.; Bauer, Andrew R.] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA. [Clark, David J.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL 32610 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Chen, Yen-Ting; Christou, Evangelos A.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA. RP Clark, DJ (reprint author), Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, 1601 SW Archer Rd 151A, Gainesville, FL 32608 USA. EM davidclark@ufl.edu OI Kautz, Steven/0000-0003-3151-8235 FU US Department of Veterans Affairs Rehabilitation Research and Development Service [B7176W]; National Institute on Aging [P30-AG028740-04, R01 AG-031769] FX This work was supported by the US Department of Veterans Affairs Rehabilitation Research and Development Service (B7176W to DJC) and by the National Institute on Aging (P30-AG028740-04 to DJC and R01 AG-031769 to EAC). NR 50 TC 6 Z9 7 U1 0 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-6964 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD AUG PY 2013 VL 41 IS 8 BP 1778 EP 1786 DI 10.1007/s10439-013-0832-4 PG 9 WC Engineering, Biomedical SC Engineering GA 179IT UT WOS:000321514300019 PM 23740367 ER PT J AU Martinez-Martin, P Rojo-Abuin, JM Dujardin, K Pontone, GM Weintraub, D Forjaz, MJ Starkstein, S Leentjens, AFG AF Martinez-Martin, P. Rojo-Abuin, J. M. Dujardin, K. Pontone, G. M. Weintraub, D. Forjaz, M. J. Starkstein, S. Leentjens, A. F. G. TI Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE anxiety; assessment; canonical correlation; Parkinson's disease; rating scales ID PSYCHOMETRIC PROPERTIES; HOSPITAL ANXIETY; DEPRESSION SCALE; RATING-SCALES; DISORDERS; INVENTORY; PREVALENCE; VALIDATION; MINI AB Background and purpose: The lack of appropriate measures has hindered the research on anxiety syndromes in Parkinson's disease (PD). The objective of the present cross-sectional, international study was to identify shared elements and grouping of components from anxiety scales as a basis for designing a new scale for use in PD. Methods: For this purpose, 342 consecutive PD patients were assessed by means of the Mini International Neuropsychiatric Inventory (depression and anxiety sections), the Clinical Global Impression of severity of the anxiety symptoms, the Hamilton Anxiety Rating Scale (HARS), the Neuropsychiatric Inventory (section E), the Beck Anxiety Inventory (BAI) and the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Results: As the HADS-A showed a weak correlation with the HARS and BAI, it was not considered for more analyses. HARS and BAI exploratory factor analysis identified nine factors (62% of the variance), with only two of them combining items from both scales. Therefore, a canonical correlation model (a method to identify relations between components of two groups of variables) was built and it showed four factors grouping items from both scales: the first factor corresponded to 'generalized anxiety'; the second factor included muscular, sensory and autonomic 'non-specific somatic symptoms'; the third factor was dominated by 'respiratory symptoms'; and the fourth factor included 'cardiovascular symptoms'. Conclusions: BAI is heavily focused on panic symptoms, whilst HARS is more focused towards generalized anxiety symptoms. The new scale should include additional components in order to assess both episodic and persistent anxiety as well as items for evaluation of avoidance behaviour. C1 [Martinez-Martin, P.; Forjaz, M. J.] Carlos III Inst Hlth, Consortium Biomed Res Neurodegenerat Dis CIBERNED, Madrid, Spain. [Rojo-Abuin, J. M.] Spanish Council Sci Res, Ctr Human & Social Sci, Dept Stat, Madrid, Spain. [Dujardin, K.] Univ Lille 2, EA 4559, Lab Neurosci Fonct & Pathol, Lille, France. [Pontone, G. M.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Weintraub, D.] Univ Penn, Pereleman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia VA Med Ctr, PADRECC, Philadelphia, PA USA. [Weintraub, D.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. [Forjaz, M. J.] Carlos III Inst Hlth, Natl Sch Publ Hlth, Madrid, Spain. [Forjaz, M. J.] Alzheimer Ctr Reina Sofia Fdn, Madrid 28031, Spain. [Starkstein, S.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia. [Starkstein, S.] Fremantle Hosp, Fremantle, WA, Australia. [Leentjens, A. F. G.] Maastricht Univ Med Ctr, Dept Psychiat, Maastricht, Netherlands. RP Martinez-Martin, P (reprint author), Alzheimer Ctr Reina Sofia Fdn, C Valderrebollo 5, Madrid 28031, Spain. EM pmartinez@fundacioncien.es OI Forjaz, Maria Joao/0000-0003-3935-962X FU Michael J. Fox Foundation for Parkinson Research FX This study was sponsored by a grant from the Michael J. Fox Foundation for Parkinson Research (MJFF; www.michaeljfox.org). NR 27 TC 9 Z9 9 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD AUG PY 2013 VL 20 IS 8 BP 1198 EP 1203 DI 10.1111/ene.12160 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 176UM UT WOS:000321331100018 PM 23581431 ER PT J AU Cheng, G Kwee, TC Basu, S Alavi, A AF Cheng, Gang Kwee, Thomas C. Basu, Sandip Alavi, Abass TI Critical considerations on the combined use of F-18-FDG and F-18-fluoride for PET assessment of metastatic bone disease SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Editorial Material ID POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; LUNG-CANCER; SKELETAL SCINTIGRAPHY; PROSTATE-CANCER; COMPLIMENTARY ROLE; CARCINOMA; MARROW; SCAN; MALIGNANCY C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Kwee, Thomas C.] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands. [Basu, Sandip] Bhabha Atom Res Ctr, Radiat Med Ctr, Tata Mem Hosp Annexe, Bombay 400012, Maharashtra, India. [Cheng, Gang; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA. RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, Div Nucl Med, 3400 Spruce St, Philadelphia, PA 19104 USA. EM abass.alavi@uphs.upenn.edu NR 43 TC 5 Z9 5 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD AUG PY 2013 VL 40 IS 8 BP 1141 EP 1145 DI 10.1007/s00259-013-2459-y PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 179LE UT WOS:000321521000002 PM 23695838 ER PT J AU Gorin, Y Block, K AF Gorin, Yves Block, Karen TI Nox4 and diabetic nephropathy: With a friend like this, who needs enemies? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE Diabetic complications; Diabetic nephropathy; Hyperglycemia; Oxidative stress; NADPH oxidases of the Nox family; Nox4; Reactive oxygen species; Glomerular cell injury; Tubulointerstitial cell injury; Free radicals ID SMOOTH-MUSCLE-CELLS; INDUCED OXIDATIVE STRESS; TUBULAR EPITHELIAL-CELLS; MESSENGER-RNA TRANSLATION; DINUCLEOTIDE PHOSPHATE OXIDASE; GLOMERULAR MESANGIAL CELLS; OXYGEN SPECIES PRODUCTION; KINASE-C-BETA; NADPH-OXIDASE; NAD(P)H OXIDASE AB Oxidative stress has been linked to the pathogenesis of diabetic nephropathy, a complication of diabetes in the kidney. NADPH oxidases of the Nox family are a major source of reactive oxygen species in the diabetic kidney and are critical mediators of redox signaling in glomerular and tubulointerstitial cells exposed to the diabetic milieu. Here, we present an overview of the current understanding of the roles of Nox catalytic and regulatory subunits in the processes that control mesangial cell, podocyte, and tubulointerstitial cell injury induced by hyperglycemia and other predominant factors enhanced in the diabetic milieu, including the renin-angiotensin system and transforming growth factor-beta. The role of the Nox isoform Nox4 in the redox processes that alter renal biology in diabetes is highlighted. (C) 2013 Elsevier Inc. All rights reserved. C1 [Gorin, Yves; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Block, Karen] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA. RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu; block@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Juvenile Diabetes Research Foundation Multiproject Grants; NIH [RO1 DK 079996, RO1 CA 131272]; Veterans Administration FX This work was supported by Juvenile Diabetes Research Foundation Multiproject Grants (Y.G. and K.B.), NIH RO1 DK 079996 (Y.G.), NIH RO1 CA 131272 (K.B.), and the Veterans Administration (K.B.). NR 190 TC 35 Z9 37 U1 1 U2 39 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD AUG PY 2013 VL 61 BP 130 EP 142 DI 10.1016/j.freeradbiomed.2013.03.014 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 168EA UT WOS:000320687300014 PM 23528476 ER PT J AU Werner, RM Konetzka, RT Polsky, D AF Werner, Rachel M. Konetzka, R. Tamara Polsky, Daniel TI The Effect of Pay-for-Performance in Nursing Homes: Evidence from State Medicaid Programs SO HEALTH SERVICES RESEARCH LA English DT Article DE Quality of care; pay-for-performance; nursing home quality; long-term care ID RESIDENT ASSESSMENT INSTRUMENT; RISK-ADJUSTMENT; HEALTH-CARE; QUALITY; IMPROVE; MDS AB Objective. Pay-for-performance (P4P) is commonly used to improve health care quality in the United States and is expected to be frequently implemented under the Affordable Care Act. However, evidence supporting its use is mixed with few large-scale, rigorous evaluations of P4P. This study tests the effect of P4P on quality of care in a large-scale setting-the implementation of P4P for nursing homes by state Medicaid agencies. Data Sources/Study Setting. 2001-2009 nursing home Minimum Data Set and Online Survey, Certification, and Reporting (OSCAR) datasets. Study Design. Between 2001 and 2009, eight state Medicaid agencies adopted P4P programs in nursing homes. We use a difference-in-differences approach to test for changes in nursing home quality under P4P, taking advantage of the variation in timing of implementation across these eight states and using nursing homes in the 42 non-P4P states plus Washington, DC as contemporaneous controls. Principal Findings. Quality improvement under P4P was inconsistent. While three clinical quality measures (the percent of residents being physically restrained, in moderate to severe pain, and developed pressure sores) improved with the implementation of P4P in states with P4P compared with states without P4P, other targeted quality measures either did not change or worsened. Of the two structural measures of quality that were tied to payment (total number of deficiencies and nurse staffing) deficiency rates worsened slightly under P4P while staffing levels did not change. Conclusions. Medicaid-based P4P in nursing homes did not result in consistent improvements in nursing home quality. Expectations for improvement in nursing home care under P4P should be tempered. C1 [Werner, Rachel M.] Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Polsky, Daniel] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu FU National Institute on Aging [R01 AG034182-01]; VA HSR&D Career Development Award FX This research was funded by a grant from the National Institute on Aging (R01 AG034182-01). Rachel Werner was supported in part by a VA HSR&D Career Development Award. The authors gratefully thank Chris Wirtalla for his outstanding programming and research assistance. NR 38 TC 13 Z9 13 U1 4 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2013 VL 48 IS 4 BP 1393 EP 1414 DI 10.1111/1475-6773.12035 PG 22 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 176IM UT WOS:000321297600010 PM 23398330 ER PT J AU Maciejewski, ML Bryson, CL Wang, V Perkins, M Liu, CF AF Maciejewski, Matthew L. Bryson, Chris L. Wang, Virginia Perkins, Mark Liu, Chuan-Fen TI Potential Bias in Medication Adherence Studies of Prevalent Users SO HEALTH SERVICES RESEARCH LA English DT Article DE Medication adherence; pharmaceutical policy; cost sharing; research design; veterans; inclusion criteria ID DRUG UTILIZATION; COPAYMENT INCREASE; RISK ADJUSTMENT; PERFORMANCE; IMPACT; EXPENDITURES; COMORBIDITY; VETERANS; HEALTH AB Purpose. We examined how the choice of historic medication use criteria for identifying prevalent users may bias estimated adherence changes associated with a medication copayment increase. Methods. From pharmacy claims data in a retrospective cohort study, we identified 6,383 prevalent users of oral diabetes medications from four VA Medical Centers. Patients were included in this prevalent cohort if they had one fill both 3 months prior and 4-12 months prior to the index date, defined as the month in which medication copayments increased. To determine whether these historic medication use criteria introduced bias in the estimated response to a $5 medication copayment increase, we compared adherence trends from cohorts defined from different medication use criteria and from different index dates of copayment change. In an attempt to validate the prior observation of an upward trend in adherence prior to the date of the policy change, we replicated time series analyses varying the index dates prior to and following the date of the policy change, hypothesizing that the trend line associated with the policy change would differ from the trend lines that were not. Results. Medication adherence trends differed when different medication use criteria were applied. Contrary to our expectations, similar adherence trends were observed when the same medication use criteria were applied at index dates when no copayment changes occurred. Conclusion. To avoid introducing bias due to study design in outcomes assessments of medication policy changes, historic medication use inclusion criteria must be chosen carefully when constructing cohorts of prevalent users. Furthermore, while pharmacy data have enormous potential for population research and monitoring, there may be inherent logical flaws that limit cohort identification solely through administrative pharmacy records. C1 [Maciejewski, Matthew L.; Wang, Virginia] Duke Univ, Dept Med, Div Gen Internal Med, Ctr Hlth Serv Res Primary Care,Durham VA Med Ctr, Durham, NC 27705 USA. [Bryson, Chris L.; Perkins, Mark; Liu, Chuan-Fen] Univ Washington, Dept Med, Div Gen Internal Med, VA Puget Sound Hlth Care Syst,Northwest Ctr Outco, Seattle, WA USA. RP Maciejewski, ML (reprint author), Duke Univ, Dept Med, Div Gen Internal Med, Ctr Hlth Serv Res Primary Care,Durham VA Med Ctr, Durham, NC 27705 USA. EM matthew.maciejewski@va.gov FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [IIR 03-200]; Department of Veterans Affairs [RCS 10-391]; Takeda Pharmaceuticals; Novartis; Surgical Review Corporation; Research Data and Assistance Center (ResDAC) at the University of Minnesota FX This work was supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number IIR 03-200. Dr. Maciejewski was also supported by a Research Career Scientist award from the Department of Veterans Affairs (RCS 10-391). The authors would like to acknowledge tremendously helpful comments and editorial suggestions from the editors, two reviewers, Hollis Weidenbacher and Jaclyn Lemon. Dr. Maciejewski has received consultation funds from Takeda Pharmaceuticals, Novartis, the Surgical Review Corporation, and the Research Data and Assistance Center (ResDAC) at the University of Minnesota, and owns stock in Amgen via his wife's employment at Amgen. The views expressed are those of the authors and do not reflect the views of the Department of Veterans Affairs and their affiliated institutions. NR 25 TC 4 Z9 4 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2013 VL 48 IS 4 BP 1468 EP 1486 DI 10.1111/1475-6773.12043 PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 176IM UT WOS:000321297600014 PM 23402554 ER PT J AU Trautner, BW Patterson, JE Petersen, NJ Hysong, S Horwitz, D Chen, GJ Grota, P Naik, AD AF Trautner, Barbara W. Patterson, Jan E. Petersen, Nancy J. Hysong, Sylvia Horwitz, Deborah Chen, G. John Grota, Patti Naik, Aanand D. TI Quality Gaps in Documenting Urinary Catheter Use and Infectious Outcomes SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID TRACT-INFECTION; CARE; PREVENTION; CONDOM AB OBJECTIVE. To describe the frequency of use of all types of urinary catheters, including but not limited to indwelling catheters, as well as positive cultures associated with the various types. We also determined the accuracy of catheter-days reporting at our institution. DESIGN. Prospective, observational trial based on patient-level review of the electronic medical record. Chart review was compared with standard methods of catheter surveillance and reporting by infection control personnel. SETTING. Ten internal medicine and 5 long-term care wards in 2 tertiary care Veterans Affairs hospitals in Texas from July 2010 through June 2011. PARTICIPANTS. The study included 7,866 inpatients. METHODS. Measurements included patient bed-days; days of use of indwelling, external, suprapubic, and intermittent urinary catheters; number of urine cultures obtained and culture results; and infection control reports of indwelling catheter-days. RESULTS. We observed 7,866 inpatients with 128,267 bed-days on acute medicine and extended care wards during the study. A urinary catheter was used on 36.9% of the total bed-days observed. Acute medicine wards collected more urine cultures per 1,000 bed-days than did the extended care wards (75.9 and 10.4 cultures per 1,000 bed-days, respectively; P < .0001). Catheter-days were divided among indwelling-catheter-days (47.8%), external-catheter-days (48.4%), and other (intermittent- and suprapubic-catheter-days, 3.8%). External catheters contributed to 376 (37.3%) of the 1,009 catheter-associated positive urine cultures. Urinary-catheter-days reported to the infection control department missed 20.1% of the actual days of indwelling catheter use, whereas 12.0% of their reported catheter-days were false. CONCLUSIONS. Urinary catheter use was extremely common. External catheters accounted for a large portion of catheter-associated bacteriuria, and standard practices for tracking urinary-catheter-days were unreliable. C1 [Trautner, Barbara W.; Petersen, Nancy J.; Hysong, Sylvia; Horwitz, Deborah; Chen, G. John; Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Houston Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA. [Trautner, Barbara W.; Petersen, Nancy J.; Hysong, Sylvia; Horwitz, Deborah; Chen, G. John; Naik, Aanand D.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Petersen, Nancy J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA. [Patterson, Jan E.; Grota, Patti] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Trautner, BW (reprint author), MEDVAMC HSR&D CoE 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM trautner@bcm.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207 FU VA Health Services Research and Development [IIR 09-104]; VA Rehabilitation Research and Development [B4623]; National Institute of Diabetes and Digestive and Kidney Diseases [DK092293]; VA Health Services Research and Development Houston Center of Excellence [HFP-090-20] FX This work was supported by the VA Health Services Research and Development (IIR 09-104); VA Rehabilitation Research and Development (B4623); and the National Institute of Diabetes and Digestive and Kidney Diseases (DK092293). This work was also partly supported by the VA Health Services Research and Development Houston Center of Excellence (HFP-090-20). B.W.T. had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of data analysis. NR 26 TC 5 Z9 5 U1 2 U2 12 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2013 VL 34 IS 8 BP 793 EP 799 DI 10.1086/671267 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 180RT UT WOS:000321613900005 PM 23838219 ER PT J AU Saunders, GH Frederick, MT Silverman, S Papesh, M AF Saunders, Gabrielle H. Frederick, Melissa Teahen Silverman, Shienpei Papesh, Melissa TI Application of the health belief model: Development of the hearing beliefs questionnaire (HBQ) and its associations with hearing health behaviors SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE Rehabilitation of hearing impaired; health behavior; health care seeking behavior; patient acceptance of health care; patient compliance; hearing aids ID HELP-SEEKING BEHAVIOR; OLDER-ADULTS; AID USE; PEOPLE; IMPAIRMENT; REHABILITATION; POPULATION; COMPLAINTS; COMMUNITY; ATTITUDES AB Objective : To develop a hearing beliefs questionnaire (HBQ) that assesses hearing beliefs within the constructs of the health belief model, and to investigate whether HBQ scores are associated with hearing health behaviors. Design: A 60-item version of the questionnaire was developed and completed by 223 participants who also provided information about their hearing health behaviors (help seeking, hearing-aid acquisition, and hearing-aid use). Study sample: Individuals aged between 22 and 90 years recruited from a primary care waiting area at a Veterans hospital. Seventy-six percent were male, 80% were Veterans. Results: A 26-item version of the HBQ with six scales was derived using factor analysis and reliability analyses. The scales measured: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, perceived self-efficacy, and cues to action. HBQ scores differed significantly between individuals with different hearing health behaviors. Logistic regression analyses resulted in robust models of hearing health behaviors that correctly classified between 59% and 100% of participant hearing health behaviors. Conclusions: The HBM appears to be an appropriate framework for examining hearing health behaviors, and the HBQ is a valuable tool for assessing hearing health beliefs and predicting hearing health behaviors. C1 [Saunders, Gabrielle H.; Frederick, Melissa Teahen; Silverman, Shienpei; Papesh, Melissa] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Saunders, GH (reprint author), Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM gabrielle.saunders@va.gov FU Unitron; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [C4844C] FX This material is based upon work supported by Unitron and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Grant # C4844C. Aspects of these data were presented at the International Hearing Aid Research Conference (IHCON), Lake Tahoe, USA, August 8-12, 2012, at the Academy of Rehabilitative Audiology Institute, Providence, USA, September 9-11, 2012, and at the British Academy of Audiology, Manchester, UK, November 12-13, 2012. NR 41 TC 18 Z9 20 U1 2 U2 20 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD AUG PY 2013 VL 52 IS 8 BP 558 EP 567 DI 10.3109/14992027.2013.791030 PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 181UJ UT WOS:000321693900006 PM 23682849 ER PT J AU Sewell, MC Luo, XD Neugroschl, J Sano, M AF Sewell, Margaret C. Luo, Xiaodong Neugroschl, Judith Sano, Mary TI Detection of mild cognitive impairment and early stage dementia with an audio-recorded cognitive scale SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE cognitive assessment; Alzheimer's disease; MCI; diagnostic accuracy ID ALZHEIMERS-DISEASE AB Background: Physicians often miss diagnosis of mild cognitive impairment (MCI) or early dementia and screening measures can be insensitive to very mild impairments. Other cognitive assessments may take too much time or be frustrating to seniors. This study examined the ability of an audio-recorded scale, developed in Australia, to detect MCI or mild Alzheimer's disease (AD) and compared cognitive domain-specific performance on the audio-recorded scale to in-person battery and common cognitive screens. Method: Seventy-six patients from the Mount Sinai Alzheimer's Disease Research Center were recruited. Patients were aged 75 years or older, with clinical diagnosis of AD or MCI (n = 51) or normal control (n = 25). Participants underwent in-person neuropsychological testing followed by testing with the audio-recorded cognitive screen (ARCS). Results: ARCS provided better discrimination between normal and impaired elderly individuals than either the Mini-Mental State Examination or the clock drawing test. The in-person battery and ARCS analogous variables were significantly correlated, most in the 0.4 to 0.7 range, including verbal memory, executive function/attention, naming, and verbal fluency. The area under the curve generated from the receiver operating characteristic curves indicated high and equivalent discrimination for ARCS and the in-person battery (0.972 vs. 0.988; p = 0.23). Conclusion: The ARCS demonstrated better discrimination between normal controls and those with mild deficits than typical screening measures. Performance on cognitive domains within the ARCS was well correlated with the in-person battery. Completion of the ARCS was accomplished despite mild difficulty hearing the instructions even in very elderly participants, indicating that it may be a useful measure in primary care settings. C1 [Sewell, Margaret C.; Luo, Xiaodong; Neugroschl, Judith; Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. RP Sewell, MC (reprint author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM margaret.sewell@mssm.edu FU National Institutes of Health [NIH U01 P50-AG005138-28] FX The authors would like to express their gratitude to Talia Sandwick, BA, for her work with subject recruitment and data collection. The authors are also grateful to the National Institutes of Health for their grant no. NIH U01 P50-AG005138-28. NR 19 TC 0 Z9 0 U1 0 U2 17 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD AUG PY 2013 VL 25 IS 8 SI SI BP 1325 EP 1333 DI 10.1017/S1041610213000598 PG 9 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 175WD UT WOS:000321263400013 PM 23635663 ER PT J AU Zhang, XY Chen, DC Xiu, MH Tan, YL Yang, FD Zhang, LY Zhang, LY Haile, CN Kosten, TR AF Zhang, Xiang Yang Chen, Da Chun Xiu, Mei Hong Tan, Yun Long Yang, Fu De Zhang, Laurence Y. Zhang, Laura Y. Haile, Colin N. Kosten, Thomas R. TI Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Schizophrenia; Cognition; Oxidative stress; MnSOD; Psychopathology ID NEVER-MEDICATED 1ST-EPISODE; OXIDATIVE STRESS; NEUROPSYCHOLOGICAL STATUS; ANTIOXIDANT ENZYMES; REPEATABLE BATTERY; GENDER-DIFFERENCES; FATTY-ACIDS; DEFICITS; PSYCHOSIS; BRAIN AB Several lines of evidence suggest that excessive reactive oxygen species-induced oxidative damage may underlie cognitive impairment in psychiatric disorders. A growing body of evidence show that oxidative damage may relate to the range of cognitive deficits associated with schizophrenia. In this study we examine one of the primary antioxidant defense enzymes manganese superoxide dismutase (MnSOD), and whether it relates to cognitive deficits in schizophrenia. We recruited 185 chronic male schizophrenia patients and 132 male controls and compared results from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and plasma MnSOD activity between groups. Symptom severity in patients with schizophrenia was assessed with the Positive and Negative Syndrome Scale (PANSS). Our results showed that MnSOD activities were significantly lower in patients than controls (p < 0.05). Cognitive scores on the RBANS and, nearly all of its five subscales (all p < 0.001) except for the Visuospatial/Constructional index were significantly lower in schizophrenia patients than normal controls. MnSOD was negatively correlated with the general psychopathology subscale of PANSS, PANSS total score, positive symptoms and RBANS total score in patients with schizophrenia. Our findings add to growing evidence that oxidative stress may be involved in the psychopathology of male schizophrenia, and its associated cognitive impairment (C) 2013 Elsevier Ltd. All rights reserved. C1 [Zhang, Xiang Yang; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Baylor Coll Med, Houston, TX USA. [Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Tan, Yun Long; Yang, Fu De; Haile, Colin N.; Kosten, Thomas R.] Peking Univ, Beijing HuiLongGuan Hosp, Beijing 100871, Peoples R China. [Zhang, Laurence Y.; Zhang, Laura Y.] Bellaire High Sch, Houston, TX USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs; VISN [16]; Mental Illness Research, Education and Clinical Center (MIRECC); United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was supported by the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. These sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 43 TC 7 Z9 7 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD AUG PY 2013 VL 47 IS 8 BP 1049 EP 1053 DI 10.1016/j.jpsychires.2013.03.014 PG 5 WC Psychiatry SC Psychiatry GA 173IU UT WOS:000321073500009 PM 23611682 ER PT J AU McKay, JR Van Horn, D Rennert, L Drapkin, M Ivey, M Koppenhaver, J AF McKay, James R. Van Horn, Deborah Rennert, Lior Drapkin, Michelle Ivey, Megan Koppenhaver, Janelle TI Factors in sustained recovery from cocaine dependence SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Cocaine dependence; Cocaine abstinence; Recovery; Predictors; Treatment response; Follow-up; Treatment ID SUBSTANCE-ABUSE TREATMENT; ADDICTION SEVERITY INDEX; CONTINUING CARE; FOLLOW-UP; PSYCHOMETRIC PROPERTIES; PSYCHOSOCIAL TREATMENT; DRINKING TRAJECTORIES; OUTPATIENT TREATMENT; TREATMENT ATTRITION; INITIAL ABSTINENCE AB The goal was to identify factors that predicted sustained cocaine abstinence and transitions from cocaine use to abstinence over 24 months. Data from baseline assessments and multiple follow-ups were obtained from three studies of continuing care for patients in intensive outpatient programs (IOPs). In the combined sample, remaining cocaine abstinent and transitioning into abstinence at the next follow-up were predicted by older age, less education, and less cocaine and alcohol use at baseline, and by higher self-efficacy, commitment to abstinence, better social support, lower depression, and lower scores on other problem severity measures assessed during the follow-up. In addition, higher self-help participation, self-help beliefs, readiness to change, and coping assessed during the follow-up predicted transitions from cocaine use to abstinence. These results were stable over 24 months. Commitment to abstinence, self-help behaviors and beliefs, and self-efficacy contributed independently to the prediction of cocaine use transitions. Implications for treatment are discussed. Published by Elsevier Inc. C1 [McKay, James R.; Van Horn, Deborah; Rennert, Lior; Drapkin, Michelle; Ivey, Megan; Koppenhaver, Janelle] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [McKay, James R.; Drapkin, Michelle] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP McKay, JR (reprint author), Univ Penn, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM jimrache@mail.med.upenn.edu FU NIAAA NIH HHS [R01 AA014850, R01 AA14850]; NIDA NIH HHS [K24 DA029062, R01 DA020623] NR 75 TC 12 Z9 12 U1 2 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD AUG PY 2013 VL 45 IS 2 BP 163 EP 172 DI 10.1016/j.jsat.2013.02.007 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 173IH UT WOS:000321072100002 PM 23561331 ER PT J AU McMillan, GP Hanson, TE Saunders, G Gallun, FJ AF McMillan, Garnett P. Hanson, Timothy E. Saunders, Gabrielle Gallun, Frederick J. TI A two-component circular regression model for repeated measures auditory localization data SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS LA English DT Article DE Angular regression; Bimodal data; B-splines; Sound localization; Symmetry models ID BAYESIAN MODEL; DISTRIBUTIONS; SPLINES; TESTS AB . Auditory localization experiments are conducted to evaluate human ability to locate the position of a source of sound, and to determine how population characteristics might affect this ability. These experiments generate data that are circular, bimodal and repeated, and have hypothesized symmetry patterns that should be included and tested within the modelling framework. We propose a two-part mixture of wrapped Cauchy densities for these bimodal angular data, with random effects to model correlation between repeated measures. The effects of signal position and types of symmetry in the signal response around the circle are modelled by using circular B-splines. The model is used to investigate the effects of age and hearing impairment on the ability to localize a low frequency signal. C1 [McMillan, Garnett P.; Saunders, Gabrielle; Gallun, Frederick J.] Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Hanson, Timothy E.] Univ S Carolina, Columbia, SC 29208 USA. RP McMillan, GP (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Garnett.McMillan@va.gov RI Gallun, Frederick/G-3792-2012; Hanson, Timothy/A-9127-2016 OI Gallun, Frederick/0000-0002-4145-2199; FU Department of Veterans Affairs, Veterans Health Administration 'Rehabilitation research and development' grant [3040] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration 'Rehabilitation research and development' grant 3040. The authors thank Anna Forsline, MA, and M. Samantha Lewis, PhD, for their assistance with data collection. We are grateful to Dr David Draper and several reviewers for helpful advice on this paper. The contents of this paper do not necessarily represent the views of the US Department of Veterans Affairs or the US Government. NR 33 TC 2 Z9 2 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0035-9254 J9 J R STAT SOC C-APPL JI J. R. Stat. Soc. Ser. C-Appl. Stat. PD AUG PY 2013 VL 62 IS 4 BP 515 EP 534 DI 10.1111/rssc.12004 PG 20 WC Statistics & Probability SC Mathematics GA 181YL UT WOS:000321706600001 ER PT J AU Liu, H Li, WJ Ahmad, M Rose, ME Miller, TM Yu, M Chen, J Pascoe, JL Poloyac, SM Hickey, RW Graham, SH AF Liu, Hao Li, Wenjin Ahmad, Muzamil Rose, Marie E. Miller, Tricia M. Yu, Mei Chen, Jie Pascoe, Jordan L. Poloyac, Samuel M. Hickey, Robert W. Graham, Steven H. TI Increased Generation of Cyclopentenone Prostaglandins after Brain Ischemia and Their Role in Aggregation of Ubiquitinated Proteins in Neurons SO NEUROTOXICITY RESEARCH LA English DT Article DE Cyclopentenone prostaglandins; Cell death; Ubiquitinated protein; Ubiquitin proteasome system; Primary neuron; Temporary focal ischemia ID 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES; THERAPEUTIC IMPLICATIONS; ENDOGENOUS ELECTROPHILE; DEGRADATION PATHWAYS; AGGRESOME FORMATION; PROTEASOME SYSTEM; HYDROLASE UCH-L1; J2 AB The cyclopentenone prostaglandin (CyPG) J(2) series, including prostaglandin J(2) (PGJ(2)), Delta(12)-PGJ(2), and 15-deoxy-a dagger(12,14)-prostaglandin J(2) (15d-PGJ(2)), are active metabolites of PGD(2), exerting multiple effects on neuronal function. However, the physiologic relevance of these effects remains uncertain as brain concentrations of CyPGs have not been precisely determined. In this study, we found that free PGD(2) and the J(2) series CyPGs (PGJ(2), Delta(12)-PGJ(2), and 15d-PGJ(2)) were increased in post-ischemic rat brain as detected by UPLC-MS/MS with 15d-PGJ(2) being the most abundant CyPG. These increases were attenuated by pre-treating with the cyclooxygenase (COX) inhibitor piroxicam. Next, effects of chronic exposure to 15d-PGJ(2) were examined by treating primary neurons with 15d-PGJ(2), CAY10410 (a 15d-PGJ(2) analog lacking the cyclopentenone ring structure), or vehicle for 24 to 96 h. Because we found that the concentration of free 15d-PGJ(2) decreased rapidly in cell culture medium, freshly prepared medium containing 15d-PGJ(2), CAY10410, or vehicle was changed twice daily to maintain steady extracellular concentrations. Incubation with 2.5 mu M 15d-PGJ(2), but not CAY10410, increased the neuronal cell death without the induction of caspase-3 or PARP cleavage, consistent with a primarily necrotic mechanism for 15d-PGJ(2)-induced cell death which was further supported by TUNEL assay results. Ubiquitinated protein accumulation and aggregation was observed after 96 h 15d-PGJ(2) incubation, accompanied by compromised 20S proteasome activity. Unlike another proteasome inhibitor, MG132, 15d-PGJ(2) treatment did not activate autophagy or induce aggresome formation. Therefore, the cumulative cytotoxic effects of increased generation of CyPGs after stroke may contribute to delayed post-ischemic neuronal injury. C1 [Liu, Hao; Li, Wenjin; Ahmad, Muzamil; Rose, Marie E.; Pascoe, Jordan L.; Graham, Steven H.] VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr GR H 00, Pittsburgh, PA 15206 USA. [Liu, Hao; Li, Wenjin; Ahmad, Muzamil; Rose, Marie E.; Yu, Mei; Chen, Jie; Pascoe, Jordan L.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr GR H 00, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM sgra@pitt.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS37459] FX This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke R01NS37459. The authors thank Pat Strickler for secretarial support. NR 53 TC 14 Z9 14 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1029-8428 J9 NEUROTOX RES JI Neurotox. Res. PD AUG PY 2013 VL 24 IS 2 BP 191 EP 204 DI 10.1007/s12640-013-9377-4 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 170VN UT WOS:000320882700009 PM 23355003 ER PT J AU Carbone, LD Chin, AS Burns, SP Svircev, JN Hoenig, H Heggeness, M Weaver, F AF Carbone, L. D. Chin, A. S. Burns, S. P. Svircev, J. N. Hoenig, H. Heggeness, M. Weaver, F. TI Morbidity following lower extremity fractures in men with spinal cord injury SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Fractures; Men; Morbidity; Pressure ulcers; Spinal cord injury ID HIP FRACTURE; TRACT-INFECTION; RISK-FACTORS; SCI QUERI; VETERANS; MANAGEMENT; DISORDERS; IMPLEMENTATION; EPIDEMIOLOGY; OSTEOPOROSIS AB The Veterans Affairs Spinal Cord Dysfunction Registry from 2002 to 2007 was reviewed to determine whether men with spinal cord injury (SCI) and lower extremity fractures had an increased risk of complications compared to those without fractures. We determined that fractures are associated with significant consequences, particularly during the first month postfracture. Despite increasing longevity, patients with SCI have a substantial number of illnesses and comorbid conditions. Lower extremity fractures are frequent events in these patients. However, whether these fractures are associated with any increased risk of complications in SCI is not certain. The purpose of this report was to determine the impact of lower extremity fractures on morbidities in men with SCI. A population-based, nested, case-control (1,027 cases and 1,027 propensity-matched controls) of men enrolled in the Veterans Affairs Spinal Cord Dysfunction Registry from fiscal years 2002 to 2007 was reviewed to determine whether lower extremity fractures were associated with an increased risk for complications. In propensity score models matched for demographic (age, race) and SCI-related injury factors (level/completeness of SCI), Veterans Affairs-service connection status, and comorbidities, at 1 month following the fracture, there was an increased risk for respiratory infections, pressure ulcers, urinary tract infections, thromboembolic events, depression, and delirium (p a parts per thousand currency signaEuro parts per thousand 0.03 for all). Over 12 months, the only complication more common in fracture cases was pressure ulcers (p < 0.01), with an absolute difference of less than 2 % when compared to controls. There was no significant increased risk of cardiac arrhythmias at any time examined following fracture (a parts per thousand yen0.12). Lower extremity fractures are associated with significant consequences in men with SCI during the first month postfracture, but they do not persist for a long term, except for pressure ulcers. Targeted interventions to prevent complications should be considered following lower extremity fractures in SCI, particularly in the first month following fracture. C1 [Carbone, L. D.] Vet Affairs Med Ctr, Memphis, TN 38163 USA. [Carbone, L. D.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Rheumatol, Memphis, TN 38163 USA. [Chin, A. S.; Weaver, F.] Edward J Hines Jr VA Hosp, Hines, IL USA. [Burns, S. P.; Svircev, J. N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, S. P.; Svircev, J. N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hoenig, H.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Heggeness, M.] Vet Affairs Med Ctr, Houston, TX 77030 USA. [Heggeness, M.] Baylor Coll Med, Dept Orthoped, Houston, TX 77030 USA. [Weaver, F.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. RP Carbone, LD (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Rheumatol, Memphis, TN 38163 USA. EM lcarbone@uthsc.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development [IIR 08-033] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development #IIR 08-033. NR 39 TC 10 Z9 10 U1 1 U2 10 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD AUG PY 2013 VL 24 IS 8 BP 2261 EP 2267 DI 10.1007/s00198-013-2295-8 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 181GH UT WOS:000321655500013 PM 23392311 ER PT J AU Yang, L Lawson, KA Teteak, CJ Zou, JH Hacquebord, J Patterson, D Ghatan, AC Mei, Q Zielinska-Kwiatkowska, A Bain, SD Fernandes, RJ Chansky, HA AF Yang, Liu Lawson, Kevin A. Teteak, Colin J. Zou, Junhui Hacquebord, Jacques Patterson, David Ghatan, Andrew C. Mei, Qi Zielinska-Kwiatkowska, Anna Bain, Steven D. Fernandes, Russell J. Chansky, Howard A. TI ESET histone methyltransferase is essential to hypertrophic differentiation of growth plate chondrocytes and formation of epiphyseal plates SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Epigenetics; Chondrogenesis; Chondrocyte hypertrophy; Chondrocyte differentiation; Epiphyseal plate; Long bone formation; Endochondral ossification; Trabecular bone; Histone deacetylase; Indian hedgehog gene Hh ID EMBRYONIC STEM-CELLS; OSTEOBLAST DIFFERENTIATION; BONE-FORMATION; CANCER-CELLS; SET DOMAIN; INTERACTS; LINEAGE; CBFA1; RUNX2; G9A AB The ESET (also called SETDB1) protein contains an N-terminal tudor domain that mediates protein-protein interactions and a C-terminal SET domain that catalyzes methylation of histone H3 at lysine 9. We report here that ESET protein is transiently upregulated in prehypertrophic chondrocytes in newborn mice. To investigate the in vivo effects of ESET on chondrocyte differentiation, we generated conditional knockout mice to specifically eliminate the catalytic SET domain of ESET protein only in mesenchymal cells. Such deletion of the ESET gene caused acceleration of chondrocyte hypertrophy in both embryos and young animals, depleting chondrocytes that are otherwise available to form epiphyseal plates for endochondral bone growth. ESET-deficient mice are thus characterized by defective long bone growth and trabecular bone formation. To understand the underlying mechanism for ESET regulation of chondrocytes, we carried out co-expression experiments and found that ESET associates with histone deacetylase 4 to bind and inhibit the activity of Runx2, a hypertrophy-promoting transcription factor. Repression of Runx2-mediated gene transactivation by ESET is dependent on its H3-K9 methyltransferase activity as well as its associated histone deacetylase activity. In addition, knockout of ESET is associated with repression of Indian hedgehog gene in pre- and early hypertrophic chondrocytes. Together, these results provide clear evidence that ESET controls hypertrophic differentiation of growth plate chondrocytes and endochondral ossification during embryogenesis and postnatal development. Published by Elsevier Inc. C1 [Yang, Liu; Lawson, Kevin A.; Teteak, Colin J.; Zou, Junhui; Hacquebord, Jacques; Patterson, David; Ghatan, Andrew C.; Zielinska-Kwiatkowska, Anna; Bain, Steven D.; Fernandes, Russell J.; Chansky, Howard A.] Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98108 USA. [Yang, Liu; Mei, Qi; Chansky, Howard A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yang, L (reprint author), Univ Washington, Dept Orthoped & Sports Med, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu OI Lawson, Kevin/0000-0002-2931-5263 FU NIH grant [RO1 AR051455, RO1 AR057025]; VA Merit Review Award FX We thank Dr. Y. Shinkai for frozen mouse embryos harboring the foxed ESET allele, Dr. J. J. Westendorf for pOG2-Luc reporter, Dr. G. Karsenty for pCMV-HA-Runx2 plasmid, and S. L. Carey for assistance in mouse breeding. This work is supported in part by NIH grant RO1 AR051455 (to L.Y.), RO1 AR057025 (to R.J.F), and by VA Merit Review Award (to H.A.C.). NR 28 TC 16 Z9 17 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD AUG 1 PY 2013 VL 380 IS 1 BP 99 EP 110 DI 10.1016/j.ydbio.2013.04.031 PG 12 WC Developmental Biology SC Developmental Biology GA 170DC UT WOS:000320829100009 PM 23652029 ER PT J AU Chase, MH AF Chase, Michael H. TI Motor control during sleep and wakefulness: Clarifying controversies and resolving paradoxes SO SLEEP MEDICINE REVIEWS LA English DT Review DE Motor control; Postsynaptic inhibition; REM sleep; Wakefulness; Reticular response-reversal; Hypocretin cataplexy ID EYE-MOVEMENT SLEEP; MUSCLE EMG AMPLITUDE; MEDULLARY RETICULAR NEURONS; NUCLEUS PONTIS ORALIS; IN-VIVO MICRODIALYSIS; REM-SLEEP; ACTIVE SLEEP; LUMBAR MOTONEURONS; BEHAVIOR DISORDER; POSTSYNAPTIC POTENTIALS AB Data accumulated during the last 40 years, since the discovery that there is a loss of muscle tone during REM sleep, have delineated many of the neurotransmitter systems, synaptic mechanisms and neuronal circuitries involved in the control of somatic motoneurons during sleep and waking states. Nevertheless, there are still a number of extant controversies as well as paradoxical and conflicting data. For example, the paradoxical modulation of motor activity that occurs in individuals with cataplexy during wakefulness compared to REM sleep is unresolved as are the mechanisms that are responsible for the control of hypoglossal motoneurons during normal states and those that are operative during sleep disorders such as obstructive sleep apnea. In addition, the circuitry whereby the hypocretinergic system promotes motor activation during wakefulness, and motor inhibition during REM sleep, has yet to be clarified. The use of new techniques, such those involving optogenetics and nanoparticles, will help to clarify the preceding issues and provide as a foundation for addressing a number of current critical unanswered questions such as those dealing with the differential control of motor activity in newborns and the aged. The resulting data will strengthen the foundation for the development of efficacious therapeutics to treat disorders of motor control that occur during sleep as well as wakefulness. (C) 2012 Published by Elsevier Ltd. C1 Univ Calif Los Angeles, Sch Med, VA Greater Angeles Healthcare Syst, WebSci Int, Los Angeles, CA 90095 USA. RP Chase, MH (reprint author), Univ Calif Los Angeles, Sch Med, VA Greater Angeles Healthcare Syst, WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90095 USA. EM mchase@websciences.org NR 116 TC 13 Z9 13 U1 1 U2 26 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 J9 SLEEP MED REV JI Sleep Med. Rev. PD AUG PY 2013 VL 17 IS 4 BP 299 EP 312 DI 10.1016/j.smrv.2012.09.003 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 173QQ UT WOS:000321094400008 PM 23499211 ER PT J AU Zhang, XY Tang, W Xiu, MH Chen, DC Yang, FD Tan, YL Wang, ZR Zhang, FX Liu, JH Liu, LJ Chen, YL Wen, N Kosten, TR AF Zhang, Xiang Yang Tang, Wei Xiu, Mei Hong Chen, Da Chun Yang, Fu De Tan, Yun Long Wang, Zhi Ren Zhang, Feixue Liu, Jiahong Liu, Linjing Chen, Yuanling Wen, Na Kosten, Thomas R. TI Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Schizophrenia; Cognition; Interleukin-18; Immune function; Psychopathology ID NEUROPSYCHOLOGICAL STATUS; INFLAMMATORY CYTOKINES; REPEATABLE BATTERY; PRENATAL INFECTION; ALZHEIMERS-DISEASE; SIGNALING PATHWAYS; GLIAL-CELLS; BRAIN; IL-18; EXPRESSION AB Alterations in the inflammatory and immune systems have been documented to occur from the earliest stages of schizophrenia, and have been associated with neurodevelopmental changes. Cognitive impairment is a core feature in the pathology of schizophrenia, and recent studies showed a significant increase in serum IL-18 in schizophrenia, and a putative role of IL-18 in neuroprogression and thus neurocognitive defects. The purpose of this study was to examine the association of IL-18 with cognitive deficits in schizophrenia. We recruited 77 first episode and drug naive schizophrenic patients and 75 healthy control subjects and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and serum IL-18 in both groups. Schizophrenic symptoms were assessed using the positive and negative syndrome scale (PANSS). We found that IL-18 levels were non-significantly higher in patients than controls (206.0 +/- 92.9 pg/ml vs 193.2 +/- 41.8 pg/ml, p = 0.28). Cognitive scores on the RBANS and nearly all of its five subscales (all p < 0.05) except for the Visuospatial/Constructional index (p > 0.05) were significantly lower in schizophrenic patients than normal controls. For the patients, IL-18 was positively associated with the Visuospatial/Constructional domain of cognitive deficits in schizophrenia. Our findings suggest that cognitive deficits occur during the acute stage of a schizophrenic episode, and IL-18 may be involved in Visuospatial/Constructional deficits of these patients. (C) 2013 Elsevier Inc. All rights reserved. C1 [Zhang, Xiang Yang; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Zhang, Xiang Yang; Xiu, Mei Hong; Chen, Da Chun; Yang, Fu De; Tan, Yun Long; Wang, Zhi Ren; Kosten, Thomas R.] Peking Univ, Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. [Tang, Wei; Zhang, Feixue; Liu, Jiahong; Liu, Linjing; Chen, Yuanling; Wen, Na] Kangning Hosp, Wenzhou 325000, Peoples R China. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu FU Wenzhou Science and Technology Bureau [Y20100324]; National Natural Science Foundation of China [81000509]; Beijing Municipal Excellent Talents Foundation [2010D003034000032]; Stanley Medical Research Institute [03T-459, 05T-726]; United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was funded by the Wenzhou Science and Technology Bureau (Y20100324), the National Natural Science Foundation of China (81000509), the Beijing Municipal Excellent Talents Foundation (2010D003034000032), the Stanley Medical Research Institute (03T-459 and 05T-726), and the United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 76 TC 12 Z9 12 U1 0 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD AUG PY 2013 VL 32 BP 105 EP 111 DI 10.1016/j.bbi.2013.03.001 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 168YG UT WOS:000320743300013 PM 23499732 ER PT J AU Rapuano, BE Singh, H Boskey, AL Doty, SB MacDonald, DE AF Rapuano, Bruce E. Singh, Herman Boskey, Adele L. Doty, Stephen B. MacDonald, Daniel E. TI Heat and radiofrequency plasma glow discharge pretreatment of a titanium alloy: Eveidence for enhanced osteoinductive properties SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE DENTAL IMPLANT; FIBRONECTIN; OSTEOBLAST; CELL DIFFERENTIATION; BONE MINERALIZATION; HYDROXYAPATITE ID OXIDE NET CHARGE; BONE SIALOPROTEIN; IN-VITRO; OSTEOBLAST ADHESION; DENTAL IMPLANTS; CELL-LINE; FIBRONECTIN; DIFFERENTIATION; MINERALIZATION; TISSUE AB It is believed that orthopedic and implant longevity can be improved by optimizing fixation, or direct bone-implant contact, through the stimulation of new bone formation around the implant. The purpose of this study was to determine whether heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD) pretreatment of Ti6Al4V stimulated calcium-phosphate mineral formation in cultures of attached MC3T3 osteoprogenitor cells with or without a fibronectin coating. Calcium-phosphate mineral was analyzed by flame atomic absorption spectrophotometry, scanning electron microscopy (SEM)/electron dispersive X-ray microanalysis (EDAX) and Fourier transformed infrared spectroscopy (FTIR). RFGD and heat pretreatments produced a general pattern of increased total soluble calcium levels, although the effect of heat pretreatment was greater than that of RFGD. SEM/EDAX showed the presence of calcium-and phosphorus-containing particles on untreated and treated disks that were more numerous on fibronectin-coated disks. These particles were observed earliest (1 week) on RFGD-pretreated surfaces. FTIR analyses showed that the heat pretreatment produced a general pattern of increased levels of apatite mineral at 2-4 weeks; a greater effect was observed for fibronectin-coated disks compared to uncoated disks. The observed findings suggest that heat pretreatment of Ti6Al4V increased the total mass of the mineral formed in MC3T3 osteoprogenitor cell cultures more than RFGD while the latter pretreatment hastened the early deposition of mineral. These findings help to support the hypothesis that the pretreatments enhance the osteoinductive properties of the alloy. J. Cell. Biochem. 114: 1917-1927, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Rapuano, Bruce E.; Singh, Herman; Boskey, Adele L.; Doty, Stephen B.; MacDonald, Daniel E.] Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA. [MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA. RP MacDonald, DE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. EM dem14@columbia.edu OI Boskey, Adele/0000-0002-6181-2219 FU National Center for Research Resources, NIH [C06-RR12538-01]; [NIH R01 DE017695] FX The project described was supported by Grant Number NIH R01 DE017695 (Awarded to DEM). The sponsor did not have any role in the study design; the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the article for publication. This material is also the result of work supported with resources and the use of facilities at the James J. Peters VA Medical Center, Bronx, New York. This investigation was also conducted at the HSS research facility constructed with support of Grant C06-RR12538-01 from the National Center for Research Resources, NIH. We would like to acknowledge Tony Labissiere for technical assistance with the SEM/EDAX analyses. We would also like to acknowledge Hayat Taleb, Kyle Hackshaw, and Carrie Guan for assistance with FTIR and atomic absorption spectroscopy. Special thanks goes to Kevin Pun for the preparation and treatment of titanium alloy disks. NR 50 TC 6 Z9 6 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD AUG PY 2013 VL 114 IS 8 BP 1917 EP 1927 DI 10.1002/jcb.24536 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 162OZ UT WOS:000320276000023 PM 23494951 ER PT J AU Kim, SH Lu, HF Alano, C AF Kim, Sun Hee Lu, Huafei Alano, Conrad TI The mitochondrial sirtuin Sirt3 protects neurons from oxidative injury SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Meeting Abstract CT 10th International Conference on Brain Energy Metabolism - Bioenergetics of Neurological Disease and Aging CY APR 17-20, 2012 CL Pacific Grove, CA SP NINDS, NIA, Int Soc Neurochemistry (ISN) Conf Comm, NCIRE, Vet Hlth Res Inst, Wiley Blackwell, Seahorse Bioscience C1 [Kim, Sun Hee; Lu, Huafei; Alano, Conrad] UCSF, San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD AUG PY 2013 VL 91 IS 8 SI SI BP 1096 EP 1096 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 171MO UT WOS:000320933700037 ER PT J AU Reyes, R Kim, JE Brennan, AM Swanson, RA AF Reyes, Reno Kim, Ji-Eun Brennan, Angela M. Swanson, Raymond A. TI Malic enzyme can support neuronal superoxide production by providing NADPH SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Meeting Abstract CT 10th International Conference on Brain Energy Metabolism - Bioenergetics of Neurological Disease and Aging CY APR 17-20, 2012 CL Pacific Grove, CA SP NINDS, NIA, Int Soc Neurochemistry (ISN) Conf Comm, NCIRE, Vet Hlth Res Inst, Wiley Blackwell, Seahorse Bioscience C1 [Reyes, Reno; Kim, Ji-Eun; Brennan, Angela M.; Swanson, Raymond A.] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. [Reyes, Reno; Kim, Ji-Eun; Brennan, Angela M.; Swanson, Raymond A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD AUG PY 2013 VL 91 IS 8 SI SI BP 1110 EP 1110 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 171MO UT WOS:000320933700069 ER PT J AU Muller, LPD Liu, J Solomon, A Rodriguez, A Brecha, NC AF Mueller, Luis Perez De Sevilla Liu, Janelle Solomon, Alexander Rodriguez, Allen Brecha, Nicholas C. TI Expression of voltage-gated calcium channel 24 subunits in the mouse and rat retina SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE calcium channel; 24 subunit; Muller cell; photoreceptor; retina; mouse; rat ID PHOTORECEPTOR RIBBON SYNAPSE; ACID TRANSPORTER EXPRESSION; TISSUE-SPECIFIC EXPRESSION; PIG HORIZONTAL CELLS; PROTEIN KINASE-C; MAMMALIAN RETINA; FUNCTIONAL ABNORMALITIES; BIPOLAR CELLS; ALPHA(2)DELTA SUBUNIT; CELLULAR-DISTRIBUTION AB High-voltage activated Ca channels participate in multiple cellular functions, including transmitter release, excitation, and gene transcription. Ca channels are heteromeric proteins consisting of a pore-forming 1 subunit and auxiliary 2 and subunits. Although there are reports of 24 subunit mRNA in the mouse retina and localization of the 24 subunit immunoreactivity to salamander photoreceptor terminals, there is a limited overall understanding of its expression and localization in the retina. 24 subunit expression and distribution in the mouse and rat retina were evaluated by using reverse transcriptase polymerase chain reaction, western blot, and immunohistochemistry with specific primers and a well-characterized antibody to the 24 subunit. 24 subunit mRNA and protein are present in mouse and rat retina, brain, and liver homogenates. Immunostaining for the 24 subunit is mainly localized to Muller cell processes and endfeet, photoreceptor terminals, and photoreceptor outer segments. This subunit is also expressed in a few displaced ganglion cells and bipolar cell dendrites. These findings suggest that the 24 subunit participates in the modulation of L-type Ca2+ current regulating neurotransmitter release from photoreceptor terminals and Ca2+-dependent signaling pathways in bipolar and Muller cells. J. Comp. Neurol. 521:2486-2501, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Mueller, Luis Perez De Sevilla; Liu, Janelle; Solomon, Alexander; Rodriguez, Allen; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Muller, LPD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM luisperez@mednet.ucla.edu FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD [W81XWH-10-2-0077]; National Institutes of Health [EY04067]; Veterans Administration Merit Review FX Grant sponsor: the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD; Grant number: W81XWH-10-2-0077; Grant sponsor: National Institutes of Health; Grant number: EY04067; Grant sponsor: Veterans Administration Merit Review (to N.C.B., who is also a Veterans Administration Career Research Scientist) J.L. and A. S. contributed equally to this work. NR 95 TC 5 Z9 5 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD AUG 1 PY 2013 VL 521 IS 11 BP 2486 EP 2501 DI 10.1002/cne.23294 PG 16 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 158KU UT WOS:000319970100005 ER PT J AU Knowles, JK Simmons, DA Nguyen, TVV Vander Griend, L Xie, YM Zhang, H Yang, T Pollak, J Chang, T Arancio, O Buckwalter, MS Wyss-Coray, T Massa, SM Longo, FM AF Knowles, Juliet K. Simmons, Danielle A. Nguyen, Thuy-Vi V. Vander Griend, Lilith Xie, Youmei Zhang, Hong Yang, Tao Pollak, Julia Chang, Timothy Arancio, Ottavio Buckwalter, Marion S. Wyss-Coray, Tony Massa, Stephen M. Longo, Frank M. TI A small molecule p75(NTR) ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimers' disease; p75 neurotrophin receptor; Neuritic dystrophy; LM11A-31 ID NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; BASAL FOREBRAIN NEURONS; LONG-TERM DEPRESSION; FACTOR GENE-THERAPY; TRANSGENIC MICE; INTRACEREBROVENTRICULAR INFUSION; ADULT-RAT; DISEASE; EXPRESSION AB The p75 neurotrophin receptor (p75(NTR)) is associated with multiple mechanisms linked to Alzheimer's disease (AD); hence, modulating its function might confer therapeutic effects. In previous in vitro work, we developed small molecule p75(NTR) ligands that inhibited amyloid-beta-induced degenerative signaling and prevented neurite degeneration. In the present study, a prototype p75(NTR) ligand, LM11A-31, was administered orally to the Thy-1 hAPP(Lond/Swe) (APP(L/S)) AD mouse model. LM11A-31 reached brain concentrations known to inhibit degenerative signaling without toxicity or induction of hyperalgesia. It prevented deficits in novel object recognition after 2.5 months and, in a separate cohort, deficits in Y-maze performance after 3 months of treatment. Stereology studies found that the number and size of basal forebrain cholinergic neurons, which are normal in APP(L/S) mice, were unaffected. Neuritic dystrophy, however, was readily apparent in the basal forebrain, hippocampus and cortex, and was significantly reduced by LM11A-31, with no effect on amyloid levels. These studies reveal that p75(NTR) is an important and tractable in vivo drug target for AD, with LM11A-31 representing a novel class of therapeutic candidates. (c) 2013 Elsevier Inc. All rights reserved. C1 [Knowles, Juliet K.; Simmons, Danielle A.; Nguyen, Thuy-Vi V.; Vander Griend, Lilith; Yang, Tao; Pollak, Julia; Chang, Timothy; Buckwalter, Marion S.; Wyss-Coray, Tony; Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. [Knowles, Juliet K.; Xie, Youmei] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. [Zhang, Hong; Arancio, Ottavio] Columbia Univ, Dept Pathol, New York, NY USA. [Zhang, Hong; Arancio, Ottavio] Columbia Univ, Taub Inst, New York, NY USA. [Wyss-Coray, Tony] Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA USA. [Massa, Stephen M.] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. [Massa, Stephen M.] San Francisco VA Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA USA. [Massa, Stephen M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Longo, FM (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. EM longo@stanford.edu FU NINDS [F30 NA051971, NIA UO1 AG032225, NS049442]; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; Eastern Chapter of the North Carolina Alzheimer's Association; Jean Perkins Foundation; Horngren Family Alzheimer's Research Fund; Richard M. Lucas Foundation; Veterans Administration FX This project was supported by funding from NINDS F30 NA051971 (J.K.K.), NIA UO1 AG032225 (F.M.L.), NS049442 (O.A.), the Alzheimer's Drug Discovery Foundation (F.M.L.), Alzheimer's Association (F.M.L.), the Eastern Chapter of the North Carolina Alzheimer's Association (F.M.L.), the Jean Perkins Foundation (F.M.L.), and the Horngren Family Alzheimer's Research Fund (F.M.L.), the Richard M. Lucas Foundation (F.M.L.) and the Veterans Administration (S.M.M. and T.W.C.). The authors thank Chihiro Ishikawa and Mary Wilson for their assistance in the execution of this work. NR 65 TC 35 Z9 37 U1 0 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD AUG PY 2013 VL 34 IS 8 BP 2052 EP 2063 DI 10.1016/j.neurobiolaging.2013.02.015 PG 12 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 156ED UT WOS:000319803100013 PM 23545424 ER PT J AU Smurzynski, M Wu, KL Schouten, JT Lok, JJ Bosch, RJ Taiwo, B Johnson, VA Collier, AC AF Smurzynski, Marlene Wu, Kunling Schouten, Jeffrey T. Lok, Judith J. Bosch, Ronald J. Taiwo, Babafemi Johnson, Victoria Anne Collier, Ann C. TI Factors associated with remaining on initial randomized efavirenz-containing regimens SO AIDS LA English DT Article DE clinical trials; cohort study; efavirenz; HAART; HIV ID COMBINATION ANTIRETROVIRAL THERAPY; HIV-INFECTED INDIVIDUALS; INJECTION-DRUG USERS; VIROLOGICAL FAILURE; TRIALS ALLRT; ADHERENCE; COHORT; PHARMACOGENETICS; DISCONTINUATION; RECOMMENDATIONS AB Objective: Efavirenz (EFV) along with two nucleoside reverse transcriptase inhibitors (NRTIs) is a recommended initial antiretroviral regimen. Understanding characteristics related to EFV success is clinically useful. Design: Data from 2220 antiretroviral-naive participants randomized to EFV and two to three NRTIs in four ACTG trials as well as a long-term cohort were analysed. Methods: Logistic regression, using inverse probability of censoring weighting to address selective-follow-up bias, was used to identify factors associated with EFV success (no treatment interruptions of >30 days, HIV RNA<200 copies/ml) 1 year post initiation and at years 2-5 if successful at year 1. Results: Pretreatment characteristics were median age 38 years, 82% male, 40% white, 10% history of IDU (HxIDU), median CD4(+) T-lymphocyte 227 cells/mu l and 33% HIV RNA more than 100 000 copies/ml. In a multivariable model, factors associated with year 1 EFV success were race [white odds ratio (OR) 1.5; P<0.001; Hispanic OR 1.5; P=0.003 vs. black], no pretreatment sign/symptom grade 3 or higher (OR 1.7; P=0.008) and no HxIDU (OR 1.7; P=0.001). Predictors of EFV success at years 2-5 were no HxIDU (years 2-5; ORs 1.9-2.2); self-reported complete (4 days prior to study visit) adherence during year 1 (years 2-4; ORs 1.6-1.9); fewer missed visits during year 1 (years 2, 4, 5; ORs 0.92-0.98/1% increase); HIV RNA less than 50 copies/ml at year 1 (years 2, 3; ORs 1.9-2.2); and older age (>50 vs. <= 30 years) (years 2-4: ORs 2.3-3.7). Conclusion: Characteristics predictive of EFV success in the short-term and longer term differed except for HxIDU. Behaviours occurring during year 1 were associated with EFV success over 5 years. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Smurzynski, Marlene; Wu, Kunling; Lok, Judith J.; Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Schouten, Jeffrey T.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Schouten, Jeffrey T.; Collier, Ann C.] Univ Washington, Seattle, WA 98195 USA. [Taiwo, Babafemi] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA. [Johnson, Victoria Anne] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria Anne] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. RP Smurzynski, M (reprint author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Epidemiol & Biostat, 2100-W Penn Ave NW,8th Floor, Washington, DC 20037 USA. EM msmurzyn@e-mail.gwu.edu FU Statistical and Data Management Center of the AIDS Clinical Trials Group, under the National Institute of Allergy and Infectious Diseases [1 UM1 AI068634, 1 UM1 AI068636]; National Institute of Allergy and Infectious Diseases grant: UAB Center for AIDS Research [P30AI27767]; National Institute of Allergy and Infectious Diseases grant: Alabama Clinical Trials Unit [UM1AI069452]; National Institute of Allergy and Infectious Diseases grant: UW Clinical HIV Integrated Research Program [5 UM1 AI 69434-06, R01AI100762] FX This work was supported by the Statistical and Data Management Center of the AIDS Clinical Trials Group, under the National Institute of Allergy and Infectious Diseases grant [1 UM1 AI068634] and the Leadership grant [1 UM1 AI068636]. Members of the team were also supported under the following National Institute of Allergy and Infectious Diseases grants: UAB Center for AIDS Research [P30AI27767], Alabama Clinical Trials Unit [UM1AI069452], UW Clinical HIV Integrated Research Program [5 UM1 AI 69434-06] and [R01AI100762]. NR 41 TC 1 Z9 1 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUL 31 PY 2013 VL 27 IS 12 BP 1887 EP 1897 DI 10.1097/QAD.0b013e328361645f PG 11 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 301IK UT WOS:000330525800006 PM 23925417 ER PT J AU O'Hare, AM AF O'Hare, Ann M. TI Vascular Access for Hemodialysis in Older Adults: A "Patient First" Approach SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; DECISION-MAKING; FISTULA 1ST; ARTERIOVENOUS-FISTULA; ELDERLY-PATIENT; REFER PATIENTS; DIALYSIS; CARE; GUIDELINE; OUTCOMES C1 Univ Washington, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP O'Hare, AM (reprint author), Univ Washington, Vet Affairs Puget Sound Healthcare Syst, 1160 South Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov NR 29 TC 9 Z9 9 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUL 31 PY 2013 VL 24 IS 8 BP 1187 EP 1190 DI 10.1681/ASN.2013050507 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 198GD UT WOS:000322909400004 PM 23813217 ER PT J AU Donaldson, GC Mullerova, H Locantore, N Hurst, JR Calverley, PMA Vestbo, J Anzueto, A Wedzicha, JA AF Donaldson, Gavin C. Muellerova, Hanna Locantore, Nicholas Hurst, John R. Calverley, Peter M. A. Vestbo, Jorgen Anzueto, Antonio Wedzicha, Jadwiga A. TI Factors associated with change in exacerbation frequency in COPD SO RESPIRATORY RESEARCH LA English DT Article DE COPD; Exacerbations; Exacerbation frequency; Exacerbation phenotype ID OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION DECLINE; QUALITY-OF-LIFE; ECLIPSE COHORT; INFLAMMATORY MARKERS; TIME; POPULATION; SEVERITY; SYMPTOMS; DISTANCE AB Background: Patients with chronic obstructive pulmonary disease (COPD) can be categorized as having frequent (FE) or infrequent (IE) exacerbations depending on whether they respectively experience two or more, or one or zero exacerbations per year. Although most patients do not change category from year to year, some will, and the factors associated with this behaviour have not been examined. Methods: 1832 patients completing two year follow-up in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study were examined at baseline and then yearly. Exacerbations were defined by health care utilisation. Patient characteristics compared between those patients who did or did not change exacerbation category from year 1 to year 2. Findings: Between years 1 and 2, 221 patients (17%) changed from IE to FE and 210 patients (39%) from FE to IE. More severe disease was associated with changing from IE to FE and less severe disease from FE to IE. Over the preceding year, small falls in FEV1 and 6-minute walking distance were associated with changing from IE to FE, and small falls in platelet count associated with changing from FE to IE. Conclusion: No parameter clearly predicts an imminent change in exacerbation frequency category. C1 [Donaldson, Gavin C.; Wedzicha, Jadwiga A.] UCL Med Sch, Ctr Resp Med, London NW3 2PF, England. [Muellerova, Hanna] GlaxoSmithKline R&D, Uxbridge UB11 1BT, Middx, England. [Locantore, Nicholas] GlaxoSmithKline, Res Triangle Pk, NC USA. [Hurst, John R.] UCL, Ctr Inflammat & Tissue Repair, London, England. [Calverley, Peter M. A.] Aintree Univ Hosp NHS Fdn Trust, Sch Ageing & Chron Dis, Liverpool L9 7AL, Merseyside, England. [Vestbo, Jorgen] Odense Univ Hosp, Dept Resp Med, DK-5000 Odense, Denmark. [Vestbo, Jorgen] Univ Southern Denmark, Odense, Denmark. [Vestbo, Jorgen] Univ Manchester, Resp Res Grp, Sch Translat Med, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr, Pulm Sect, San Antonio, TX USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Donaldson, GC (reprint author), UCL Med Sch, Ctr Resp Med, Royal Free Campus,Rowland Hill St Hampstead, London NW3 2PF, England. EM g.donaldson@ucl.ac.uk OI Vestbo, Jorgen/0000-0001-6355-6362; Mullerova, Hana/0000-0002-0949-0101 FU GlaxoSmithKline FX This work was funded by GlaxoSmithKline. The authors acknowledge the principle investigators, steering and scientific committee of the ECLIPSE study. The authors would also like to thank the patients participating in the ECLIPSE study. NR 39 TC 22 Z9 22 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X J9 RESP RES JI Respir. Res. PD JUL 30 PY 2013 VL 14 AR 79 DI 10.1186/1465-9921-14-79 PG 9 WC Respiratory System SC Respiratory System GA 193ZX UT WOS:000322601100001 PM 23899210 ER PT J AU Hanlon, CA Hartwell, KJ Canterberry, M Li, XB Owens, M LeMatty, T Prisciandaro, JJ Borckardt, J Brady, KT George, MS AF Hanlon, Colleen A. Hartwell, Karen J. Canterberry, Melanie Li, Xingbao Owens, Max LeMatty, Todd Prisciandaro, James J. Borckardt, Jeffrey Brady, Kathleen T. George, Mark S. TI Reduction of cue-induced craving through realtime neurofeedback in nicotine users: The role of region of interest selection and multiple visits SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Addiction; Prefrontal cortex; Cingulate ID SELF-CONTROL; SMOKING; ADDICTION; ACTIVATION; CESSATION; SMOKERS; LOCUS AB This multi-visit, real-time functional magnetic resonance imaging feedback study demonstrates that treatment-seeking smokers can effectively modulate their behavioral and brain responses to smoking cues. They are more effective at decreasing activity in functionally defined regions involved in "craving" (e.g. ventral anterior cingulate cortex (vACC)) rather than increasing activity in regions involved in "resisting" (e.g. dorsal medial prefrontal cortex (dmPFC)). (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Hanlon, Colleen A.; Hartwell, Karen J.; Canterberry, Melanie; Li, Xingbao; Owens, Max; LeMatty, Todd; Prisciandaro, James J.; Borckardt, Jeffrey; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, Ctr Biomed Imaging, 67 President St, Charleston, SC 29425 USA. EM hanlon@musc.edu FU National Institutes of Health [K01DA027756, GA30523K, UL1 RR029882]; [R33DA026085] FX Funding was provided by R33DA026085 (Brady) with additional support from K01DA027756 (Hanlon), GA30523K and UL1 RR029882 (CSTA) from the National Institutes of Health. The authors received no compensation from other external organizations related to this manuscript. NR 16 TC 24 Z9 24 U1 2 U2 23 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD JUL 30 PY 2013 VL 213 IS 1 BP 79 EP 81 DI 10.1016/j.pscychresns.2013.03.003 PG 3 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 169DF UT WOS:000320756700011 PM 23683344 ER PT J AU Jones, V Katiyar, SK AF Jones, Virginia Katiyar, Santosh K. TI Emerging phytochemicals for prevention of melanoma invasion SO CANCER LETTERS LA English DT Review DE Cyclooxygenase-2; Melanoma; Phytochemicals; Prostaglandins; beta-Catenin ID E-CADHERIN EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; NF-KAPPA-B; BETA-CATENIN; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; CELL-LINES; GREEN TEA; PANCREATIC-CARCINOMA AB Cutaneous malignant melanoma is the leading cause of death from skin diseases due to its propensity to metastasize. Once diagnosed with metastatic melanoma, most patients will die of their disease within 2 years. As suppression of metastases requires long-term interventions, potential anti-metastatic agents must not only be efficacious but also have low toxicity. Many phytochemicals used in traditional medicine have low toxicity and recent studies suggest that some are promising candidates for the prevention or treatment of metastatic melanoma. Here, we review the recent literature regarding phytochemicals that have shown inhibitory effects on melanoma cell migration or invasion. (c) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Jones, Virginia; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670,Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award [1I01BX001410]; National Institutes of Health/NCI [CA166883] FX The work reported from Dr. Katiyar's laboratory was supported by Veterans Administration Merit Review Award (1I01BX001410) and National Institutes of Health/NCI (CA166883). The content of this article does not necessarily reflect the views or policies of the funding sources. We thank Dr. Fiona Hunter for her assistance in editing the manuscript. NR 77 TC 10 Z9 10 U1 3 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 J9 CANCER LETT JI Cancer Lett. PD JUL 28 PY 2013 VL 335 IS 2 BP 251 EP 258 DI 10.1016/j.canlet.2013.02.056 PG 8 WC Oncology SC Oncology GA 168CE UT WOS:000320682500001 PM 23474498 ER PT J AU Galaleldeen, A Taylor, AB Chen, D Schuermann, JP Holloway, SP Hou, SP Gong, SQ Zhong, GM Hart, PJ AF Galaleldeen, Ahmad Taylor, Alexander B. Chen, Ding Schuermann, Jonathan P. Holloway, Stephen P. Hou, Shuping Gong, Siqi Zhong, Guangming Hart, P. John TI Structure of the Chlamydia trachomatis Immunodominant Antigen Pgp3 SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Bacterial Pathogenesis; Chlamydia; Immunology; Tumor Necrosis Factor (TNF); X-ray Crystallography; Beta-Helix; Beta-Propeller; Helical Coiled-coil; Pgp3; Sexually Transmitted Disease ID SEGMENTED COILED-COIL; TUMOR-NECROSIS-FACTOR; C-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; BACTERIOPHAGE-T4 FIBRITIN; BACILLUS-ANTHRACIS; TRANSCRIPTIONAL REGULATOR; VIRULENCE FACTOR; PROTEIN; PLASMID AB Chlamydia trachomatis infection is the most common sexually transmitted bacterial disease. Left untreated, it can lead to ectopic pregnancy, pelvic inflammatory disease, and infertility. Here we present the structure of the secreted C. trachomatis protein Pgp3, an immunodominant antigen and putative virulence factor. The approximate to 84-kDa Pgp3 homotrimer, encoded on a cryptic plasmid, consists of globular N- and C-terminal assemblies connected by a triple-helical coiled-coil. The C-terminal domains possess folds similar to members of the TNF family of cytokines. The closest Pgp3 C-terminal domain structural homologs include a lectin from Burkholderia cenocepacia, the C1q component of complement, and a portion of the Bacillus anthracis spore surface protein BclA, all of which play roles in bioadhesion. The N-terminal domain consists of a concatenation of structural motifs typically found in trimeric viral proteins. The central parallel triple-helical coiled-coil contains an unusual alternating pattern of apolar and polar residue pairs that generate a rare right-handed superhelical twist. The unique architecture of Pgp3 provides the basis for understanding its role in chlamydial pathogenesis and serves as the platform for its optimization as a potential vaccine antigen candidate. C1 [Galaleldeen, Ahmad; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Chen, Ding; Hou, Shuping; Gong, Siqi; Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Galaleldeen, Ahmad] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA. [Schuermann, Jonathan P.] Cornell Univ, Dept Chem & Chem Biol, Northeastern Collaborat Access Team, Ithaca, NY 14853 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Zhong, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. EM zhongg@uthscsa.edu; pjhart@biochem.uthscsa.edu FU National Institutes of Health [AI47997, AI64537]; Robert A. Welch Foundation [AQ-1399]; National Center for Research Resources at the National Institute of Health [RR-15301]; U.S. Department of Energy, Office of Basic Energy Sciences [W-31-109-ENG-38]; Cancer Therapy & Research Center Cancer Center [NCI P30CA054174]; United States Department of Defense to the UTSA/UTHSCSA Center for Excellence in Genomics Research [W911NF-11-1-0136] FX This work was supported, in whole or in part, by National Institutes of Health Grants AI47997 and AI64537 (to G.Z.). This work was also supported by Robert A. Welch Foundation Grant AQ-1399 (to P.J.H.). This work is partially the result of research conducted at the Northeastern Collaborative Access Team beamlines of the Advanced Photon Source, supported by Award RR-15301 from the National Center for Research Resources at the National Institute of Health. Use of the Advanced Photon Source is supported by the U.S. Department of Energy, Office of Basic Energy Sciences under Contract W-31-109-ENG-38. This work was also supported in part by Cancer Therapy & Research Center Cancer Center Support Grant NCI P30CA054174 and Contract Number W911NF-11-1-0136 from the United States Department of Defense to the UTSA/UTHSCSA Center for Excellence in Genomics Research. NR 76 TC 7 Z9 9 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 26 PY 2013 VL 288 IS 30 BP 22068 EP 22079 DI 10.1074/jbc.M113.475012 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 277TJ UT WOS:000328841900052 PM 23703617 ER PT J AU Fernandez, TF Samal, AB Bedwell, GJ Chen, YB Saad, JS AF Fernandez, Timothy F. Samal, Alexandra B. Bedwell, Gregory J. Chen, Yabing Saad, Jamil S. TI Structural and Biophysical Characterization of the Interactions between the Death Domain of Fas Receptor and Calmodulin SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Apoptosis; Calmodulin; Fas; NMR; Surface Plasmon Resonance (SPR); Cholangiocarcinoma ID SIZE-DISTRIBUTION ANALYSIS; HIV-1 MATRIX PROTEIN; CHOLANGIOCARCINOMA CELLS; ANALYTICAL ULTRACENTRIFUGATION; TARGET RECOGNITION; BINDING DOMAIN; PEPTIDE INTERACTION; MEDIATED APOPTOSIS; INHIBITORY PROTEIN; NMR-SPECTROSCOPY AB The extrinsic apoptotic pathway is initiated by cell surface death receptors such as Fas. Engagement of Fas by Fas ligand triggers a conformational change that allows Fas to interact with adaptor protein Fas-associated death domain (FADD) via the death domain, which recruits downstream signaling proteins to form the death-inducing signaling complex (DISC). Previous studies have shown that calmodulin (CaM) is recruited into the DISC in cholangiocarcinoma cells, suggesting a novel role of CaM in Fas-mediated signaling. CaM antagonists induce apoptosis through a Fas-related mechanism in cholangiocarcinoma and other cancer cell lines possibly by inhibiting Fas-CaM interactions. The structural determinants of Fas-CaM interaction and the underlying molecular mechanisms of inhibition, however, are unknown. Here we employed NMR and biophysical techniques to elucidate these mechanisms. Our data show that CaM binds to the death domain of Fas (FasDD) with an apparent dissociation constant (K-d) of approximate to 2 m and 2:1 CaM:FasDD stoichiometry. The interactions between FasDD and CaM are endothermic and entropically driven, suggesting that hydrophobic contacts are critical for binding. We also show that both the N- and C-terminal lobes of CaM are important for binding. NMR and surface plasmon resonance data show that three CaM antagonists (N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, tamoxifen, and trifluoperazine) greatly inhibit Fas-CaM interactions by blocking the Fas-binding site on CaM. Our findings provide the first structural evidence for Fas-CaM interactions and mechanism of inhibition and provide new insight into the molecular basis for a novel role of CaM in regulating Fas-mediated apoptosis. C1 [Fernandez, Timothy F.; Samal, Alexandra B.; Bedwell, Gregory J.; Saad, Jamil S.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Chen, Yabing] Birmingham Vet Affairs Med Ctr, Res Dept, Birmingham, AL 35294 USA. RP Saad, JS (reprint author), 845 19th St S, Birmingham, AL 35294 USA. EM saad@uab.edu FU NCI, National Institutes of Health (NIH) [P30CA13148]; NIH [1S10RR026478] FX We thank members of our laboratories and Dr. Jay McDonald (University of Alabama at Birmingham) for helpful discussions. We thank Diego Esposito and Paul Driscoll (Medical Research Council National Institute for Medical Research, United Kingdom) for providing NMR signal assignments of FasDD. We thank the University of Alabama Comprehensive Cancer Center X-ray core facility, funded by NCI, National Institutes of Health (NIH) Grant P30CA13148, which houses the Auto-ITC200, acquired through NIH Grant 1S10RR026478. NR 68 TC 11 Z9 11 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 26 PY 2013 VL 288 IS 30 AR 21898 DI 10.1074/jbc.M113.471821 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 277TJ UT WOS:000328841900038 PM 23760276 ER PT J AU Huik, K Avi, R Carrillo, A Harper, N Pauskar, M Sadam, M Karki, T Krispin, T Kongo, UK Jermilova, T Ruutel, K Talu, A Abel-Ollo, K Uuskula, A Ahuja, SK He, WJ Lutsar, I AF Huik, Kristi Avi, Radko Carrillo, Andrew Harper, Nathan Pauskar, Merit Sadam, Maarja Karki, Tonis Krispin, Tonu Kongo, Ulvi-Kaire Jermilova, Tatiana Rueuetel, Kristi Talu, Ave Abel-Ollo, Katri Uuskuela, Anneli Ahuja, Sunil K. He, Weijing Lutsar, Irja TI CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users SO PLOS ONE LA English DT Article ID CHRONIC HEPATITIS-C; HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; HIV-1 INFECTION; INJECT DRUGS; CHEMOKINE; EXPRESSION; CCR5-DELTA-32; ASSOCIATION; FREQUENCY AB Background: Up to 90% HIV-1 positive intravenous drug users (IDUs) are co-infected with HCV. Although best recognized for its function as a major co-receptor for cell entry of HIV, CC chemokine receptor 5 (CCR5) has also been implicated in the pathogenesis of HCV infection. Here, we investigated whether CCR5 haplotypes influence HIV-1 and HCV seropositivity among 373 Caucasian IDUs from Estonia. Methods: Of these IDUs, 56% and 44% were HIV and HCV seropositive, respectively, and 47% were coinfected. 500 blood donors seronegative for HIV and HCV were also evaluated. CCR5 haplotypes (HHA to HHG*2) were derived after genotyping nine CCR2-CCR5 polymorphisms. The association between CCR5 haplotypes with HIV and/or HCV seropositivity was determined using logistic regression analysis. Co-variates included in the models were length of intravenous drug use, HBV serostatus and copy number of CCL3L1, the gene encoding the most potent HIV-suppressive chemokine and ligand for CCR5. Results: Compared to IDUs seronegative for both HCV and HIV (HCV2/HIV-), IDUs who were HCV+/HIV- and HCV+/HIV+ were 92% and 82%, respectively, less likely to possess the CCR5-HHG*1 haplotype, after controlling for co-variates (P-adjusted = 1.89x10(-4) and 0.003, respectively). This association was mostly due to subjects bearing the CCR5 HHE and HHG*1 haplotype pairs. Approximately 25% and < 10% of HCV-/HIV- IDUs and HCV2/HIV- blood donors, respectively, possessed the HHE/HHG*1 genotype. Conclusions: Our findings suggest that HHG*1-bearing CCR5 genotypes influence HCV seropositivity in a group of Caucasian IDUs. C1 [Huik, Kristi; Avi, Radko; Pauskar, Merit; Sadam, Maarja; Karki, Tonis; Krispin, Tonu; Lutsar, Irja] Univ Tartu, Fac Med, Dept Microbiol, EE-50090 Tartu, Estonia. [Carrillo, Andrew; Harper, Nathan; Ahuja, Sunil K.; He, Weijing] South Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV 1 Infect, San Antonio, TX USA. [Carrillo, Andrew; Harper, Nathan; Ahuja, Sunil K.; He, Weijing] South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA. [Carrillo, Andrew; Harper, Nathan; Ahuja, Sunil K.; He, Weijing] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Kongo, Ulvi-Kaire] North Estonia Med Ctr Fdn, Immunoheamatol Reference Lab, Tallinn, Estonia. [Jermilova, Tatiana] Blood Ctr Kohtla Jarve, Kohtla Jarve, Estonia. [Rueuetel, Kristi; Talu, Ave; Abel-Ollo, Katri] Natl Inst Hlth Dev, Tallinn, Estonia. [Uuskuela, Anneli] Univ Tartu, Fac Med, Dept Publ Hlth, EE-50090 Tartu, Estonia. RP He, WJ (reprint author), South Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV 1 Infect, San Antonio, TX USA. EM hew@uthscsa.edu; Irja.Lutsar@ut.ee RI lutsar, irja/H-3177-2015; Uuskula, Anneli/H-3303-2015 FU Veterans Affairs (VA) Center for AIDS and HIV Infection; VA Center for Personalized Medicine of the South Texas Veterans Health Care System; National Institutes of Health (NIH) [R37AI046326]; Doris Duke Distinguished Clinical Scientist Award; VA MERIT award; Elizabeth Glaser Pediatric AIDS Foundation; Max and Minnie Tomerlin Voelcker Fund; European Union through the European Regional Development Fund; Estonian Science Foundation [8004, 8415, 8856]; Basic Financing and the Target Financing of Estonian Ministry of Education and Research [SF0180004s12]; European Commission funded project Expanding Network for Comprehensive; Coordinated Action on HIV/AIDS prevention among IDUs and Bridging Population [2005305]; Global Fund; National HIV/AIDS Strategy; US Civilian Research Development Foundation [ESX0-2722-TA06]; US National Institutes of Health, National Institute on Drug Abuse [R01DA03574]; Archimedes Foundation and Norwegian Financial Mechanism/ EEA [EE0016] FX The work at San Antonio was supported by the Veterans Affairs (VA) Center for AIDS and HIV Infection and VA Center for Personalized Medicine of the South Texas Veterans Health Care System, a National Institutes of Health (NIH) MERIT grant (R37AI046326), and the Doris Duke Distinguished Clinical Scientist Award to S.K.A. S.K.A. is also supported by a VA MERIT award, the Elizabeth Glaser Pediatric AIDS Foundation, the Burroughs Welcome Clinical Scientist Award in Translational Research and the Senior Scholar Award from the Max and Minnie Tomerlin Voelcker Fund. The work at Estonia was supported by European Union through the European Regional Development Fund; Estonian Science Foundation (grants 8004, 8415 and 8856); Basic Financing and the Target Financing of Estonian Ministry of Education and Research (SF0180004s12); European Commission funded project Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS prevention among IDUs and Bridging Population Nr. 2005305 (ENCAP); Global Fund to Fight HIV, Tuberculosis and Malaria Program "Scaling up the response to HIV in Estonia'' for 2003-2007; National HIV/AIDS Strategy for 2006-2015; US Civilian Research Development Foundation (grant ESX0-2722-TA06); US National Institutes of Health, National Institute on Drug Abuse (grant R01DA03574); the Archimedes Foundation and Norwegian Financial Mechanism/EEA(grant EE0016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 1 Z9 1 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 25 PY 2013 VL 8 IS 7 AR e70561 DI 10.1371/journal.pone.0070561 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 191SQ UT WOS:000322433300109 PM 23936229 ER PT J AU McEvoy, J Baillie, RA Zhu, HJ Buckley, P Keshavan, MS Nasrallah, HA Dougherty, GG Yao, JK Kaddurah-Daouk, R AF McEvoy, Joseph Baillie, Rebecca A. Zhu, Hongjie Buckley, Peter Keshavan, Matcheri S. Nasrallah, Henry A. Dougherty, George G. Yao, Jeffrey K. Kaddurah-Daouk, Rima TI Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics SO PLOS ONE LA English DT Article ID FATTY-ACIDS; SEROTONIN AB There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naive patients with a first episode of schizophrenia (FE group), 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease. C1 [McEvoy, Joseph; Zhu, Hongjie; Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA. [Baillie, Rebecca A.] Rosa & Co LLC, San Carlos, CA USA. [Buckley, Peter] Med Coll Georgia, Augusta, GA 30912 USA. [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Keshavan, Matcheri S.] Harvard Univ, Sch Med, Boston, MA USA. [Nasrallah, Henry A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dougherty, George G.; Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Kaddurah-Daouk, R (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA. EM kaddu001@mc.duke.edu FU National Institute of Mental Health (NIMH) [1R01MH084941-01A2]; Department of Veterans Affairs Senior Research Career Scientist Award FX Funding for this study was provided by National Institute of Mental Health (NIMH) Grant # 1R01MH084941-01A2 (RKD) and the Department of Veterans Affairs Senior Research Career Scientist Award (JKY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 17 TC 25 Z9 26 U1 1 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 24 PY 2013 VL 8 IS 7 AR e68717 DI 10.1371/journal.pone.0068717 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 188BY UT WOS:000322167900022 PM 23894336 ER PT J AU Jackevicius, CA Tu, JV Ko, DT de Leon, N Krumholz, HM AF Jackevicius, Cynthia A. Tu, Jack V. Ko, Dennis T. de Leon, Noelle Krumholz, Harlan M. TI Use of Niacin in the United States and Canada SO JAMA INTERNAL MEDICINE LA English DT Letter ID THERAPY; DISEASE C1 [Jackevicius, Cynthia A.; de Leon, Noelle] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.; Tu, Jack V.; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.; Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovascr Med Epidemiol & Publ Hlth & Hlth, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu OI Ko, Dennis/0000-0001-6840-8051 FU Canadian Institutes of Health Research; NHLBI NIH HHS [U01-HL105270-03] NR 9 TC 11 Z9 11 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL 22 PY 2013 VL 173 IS 14 BP 1379 EP 1383 DI 10.1001/jamainternmed.2013.6489 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 214TX UT WOS:000324160100027 PM 23753308 ER PT J AU Yaffe, K Falvey, CM Hamilton, N Harris, TB Simonsick, EM Strotmeyer, ES Shorr, RI Metti, A Schwartz, AV AF Yaffe, Kristine Falvey, Cherie M. Hamilton, Nathan Harris, Tamara B. Simonsick, Eleanor M. Strotmeyer, Elsa S. Shorr, Ronald I. Metti, Andrea Schwartz, Ann V. CA Hlth ABC Study TI Association Between Hypoglycemia and Dementia in a Biracial Cohort of Older Adults With Diabetes Mellitus SO JAMA INTERNAL MEDICINE LA English DT Article ID COGNITIVE FUNCTION; ALZHEIMERS-DISEASE; RISK; DYSFUNCTION; IMPAIRMENT; VETERANS; TRIAL AB IMPORTANCE Hypoglycemia commonly occurs in patients with diabetes mellitus (DM) and may negatively influence cognitive performance. Cognitive impairment in turn can compromise DM management and lead to hypoglycemia. OBJECTIVE To prospectively evaluate the association between hypoglycemia and dementia in a biracial cohort of older adults with DM. DESIGN AND SETTING Prospective population-based study. PARTICIPANTS We studied 783 older adults with DM (mean age, 74.0 years; 47.0% of black race/ethnicity; and 47.6% female) who were participating in the prospective population-based Health, Aging, and Body Composition Study beginning in 1997 and who had baseline Modified Mini-Mental State Examination scores of 80 or higher. MAIN OUTCOME MEASURES Dementia diagnosis was determined during the follow-up period from hospital records indicating an admission associated with dementia or the use of prescribed dementia medications. Hypoglycemic events were determined during the follow-up period by hospital records. RESULTS During the 12-year follow-up period, 61 participants (7.8%) had a reported hypoglycemic event, and 148 (18.9%) developed dementia. Those who experienced a hypoglycemic event had a 2-fold increased risk for developing dementia compared with those who did not have a hypoglycemic event (34.4% vs 17.6%, P < .001; multivariate-adjusted hazard ratio, 2.1; 95% CI, 1.0-4.4). Similarly, older adults with DM who developed dementia had a greater risk for having a subsequent hypoglycemic event compared with participants who did not develop dementia (14.2% vs 6.3%, P < .001; multivariate-adjusted hazard ratio, 3.1; 95% CI, 1.5-6.6). Further adjustment for stroke, hypertension, myocardial infarction, and cognitive change scores produced similar results. CONCLUSION AND RELEVANCE Among older adults with DM, there seems to be a bidirectional association between hypoglycemia and dementia. C1 [Yaffe, Kristine; Falvey, Cherie M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine; Schwartz, Ann V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine; Falvey, Cherie M.; Hamilton, Nathan] San Francisco VA Med Ctr, San Francisco, CA USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Baltimore, MD 21224 USA. [Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Strotmeyer, Elsa S.; Metti, Andrea] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Shorr, Ronald I.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,POB 181, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu RI Strotmeyer, Elsa/F-3015-2014; Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Strotmeyer, Elsa/0000-0002-4093-6036 FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, K24AG031155]; National Institute of Nursing Research [R01-AG028050, R01-NR012459]; Intramural Research Program of the National Institutes of Health; American Health Assistance Foundation [A201-0029] FX This study was supported by grants N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National Institute on Aging and by grants R01-AG028050 and R01-NR012459 from the National Institute of Nursing Research. This research was supported in part by the Intramural Research Program of the National Institutes of Health, by the National Institute on Aging, and by grant A201-0029 from the American Health Assistance Foundation. Dr Yaffe is supported in part by grant K24AG031155 from the National Institute on Aging. NR 33 TC 79 Z9 82 U1 5 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL 22 PY 2013 VL 173 IS 14 BP 1300 EP + DI 10.1001/jamainternmed.2013.6176 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 214TX UT WOS:000324160100007 PM 23753199 ER PT J AU Ryoo, JJ Ordin, DL Antonio, ALM Oishi, SM Gould, MK Asch, SM Malin, JL AF Ryoo, Joan J. Ordin, Diana L. Antonio, Anna Liza M. Oishi, Sabine M. Gould, Michael K. Asch, Steven M. Malin, Jennifer L. TI Patient Preference and Contraindications in Measuring Quality of Care: What Do Administrative Data Miss? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CELL LUNG-CANCER; CORONARY-ARTERY-DISEASE; RACIAL-DIFFERENCES; PERFORMANCE-MEASURES; INITIAL TREATMENT; MEDICARE PATIENTS; PRIVATE-SECTOR; VETERANS; SURVIVAL; CHEMOTHERAPY AB Purpose Prior studies report that half of patients with lung cancer do not receive guideline-concordant care. With data from a national Veterans Health Administration (VHA) study on quality of care, we sought to determine what proportion of patients refused or had a contraindication to recommended lung cancer therapy. Patients and Methods Through medical record abstraction, we evaluated adherence to six quality indicators addressing lung cancer-directed therapy for patients diagnosed within the VHA during 2007 and calculated the proportion of patients receiving, refusing, or having contraindications to recommended treatment. Results Mean age of the predominantly male population was 67.7 years (standard deviation, 9.4 years), and 15% were black. Adherence to quality indicators ranged from 81% for adjuvant chemotherapy to 98% for curative resection; however, many patients met quality indicator criteria without actually receiving recommended therapy by having a refusal (0% to 14%) or contraindication (1% to 30%) documented. Less than 1% of patients refused palliative chemotherapy. Black patients were more likely to refuse or bear a contraindication to surgery even when controlling for comorbidity; race was not associated with refusals or contraindications to other treatments. Conclusion Refusals and contraindications are common and may account for previously demonstrated low rates of recommended lung cancer therapy performance at the VHA. Racial disparities in treatment may be explained, in part, by such factors. These results sound a cautionary note for quality measurement that depends on data that do not reflect patient preference or contraindications in conditions where such considerations are important. (C) 2013 by American Society of Clinical Oncology C1 [Ryoo, Joan J.; Ordin, Diana L.; Antonio, Anna Liza M.; Malin, Jennifer L.] Vet Adm Greater Los Angeles Healthcare Syst, West Los Angeles, CA USA. [Ryoo, Joan J.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Ryoo, Joan J.] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA 90027 USA. [Antonio, Anna Liza M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Oishi, Sabine M.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gould, Michael K.] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Asch, Steven M.] Vet Adm Palo Alto Healthcare Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Sch Med, Palo Alto, CA USA. [Ordin, Diana L.] Vet Hlth Adm, Washington, DC USA. [Malin, Jennifer L.] WellPoint, Indianapolis, IN USA. RP Ryoo, JJ (reprint author), Kaiser Permanente Los Angeles Med Ctr, Dept Radiat Oncol, 4950 Sunset Blvd,Second Floor, Los Angeles, CA 90027 USA. EM joan.j.ryoo@kp.org FU Robert Wood Johnson Clinical Scholars Program; University of California, Los Angeles Career Development Program in Cancer Prevention and Control Research National Cancer Institute R25 Grant FX Supported in part by the Robert Wood Johnson Clinical Scholars Program (J.J.R.) and the University of California, Los Angeles Career Development Program in Cancer Prevention and Control Research National Cancer Institute R25 Grant (J.J.R.). NR 58 TC 17 Z9 17 U1 2 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUL 20 PY 2013 VL 31 IS 21 BP 2716 EP + DI 10.1200/JCO.2012.45.7473 PG 9 WC Oncology SC Oncology GA 301NJ UT WOS:000330538700020 PM 23752110 ER PT J AU Kotloff, KL Nataro, JP Blackwelder, WC Nasrin, D Farag, TH Panchalingam, S Wu, Y Sow, SO Sur, D Breiman, RF Faruque, ASG Zaidi, AKM Saha, D Alonso, PL Tamboura, B Sanogo, D Onwuchekwa, U Manna, B Ramamurthy, T Kanungo, S Ochieng, JB Omore, R Oundo, JO Hossain, A Das, SK Ahmed, S Qureshi, S Quadri, F Adegbola, RA Antonio, M Hossain, MJ Akinsola, A Mandomando, I Nhampossa, T Acacio, S Biswas, K O'Reilly, CE Mintz, ED Berkeley, LY Muhsen, K Sommerfelt, H Robins-Browne, RM Levine, MM AF Kotloff, Karen L. Nataro, James P. Blackwelder, William C. Nasrin, Dilruba Farag, Tamer H. Panchalingam, Sandra Wu, Yukun Sow, Samba O. Sur, Dipika Breiman, Robert F. Faruque, Abu S. G. Zaidi, Anita K. M. Saha, Debasish Alonso, Pedro L. Tamboura, Boubou Sanogo, Doh Onwuchekwa, Uma Manna, Byomkesh Ramamurthy, Thandavarayan Kanungo, Suman Ochieng, John B. Omore, Richard Oundo, Joseph O. Hossain, Anowar Das, Sumon K. Ahmed, Shahnawaz Qureshi, Shahida Quadri, Farheen Adegbola, Richard A. Antonio, Martin Hossain, M. Jahangir Akinsola, Adebayo Mandomando, Inacio Nhampossa, Tacilta Acacio, Sozinho Biswas, Kousick O'Reilly, Ciara E. Mintz, Eric D. Berkeley, Lynette Y. Muhsen, Khitam Sommerfelt, Halvor Robins-Browne, Roy M. Levine, Myron M. TI Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study SO LANCET LA English DT Article ID ENTEROPATHOGENIC ESCHERICHIA-COLI; SUB-SAHARAN AFRICA; ROTAVIRUS VACCINATION; CHILDHOOD MORTALITY; ATTRIBUTABLE RISK; EPIDEMIOLOGY; CASE/CONTROL; CRYPTOSPORIDIOSIS; PERFORMANCE; POPULATION AB Background Diarrhoeal diseases cause illness and death among children younger than 5 years in low-income countries. We designed the Global Enteric Multicenter Study (GEMS) to identify the aetiology and population-based burden of paediatric diarrhoeal disease in sub-Saharan Africa and south Asia. Methods The GEMS is a 3-year, prospective, age-stratified, matched case-control study of moderate-to-severe diarrhoea in children aged 0-59 months residing in censused populations at four sites in Africa and three in Asia. We recruited children with moderate-to-severe diarrhoea seeking care at health centres along with one to three randomly selected matched community control children without diarrhoea. From patients with moderate-to-severe diarrhoea and controls, we obtained clinical and epidemiological data, anthropometric measure ments, and a faecal sample to identify enteropathogens at enrolment; one follow-up home visit was made about 60 days later to ascertain vital status, clinical outcome, and interval growth. Findings We enrolled 9439 children with moderate-to-severe diarrhoea and 13 129 control children without diarrhoea. By analysing adjusted population attributable fractions, most attributable cases of moderate-to-severe diarrhoea were due to four pathogens: rotavirus, Cryptosporidium, enterotoxigenic Escherichia coli producing heat-stable toxin (ST-ETEC; with or without co-expression of heat-labile enterotoxin), and Shigella. Other pathogens were important in selected sites (eg, Aeromonas, Vibrio cholerae O1, Campylobacter jejuni). Odds of dying during follow-up were 8.5-fold higher in patients with moderate-to-severe diarrhoea than in controls (odd ratio 8.5, 95% CI 5.8-12.5, p<0.0001); most deaths (167 [87.9%]) occurred during the first 2 years of life. Pathogens associated with increased risk of case death were ST-ETEC (hazard ratio [HR] 1.9; 0.99-3.5) and typical enteropathogenic E coli (HR 2.6; 1.6-4.1) in infants aged 0-11 months, and Cryptosporidium (HR 2.3; 1.3-4.3) in toddlers aged 12-23 months. Interpretation Interventions targeting five pathogens (rotavirus, Shigella, ST-ETEC, Cryptosporidium, typical enteropathogenic E coli) can substantially reduce the burden of moderate-to-severe diarrhoea. New methods and accelerated implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent disease and improve outcomes. C1 [Kotloff, Karen L.; Nataro, James P.; Blackwelder, William C.; Nasrin, Dilruba; Farag, Tamer H.; Panchalingam, Sandra; Wu, Yukun; Berkeley, Lynette Y.; Muhsen, Khitam; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA. [Kotloff, Karen L.; Nataro, James P.; Blackwelder, William C.; Nasrin, Dilruba; Farag, Tamer H.; Panchalingam, Sandra; Wu, Yukun; Muhsen, Khitam; Levine, Myron M.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA. [Sow, Samba O.; Tamboura, Boubou; Sanogo, Doh; Onwuchekwa, Uma] Ctr Dev Vaccins, Bamako, Mali. [Sur, Dipika; Manna, Byomkesh; Ramamurthy, Thandavarayan; Kanungo, Suman] Natl Inst Cholera & Enter Dis, Kolkata, India. [Breiman, Robert F.] US Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Div, Nairobi, Kenya. [Faruque, Abu S. G.; Hossain, Anowar; Das, Sumon K.; Ahmed, Shahnawaz] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Zaidi, Anita K. M.; Qureshi, Shahida; Quadri, Farheen] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Saha, Debasish; Adegbola, Richard A.; Antonio, Martin; Hossain, M. Jahangir; Akinsola, Adebayo] Med Res Council UK Unit, Fajara, Gambia. [Alonso, Pedro L.; Mandomando, Inacio; Nhampossa, Tacilta; Acacio, Sozinho] Ctr Invest Saude Manhica, Maputo, Mozambique. [Alonso, Pedro L.] Hosp Clin Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain. [Ochieng, John B.; Omore, Richard; Oundo, Joseph O.] Ctr Dis Control & Prevent KEMRI CDC, Kenya Med Res Inst, Kisumu, Kenya. [Adegbola, Richard A.] GlaxoSmithKline Biol, Global Med Affairs, Wavre, Belgium. [Akinsola, Adebayo] Daffodils Pediat & Family Med, Tucker, GA USA. [Mandomando, Inacio; Nhampossa, Tacilta; Acacio, Sozinho] Minist Saude, Inst Nacl Saude, Maputo, Mozambique. [Biswas, Kousick] US Dept Vet Affairs, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [O'Reilly, Ciara E.; Mintz, Eric D.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Berkeley, Lynette Y.] Ctr Drug Evaluat & Res, Off Antimicrobial Prod, Div Antiinfect Prod, Silver Spring, MD USA. [Sommerfelt, Halvor] Univ Bergen, Ctr Int Hlth, Bergen, Norway. [Sommerfelt, Halvor] Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway. [Robins-Browne, Roy M.] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia. RP Kotloff, KL (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. EM kkotloff@medicine.umaryland.edu OI Robins-Browne, Roy/0000-0001-9179-7884 FU Bill & Melinda Gates Foundation FX The Bill & Melinda Gates Foundation. NR 36 TC 612 Z9 624 U1 17 U2 138 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD JUL 20 PY 2013 VL 382 IS 9888 BP 209 EP 222 DI 10.1016/S0140-6736(13)60844-2 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 193FL UT WOS:000322543700031 PM 23680352 ER PT J AU Yang, XH Meyer, K Friedl, A AF Yang, Xinhai Meyer, Kristy Friedl, Andreas TI STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; N-TERMINAL FRAGMENTS; ANTIANGIOGENIC FACTOR; RECEPTOR ANTAGONISTS; MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION; CELL PROLIFERATION; PITUITARY-TUMORS; RETINOIC ACID; FACTOR VEGF AB We have shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal role in angiogenesis induced by the FGF2/STAT5 signaling cascade. To delineate the signaling pathway downstream of STAT5 in the human system, where proliferin does not exist, we expressed constitutively active (CA) or dominant-negative (DN) mutant STAT5A in hCMEC/D3 human brain endothelial cells. We found that conditioned medium from CA-STAT5A- but not from DN-STAT5A-overexpressing endothelial cells (EC) is sufficient to induce EC migration and tube formation but not proliferation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors. We identified prolactin (PRL) as a candidate autocrine factor. CA-STAT5A expression stimulates PRL production at the RNA and protein level, and STAT5A binds to the PRL promoter region, suggesting direct transcriptional regulation. Medium conditioned by CA-STAT5A-over-expressing EC induces phosphorylation of the PRL receptor and activates MAPK. Knockdown of PRL expression by shRNA or blocking of PRL activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC. The addition of recombinant PRL restores this activity. STAT5A-induced PRL in the conditioned medium can activate STAT5, STAT1, and to a lesser extent STAT3 in hCMEC/D3 cells, suggesting the existence of a positive feedback loop between STAT5 and PRL that promotes angiogenesis. Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A, and VEGF induction depends on PRL expression. These observations demonstrate a STAT5/PRL/VEGF signaling cascade in human brain EC and implicate PRL and VEGF as autocrine regulators of EC migration, invasion, and tube formation. C1 [Yang, Xinhai; Meyer, Kristy; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, Madison, WI 53705 USA. [Friedl, Andreas] UW Carbone Canc Ctr, Madison, WI 53792 USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, 6051 WIMR,MC-2275,1111 Highland Ave, Madison, WI 53705 USA. EM afriedl@wisc.edu FU UW Department of Pathology and Laboratory Medicine; UW Carbone Cancer Center [P30 CA014520] FX We thank Dr. Charles Clevenger, Northwestern University, for immunohistochemical labeling of the glioma samples and Dr. Babette Weksler, Weill Cornell Medical College, for kindly providing hCMEC/D3 cells. Korise Rasmusson helped with manuscript preparation. We thank the University of Wisconsin Translational Research Initiatives in Pathology laboratory, in part supported by the UW Department of Pathology and Laboratory Medicine and UW Carbone Cancer Center Grant P30 CA014520 for use of its facilities and services. NR 63 TC 16 Z9 16 U1 0 U2 20 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 19 PY 2013 VL 288 IS 29 BP 21184 EP 21196 DI 10.1074/jbc.M113.481119 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 186AU UT WOS:000322014400038 PM 23729680 ER PT J AU Linger, RMA Cohen, RA Cummings, CT Sather, S Migdall-Wilson, J Middleton, DHG Lu, X Baron, AE Franklin, WA Merrick, DT Jedlicka, P DeRyckere, D Heasley, LE Graham, DK AF Linger, R. M. A. Cohen, R. A. Cummings, C. T. Sather, S. Migdall-Wilson, J. Middleton, D. H. G. Lu, X. Baron, A. E. Franklin, W. A. Merrick, D. T. Jedlicka, P. DeRyckere, D. Heasley, L. E. Graham, D. K. TI Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer SO ONCOGENE LA English DT Article DE targeted therapy; receptor tyrosine kinase; MerTK; signal transduction; xenograft; chemosensitivity ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ELEMENT-BINDING PROTEIN; NF-KAPPA-B; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; THERAPEUTIC TARGETS; PROLONGS SURVIVAL; DISEASE-ACTIVITY; DRUG-RESISTANCE AB Non-small cell lung cancer (NSCLC) is a prevalent and devastating disease that claims more lives than breast, prostate, colon and pancreatic cancers combined. Current research suggests that standard chemotherapy regimens have been optimized to maximal efficiency. Promising new treatment strategies involve novel agents targeting molecular aberrations present in subsets of NSCLC. We evaluated 88 human NSCLC tumors of diverse histology and identified Mer and Axl as receptor tyrosine kinases (RTKs) overexpressed in 69% and 93%, respectively, of tumors relative to surrounding normal lung tissue. Mer and Axl were also frequently overexpressed and activated in NSCLC cell lines. Ligand-dependent Mer or Axl activation stimulated MAPK, AKT and FAK signaling pathways indicating roles for these RTKs in multiple oncogenic processes. In addition, we identified a novel pro-survival pathway-involving AKT, CREB, Bcl-xL, survivin, and Bcl-2-downstream of Mer, which is differentially modulated by Axl signaling. We demonstrated that short hairpin RNA (shRNA) knockdown of Mer or Axl significantly reduced NSCLC colony formation and growth of subcutaneous xenografts in nude mice. Mer or Axl knockdown also improved in vitro NSCLC sensitivity to chemotherapeutic agents by promoting apoptosis. When comparing the effects of Mer and Axl knockdown, Mer inhibition exhibited more complete blockade of tumor growth while Axl knockdown more robustly improved chemosensitivity. These results indicate that Mer and Axl have complementary and overlapping roles in NSCLC and suggest that treatment strategies targeting both RTKs may be more effective than singly-targeted agents. Our findings validate Mer and Axl as potential therapeutic targets in NSCLC and provide justification for development of novel therapeutic compounds that selectively inhibit Mer and/or Axl. C1 [Linger, R. M. A.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; DeRyckere, D.; Graham, D. K.] Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Aurora, CO 80045 USA. [Middleton, D. H. G.] Univ Colorado, Program Canc Biol, Aurora, CO 80045 USA. [Lu, X.; Baron, A. E.] Univ Colorado, Dept Biostat & Informat, Aurora, CO 80045 USA. [Franklin, W. A.; Merrick, D. T.; Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA. [Merrick, D. T.] Denver VA Med Ctr, Dept Pathol, Denver, CO USA. [Heasley, L. E.] Denver VA Med Ctr, Dept Craniofacial Biol, Denver, CO USA. RP Graham, DK (reprint author), Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Anschutz Med Campus,Mail Stop 8302,12800 East 19t, Aurora, CO 80045 USA. EM doug.graham@ucdenver.edu FU Uniting Against Lung Cancer: Elliot's Legacy (RMAL); Lung Cancer Research Foundation (RMAL); American Cancer Society [RSG-08-291-01-LIB]; National Institutes of Health [RO1CA137078]; University of Colorado Cancer Center SPORE in Lung Cancer [NIH 5P50CA058187]; Damon Runyon Cancer Research Foundation [CI-39-07] FX This work was supported in part by grants from Uniting Against Lung Cancer: Elliot's Legacy (RMAL), the Lung Cancer Research Foundation (RMAL), the American Cancer Society (RSG-08-291-01-LIB, DKG) and the National Institutes of Health (RO1CA137078, DKG). RMA Linger received a Career Development Award from the University of Colorado Cancer Center SPORE in Lung Cancer (NIH 5P50CA058187). DK Graham is the Damon Runyon-Novartis Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-39-07). The authors wish to thank Karen Helm, Christine Childs and Lester Acosta in the University of Colorado Cancer Center Flow Cytometry Core for their expert technical assistance, Randall Wong in the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core Facility (NIH P30 DK57516) for cell line authentication services, Patricia Lenhart for help optimizing Mer and Axl immunohistochemistry of human tissues, and Storey Wilson and Andrea Abeyta for technical assistance with the Aperio imaging system used to digitize stained tumor microarray slides. NR 65 TC 46 Z9 46 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD JUL 18 PY 2013 VL 32 IS 29 BP 3420 EP 3431 DI 10.1038/onc.2012.355 PG 12 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 186AZ UT WOS:000322014900003 PM 22890323 ER PT J AU Dowling, NM Gleason, CE Manson, JE Hodis, HN Miller, VM Brinton, EA Neal-Perry, G Santoro, MN Cedars, M Lobo, R Merriam, GR Wharton, W Naftolin, F Taylor, H Harman, SM Asthana, S AF Dowling, N. Maritza Gleason, Carey E. Manson, JoAnn E. Hodis, Howard N. Miller, Virginia M. Brinton, Eliot A. Neal-Perry, Genevieve Santoro, M. Nanette Cedars, Marcelle Lobo, Rogerio Merriam, George R. Wharton, Whitney Naftolin, Frederick Taylor, Hugh Harman, S. Mitchell Asthana, Sanjay TI Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance SO PLOS ONE LA English DT Article ID CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; EARLY ESTROGEN PREVENTION; APOLIPOPROTEIN-E GENOTYPE; NON-HISPANIC WHITES; BODY-MASS INDEX; CARDIOVASCULAR RISK; ALZHEIMERS-DISEASE; SOCIOECONOMIC-STATUS; DENSITY-LIPOPROTEIN AB Objectives: While global measures of cardiovascular (CV) risk are used to guide prevention and treatment decisions, these estimates fail to account for the considerable interindividual variability in pre-clinical risk status. This study investigated heterogeneity in CV risk factor profiles and its association with demographic, genetic, and cognitive variables. Methods: A latent profile analysis was applied to data from 727 recently postmenopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Women were cognitively healthy, within three years of their last menstrual period, and free of current or past CV disease. Education level, apolipoprotein E epsilon 4 allele (APOE4), ethnicity, and age were modeled as predictors of latent class membership. The association between class membership, characterizing CV risk profiles, and performance on five cognitive factors was examined. A supervised random forest algorithm with a 10-fold cross-validation estimator was used to test accuracy of CV risk classification. Results: The best-fitting model generated two distinct phenotypic classes of CV risk 62% of women were "low-risk" and 38% "high-risk". Women classified as low-risk outperformed high-risk women on language and mental flexibility tasks (p = 0.008) and a global measure of cognition (p = 0.029). Women with a college degree or above were more likely to be in the low-risk class (OR = 1.595, p = 0.044). Older age and a Hispanic ethnicity increased the probability of being at high-risk (OR = 1.140, p = 0.002; OR = 2.622, p = 0.012; respectively). The prevalence rate of APOE-epsilon 4 was higher in the high-risk class compared with rates in the low-risk class. Conclusion: Among recently menopausal women, significant heterogeneity in CV risk is associated with education level, age, ethnicity, and genetic indicators. The model-based latent classes were also associated with cognitive function. These differences may point to phenotypes for CV disease risk. Evaluating the evolution of phenotypes could in turn clarify preclinical disease, and screening and preventive strategies. ClinicalTrials.gov NCT00154180 C1 [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Dowling, N. Maritza; Gleason, Carey E.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Gleason, Carey E.; Wharton, Whitney; Asthana, Sanjay] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gleason, Carey E.; Wharton, Whitney; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Miller, Virginia M.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN USA. [Brinton, Eliot A.] Univ Utah, Dept Cardiovasc Genet, Salt Lake City, UT USA. [Neal-Perry, Genevieve] Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA. [Neal-Perry, Genevieve] Albert Einstein Coll Med, Dominick Purpura Dept Neurosci, Bronx, NY 10467 USA. [Santoro, M. Nanette] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO USA. [Cedars, Marcelle] Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA. [Lobo, Rogerio] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Merriam, George R.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Naftolin, Frederick] NYU, Dept Obstet & Gynecol, New York, NY 10016 USA. [Taylor, Hugh] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06510 USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ USA. [Harman, S. Mitchell] Phoenix VA Med Ctr, Phoenix, AZ USA. RP Dowling, NM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA. EM nmdowlin@biostat.wisc.edu FU National Institutes of Health (NIH) [R01 AG029624, P50AG033514, R01AG031790]; Aurora Foundation; NIH [HL90639]; Mayo [CTSA1 UL1 RR024150]; Einstein College of Medicine CTSA [UL1 RR025750, KL2 RR025749, TL1 RR025748]; Mayo Foundation; United States Department of Veterans Affairs Puget Sound Health Care System; Brigham and Women's Hospital/Harvard Medical School CTSA; CTSA [UL1 RR024139]; UCSF CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [UL1 RR024131]; NIH Roadmap for Medical Research FX The KEEPS-cog project was supported by grants from the National Institutes of Health (NIH) R01 AG029624, P50AG033514, and R01AG031790. The parent KEEPS trial is funded by grants from the Aurora Foundation to the Kronos Longevity Research Institute, NIH HL90639 to VMM, Mayo CTSA1 UL1 RR024150, the Einstein College of Medicine CTSA UL1 RR025750, KL2 RR025749 and TL1 RR025748, the Mayo Foundation, the United States Department of Veterans Affairs Puget Sound Health Care System, Brigham and Women's Hospital/Harvard Medical School CTSA, CTSA UL1 RR024139 and UCSF CTSA UL1 RR024131 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH and NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 79 TC 4 Z9 4 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 17 PY 2013 VL 8 IS 7 AR UNSP e68741 DI 10.1371/journal.pone.0068741 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 185WH UT WOS:000322000600022 PM 23874743 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Operative diagnosis for revision total hip arthroplasty is associated with patient-reported outcomes (PROs) SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Total hip replacement; Arthroplasty; Joint replacement; Patient-reported outcomes; Diagnosis ID TOTAL KNEE ARTHROPLASTY; UNITED-STATES; PREDICTORS; PAIN; RESPONSIVENESS; QUESTIONNAIRE; COMORBIDITY; REPLACEMENT; FRACTURES; MORBIDITY AB Background: Little is known about the impact of the reason for revision total hip arthroplasty (THA) on the outcomes following revision THA. In this study, our objective was to assess the association of operative diagnosis with patient-reported outcomes (PROs) after revision THA. Methods: We used prospectively collected data from the Mayo Clinic Total Joint Registry that collects pre- and post-operative pain and function outcomes using a validated Hip questionnaire, on all revision THAs from 1993-2005. We used logistic regression to assess the odds of moderate-severe index hip pain and moderate-severe limitation in activities of daily living (ADLs) 2- and 5-years after revision THA. We calculated odds ratios (OR) and 95% confidence intervals (CIs). Results: For the 2- and 5-year cohorts, the operative diagnosis was loosening/wear/osteolysis in 73% and 75%; dislocation/bone or prosthesis fracture/instability or non-union in 17% and 15%; and failed prior arthroplasty with components removed/infection in 11% and 11%, respectively. In multivariable-adjusted analyses that included preoperative ADL limitations, compared to patients with loosening/wear/osteolysis, patients with dislocation/fracture/instability/non-union had OR of 2.2 (95% CI, 1.3-3.5; p = 0.002) for overall moderate-severe ADL limitation and those with failed prior arthroplasty/infection had OR of 1.6 (95% CI, 1.0-2.8; p = 0.06). At 5-years, ORs were lower and differences were no longer significant. Moderate-severe pain did not differ significantly by diagnosis, at 2- or 5-years in multivariable adjusted analyses, with one exception, i.e. failed prior arthroplasty/infection had a trend towards significance with odds ratio of 1.9 (95% CI, 0.9-3.8; p = 0.07). Conclusions: Operative diagnosis is independently associated with ADL limitations, but not pain, at 2-years after revision THA. Patients should be informed of the risk of poorer short-term outcomes based on their diagnosis. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthopaed Surg, Rochester, MN USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Mayo Clinic Orthopedic Surgery research funds; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX This material is the result of work supported Mayo Clinic Orthopedic Surgery research funds and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). NR 31 TC 3 Z9 3 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD JUL 17 PY 2013 VL 14 AR 210 DI 10.1186/1471-2474-14-210 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 188KY UT WOS:000322193100001 PM 23866848 ER PT J AU Gellad, WF Donohue, JM Zhao, XH Mor, MK Thorpe, CT Smith, J Good, CB Fine, MJ Morden, NE AF Gellad, Walid F. Donohue, Julie M. Zhao, Xinhua Mor, Maria K. Thorpe, Carolyn T. Smith, Jeremy Good, Chester B. Fine, Michael J. Morden, Nancy E. TI Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes A National Cohort Comparison SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID HEALTH-CARE-SYSTEM; QUALITY-OF-CARE; GEOGRAPHIC-VARIATION; OLDER-ADULTS; COST; PRICES; IMPLEMENTATION; HYPERTENSION; MEDICATIONS; PHYSICIANS AB Background: Medicare Part D and the U.S. Department of Veterans Affairs (VA) use different approaches to manage prescription drug benefits, with implications for spending. Medicare relies on private plans with distinct formularies, whereas the VA administers its own benefit using a national formulary. Objective: To compare overall and regional rates of brand-name drug use among older adults with diabetes in Medicare and the VA. Design: Retrospective cohort. Setting: Medicare and the VA, 2008. Patients: 1 061 095 Medicare Part D beneficiaries and 510 485 veterans aged 65 years or older with diabetes. Measurements: Percentage of patients taking oral hypoglycemics, statins, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-name drug prescriptions and percentage of patients taking long-acting insulins who filled analogue prescriptions. Sociodemographic-and health status-adjusted hospital referral region (HRR) brand-name drug use was compared, and changes in spending were calculated if use of brand-name drugs in 1 system mirrored the other. Results: Brand-name drug use in Medicare was 2 to 3 times that in the VA: 35.3% versus 12.7% for oral hypoglycemics, 50.7% versus 18.2% for statins, 42.5% versus 20.8% for ACE inhibitors or ARBs, and 75.1% versus 27.0% for insulin analogues. Adjusted HRR-level brand-name statin use ranged (from the 5th to 95th percentiles) from 41.0% to 58.3% in Medicare and 6.2% to 38.2% in the VA. For each drug group, the 95th-percentile HRR in the VA had lower brand-name drug use than the 5th-percentile HRR in Medicare. Medicare spending in this population would have been $1.4 billion less if brand-name drug use matched that of the VA. Limitation: This analysis cannot fully describe the factors underlying differences in brand-name drug use. Conclusion: Medicare beneficiaries with diabetes use 2 to 3 times more brand-name drugs than a comparable group within the VA, at substantial excess cost. C1 Univ Pittsburgh, RAND Corp, Vet Affairs Pittsburgh Healthcare Syst, Grad Sch Publ Hlth,Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Smith, Jeremy; Morden, Nancy E.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA. US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. Geisel Sch Med Dartmouth, Hanover, NH USA. RP Gellad, WF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM walid.gellad@va.gov FU U.S. Department of Veterans Affairs; National Institutes of Health; Robert Wood Johnson Foundation FX Primary Funding Source: U.S. Department of Veterans Affairs, National Institutes of Health, and Robert Wood Johnson Foundation. NR 49 TC 17 Z9 17 U1 1 U2 15 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 16 PY 2013 VL 159 IS 2 BP 105 EP W39 DI 10.7326/0003-4819-159-2-201307160-00664 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 187IX UT WOS:000322112000016 PM 23752663 ER PT J AU Khera, N Storer, B Sandmaier, BM Chapko, MK Lee, SJ AF Khera, Nandita Storer, Barry Sandmaier, Brenda M. Chapko, Michael K. Lee, Stephanie J. TI Costs of Second Allogeneic Hematopoietic Cell Transplantation SO TRANSPLANTATION LA English DT Article DE Hematopoietic cell transplantation; Economics; Costs; Cost effectiveness; Pharmacoeconomics ID BONE-MARROW-TRANSPLANTATION; MULTIPLE-MYELOMA; ACUTE-LEUKEMIA; GRAFT FAILURE; RELAPSE; CHEMOTHERAPY; LYMPHOMA; SURVIVAL; BLOOD; SCT AB Background. A second allogeneic transplantation after a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually performed for graft failure, disease recurrence, secondary malignancy, and, as planned, auto-allo transplantation for some diseases. Methods. We sought to describe the costs of second allogeneic HCT and evaluate their relationship with patient characteristics and posttransplantation complications. Clinical information and medical costs for the first 100 days after transplantation of 245 patients (allo-allo, 55; auto-allo, 190) who underwent a second HCT between 2004 and 2010 were collected. Results. Median costs of the second allogeneic HCT were U.S. $151,000 (range, U.S. $62,000-405,000) for the allo-allo group and U.S. $109,000 (range, U.S. $26,000-490,000) for the auto-allo group. Median length of hospital stay was 23 days (range, 0-76) for the allo-allo group and 9 days (range, 0-96) for the auto-allo group. Only the year of transplantation and posttransplantation complications were significantly associated with costs in both groups when both pre- and posttransplantation variables were considered. The overall costs of the second HCT were higher than the first in the allo-allo group. For the auto-allo group, there was no difference between the costs whether preformed as a planned tandem or as salvage for relapse. Conclusions. Our results suggest that second allogeneic HCT is costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs of complications. C1 [Khera, Nandita] Mayo Clin Arizona, Div Hematol Oncol, Phoenix, AZ USA. [Storer, Barry; Sandmaier, Brenda M.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Chapko, Michael K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Khera, N (reprint author), 5777 East Mayo Blvd,C-211, Phoenix, AZ 85054 USA. EM khera.nandita@mayo.edu FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000423]; National Institutes of Health [CA 78902, HL36444, CA18029] FX The study was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000423 and grants CA 78902, HL36444, and CA18029 from the National Institutes of Health. NR 25 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUL 15 PY 2013 VL 96 IS 1 BP 108 EP 115 DI 10.1097/TP.0b013e318294caf1 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 299EJ UT WOS:000330378000018 PM 23694949 ER PT J AU Bethel, MA Chacra, AR Deedwania, P Fulcher, GR Holman, RR Jenssen, T Kahn, SE Levitt, NS McMurray, JJV Califf, RM Raptis, SA Thomas, L Sun, JL Haffner, SM AF Bethel, M. Angelyn Chacra, Antonio R. Deedwania, Prakash Fulcher, Gregory R. Holman, Rury R. Jenssen, Trond Kahn, Steven E. Levitt, Naomi S. McMurray, John J. V. Califf, Robert M. Raptis, Sotirios A. Thomas, Laine Sun, Jie-Lena Haffner, Steven M. TI A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; FASTING GLUCOSE; LIVER FIBROSIS; TASK-FORCE; HEART; TRIAL; NATEGLINIDE; PREVENTION AB We used baseline data from the NAVIGATOR trial to (1) identify risk factors for diabetes progression in those with impaired glucose tolerance and high cardiovascular risk, (2) create models predicting 5-year incident diabetes, and (3) provide risk classification tools to guide clinical interventions. Multivariate Cox proportional hazards models estimated 5-year incident diabetes risk and simplified models examined the relative importance of measures of glycemia in assessing diabetes risk. The C-statistic was used to compare models; reclassification analyses compare the models' ability to identify risk groups defined by potential therapies (routine or intensive lifestyle advice or pharmacologic therapy). Diabetes developed in 3,254 (35%) participants over 5 years median follow-up. The full prediction model included fasting and 2-hour glucose and hemoglobin A1c (HbA1c) values but demonstrated only moderate discrimination for diabetes (C = 0.70). Simplified models with only fasting glucose (C = 0.67) or oral glucose tolerance test values (C = 0.68) had higher C statistics than models with HbA1c alone (C = 0.63). The models were unlikely to inappropriately reclassify participants to risk groups that might receive pharmacologic therapy. Our results confirm that in a population with dysglycemia and high cardiovascular risk, traditional risk factors are appropriate predictors and glucose values are better predictors than HbA1c, but discrimination is moderate at best, illustrating the challenges of predicting diabetes in a high-risk population. In conclusion, our novel risk classification paradigm based on potential treatment could be used to guide clinical practice based on cost and availability of screening tests. (C) 2013 Elsevier Inc. All rights reserved. C1 [Bethel, M. Angelyn; Holman, Rury R.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. [Bethel, M. Angelyn] Duke Univ, Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, Durham, NC 27710 USA. [Chacra, Antonio R.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Deedwania, Prakash] Univ Calif San Francisco Program Fresno, Fresno, CA USA. [Deedwania, Prakash] Vet Adm Cent Calif Hlth Care Syst, Fresno, CA USA. [Fulcher, Gregory R.] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia. [Jenssen, Trond] Univ Tromso, Oslo Univ Hosp, Rigshosp, Inst Clin Med, Oslo, Norway. [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Levitt, Naomi S.] Univ Cape Town, Dept Med, Groote Schuur Hosp, Endocrine Unit, ZA-7925 Cape Town, South Africa. [McMurray, John J. V.] Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland. [Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA. [Raptis, Sotirios A.] Attikon Univ Hosp, Hellen Natl Diabet Ctr, Dept Internal Med Endocrinol & Diabetol 2, Athens, Greece. [Thomas, Laine] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. [Thomas, Laine; Sun, Jie-Lena] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. RP Bethel, MA (reprint author), Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. EM angelyn.bethel@dtu.ox.ac.uk OI Kahn, Steven/0000-0001-7307-9002; mcmurray, john/0000-0002-6317-3975 FU Novartis Pharmaceuticals FX The NAVIGATOR trial was funded by Novartis Pharmaceuticals. NR 21 TC 2 Z9 2 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 15 PY 2013 VL 112 IS 2 BP 231 EP 237 DI 10.1016/j.amjcard.2013.03.019 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 188PR UT WOS:000322206500015 PM 23608615 ER PT J AU Jubran, A AF Jubran, Amal TI Has the Twitching Hour Arrived for the Ventilated Patient? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID MECHANICAL VENTILATION; RANDOMIZED-TRIAL; PRESSURE; DURATION; FAILURE; SUPPORT; HUMANS; MUSCLE C1 [Jubran, Amal] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Jubran, Amal] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. RP Jubran, A (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 12 TC 2 Z9 2 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 15 PY 2013 VL 188 IS 2 BP 126 EP 128 DI 10.1164/rccm.201305-0890ED PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 183LV UT WOS:000321817400004 PM 23855688 ER PT J AU Esteban, A Frutos-Vivar, F Muriel, A Ferguson, ND Penuelas, O Abraira, V Raymondos, K Rios, F Nin, N Apezteguia, C Violi, DA Thille, AW Brochard, L Gonzalez, M Villagomez, AJ Hurtado, J Davies, AR Du, B Maggiore, SM Pelosi, P Soto, L Tomicic, V D'Empaire, G Matamis, D Abroug, F Moreno, RP Soares, MA Arabi, Y Sandi, F Jibaja, M Amin, P Koh, Y Kuiper, MA Bulow, HH Zeggwagh, AA Anzueto, A AF Esteban, Andres Frutos-Vivar, Fernando Muriel, Alfonso Ferguson, Niall D. Penuelas, Oscar Abraira, Victor Raymondos, Konstantinos Rios, Fernando Nin, Nicolas Apezteguia, Carlos Violi, Damian A. Thille, Arnaud W. Brochard, Laurent Gonzalez, Marco Villagomez, Asisclo J. Hurtado, Javier Davies, Andrew R. Du, Bin Maggiore, Salvatore M. Pelosi, Paolo Soto, Luis Tomicic, Vinko D'Empaire, Gabriel Matamis, Dimitrios Abroug, Fekri Moreno, Rui P. Soares, Marco Antonio Arabi, Yaseen Sandi, Freddy Jibaja, Manuel Amin, Pravin Koh, Younsuck Kuiper, Michael A. Bulow, Hans-Henrik Zeggwagh, Amine Ali Anzueto, Antonio TI Evolution of Mortality over Time in Patients Receiving Mechanical Ventilation SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE mechanical ventilation; mortality; epidemiology; cohort study ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; END-EXPIRATORY PRESSURE; LOWER TIDAL VOLUMES; CRITICALLY-ILL PATIENTS; PROTECTIVE-VENTILATION; STRATEGY; METAANALYSIS; SEDATION AB Rationale: Baseline characteristics and management have changed over time in patients requiring mechanical ventilation; however, the impact of these changes on patient outcomes is unclear. Objectives: To estimate whether mortality in mechanically ventilated patients has changed over time. Methods: Prospective cohort studies conducted in 1998, 2004, and 2010, including patients receiving mechanical ventilation for more than 12 hours in a 1-month period, from 927 units in 40 countries. To examine effects over time on mortality in intensive care units, we performed generalized estimating equation models. Measurements and Main Results: We included 18,302 patients. The reasons for initiating mechanical ventilation varied significantly among cohorts. Ventilatory management changed over time (P, 0.001), with increased use of noninvasive positive-pressure ventilation (5% in 1998 to 14% in 2010), a decrease in tidal volume (mean 8.8 ml/kg actual body weight [SD = 2.1] in 1998 to 6.9 ml/kg [SD = 1.9] in 2010), and an increase in applied positive end-expiratory pressure (mean 4.2 cm H2O [SD = 3.8] in 1998 to 7.0 cm of H2O [SD = 3.0] in 2010). Crude mortality in the intensive care unit decreased in 2010 compared with 1998 (28 versus 31%; odds ratio, 0.87; 95% confidence interval, 0.80-0.94), despite a similar complication rate. Hospital mortality decreased similarly. After adjusting for baseline and management variables, this difference remained significant (odds ratio, 0.78; 95% confidence interval, 0.67-0.92). Conclusions: Patient characteristics and ventilation practices have changed over time, and outcomes of mechanically ventilated patients have improved. Clinical trials registered with www.clinicaltrials.gov (NCT01093482). C1 [Esteban, Andres; Frutos-Vivar, Fernando; Penuelas, Oscar; Nin, Nicolas] Hosp Univ Getafe, Madrid 28905, Spain. [Muriel, Alfonso; Abraira, Victor] Hosp Ramon & Cajal, Dept Clin Biostat, Inst Ramon y Cajal Invest Sanitaria, Madrid, Spain. [Ferguson, Niall D.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON M5S 1A1, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada. [Ferguson, Niall D.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada. [Raymondos, Konstantinos] Hannover Med Sch, Hannover, Germany. [Rios, Fernando; Apezteguia, Carlos] Hosp Nacl Alejandro Posadas, Buenos Aires, DF, Argentina. [Violi, Damian A.] Hosp Interzonal Gen Agudos Dr Luis Guemes, Haedo, Argentina. [Thille, Arnaud W.] CHU Henri Mondor, F-94010 Creteil, France. [Brochard, Laurent] Univ Hosp Geneva, Geneva, Switzerland. [Gonzalez, Marco] Clin Medellin, Medellin, Colombia. [Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia. [Villagomez, Asisclo J.] Hosp Reg 1 Octubre, Inst Seguridad & Serv Sociales Trabajadores Estad, Mexico City, DF, Mexico. [Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay. [Davies, Andrew R.] Alfred Hosp, Melbourne, Vic, Australia. [Davies, Andrew R.] Monash Univ, Melbourne, Vic 3004, Australia. [Du, Bin] Beijing Union Med Coll Hosp, Beijing, Peoples R China. [Maggiore, Salvatore M.] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy. [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Genoa, Italy. [Soto, Luis] Inst Nacl Torax Santiago, Santiago, Chile. [Tomicic, Vinko] Clin Las Lilas Santiago, Santiago, Chile. [D'Empaire, Gabriel] Hosp Clin Caracas, Caracas, Venezuela. [Matamis, Dimitrios] Papageorgiou Hosp, Thessaloniki, Greece. [Abroug, Fekri] Hosp Fattouma Bourguina, Monastir, Tunisia. [Moreno, Rui P.] Ctr Hosp Lisboa Cent, Hosp Sao Jose, Unidade Cuidados Intens Neurocrit, Lisbon, Portugal. [Soares, Marco Antonio] Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil. [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia. [Sandi, Freddy] Hosp Obrero 1, La Paz, Bolivia. [Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador. [Amin, Pravin] Bombay Hosp Inst Med Sci, Bombay, Maharashtra, India. [Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Seoul, South Korea. [Kuiper, Michael A.] Med Ctr Leeuwarden, Leeuwarden, Netherlands. [Bulow, Hans-Henrik] Reg Zealand Univ Copenhagen, Holbak Hosp, Copenhagen, Denmark. [Zeggwagh, Amine Ali] Hop Ibn Sina, Rabat, Morocco. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Esteban, A (reprint author), Hosp Univ Getafe, Intens Care Unit, Carretera Toledo,Km 12,500, Madrid 28905, Spain. EM aesteban@ucigetafe.com OI Abraira, Victor/0000-0002-4615-8503; Frutos-Vivar, Fernando/0000-0002-4648-9636; MAGGIORE, Salvatore Maurizio/0000-0002-1828-9143; Ferguson, Niall/0000-0002-6213-5264; Muriel, Alfonso /0000-0002-4805-4011 FU Centro de Investigacion Biomedica en red Enfermedades Respiratorias, CIBER en Epidemiologia y Salud Publica; Instituto de Salud Carlos III, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Canadian Institutes of Health Research (Ottawa, ON, Canada) FX Supported by Centro de Investigacion Biomedica en red Enfermedades Respiratorias, CIBER en Epidemiologia y Salud Publica. Instituto de Salud Carlos III, Madrid, Spain, Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain, and by a Canadian Institutes of Health Research (Ottawa, ON, Canada) New Investigator Award (N.D.F.). NR 43 TC 126 Z9 135 U1 2 U2 14 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 15 PY 2013 VL 188 IS 2 BP 220 EP 230 DI 10.1164/rccm.201212-2169OC PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 183LV UT WOS:000321817400017 PM 23631814 ER PT J AU Archambault, AS Carrero, JA Barnett, LG McGee, NG Sim, J Wright, JO Raabe, T Chen, PQ Ding, H Allenspach, EJ Dragatsis, I Laufer, TM Wu, GF AF Archambault, Angela S. Carrero, Javier A. Barnett, Lisa G. McGee, Nigel G. Sim, Julia Wright, Jonathan O. Raabe, Tobias Chen, Peiquin Ding, Hua Allenspach, Eric J. Dragatsis, Ioannis Laufer, Terri M. Wu, Gregory F. TI Cutting Edge: Conditional MHC Class II Expression Reveals a Limited Role for B Cell Antigen Presentation in Primary and Secondary CD4 T Cell Responses SO JOURNAL OF IMMUNOLOGY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DENDRITIC CELLS; IN-VIVO; MICE; REQUIREMENT; PROGRESSION; MUTATIONS; IMMUNITY; DISEASE AB The activation, differentiation, and subsequent effector functions of CD4 T cells depend on interactions with a multitude of MHC class II (MHCII)-expressing APCs. To evaluate the individual contribution of various APCs to CD4 T cell function, we have designed a new murine tool for selective in vivo expression of MHCII in subsets of APCs. Conditional expression of MHCII in B cells was achieved using a cre-loxP approach. After i.v. or s.c. priming, partial proliferation and activation of CD4 T cells was observed in mice expressing MHCII only by B cells. Restricting MHCII expression to B cells constrained secondary CD4 T cell responses in vivo, as demonstrated in a CD4 T cell-dependent model of autoimmunity, experimental autoimmune encephalomyelitis. These results highlight the limitations of B cell Ag presentation during initiation and propagation of CD4 T cell function in vivo using a novel system to study individual APCs by the conditional expression of MHCII. C1 [Archambault, Angela S.; McGee, Nigel G.; Wright, Jonathan O.; Wu, Gregory F.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Carrero, Javier A.; Wu, Gregory F.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Barnett, Lisa G.; Allenspach, Eric J.; Laufer, Terri M.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19004 USA. [Sim, Julia] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA. [Raabe, Tobias; Chen, Peiquin] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19004 USA. [Ding, Hua] Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19004 USA. [Dragatsis, Ioannis] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA. [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19004 USA. RP Wu, GF (reprint author), Washington Univ, Sch Med, 660 South Euclid Ave,Box 8111, St Louis, MO 63110 USA. EM wug@neuro.wustl.edu OI Allenspach, Eric/0000-0001-7346-5835 FU National Cancer Institute Cancer Center Support Grant [P30 CA91842]; National Institute of Neurological Disorders and Stroke [5K08NS062138]; Barnes-Jewish Foundation FX We thank the Alvin J. Siteman Cancer Center (supported in part by National Cancer Institute Cancer Center Support Grant #P30 CA91842) and the Barnes-Jewish Hospital for the use of the Embryonic Stem Cell Core, which provided all ES cell services.; This work was supported by the National Institute of Neurological Disorders and Stroke (Grant 5K08NS062138) and the Barnes-Jewish Foundation. NR 25 TC 9 Z9 9 U1 0 U2 6 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JUL 15 PY 2013 VL 191 IS 2 BP 545 EP 550 DI 10.4049/jimmunol.1201598 PG 6 WC Immunology SC Immunology GA 175UW UT WOS:000321260100006 PM 23772037 ER PT J AU Liu, Z Jiang, Y Li, YH Wang, J Fan, LY Scott, MJ Xiao, GZ Li, S Billiar, TR Wilson, MA Fan, J AF Liu, Zheng Jiang, Yong Li, Yuehua Wang, Juan Fan, Liyan Scott, Melanie J. Xiao, Guozhi Li, Song Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI TLR4 Signaling Augments Monocyte Chemotaxis by Regulating G Protein-Coupled Receptor Kinase 2 Translocation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CHEMOKINE RECEPTORS; NEUTROPHIL MIGRATION; CELL RECRUITMENT; EXPRESSION; GRK2; MICE; CHEMOATTRACTANT; DESENSITIZATION; INFLAMMATION; ACTIVATION AB Monocytes are critical effector cells of the innate immune system that protect the host by migrating to inflammatory sites, differentiating to macrophages and dendritic cells, eliciting immune responses, and killing pathogenic microbes. MCP-1, also known as CCL2, plays an important role in monocyte activation and migration. The chemotactic function of MCP-1 is mediated by binding to the CCR2 receptor, a member of the G protein-coupled receptor (GPCR) family. Desensitization of GPCR chemokine receptors is an important regulator of the intensity and duration of chemokine stimulation. GPCR kinases (GRKs) induce GPCR phosphorylation, and this leads to GPCR desensitization. Regulation of subcellular localization of GRKs is considered an important early regulatory mechanism of GRK function and subsequent GPCR desensitization. Chemokines and LPS are both present during Gram-negative bacterial infection, and LPS often synergistically exaggerates leukocyte migration in response to chemokines. In this study, we investigated the role and mechanism of LPS-TLR4 signaling on the regulation of monocyte chemotaxis. We demonstrate that LPS augments MCP-1-induced monocyte migration. We also show that LPS, through p38 MAPK signaling, induces phosphorylation of GRK2 at serine 670, which, in turn, suppresses GRK2 translocation to the membrane, thereby preventing GRK2-initiated internalization and desensitization of CCR2 in response to MCP-1. This results in enhanced monocyte migration. These findings reveal a novel function for TLR4 signaling in promoting innate immune cell migration. The Journal of Immunology, 2013, 191: 857-864. C1 [Liu, Zheng; Jiang, Yong; Wang, Juan] Southern Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, Peoples R China. [Liu, Zheng; Li, Yuehua; Wang, Juan; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA 15213 USA. [Xiao, Guozhi] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Li, Song] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA. [Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA. [Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. EM jiang48231@163.com; jif7@pitt.edu FU National Institutes of Health [R01-HL-079669, R01-GM-50441]; National Institutes of Health Center [P50-GM-53789]; Veterans Affairs Merit Award; National Key Basic Research (973) Program of China [2011CB510200]; National Natural Science Foundation of China [81030055]; Natural Science Foundation of China-Guangdong Joint Fund [U0632004]; Program for Changjiang Scholars and Innovative Research Team in University [IRT0731] FX This work was supported by National Institutes of Health Grant R01-HL-079669 (to J.F. and M. A. W.), National Institutes of Health Center Grant P50-GM-53789 (to T. R. B. and J.F.), National Institutes of Health Grant R01-GM-50441 (to T. R. B.), a Veterans Affairs Merit Award (to J.F.), National Key Basic Research (973) Program of China 2011CB510200 (to Y.J.), National Natural Science Foundation of China 81030055 (to Y.J.), Natural Science Foundation of China-Guangdong Joint Fund U0632004 (to Y.J.), and Program for Changjiang Scholars and Innovative Research Team in University IRT0731 (to Y.J.). NR 45 TC 17 Z9 17 U1 0 U2 12 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JUL 15 PY 2013 VL 191 IS 2 BP 857 EP 864 DI 10.4049/jimmunol.1300790 PG 8 WC Immunology SC Immunology GA 175UW UT WOS:000321260100038 PM 23772028 ER PT J AU D'Ascenzo, F Biondi-Zoccai, G Reed, MJ Gabayan, GZ Suzuki, M Costantino, G Furlan, R Del Rosso, A Sarasin, FP Sun, BC Modena, MG Gaita, F AF D'Ascenzo, Fabrizio Biondi-Zoccai, Giuseppe Reed, Matthew J. Gabayan, Gelareh Z. Suzuki, Masaru Costantino, Giorgio Furlan, Raffaello Del Rosso, Andrea Sarasin, Francois P. Sun, Benjamin C. Modena, Maria Grazia Gaita, Fiorenzo TI Incidence, etiology and predictors of adverse outcomes in 43,315 patients presenting to the Emergency Department with syncope: An international meta-analysis SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Syncope; Meta-analysis; Prognosis; Prognosis; Multivariate predictors; Emergency Department ID RISK STRATIFICATION; SHORT-TERM; CLINICAL PREDICTORS; UNEXPLAINED SYNCOPE; SCORE; MANAGEMENT; ARRHYTHMIAS; GUIDELINES; PROGNOSIS; QUALITY AB Background: Syncope remains challenging for Emergency Department (ED) physicians due to difficulties in assessing the risk of future adverse outcomes. The aim of this meta-analysis is to establish the incidence and etiology of adverse outcomes as well as the predictors, in patients presenting with syncope to the ED. Methods: A systematic electronic literature review was performed looking for eligible studies published between 1990 and 2010. Studies reporting multivariate predictors of adverse outcomes in patients presenting with syncope to the ED were included and pooled, when appropriate, using a random-effect method. Adverse events were defined as 'incidence of death, or of hospitalization and interventional procedures because of arrhythmias, ischemic heart disease or valvular heart disease'. Results: 11 studies were included. Pooled analysis showed 42% (CI 95%; 32-52) of patients were admitted to hospital. Risk of death was 4.4% (CI 95%; 3.1-5.1) and 1.1% (CI 95%; 0.7-1.5) had a cardiovascular etiology. One third of patients were discharged without a diagnosis, while the most frequent diagnosis was 'situational, orthostatic or vasavagal syncope' in 29% (CI 95%; 12-47). 10.4% (CI 95%; 7.8-16) was diagnosed with heart disease, the most frequent type being bradyarrhythmia, 4.8% (CI 95%; 2.2-6.4) and tachyarrhythmia 2.6% (CI 95%; 1.1-3.1). Palpitations preceding syncope, exertional syncope, a history consistent of heart failure or ischemic heart disease, and evidence of bleeding were the most powerful predictors of an adverse outcome. Conclusion: Syncope carries a high risk of death, mainly related to cardiovascular disease. This large study which has established the most powerful predictors of adverse outcomes, may enable care and resources to be better focused at high risk patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [D'Ascenzo, Fabrizio; Gaita, Fiorenzo] Univ Turin, Div Cardiol, I-10126 Turin, Italy. [Biondi-Zoccai, Giuseppe; Modena, Maria Grazia] Univ Modena & Reggio Emilia, Div Cardiol, Modena, Italy. [Gabayan, Gelareh Z.; Sun, Benjamin C.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA. [Reed, Matthew J.] Dept Emergency Med, Edinburgh, Midlothian, Scotland. [Suzuki, Masaru] Keio Univ, Sch Med, Dept Emergency Med, Tokyo, Japan. [Costantino, Giorgio; Furlan, Raffaello] Univ Milan, L Sacco Hosp, Syncope Unit, Milan, Italy. [Del Rosso, Andrea] Azienda USL 11 Empoli, Dept Cardiol, Empoli, Italy. [Sarasin, Francois P.] Univ Geneva, Hop Cantonal, Sch Med, Div Emergency Med, CH-1211 Geneva, Switzerland. RP D'Ascenzo, F (reprint author), Univ Turin, S Giovanni Battista Molinette Hosp, Div Cardiol, Corso Bramante 88-90, I-10126 Turin, Italy. EM fabrizio.dascenzo@gmail.com RI modena, maria grazia/N-2442-2015 OI modena, maria grazia/0000-0002-4704-4663; Furlan, Raffaello/0000-0001-5209-6786; Reed, Matthew/0000-0003-1308-4824; Gaita, Fiorenzo/0000-0003-3178-6205 FU Chief Scientist Office [CAF/06/01] NR 38 TC 20 Z9 20 U1 1 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD JUL 15 PY 2013 VL 167 IS 1 BP 57 EP 62 DI 10.1016/j.ijcard.2011.11.083 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 167AR UT WOS:000320603100019 PM 22192287 ER PT J AU Levitan, EB Shikany, JM Ahmed, A Snetselaar, LG Martin, LW Curb, JD Lewis, CE AF Levitan, Emily B. Shikany, James M. Ahmed, Ali Snetselaar, Linda G. Martin, Lisa W. Curb, J. David Lewis, Cora E. TI Calcium, magnesium and potassium intake and mortality in women with heart failure: the Women's Health Initiative SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Heart failure; Mortality; Calcium; Magnesium; Potassium ID QUALITY-OF-LIFE; PRIMARY HYPERTENSION; ENDOTHELIAL DYSFUNCTION; SUPPLEMENTATION; MANAGEMENT; ADULTS; RISK; INFLAMMATION; ASSOCIATION; DISEASE AB Although diet is thought to affect the natural history of heart failure (HF), nutrient intake in HF patients has not been well studied. Based on prior research linking high intake of Ca, Mg and K to improved cardiovascular health, we hypothesised that these nutrients would be inversely associated with mortality in people with HF. Of the 161 808 participants in the Women's Health Initiative (WHI), we studied 3340 who experienced a HF hospitalisation. These participants were followed for post-hospitalisation all- cause mortality. Intake was assessed using questionnaires on food and supplement intake. Hazard ratios (HR) and 95% CI were calculated using Cox proportional hazards models adjusted for demographics, physical function, co-morbidities and dietary covariates. Over a median of 4.6 years of follow-up, 1433 (42.9%) of the women died. HR across quartiles of dietary Ca intake were 1.00 (referent), 0.86 (95% CI 0.73, 1.00), 0.88 (95% CI 0.75, 1.04) and 0.92 (95% CI 0.76, 1.11) (P for trend=0.63). Corresponding HR were 1.00 (referent), 0.86 (95% CI 0.71, 1.04), 0.88 (95% CI 0.69, 1.11) and 0.84 (95% CI 0.63, 1.12) (P for trend=0.29), across quartiles of dietary Mg intake, and 1.00 (referent), 1.20 (95% CI 1.01, 1.43), 1.06 (95% CI 0.86, 1.32) and 1.16 (95% CI 0.90, 1.51) (P for trend=0.35), across quartiles of dietary K intake. Results were similar when total (dietary plus supplemental) nutrient intakes were examined. In summary, among WHI participants with incident HF hospitalisation, intakes of Ca, Mg and K were not significantly associated with subsequent mortality. C1 [Levitan, Emily B.; Shikany, James M.; Ahmed, Ali; Lewis, Cora E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35924 USA. [Ahmed, Ali] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Snetselaar, Linda G.] Univ Iowa, Iowa City, IA 52246 USA. [Martin, Lisa W.] George Washington Univ, Washington, DC 20052 USA. [Curb, J. David] Univ Hawaii Manoa, Honolulu, HI 96822 USA. RP Levitan, EB (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1530 3rd Ave South,RPHB 230K, Birmingham, AL 35924 USA. EM elevitan@uab.edu OI Martin, Lisa Warsinger/0000-0003-4352-0914 FU National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH 22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221] FX All authors were involved in the design of the study. J. M. S., L. G. S., L. W. M., J. D. C. and C. E. L. collected the data. E. B. L. performed the statistical analysis and wrote the paper. All authors revised the paper and are responsible for the final manuscript. The authors declare no conflict of interest. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH 22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32 and 44221. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. NR 35 TC 9 Z9 9 U1 1 U2 17 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 J9 BRIT J NUTR JI Br. J. Nutr. PD JUL 14 PY 2013 VL 110 IS 1 BP 179 EP 185 DI 10.1017/S0007114512004667 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 160MK UT WOS:000320123500020 PM 23199414 ER PT J AU Johnstone, DB Ikizler, O Zhang, JD Holzman, LB AF Johnstone, Duncan B. Ikizler, Omer Zhang, Jidong Holzman, Lawrence B. TI Background Strain and the Differential Susceptibility of Podocyte-Specific Deletion of Myh9 on Murine Models of Experimental Glomerulosclerosis and HIV Nephropathy SO PLOS ONE LA English DT Article ID DECAY-ACCELERATING FACTOR; NEPHROTOXIC NEPHRITIS; AFRICAN-AMERICANS; KIDNEY-DISEASE; MYH9-RELATED DISEASE; EUROPEAN-AMERICANS; BASEMENT-MEMBRANE; LUPUS NEPHRITIS; II-A; MICE AB We previously reported that podocyte-specific deletion of Myh9 (conventional myosin heavy chain 2A) in C57BL/6 mice does not cause spontaneous kidney disease but instead results in a predisposition to glomerulosclerosis in response to a second model of glomerular injury. In contrast, other investigators reported that podocyte-specific deletion of Myh9 (Pod Delta Myh9) resulted in spontaneous glomerulosclerosis in mice on a mixed background, suggesting that the glomerulosclerosis is dependent on background strain. In order to elucidate the cause of this strain dependent effect Podocin::Cre and Myh9(flox) alleles were backcrossed to mouse strain FVB/N, which is highly susceptible to glomerulosclerosis, with the aim of intercrossing susceptible FVB/N and resistant C57BL/6 mice in subsequent congenic analyses. However, after backcrossing mice to FVB/N and aging mice to 28 weeks, we found no evidence of glomerular disease in Pod Delta Myh9 mice vs control littermates (urine MAC ratio all p > 0.05). We also tested C57BL/6 Pod Delta Myh9 mice for a predisposition to injury from models other than Adriamycin including HIV nephropathy (HIVAN), puromycin nephropathy, and sheep nephrotoxic serum. In the Tg26 model of HIVAN, we found that podocyte-specific deletion of Myh9 resulted in a modest hypersensitivity in adults compared to Tg26+ control littermates (urine MAC ratio, p < 0.05 or less). In contrast, we found that Pod Delta Myh9 mice were not predisposed to injury in response to other injury models including puromycin nephropathy and sheep nephrotoxic serum. While the mechanism of injury in these models is not fully understood, we conclude that Pod Delta Myh9 results in a variable susceptibility to glomerulosclerosis in response to different models of glomerular injury. In addition, based on the lack of a spontaneous phenotype of glomerulosclerosis in both C57BL/6 and FVB/N mice, we propose that Myh9 is not absolutely required in adult podocytes. C1 [Johnstone, Duncan B.] Temple Univ, Sch Med, Div Nephrol, Philadelphia, PA 19122 USA. [Ikizler, Omer; Zhang, Jidong; Holzman, Lawrence B.] Univ Penn, Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Holzman, Lawrence B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Johnstone, DB (reprint author), Temple Univ, Sch Med, Div Nephrol, Philadelphia, PA 19122 USA. EM duncan.johnstone@tuhs.temple.edu FU VA merit award; [K08DK082616] FX Sources of funding for this study were K08DK082616 (to DBJ) and VA merit award (to LBH). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 11 Z9 11 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 10 PY 2013 VL 8 IS 7 AR e67839 DI 10.1371/journal.pone.0067839 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 182SU UT WOS:000321765300014 PM 23874454 ER PT J AU Madison, K Schmidt, H Volpp, KG AF Madison, Kristin Schmidt, Harald Volpp, Kevin G. TI Smoking, Obesity, Health Insurance, and Health Incentives in the Affordable Care Act SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Madison, Kristin] Northeastern Univ, Sch Law, Boston, MA 02115 USA. [Madison, Kristin] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Schmidt, Harald] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. RP Madison, K (reprint author), Northeastern Univ, Sch Law, 400 Huntington Ave, Boston, MA 02115 USA. EM k.madison@neu.edu NR 6 TC 17 Z9 17 U1 0 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 10 PY 2013 VL 310 IS 2 BP 143 EP 144 DI 10.1001/jama.2013.7617 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 179HU UT WOS:000321511500009 PM 23765171 ER PT J AU Matlock, DD Groeneveld, PW Sidney, S Shetterly, S Goodrich, G Glenn, K Xu, S Yang, L Farmer, SA Reynolds, K Cassidy-Bushrow, AE Lieu, T Boudreau, DM Greenlee, RT Tom, J Vupputuri, S Adams, KF Smith, DH Gunter, MJ Go, AS Magid, DJ AF Matlock, Daniel D. Groeneveld, Peter W. Sidney, Steve Shetterly, Susan Goodrich, Glenn Glenn, Karen Xu, Stan Yang, Lin Farmer, Steven A. Reynolds, Kristi Cassidy-Bushrow, Andrea E. Lieu, Tracy Boudreau, Denise M. Greenlee, Robert T. Tom, Jeffrey Vupputuri, Suma Adams, Kenneth F. Smith, David H. Gunter, Margaret J. Go, Alan S. Magid, David J. TI Geographic Variation in Cardiovascular Procedure Use Among Medicare Fee-for-Service vs Medicare Advantage Beneficiaries SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LIFE TREATMENT INTENSITY; REGIONAL-VARIATION; UNITED-STATES; RESOURCE USE; HEALTH-CARE; QUALITY; PERCEPTIONS; OUTCOMES; POLICY; RISK AB IMPORTANCE Little is known about how different financial incentives between Medicare Advantage and Medicare fee-for-service (FFS) reimbursement structures influence use of cardiovascular procedures. OBJECTIVE To compare regional cardiovascular procedure rates between Medicare Advantage and Medicare FFS beneficiaries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of Medicare beneficiaries older than 65 years between 2003-2007 comparing rates of coronary angiography, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery across 32 hospital referral regions in 12 states. MAIN OUTCOMES AND MEASURES Rates of coronary angiography, PCI, and CABG surgery. RESULTS We evaluated a total of 878 339 Medicare Advantage patients and 5 013 650 Medicare FFS patients. Compared with Medicare FFS patients, Medicare Advantage patients had lower age-, sex-, race-, and income-adjusted procedure rates per 1000 person-years for angiography (16.5 [95% CI, 14.8-18.2] vs 25.9 [95% CI, 24.0-27.9]; P < .001) and PCI (6.8 [95% CI, 6.0-7.6] vs 9.8 [95% CI, 9.0-10.6]; P < .001) but similar rates for CABG surgery (3.1 [95% CI, 2.8-3.5] vs 3.4 [95% CI, 3.1-3.7]; P = .33). There were no significant differences between Medicare Advantage and Medicare FFS patients in the rates per 1000 person-years of urgent angiography (3.9 [95% CI, 3.6-4.2] vs 4.3 [95% CI, 4.0-4.6]; P = .24) or PCI (2.4 [95% CI, 2.2-2.7] vs 2.7 [95% CI, 2.5-2.9]; P = .16). Procedure rates varied widely across hospital referral regions among Medicare Advantage and Medicare FFS patients. For angiography, the rates per 1000 person-years ranged from 9.8 to 40.6 for Medicare Advantage beneficiaries and from 15.7 to 44.3 for Medicare FFS beneficiaries. For PCI, the rates ranged from 3.5 to 16.8 for Medicare Advantage and from 4.7 to 16.1 for Medicare FFS. The rates for CABG surgery ranged from 1.5 to 6.1 for Medicare Advantage and from 2.5 to 6.0 for Medicare FFS. Across regions, we found no statistically significant correlation between Medicare Advantage and Medicare FFS beneficiary utilization for angiography (Spearman r = 0.19, P = .29) and modest correlations for PCI (Spearman r = 0.33, P = .06) and CABG surgery (Spearman r = 0.35, P = .05). Among Medicare Advantage beneficiaries, adjustment for additional cardiac risk factors had little influence on procedure rates. CONCLUSIONS AND RELEVANCE Although Medicare beneficiaries enrolled in capitated Medicare Advantage programs had lower angiography and PCI procedure rates than those enrolled in Medicare FFS, the degree of geographic variation in procedure rates was substantial among Medicare Advantage beneficiaries and was similar in magnitude to that observed among Medicare FFS beneficiaries. C1 [Matlock, Daniel D.] Univ Colorado, Sch Med, Aurora, CO USA. [Matlock, Daniel D.; Shetterly, Susan; Xu, Stan; Magid, David J.] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA. [Matlock, Daniel D.; Shetterly, Susan; Goodrich, Glenn; Glenn, Karen; Xu, Stan; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Groeneveld, Peter W.; Yang, Lin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Sidney, Steve; Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Farmer, Steven A.] Northwestern Univ, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. [Farmer, Steven A.] Northwestern Univ, Kellogg Sch Management, Chicago, IL 60611 USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Cassidy-Bushrow, Andrea E.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA. [Lieu, Tracy] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Lieu, Tracy] Harvard Univ, Sch Med, Boston, MA USA. [Boudreau, Denise M.] Grp Hlth Res Inst, Seattle, WA USA. [Greenlee, Robert T.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Tom, Jeffrey] Kaiser Permanente Ctr Hlth Res, Honolulu, HI USA. [Vupputuri, Suma] Kaiser Permanente Ctr Hlth Res Southeast, Atlanta, GA USA. [Adams, Kenneth F.] HealthPartners Res Fdn, Minneapolis, MN USA. [Smith, David H.] Kaiser Permanente Northwest Ctr Hlth Res, Portland, OR USA. [Gunter, Margaret J.] Lovelace Clin Fdn, Albuquerque, NM USA. [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. RP Matlock, DD (reprint author), Univ Colorado Denver, Sch Med, Div Gen Internal Med, Acad Off 1, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu OI Cassidy-Bushrow, Andrea/0000-0001-8272-4448 FU National Institute on Aging [1K23AG040696]; National Heart, Lung, and Blood Institute; Cardiovascular Research Network [U19 HL91179-01, 1RC2HL101666-01, 1R01HL086919]; Agency for Healthcare Research and Quality [1R01HS018403] FX Dr Matlock was supported by a career development award from the National Institute on Aging (1K23AG040696). The study was supported by the National Heart, Lung, and Blood Institute and the Cardiovascular Research Network (U19 HL91179-01, 1RC2HL101666-01, and 1R01HL086919). Medicare data for the project were obtained under Agency for Healthcare Research and Quality grant 1R01HS018403. NR 30 TC 24 Z9 24 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 10 PY 2013 VL 310 IS 2 BP 155 EP 162 DI 10.1001/jama.2013.7837 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 179HU UT WOS:000321511500014 PM 23839749 ER PT J AU Hanlon, CA Canterberry, M Taylor, JJ DeVries, W Li, XB Brown, TR George, MS AF Hanlon, Colleen A. Canterberry, Melanie Taylor, Joseph J. DeVries, William Li, Xingbao Brown, Truman R. George, Mark S. TI Probing the Frontostriatal Loops Involved in Executive and Limbic Processing via Interleaved TMS and Functional MRI at Two Prefrontal Locations: A Pilot Study SO PLOS ONE LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; RHESUS-MONKEY; MOTOR CORTEX; BOLD-FMRI; MEMORY FORMATION; WORKING-MEMORY; BASAL GANGLIA; REWARD SYSTEM; ACTIVATION; ORGANIZATION AB Background: The prefrontal cortex (PFC) is an anatomically and functionally heterogeneous area which influences cognitive and limbic processing through connectivity to subcortical targets. As proposed by Alexander et al. (1986) the lateral and medial aspects of the PFC project to distinct areas of the striatum in parallel but functionally distinct circuits. The purpose of this preliminary study was to determine if we could differentially and consistently activate these lateral and medial cortical-subcortical circuits involved in executive and limbic processing though interleaved transcranial magnetic stimulation (TMS) in the MR environment. Methods: Seventeen healthy individuals received interleaved TMS-BOLD imaging with the coil positioned over the dorsolateral (EEG: F3) and ventromedial PFC (EEG: FP1). BOLD signal change was calculated in the areas directly stimulated by the coil and in subcortical regions with afferent and efferent connectivity to the TMS target areas. Additionally, five individuals were tested on two occasions to determine test-retest reliability. Results: Region of interest analysis revealed that TMS at both prefrontal sites led to significant BOLD signal increases in the cortex under the coil, in the striatum, and the thalamus, but not in the visual cortex (negative control region). There was a significantly larger BOLD signal change in the caudate following medial PFC TMS, relative to lateral TMS. The hippocampus in contrast was significantly more activated by lateral TMS. Post-hoc voxel-based analysis revealed that within the caudate the location of peak activity was in the ventral caudate following medial TMS and the dorsal caudate following lateral TMS. Test-retest reliability data revealed consistent BOLD responses to TMS within each individual but a large variation between individuals. Conclusion: These data demonstrate that, through an optimized TMS/BOLD sequence over two unique prefrontal targets, it is possible to selectively interrogate the patency of these established cortical-subcortical networks in healthy individuals, and potentially patient populations. C1 [Hanlon, Colleen A.; Canterberry, Melanie; Taylor, Joseph J.; DeVries, William; Li, Xingbao; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Hanlon, Colleen A.; Brown, Truman R.; George, Mark S.] Med Univ S Carolina, Ctr Biomed Imaging, Charleston, SC 29425 USA. [Brown, Truman R.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Hanlon, CA (reprint author), Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. EM hanlon@musc.edu FU National Institutes of Health [K01DA027756, 1F30DA033748-01, T32DA007288] FX This work was supported by the National Institutes of Health (grant numbers, K01DA027756 (CAH), 1F30DA033748-01 (JJT), T32DA007288). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 10 Z9 10 U1 2 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 9 PY 2013 VL 8 IS 7 AR e67917 DI 10.1371/journal.pone.0067917 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 182JD UT WOS:000321736900036 PM 23874466 ER PT J AU Bekelman, DB Plomondon, ME Sullivan, MD Nelson, K Hattler, B McBryde, C Lehmann, KG Potfay, J Heidenreich, P Rumsfeld, JS AF Bekelman, David B. Plomondon, Mary E. Sullivan, Mark D. Nelson, Karin Hattler, Brack McBryde, Connor Lehmann, Kenneth G. Potfay, Jonathan Heidenreich, Paul Rumsfeld, John S. TI Patient-centered disease management (PCDM) for heart failure: study protocol for a randomised controlled trial SO BMC CARDIOVASCULAR DISORDERS LA English DT Article DE Heart failure; Clinical trial; Patient reported outcomes; Quality of life; Health status ID HEALTH-STATUS; RESOURCE UTILIZATION; CARE MANAGEMENT; HOSPITALIZATION; DEPRESSION; POPULATION; OUTCOMES; TRENDS; DEATH; RISK AB Background: Chronic heart failure (HF) disease management programs have reported inconsistent results and have not included comorbid depression management or specifically focused on improving patient-reported outcomes. The Patient Centered Disease Management (PCDM) trial was designed to test the effectiveness of collaborative care disease management in improving health status (symptoms, functioning, and quality of life) in patients with HF who reported poor HF-specific health status. Methods/design: Patients with a HF diagnosis at four VA Medical Centers were identified through population-based sampling. Patients with a Kansas City Cardiomyopathy Questionnaire (KCCQ, a measure of HF-specific health status) score of < 60 (heavy symptom burden and impaired quality of life) were invited to enroll in the PCDM trial. Enrolled patients were randomized to receive usual care or the PCDM intervention, which included: (1) collaborative care management by VA clinicians including a nurse, cardiologist, internist, and psychiatrist, who worked with patients and their primary care providers to provide guideline-concordant care management, (2) home telemonitoring and guided patient self-management support, and (3) screening and treatment for comorbid depression. The primary study outcome is change in overall KCCQ score. Secondary outcomes include depression, medication adherence, guideline-based care, hospitalizations, and mortality. Discussion: The PCDM trial builds on previous studies of HF disease management by prioritizing patient health status, implementing a collaborative care model of health care delivery, and addressing depression, a key barrier to optimal disease management. The study has been designed as an 'effectiveness trial' to support broader implementation in the healthcare system if it is successful. C1 [Bekelman, David B.; McBryde, Connor] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO 80220 USA. [Bekelman, David B.; Hattler, Brack; McBryde, Connor; Rumsfeld, John S.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Plomondon, Mary E.; Hattler, Brack; Rumsfeld, John S.] Eastern Colorado Hlth Care Syst Cardiol 111B, Dept Vet Affairs, Denver, CO 80220 USA. [Sullivan, Mark D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Nelson, Karin; Lehmann, Kenneth G.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Nelson, Karin; McBryde, Connor] Northwest HSR&D Ctr Excellence, Seattle, WA USA. [Nelson, Karin] Univ Washington, Dept Med, Seattle, WA USA. [Potfay, Jonathan] Richmond VA Med Ctr, Richmond, VA 23249 USA. [Heidenreich, Paul] VA Palo Alto Hlth Care Syst Cardiol 111C, Palo Alto, CA 94304 USA. RP Bekelman, DB (reprint author), Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Res 151,1055 Clermont St, Denver, CO 80220 USA. EM david.bekelman@va.gov OI Heidenreich, Paul/0000-0001-7730-8490 FU Department of Veterans Affairs HSRD [IIR 06-068]; Department of Veterans Affairs [HSRD CDA 08-022] FX The PCDM trial is funded by the Department of Veterans Affairs HSR&D grant IIR 06-068. Dr. Bekelman is funded by the Department of Veterans Affairs (HSR&D CDA 08-022). After approval of funding, the funding organizations did not participate in the study design or manuscript preparation. We thank our nurse coordinators, Darcy Donaldson, Laura Gaskin, Julie LaGuire, Susan Walker, and Barbara Watson for the care they provided. The views in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 27 TC 4 Z9 4 U1 3 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2261 J9 BMC CARDIOVASC DISOR JI BMC Cardiovasc. Disord. PD JUL 9 PY 2013 VL 13 AR 49 DI 10.1186/1471-2261-13-49 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 186IU UT WOS:000322037600001 PM 23837415 ER PT J AU Smith, AK Lo, B Sudore, R AF Smith, Alexander K. Lo, Bernard Sudore, Rebecca TI When Previously Expressed Wishes Conflict With Best Interests SO JAMA INTERNAL MEDICINE LA English DT Article ID SURROGATE DECISION-MAKING; ADVANCE DIRECTIVES; LIFE; END; RECOMMENDATIONS; PREFERENCES; AUTONOMY; WANT AB Rising use of advance directives has made surrogate decision making both easier and harder. In many cases, these directives help guide decision making for patients who have lost decision-making capacity. In some cases, however, directives may conflict with what physicians or surrogates view as what is in the patient's best interest. These conflicts can place substantial emotional and moral burdens on physicians and surrogates, and there is little practical guidance for how to address them. We propose a 5-question framework for untangling the conflict between advance directives and best interests of a patient with a surrogate decision maker: (1) Is the clinical situation an emergency? (2) In view of the patient's values and goals, how likely is it that the benefits of the intervention will outweigh the burdens? (3) How well does the advance directive fit the situation at hand? (4) How much leeway did the patient provide the surrogate for overriding the advance directive? (5) How well does the surrogate represent the patient's best interests? We use 2 clinical cases with contrasting outcomes to demonstrate how this framework can help resolve common dilemmas. C1 [Smith, Alexander K.; Sudore, Rebecca] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94941 USA. [Lo, Bernard] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, San Francisco, CA 94941 USA. [Smith, Alexander K.; Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Lo, Bernard] Greenwall Fdn, New York, NY USA. RP Smith, AK (reprint author), Univ Calif San Francisco, 4150 Clement St 181G, San Francisco, CA 94941 USA. EM aksmith@ucsf.edu FU Greenwall Faculty Scholars in Bioethics award from Greenwall Foundation FX Dr Smith was supported by a Greenwall Faculty Scholars in Bioethics award from the Greenwall Foundation. NR 24 TC 9 Z9 9 U1 2 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL 8 PY 2013 VL 173 IS 13 BP 1241 EP 1245 DI 10.1001/jamainternmed.2013.6053 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 207LU UT WOS:000323602100018 PM 23712743 ER PT J AU Linos, E Wehner, MR Frosch, DL Walter, L Chren, MM AF Linos, Eleni Wehner, Mackenzie R. Frosch, Dominick L. Walter, Louise Chren, Mary Margaret TI Patient-Reported Problems After Office Procedures SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Linos, Eleni; Wehner, Mackenzie R.; Chren, Mary Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Frosch, Dominick L.] Gordon & Betty Moore Fdn, Patient Care Program, San Francisco, CA USA. [Walter, Louise] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,N421,Box 0808, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu RI Linos, Eleni/C-4392-2014 OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU NIA NIH HHS [K24 AG041180]; NIAMS NIH HHS [K24 AR052667] NR 4 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL 8 PY 2013 VL 173 IS 13 BP 1249 EP 1250 DI 10.1001/jamainternmed.2013.1040 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 207LU UT WOS:000323602100020 PM 23689235 ER PT J AU Katsel, P Tan, WL Fam, P Purohit, DP Haroutunian, V AF Katsel, Pavel Tan, Weilun Fam, Peter Purohit, Dushyant P. Haroutunian, Vahram TI Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimer's Disease SO PLOS ONE LA English DT Article ID MULTIPLE BRAIN-REGIONS; NEURONAL CELL-DEATH; GENE-EXPRESSION; ATAXIA-TELANGIECTASIA; TAU PHOSPHORYLATION; ELDERLY-PATIENTS; DNA-REPLICATION; RATING-SCALE; G2/M PHASE; SCHIZOPHRENIA AB Background: Increasing evidence suggests an association between neuronal cell cycle (CCL) events and the processes that underlie neurodegeneration in Alzheimer's disease (AD). Elevated levels of oxidative stress markers and mitochondrial dysfunction are also among early events in AD. Recent studies have reported the role of CCL checkpoint proteins and tumor suppressors, such as ATM and p53 in the control of glycolysis and oxidative metabolism in cancer, but their involvement in AD remains uncertain. Methods and Findings: In this postmortem study, we measured gene expression levels of eight CCL checkpoint proteins in the superior temporal cortex (STC) of persons with varying severities of AD dementia and compare them to those of cognitively normal controls. To assess whether the CCL changes associated with cognitive impairment in AD are specific to dementia, gene expression of the same proteins was also measured in STC of persons with schizophrenia (SZ), which is also characterized by mitochondrial dysfunction. The expression of CCL-checkpoint and DNA damage response genes: MDM4, ATM and ATR was strongly upregulated and associated with progression of dementia (cognitive dementia rating, CDR), appearing as early as questionable or mild dementia (CDRs 0.5-1). In addition to gene expression changes, the downstream target of ATM-p53 signaling - TIGAR, a p53-inducible protein, the activation of which can regulate energy metabolism and protect against oxidative stress was progressively decreased as severity of dementia evolved, but it was unaffected in subjects with SZ. In contrast to AD, different CCL checkpoint proteins, which include p53, CHEK1 and BRCA1 were significantly downregulated in SZ. Conclusions: These results support the activation of an ATM signaling and DNA damage response network during the progression of AD dementia, while the progressive decrease in the levels of TIGAR suggests loss of protection initiated by ATM-p53 signaling against intensifying oxidative stress in AD. C1 [Katsel, Pavel; Tan, Weilun; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Fam, Peter; Haroutunian, Vahram] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. [Haroutunian, Vahram] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Purohit, Dushyant P.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. RP Katsel, P (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. EM pavel.katsel@mssm.edu FU National Institutes of Health [P01-AG02219, P50-AG05138, MH066392, MH064673]; Veteran Administration MIRECC, Leir Foundation FX This work was supported by National Institutes of Health (P01-AG02219, P50-AG05138, MH066392 and by MH064673 to VH), Veteran Administration MIRECC, Leir Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 85 TC 16 Z9 16 U1 1 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 5 PY 2013 VL 8 IS 7 AR e68361 DI 10.1371/journal.pone.0068361 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 178DW UT WOS:000321425300059 PM 23861893 ER PT J AU Zorick, T Mandelkern, MA AF Zorick, Todd Mandelkern, Mark A. TI Multifractal Detrended Fluctuation Analysis of Human EEG: Preliminary Investigation and Comparison with the Wavelet Transform Modulus Maxima Technique SO PLOS ONE LA English DT Article ID NEURONAL AVALANCHES; HUMAN BRAIN; FUNCTIONAL-STATE; SLEEP-APNEA; SIGNALS; OSCILLATIONS; DYNAMICS; CORTEX; SERIES AB Recently, many lines of investigation in neuroscience and statistical physics have converged to raise the hypothesis that the underlying pattern of neuronal activation which results in electroencephalography (EEG) signals is nonlinear, with self-affine dynamics, while scalp-recorded EEG signals themselves are nonstationary. Therefore, traditional methods of EEG analysis may miss many properties inherent in such signals. Similarly, fractal analysis of EEG signals has shown scaling behaviors that may not be consistent with pure monofractal processes. In this study, we hypothesized that scalp-recorded human EEG signals may be better modeled as an underlying multifractal process. We utilized the Physionet online database, a publicly available database of human EEG signals as a standardized reference database for this study. Herein, we report the use of multifractal detrended fluctuation analysis on human EEG signals derived from waking and different sleep stages, and show evidence that supports the use of multifractal methods. Next, we compare multifractal detrended fluctuation analysis to a previously published multifractal technique, wavelet transform modulus maxima, using EEG signals from waking and sleep, and demonstrate that multifractal detrended fluctuation analysis has lower indices of variability. Finally, we report a preliminary investigation into the use of multifractal detrended fluctuation analysis as a pattern classification technique on human EEG signals from waking and different sleep stages, and demonstrate its potential utility for automatic classification of different states of consciousness. Therefore, multifractal detrended fluctuation analysis may be a useful pattern classification technique to distinguish among different states of brain function. C1 [Zorick, Todd] Greater Los Angeles Vet Adm Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Mandelkern, Mark A.] Greater Los Angeles Vet Adm Healthcare Syst, Dept Imaging, Los Angeles, CA USA. [Zorick, Todd] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Zorick, T (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. EM tzorick@mednet.ucla.edu NR 50 TC 14 Z9 14 U1 2 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 3 PY 2013 VL 8 IS 7 AR e68360 DI 10.1371/journal.pone.0068360 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 182HT UT WOS:000321733000141 PM 23844189 ER PT J AU Sandoval, KE Farr, SA Banks, WA Crider, AM Morlef, JE Witt, KA AF Sandoval, Karin E. Farr, Susan A. Banks, William A. Crider, Albert M. Morlef, John E. Witt, Ken A. TI Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble A beta(42) oligomers via a metalloproteinase-dependent mechanism SO BRAIN RESEARCH LA English DT Article DE Phosphoramidon; NNC 26-9100; Somatostatin receptor subtype-4; Amyloid-beta oligomer ID AMYLOID-BETA PEPTIDE; INTRANEURONAL A-BETA-42 ACCUMULATION; ENDOTHELIN-CONVERTING ENZYME; ALZHEIMERS-DISEASE; SAMP8 MICE; A-BETA; SYNAPTIC PLASTICITY; WILD-TYPE; DEGRADING ENZYMES; TRANSGENIC MODEL AB Soluble amyloid-beta peptide (A beta) oligomers have been hypothesized to be primary mediators of Alzheimer's disease progression. In this regard, reduction of soluble A beta-oligomers levels within the brain may provide a viable means in which to treat the disease. Somatostatin receptor subtype-4 (SSTR4) agonists have been proposed to reduce A beta levels in the brain via enhancement of enzymatic degradation. Herein we evaluated the effect of selective SSTR4 agonist NNC 26-9100 on the changes in learning and soluble A beta(42) oligomer brain content with and without co-administration of the M13-metalloproteinase family enzyme-inhibitor phosphoramidon, using the senescence-accelerated mouse prone-8 (SAMP8) model. NNC 26-9100 treatment (0.2 mu g i.c.v. in 2 mu L) improved learning, which was blocked by phosphoramidon (1 and 10 mM, respectively). NNC 26-9100 decreased total soluble A beta(42), an effect which was blocked by phosphoramidon (10 mM). Extracellular, intracellular, and membrane fractions were then isolated from cortical tissue and assessed for soluble oligomer alterations. NNC 26-9100 decreased the A beta(42) trimeric (12 kDa) form within the extracellular and intracellular fractions, and produced a band-split effect of the A beta(42) hexameric (25 kDa) form within the extracellular fraction. These effects were also blocked by phosphoramdon (1 and 10 mM, respectively). Subsequent evaluation of NNC 26-9100 in APPswe Tg2576 transgenic mice showed a similar learning improvement and corresponding reduction in soluble A beta(42) oligomers within extracellular, intracellular, and membrane fractions. These data support the hypothesis that NNC 26-9100 reduces soluble A beta(42) oligomers and enhances learning through a phosphoramidon-sensitive metalloproteinase-dependent mechanism. (c) 2013 Elsevier B.V. All rights reserved. C1 [Sandoval, Karin E.; Crider, Albert M.; Witt, Ken A.] So Illinois Univ, Sch Pharm, Edwardsville, IL 62026 USA. [Farr, Susan A.] Vet Affairs Med Ctr St Louis, Res & Dev, St Louis, MO USA. [Farr, Susan A.; Morlef, John E.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63103 USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Morlef, John E.] St Louis Univ, Sch Med, Dept Internal Med, Div Endocrinol, St Louis, MO 63103 USA. RP Witt, KA (reprint author), So Illinois Univ, Sch Pharm, 200 Univ Pk Dr, Edwardsville, IL 62026 USA. EM kwitt@siue.edu FU VA Merit Review; National Institutes of Health National Institute on Aging [R21AG029318] FX This work was supported by VA Merit Review, and the National Institutes of Health National Institute on Aging (Grant: R21AG029318). A use-patent has been obtained for NNC 26-9100 by Southern Illinois University Edwardsville. No other disclosures. NR 53 TC 4 Z9 6 U1 2 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JUL 3 PY 2013 VL 1520 BP 145 EP 156 DI 10.1016/j.brainres.2013.05.006 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 178XO UT WOS:000321480900014 PM 23669069 ER PT J AU Bigler, ED Deibert, E Filley, CM AF Bigler, Erin D. Deibert, Ellen Filley, Christopher M. TI When is a concussion no longer a concussion? SO NEUROLOGY LA English DT Editorial Material ID TRAUMATIC BRAIN-INJURY; SPORT C1 [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA. [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA. [Deibert, Ellen] Univ Massachusetts, Dept Neurol, Amherst, MA 01003 USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol & Psychiat, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Bigler, ED (reprint author), Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA. EM erin_bigler@byu.edu NR 10 TC 2 Z9 2 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JUL 2 PY 2013 VL 81 IS 1 BP 14 EP 15 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 304JC UT WOS:000330741900006 PM 23709592 ER PT J AU Smith, MEB Totten, A Hickam, DH Fu, RW Wasson, N Rahman, B Motu'apuaka, M Saha, S AF Smith, M. E. Beth Totten, Annette Hickam, David H. Fu, Rongwei Ngoc Wasson Rahman, Basmah Motu'apuaka, Makalapua Saha, Somnath TI Pressure Ulcer Treatment Strategies A Systematic Comparative Effectiveness Review SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; III DECUBITUS ULCERS; GROWTH FACTOR-BB; AIR-FLUIDIZED THERAPY; LEVEL LASER THERAPY; CLINICAL-TRIAL; ELDERLY-PATIENTS; STAGE-II; HYDROCOLLOID DRESSINGS AB Background: Pressure ulcers affect as many as 3 million Americans and are major sources of morbidity, mortality, and health care costs. Purpose: To summarize evidence comparing the effectiveness and safety of treatment strategies for adults with pressure ulcers. Data Sources: MEDLINE, EMBASE, CINAHL, Evidence-Based Medicine Reviews, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and Health Technology Assessment Database for English-or foreign-language studies; reference lists; gray literature; and individual product packets from manufacturers (January 1985 to October 2012). Study Selection: Randomized trials and comparative observational studies of treatments for pressure ulcers in adults and noncomparative intervention series (n > 50) for surgical interventions and evaluation of harms. Data Extraction: Data were extracted and evaluated for accuracy of the extraction, quality of included studies, and strength of evidence. Data Synthesis: 174 studies met inclusion criteria and 92 evaluated complete wound healing. In comparison with standard care, placebo, or sham interventions, moderate-strength evidence showed that air-fluidized beds (5 studies [n = 908]; high consistency), protein-containing nutritional supplements (12 studies [n = 562]; high consistency), radiant heat dressings (4 studies [n = 160]; moderate consistency), and electrical stimulation (9 studies [n = 397]; moderate consistency) improved healing of pressure ulcers. Low-strength evidence showed that alternating-pressure surfaces, hydrocolloid dressings, platelet-derived growth factor, and light therapy improved healing of pressure ulcers. The evidence about harms was limited. Limitation: Applicability of results is limited by study quality, heterogeneity in methods and outcomes, and inadequate duration to assess complete wound healing. Conclusion: Moderate-strength evidence shows that healing of pressure ulcers in adults is improved with the use of air-fluidized beds, protein supplementation, radiant heat dressings, and electrical stimulation. C1 Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Smith, MEB (reprint author), Oregon Hlth & Sci Univ, 3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA. EM smithbet@ohsu.edu FU AHRQ [290-2007-10057-I]; U.S. Department of Veterans Affairs; Agency for Healthcare Research and Quality FX Grant Support: By AHRQ (contract 290-2007-10057-I, Task Order 8). Dr. Saha is supported by the U.S. Department of Veterans Affairs.; Primary Funding Source: Agency for Healthcare Research and Quality. NR 167 TC 28 Z9 31 U1 1 U2 31 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 2 PY 2013 VL 159 IS 1 BP 39 EP + DI 10.7326/0003-4819-159-1-201307020-00007 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 179JJ UT WOS:000321516200005 PM 23817703 ER PT J AU Das, M Volberding, P AF Das, Moupali Volberding, Paul TI Bringing the End in Sight: Consensus Regarding HIV Screening Strategies SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID ANTIRETROVIRAL THERAPY; RECOMMENDATIONS; INFECTION C1 [Das, Moupali; Volberding, Paul] Univ Calif San Francisco, San Francisco, CA 94105 USA. [Volberding, Paul] San Francisco VA Med Ctr, San Francisco, CA USA. RP Volberding, P (reprint author), Univ Calif San Francisco, AIDS Res Inst, 50 Beale St,Suite 1300, San Francisco, CA 94105 USA. EM paul.volberding@ucsf.edu NR 10 TC 3 Z9 3 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 2 PY 2013 VL 159 IS 1 BP 63 EP + DI 10.7326/0003-4819-159-1-201307020-00643 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 179JJ UT WOS:000321516200008 PM 23698261 ER PT J AU Miura, LN Boxer, RS AF Miura, Lisa N. Boxer, Rebecca S. TI Women in Medicine and the Ticking Clock SO ANNALS OF FAMILY MEDICINE LA English DT Editorial Material DE delayed childbearing; pregnancy complications; maternal age; infertility AB Our careers began with the long, arduous, and intensely focused commitments of premed, medical school, residency, and fellowship. We planned our lives rationally and enacted our plans with care. Now we have long-desired and satisfying careers. We discovered something, however, that the culture of medical training and our plans had failed to anticipate: We did not allow time for the unexpected. C1 [Miura, Lisa N.] Oregon Hlth & Sci Univ, Portland, OR USA. [Boxer, Rebecca S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Miura, LN (reprint author), P3MED, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM miural@ohsu.edu NR 2 TC 1 Z9 1 U1 1 U2 4 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD JUL-AUG PY 2013 VL 11 IS 4 BP 381 EP 382 DI 10.1370/afm.1515 PG 2 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AI3XH UT WOS:000336798500012 PM 23835825 ER PT J AU Rigg, KK Murphy, JW AF Rigg, Khary K. Murphy, John W. TI Understanding the Etiology of Prescription Opioid Abuse: Implications for Prevention and Treatment SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE addiction / substance use; illness and disease, prevention; interviews, semistructured; mental health and illness; psychosocial issues; social constructionism; sociology ID METHADONE-MAINTENANCE TREATMENT; LIFE-COURSE PERSPECTIVE; INJECTION-DRUG USERS; ILLICIT USE; PHARMACEUTICAL OPIOIDS; DEPENDENCE; INITIATION; DIVERSION; PAIN; PERSISTENCE AB Although studies on the initiation of substance abuse abound, the body of literature on prescription opioid abuse (POA) etiology is small. Little is known about why and how the onset of POA occurs, especially among high-risk populations. In this study we aimed to fill this important knowledge gap by exploring the POA initiation experiences of 90 prescription opioid abusers currently in treatment and their narrative accounts of the circumstances surrounding their POA onset. This research was conducted within a storyline framework, which operates on the premise that the path to drug abuse represents a biography or a process rather than a static condition. Audiotapes of in-depth interviews were transcribed, coded, and thematically analyzed. Analyses revealed the presence of four trajectories leading to POA. This study adds to the limited research on POA etiology by not only illuminating the psychosocial factors that contribute to POA onset, but also by situating initiation experiences within broader life processes. The study findings provide crucial insights to policymakers and interventionists in identifying who is at risk for POA, and more important, when and how to intervene most efficaciously. C1 [Rigg, Khary K.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Murphy, John W.] Univ Miami, Coral Gables, FL 33124 USA. RP Rigg, KK (reprint author), Philadelphia VA Med Ctr CHERP, 3900 Woodland Ave,Bldg 4100,Suite 202, Philadelphia, PA 19104 USA. EM kharyrigg@gmail.com FU NIDA NIH HHS [R01DA021330, R01 DA021330] NR 46 TC 10 Z9 10 U1 4 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 EI 1552-7557 J9 QUAL HEALTH RES JI Qual. Health Res. PD JUL PY 2013 VL 23 IS 7 BP 963 EP 975 DI 10.1177/1049732313488837 PG 13 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA AH6RJ UT WOS:000336258100009 PM 23656723 ER PT J AU Hamlett-Berry, K Christofferson, DE Martinello, RA AF Hamlett-Berry, Kim Christofferson, Dana E. Martinello, Richard A. TI SMOKING AND TOBACCO USE WITHIN THE DEPARTMENT OF VETERANS AFFAIRS SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Hamlett-Berry, Kim; Christofferson, Dana E.; Martinello, Richard A.] US Dept Vet Affairs, Vet Hlth Adm, Washington, DC 20460 USA. RP Hamlett-Berry, K (reprint author), Dept Vet Affairs, 810 Vermont Ave 10P3B, Washington, DC 20460 USA. EM kim.hamlett@va.gov NR 6 TC 3 Z9 3 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2013 VL 103 IS 7 BP E3 EP E3 DI 10.2105/AJPH.2013.301375 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3FP UT WOS:000330978600003 PM 23678898 ER PT J AU Kilbourne, AM Goodrich, DE Lai, ZS Post, EP Schumacher, K Nord, KM Bramlet, M Chermack, S Bialy, D Bauer, MS AF Kilbourne, Amy M. Goodrich, David E. Lai, Zongshan Post, Edward P. Schumacher, Karen Nord, Kristina M. Bramlet, Margretta Chermack, Stephen Bialy, David Bauer, Mark S. TI Randomized Controlled Trial to Assess Reduction of Cardiovascular Disease Risk in Patients With Bipolar Disorder: The Self-Management Addressing Heart Risk Trial (SMAHRT) SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SERIOUS MENTAL-ILLNESS; COLLABORATIVE CARE; INTERVENTION; DEPRESSION; RATIONALE; MORTALITY; SETTINGS; PROGRAM; BURDEN; ACCESS AB Objectives: Persons with bipolar disorder experience a disproportionate burden of medical conditions, notably cardiovascular disease (CVD), leading to impaired functioning and premature mortality. We hypothesized that the Life Goals Collaborative Care (LGCC) intervention, compared to enhanced usual care, would reduce CVD risk factors and improve physical and mental health outcomes in US Department of Veterans Affairs patients with bipolar disorder. Method: Patients with an ICD-9 diagnosis of bipolar disorder and = 1 CVD risk factor (N = 118) enrolled in the Self-Management Addressing Heart Risk Trial, conducted April 2008-May 2010, were randomized to LGCC (n = 58) or enhanced usual care (n = 60). Life Goals Collaborative Care included 4 weekly self-management sessions followed by tailored contacts combining health behavior change strategies, medical care management, registry tracking, and provider guideline support. Enhanced usual care included quarterly wellness newsletters sent during a 12-month period in addition to standard treatment. Primary outcome measures included systolic and diastolic blood pressure, nonfasting total cholesterol, and physical health-related quality of life. Results: Of the 180 eligible patients identified for study participation, 134 were enrolled (74%) and 118 completed outcomes assessments (mean age = 53 years, 17% female, 5% African American). Mixed effects analyses comparing changes in 24-month outcomes among patients in LGCC (n = 57) versus enhanced usual care (n = 59) groups revealed that patients receiving LGCC had reduced systolic (beta = -3.1, P = .04) and diastolic blood pressure (beta = -2.1, P = .04) as well as reduced manic symptoms (beta = -23.9, P = .01). Life Goals Collaborative Care had no significant impact on other primary outcomes (total cholesterol and physical health-related quality of life). Conclusions: Life Goals Collaborative Care, compared to enhanced usual care, may lead to reduced CVD risk factors, notably through decreased blood pressure, as well as reduced manic symptoms, in patients with bipolar disorder. (C) Copyright 2013 Physicians Postgraduate Press, Inc. C1 [Kilbourne, Amy M.; Goodrich, David E.; Lai, Zongshan; Post, Edward P.; Schumacher, Karen; Nord, Kristina M.; Bramlet, Margretta; Chermack, Stephen; Bialy, David] US Dept Vet Affairs, VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA. [Kilbourne, Amy M.; Goodrich, David E.; Lai, Zongshan; Nord, Kristina M.; Chermack, Stephen] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Post, Edward P.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Bauer, Mark S.] VA Boston Ctr Org Leadership & Management Res COL, Boston, MA USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Boston, MA USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Ctr Clin Management Res, North Campus Res Complex,2800 Plymouth Rd,Bldg 14, Ann Arbor, MI 48109 USA. EM amykilbo@umich.edu OI Post, Edward/0000-0002-5782-8736; Goodrich, David/0000-0003-3232-2189 FU Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development [CSRD S06]; VA Health Services Research and Development Center for Organization, Leadership, and Management Research (COLMR); National Institute of Mental Health [R34MH74509] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development (CSRD S06), the VA Health Services Research and Development Center for Organization, Leadership, and Management Research (COLMR), and the National Institute of Mental Health (R34MH74509). NR 40 TC 22 Z9 22 U1 0 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUL PY 2013 VL 74 IS 7 BP E655 EP E662 DI 10.4088/JCP.12m08082 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AA5DO UT WOS:000331116400004 PM 23945460 ER PT J AU Lawson, EH Hall, BL Louie, R Ettner, SL Zingmond, DS Han, L Rapp, M Ko, CY AF Lawson, Elise H. Hall, Bruce Lee Louie, Rachel Ettner, Susan L. Zingmond, David S. Han, Lein Rapp, Michael Ko, Clifford Y. TI Association Between Occurrence of a Postoperative Complication and Readmission Implications for Quality Improvement and Cost Savings SO ANNALS OF SURGERY LA English DT Article DE complications; cost savings; postoperative; quality improvement; readmission ID PROFILING HOSPITAL PERFORMANCE; COLORECTAL SURGERY; HEART-FAILURE; RISK-FACTORS; CLAIMS DATA; CANCER; RATES; DISCHARGE; REGISTRY; PROGRAM AB Objective: To estimate the effect of preventing postoperative complications on readmission rates and costs. Background: Policymakers are targeting readmission for quality improvement and cost savings. Little is known regarding mutable factors associated with postoperative readmissions. Methods: Patient records (2005-2008) from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) were linked to Medicare inpatient claims. Risk factors, procedure, and 30-day postoperative complications were determined from ACS-NSQIP. The 30-day postoperative readmission and costs were determined from Medicare. Occurrence of a postoperative complication included surgical site infections and cardiac, pulmonary, neurologic, and renal complications. Multivariate regression models predicted the effect of reducing complication rates on risk-adjusted readmission rates and costs by procedure. Results: The 30-day postoperative readmission rate was 12.8%. Complication rates for readmitted and nonreadmitted patients were 53% and 16% (P < 0.001). Patients with a postoperative complication had higher predicted probability of readmission and cost of readmission than patients without a complication. For the 20 procedures accounting for the greatest number of readmissions, reducing ACS-NSQIP complication rates by a relative 5% could result in prevention of 2092 readmissions per year and a savings to Medicare of $31.0 million per year. Preventing all ACS-NSQIP complications for these procedures could result in prevention of 41,846 readmissions per year and a savings of $620.3 million per year. Conclusions: This study provides substantial evidence that efforts to reduce postoperative readmissions should begin by focusing on postoperative complications that can be reliably and validly measured. Such an approach will not eliminate all postoperative readmissions but will likely have a major effect on readmission rates. C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Louie, Rachel; Ettner, Susan L.; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Han, Lein; Rapp, Michael] Ctr Medicare Serv, Baltimore, MD USA. [Han, Lein; Rapp, Michael] Ctr Medicaid Serv, Baltimore, MD USA. [Rapp, Michael] George Washington Univ, Sch Med & Hlth Sci, Dept Emergency Med, Washington, DC 20052 USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program; CMS FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program. This study was partially funded by a contract from the CMS. For the remaining authors, none were declared. The views expressed in this article represent the authors' views and do not necessarily represent official policy or opinions of the Department of Health and Human Services, the CMS. The authors declare no conflicts of interest. NR 27 TC 91 Z9 91 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUL PY 2013 VL 258 IS 1 BP 10 EP 18 DI 10.1097/SLA.0b013e31828e3ac3 PG 9 WC Surgery SC Surgery GA 300JO UT WOS:000330460400011 PM 23579579 ER PT J AU Cheng, G Alavi, A Del Bello, CV Akers, SR AF Cheng, Gang Alavi, Abass Del Bello, Catherine V. Akers, Scott R. TI Differential Washout of FDG Activity in Two Different Inflammatory Lesions Implications for Delayed Imaging SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE FDG; PET; inflammation; delayed imaging ID DUAL-TIME-POINT; POSITRON-EMISSION-TOMOGRAPHY; SOLITARY PULMONARY NODULES; F-18-FDG PET; BREAST-CANCER; BENIGN; DIAGNOSIS AB We describe the changes of FDG uptake in different inflammatory lesions on multiple time point FDG PET/CT. FDG uptake in granulomatous lesions was more intense and focal, with higher intensity on delayed images. In contrast, FDG uptake in chronic arthritic joint inflammation was diffuse and mild, without significant change over time, while FDG uptake in nonarthritic joints was at near-background level with decreased activity on delayed images. The retention index was significantly higher in patients with granulomatous lesions than that in other groups. Our finding indicates differential FDG uptake and clearance in active granulomas versus chronic inflammation. C1 [Cheng, Gang; Del Bello, Catherine V.; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. RP Akers, SR (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM akerssco@me.com NR 21 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD JUL PY 2013 VL 38 IS 7 BP 576 EP 579 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 298WG UT WOS:000330354600029 PM 23640221 ER PT J AU Stewart, JM Sommers, MS Brawner, BM AF Stewart, Jennifer M. Sommers, Marilyn S. Brawner, Bridgette M. TI The Black Church, Sexual Health, and Sexuality A Conceptual Framework to Promote Health Through Faith-Based Organizations SO FAMILY & COMMUNITY HEALTH LA English DT Article DE black populations; church; faith-based organizations; implementation science; sexual health ID AFRICAN-AMERICAN CHURCH; SOCIAL SUPPORT; UNITED-STATES; HIV; COMMUNITY; ATTITUDES; MEN; PREVENTION; EDUCATION; BEHAVIOR AB There is a growing body of literature that documents the unique impact of black churches on social and health-related changes in the black community. Sexual health and sexuality, however, have long been sources of contention within the institution. The purpose of this article was to refine existing theoretical models that undergird sexual health research in faith-based organizations. The proposed conceptual model explores social-level factors (racism, homophobia, and heterosexism) and church organizational-level factors (beliefs, social trust, norms, and social support/influence). We make an argument in favor of illuminating the negative social-level barriers and affirming the internal cultural supports. C1 [Stewart, Jennifer M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Stewart, Jennifer M.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. RP Stewart, JM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,233L, Philadelphia, PA 19104 USA. EM stewj@nursing.upenn.edu NR 55 TC 1 Z9 1 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 EI 1550-5057 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JUL-SEP PY 2013 VL 36 IS 3 BP 269 EP 279 DI 10.1097/FCH.0b013e318292eb2d PG 11 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 298ZH UT WOS:000330363200010 PM 23718962 ER PT J AU Hopchik, J AF Hopchik, Jordan TI EXPANDING THE ROLE OF THE ADVANCED PRACTICE REGISTERED NURSE AS AN ENDOSCOPIST SO GASTROENTEROLOGY NURSING LA English DT Letter C1 [Hopchik, Jordan] La Salle Univ, Philadelphia VA Med Ctr, Philadelphia, PA 19141 USA. [Hopchik, Jordan] La Salle Univ, Philadelphia, PA 19141 USA. RP Hopchik, J (reprint author), 15 Stokes Ave, Voorhees, NJ 08043 USA. EM jhopchik@aol.com NR 7 TC 2 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1042-895X EI 1538-9766 J9 GASTROENTEROL NURS JI Gastroenterol. Nurs. PD JUL-AUG PY 2013 VL 36 IS 4 BP 289 EP 290 DI 10.1097/SGA.0b013e3182a14e3f PG 2 WC Gastroenterology & Hepatology; Nursing SC Gastroenterology & Hepatology; Nursing GA 298ZW UT WOS:000330364800008 PM 23899489 ER PT J AU Mittal, S El-Serag, HB AF Mittal, Sahil El-Serag, Hashem B. TI Epidemiology of Hepatocellular Carcinoma Consider the Population SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE hepatocellular carcinoma; epidemiology; chronic hepatitis B; chronic hepatitis C; prevention ID HEPATITIS-C VIRUS; FATTY LIVER-DISEASE; TERM-FOLLOW-UP; NONALCOHOLIC STEATOHEPATITIS; RISK-FACTORS; NATURAL-HISTORY; UNITED-STATES; LONG-TERM; CRYPTOGENIC CIRRHOSIS; VIRAL-HEPATITIS AB Hepatocellular carcinoma (HCC) is increasing in incidence and has a very high fatality rate. Cirrhosis due to chronic hepatitis B or hepatitis C is the leading risk factor for HCC. Global epidemiology of HCC is determined by the prevalence of dominant viral hepatitis and the age it is acquired in the underlying population. Upcoming risk factors include obesity, diabetes, and related nonalcoholic fatty liver disease. This review discusses the latest trends of HCC globally and in the United States. It also provides an evidence-based commentary on the risk factors and lists some of the preventive measures to reduce the incidence of HCC. C1 [Mittal, Sahil; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Mittal, Sahil; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2022 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.edu FU NCI NIH HHS [R01 CA125487]; NIDDK NIH HHS [K24 DK078154, P30 DK056338] NR 58 TC 182 Z9 186 U1 3 U2 24 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JUL PY 2013 VL 47 SU 1 BP S2 EP S6 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 298UJ UT WOS:000330349700002 PM 23632345 ER PT J AU Mohamed, BA Yang, W Litt, H Rosas, SE AF Mohamed, Bonita A. Yang, Wei Litt, Harold Rosas, Sylvia E. TI Valvular Calcification, Inflammation, and Mortality in Dialysis Patients SO JOURNAL OF HEART VALVE DISEASE LA English DT Article ID CARDIAC-VALVE CALCIFICATION; CHRONIC KIDNEY-DISEASE; ALL-CAUSE MORTALITY; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR MORTALITY; PLASMA INTERLEUKIN-6; FETUIN-A; CALCIUM; ASSOCIATION; ATHEROSCLEROSIS AB Background and aim of the study: The study aim was to determine the correlates of valvular calcification (VC), including clinical and physiologic parameters, in individuals new to dialysis. In addition, the association of VC with coronary artery calcification (CAC) progression and mortality was investigated. Methods: A total of 101 incident dialysis individuals underwent electrocardiogram-triggered multislice computed tomography (CT) to monitor the presence and quantification of calcification. The average follow up was 2.85 +/- 0.72 years. Results: Twenty-six (25.7%) patients had only one valve calcified, while 10 (9.9%) had calcifications in both valves. Patients with VC were older, more likely to have a history of diabetes and/or cardiovascular disease (CVD), more likely to have CAC, and to be Caucasian; fibrinogen and interleukin-6 (IL-6) levels were also higher in these patients. Multivariable Poisson regression analysis revealed older age, history of CVD, increasing fibrinogen, and presence of CAC were independently associated with the presence of VC. Patients with VC also had a higher median annualized CAC progression compared to those without VC (2.90 versus 105.2, p = 0.004). The mortality rate per 100 years was 2.57 in patients without VC, compared to 4.20 and 13.76, respectively, for those with one or two calcified valves. An increasing number of calcified valves was associated with a higher mortality after adjustment for gender and race [HR 2.2 (1.03-4.69), p = 0.04], but was not statistically significant after adjustment for inflammatory markers such as IL-6 or fibrinogen. Conclusion: Traditional and novel risk factors are associated with the presence of VC, which is a risk marker for CAC progression and mortality in incident dialysis patients. C1 [Mohamed, Bonita A.] Penn Hosp, Dept Med, Philadelphia, PA 19107 USA. [Yang, Wei] Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Litt, Harold] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104 USA. [Rosas, Sylvia E.] Univ Penn, Perelman Sch Med, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Rosas, Sylvia E.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA USA. RP Rosas, SE (reprint author), Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, 1 Founders,3400 Spruce St, Philadelphia, PA 19104 USA. EM Sylvia.Rosas@uphs.upenn.edu FU NIH [R21 HL 086971]; Veterans Health Administration; National Center for Research Resources [UL1RR024134]; [R01 DK 080033] FX These studies were supported by NIH grants R21 HL 086971 and an American Recovery and Reinvestment Act supplement. Salary support was also provided by the Veterans Health Administration and R01 DK 080033 (S.E.R.). The project was supported by Grant Number UL1RR024134 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 19 TC 4 Z9 5 U1 0 U2 3 PU I C R PUBLISHERS PI NORTHWOOD PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET, ENGLAND SN 0966-8519 J9 J HEART VALVE DIS JI J. Heart Valve Dis. PD JUL PY 2013 VL 22 IS 4 BP 584 EP 590 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 303OE UT WOS:000330683000021 PM 24224425 ER PT J AU King, BJ Gilmore-Bykovskyi, AL Roiland, RA Polnaszek, BE Bowers, BJ Kind, AJH AF King, Barbara J. Gilmore-Bykovskyi, Andrea L. Roiland, Rachel A. Polnaszek, Brock E. Bowers, Barbara J. Kind, Amy J. H. TI The Consequences of Poor Communication During Transitions from Hospital to Skilled Nursing Facility: A Qualitative Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE care transitions; communication; hospital to skilled nursing facility ID CARE TRANSITIONS; BOUNCING BACK; PHYSICIANS; STROKE AB OBJECTIVES: To examine how skilled nursing facility (SNF) nurses transition the care of individuals admitted from hospitals, the barriers they experience, and the outcomes associated with variation in the quality of transitions. DESIGN: Qualitative study using grounded dimensional analysis, focus groups, and in-depth interviews. SETTING: Five Wisconsin SNFs. PARTICIPANTS: Twenty-seven registered nurses. MEASUREMENTS: Semistructured questions guided the focus group and individual interviews. RESULTS: SNF nurses rely heavily on written hospital discharge communication to transition individuals into the SNF effectively. Nurses cited multiple inadequacies of hospital discharge information, including regular problems with medication orders (including the lack of opioid prescriptions for pain), little psychosocial or functional history, and inaccurate information regarding current health status. These communication inadequacies necessitated repeated telephone clarifications, created care delays (including delays in pain control), increased SNF staff stress, frustrated individuals and family members, contributed directly to negative SNF facility image, and increased risk of rehospitalization. SNF nurses identified a specific list of information and components that they need to facilitate a safe, high-quality transition. CONCLUSION: Nurses note multiple deficiencies in hospital-to-SNF transitions, with poor quality discharge communication being identified as the major barrier to safe and effective transitions. This information should be used to refine and support the dissemination of evidence-based interventions that support transitions of care, including the Interventions to Reduce Acute Care Transfers program. C1 [King, Barbara J.; Gilmore-Bykovskyi, Andrea L.; Roiland, Rachel A.; Bowers, Barbara J.] Univ Wisconsin, Sch Nursing, Madison, WI 53792 USA. [Gilmore-Bykovskyi, Andrea L.; Polnaszek, Brock E.; Kind, Amy J. H.] Univ Wisconsin, Div Geriatr, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Gilmore-Bykovskyi, Andrea L.; Polnaszek, Brock E.; Kind, Amy J. H.] Univ Wisconsin, Hlth Innovat Program, Madison, WI 53792 USA. [Roiland, Rachel A.; Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP King, BJ (reprint author), Univ Wisconsin, Sch Nursing, H6-246 CSC,600 Highland Ave, Madison, WI 53792 USA. EM bjking2@wisc.edu OI King, Barbara/0000-0003-0577-9028; Bowers, Barbara/0000-0002-3226-0718 FU National Institute on Aging [K23AG034551]; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Madison VA Geriatric Research, Education and Clinical Center (GRECC) [2013-05]; John A. Hartford Foundation Building Academic Geriatric Nursing Capacity Program; National Institute of Nursing Research [F31NR013097-01]; University of Wisconsin School of Medicine and Public Health's Health Innovation Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX This project was supported by the National Institute on Aging Paul B. Beeson Patient-Oriented Research Career Development Award (K23AG034551, PI, Kind), in partnership with the American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, and the Starr Foundation and the Madison VA Geriatric Research, Education and Clinical Center (GRECC-Manuscript 2013-05). Roiland and Gilmore-Bykovskyi received support from the John A. Hartford Foundation Building Academic Geriatric Nursing Capacity Program. Roiland's contributions were supported by an F31 National Research Service Award from the National Institute of Nursing Research (F31NR013097-01). Additional support was provided by the University of Wisconsin School of Medicine and Public Health's Health Innovation Program; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; and the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (1UL1RR025011). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 26 TC 36 Z9 37 U1 5 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2013 VL 61 IS 7 BP 1095 EP 1102 DI 10.1111/jgs.12328 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 297FT UT WOS:000330241800007 PM 23731003 ER PT J AU Li, LDT Mills, WL White, DL Li, A Gutierrez, AM Berger, DH Naik, AD AF Li, Linda T. Mills, Whitney L. White, Donna L. Li, Alexa Gutierrez, Amanda M. Berger, David H. Naik, Aanand D. TI Causes and Prevalence of Unplanned Readmissions After Colorectal Surgery: A Systematic Review and Meta-Analysis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Review DE epidemiology; geriatric; outcomes; rehospitalization ID HOSPITAL READMISSION; LAPAROSCOPIC COLECTOMY; INTESTINAL SURGERY; CONTROLLED-TRIAL; HEART-FAILURE; CARE; CANCER; QUALITY; TRANSITIONS; OUTCOMES AB A systematic review and meta-analysis of the current literature was conducted to compare the overall and cause-specific readmission rates after colorectal surgery of older adults with those of younger individuals. Potential predictors of unplanned readmission were also identified. Estimated pooled readmission rates were calculated and reported as pooled proportions with associated 95% confidence intervals (CI) in 60,131 total readmissions; 11.0% (95% CI = 10.0-12.0) of all admissions after colorectal surgery resulted in unplanned readmission at 30 days. Older adults had a lower rate of readmission than younger individuals. Bowel obstruction was the most common cause of unplanned readmission, accounting for 33.4% of all unplanned readmissions, followed by surgical site infection (15.7%) and intraabdominal abscess (12.6%). Several age-related predictors of unplanned readmission were identified, such as poor functional capacity, multiple comorbidities, chronic obstructive pulmonary disease, and discharge to a nonhome destination. The findings of this review will help guide the development of future interventions to reduce preventable readmissions after colorectal surgery in older adults. C1 [Li, Linda T.; Berger, David H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Li, Linda T.; Mills, Whitney L.; White, Donna L.; Berger, David H.; Naik, Aanand D.] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Houston, TX 77030 USA. [White, Donna L.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Li, Alexa; Gutierrez, Amanda M.] Rice Univ, Houston, TX USA. [Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Naik, Aanand D.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA. [Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Li, LDT (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, 1 Baylor Plaza,Rm 404D, Houston, TX 77030 USA. EM linday@bcm.edu OI Gutierrez, Amanda/0000-0002-4496-5328 FU Doris Duke Charitable Foundation; Cancer Prevention and Research Institute of Texas; Veterans Integrated Service Network [16]; Veterans Affairs Office of Academic Affiliations; National Institute of Diabetes and Digestive and Kidney Diseases [DK081736-01]; Texas Medical Center Digestive Diseases Center [NIH DK58338] FX This review was supported with resources and the use of facilities at the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020) at the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. Dr. Naik receives support from a Doris Duke Charitable Foundation Clinical Scientist Development award. Dr. Berger holds a grant from the Cancer Prevention and Research Institute of Texas and a Veterans Engineering Resource Center grant from Veterans Integrated Service Network 16. Dr. Mills is a postdoctoral fellow in health services research supported by the Veterans Affairs Office of Academic Affiliations. Dr. White was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award DK081736-01 and the Texas Medical Center Digestive Diseases Center (NIH DK58338). NR 27 TC 15 Z9 16 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2013 VL 61 IS 7 BP 1175 EP 1181 DI 10.1111/jgs.12307 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 297FT UT WOS:000330241800019 PM 23730901 ER PT J AU Bhakta, A Bloom, M Warren, H Shah, N Casas, T Ewing, T Bukur, M Chung, R Ley, E Margulies, D Malinoski, D AF Bhakta, Akash Bloom, Matthew Warren, Heather Shah, Nirvi Casas, Tamara Ewing, Tyler Bukur, Marko Chung, Rex Ley, Eric Margulies, Daniel Malinoski, Darren TI The impact of implementing a 24/7 open trauma bed protocol in the surgical intensive care unit on throughput and outcomes SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 26th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma CY JAN 15-19, 2013 CL Scottsdale, AZ SP Eastern Assoc Surg Trauma DE Emergency department throughput; emergency department length of stay; ICU triage ID LENGTH-OF-STAY; EMERGENCY-DEPARTMENT; AMBULANCE DIVERSION; ADMITTED PATIENTS; ADMISSION; OCCUPANCY AB BACKGROUND: Increased emergency department (ED) length of stay (LOS) has been associated with increased mortality in trauma patients. In 2010, we implemented a 24/7 open trauma bed protocol in our designated trauma intensive care units (TICUs) to facilitate rapid admission from the ED. This required maintenance of a daily bump list and timely transferring of patients out of the TICU. We hypothesized that ED LOS and mortality would decrease after implementation. METHODS: The following data from patients admitted directly from the ED to any ICU were retrospectively compared before (2009) and after (2011) the implementation of a trauma bed protocol at a Level I trauma center: age, sex, Glasgow Coma Scale (GCS) score, shock on admission (systolic blood pressure G 90 mm Hg), mechanism, injury severity scores (Injury Severity Score [ISS] and Abbreviated Injury Scale [AIS] score), ED LOS, ICU readmission rates, and mortality. RESULTS: Of the patients, 267 (17%) of 1,611 before and 262 (21%) of 1,266 (p < 0.01) after the protocol were admitted directly to the ICU, despite similar characteristics. ED LOS decreased from 4.2 +/- 4.0 hours to 3.1 +/- 2.1 hours (p < 0.01) in all patients as well as patients with an ISS of greater than 24 (3.1 +/- 2.5 vs. 2.2 +/- 1.6, p < 0.05) and a head AIS score of greater than 2 (4.2 +/- 4.9 vs. 3.1 +/- 2.0, p = 0.01). Mortality was unchanged for all patients (9% vs. 8%, p = 0.58) but trends toward improved mortality were found after protocol implementation inpatients with an ISS of greater than 24 (30% vs. 13%, p = 0.07) and in patients with a head AIS score of greater than 2 (12% vs. 6%, p = 0.08). A greater proportion of total patients were admitted to a designated TICU after implementation (83% vs. 93%, p G 0.01). ICU readmissions were unchanged (0.3% vs. 1.5%, p = 0.21). CONCLUSION: The implementation of a 24/7 open trauma bed protocol in the surgery ICU was associated with a decreased ED LOS and increased admissions to designated TICUs in all patients. Improved throughput was achieved without increases in ICU readmissions. (J Trauma Acute Care Surg. 2013; 75: 97-101. Copyright (C) 2013 by Lippincott Williams & Wilkins) C1 [Bhakta, Akash] Midwestern Univ, Glendale, AZ USA. [Bloom, Matthew; Warren, Heather; Casas, Tamara; Bukur, Marko; Chung, Rex; Ley, Eric; Margulies, Daniel] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Shah, Nirvi] Western Univ Hlth Sci, Pomona, CA USA. [Ewing, Tyler] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. [Malinoski, Darren] Portland VA Med Ctr, Dept Surg, Portland, OR USA. RP Malinoski, D (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Sect Surg Crit Care, POB 1034-P3ANES, Portland, OR 97207 USA. EM Darren.malinoski@va.gov NR 25 TC 6 Z9 6 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD JUL PY 2013 VL 75 IS 1 BP 97 EP 101 DI 10.1097/TA.0b013e31829849e5 PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 300EV UT WOS:000330448100026 PM 23778446 ER PT J AU McNichol, L Lund, C Rosen, T Gray, M AF McNichol, Laurie Lund, Carolyn Rosen, Ted Gray, Mikel TI Medical Adhesives and Patient Safety: State of the Science Consensus Statements for the Assessment, Prevention, and Treatment of Adhesive-Related Skin Injuries SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE Bandages; Dressings; Medical adhesive; Skin integrity; Skin stripping; Skin tear; Surgical tape ID TAPE; INFECTION; OUTBREAK; BACTERIA; ZYGOMYCOSIS AB Skin injury related to medical adhesive usage is a prevalent but underrecognized complication that occurs across all care settings and among all age groups. If proper technique for application and/or removal of adhesive products is not used, tissue trauma can occur, impacting patient safety and quality of life and increasing healthcare costs. Little guidance exists in the literature regarding appropriate selection and proper use of adhesive products to minimize medical adhesive-related skin injury, as well as best practices for skin care preventive strategies, application and removal techniques, and assessment and treatment of such injuries. In an effort to define best practices for prevention of such injury, a consensus panel of 23 recognized key opinion leaders convened to establish consensus statements on the assessment, prevention, and treatment of medical adhesive-related skin injury. The consensus summit was held in December 2012 and was made possible by an unrestricted educational grant from 3M. This document details the consensus definitions and statements and identifies research priorities for development of new adhesive technologies and protocols for skin protection. C1 [McNichol, Laurie] Cone Hlth Syst, Greensboro, NC USA. [Lund, Carolyn] Childrens Hosp, Oakland, CA 94609 USA. [Lund, Carolyn] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Rosen, Ted] Baylor Coll Med, Houston, TX 77030 USA. [Rosen, Ted] Houston Vet Affairs Med Ctr, Houston, TX USA. [Gray, Mikel] Univ Virginia, Charlottesville, VA 22908 USA. RP Gray, M (reprint author), Univ Virginia, Dept Urol, POB 800422, Charlottesville, VA 22908 USA. EM MG5K@hscmail.mcc.virginia.edu FU 3M; 3M, St. Paul, Minnesota FX The Medical Adhesives & Patient Safety Consensus Panel thanks the following individuals for their special contributions to the project: Laurie McNichol, Carolyn Lund, and Ted Rosen for their leadership, dedication, and time commitment in making this project a reality; 3M for the educational grant support and Summit venue, without which this project would not have been possible; Magellan Medical Technology Consultants for their role in planning and facilitating the Summit; Mikel Gray for his expertise in moderating the Summit; and Marie Sabo Recine, MS, MT(ASCP), for providing medical writing assistance.; The content of this document is based on the results of a 2-day roundtable discussion held December 10 to 11, 2012, in St. Paul, Minnesota, and was made possible by an unrestricted educational grant from 3M, St. Paul, Minnesota. The information contained herein does not necessarily represent the opinions of all authors and panel members, 3M, or Magellan Medical Technology Consultants. NR 78 TC 17 Z9 20 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD JUL-AUG PY 2013 VL 40 IS 4 BP 365 EP 380 DI 10.1097/WON.0b013e3182995516 PG 16 WC Nursing SC Nursing GA 300JZ UT WOS:000330461500006 PM 23759927 ER PT J AU Hauptman, JS Dadour, A Oh, T Baca, CB Vickrey, BG Vassar, S Sankar, R Salamon, N Vinters, HV Mathern, GW AF Hauptman, Jason S. Dadour, Andrew Oh, Taemin Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie Sankar, Raman Salamon, Noriko Vinters, Harry V. Mathern, Gary W. TI Time to Pediatric Epilepsy Surgery Is Longer and Developmental Outcomes Lower for Government Compared With Private Insurance SO NEUROSURGERY LA English DT Article DE Craniotomy; Disparities; Health inequity; Hemispherectomy; Socioeconomic ID TEMPORAL-LOBE EPILEPSY; POPULATION-BASED-ANALYSIS; UNITED-STATES; INTERNATIONAL LEAGUE; PUBLIC INSURANCE; INFANTILE SPASMS; UCLA EXPERIENCE; SEIZURE FREEDOM; SPECIALTY CARE; HEALTH-CARE AB BACKGROUND: It is unclear if socioeconomic factors like type of insurance influence time to referral and developmental outcomes for pediatric patients undergoing epilepsy surgery. OBJECTIVE: This study determined whether private compared with state government insurance was associated with shorter intervals of seizure onset to surgery and better developmental quotients for pediatric patients undergoing epilepsy surgery. METHODS: A consecutive cohort (n = 420) of pediatric patients undergoing epilepsy surgery were retrospectively categorized into those with Medicaid (California Children's Services; n = 91) or private (Preferred Provider Organization, Health Maintenance Organization, Indemnity; n = 329) insurance. Intervals from seizure onset to referral and surgery and Vineland developmental assessments were compared by insurance type with the use of log-rank tests. RESULTS: Compared with private insurance, children with Medicaid had longer intervals from seizure onset to referral for evaluation (log-rank test, P = .034), and from seizure onset to surgery (P = .017). In a subset (25%) that had Vineland assessments, children with Medicaid compared with private insurance had lower Vineland scores presurgery (P = .042) and postsurgery (P = .003). Type of insurance was not associated with seizure severity, types of operations, etiology, postsurgical seizure-free outcomes, and complication rate. CONCLUSION: Compared with Medicaid, children with private insurance had shorter intervals from seizure onset to referral and to epilepsy surgery, and this was associated with lower Vineland scores before surgery. These findings may reflect delayed access for uninsured children who eventually obtained state insurance. Reasons for the delay and whether longer intervals before epilepsy surgery affect long-term cognitive and developmental outcomes warrant further prospective investigations. C1 [Hauptman, Jason S.; Dadour, Andrew; Oh, Taemin; Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie; Sankar, Raman; Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA. [Salamon, Noriko] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neuroradiol, Los Angeles, CA 90095 USA. [Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Sect Neuropathol, Los Angeles, CA 90095 USA. [Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Psychiat & Biobehav Med, Los Angeles, CA 90095 USA. RP Mathern, GW (reprint author), 710 Westwood Plaza,Room 2123, Los Angeles, CA 90095 USA. EM gmathern@ucla.edu FU NIH [R01 NS38992]; Epilepsy Foundation Grant [213971]; University of California Pediatric Neuropathology Consortium FX This research was supported in part by NIH R01 NS38992 and Epilepsy Foundation Grant 213971. Dr Vinters was supported in part by the University of California Pediatric Neuropathology Consortium. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. NR 39 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X EI 1524-4040 J9 NEUROSURGERY JI Neurosurgery PD JUL PY 2013 VL 73 IS 1 BP 152 EP 157 DI 10.1227/01.neu.0000429849.99330.6e PG 6 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 299FJ UT WOS:000330380900044 PM 23615092 ER PT J AU Tan, G Teo, I Srivastava, D Smith, D Smith, SL Williams, W Jensen, MP AF Tan, Gabriel Teo, Irene Srivastava, Devika Smith, Donna Smith, Shirley L. Williams, Wright Jensen, Mark P. TI Improving Access to Care for Women Veterans Suffering from Chronic Pain and Depression Associated with Trauma SO PAIN MEDICINE LA English DT Article DE Rural; Women Veterans; Chronic Pain; Depression; Trauma; Biofeedback ID HEART-RATE-VARIABILITY; POSTTRAUMATIC-STRESS-DISORDER; MEMORY-CONCENTRATION TEST; HEALTH-CARE; PSYCHOMETRIC PROPERTIES; IRAQI FREEDOM; BIOFEEDBACK; VALIDATION; PTSD; SYMPTOMS AB Objective. Access to care has become a priority for the Veterans Administration (VA) health care system as a significant number of veterans enrolled in the VA health care system reside in rural areas. The feasibility and effects of a novel clinical intervention that combined group therapy and biofeedback training was evaluated on women veterans living in rural areas. Methods. The study was conducted at selected community-based outpatient clinics (CBOCs) in Texas. Thirty four women veterans with chronic pain and comorbid depression and/or posttraumatic stress disorder (PTSD) were recruited. Five sessions of education/therapy were delivered via telemedicine in combination with daily home practice of a portable biofeedback device (Stress Eraser (R), Helicor, New York, NY, USA). Participants responded to self-report questionnaires at baseline, at posttreatment, and at 6-week follow-up. Daily practice logs were also maintained by participants. Results. The clinical protocol was acceptable, easy to administer, and associated with statistically significant decreases in self-reported pain unpleasantness, pain interference, depressive symptoms, PTSD symptoms, and sleep disturbance at posttreatment. Improvements were maintained at 6-week follow-up. Qualitative analyses indicated that many participants 1) wished to continue to meet as a support group in their respective CBOCs and 2) felt less isolated and more empowered to cope with their problems of daily living as a result of the treatment. Conclusions. It is feasible to provide treatment to women veterans living in rural areas by utilizing video-teleconferencing technology between larger VA medical centers and facilities at CBOCs in more rural settings. A controlled trial of the intervention is warranted. C1 [Tan, Gabriel] Natl Univ Singapore, Singapore 119077, Singapore. [Teo, Irene] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Srivastava, Devika] Fordham Univ, New York, NY 10023 USA. [Smith, Donna; Smith, Shirley L.; Williams, Wright] Michael E DeBakey Vet Affair Med Ctr, Houston, TX USA. [Williams, Wright] Baylor Coll Med, Houston, TX 77030 USA. [Jensen, Mark P.] Univ Washington, Seattle, WA 98195 USA. RP Tan, G (reprint author), Natl Univ Singapore, Clin Psychol Program, 21 Lower Kent Ridge Rd, Singapore 119077, Singapore. EM psygt@nus.edu.sg FU Alergan; Covidien; Depomed; Endo Pharmaceuticals; Merck; Pfizer; RTI Health Solutions; ZARS Pharma; Zogeniz FX In the past 12 months, Dr. Jensen has received grant or research support, or fees for consulting services, from Alergan, Covidien, Depomed, Endo Pharmaceuticals, Merck, Pfizer, RTI Health Solutions, ZARS Pharma, and Zogeniz. NR 48 TC 2 Z9 2 U1 4 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUL PY 2013 VL 14 IS 7 BP 1010 EP 1020 DI 10.1111/pme.12131 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 297GY UT WOS:000330245100015 PM 23659470 ER PT J AU Igoe, A Scofield, RH AF Igoe, Ann Scofield, R. Hal TI Autoimmunity and infection in Sjogren's syndrome SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE autoimmunity; infection; Sjogren's syndrome; virus ID HEPATITIS-C-VIRUS; ARYL-HYDROCARBON RECEPTOR; EPSTEIN-BARR-VIRUS; PARVOVIRUS B19 INFECTION; SALIVARY-GLANDS; MURINE CYTOMEGALOVIRUS; SICCA SYNDROME; ALPHA-FODRIN; IN-VIVO; B-CELLS AB Purpose of review To summarize the recent developments concerning the potential viral pathomechanisms and involvement of viruses in Sjogren's syndrome, and to highlight the areas for future research and therapies. Recent findings Activated IFN-1 pathway plays an important part in the autoimmune disease process of Sjogren's syndrome; therefore, several therapies aiming to reduce or inhibit the IFN-1 production and its effects may be a target for future treatment plans. Activated aryl hydrocarbon receptor may interact with latent Epstein-Barr virus (EBV) infection, which in turn may predispose to the development of Sjogren's syndrome. It is estimated that the population is 95% positive for EBV serology. Microbial factors may incite autoimmune disease. Although this hypothesis is proven in a few illnesses such as rheumatic fever, there is no definitive evidence of an infectious environmental trigger in Sjogren's syndrome. However, there are circumstantial data with regard to viruses and several potential mechanisms of disease. These include antigen mimicry, polyclonal lymphocyte activation, and infection-mediated innate end-organ inflammation. In addition, hepatitis C virus infection clearly causes a Sjogren's-syndrome-like illness. Summary Data continue to implicate viral infection in the cause of Sjogren's syndrome, but there are no definitive studies incriminating a particular virus. C1 [Igoe, Ann; Scofield, R. Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Igoe, Ann; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Igoe, Ann; Scofield, R. Hal] US Dept Vet Affairs, Oklahoma City, OK USA. RP Scofield, RH (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM hal-scofield@omrf.ouhsc.edu FU NIH [1 P50 AR060804] FX The authors acknowledge the support provided by the NIH grants to RHS 1 P50 AR060804. NR 95 TC 18 Z9 19 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 EI 1531-6963 J9 CURR OPIN RHEUMATOL JI Curr. Opin. Rheumatol. PD JUL PY 2013 VL 25 IS 4 BP 480 EP 487 DI 10.1097/BOR.0b013e32836200d2 PG 8 WC Rheumatology SC Rheumatology GA 298YF UT WOS:000330359900011 PM 23719365 ER PT J AU Byeon, HK Duvvuri, U Kim, WS Park, YM Hong, HJ Koh, YW Choi, EC AF Byeon, Hyung Kwon Duvvuri, Umamaheswar Kim, Won Shik Park, Young Min Hong, Hyun Jun Koh, Yoon Woo Choi, Eun Chang TI Transoral Robotic Retropharyngeal Lymph Node Dissection With or Without Lateral Oropharyngectomy SO JOURNAL OF CRANIOFACIAL SURGERY LA English DT Article DE Transoral robotic surgery; retropharyngeal lymph node dissection; minimally invasive surgery; oropharyngeal and hypopharyngeal carcinoma ID SQUAMOUS-CELL CARCINOMA; MODIFIED FACELIFT; NECK DISSECTION; THYROID-CANCER; METASTASIS; SURGERY; HEAD; HYPOPHARYNX; IMPACT; SPACE AB Retropharyngeal lymph node (RPLN) metastases can occur from advanced head and neck malignancies. Surgical access to RPLNs can be challenging. Considering the more aggressive conventional approach methods, there is an increasing need for minimally invasive techniques. Applying transoral robotic surgery (TORS) to access the RPLN has never been reported in the literature. The purpose of this study was to describe our experience with transoral robotic RPLN dissection for oropharyngeal and hypopharyngeal squamous cell carcinomas. We conducted a retrospective review of TORS cases performed at Severance Hospital, a tertiary care medical center from December 2011 to July 2012. Demographic, clinicopathologic, and treatment characteristics were abstracted from the medical record as well as complications and were analyzed descriptively. A total of 5 TORS procedures with transoral robotic RPLN dissection have been performed at Severance Hospital. Of these, 4 patients were treated for oropharyngeal squamous cell carcinoma and 1 for hypopharyngeal squamous cell carcinoma. The mean operation time for TORS including the robotic RPLN dissection was 84 +/- 18.5 minutes. The operation time included time for docking of the robotic arms (4.8 +/- 1.3 minutes), console working time for primary tumor removal (50 +/- 8.9 minutes), and console working time for RPLN dissection (29.2 +/- 9.4 minutes). No patients experienced complications related to the transoral robotic RPLN dissection. Transoral robotic RPLN dissection is a feasible approach for accessing retropharyngeal lymph nodes. This particular operative technique can serve as a minimal invasive surgery in removing pathologic RPLNs. C1 [Byeon, Hyung Kwon; Kim, Won Shik; Park, Young Min; Hong, Hyun Jun; Koh, Yoon Woo; Choi, Eun Chang] Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. RP Koh, YW (reprint author), Yonsei Univ Hlth Syst, Severance Hosp, Yonsei Univ, Dept Otorhinolaryngol,Coll Med, 50 Yonsei Ro, Seoul 120752, South Korea. EM ywkohent@yuhs.ac NR 23 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1049-2275 EI 1536-3732 J9 J CRANIOFAC SURG JI J. Craniofac. Surg. PD JUL PY 2013 VL 24 IS 4 BP 1156 EP 1161 DI 10.1097/SCS.0b013e318293f860 PG 6 WC Surgery SC Surgery GA 295PW UT WOS:000330129000075 PM 23851761 ER PT J AU Lorenzo, L AF Lorenzo, Lenora TI Partnering with patients to promote holistic diabetes management: Changing paradigms SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS LA English DT Review DE Nurse practitioners; diabetes; behavioral health; coaching; empowerment; health promotion; Motivational Interviewing ID CHRONIC CARE MODEL; SELF-MANAGEMENT; GROUP VISITS; BEHAVIOR-CHANGE; INTERVENTIONS; HEALTH; CHALLENGES; STRATEGIES; ADHERENCE; DISPARITIES AB Purpose: To provide a review of best practice for clinical management of diabetes mellitus (DM) for nurse practitioners (NPs) and accelerate incorporation of key findings into current practice. Data source: A search was conducted in Pub Med, Ovid, CINAHL, and Cochrane's Database of Systematic Reviews. Conclusions: There are many challenges for DM care identified in the current health system. There is a great need to change care paradigms to engage patients in partnership for enhanced management and self-management in DM. A review of the best practice evidence revealed numerous models of care, strategies, and tools available to enhance diabetes care and promote health and well-being. The primary focus of this article is to engage NP clinicians to incorporate new strategies to augment management and improve clinical outcomes. Implications for practice: Incorporation of best practice for DM management may accelerate the paradigm shift tomore patient-focused care. Engaged, informed, and activated patients along with clinicians working in partnerships may enhance clinical outcomes. C1 [Lorenzo, Lenora] US Dept Vet Affairs, Pacific Isl Hlth Care Syst, Spark Matsunaga Ctr, Honolulu, HI 96783 USA. [Lorenzo, Lenora] Univ Hawaii Manoa, Sch Nursing & Dent Hyg, Honolulu, HI 96822 USA. RP Lorenzo, L (reprint author), US Dept Vet Affairs, Pacific Isl Hlth Care Syst, Spark Matsunaga Ctr, 459 Patterson Rd, Honolulu, HI 96783 USA. EM lenora.lorenzo@va.gov NR 62 TC 4 Z9 4 U1 4 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2327-6886 EI 2327-6924 J9 J AM ASSOC NURSE PRA JI J. Am. Assoc. Nurs. Pract. PD JUL PY 2013 VL 25 IS 7 BP 351 EP 361 DI 10.1111/1745-7599.12004 PG 11 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA 296GU UT WOS:000330174000003 PM 24170618 ER PT J AU Whitten, SK Stanik-Hutt, J AF Whitten, Stacey K. Stanik-Hutt, Julie TI Group cognitive behavioral therapy to improve the quality of care to opioid-treated patients with chronic noncancer pain: A practice improvement project SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS LA English DT Article DE Quality improvement; primary care; pain management; cognitive behavioral therapy (CBT); outpatient ID BECK DEPRESSION INVENTORY; MANAGEMENT; OUTCOMES; MULTIDISCIPLINARY; INTERVENTIONS; METAANALYSIS; GUIDELINES; TRIALS; LIFE AB Purpose: To enhance outcomes of patients with chronic noncancer pain (CNCP) treated with opioids in a primary care setting by implementing an evidence-based quality improvement project. Data sources: The project consisted of the implementation of a 6-week cognitive behavioral therapy (CBT) program. Twenty-two patients with CNCP completed the program. Impact of the project was evaluated by comparing pre-and postintervention participant self-reports of mood on the Beck Depression Inventory and functional status on the Brief Pain Inventory and Short Form-36. Patient perception of treatment benefit was also measured using the Patient Global Impression of Change. Qualitative provider perceptions of the program were also collected. Paired t-test statistics were used to analyze the data. Conclusions: Mood (including negative attitude, performance difficulty, and physical complaints), and patient impression of treatment benefit improved significantly after CBT was added. Primary care providers reported that the CBT supported their overall management of these complex patients. Implications for practice: The addition of a CBT program improved selected outcomes in this self-selected sample of patients with CNCP treated with opioids. C1 [Whitten, Stacey K.] US Dept Vet Affairs, Community Based Outreach Clin, Bennington, VT 05201 USA. [Stanik-Hutt, Julie] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. [Stanik-Hutt, Julie] Johns Hopkins Univ Hosp, Dept Acute & Chron Care, Baltimore, MD 21287 USA. RP Whitten, SK (reprint author), US Dept Vet Affairs, Community Based Outreach Clin, Bennington, VT 05201 USA. EM stacey.whitten@va.gov OI Stanik - Hutt, Julie/0000-0003-0728-7297 NR 28 TC 1 Z9 1 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2327-6886 EI 2327-6924 J9 J AM ASSOC NURSE PRA JI J. Am. Assoc. Nurs. Pract. PD JUL PY 2013 VL 25 IS 7 BP 368 EP 376 DI 10.1111/j.1745-7599.2012.00800.x PG 9 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA 296GU UT WOS:000330174000005 PM 24170620 ER PT J AU Liachko, NF McMillan, PJ Guthrie, CR Bird, TD Leverenz, JB Kraemer, BC AF Liachko, Nicole F. McMillan, Pamela J. Guthrie, Chris R. Bird, Thomas D. Leverenz, James B. Kraemer, Brian C. TI CDC7 Inhibition Blocks Pathological TDP-43 Phosphorylation and Neurodegeneration SO ANNALS OF NEUROLOGY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; TAU-INDUCED NEUROTOXICITY; CAENORHABDITIS-ELEGANS; DNA-REPLICATION; KINASE INHIBITORS; C-ELEGANS; S PHASE; HEXANUCLEOTIDE REPEAT; CHROMATIN BINDING AB ObjectiveKinase hyperactivity occurs in both neurodegenerative disease and cancer. Lesions containing hyperphosphorylated aggregated TDP-43 characterize amyotrophic lateral sclerosis and frontotemporal lobar degeneration with TDP-43 inclusions. Dual phosphorylation of TDP-43 at serines 409/410 (S409/410) drives neurotoxicity in disease models; therefore, TDP-43-specific kinases are candidate targets for intervention. MethodsTo find therapeutic targets for the prevention of TDP-43 phosphorylation, we assembled and screened a comprehensive RNA interference library targeting kinases in TDP-43 transgenic Caenorhabditis elegans. ResultsWe show CDC7 robustly phosphorylates TDP-43 at pathological residues S409/410 in C. elegans, in vitro, and in human cell culture. In frontotemporal lobar degeneration (FTLD)-TDP cases, CDC7 immunostaining overlaps with the phospho-TDP-43 pathology found in frontal cortex. Furthermore, PHA767491, a small molecule inhibitor of CDC7, reduces TDP-43 phosphorylation and prevents TDP-43-dependent neurodegeneration in TDP-43-transgenic animals. InterpretationTaken together, these data support CDC7 as a novel therapeutic target for TDP-43 proteinopathies, including FTLD-TDP and amyotrophic lateral sclerosis. Ann Neurol 2013;74:39-52 C1 [Liachko, Nicole F.; Guthrie, Chris R.; Bird, Thomas D.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Liachko, Nicole F.; Bird, Thomas D.; Kraemer, Brian C.] Univ Washington, Dept Med, Seattle, WA USA. [McMillan, Pamela J.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [McMillan, Pamela J.; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bird, Thomas D.; Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Kraemer, BC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, S182,1660 South Columbian Way, Seattle, WA 98108 USA. EM kraemerb@u.washington.edu FU Department of Veterans Affairs [1147891]; Career Development Award [CDA1]; National Institute on Aging [AG 000057-31]; NIH [NINDS R01NS064131]; NIA [P50AG005136-27]; NINDS [P50NS2062684-02]; Muscular Dystrophy Association, ALS Division [218523] FX This work was supported by grants from the Department of Veterans Affairs (Merit Review Grant #1147891, B.C.K.; Career Development Award [CDA1], N.F.L.), a National Institute on Aging training grant (AG 000057-31, N.F.L.), the NIH (NINDS R01NS064131, B.C.K.; NIA P50AG005136-27 and NINDS P50NS2062684-02, J.B.L.), and the Muscular Dystrophy Association (218523), ALS Division (B.C.K.). NR 61 TC 22 Z9 22 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD JUL PY 2013 VL 74 IS 1 BP 39 EP 52 DI 10.1002/ana.23870 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 282UH UT WOS:000329198600007 PM 23424178 ER PT J AU Romanova, M Liang, LJ Deng, ML Li, ZP Heber, D AF Romanova, Maria Liang, Li-Jung Deng, Max L. Li, Zhaoping Heber, David TI Effectiveness of the MOVE! Multidisciplinary Weight Loss Program for Veterans in Los Angeles SO PREVENTING CHRONIC DISEASE LA English DT Article ID LIFE-STYLE INTERVENTION; OBESE ADULTS; OLDER-ADULTS; POUNDS LOST; TRIAL; PREVALENCE; MANAGEMENT; ADHERENCE; DESIGN; BURDEN AB Introduction The purpose of this study was to evaluate the effectiveness of the MOVE! Weight Management Program for Veterans (MOVE!) in achieving weight loss in veterans who attended the multidisciplinary weight management program in the VA Greater Los Angeles Healthcare System. Methods From April 1, 2006, to December 31, 2009, 382 veterans enrolled in the MOVE! program; 377 veterans attended at least 3 group sessions and were included in this study. All veterans were encouraged to complete 8 weekly group sessions on nutrition, lifestyle changes, and behavior modification in a group setting led by a multidisciplinary team. After completing the session, veterans had the option of continuing with a support group that meets monthly. The change in weight from 1 year pre-enrollment in MOVE! to 1, 2, and 3 years postenrollment was analyzed. Results Veterans gained 1.4 kg per year (standard error [SE] = 0.47, P = .003) before enrolling in MOVE!. One year after the enrollment participants lost on average 2.2 kg (SE = 0.42; P < .001). The pre-enrollment slope for weight change was significantly different from the postenrollment slope. Conclusion Findings from this study support the need for a long-term weight management program such as MOVE! in primary care settings to assist overweight and obese VA patients in achieving and maintaining weight loss to reduce the risk and progression of age-related chronic diseases such as diabetes and heart disease. C1 [Romanova, Maria; Deng, Max L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Liang, Li-Jung; Heber, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Li, Zhaoping] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Li, Zhaoping] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA. RP Li, ZP (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, W111A, Los Angeles, CA 90073 USA. EM zhaoping.li@va.gov NR 28 TC 8 Z9 8 U1 3 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2013 VL 10 AR UNSP 120325 DI 10.5888/pcd10.120325 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KF UT WOS:000329392200004 ER PT J AU Zhao, J Mialki, RK Wei, JX Coon, TA Zou, CB Chen, BB Mallampalli, RK Zhao, YT AF Zhao, Jing Mialki, Rachel K. Wei, Jianxin Coon, Tiffany A. Zou, Chunbin Chen, Bill B. Mallampalli, Rama K. Zhao, Yutong TI SCF E3 ligase F-box protein complex SCFFBXL19 regulates cell migration by mediating Rac1 ubiquitination and degradation SO FASEB JOURNAL LA English DT Article DE small GTPase protein; protein stability; phosphorylation; cell motility ID I-KAPPA-B; SIGNAL-INDUCED UBIQUITINATION; BRONCHIAL EPITHELIAL-CELLS; DEPENDENT PROTEOLYSIS; C-MYC; PHOSPHORYLATION; KINASE; UBIQUITYLATION; ACETYLATION; RECEPTOR AB Rac1, a member of the Rho family of GTPases, regulates diverse cellular functions, including cytoskeleton reorganization and cell migration. F-box proteins are major subunits within the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligases that recognize specific substrates for ubiquitination. The role of F-box proteins in regulating Rac1 stability has not been studied. Mouse lung epithelial (MLE12) cells were used to investigate Rac1 stability and cell migration. Screening of an F-box protein library and in vitro ubiquitination assays identified FBXL19, a relatively new member of the F-box protein family that targets Rac1 for its polyubiquitination and proteasomal degradation. Overexpression of FBXL19 decreased both Rac1 active and inactive forms and significantly reduced cellular migration. Protein kinase AKT-mediated phosphorylation of Rac1 at serine(71) was essential for FBXL19-mediated Rac1 ubiquitination and depletion. Lysine(166) within Rac1 was identified as a polyubiquitination acceptor site. Rac1(S71A) and Rac1(K166R) mutant proteins were resistant to FBXL19-mediated ubiquitination and degradation. Further, ectopically expressed FBXL19 reduced cell migration in Rac1-overexpressing cells (P<0.01, Rac1 cells vs. FBXL19+Rac1 cells), but not in Rac1 lysine(166) mutant-overexpressing cells. FBXL19 diminished formation of the migratory leading edge. Thus, SCFFBXL19 targets Rac1 for its disposal, a process regulated by AKT. These findings provide the first evidence of an F-box protein targeting a small G protein for ubiquitination and degradation to modulate cell migration.Zhao, J., Mialki, R. K., Wei, J., Coon, T. A., Zou, C., Chen, B. B., Mallampalli, R. K., Zhao, Y. SCF E3 ligase F-box protein complex SCFFBXL19 regulates cell migration by mediating Rac1 ubiquitination and degradation. C1 [Zhao, Jing; Mialki, Rachel K.; Wei, Jianxin; Coon, Tiffany A.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Zhao, Jing; Mialki, Rachel K.; Wei, Jianxin; Coon, Tiffany A.; Zou, Chunbin; Chen, Bill B.; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Zhao, YT (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 3459 5th Ave,NW 628 MUH, Pittsburgh, PA 15213 USA. EM zhaoy3@upmc.edu RI Wei, Jianxin/P-5431-2016 FU U.S. National Institutes of Health [RO1 HL01916, HL112791, HL097376, HL098174, HL116472]; American Heart Association [12SDG9050005, 12SDG12040330]; Merit Review Award from the United States FX This study was supported by U.S. National Institutes of Health grants RO1 HL01916 and HL112791 (to Y.Z.), HL097376 and HL098174 (to R. K. M.), and HL116472 (to B. B. C.); American Heart Association awards 12SDG9050005 (to J.Z.) and 12SDG12040330 (to C.Z.); and a Merit Review Award from the United States (to R. K. M.). The authors declare no conflicts of interest. NR 45 TC 12 Z9 13 U1 3 U2 8 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD JUL PY 2013 VL 27 IS 7 BP 2611 EP 2619 DI 10.1096/fj.12-223099 PG 9 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 277TA UT WOS:000328841000010 PM 23512198 ER PT J AU Crowder, SW Horton, LW Lee, SH McClain, CM Hawkins, OE Palmer, AM Bae, H Richmond, A Sung, HJ AF Crowder, Spencer W. Horton, Linda W. Lee, Sue Hyun McClain, Colt M. Hawkins, Oriana E. Palmer, Amanda M. Bae, Hojae Richmond, Ann Sung, Hak-Joon TI Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia SO FASEB JOURNAL LA English DT Article DE aging; reactive oxygen species; p53; experimental models ID BONE-MARROW; MATRIX METALLOPROTEINASES; REPLICATIVE SENESCENCE; DOWN-REGULATION; TUMOR INVASION; DIFFERENTIATION; P53; CULTURE; PROLIFERATION; MECHANISMS AB Bone marrow-derived human mesenchymal stem cells (hMSCs) either promote or inhibit cancer progression, depending on factors that heretofore have been undefined. Here we have utilized extreme hypoxia (0.5% O-2) and concurrent treatment with metal carcinogen (nickel) to evaluate the passage-dependent response of hMSCs toward cancerous transformation. Effects of hypoxia and nickel treatment on hMSC proliferation, apoptosis, gene and protein expression, replicative senescence, reactive oxygen species (ROS), redox mechanisms, and in vivo tumor growth were analyzed. The behavior of late passage hMSCs in a carcinogenic hypoxia environment follows a profile similar to that of transformed cancer cells (i.e., increased expression of oncogenic proteins, decreased expression of tumor suppressor protein, increased proliferation, decreased apoptosis, and aberrant redox mechanisms), but this effect was not observed in earlier passage control cells. These events resulted in accumulated intracellular ROS in vitro and excessive proliferation in vivo. We suggest a mechanism by which carcinogenic hypoxia modulates the activity of three critical transcription factors (c-MYC, p53, and HIF1), resulting in accumulated ROS and causing hMSCs to undergo cancer-like behavioral changes. This is the first study to utilize carcinogenic hypoxia as an environmentally relevant experimental model for studying the age-dependent cancerous transformation of hMSCs.Crowder, S. W., Horton, L. W., Lee, H. H., McClain, C. M., Hawkins, O. E., Palmer, A. M. Bae, H., Richmond, A., Sung, H.-J. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. C1 [Crowder, Spencer W.; Lee, Sue Hyun; Palmer, Amanda M.; Sung, Hak-Joon] Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN 37235 USA. [Crowder, Spencer W.; Sung, Hak-Joon] Vanderbilt Univ, Med Ctr, Ctr Stem Cell Biol, Nashville, TN 37235 USA. [Horton, Linda W.; Hawkins, Oriana E.; Richmond, Ann] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA. [McClain, Colt M.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37235 USA. [Horton, Linda W.; Hawkins, Oriana E.; Richmond, Ann] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. [Bae, Hojae; Sung, Hak-Joon] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul, South Korea. RP Sung, HJ (reprint author), Vanderbilt Univ, Dept Biomed Engn, VU Stn B, Box 351631, Nashville, TN 37235 USA. EM hak-joon.sung@vanderbilt.edu RI Richmond, Ann/A-3048-2014 FU Vanderbilt Start-Up; U.S. National Institutes of Health [HL091465]; National Cancer Institute [CA34590-30]; U.S. Department of Veterans Affairs FX The authors are grateful for technical help from Dae Kwang Jung. This research is supported by Vanderbilt Start-Up, the U.S. National Institutes of Health (HL091465), the National Cancer Institute (CA34590-30; A.R.), and a Senior Research Career Scientist Award from the U.S. Department of Veterans Affairs (A.R.). NR 46 TC 11 Z9 12 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD JUL PY 2013 VL 27 IS 7 BP 2788 EP 2798 DI 10.1096/fj.13-228288 PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 277TA UT WOS:000328841000027 PM 23568779 ER PT J AU Katz, IR Kemp, JE Blow, FC McCarthy, JF Bossarte, RM AF Katz, Ira R. Kemp, Janet E. Blow, Frederic C. McCarthy, John F. Bossarte, Robert M. TI Changes in Suicide Rates and in Mental Health Staffing in the Veterans Health Administration, 2005-2009 SO PSYCHIATRIC SERVICES LA English DT Article ID SYSTEM; RISK; MORTALITY AB Objective: Between 2005 and 2009, the Veterans Health Administration (VHA) enhanced its mental health programs and increased outpatient mental health staffing by 52.8%. However, suicide rates among VHA patients remained the same. This study evaluated this finding by examining variability in staffing increases between VHA's 21 regional networks (Veterans Integrated Service Networks) (VISNs) and associations with suicide rates. Methods: Suicide rates among VHA patients were derived from the National Death Index and VHA clinical and administrative records for 2005 and 2009. Comparisons across VISNs used measures of proportional change in mental health staffing (overall and in inpatient, residential, intensive case management, and outpatient programs) and comparable measures of mental health staffing per 1,000 mental health patients. Results: Significant correlations were found between proportional changes from 2005 to 2009 in suicide rates and outpatient mental health staffing (r=-.453, p=.039) and outpatient mental health staffing per 1,000 patients (r=-.533, p=.013). The ten VISNs above the median in proportional changes in mental health staffing had average decreases in suicide rates of 12.6% while those below had increases of 11.6% (p=.005). For proportional changes in mental health staffing per 1,000 patients, those above the median had decreases of 11.2% and those below had increases of 13.8%(p=.014). For the average VISN, it would have required a 27.5%-36.8% increase in outpatient staff over 2005 levels to decrease suicide rates by 10%. Conclusions: Mental health enhancements in VHA were associated with decreases in suicide rates in VISNs where the increases in mental health outpatient staffing were greatest. C1 [Katz, Ira R.] US Dept Vet Affairs VA, Off Mental Hlth Operat, Philadelphia, PA USA. [Katz, Ira R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Kemp, Janet E.] VA Cent Off, Off Suicide Prevent, Off Mental Hlth Serv, Washington, DC USA. [Blow, Frederic C.; McCarthy, John F.] VA Med Ctr, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA. [Blow, Frederic C.; McCarthy, John F.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bossarte, Robert M.] VA Med Ctr, Ctr Excellence, Canandaigua, NY USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Katz, IR (reprint author), Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM ira.katz2@va.gov FU Office of Mental Health Operations; Office of Suicide Prevention of the VHA FX Support was provided by the Office of Mental Health Operations and the Office of Suicide Prevention of the VHA. Data for this report were acquired and analyses were conducted by the VHA for evaluation of its mental health and suicide prevention programs. NR 18 TC 5 Z9 6 U1 3 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2013 VL 64 IS 7 BP 620 EP 625 DI 10.1176/appi.ps.201200253 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255XW UT WOS:000327274400005 PM 23494171 ER PT J AU Felsenfeld, A Rodriguez, M Levine, B AF Felsenfeld, Arnold Rodriguez, Mariano Levine, Burton TI New insights in regulation of calcium homeostasis SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE calcium; calcium sensing receptor; hypercalcemia; hypocalcemia; parathyroid hormone ID SENSING RECEPTOR GENE; PARATHYROID-HORMONE; AZOTEMIC RATS; PHOSPHATE; DISEASE; KIDNEY; GROWTH; PTH; HYPERPARATHYROIDISM; PHOSPHORUS AB Purpose of reviewRegulation of calcium homeostasis during a lifetime is a complex process reflecting a balance among intestinal calcium absorption, bone calcium influx and efflux, and renal calcium excretion. Perturbations can result in hypocalcemia or hypercalcemia and adaptations in calcium handling must occur during growth and aging.Recent findingsStudy of the calcium sensing receptor in the thick ascending limb of Henle and TRPV5 in the distal tubule continues to provide insights into regulation of renal calcium excretion. Hypercalcemia-induced secretion of calcitonin via activation of the calcium-sensing receptor may protect against the development of hypercalcemia. A calcilytic was shown to increase serum calcium by decreasing renal calcium excretion. Ezrin, a cross-linking protein important for renal phosphate handling, is also involved in the regulation of intestinal calcium absorption. Increased 1,25-hydroxyvitamin D (1,25D) values were shown to protect against the development of hypocalcemia by increasing calcium efflux and decreasing calcium influx in bone. Finally, fibroblast growth factor 23 stimulation, which should result in suppression of 1,25D, was shown to be prevented in a model of vitamin D deficiency in which maintenance of 1,25D is important in minimizing hypocalcemia.SummaryRecent information has provided new insights on how intestinal, bone and renal mechanisms are regulated to maintain calcium homeostasis. C1 [Felsenfeld, Arnold; Levine, Burton] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Felsenfeld, Arnold; Levine, Burton] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rodriguez, Mariano] Hosp Univ Reina Sofia, IMIBIC, REDINREN, Serv Nefrol, Cordoba 14004, Spain. RP Rodriguez, M (reprint author), Hosp Univ Reina Sofia, Lab Unidad Invest Imib, Avd Menendez Pidal S-N, Cordoba 14004, Spain. EM marianorodriguezportillo@gmail.com FU Syskid grant; Government grant [SAS111221, CTS-5205, CVI/7925, PI11/02055] FX Part of the work was sponsored by Syskid and Government grants (SAS111221; CTS-5205; CVI/7925 and PI11/02055). NR 32 TC 11 Z9 11 U1 3 U2 42 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 EI 1473-6543 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD JUL PY 2013 VL 22 IS 4 BP 371 EP 376 DI 10.1097/MNH.0b013e328362141e PG 6 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 247BJ UT WOS:000326588200002 PM 23736839 ER PT J AU Broyles, LM Kraemer, KL Kengor, C Gordon, AJ AF Broyles, Lauren M. Kraemer, Kevin L. Kengor, Caroline Gordon, Adam J. TI A Tailored Curriculum of Alcohol Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Nurses in Inpatient Settings SO JOURNAL OF ADDICTIONS NURSING LA English DT Article DE alcohol consumption; continuing education; counseling; curricula; inpatients; nurses; screening; training ID EMERGENCY-DEPARTMENT; SUBSTANCE USE; IMPLEMENTATION; CARE; DRINKERS; DRINKING; PROGRAM AB A package of clinical strategies known as alcohol screening, brief intervention, and referral to treatment (SBIRT) is increasingly recommended for reducing unhealthy alcohol use, the spectrum of alcohol consumption from at-risk drinking (defined as consumption above recommended guidelines) to alcohol abuse and alcohol dependence. The United States' Joint Commission issued new SBIRT-related hospital accreditation measures for alcohol. Ongoing initiatives aim to promote, support, and sustain SBIRT implementation in hospital settings. In hospital settings, nurse-delivered SBIRT may be a particularly viable and efficient model for SBIRT implementation. However, like physicians, most nurses have not been trained in how to perform SBIRT, and few authors have described alcohol-related curricula specifically for nurses. In addition, historical differences in nurse and physician professional scopes of practice, role perceptions, and patterns of care delivery suggest the need for effective SBIRT initial and continuing education and training that are tailored to the nursing profession and inpatient environments. In this article, we provide an in-depth description of the registered nurse SBIRT curriculum and describe its development and contents as well as various nurse-and setting-specific adaptations. In addition, we describe how we engaged nursing stakeholders in the development and implementation of the curriculum and discuss potential implications for future SBIRT training and delivery by nurses. SBIRT continuing education and training for nurses represents one of the first steps in expanded SBIRT implementation. Comprehensive workforce and organizational development of inpatient and nurse-delivered SBIRT may provide the means to address the entire spectrum of unhealthy alcohol use across healthcare settings. C1 [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Vet Integrated Serv, Network Mental Illness 4, Res Educ & Clin Ctr,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Kengor, Caroline] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Rm 4020W 151C H, Pittsburgh, PA 15206 USA. EM lauren.broyles@va.gov FU VA Quality Enhancement Research Initiative Program [RRP 09-064]; Health Services Research & Development service of the U.S. Department of Veterans Affairs [CDA 10-014] FX We acknowledge the staff nurses and nursing administrators from the five West patient care units and the nursing leadership at the VA Pittsburgh Healthcare System (VAPHS) for their support and participation in the study. We also extend acknowledgment to Mr. Scott Guido, audio visual production specialist, and the medical media department at VAPHS for their assistance in the development of audiovisual materials for this curriculum. Funding for this study was provided by VA Quality Enhancement Research Initiative Program (RRP 09-064, Principal Investigator, L. M. Broyles). The funding body played no role in the design; data collection, analysis, and interpretation of the data; the writing of the manuscript; nor the decision to submit the manuscript for publication. Dr. Broyles is currently supported by a Career Development Award (CDA 10-014) from the Health Services Research & Development service of the U.S. Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the VAPHS, Pittsburgh, PA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 68 TC 3 Z9 3 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1088-4602 EI 1548-7148 J9 J ADDICT NURS JI J. Addict. Nurs. PD JUL-SEP PY 2013 VL 24 IS 3 BP 130 EP 141 DI 10.1097/JAN.0b013e3182a4cb0b PG 12 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA 245YE UT WOS:000326500000002 PM 24621542 ER PT J AU Strobbe, S Perhats, C Broyles, LM AF Strobbe, Stephen Perhats, Cydne Broyles, Lauren M. TI Expanded Roles and Responsibilities for Nurses in Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Alcohol Use SO JOURNAL OF ADDICTIONS NURSING LA English DT Editorial Material DE alcohol; brief intervention; nurses; referral to treatment; SBIRT; screening AB It is the position of the International Nurses Society on Addictions and the Emergency Nurses Association that nurses in all practice settings be prepared to deliver screening, brief intervention, and referral to treatment, or SBIRT, to identify and effectively respond to alcohol use and related disorders across the lifespan. C1 [Strobbe, Stephen] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Strobbe, Stephen] Int Nurses Soc Addict, Lenexa, KS USA. [Perhats, Cydne] Emergency Nurses Assoc, Inst Emergency Nursing Res, Des Plaines, IL USA. [Broyles, Lauren M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.] Univ Pittsburgh, Pittsburgh, PA USA. RP Strobbe, S (reprint author), Univ Michigan, Sch Nursing, 400 North Ingalls St, Ann Arbor, MI 48109 USA. EM strobbe@umich.edu NR 10 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1088-4602 EI 1548-7148 J9 J ADDICT NURS JI J. Addict. Nurs. PD JUL-SEP PY 2013 VL 24 IS 3 BP 203 EP 204 DI 10.1097/JAN.0b013e3182a6914f PG 2 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA 245YE UT WOS:000326500000014 PM 24621553 ER PT J AU Feeney, MP AF Feeney, M. Patrick TI Eriksholm Workshop on Wideband Absorbance Measures of the Middle Ear SO EAR AND HEARING LA English DT Editorial Material C1 [Feeney, M. Patrick] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Feeney, MP (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM patrick.feeney@va.gov NR 0 TC 0 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD JUL PY 2013 VL 34 SU 1 BP S1 EP S2 DI 10.1097/AUD.0b013e31829c70f0 PG 2 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 242XC UT WOS:000326278100001 PM 23900175 ER PT J AU Lilly, DJ Margolis, RH AF Lilly, David J. Margolis, Robert H. TI Wideband Acoustic Immittance Measurements of the Middle Ear: Introduction and Some Historical Antecedents SO EAR AND HEARING LA English DT Article ID TYMPANOMETRY; IMPEDANCE; FREQUENCY; EFFUSION; INFANTS C1 [Lilly, David J.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Margolis, Robert H.] Audiology Inc, Arden Hills, MN USA. RP Lilly, DJ (reprint author), Vet Adm Med Ctr, 3710 SW VA Hosp Rd, Portland, OR 97207 USA. EM lillyd@ohsu.edu NR 25 TC 0 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD JUL PY 2013 VL 34 SU 1 BP S4 EP S8 DI 10.1097/AUD.0b013e31829db80f PG 5 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 242XC UT WOS:000326278100003 PM 23900181 ER PT J AU Schairer, KS Feeney, MP Sanford, CA AF Schairer, Kim S. Feeney, M. Patrick Sanford, Chris A. TI Acoustic Reflex Measurement SO EAR AND HEARING LA English DT Article ID MIDDLE-EAR; REFLECTANCE; THRESHOLDS; ADMITTANCE; IMPEDANCE; CHILDREN; HEARING; INFANTS C1 [Schairer, Kim S.] James H Quillen Vet Affairs Med Ctr, Audiol & Speech Language Pathol Serv, Mountain Home, TN 37684 USA. [Feeney, M. Patrick] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Sanford, Chris A.] Idaho State Univ, Dept Commun Sci & Disorders, Pocatello, ID 83209 USA. RP Schairer, KS (reprint author), James H Quillen Vet Affairs Med Ctr, Box 4000, Mountain Home, TN 37684 USA. EM kim.schairer@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service Research Enhancement Award Program FX This work was supported by Department of Veterans Affairs Rehabilitation Research and Development Service Research Enhancement Award Program. NR 23 TC 3 Z9 3 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD JUL PY 2013 VL 34 SU 1 BP S43 EP S47 DI 10.1097/AUD.0b013e31829c70d9 PG 5 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 242XC UT WOS:000326278100008 PM 23900179 ER PT J AU Sachs, MC Zhou, XH AF Sachs, Michael C. Zhou, Xiao-Hua TI Partial summary measures of the predictiveness curve SO BIOMETRICAL JOURNAL LA English DT Article DE Biomarker; Classification; Prediction; Summary statistic ID LOGISTIC-REGRESSION; ALZHEIMERS-DISEASE; MARKER; RISK; STATISTICS; MODELS AB In the evaluation of a biomarker for risk prediction, one can assess the performance of the biomarker in the population of interest by displaying the predictiveness curve. In conjunction with an assessment of the classification accuracy of a biomarker, the predictiveness curve is an important tool for assessing the usefulness of a risk prediction model. Inference for a single biomarker or for multiple biomarkers can be performed using summary measures of the predictiveness curve. We propose two partial summary measures, the partial total gain and the partial proportion of explained variation, that summarize the predictiveness curve over a restricted range of risk. The methods we describe can be used to compare two biomarkers when there are existing thresholds for risk stratification. We describe inferential tools for one and two samples that are shown to have adequate power in a simulation study. The methods are illustrated by assessing the accuracy of a risk score for predicting the onset of Alzheimer's disease. C1 [Sachs, Michael C.] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA. [Sachs, Michael C.] Univ Washington, Div Nephrol, Seattle, WA 98104 USA. [Zhou, Xiao-Hua] Univ Washington, HSRD Ctr Excellence, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98108 USA. RP Sachs, MC (reprint author), Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA. EM sachsmc@u.washington.edu FU NIA [U01 AG016976]; NIMH [T32 MH073521] FX The authors are grateful to Margaret Pepe and Carolyn Rutter in addition to an associate editor and the reviewers for their helpful comments and suggestions. This work was supported, in part, by NIA grant U01 AG016976 and NIMH grant T32 MH073521. NR 18 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0323-3847 EI 1521-4036 J9 BIOMETRICAL J JI Biom. J. PD JUL PY 2013 VL 55 IS 4 BP 589 EP 602 DI 10.1002/bimj.201200146 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 237RA UT WOS:000325887000009 PM 23508801 ER PT J AU de Groot, NL Spiegel, BMR van Haalen, HGM de Wit, NJ Siersema, PD van Oijen, MGH AF de Groot, N. L. Spiegel, B. M. R. van Haalen, H. G. M. de Wit, N. J. Siersema, P. D. van Oijen, M. G. H. TI Gastroprotective Strategies in Chronic NSAID Users: A Cost-Effectiveness Analysis Comparing Single-Tablet Formulations with Individual Components SO VALUE IN HEALTH LA English DT Article DE compliance; cost-effectiveness; cost-utility; dyspepsia; gastrointestinal bleeding; nonsteroidal anti-inflammatory drugs; proton pump inhibitors. ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLO-OXYGENASE-2 INHIBITORS; PROTON PUMP INHIBITORS; RHEUMATOID-ARTHRITIS; PEPTIC-ULCER; GASTROINTESTINAL COMPLICATIONS; TRADITIONAL NSAIDS; COX-2 INHIBITORS; ELDERLY-PATIENTS; CONTROLLED-TRIAL AB Objectives: To evaluate the cost-effectiveness of competing gastroprotective strategies, including single-tablet formulations, in the prevention of gastrointestinal (GI) complications in patients with chronic arthritis taking nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: We performed a cost-utility analysis to compare eight gastroprotective strategies including NSAIDs, cyclooxygenase-2 inhibitors, proton pump inhibitors (PPIs), histamine-2 receptor antagonists, misoprostol, and single-tablet formulations. We derived estimates for outcomes and costs from medical literature. The primary outcome was incremental cost per quality-adjusted life-year gained. We performed sensitivity analyses to assess the effect of GI complications, compliance rates, and drug costs. Results: For average-risk patients, NSAID + PPI cotherapy was most cost-effective. The NSAID/PPI single-tablet formulation became cost-effective only when its price decreased from (sic)0.78 to (sic)0.56 per tablet, or when PPI compliance fell below 51% in the NSAID + PPI strategy. All other strategies were more costly and less effective. The model was highly sensitive to the GI complication risk, costs of PPI and NSAID/PPI single-tablet formulation, and compliance to PPI. In patients with a threefold higher risk of GI complications, both NSAID + PPI cotherapy and single-tablet formulation were cost-effective. Conclusions: NSAID + PPI cotherapy is the most cost-effective strategy in all patients with chronic arthritis irrespective of their risk for GI complications. For patients with increased GI risk, the NSAID/PPI single-tablet formulation is also cost-effective. C1 [de Groot, N. L.; van Haalen, H. G. M.; Siersema, P. D.; van Oijen, M. G. H.] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, NL-3508 GA Utrecht, Netherlands. [Spiegel, B. M. R.] Vet Affairs Greater Los Angeles Hlth Care Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. [Spiegel, B. M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, B. M. R.; van Oijen, M. G. H.] Univ Calif Los Angeles, Vet Affairs Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [de Wit, N. J.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands. RP de Groot, NL (reprint author), Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, POB 85500,Internal Code F02-618, NL-3508 GA Utrecht, Netherlands. EM n.l.degroot-3@umcutrecht.nl FU AstraZeneca FX This study has been sponsored by an unrestricted educational research grant by AstraZeneca. NR 51 TC 2 Z9 2 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUL-AUG PY 2013 VL 16 IS 5 BP 769 EP 777 DI 10.1016/j.jval.2013.05.002 PG 9 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 232CL UT WOS:000325466600010 PM 23947970 ER PT J AU Lin, VW Wong, ES Wright, A Flum, DR Garrison, LP Alfonso-Cristancho, R Sullivan, SD AF Lin, Vincent W. Wong, Edwin S. Wright, Andrew Flum, David R. Garrison, Louis P., Jr. Alfonso-Cristancho, Rafael Sullivan, Sean D. TI Association between Health-Related Quality of Life and Body Mass After Adjustable Gastric Banding: A Nonlinear Approach SO VALUE IN HEALTH LA English DT Article DE EQ-5D; gastric banding; health-related quality of life; health utility; obesity ID BARIATRIC SURGERY; WEIGHT-LOSS; COST-EFFECTIVENESS; MORBID-OBESITY; EQ-5D UTILITY; BYPASS; INDEX; SCORES; STATES; TRIAL AB Objective: To estimate the relationship between health utilities and body mass index (BMI) among a cohort of obese patients who underwent laparoscopic adjustable gastric banding (LAGB). Methods: We used a cross-sectional survey to ascertain demographic, clinical, and health utility data from patients who had undergone LAGB in Washington State from 2004 to 2010. The EuroQol five-dimensional (EQ-5D) questionnaire was used for health utility estimation. We calculated adjusted EQ-5D questionnaire indices across BMI categories by using a two-part model. We also used logistic regression to examine the relationship between BMI and the likelihood of reporting problems on each of the EQ-5D questionnaire dimension. Results: Data were obtained from 790 subjects. The mean adjusted EQ-5D questionnaire indices for all obese BMI categories were significantly lower than those in the normal weight category. The relationship between BMI and EQ-5D questionnaire indices was nonlinear. Respondents classified as morbidly obese II (BMI > 50 kg/m(2)) had the greatest decrement (-0.15, 95% confidence interval -0.28 to -0.01) in EQ-5D questionnaire indices. The association between EQ-5D questionnaire indices and BMI at the time of the survey was weaker after adjusting for weight loss after LAGB. Respondents with higher BMI were more likely to report having problems in the mobility, usual/activity, pain/discomfort, and anxiety/depression dimensions (trend test, P < 0.05), but not for the self-care dimension (trend test, P = 0.08). Conclusions: The EQ-5D questionnaire has a negative and nonlinear relationship with BMI for obese patients who had LAGB. The relationship is confounded by weight loss. Within the EQ-5D questionnaire dimensions, patients are more likely to report having problems in the mobility, usual/activity, pain/discomfort, and anxiety/depression dimensions in higher BMI categories, but not in the self-care dimension. C1 [Lin, Vincent W.; Flum, David R.; Garrison, Louis P., Jr.; Alfonso-Cristancho, Rafael; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Wong, Edwin S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Wright, Andrew; Flum, David R.; Alfonso-Cristancho, Rafael] Univ Washington, Dept Surg, Seattle, WA 98195 USA. RP Sullivan, SD (reprint author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, 1959 Northeast Pacific Ave,H-375Q,Box 357630, Seattle, WA 98195 USA. EM sdsull@u.washington.edu FU Department of Defense Agreement [FA7014-08-0002]; National Institutes of Digestive Disease and Kidney [1R21DK069677] FX The study was supported by Department of Defense Agreement (grant no. FA7014-08-0002) and National Institutes of Digestive Disease and Kidney (grant no. 1R21DK069677). NR 37 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUL-AUG PY 2013 VL 16 IS 5 BP 823 EP 829 DI 10.1016/j.jval.2013.05.001 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 232CL UT WOS:000325466600016 PM 23947976 ER PT J AU Spence, MM Shin, PJ Lee, EA Gibbs, NE AF Spence, Michele M. Shin, Patrick J. Lee, Eric A. Gibbs, Nancy E. TI Risk of Injury Associated with Skeletal Muscle Relaxant Use in Older Adults SO ANNALS OF PHARMACOTHERAPY LA English DT Article ID MEDICATION USE; CLAIMS AB BACKGROUND: The use of skeletal muscle relaxants (SMRs) among older adults is associated with sedation and confusion, which may lead to an increased risk of falls and injuries. SMRs continue to be used among older adults, although they are on the Beers list as drugs to avoid in the elderly. OBJECTIVE: To investigate the relationship between SMR use and subsequent risk of injury. METHODS: This was a retrospective case-control study of members aged 65 years or older enrolled in an integrated health care system. Cases were defined as patients with a documented injury resulting in either a hospitalization or an emergency department or urgent care visit from January 2009 through December 2010. Cases were matched to controls in a 1: 4 ratio by age and sex. Patients had to be enrolled and alive on the date of an injury (index date). SMR exposure for all cases and controls was evaluated within 60 days prior to the index date. Conditional logistic regression adjusted for covariates was performed, with risk estimates presented as odds ratios with 95% confidence intervals. RESULTS: From a base population of 322,806 older adults, we identified 27,974 cases of injury and 104,303 matched controls. Among the cases, 365 (1.30%) used an SMR; among the controls, 801 (0.77%) used an SMR in the 60 days prior to the index date. After adjustment for demographic and clinical covariates, risk of injury was significantly increased for patients using an SMR compared to no use (OR 1.32, 95% CI 1.16-1.50; p < 0.001). Carisoprodol was associated with an increased risk of injury (OR 1.73, 95% CI 1.04-2.88; p = 0.036), as were methocarbamol (OR 1.42, 95% CI 1.16-1.75; p = 0.001) and cyclobenzaprine (OR 1.22, 95% CI 1.02-1.45; p = 0.029). CONCLUSIONS: Older adults using SMRs have an increased risk of injury. These findings provide evidence to support current recommendations to avoid the use of SMRs in elderly patients. C1 [Spence, Michele M.] Kaiser Permanente, Pharm Outcomes Res Grp, Downey, CA USA. [Shin, Patrick J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lee, Eric A.] Kaiser Permanente, West Los Angeles Med Ctr, Dept Internal Med, Los Angeles, CA USA. [Lee, Eric A.; Gibbs, Nancy E.] Kaiser Permanente Southern Calif Reg, High Risk Drugs Elderly, Oakland, CA USA. [Gibbs, Nancy E.] Kaiser Permanente, Baldwin Pk Med Ctr, Dept Family Practice, Baldwin Pk, CA USA. RP Spence, MM (reprint author), Kaiser Permanente, Pharm Outcomes Res Grp, Downey, CA USA. EM Michele.M.Spence@kp.org NR 21 TC 6 Z9 6 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD JUL-AUG PY 2013 VL 47 IS 7-8 BP 993 EP 998 DI 10.1345/aph.1R735 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 225UP UT WOS:000324989500017 PM 23821610 ER PT J AU Allen, JL Kautz, SA Neptune, RR AF Allen, Jessica L. Kautz, Steven A. Neptune, Richard R. TI The influence of merged muscle excitation modules on post-stroke hemiparetic walking performance SO CLINICAL BIOMECHANICS LA English DT Article DE Forward dynamics simulation; Muscle synergies; Gait; Biomechanics ID MOTOR CONTROL; COORDINATION; PATTERNS; STROKE; PROGRESSION; LOCOMOTION; GAIT AB Background: Post-stroke subjects with hemiparesis typically utilize a reduced number of modules or co-excited muscles compared to non-impaired controls, with at least one module resembling the merging of two or more non-impaired modules. In non-impaired walking, each module has distinct contributions to important biomechanical functions, and thus different merged module combinations post-stroke may result in different functional consequences. Methods: Three-dimensional forward dynamics simulations were developed for non-impaired controls and two groups of post-stroke hemiparetic subjects with different merged module combinations to analyze how paretic leg muscle contributions to body support, forward propulsion, mediolateral control and leg swing are altered. Findings: The potential of the plantarflexors to generate propulsion was impaired in both hemiparetic groups while the remaining functional consequences differed depending on which modules were merged. Paretic leg swing was impaired during pre-swing when Modules 1 (hip abductors and knee extensors during early stance), and 2 (plantarflexors during late stance) were merged and during late swing when Modules 1 and 4 (hamstrings during late swing into early stance) were merged. When Modules 1 and 4 were merged, body support during early stance was also impaired. Interpretation: These results suggest that improving plantarflexor ability to generate propulsion is critical during rehabilitation regardless of module composition. If Modules 1 and 2 are merged, then rehabilitation should also focus on improving paretic leg pre-swing whereas if Modules 1 and 4 are merged, then rehabilitation should also focus on improving early stance body support and late paretic leg swing. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Allen, Jessica L.; Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 204 E Dean Keeton St,Stop C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu OI Kautz, Steven/0000-0003-3151-8235 FU NIH [R01 HD46820]; National Science Foundation FX This work was supported by NIH Grant R01 HD46820 and the National Science Foundation Graduate Research Fellowship Program. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NICHD or NSF. NR 27 TC 18 Z9 19 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD JUL PY 2013 VL 28 IS 6 BP 697 EP 704 DI 10.1016/j.clinbiomech.2013.06.003 PG 8 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 225PT UT WOS:000324975500015 PM 23830138 ER PT J AU Metti, AL Cauley, JA Ayonayon, HN Harris, TB Rosano, C Williamson, JD Yaffe, K AF Metti, Andrea L. Cauley, Jane A. Ayonayon, Hilsa N. Harris, Tamara B. Rosano, Caterina Williamson, Jeff D. Yaffe, Kristine CA Hlth Aging & Body Composition Stud TI The Demographic and Medical Correlates of Plasma A beta 40 and A beta 42 SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE plasma amyloid beta; dementia; cognitive decline; biomarker; epidemiology ID MILD COGNITIVE IMPAIRMENT; INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; BODY-COMPOSITION; INFLAMMATORY MARKERS; AFRICAN-AMERICAN; APOLIPOPROTEIN-E; AMYLOID-BETA; RISK AB Plasma amyloid -42 (A42) and A42/A40 are increasingly recognized as biomarkers for dementia, with low levels indicating increased risk. Little is known about the demographic and medical correlates of plasma A40 or A42. In 997 community-dwelling, nondemented older adults from the Health, Aging, and Body Composition Study, we determined the cross-sectional association between a wide range of demographic and medical variables with A40 and A42. In multivariate stepwise linear regression models, A40 was significantly associated with race (=-14.70, F=22.01, P<0.0001), age (=1.34, F=6.39, P=0.01), creatinine (=52.91, F=151.77, P<0.0001), and the serum brain-derived neurotrophic factor (=-0.0004, F=7.34, P=0.007); A42 was significantly associated with race (=-3.72, F=30.83, P<0.0001), sex (=1.39, F=4.32, P=0.04), education (=1.50, F=4.78, P=0.03), apolipoprotein E e4 genotype (=-2.82, F=16.57, P<0.0001), and creatinine (=9.32, F=120.09, P<0.0001). These correlates should be considered as potential confounders in future studies investigating plasma A as a biomarker of dementia. Understanding fully how these correlates mediate or modify the association between plasma A and dementia will be a fundamental step in determining the biological pathways through which plasma A40 and A42 are associated with dementia, and in determining their full potential as biomarkers. C1 [Metti, Andrea L.; Cauley, Jane A.; Rosano, Caterina] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Aging & Populat Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Ayonayon, Hilsa N.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Harris, Tamara B.] NIH, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Williamson, Jeff D.] Wake Forest Univ, Med Ctr, Dept Geriatr & Gerontol, Winston Salem, NC USA. RP Metti, AL (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Aging & Populat Hlth, Dept Epidemiol, 130 N Bellefield,4th Floor,Room 456, Pittsburgh, PA 15213 USA. EM alw111@pitt.edu OI Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, K24 AG031155]; NINR [R01-NR012459]; NIH, National Institute on Aging; National Institutes of Health [2T32AG000181] FX The Health, Aging and Body Composition Study is supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. A. L. M. is supported by the National Institutes of Health Training Grant (2T32AG000181). K.Y. is supported in part by NIA Grant K24 AG031155. The remaining authors declare no conflicts of interest. NR 34 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD JUL-SEP PY 2013 VL 27 IS 3 BP 244 EP 249 DI 10.1097/WAD.0b013e318260a8cb PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 210FM UT WOS:000323814700008 PM 22732677 ER PT J AU Routson, RL Clark, DJ Bowden, MG Kautz, SA Neptune, RR AF Routson, Rebecca L. Clark, David J. Bowden, Mark G. Kautz, Steven A. Neptune, Richard R. TI The influence of locomotor rehabilitation on module quality and post-stroke hemiparetic walking performance SO GAIT & POSTURE LA English DT Article DE Hemiparesis; Biomechanics; Therapy; Muscle synergies ID MUSCLE CONTRIBUTIONS; BODY SUPPORT; PROPULSION; STROKE; GAIT; SPEED AB Recent studies have suggested the biomechanical subtasks of walking can be produced by a reduced set of co-excited muscles or modules. Individuals post-stroke often exhibit poor inter-muscular coordination characterized by poor timing and merging of modules that are normally independent in healthy individuals. However, whether locomotor therapy can influence module composition and timing and whether these improvements lead to improved walking performance is unclear. The goal of this study was to examine the influence of a locomotor rehabilitation therapy on module composition and timing and post-stroke hemiparetic walking performance. Twenty-seven post-stroke hemiparetic subjects participated in a 12-week locomotor intervention incorporating treadmill training with body weight support and manual trainers accompanied by training overground walking. Electromyography (EMG), kinematic and ground reaction force data were collected from subjects both pre- and post-therapy and from 19 age-matched healthy controls walking on an instrumented treadmill at their self-selected speed. Non-negative matrix factorization was used to identify the module composition and timing from the EMG data. Module timing and composition, and various measures of walking performance were compared pre- and post-therapy. In subjects with four modules pre- and post-therapy, locomotor training resulted in improved timing of the ankle plantarflexor module and a more extended paretic leg angle that allowed the subjects to walk faster and with more symmetrical propulsion. In addition, subjects with three modules pre-therapy increased their number of modules and improved walking performance post-therapy. Thus, locomotor training has the potential to influence module composition and timing, which can lead to improvements walking performance. (C) 2013 Elsevier B.V. All rights reserved. C1 [Routson, Rebecca L.; Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Clark, David J.] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA. [Clark, David J.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. [Bowden, Mark G.; Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bowden, Mark G.; Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 204 E Dean Keeton St,Stop C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu OI Kautz, Steven/0000-0003-3151-8235 FU NIH [R01 HD46820]; Department of Veterans Affairs RRD Merit Review [B3983-R]; NSF GRFP FX This work was supported by NIH Grant R01 HD46820, Department of Veterans Affairs RR&D Merit Review B3983-R, and the NSF GRFP. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NICHD, NSF, the Department of Veterans Affairs or the United States Government. NR 24 TC 31 Z9 32 U1 2 U2 15 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD JUL PY 2013 VL 38 IS 3 BP 511 EP 517 DI 10.1016/j.gaitpost.2013.01.020 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 216KZ UT WOS:000324283600026 PM 23489952 ER PT J AU Prasad, R Katiyar, SK AF Prasad, Ram Katiyar, Santosh K. TI Prostaglandin E-2 Promotes UV Radiation-Induced Immune Suppression through DNA Hypermethylation SO NEOPLASIA LA English DT Article ID GREEN TEA POLYPHENOLS; INDUCED SYSTEMIC IMMUNOSUPPRESSION; NONMELANOMA SKIN-CANCER; ULTRAVIOLET-RADIATION; MOUSE SKIN; MICE; RECEPTOR; GENES; METHYLATION; IRRADIATION AB Exposure of mice to UV radiation results in suppression of the contact hypersensitivity (CHS) response. Here, we report that the UV-induced suppression of CHS is associated with increases in the levels of cyclooxygenase-2 (COX-2), prostaglandin E-2 (PGE(2)), and PGE2 receptors in the exposed skin. UV radiation-induced suppression of CHS was inhibited by topical treatment of the skin with celecoxib or indomethacin (inhibitors of COX-2) or AH6809 (an EP2 antagonist). Moreover, mice deficient in COX-2 were found to be resistant to UV-induced suppression of CHS. The exposure of wild-typemice to UVB radiation resulted in DNA hypermethylation, increased DNA methyltransferase (Dnmt) activity, and elevated levels of Dnmt1, Dnmt3a, and Dnmt3b proteins in the skin, and these responses were downregulated on topical treatment of the site of exposure after irradiation with indomethacin or EP2 antagonist. Topical treatment of UVB-exposed COX-2-deficient mice with PGE(2) enhanced the UVB-induced suppression of CHS as well as global DNA methylation and elevated the levels of Dnmt activity and Dnmt proteins in the skin. Intraperitoneal injection of 5-aza-2'-deoxycytidine (5-Aza-dc), a DNA demethylating agent, restored the CHS response to 2,4-dinitrofluorobenzene in UVB-exposed skin and this was associated with the reduction in global DNA methylation and Dnmt activity and reduced levels of Dnmt proteins. Furthermore, treatment with 5-Aza-dc reversed the effect of PGE(2) on UV-induced suppression of CHS in COX-2-deficient mice. These findings reveal a previously unrecognized role for PGE(2) in the promotion of UVB-induced immunosuppression and indicate that it is mediated through PGE(2) regulation of DNA methylation. C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health/National Center for Complementary and Alternative Medicine/National Cancer Institute [CA140197, AT002536]; Veterans Administration Merit Review Award [1I01BX001410-01] FX This research was financially supported by the National Institutes of Health/National Center for Complementary and Alternative Medicine/National Cancer Institute (CA140197 and AT002536 to S. K. K.) and the Veterans Administration Merit Review Award (1I01BX001410-01 to S. K. K.). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 7 Z9 7 U1 0 U2 6 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD JUL PY 2013 VL 15 IS 7 BP 795 EP 804 DI 10.1593/neo.13424 PG 10 WC Oncology SC Oncology GA 219DY UT WOS:000324487100011 PM 23814491 ER PT J AU Ruddy, JM Jones, JA Ikonomidis, JS AF Ruddy, Jean Marie Jones, Jeffery A. Ikonomidis, John S. TI Pathophysiology of Thoracic Aortic Aneurysm (TAA): Is It Not One Uniform Aorta? Role of Embryologic Origin SO PROGRESS IN CARDIOVASCULAR DISEASES LA English DT Review DE Thoracic Aortic Aneurysm; Matrix metalloproteinases; Transforming growth factor-beta; Extracellular matrix remodeling ID SMOOTH-MUSCLE-CELLS; TGF-BETA ACTIVATION; PROTEIN-KINASE-C; SYNDROME TYPE-IV; MARFAN-SYNDROME; ANGIOTENSIN-II; MOUSE MODEL; GROWTH; RECEPTOR; MUTATIONS AB Thoracic aortic aneurysm (TAA) is a clinically silent and potentially fatal disease whose pathophysiology is poorly understood. Application of data derived from animal models and human tissue analysis of abdominal aortic aneurysms may prove misleading given current evidence of structural and biochemical aortic heterogeneity above and below the diaphragm. Genetic predisposition is more common in TAA and includes multi-faceted syndromes such as Marfan, Loeys-Dietz, and type IV Ehlers-Danlos as well as autosomal-dominant familial patterns of inheritance. Investigation into the consequences of these known mutations has provided insight into the cell signaling cascades leading to degenerative remodeling of the aortic medial extracellular matrix (ECM) with TGF-beta playing a major role. Targeted research into modifying the upstream regulation or downstream effects of the TGF-beta 1 pathway may provide opportunities for intervention to attenuate TAA progression. (C) 2013 Elsevier Inc. All rights reserved. C1 [Ruddy, Jean Marie; Jones, Jeffery A.; Ikonomidis, John S.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA. [Ruddy, Jean Marie; Jones, Jeffery A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, 25 Courtenay Dr,Suite 7030, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NIH/NIA [AG036954]; NIH/NHLBI [HL102121]; Veterans Affairs Merit Award [1 I01 BX000904-01] FX This study was supported by the following grants: NIH/NIA AG036954, NIH/NHLBI HL102121 and Veterans Affairs Merit Award 1 I01 BX000904-01. NR 57 TC 17 Z9 18 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-0620 EI 1873-1740 J9 PROG CARDIOVASC DIS JI Prog. Cardiovasc. Dis. PD JUL-AUG PY 2013 VL 56 IS 1 BP 68 EP 73 DI 10.1016/j.pcad.2013.04.002 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 214RJ UT WOS:000324153000009 PM 23993239 ER PT J AU Chahine, LM Qiang, J Ashbridge, E Minger, J Yearout, D Horn, S Colcher, A Hurtig, HI Lee, VMY Van Deerlin, VM Leverenz, JB Siderowf, AD Trojanowski, JQ Zabetian, CP Chen-Plotkin, A AF Chahine, Lama M. Qiang, Judy Ashbridge, Emily Minger, James Yearout, Dora Horn, Stacy Colcher, Amy Hurtig, Howard I. Lee, Virginia M-Y. Van Deerlin, Vivianna M. Leverenz, James B. Siderowf, Andrew D. Trojanowski, John Q. Zabetian, Cyrus P. Chen-Plotkin, Alice TI Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without GBA Mutations SO JAMA NEUROLOGY LA English DT Article ID GLUCOCEREBROSIDASE GENE-MUTATIONS; LEWY BODY DISORDERS; GAUCHER-DISEASE; RISK-FACTOR; ONSET; NEUROINFLAMMATION; SUSCEPTIBILITY; CARRIERS; TYPE-2; MODEL AB IMPORTANCE Biochemical abnormalities present in GBA (mut/wt) carriers may offer new pathogenetic insights to and potential therapeutic targets in Parkinson disease (PD). OBJECTIVE To determine whether patients having PD with vs without GBA mutations differ in clinical phenotype or plasma protein expression. DESIGN AND SETTING Case-control study of patients having PD with vs without GBA mutations. Clinical characteristics were compared between groups, and biochemical profiling of 40 plasma proteins was performed to identify proteins that differed in expression between groups. PARTICIPANTS The discovery cohort included 20 patients having PD with GBA mutations. Clinical characteristics of GBA-associated PD cases were compared with those of 242 patients having PD in whom GBA mutations were excluded by full gene sequencing. MAIN OUTCOME MEASURES Biochemical profiling was available for all 20 GBA-associated PD cases, as well as a subset (87 of 242) of the GBA-negative PD cases. The replication cohort included 19 patients having PD with GBA mutations and 41 patients having PD without GBA mutations. RESULTS Compared with patients having PD without GBA mutations, patients having PD with GBA mutations were younger at disease onset (P = .04) and were more likely to demonstrate cognitive dysfunction (P = .001). In a multiple regression model that included age, sex, and assay batch as covariates, GBA mutation status was significantly associated with plasma levels of interleukin 8 (P = .001), monocyte chemotactic protein 1 (P = .008), and macrophage inflammatory protein 1 alpha (P = .005). The association between interleukin 8 and GBA mutation status was replicated (P = .03) in a separate cohort of patients having PD with vs without GBA mutations. CONCLUSIONS AND RELEVANCE Patients having PD with GBA mutations have earlier age at disease onset and are more likely to demonstrate cognitive dysfunction. Monocyte-associated inflammatory mediators may be elevated in patients having PD with GBA mutations. C1 [Chahine, Lama M.; Qiang, Judy; Ashbridge, Emily; Minger, James; Horn, Stacy; Colcher, Amy; Hurtig, Howard I.; Chen-Plotkin, Alice] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lee, Virginia M-Y.; Van Deerlin, Vivianna M.; Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Horn, Stacy; Colcher, Amy; Hurtig, Howard I.; Lee, Virginia M-Y.; Van Deerlin, Vivianna M.; Trojanowski, John Q.; Chen-Plotkin, Alice] Univ Penn, Morris K Udall Ctr Excellence Parkinsons Dis Res, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lee, Virginia M-Y.; Van Deerlin, Vivianna M.; Trojanowski, John Q.; Chen-Plotkin, Alice] Univ Penn, Inst Aging, Perelman Sch Med, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.] Avid Radiopharmaceut, Philadelphia, PA USA. [Yearout, Dora; Leverenz, James B.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Yearout, Dora; Leverenz, James B.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Chen-Plotkin, A (reprint author), Univ Penn, Dept Neurol, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA. EM chenplot@mail.med.upenn.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU University of Pennsylvania; Pfizer (Penn Pfizer Alliance); Morris K. Udall Center of Excellence for Parkinson's Disease Research from the National Institute of Neurological Disorders and Stroke [NS-053488, P50 NS062684]; National Institutes of Health [R01 NS065070, AG-033101]; Department of Veterans Affairs [1I01BX000531]; Burroughs Wellcome Fund Career Award for Medical Scientists; Doris Duke Clinician Scientist Development Award; Benaroya Fund FX The biomarker data in this project were obtained through a partnership grant between the University of Pennsylvania and Pfizer (Penn Pfizer Alliance). The clinical data in this project were collected through the support of Morris K. Udall Center of Excellence for Parkinson's Disease Research grants NS-053488 and P50 NS062684 from the National Institute of Neurological Disorders and Stroke. Dr Zabetian is supported by grant R01 NS065070 from the National Institutes of Health and by Merit Award 1I01BX000531 from the Department of Veterans Affairs. Dr Chen-Plotkin is supported by grant AG-033101 from the National Institutes of Health and by a Burroughs Wellcome Fund Career Award for Medical Scientists, a Doris Duke Clinician Scientist Development Award, and the Benaroya Fund. NR 33 TC 29 Z9 31 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD JUL PY 2013 VL 70 IS 7 BP 852 EP 858 DI 10.1001/jamaneurol.2013.1274 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 206YN UT WOS:000323563000007 PM 23699752 ER PT J AU Friedman, SD Baker, LD Borson, S Jensen, JE Barsness, SM Craft, S Merriam, GR Otto, RK Novotny, EJ Vitiello, MV AF Friedman, Seth D. Baker, Laura D. Borson, Soo Jensen, J. Eric Barsness, Suzanne M. Craft, Suzanne Merriam, George R. Otto, Randolph K. Novotny, Edward J. Vitiello, Michael V. TI Growth Hormone-Releasing Hormone Effects on Brain gamma-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging SO JAMA NEUROLOGY LA English DT Article ID AGE-RELATED DECLINE; ALZHEIMERS-DISEASE; GABA CONCENTRATION; OLDER-ADULTS; N-ACETYLASPARTYLGLUTAMATE; INDIVIDUAL-DIFFERENCES; BODY-COMPOSITION; CONTROLLED-TRIAL; H-1 MRS; CORTEX AB IMPORTANCE Growth hormone-releasing hormone (GHRH) has been previously shown to have cognition-enhancing effects. The role of neurotransmitter changes, measured by proton magnetic resonance spectroscopy, may inform the mechanisms for this response. OBJECTIVE To examine the neurochemical effects of GHRH in a subset of participants from the parent trial. DESIGN Randomized, double-blind, placebo-controlled substudy of a larger trial. SETTING Clinical research unit at the University of Washington School of Medicine. PARTICIPANTS Thirty adults (17 with mild cognitive impairment [MCI]), ranging in age from 55 to 87 years, were enrolled and successfully completed the study. INTERVENTIONS Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologies Inc), a stabilized analogue of human GHRH (1 mg/d), or placebo 30 minutes before bedtime for 20 weeks. At baseline and weeks 10 and 20, participants underwent brain magnetic resonance imaging and spectroscopy protocols and cognitive testing and provided blood samples after fasting. Participants also underwent glucose tolerance tests before and after intervention. MAIN OUTCOMES AND MEASURES Brain levels of glutamate, inhibitory transmitters.-aminobutyric acid (GABA) and N-acetylaspartylglutamate (NAAG), and myo-inositol (MI), an osmolyte linked to Alzheimer disease in humans, were measured in three 2 x 2 x 2-cm(3) left-sided brain regions (dorsolateral frontal, posterior cingulate, and posterior parietal). Glutamate, GABA, and MI levels were expressed as ratios to creatine plus phosphocreatine, and NAAG was expressed as a ratio to N-acetylaspartate. RESULTS After 20 weeks of GHRH administration, GABA levels were increased in all brain regions (P < .04), NAAG levels were increased (P = .03) in the dorsolateral frontal cortex, and MI levels were decreased in the posterior cingulate (P = .002). These effects were similar in adults with MCI and older adults with normal cognitive function. No changes in the brain levels of glutamate were observed. In the posterior cingulate, treatment-related changes in serum insulin-like growth factor 1 were positively correlated with changes in GABA (r = 0.47; P = .001) and tended to be negatively correlated with MI (r = -0.34; P = .06). Consistent with the results of the parent trial, a favorable treatment effect on cognition was observed in substudy participants (P = .03). No significant associations were observed between treatment-related changes in neurochemical and cognitive outcomes. Glucose homeostasis in the periphery was not reliably affected by GHRH administration and did not account for treatment neurochemical effects. CONCLUSIONS Twenty weeks of GHRH administration increased GABA levels in all 3 brain regions, increased NAAG levels in the frontal cortex, and decreased MI levels in the posterior cingulate. To our knowledge, this is the first evidence that 20 weeks of somatotropic supplementation modulates inhibitory neurotransmitter and brain metabolite levels in a clinical trial, and it provides preliminary support for one possible mechanism to explain favorable GHRH effects on cognition in adults with MCI and in healthy older adults. C1 [Friedman, Seth D.; Otto, Randolph K.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA 98105 USA. [Novotny, Edward J.] Seattle Childrens Hosp, Dept Neurol, Seattle, WA 98105 USA. [Baker, Laura D.; Borson, Soo; Barsness, Suzanne M.; Craft, Suzanne; Vitiello, Michael V.] Univ Washington, Dept Psychiat, Sch Med, Seattle, WA 98195 USA. [Baker, Laura D.; Borson, Soo; Barsness, Suzanne M.; Craft, Suzanne; Vitiello, Michael V.] Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA USA. [Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Baker, Laura D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Jensen, J. Eric] Harvard Univ, McLean Hosp, Belmont, MA 02178 USA. RP Friedman, SD (reprint author), Seattle Childrens Hosp, Dept Radiol, 4800 Sandpoint Way,Room R4488, Seattle, WA 98105 USA. EM seth.friedman@seattlechildrens.org OI Vitiello, Michael/0000-0002-9776-0473 FU National Institute on Aging, National Institutes of Health [R01 AG030484-01, AG025515]; National Center for Research Resources, National Institutes of Health [ULRR025014] FX This project was supported by the National Institute on Aging, National Institutes of Health (grants R01 AG030484-01 [principal investigator, Dr Friedman] and AG025515 [principal investigator, Dr Vitiello]). A portion of this work was conducted through the Clinical Research Center Facility at the University of Washington Medical Center, which is supported by the National Center for Research Resources, National Institutes of Health (grant ULRR025014). NR 50 TC 11 Z9 12 U1 2 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD JUL PY 2013 VL 70 IS 7 BP 883 EP 890 DI 10.1001/jamaneurol.2013.1425 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 206YN UT WOS:000323563000011 PM 23689947 ER PT J AU Merkow, RP Bilimoria, KY Ko, CY AF Merkow, Ryan P. Bilimoria, Karl Y. Ko, Clifford Y. TI Surgical Quality Measurement An Evolving Science SO JAMA SURGERY LA English DT Editorial Material ID CARE C1 [Merkow, Ryan P.; Bilimoria, Karl Y.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement Ctr, Dept Surg, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Northwestern Inst Comparat Effectiveness Res NICE, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Fl, Chicago, IL 60611 USA. EM rmerkow@facs.org NR 6 TC 9 Z9 9 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 J9 JAMA SURG JI JAMA Surg. PD JUL PY 2013 VL 148 IS 7 BP 586 EP 587 DI 10.1001/jamasurg.2013.128 PG 2 WC Surgery SC Surgery GA 206WP UT WOS:000323556600001 PM 23864242 ER PT J AU Epstein, AJ Groeneveld, PW Harhay, MO Yang, FF Polsky, D AF Epstein, Andrew J. Groeneveld, Peter W. Harhay, Michael O. Yang, Feifei Polsky, Daniel TI Impact of Minimally Invasive Surgery on Medical Spending and Employee Absenteeism SO JAMA SURGERY LA English DT Article ID LAPAROSCOPIC CHOLECYSTECTOMY; MODELS; COSTS AB IMPORTANCE As many surgical procedures have undergone a transition from a standard, open surgical approach to a minimally invasive one in the past 2 decades, the diffusion of minimally invasive surgery may have had sizeable but overlooked effects on medical expenditures and worker productivity. OBJECTIVE To examine the impact of standard vs minimally invasive surgery on health plan spending and workplace absenteeism for 6 types of surgery. DESIGN Cross-sectional regression analysis. SETTING National health insurance claims data and matched workplace absenteeism data from January 1, 2000, to December 31, 2009. PARTICIPANTS A convenience sample of adults with employer-sponsored health insurance who underwent either standard or minimally invasive surgery for coronary revascularization, uterine fibroid resection, prostatectomy, peripheral revascularization, carotid revascularization, or aortic aneurysm repair. MAIN OUTCOMES AND MEASURE Health plan spending and workplace absenteeism from 14 days before through 352 days after the index surgery. RESULTS There were 321 956 patients who underwent surgery; 23 814 were employees with workplace absenteeism data. After multivariable adjustment, mean health plan spending was lower for minimally invasive surgery for coronary revascularization (-$30 850; 95% CI, -$31 629 to -$30 091), uterine fibroid resection (-$1509; 95% CI, -$1754 to -$1280), and peripheral revascularization (-$12 031; 95% CI, -$15 552 to -$8717) and higher for prostatectomy ($1350; 95% CI, $611 to $2212) and carotid revascularization ($4900; 95% CI, $1772 to $8370). Undergoing minimally invasive surgery was associated with missing significantly fewer days of work for coronary revascularization (mean difference, -37.7 days; 95% CI, -41.1 to -34.3), uterine fibroid resection (mean difference, -11.7 days; 95% CI, -14.0 to -9.4), prostatectomy (mean difference, -9.0 days; 95% CI, -14.2 to -3.7), and peripheral revascularization (mean difference, -16.6 days; 95% CI, -28.0 to -5.2). CONCLUSIONS AND RELEVANCE For 3 of 6 types of surgery studied, minimally invasive procedures were associated with significantly lower health plan spending than standard surgery. For 4 types of surgery, minimally invasive procedures were consistently associated with significantly fewer days of absence from work. C1 [Epstein, Andrew J.; Groeneveld, Peter W.] US Dept Vet Affairs, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Epstein, Andrew J.; Groeneveld, Peter W.; Harhay, Michael O.; Yang, Feifei; Polsky, Daniel] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA USA. [Epstein, Andrew J.; Groeneveld, Peter W.; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Epstein, AJ (reprint author), Univ Penn, Perelman Sch Med, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM eandrew@mail.med.upenn.edu OI Harhay, Michael/0000-0002-0553-674X FU Institute for Health Technology Studies FX This work was supported by a research grant from the Institute for Health Technology Studies. NR 14 TC 21 Z9 21 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 J9 JAMA SURG JI JAMA Surg. PD JUL PY 2013 VL 148 IS 7 BP 641 EP 647 DI 10.1001/jamasurg.2013.131 PG 7 WC Surgery SC Surgery GA 206WP UT WOS:000323556600016 PM 23552709 ER PT J AU Werner, RM Konetzka, RT Kim, M AF Werner, Rachel M. Konetzka, Rita T. Kim, Michelle TI Quality Improvement Under Nursing Home Compare: The Association Between Changes in Process and Outcome Measures SO MEDICAL CARE LA English DT Article DE nursing homes; quality improvement; quality of care ID LONG-TERM-CARE; HOSPITAL QUALITY; OF-CARE; PERFORMANCE; RESIDENTS; MORTALITY; IMPACT; PAIN; ASSESSMENTS; MANAGEMENT AB Background: Changes in resident outcomes may be driven by many factors, including changes in nursing home care processes. Understanding what processes, if any, lead to successful improvements in resident outcomes could create a stronger case for the continued use of these outcome measures in nursing home report cards.Objective: To test the extent to which improvements in outcomes of care are explained by changes in nursing home processes, a setting where, to our knowledge, this link has not been previously studied.Research Design/Measures: We describe facility-level changes in resident processes and outcomes before and after outcomes were publicly reported. We then assess the extent to which the changes in outcomes are associated with changes in nursing home processes of care, using the public release of information on nursing home outcomes as a source of variation in nursing home outcomes to identify the process-outcome relationship.Subjects: All 16,623 US nursing homes included in public reporting from 2000 to 2009 in Online Survey, Certification and Reporting and the nursing home Minimum Data Set.Results: Of the 5 outcome measures examined, only improvements in the percentage of nursing home residents in moderate or severe pain were associated with changes in nursing home processes of care. Furthermore, these changes in the measured process of care explained only a small part of the overall improvement in pain prevalence.Conclusions: A large portion of the improvements in nursing home outcomes were not associated with changes in measured processes of care suggesting that processes of care typically measured in nursing homes do little to improve nursing home performance on outcome measures. Developing quality measures that are related improved patient outcomes would likely benefit quality improvement. Understanding the mechanism behind improvements in nursing home outcomes is key to successfully achieving broad quality improvements across nursing homes. C1 [Werner, Rachel M.] Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Konetzka, Rita T.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Kim, Michelle] Univ Chicago, Dept Hlth Care Syst, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Blockley Hall,Room 1230,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu FU National Institute on Aging [R01 AG034182]; VA HSR&D Career Development Award FX Funded by the National Institute on Aging under Grant number R01 AG034182. R.M.W. was supported in part by a VA HSR&D Career Development Award. NR 30 TC 4 Z9 4 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUL PY 2013 VL 51 IS 7 BP 582 EP 588 DI 10.1097/MLR.0b013e31828dbae4 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 202ML UT WOS:000323221000005 PM 23756645 ER PT J AU Merkow, RP Bentrem, DJ Chung, JW Paruch, JL Ko, CY Bilimoria, KY AF Merkow, Ryan P. Bentrem, David J. Chung, Jeanette W. Paruch, Jennifer L. Ko, Clifford Y. Bilimoria, Karl Y. TI Differences in Patients, Surgical Complexity, and Outcomes After Cancer Surgery at National Cancer Institute-designated Cancer Centers Compared to Other Hospitals SO MEDICAL CARE LA English DT Article DE outcomes; quality; ACS NSQIP; surgery; risk adjustment; oncology; cancer; surgical oncology; American College of Surgeons; National Cancer Institute Cancer Center ID QUALITY IMPROVEMENT INITIATIVES; RISK-ADJUSTMENT; VOLUME; MORTALITY; PROGRAM; CARE; SURVIVAL; SAFETY AB Background: Interest in comparing hospital surgical quality continues to increase, particularly with respect to examining certain hospital designations such as National Cancer Institute-designated Cancer Centers (NCI-CC). Our objectives were to compare patients, surgical complexity, and risk-adjusted 30-day outcomes following major cancer surgery at NCI-CC versus non-NCI centers. Methods: From the American College of Surgeons National Surgical Quality Improvement Program, patients were identified who underwent colorectal, pancreatic, or esophagogastric resection for cancer (2007-2011). Regression methods were used to evaluate characteristics associated with undergoing treatment at NCI-CCs and surgical-complexity-adjusted 30-day morbidity, mortality, and prolonged length-of-stay at NCI-CC versus non-NCI centers. Results: NCI-CCs performed 20.2% of colorectal (10,555/52,265), 53.5% of pancreatic (6335/11,838), and 49.8% of esophagogastric (1596/3208) operations for cancer. NCI-CCs were more likely to treat patients who were younger, white, and with fewer comorbidities, but were more likely to perform more complex procedures including synchronous liver resection (eg, colorectal), adjacent organ resections (rectal cancer), and vascular reconstructions (eg, pancreas) (all P<0.05). NCI-CCs had a lower mortality rate for colorectal surgery only (1.2% vs. 1.9%) and increased rates of superficial surgical site infection (SSI) for colorectal (9.8% vs. 7.1%) and pancreatic (10.7% vs. 8.8%) surgery. No differences existed for the remaining complications by NCI-CC designation status. NCI-CCs were distributed throughout hospital quality rankings for all procedures and complications assessed. Conclusions: NCI-CCs treated younger, healthier patients, but performed more complex procedures. Patients treated at NCI-CCs had a lower risk of mortality for colorectal resection, but morbidity was similar to non-NCI centers. Comparison of cancer surgery hospital quality is feasible and should adjust for differences in patient demographics, comorbidities, and surgical complexity. C1 [Merkow, Ryan P.; Paruch, Jennifer L.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bentrem, David J.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement Ctr, Dept Surg, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bentrem, David J.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Northwestern Inst Comparat Effectiveness Res NICE, Chicago, IL 60611 USA. [Merkow, Ryan P.; Paruch, Jennifer L.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 636 St Clair St,22nd Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org FU NICER FX R.P.M., D.J.B., and K.Y.B. are supported by NICER. NR 34 TC 7 Z9 7 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUL PY 2013 VL 51 IS 7 BP 606 EP 613 DI 10.1097/MLR.0b013e3182928f44 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 202ML UT WOS:000323221000008 PM 23604012 ER PT J AU Tyson, GL Richardson, PA White, DL Kuzniarek, J Ramsey, DJ Tavakoli-Tabasi, S El-Serag, HB AF Tyson, Gia L. Richardson, Peter A. White, Donna L. Kuzniarek, Jill Ramsey, David J. Tavakoli-Tabasi, Shahriar El-Serag, Hashem B. TI Dietary Fructose Intake and Severity of Liver Disease in Hepatitis C Virus-infected Patients SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE sugar; viral hepatitis; epidemiology; nutrition ID BIOCHEMICAL MARKERS; COMBINATION THERAPY; INSULIN-RESISTANCE; CORN SYRUP; FIBROSIS; STEATOSIS; CONSUMPTION; VALIDATION; PEGINTERFERON AB Background and Goals: Dietary fructose intake in the United States has been increasing, and fructose intake has been associated with the metabolic syndrome and hepatic steatosis. This study aimed to determine whether dietary fructose intake is associated with advanced hepatic fibrosis and inflammation in an hepatitis C virus (HCV)-infected male population. Study: We conducted a cross-sectional study of HCV-infected male veterans. The main exposure variable was daily dietary fructose calculated from the National Cancer Institute Diet History Questionnaire and the main outcome variables were FibroSURE-ActiTest determined hepatic fibrosis (F0-F3=mild vs. F3/F4-F4=advanced) and inflammation (A0-A2=mild vs. A2/A3-A3=advanced). We examined this association in logistic regression adjusting for demographic, clinical, and other dietary variables. Results: Among 313 HCV+ males, 103 (33%) had advanced fibrosis and 89 (28%) had advanced inflammation. Median daily fructose intake was 46.8 g (interquartile range, 30.4 to 81.0). Dietary fructose intake across quartiles among males with advanced versus mild fibrosis was 21.4% versus 25.2%, 32.0% versus 24.8%, 24.3% versus 25.2%, and 22.3% versus 24.8%, respectively, and among males with advanced versus mild inflammation was 20.2% versus 25.5%, 41.6% versus 21.4%, 22.5% versus 25.9%, and 15.7% versus 27.2%, respectively. In multivariate analysis, there were no significant associations between daily fructose intake and advanced fibrosis. There was a significant association only between the second quartile of daily fructose intake (30 to 48 g) and advanced inflammation. Conclusions: There were no significant associations between dietary fructose intake and hepatic fibrosis risk, as assessed by FibroSURE, in HCV-infected males. Additional research is needed to clarify the potential role of fructose intake and HCV-related hepatic inflammation. C1 [Tyson, Gia L.; Richardson, Peter A.; White, Donna L.; Kuzniarek, Jill; Ramsey, David J.; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Tavakoli-Tabasi, Shahriar] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Tyson, Gia L.; White, Donna L.; El-Serag, Hashem B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [Tyson, Gia L.; White, Donna L.; El-Serag, Hashem B.] Baylor Coll Med, Sect Hepatol, Houston, TX 77030 USA. [Tyson, Gia L.; Richardson, Peter A.; White, Donna L.; Kuzniarek, Jill; Ramsey, David J.; El-Serag, Hashem B.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Tyson, GL (reprint author), 2450 Holcombe Blvd,Suite 01Y, Houston, TX 77021 USA. EM giatyson@hotmail.com FU VA Clinical Research and Development Merit Review Award [H-22934, T32 DK083266-01A1]; National Institute of Diabetes Digestive and Kidney Diseases [DK081736-01, DK078154-03]; Houston Veterans Affairs Health Services Research and Development Center of Excellence [HFP90-020] FX Supported partly by VA Clinical Research and Development Merit Review Award H-22934, T32 DK083266-01A1, the National Institute of Diabetes Digestive and Kidney Diseases DK081736-01 and DK078154-03, and the Houston Veterans Affairs Health Services Research and Development Center of Excellence HFP90-020. NR 26 TC 1 Z9 1 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD JUL PY 2013 VL 47 IS 6 BP 545 EP 552 DI 10.1097/MCG.0b013e31827244d9 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 202LM UT WOS:000323217700016 PM 23426443 ER PT J AU Birdsill, AC Carlsson, CM Willette, AA Okonkwo, OC Johnson, SC Xu, GF Oh, JM Gallagher, CL Koscik, RL Jonaitis, EM Hermann, BP LaRue, A Rowley, HA Asthana, S Sager, MA Bendlin, BB AF Birdsill, Alex C. Carlsson, Cynthia M. Willette, Auriel A. Okonkwo, Ozioma C. Johnson, Sterling C. Xu, Guofan Oh, Jennifer M. Gallagher, Catherine L. Koscik, Rebecca L. Jonaitis, Erin M. Hermann, Bruce P. LaRue, Asenath Rowley, Howard A. Asthana, Sanjay Sager, Mark A. Bendlin, Barbara B. TI Low Cerebral Blood Flow is Associated with Lower Memory Function in Metabolic Syndrome SO OBESITY LA English DT Article ID PRECLINICAL ALZHEIMERS-DISEASE; MILD COGNITIVE IMPAIRMENT; PERFUSION MRI; DEMENTIA; RISK; INVERSION; DECLINE; PET AB Background: Metabolic syndrome (MetS)-a cluster of cardiovascular risk factors-is linked with cognitive decline and dementia. However, the brain changes underlying this link are presently unknown. In this study, we tested the relationship between MetS, cerebral blood flow (CBF), white matter hyperintensity burden, and gray matter (GM) volume in cognitively healthy late middle-aged adults. Additionally, the extent to which MetS was associated with cognitive performance was assessed. Design and Methods: Late middle-aged adults from the Wisconsin Registry for Alzheimer's Prevention (N = 69, mean age = 60.4 years) underwent a fasting blood draw, arterial spin labeling perfusion MRI, T1-weighted MRI, T2FLAIR MRI, and neuropsychological testing. MetS was defined as abnormalities on three or more factors, including abdominal obesity, triglycerides, HDL-cholesterol, blood pressure, and fasting glucose. Results: Mean GM CBF was 15% lower in MetS compared to controls. Voxel-wise image analysis indicated that the MetS group had lower CBF across a large portion of the cortical surface, with the exception of medial and inferior parts of the occipital and temporal lobes. The MetS group also had lower immediate memory function; a mediation analysis indicated this relationship was partially mediated by CBF. Among the MetS factors, abdominal obesity and elevated triglycerides were most strongly associated with lower CBF. Conclusions: The results underscore the importance of reducing the number of cardiovascular risk factors for maintaining CBF and cognition in an aging population. C1 [Birdsill, Alex C.; Carlsson, Cynthia M.; Okonkwo, Ozioma C.; Johnson, Sterling C.; Xu, Guofan; Oh, Jennifer M.; Asthana, Sanjay; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Birdsill, Alex C.; Carlsson, Cynthia M.; Okonkwo, Ozioma C.; Johnson, Sterling C.; Xu, Guofan; Oh, Jennifer M.; Gallagher, Catherine L.; Rowley, Howard A.; Asthana, Sanjay; Sager, Mark A.; Bendlin, Barbara B.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Willette, Auriel A.] NIA, Baltimore, MD 21224 USA. [Gallagher, Catherine L.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. [Gallagher, Catherine L.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA. [Koscik, Rebecca L.; Jonaitis, Erin M.; Hermann, Bruce P.; LaRue, Asenath; Sager, Mark A.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Bendlin, BB (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU Alzheimer's Association [NIRG-09-132626]; National Institute on Aging [R01 AG027161, ADRC P50 AG033514]; National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award [1UL1RR025011]; University of Wisconsin Institute for Clinical and Translational Research FX This project was supported by the Alzheimer's Association, NIRG-09-132626, and in part by the National Institute on Aging (R01 AG027161 [MAS], ADRC P50 AG033514 [SA]), and the University of Wisconsin Institute for Clinical and Translational Research, funded through a National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award, 1UL1RR025011. The project was also facilitated by the facilities and resources at the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI. GRECC MS # 2012-10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 27 Z9 28 U1 2 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD JUL PY 2013 VL 21 IS 7 BP 1313 EP 1320 DI 10.1002/oby.20170 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 204FV UT WOS:000323351400002 PM 23687103 ER PT J AU Rosland, AM Nelson, K Sun, HL Dolan, ED Maynard, C Bryson, C Stark, R Shear, JM Kerr, E Fihn, SD Schectman, G AF Rosland, Ann-Marie Nelson, Karin Sun, Haili Dolan, Emily D. Maynard, Charles Bryson, Christopher Stark, Richard Shear, Joanne M. Kerr, Eve Fihn, Stephan D. Schectman, Gordon TI The Patient-Centered Medical Home in the Veterans Health Administration SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID PRIMARY-CARE; TRANSFORMATION; MODEL; COST AB Background:The Veterans Health Administration (VHA) is the largest integrated US health system to implement the patient-centered medical home. The Patient Aligned CareTeam (PACT) initiative (implemented 2010-20141 aims to achieve team-based care, improved access, and care management for more than 5 million primary care patients nationwide. Objectives: To describe PACT and evaluate interim changes in PACT-related care processes. Study Design: Data from the VHA Corporate Data Warehouse were obtained from April 2009 (pre-PACT) to September 2012. All patients assigned to a primary care provider (PCP) at all VHA facilities were included. Methods: Nonparametric tests of trend across time points. Results: VHA increased primary care staff levels from April 2010 to December 2011 (2.3 to 3.0 staff per PCP full-time equivalent). In-person PCP visit rates slightly decreased from April 2009 to April 2012 (53 to 43 per 100 patients per calendar quarter; P <.01), while in-person nurse encounter rates remained steady. Large increases were seen in phone encounters (2.7 to 28.8 per 100 patients per quarter; P <.01), enhanced personal health record use (3% to 13% of patients enrolled), and electronic messaging to providers (0.01% to 2.3% of patients per quarter). Post hospitalization follow-up improved (6.6% to 61% of VA hospital discharges), but home telemonitoring (0.8% to 1.4% of patients) and group visits (0.2 to 0.65 per 100 patients per quarter; P <.01) grew slowly. Conclusions:Thirty months into PACT, primary care staff levels and phone and electronic encounters have greatly increased; other changes have been positive but slower. C1 [Rosland, Ann-Marie; Kerr, Eve] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA. [Rosland, Ann-Marie; Kerr, Eve] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Nelson, Karin; Sun, Haili; Dolan, Emily D.; Maynard, Charles; Bryson, Christopher] Northwest HSR&D Ctr Excellence, VA Puget Sound Healthcare Syst, Seattle, WA USA. [Nelson, Karin; Bryson, Christopher] Gen Internal Med Serv, Seattle, WA USA. [Nelson, Karin; Bryson, Christopher; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Maynard, Charles; Fihn, Stephan D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Stark, Richard; Schectman, Gordon] VHA Off Patient Care Serv, Washington, DC USA. [Shear, Joanne M.] VHA Off Primary Care Operat & Primary Care Serv, Washington, DC USA. RP Rosland, AM (reprint author), 2215 Fuller Rd 152, Ann Arbor, MI 48105 USA. EM arosland@umich.edu RI Maynard, Charles/N-3906-2015; Rosland, Annmarie/B-7750-2016 OI Maynard, Charles/0000-0002-1644-7814; NR 25 TC 68 Z9 70 U1 4 U2 13 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUL PY 2013 VL 19 IS 7 BP E263 EP + PG 22 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 195CY UT WOS:000322681100010 PM 23919446 ER PT J AU Braunstein, I Werth, V AF Braunstein, Inbal Werth, Victoria TI Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy SO DERMATOLOGIC THERAPY LA English DT Article DE autoimmune skin disease; blistering disease; blistering disorders; cutaneous lupus erythematosus; dermatomyositis; lactation; morphea; pemphigoid gestationis; pemphigus foliaceus; pemphigus vulgaris; pregnancy; rheumatic skin disease ID OF-THE-LITERATURE; INFLAMMATORY-BOWEL-DISEASE; RHEUMATOID-ARTHRITIS; PEMPHIGOID GESTATIONIS; MYCOPHENOLATE-MOFETIL; REPRODUCTIVE-SYSTEM; ANTIRHEUMATIC DRUGS; CORTICOSTEROID USE; LUPUS PREGNANCY; OCULAR TOXICITY AB Autoimmune skin disease occurs in pregnancy, and treatment is often required to control both maternal disease and fetal outcomes. Here we present the available safety data in pregnancy and lactation for medications used to treat autoimmune skin diseases, including cutaneous lupus erythematosus, dermatomyositis, morphea and systemic sclerosis, pemphigus vulgaris, pemphigus foliaceus, and pemphigoid gestationis. A PubMed search of the English-language literature using keywords, "pregnancy" "rheumatic disease," and "connective tissue disease" was performed. Relevant articles found in the search and references were included. Reasonable evidence supports the careful and cautious use of topical steroids, topical calcineurin inhibitors, systemic corticosteroids, hydroxychloroquine, and azathioprine in pregnancy. Case reports or clinical experience suggest intravenous immunoglobulin, dapsone, phototherapy, rituximab, and plasmapheresis may be safe. Several treatment options exist for autoimmune skin disease in pregnancy and lactation, and should be considered when treating these patients. C1 [Braunstein, Inbal; Werth, Victoria] Univ Penn, Philadelphia Vet Affairs Med Ctr, Div Dermatol, Philadelphia, PA 19104 USA. [Braunstein, Inbal; Werth, Victoria] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Werth, V (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM, Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Merit Review Grant from the CDC; Department of Veterans Affairs Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development; National Institutes of Health [NIH K24-AR 02207] FX Grant support: Merit Review Grant from the CDC, Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (NIH K24-AR 02207) to Dr. Victoria P. Werth. NR 62 TC 13 Z9 13 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1396-0296 EI 1529-8019 J9 DERMATOL THER JI Dermatol. Ther. PD JUL PY 2013 VL 26 IS 4 SI SI BP 354 EP 363 DI 10.1111/dth.12076 PG 10 WC Dermatology SC Dermatology GA 195RA UT WOS:000322720100011 PM 23914893 ER PT J AU Martin, MG Lindberg, I Solorzano-Vargas, RS Wang, JF Avitzur, Y Bandsma, R Sokollik, C Lawrence, S Pickett, LA Chen, ZJ Egritas, O Dalgic, B Albornoz, V de Ridder, L Hulst, J Gok, F Aydogan, A Al-Hussaini, A Gok, DE Yourshaw, M Wu, SV Cortina, G Stanford, S Georgia, S AF Martin, Martin G. Lindberg, Iris Solorzano-Vargas, R. Sergio Wang, Jiafang Avitzur, Yaron Bandsma, Robert Sokollik, Christiane Lawrence, Sarah Pickett, Lindsay A. Chen, Zijun Egritas, Odul Dalgic, Buket Albornoz, Valeria de Ridder, Lissy Hulst, Jessie Gok, Faysal Aydogan, Aysen Al-Hussaini, Abdulrahman Gok, Deniz Engin Yourshaw, Michael Wu, S. Vincent Cortina, Galen Stanford, Sara Georgia, Senta TI Congenital Proprotein Convertase 1/3 Deficiency Causes Malabsorptive Diarrhea and Other Endocrinopathies in a Pediatric Cohort SO GASTROENTEROLOGY LA English DT Article DE Genetic; Congenital Diarrheal Disorder; Enteroendocrine Development; Neurogenin ID PROHORMONE CONVERTASES; OBESITY; PC1; MUTATIONS; HORMONE; GENE; MICE; HYPERPHAGIA; EXPRESSION; DEFECTS AB BACKGROUND & AIMS: Proprotein convertase 1/3 (PC1/3) deficiency, an autosomal-recessive disorder caused by rare mutations in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, has been associated with obesity, severe malabsorptive diarrhea, and certain endocrine abnormalities. Common variants in PCSK1 also have been associated with obesity in heterozygotes in several population-based studies. PC1/3 is an endoprotease that processes many prohormones expressed in endocrine and neuronal cells. We investigated clinical and molecular features of PC1/3 deficiency. METHODS: We studied the clinical features of 13 children with PC1/3 deficiency and performed sequence analysis of PCSK1. We measured enzymatic activity of recombinant PC1/3 proteins. RESULTS: We identified a pattern of endocrinopathies that develop in an age-dependent manner. Eight of the mutations had severe biochemical consequences in vitro. Neonates had severe malabsorptive diarrhea and failure to thrive, required prolonged parenteral nutrition support, and had high mortality. Additional endocrine abnormalities developed as the disease progressed, including diabetes insipidus, growth hormone deficiency, primary hypogonadism, adrenal insufficiency, and hypothyroidism. We identified growth hormone deficiency, central diabetes insipidus, and male hypogonadism as new features of PCSK1 insufficiency. Interestingly, despite early growth abnormalities, moderate obesity, associated with severe polyphagia, generally appears. CONCLUSIONS: In a study of 13 children with PC1/3 deficiency caused by disruption of PCSK1, failure of enteroendocrine cells to produce functional hormones resulted in generalized malabsorption. These findings indicate that PC1/3 is involved in the processing of one or more enteric hormones that are required for nutrient absorption. C1 [Martin, Martin G.; Solorzano-Vargas, R. Sergio; Wang, Jiafang; Chen, Zijun; Stanford, Sara] Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. [Yourshaw, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Cortina, Galen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Georgia, Senta] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lindberg, Iris; Pickett, Lindsay A.; Albornoz, Valeria] Univ Maryland, Dept Anat & Neurobiol, Baltimore, MD 21201 USA. [Avitzur, Yaron; Bandsma, Robert; Sokollik, Christiane] Univ Toronto, Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada. [Lawrence, Sarah] Childrens Hosp Eastern Ontario, Div Endocrinol & Metab, Ottawa, ON K1H 8L1, Canada. [Egritas, Odul; Dalgic, Buket] Gazi Univ, Sch Med, Dept Pediat Gastroenterol, Ankara, Turkey. [de Ridder, Lissy; Hulst, Jessie] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands. [Gok, Faysal] Gulhane Mil Med Acad, Sch Med, Dept Pediat Nephrol, Ankara, Turkey. [Gok, Deniz Engin] Gulhane Mil Med Acad, Sch Med, Dept Endocrinol, Ankara, Turkey. [Aydogan, Aysen] Kocaeli Univ, Dept Pediat Gastroenterol Hepatol & Nutr, Fac Med, Kocaeli, Turkey. [Al-Hussaini, Abdulrahman] King Fahad Med City, Childrens Hosp, Riyadh, Saudi Arabia. [Wu, S. Vincent] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Martin, MG (reprint author), Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. EM mmartin@mednet.ucla.edu RI Solorano, Sergio/D-4869-2016; Egritas Gurkan, Odul/O-1363-2016; Yourshaw, Michael/F-9807-2015 OI Egritas Gurkan, Odul/0000-0003-0230-7551; Yourshaw, Michael/0000-0001-7612-0437 FU National Institute of Diabetes and Digestive and Kidney Diseases [DK083762]; National Institute of Drug Abuse [DA05084]; California Institute of Regenerative Medicine (CIRM) [RT2-01985] FX This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK083762 to MGM) and the National Institute of Drug Abuse (DA05084 to IL); and the California Institute of Regenerative Medicine (CIRM), RT2-01985 to MGM. NR 28 TC 35 Z9 35 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUL PY 2013 VL 145 IS 1 BP 138 EP 148 DI 10.1053/j.gastro.2013.03.048 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 172ZR UT WOS:000321047300028 PM 23562752 ER PT J AU Lee, RJ Cohen, NA AF Lee, Robert J. Cohen, Noam A. TI The emerging role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID ANTIMICROBIAL ACTIVITY; CHRONIC SINUSITIS; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; INNATE IMMUNITY; NITRIC-OXIDE; BIOFILMS; DISEASE; SYSTEMS; POLYPS AB Background: Maintaining a clean upper respiratory tract requires efficient detection of pathogenic bacteria so that the airway mucosa can mount proper defenses to neutralize and clear the offending microbes. Bitter taste receptors (T2Rs) may play a critical role in this process. T2Rs were originally identified in taste cells of the tongue, where they protect against the ingestion of toxic plant and/or bacterial products. However, T2Rs are also expressed in extragustatory tissue including the airways. One specific T2R isoform, T2R38, was recently shown to be expressed in cilia of sinonasal epithelial cells, suggesting that respiratory cilia may function as a chemosensory organelle, possibly to detect bacterial presence in the airway. T2R38 is encoded by the TAS2R38 gene, which has several common genetic polymorphisms that result in altered receptor functionality. Genetic variation in T2R38 may thus contribute to individual differences in susceptibility to upper airway infection. This study provides an overview of our current knowledge of T2R38 function in sinonasal defense and the implications for patients with chronic rhinosinusitis (CRS). Methods: A literature review was performed of the current knowledge of the bitter taste receptor T2R38 in sinonasal physiology and CRS patient outcomes. Results: Basic science research has indicated that the T2R38 receptor is activated by acyl-homoserine lactone (AHL) molecules secreted by gram-negative bacteria, including Pseudomonas aeruginosa. In sinonasal epithelial cells T2R38 stimulates an increase in nitric oxide production that increases mucociliary clearance and directly kills bacteria. Recent clinical studies have also found clinical correlations of TAS2R38 genotype with susceptibility to gram-negative upper respiratory infection as well as necessity for surgical intervention in CRS management. Conclusion: T2R38 appears to be an important mediator of sinonasal epithelial defense, but further study is needed to more clearly determine how TAS2R38 genotype affects patient outcomes in CRS and other upper airway diseases. C1 [Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute [082478] FX NA Cohen's research in the laboratory was funded by a grant from the Flight Attendants Medical Research Institute (082478) and a philanthropic contribution from the RLG Foundation, Inc. The remaining author has no conflicts of interest to declare pertaining to this article NR 32 TC 21 Z9 21 U1 2 U2 24 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JUL-AUG PY 2013 VL 27 IS 4 BP 283 EP 286 DI 10.2500/ajra.2013.27.3911 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA 193HK UT WOS:000322549600013 PM 23883809 ER PT J AU Nguyen, HQ Fan, VS Herting, J Lee, J Fu, M Chen, ZJ Borson, S Kohen, R Matute-Bello, G Pagalilauan, G Adams, SG AF Nguyen, Huong Q. Fan, Vincent S. Herting, Jerald Lee, Jungeun Fu, Musetta Chen, Zijing Borson, Soo Kohen, Ruth Matute-Bello, Gustavo Pagalilauan, Genevieve Adams, Sandra G. TI Patients With COPD With Higher Levels of Anxiety Are More Physically Active SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; POPULATION-BASED COHORT; QUALITY-OF-LIFE; FUNCTIONAL STATUS; HEALTH OUTCOMES; DEPRESSION; DYSPNEA; REHABILITATION; MORTALITY; RISK AB Background: Physical activity (PA) has been found to be an excellent predictor of mortality beyond traditional measures in COPD. We aimed to determine the association between depression and anxiety with accelerometry-based PA in patients with COPD. Methods: We performed a cross-sectional analysis of baseline data from 148 stable patients with COPD enrolled in an ongoing, longitudinal, observational study. We measured PA (total daily step count) with a Stepwatch Activity Monitor over 7 days, depression and anxiety with the Hospital Anxiety and Depression Scales (HADSs), dyspnea with the Shortness of Breath Questionnaire, and functional capacity with the 6-min walk test. Results: Increased anxiety was associated with higher levels of PA such that for every one-point increase in the HADS-Anxiety score there was a corresponding increase of 288 step counts per day (beta = 288 steps, P < .001), after adjusting for all other variables. Higher levels of depressive symptoms were associated with lower PA (beta = -176 steps, P = .02) only when anxiety was in the model. The interaction term for anxiety and depression approached significance (beta = 26, P = .10), suggesting that higher levels of anxiety mitigate the negative effects of depression on PA. Conclusions: The increased PA associated with anxiety in COPD is, to our knowledge, a novel finding. However, it is unclear whether anxious patients with COPD are more restless, and use increased psychomotor activity as a coping mechanism, or whether those with COPD who push themselves to be more physically active experience more anxiety symptoms. Future studies should evaluate for anxiety and PA to better inform how to improve clinical outcomes. Trial Registry: Clinicaltrials.gov; No.: NCT01074515; URL: www.clinicaltrials.gov C1 [Nguyen, Huong Q.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Fan, Vincent S.; Herting, Jerald; Lee, Jungeun; Fu, Musetta; Chen, Zijing; Borson, Soo; Kohen, Ruth; Matute-Bello, Gustavo; Pagalilauan, Genevieve] Univ Washington, Seattle, WA 98195 USA. [Fan, Vincent S.] Puget Sound Vet Adm, Seattle, WA USA. [Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Adams, Sandra G.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Nguyen, HQ (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Los Robles, Pasadena, CA 91101 USA. EM huong.q2.nguyen@kp.org FU US National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [5R01HL093146]; NIH National Center for Research Resources [UL1RR025014]; Department of Veterans Affairs FX This work was supported in part by grants from the US National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [5R01HL093146] and the NIH National Center for Research Resources [UL1RR025014]. Dr Fan has funding through the Department of Veterans Affairs. NR 43 TC 12 Z9 12 U1 1 U2 12 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUL PY 2013 VL 144 IS 1 BP 145 EP 151 DI 10.1378/chest.12-1873 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 180OW UT WOS:000321605500024 PM 23370503 ER PT J AU Kangovi, S Barg, FK Carter, T Long, JA Shannon, R Grande, D AF Kangovi, Shreya Barg, Frances K. Carter, Tamala Long, Judith A. Shannon, Richard Grande, David TI Understanding Why Patients Of Low Socioeconomic Status Prefer Hospitals Over Ambulatory Care SO HEALTH AFFAIRS LA English DT Article ID MEDICAL-CARE; PREVENTABLE HOSPITALIZATIONS; EMERGENCY-DEPARTMENT; HEALTH-CARE; ACCESS; SATISFACTION; MORTALITY; EQUITY; TRENDS; IMPACT AB Patients with low socioeconomic status (SES) use more acute hospital care and less primary care than patients with high socioeconomic status. This low-value pattern of care use is harmful to these patients' health and costly to the health care system. Many current policy initiatives, such as the creation of accountable care organizations, aim to improve both health outcomes and the cost-effectiveness of health services. Achieving those goals requires understanding what drives low-value health care use. We conducted qualitative interviews with forty urban low-SES patients to explore why they prefer to use hospital care. They perceive it as less expensive, more accessible, and of higher quality than ambulatory care. Efforts that focus solely on improving the quality of hospital care to reduce readmissions could, paradoxically, increase hospital use. Two different profile types emerged from our research. Patients in Profile A (five or more acute care episodes in six months) reported social dysfunction and disability. Those in Profile B (fewer than five acute care episodes in six months) reported social stability but found accessing ambulatory care to be difficult. Interventions to improve outcomes and values need to take these differences into account. C1 [Kangovi, Shreya] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. [Kangovi, Shreya] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Barg, Frances K.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia Vet Affairs Ctr, Philadelphia, PA USA. [Shannon, Richard] Perelman Sch Med, Dept Med, Philadelphia, PA USA. [Grande, David] Perelman Sch Med, Philadelphia, PA USA. RP Kangovi, S (reprint author), Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. EM kangovi@upenn.edu FU Leonard Davis Institute of Health Economics at the University of Pennsylvania; HealthWell Foundation; National Human Genome Research Institute; Agency for Healthcare Research and Quality FX This study was supported by the Leonard Davis Institute of Health Economics at the University of Pennsylvania. David Grande has received honoraria from the Johns Hopkins University Continuing Medical Education Program; had a consultancy with the National Nursing Centers Consortium; and has received grant support from or has grants pending with the HealthWell Foundation, the National Human Genome Research Institute, and the Agency for Healthcare Research and Quality. Richard Shannon is the founder of a biotech company, Ventrigen; is a senior fellow at the Institute for Healthcare Improvement; and is on the scientific advisory boards for GlaxoSmithKline, Pfizer, Merck, and Value Capture. He also is a member of the board of directors of the American Board of Internal Medicine. The authors thank the Mixed Methods Research Laboratory at the University of Pennsylvania for its guidance and technical assistance with this study. NR 37 TC 59 Z9 59 U1 2 U2 31 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUL PY 2013 VL 32 IS 7 BP 1196 EP 1203 DI 10.1377/hlthaff.2012.0825 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 187IS UT WOS:000322111200004 PM 23836734 ER PT J AU Psotka, MA Teerlink, JR AF Psotka, Mitchell A. Teerlink, John R. TI Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure SO HEART FAILURE CLINICS LA English DT Article DE Hospitalized heart failure; Acute heart failure; Mortality; Readmission; Adverse events ID PRESERVED EJECTION FRACTION; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIALS; NATIONAL REGISTRY ADHERE; CARDIAC-RESYNCHRONIZATION THERAPY; OBSTRUCTIVE PULMONARY-DISEASE; LENGTH-OF-STAY; CLINICAL-OUTCOMES; MEDICARE BENEFICIARIES; VASOPRESSIN ANTAGONISM AB Hospitalizations for heart failure (HF) are increasing, and HF is the primary cause of readmission for all Medicare patients. Inpatient HF mortality is poor, but most morbidity and mortality occurs after hospital discharge. Readmissions attributable to HF persist or increase over time after discharge, and past HF admissions predict both readmission and mortality. The heightened risk of readmission dissipates slowly after discharge, suggesting that any intervention should be part of a lasting care package in the outpatient setting. Interventions that apply to multiple common medical comorbidities may be more likely to reduce overall adverse events. C1 [Psotka, Mitchell A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, 111C,Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. EM John.Teerlink@ucsf.edu FU Amgen; Corthera; Cytokinetics; Merck; Novartis; Takeda; Trevena FX J.R. Teerlink has received research grants or consulting fees from Amgen, Corthera, Cytokinetics, Merck, Novartis, Takeda, and Trevena. NR 167 TC 4 Z9 4 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7136 J9 HEART FAIL CLIN JI Heart Fail. Clin. PD JUL PY 2013 VL 9 IS 3 BP 303 EP + DI 10.1016/j.hfc.2013.04.005 PG 19 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 191NX UT WOS:000322421000007 PM 23809417 ER PT J AU Li, G Kiel, JW Cardenas, DP De La Garza, BH Duong, TQ AF Li, Guang Kiel, Jeffrey W. Cardenas, Damon P. De La Garza, Bryan H. Duong, Timothy Q. TI Postocclusive Reactive Hyperemia Occurs in the Rat Retinal Circulation but Not in the Choroid SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE BOLD; MRI; laser speckle imaging; laser Doppler flowmetry; retinal blood flow; choroidal blood flow; reactive hyperemia ID OPTIC-NERVE HEAD; OCULAR BLOOD-FLOW; FUNCTIONAL MRI; INDUCED DILATION; OXYGEN; PRESSURE; FLICKER; VASODILATATION; ARTERIOLES; MECHANISM AB PURPOSE. We tested the hypothesis that retinal blood flow has a postocclusive reactive hyperemia response modulated by occlusion duration and metabolic activity, and that choroidal blood flow does not. METHODS. Anesthetized and paralyzed rats (n = 34) were studied. Retinal and choroidal blood flow was measured by laser speckle imaging and laser Doppler flowmetry, respectively. Blood oxygenation level-dependent functional magnetic resonance imaging (BOLD fMRI) was used to measure changes in relative blood oxygenation of the retinal and choroidal circulations. Transient carotid occlusion was elicited with a hydraulic occluder on the common carotid artery. Several occlusion durations were tested during dark, constant light, and flicker light conditions to modulate metabolic demand. The hyperemia response magnitude was quantified by integrating the area above the blood flow baseline for the 3 minutes after release of the occlusion. RESULTS. Systemic arterial pressure (108.2 +/- 1.4 mm Hg) was unaffected by the carotid occlusions, and was similar among animals and conditions. Retinal blood flow had a reactive hyperemia, but choroidal blood flow did not (e.g., 14 +/- 2%.sec versus 0.5 +/- 4%.sec after 60-second occlusion). The hyperemia magnitude increased as a nonlinear function of occlusion duration and reached a plateau at occlusion durations <60 second. The hyperemia magnitude was not altered by different lighting conditions at occlusion durations of 15 and 60 seconds. BOLD fMRI results were similar to the laser-based blood flow measurements. CONCLUSIONS. The results indicate that metabolic local control has a negligible role in choroidal blood flow regulation and only partially accounts for the blood flow behavior in the retinal circulation. C1 [Li, Guang; Cardenas, Damon P.; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Li, Guang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Kiel, Jeffrey W.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kiel@uthscsa.edu; duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU NIH/NEI [R01 EY014211, EY018855, EY009702]; MERIT Award from the Department of Veterans Affairs; San Antonio Life Science Institute; CTSA [CTSA-8UL1TR000149]; AHA SWA Predoctoral Fellowship [AHA-13PRE14680087] FX Supported in part by the NIH/NEI (R01 EY014211, EY018855, and EY009702), MERIT Award from the Department of Veterans Affairs, and San Antonio Life Science Institute (TQD), and CTSA Pilot Project & Translational Technology (CTSA-8UL1TR000149) and AHA SWA 2012 Predoctoral Fellowship (AHA-13PRE14680087; GL). NR 41 TC 3 Z9 3 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUL PY 2013 VL 54 IS 7 BP 5123 EP 5131 DI 10.1167/iovs.13-12404 PG 9 WC Ophthalmology SC Ophthalmology GA 194MI UT WOS:000322637000089 PM 23821190 ER PT J AU Reid, JG Gitlin, MJ Altshuler, LL AF Reid, Jennifer G. Gitlin, Michael J. Altshuler, Lori L. TI Lamotrigine in Psychiatric Disorders SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Review ID TREATMENT-RESISTANT DEPRESSION; BIPOLAR-I-DISORDER; BORDERLINE PERSONALITY-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; LITHIUM MAINTENANCE TREATMENT; CONTROLLED CLINICAL-TRIALS; CONTROLLED 18-MONTH TRIAL; ADD-ON TREATMENT; DOUBLE-BLIND AB Objective: Owing to the prevalence of medication side effects and treatment resistance, prescribers often consider off-label uses of US Food and Drug Administration (FDA)-approved agents for the treatment of persistent symptoms. The authors review the available literature on the FDA-approved and non-FDA-approved uses of lamotrigine in adults with psychiatric disorders. Data Sources: We used PubMed, MEDLINE, and a hand search of relevant literature to find studies published between 1990 and 2012 and available in English language. The following keywords were searched: lamotrigine, psychiatric, mood disorders, depression, personality disorders, anxiety, schizophrenia, side effects, and rash. Study Selection: Data were selected from 29 randomized controlled trials (RCTs). When RCTs were not available, open-label trials (6), retrospective case reviews (10), and case series (4) were summarized. Data Extraction: We extracted results of monotherapy and augmentation trials of lamotrigine on primary and secondary outcome measures. Results: Lamotrigine is generally well tolerated, with the best evidence for the maintenance treatment of bipolar disorder, particularly in prevention of depressive episodes. In acute bipolar depression, meta-analyses suggested a modest benefit, especially for more severely depressed subjects, with switch rates similar to placebo. In unipolar depression, double-blind RCTs noted benefit on subsets of symptoms and improved response in more severely depressed subjects. Data are limited but promising in borderline personality disorder. Use of lamotrigine in schizophrenia and anxiety disorders has little supportive evidence. Conclusions: Lamotrigine is recommended in bipolar maintenance when depression is prominent. It also has a role in treating acute bipolar depression and unipolar depression, though the latter warrants more research. Data are too limited in other psychiatric disorders to recommend its use at this time. (C) Copyright 2013 Physicians Postgraduate Press, Inc. C1 [Reid, Jennifer G.; Gitlin, Michael J.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] VA Greater Angeles Healthcare Syst, West Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. RP Gitlin, MJ (reprint author), 300 UCLA Med Plaza,Ste 2347, Los Angeles, CA 90095 USA. EM mgitlin@mednet.ucla.edu FU Carl and Roberta Deutsch Foundation; UCLA Mood Disorders Fellowship at the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA FX Funding for this review was provided by the Carl and Roberta Deutsch Foundation, through their support of the UCLA Mood Disorders Fellowship at the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA. NR 62 TC 27 Z9 27 U1 1 U2 19 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUL PY 2013 VL 74 IS 7 BP 675 EP 684 DI 10.4088/JCP.12r08046 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 193ML UT WOS:000322563800002 PM 23945444 ER PT J AU Wollstein, R Wollstein, A Rodgers, J Ogden, TJ AF Wollstein, Ronit Wollstein, Adi Rodgers, John Ogden, Thomas J. TI A hand therapy protocol for the treatment of lunate overload or early Kienbock's disease SO JOURNAL OF HAND THERAPY LA English DT Article DE Early Kienbock's disease; Therapy protocol; Lunate; Overload ID WRIST; BONE; MORPHOLOGY; ULTRASOUND; NECROSIS; MOTION AB We describe a hand therapy protocol aimed at unloading the wrist and increasing blood supply to the wrist, specifically to the lunate. The protocol was used in a series of patients with clinical radial wrist pain, dysfunction and changes on wrist imaging studies. The patients were not candidates for surgical treatment. Application of the therapy protocol improved objective and subjective parameters such as pain and motion, and may provide a viable treatment option for patients with lunate overload or early Kienbock's disease that are not candidates for surgery. (c) 2013 Hanley & Belfus, an imprint of Elsevier Inc. All rights reserved. C1 [Wollstein, Ronit; Wollstein, Adi] Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA USA. [Wollstein, Ronit; Wollstein, Adi] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA. [Rodgers, John] UPMC Ctr Rehab Serv, Pittsburgh, PA USA. [Ogden, Thomas J.] VA Pittsburgh Healthcare Syst, Occupat Therapy Serv, Pittsburgh, PA USA. RP Wollstein, R (reprint author), 3550 Terrace St,Scaife Hall,Suite 6B, Pittsburgh, PA 15261 USA. EM wollsteinr@upmc.edu NR 38 TC 3 Z9 3 U1 0 U2 2 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0894-1130 J9 J HAND THER JI J. Hand Ther. PD JUL-SEP PY 2013 VL 26 IS 3 BP 255 EP 260 DI 10.1016/j.jht.2012.12.004 PG 6 WC Orthopedics; Rehabilitation; Surgery SC Orthopedics; Rehabilitation; Surgery GA 192QE UT WOS:000322499500010 PM 23465629 ER PT J AU Luo, YX Kaz, AM Kanngurn, S Welsch, P Morris, SM Wang, JP Lutterbaugh, JD Markowitz, SD Grady, WM AF Luo, Yanxin Kaz, Andrew M. Kanngurn, Samornmas Welsch, Piri Morris, Shelli M. Wang, Jianping Lutterbaugh, James D. Markowitz, Sanford D. Grady, William M. TI NTRK3 Is a Potential Tumor Suppressor Gene Commonly Inactivated by Epigenetic Mechanisms in Colorectal Cancer SO PLOS GENETICS LA English DT Article ID SIGNAL-TRANSDUCTION; ESOPHAGEAL ADENOCARCINOMA; BARRETTS-ESOPHAGUS; TRKC; EXPRESSION; DNA; RECEPTORS; GROWTH; CARCINOMA; APOPTOSIS AB NTRK3 is a member of the neurotrophin receptor family and regulates cell survival. It appears to be a dependence receptor, and thus has the potential to act as an oncogene or as a tumor suppressor gene. NTRK3 is a receptor for NT-3 and when bound to NT-3 it induces cell survival, but when NT-3 free, it induces apoptosis. We identified aberrantly methylated NTRK3 in colorectal cancers through a genome-wide screen for hypermethylated genes. This discovery led us to assess whether NTRK3 could be a tumor suppressor gene in the colon. NTRK3 is methylated in 60% of colon adenomas and 67% of colon adenocarcinomas. NTRK3 methylation suppresses NTRK3 expression. Reconstitution of NTRK3 induces apoptosis in colorectal cancers, if NT-3 is absent. Furthermore, the loss of NTRK3 expression associates with neoplastic transformation in vitro and in vivo. We also found that a naturally occurring mutant NTRK3 found in human colorectal cancer inhibits the tumor suppressor activity of NTRK3. In summary, our findings suggest NTRK3 is a conditional tumor suppressor gene that is commonly inactivated in colorectal cancer by both epigenetic and genetic mechanisms whose function in the pathogenesis of colorectal cancer depends on the expression status of its ligand, NT-3. C1 [Luo, Yanxin; Wang, Jianping] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China. [Luo, Yanxin; Kaz, Andrew M.; Morris, Shelli M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kanngurn, Samornmas] Prince Songkla Univ, Fac Med, Tumor Biol Res Unit, Hat Yai, Songkhla, Thailand. [Kanngurn, Samornmas] Prince Songkla Univ, Fac Med, Dept Pathol, Hat Yai, Songkhla, Thailand. [Welsch, Piri] Univ Washington, Sch Med, Div Med Genet, Seattle, WA USA. [Lutterbaugh, James D.; Markowitz, Sanford D.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA. [Lutterbaugh, James D.; Markowitz, Sanford D.] Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA. [Lutterbaugh, James D.; Markowitz, Sanford D.] Case Med Ctr, Cleveland, OH USA. RP Luo, YX (reprint author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China. EM wgrady@fhcrc.org FU NIH [RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, P01CA077852]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist; Programme of Introducing Talents of Discipline to Universities of China [B12003]; International Science & Technology Cooperation Program of China [2011DFA32570]; [5P50CA150964] FX Support for these studies was provided by the NIH (RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, and P01CA077852, WMG), a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG) (URL: www.bwfund.org), Programme of Introducing Talents of Discipline to Universities of China (B12003, JW) and International Science & Technology Cooperation Program of China (2011DFA32570, JW); and 5P50CA150964 (to SDM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 19 Z9 19 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD JUL PY 2013 VL 9 IS 7 AR e1003552 DI 10.1371/journal.pgen.1003552 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA 190EG UT WOS:000322321100001 PM 23874207 ER PT J AU Meis, LA Schaaf, KW Erbes, CR Polusny, MA Miron, LR Schmitz, TM Nugent, SM AF Meis, Laura A. Schaaf, Kathryn Wilder Erbes, Christopher R. Polusny, Melissa A. Miron, Lynsey R. Schmitz, Theresa M. Nugent, Sean M. TI Interest in Partner-Involved Services Among Veterans Seeking Mental Health Care From a VA PTSD Clinic SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE PTSD; couples; veterans; treatment preferences ID POSTTRAUMATIC-STRESS-DISORDER; TREATMENT PREFERENCES; FAMILY; ADJUSTMENT; SYMPTOMS; COUPLES; INTERVENTION; SATISFACTION; PREDICTORS; ENGAGEMENT AB Associations between PTSD and difficulties in intimate relationships have prompted national calls for partner-involvement in treatment for PTSD. However, research is limited evaluating patient preferences for the format of these services or predictors of these preferences. Such information is vital to shaping services so they are relevant to those most interested in them and to those with greatest need. To address these gaps, we surveyed 185 coupled veterans as they presented for mental health appointments at a VA PTSD treatment clinic. We assessed broad interest in greater partner-involvement, specific interest in couple therapy, and potential predictors of these interests, including family concerns, relationship satisfaction, PTSD symptom severity, and combat era. We found unique positive associations between interest in partner-involvement and both family concerns and relationship satisfaction, suggesting those most interested in partner-involvement are likely those experiencing the greatest family concerns and the most satisfied in their intimate relationships. Associations between interest and PTSD severity were nonsignificant. Interest in couple therapy was significantly greater among returning veterans than Vietnam/Korean War Veterans. However, these two groups did not vary significantly in their interest in greater partner-involvement more broadly. Discussion of findings considers the roles of both insight into PTSD-related family problems and relationship satisfaction in motivating interest in partner-involvement in care, the potential need to address motivation for partner-involvement among veterans in distressed relationships, and the importance of alternative methods of partner-involvement to full courses of couple therapy, particularly for Vietnam/Korean War era veterans. C1 [Meis, Laura A.; Polusny, Melissa A.; Nugent, Sean M.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. [Meis, Laura A.; Nugent, Sean M.] Univ Minnesota, Dept Med, Sch Med, Minneapolis, MN 55455 USA. [Schaaf, Kathryn Wilder; Erbes, Christopher R.; Miron, Lynsey R.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA. [Schaaf, Kathryn Wilder] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [Erbes, Christopher R.; Polusny, Melissa A.] Univ Minnesota, Dept Psychiat, Sch Med, Minneapolis, MN 55455 USA. [Schmitz, Theresa M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Schmitz, Theresa M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Meis, LA (reprint author), Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, 1 Vet Dr 152, Minneapolis, MN 55417 USA. EM laura.meis@va.gov OI Polusny, Melissa/0000-0002-4932-305X NR 39 TC 7 Z9 7 U1 1 U2 12 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD JUL PY 2013 VL 5 IS 4 BP 334 EP 342 DI 10.1037/a0028366 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 189RT UT WOS:000322286700005 ER PT J AU Restrepo, MI Peterson, J Fernandez, JF Qin, ZH Fisher, AC Nicholson, SC AF Restrepo, Marcos I. Peterson, Janet Fernandez, Juan F. Qin, Zhihai Fisher, Alan C. Nicholson, Susan C. TI Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies SO RESPIRATORY CARE LA English DT Article DE ventilator-associated pneumonia; ICU; outcome and process assessment; critical care; microbiology; early onset; late onset; mechanical ventilation ID INADEQUATE ANTIMICROBIAL TREATMENT; INTENSIVE-CARE-UNIT; LARGE US DATABASE; NOSOCOMIAL PNEUMONIA; EPIDEMIOLOGY; OUTCOMES; SAFETY; MULTICENTER; INFECTIONS; MORTALITY AB BACKGROUND: Ventilator-associated pneumonia (YAP) is classified as early-onset or late-onset, in part, to identify subjects at risk for infection with resistant pathogens. We assessed differences in the bacterial etiology of early-onset versus late-onset YAP. METHODS: Subjects enrolled in 2004-2006 in 2 clinical studies of doripenem versus imipenem or piperacillin/tazobactam, with a diagnosis of VAP (n = 500) were included in the analysis. Subjects were classified by ventilator status: early-onset YAP (< 5 d of ventilation) or late-onset VAP (>= 5 d of ventilation). Baseline demographics and bacterial etiology were analyzed by YAP status. RESULTS: Late-onset YAP subjects had higher Acute Physiology and Chronic Health Evaluation (APACHE II) scores (mean 16.6 versus 15.5, P = .008). There were no significant differences in Clinical Pulmonary Infection Score, sex, age, or presence of bacteremia between the groups. A total of 496 subjects had a baseline pathogen, and 50% of subjects in each group had >= 2 pathogens. With the exception of Staphylococcus aureus, which was common in early-onset YAP, the pathogens (including potentially multidrug-resistant (MDR) pathogens) isolated from early-onset versus late-onset YAP were not significantly different between groups. Acinetobacter baumannii or Pseudomonas aeruginosa with decreased susceptibility to any study drug was observed in early-onset and late-onset YAP subjects. CONCLUSIONS: There were no significant differences in the prevalence of potential MDR pathogens associated with early-onset or late-onset YAP, even in subjects with prior antibiotics. Empiric therapy for early-onset YAP should also include agents likely to be effective for potential MDR pathogens. Further prospective studies should evaluate microbiology trends in subjects with YAP. C1 [Restrepo, Marcos I.; Fernandez, Juan F.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care, San Antonio, TX 78229 USA. [Peterson, Janet; Qin, Zhihai; Fisher, Alan C.; Nicholson, Susan C.] Johnson & Johnson Pharmaceut, Janssen Sci Affairs, Raritan, NJ USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, Audie Murphy Div L, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, 11C6,ALMD 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 FU National Heart, Lung, and Blood Institute of the National Institutes of Health [K23HL096054] FX Dr Restrepo was partly supported by grant K23HL096054 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; the Department of Veterans Affairs; nor the University of Texas Health Science Center at San Antonio. NR 24 TC 26 Z9 26 U1 0 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD JUL PY 2013 VL 58 IS 7 BP 1220 EP 1225 DI 10.4187/respcare.02173 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 185BF UT WOS:000321939500013 PM 23307825 ER PT J AU Wenger, A Wirth, W Hudelmaier, M Noebauer-Huhmann, I Trattnig, S Bloecker, K Frobell, RB Kwoh, CK Eckstein, F Englund, M AF Wenger, Andrea Wirth, Wolfgang Hudelmaier, Martin Noebauer-Huhmann, Iris Trattnig, Siegfried Bloecker, Katja Frobell, Richard B. Kwoh, C. Kent Eckstein, Felix Englund, Martin TI Meniscus Body Position, Size, and Shape in Persons With and Persons Without Radiographic Knee Osteoarthritis: Quantitative Analyses of Knee Magnetic Resonance Images From the Osteoarthritis Initiative SO ARTHRITIS AND RHEUMATISM LA English DT Article ID ARTICULAR-CARTILAGE; ELDERLY PERSONS; FOLLOW-UP; JOINT; MRI; PATHOLOGY; LESIONS; TEARS; ASSOCIATION; SURGERY AB ObjectiveTo quantitatively evaluate the position, size, and shape of the menisci in subjects with radiographic knee osteoarthritis (OA) compared to subjects without OA, using magnetic resonance imaging (MRI). MethodsWe studied the right knees of 39 Osteoarthritis Initiative participants (24 women and 15 men with a mean age of 59.6 +/- 8.7 years) with medial compartment radiographic tibiofemoral OA (Kellgren/Lawrence grade of 2 or 3). Subjects were matched individually for age, sex, and height to controls without knee OA and without risk factors for knee OA. The right knees of the controls were used as references. One observer performed manual segmentation of the tibial plateau and the medial and lateral meniscus based on a coronally reconstructed double-echo steady-state sequence with water excitation, focusing on 5 central 3T MRIs. ResultsIn OA knees, there was less meniscal coverage of the medial tibial plateau (435 mm(2) versus 515 mm(2); P = 0.0004), the medial meniscus body showed more extrusion (2.64 mm versus 0.53 mm; P < 0.0001), and the peripheral margin had a more convex shape, i.e., bulged more (mean 0.61 mm versus 0.27 mm; P < 0.0001). The thickness or volume of the medial meniscus body of OA knees did not differ substantially from reference knees. In contrast, in OA knees the lateral meniscus body had a larger volume (mean 266 mm(3) versus 224 mm(3); P = 0.0005) and extruded more (mean 1.16 mm versus -1.01 mm; P < 0.0001), and the external margin bulged more (mean 0.53 mm versus 0.35 mm; P < 0.0001), than in reference knees. ConclusionOur findings indicate altered meniscal position and shape (i.e., more bulging) in both compartments in medial compartment knee OA. These changes may be important features of OA pathogenesis and/or disease consequences. C1 [Wenger, Andrea; Wirth, Wolfgang; Hudelmaier, Martin; Bloecker, Katja; Frobell, Richard B.; Eckstein, Felix] Paracelsus Med Univ, A-5020 Salzburg, Austria. [Wirth, Wolfgang; Hudelmaier, Martin] Chondrometrics GmbH, Ainring, Germany. [Noebauer-Huhmann, Iris; Trattnig, Siegfried] Med Univ Vienna, Vienna, Austria. [Frobell, Richard B.; Englund, Martin] Lund Univ, Lund, Sweden. [Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Englund, Martin] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Wenger, A (reprint author), Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. EM andrea.wenger@pmu.ac.at RI Wirth, Wolfgang/C-8724-2011 OI Wirth, Wolfgang/0000-0002-2297-8283; Englund, Martin/0000-0003-3320-2437 FU Swedish Research Council; Kock Foundation; King Gustaf V's 80-Year Foundation; Lund University Faculty of Medicine; Royal Physiographic Society in Lund; Osteoarthritis Initiative (OAI); NIH [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; GlaxoSmithKline; Paracelsus Medical University Research Fund [R-10-05-021-HUD]; Merck Serono; Perceptive Imaging; Pfizer; Abbott; BioClinica; Medtronic; Sanofi; Novartis FX Dr. Englund's work was supported by the Swedish Research Council, the Kock Foundation, King Gustaf V's 80-Year Foundation, the Lund University Faculty of Medicine, and the Royal Physiographic Society in Lund. The study and image acquisition were supported by the Osteoarthritis Initiative (OAI). The OAI is a public-private partnership comprising 5 NIH contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) and conducted by the OAI Study Investigators. Private funding partners include Pfizer Inc., Novartis Pharmaceuticals Corporation, Merck Research Laboratories, and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This article has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation. The image analysis was supported by the Paracelsus Medical University Research Fund (grant R-10-05-021-HUD).; Dr. Wirth has received consulting fees from Merck Serono (less than $10,000) and is co-owner of Chondrometrics GmbH. Dr. Hudelmaier has received consulting fees from Perceptive Imaging (less than $10,000) and has a part-time appointment with Chondrometrics GmbH. Dr. Kwoh has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000). Dr. Eckstein has received consulting fees, speaking fees, and/or honoraria from Abbott, BioClinica, Perceptive Imaging, and Medtronic (less than $10,000 each) and from Merck Serono, Sanofi, and Novartis (more than $10,000 each), and he is co-owner and chief executive officer of Chondrometrics GmbH. NR 42 TC 23 Z9 23 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD JUL PY 2013 VL 65 IS 7 BP 1804 EP 1811 DI 10.1002/art.37947 PG 8 WC Rheumatology SC Rheumatology GA 187XM UT WOS:000322155000016 PM 23529645 ER PT J AU Bastian, LA Bosworth, HB Washington, DL Yano, EM AF Bastian, Lori A. Bosworth, Hayden B. Washington, Donna L. Yano, Elizabeth M. TI Setting the Stage: Research to Inform Interventions, Practice and Policy to Improve Women Veterans' Health and Health Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, VA Connecticut Healthcare Syst, Newington, CT 06011 USA. [Bosworth, Hayden B.] Duke Univ, Durham VA Med Ctr, Durham, NC USA. [Washington, Donna L.] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bastian, LA (reprint author), Univ Connecticut, Ctr Hlth, VA Connecticut Healthcare Syst, 555 Willard Ave, Newington, CT 06011 USA. EM Lori.bastian@va.gov FU HSRD VA [SDR 10-012] NR 17 TC 6 Z9 6 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S491 EP S494 DI 10.1007/s11606-013-2470-9 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900001 PM 23807053 ER PT J AU Cordasco, KM Zephyrin, LC Kessler, CS Mallard, M Canelo, I Rubenstein, LV Yano, EM AF Cordasco, Kristina M. Zephyrin, Laurie C. Kessler, Chad S. Mallard, Meri Canelo, Ismelda Rubenstein, Lisa V. Yano, Elizabeth M. TI An Inventory of VHA Emergency Departments' Resources and Processes for Caring for Women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE veterans' health; women's health; emergency medicine; organization of care ID SEXUAL ASSAULT; VETERANS AB BACKGROUND: More women are using Veterans' Health Administration (VHA) Emergency Departments (EDs), yet VHA ED capacities to meet the needs of women are unknown. OBJECTIVE: We assessed VHA ED resources and processes for conditions specific to, or more common in, women Veterans. DESIGN/SUBJECTS: Cross-sectional questionnaire of the census of VHA ED directors MAIN MEASURES: Resources and processes in place for gynecologic, obstetric, sexual assault and mental health care, as well as patient privacy features, stratified by ED characteristics. KEY RESULTS: All 120 VHA EDs completed the questionnaire. Approximately nine out of ten EDs reported having gynecologic examination tables within their EDs, 24/7 access to specula, and Gonorrhea/Chlamydia DNA probes. All EDs reported 24/7 access to pregnancy testing. Fewer than two-fifths of EDs reported having radiologist review of pelvic ultrasound images available 24/7; one-third reported having emergent consultations from gynecologists available 24/7. Written transfer policies specific to gynecologic and obstetric emergencies were reported as available in fewer than half of EDs. Most EDs reported having emergency contraception 24/7; however, only approximately half reported having Rho(D) Immunoglobulin available 24/7. Templated triage notes and standing orders relevant to gynecologic conditions were reported as uncommon. Consistent with VHA policy, most EDs reported obtaining care for victims of sexual assault by transferring them to another institution. Most EDs reported having some access to private medical and mental health rooms. Resources and processes were found to be more available in EDs with more encounters by women, more ED staffed beds, and that were located in more complex facilities in metropolitan areas. CONCLUSIONS: Although most VHA EDs have resources and processes needed for delivering emergency care to women Veterans, some gaps exist. Studies in non-VA EDs are required for comparison. Creative solutions are needed to ensure that women presenting to VHA EDs receive efficient, timely, and consistently high-quality care. (C) Society of General Internal Medicine 2013 C1 [Cordasco, Kristina M.; Canelo, Ismelda; Rubenstein, Lisa V.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D Ctr Excellence Study, Los Angeles, CA 90073 USA. [Cordasco, Kristina M.; Rubenstein, Lisa V.; Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Cordasco, Kristina M.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA. [Zephyrin, Laurie C.; Mallard, Meri] Vet Hlth Adm, Off Patient Care Serv, Womens Hlth Serv, Washington, DC USA. [Zephyrin, Laurie C.] VA New York Harbor Healthcare Syst, New York, NY USA. [Kessler, Chad S.] Durham VA Med Ctr, Durham, NC USA. [Kessler, Chad S.] Duke Univ, Sch Med, Durham, NC USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. RP Cordasco, KM (reprint author), VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D Ctr Excellence Study, 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM Kristina.Cordasco@va.gov FU VHA Office of Women's Health Services [XVA 65-027]; VA Women's Health Research Consortium [SDR 10-012]; VA HSR&D Research Career Scientist Award (RCS) [05-195] FX This project was funded by the VHA Office of Women's Health Services (Project # XVA 65-027), with in-kind support from the VA Women's Health Research Consortium (Project # SDR 10-012). Dr. Yano's effort was covered by a VA HSR&D Research Career Scientist Award (RCS #05-195). NR 14 TC 7 Z9 7 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S583 EP S590 DI 10.1007/s11606-012-2327-7 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900017 PM 23807069 ER PT J AU Hamilton, AB Frayne, SM Cordasco, KM Washington, DL AF Hamilton, Alison B. Frayne, Susan M. Cordasco, Kristina M. Washington, Donna L. TI Factors Related to Attrition from VA Healthcare Use: Findings from the National Survey of Women Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Veterans; women's health; access to care; attrition ID MILITARY SEXUAL TRAUMA; PATIENT SATISFACTION; MEDICAL-CARE; CONTINUITY; SERVICES; PERCEPTIONS; POPULATION; PROVIDER; QUALITY; AFFAIRS AB BACKGROUND: While prior research characterizes women Veterans' barriers to accessing and using Veterans Health Administration (VA) care, there has been little attention to women who access VA and use services, but then discontinue use. Recent data suggest that among women Veterans, there is a 30 % attrition rate within 3 years of initial VA use. OBJECTIVES: To compare individual characteristics and perceptions about VA care between women Veteran VA attriters (those who discontinue use) and non-attriters (those who continue use), and to compare recent versus remote attriters. DESIGN: Cross-sectional, population-based 20082009 national telephone survey. PARTICIPANTS: Six hundred twenty-six attriters and 2,065 non-attriters who responded to the National Survey of Women Veterans. MAIN MEASURES: Population weighted demographic, military and health characteristics; perceptions about VA healthcare; length of time since last VA use; among attriters, reasons for no longer using VA care. KEY RESULTS: Fifty-four percent of the weighted VA ever user population reported that they no longer use VA. Forty-five percent of attrition was within the past ten years. Attriters had better overall health (p=0.007), higher income (p<0.001), and were more likely to have health insurance (p<0.001) compared with non-attriters. Attriters had less positive perceptions of VA than non-attriters, with attriters having lower ratings of VA quality and of gender-specific features of VA care (p<0.001). Women Veterans who discontinued VA use since 2001 did not differ from those with more remote VA use on most measures of VA perceptions. Overall, among attriters, distance to VA sites of care and having alternate insurance coverage were the most common reasons for discontinuing VA use. CONCLUSIONS: We found high VA attrition despite recent advances in VA care for women Veterans. Women's attrition from VA could reduce the critical mass of women Veterans in VA and affect current system-wide efforts to provide high-quality care for women Veterans. An understanding of reasons for attrition can inform organizational efforts to re-engage women who have attrited, to retain current users, and potentially to attract new VA patients. (C) Society of General Internal Medicine 2013 C1 [Hamilton, Alison B.; Cordasco, Kristina M.; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Frayne, Susan M.] VA Palo Alto Healthcare Syst, VA HSR&D Ctr Excellence, Palo Alto, CA USA. [Frayne, Susan M.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Cordasco, Kristina M.] RAND Corp, Santa Monica, CA USA. [Cordasco, Kristina M.; Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Hamilton, AB (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSRD Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. EM alison.hamilton@va.gov FU Department of Veterans Affairs (VA), Women's Health Services within the Office of Patient Care Services; VA Health Services Research and Development (HSRD) Service [SDR-08-270] FX This study was funded by the Department of Veterans Affairs (VA), Women's Health Services within the Office of Patient Care Services, and the VA Health Services Research and Development (HSR&D) Service (SDR-08-270). NR 34 TC 15 Z9 15 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S510 EP S516 DI 10.1007/s11606-013-2347-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900006 PM 23807058 ER PT J AU Katon, J Reiber, G Rose, D Bean-Mayberry, B Zephyrin, L Washington, DL Yano, EM AF Katon, Jodie Reiber, Gayle Rose, Danielle Bean-Mayberry, Bevanne Zephyrin, Laurie Washington, Donna L. Yano, Elizabeth M. TI VA Location and Structural Factors Associated with On-Site Availability of Reproductive Health Services SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women veterans; reproductive health; reproductive health services; Department of Veterans Affairs ID OF-VETERANS-AFFAIRS; PRIMARY-CARE; WOMEN VETERANS; OUTPATIENT CLINICS; MEDICAL-CENTER AB INTRODUCTION: With the increasing number of women Veterans enrolling in the Veterans Health Administration (VA), there is growing demand for reproductive health services. Little is known regarding the on-site availability of reproductive health services at VA and how this varies by site location and type. OBJECTIVE: To describe the on-site availability of hormonal contraception, intrauterine device (IUD) placement, infertility evaluation or treatment, and prenatal care by site location and type; the characteristics of sites providing these services; and to determine whether, within this context, site location and type is associated with on-site availability of these reproductive health services. METHODS: We used data from the 2007 Veterans Health Administration Survey of Women Veterans Health Programs and Practices, a national census of VA sites serving 300 or more women Veterans assessing practice structure and provision of care for women. Hierarchical models were used to test whether site location and type (metropolitan hospital-based clinic, non-metropolitan hospital-based clinic, metropolitan community-based outpatient clinic [CBOC]) were associated with availability of IUD placement and infertility evaluation/treatment. Non-metropolitan CBOCs were excluded from this analysis (n=2). RESULTS: Of 193 sites, 182 (94 %) offered on-site hormonal contraception, 97 (50 %) offered on-site IUD placement, 57 (30 %) offered on-site infertility evaluation/treatment, and 11 (6 %) offered on-site prenatal care. After adjustment, compared with metropolitan hospital based-clinics, metropolitan CBOCs were less likely to offer on-site IUD placement (OR 0.33; 95 % CI 0.14, 0.74). CONCLUSION: Compared with metropolitan hospital-based clinics, metropolitan CBOCs offer fewer specialized reproductive health services on-site. Additional research is needed regarding delivery of specialized reproductive health care services for women Veterans in CBOCs and clinics in non-metropolitan areas. (C) Society of General Internal Medicine 2012 C1 [Katon, Jodie; Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Katon, Jodie; Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98108 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98108 USA. [Rose, Danielle; Bean-Mayberry, Bevanne; Washington, Donna L.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Provider Be, Los Angeles, CA USA. [Bean-Mayberry, Bevanne; Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Zephyrin, Laurie] VA Cent Off, Off Patient Serv, Women Vet Hlth Serv, Washington, DC USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. RP Katon, J (reprint author), Univ Washington, Sch Publ Hlth, Dept Vet Affairs VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM jkaton@u.washington.edu FU U.S. Department of Veteran Affairs, Office of Research and Development, Health Services Research and Development [IIR 04-036]; WHR Consortium [10-012]; Office of Academic Affiliations [TPP 61-026]; VA HSR&D Senior Career Scientist Award [RCS 98-353]; VA HSR&D Career Scientist Award [RCS 05-195] FX This material is based on work supported by the U.S. Department of Veteran Affairs, Office of Research and Development, Health Services Research and Development (grant IIR 04-036) and the WHR Consortium (Project SDR# 10-012), an Office of Academic Affiliations' Associated Health Postdoctoral Fellowship to Dr. Katon (#TPP 61-026), a VA HSR&D Senior Career Scientist Award to Dr. Reiber (grant RCS 98-353) and a VA HSR&D Career Scientist Award to Dr. Yano (grant RCS 05-195). The authors would like to thank Ismelda Canelo for her work managing the data. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 19 TC 9 Z9 9 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S591 EP S597 DI 10.1007/s11606-012-2289-9 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900018 PM 23807070 ER PT J AU Lehavot, K Simpson, TL AF Lehavot, Keren Simpson, Tracy L. TI Incorporating Lesbian and Bisexual Women into Women Veterans' Health Priorities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women veterans; lesbian and bisexual women; sexual minority veterans ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ORIENTATION DISCLOSURE; NATIONAL COMORBIDITY SURVEY; POPULATION-BASED SURVEY; HETEROSEXUAL WOMEN; FEMALE VETERANS; MENTAL-HEALTH; PROBABILITY SAMPLE; MINORITY ADULTS; CIVILIAN WOMEN AB Relative to the general population, lesbian and bisexual (LB) women are overrepresented in the military and are significantly more likely to have a history of military service compared to all adult women. Due to institutional policies and stigma associated with a gay or lesbian identity, very little empirical research has been done on this group of women veterans. Available data suggest that compared to heterosexual women veterans, LB women veterans are likely to experience heightened levels of prejudice and discrimination, victimization, including greater incidence of rape, as well as adverse health and substance use disorders. They are also likely to encounter a host of unique issues when accessing health care, including fears of insensitive care and difficulty disclosing sexual orientation to Veterans Health Administration (VHA) providers. Training of staff and providers, education efforts, outreach activities, and research on this subpopulation are critical to ensure equitable and high quality service delivery. C1 [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,116 POC, Seattle, WA 98108 USA. EM klehavot@uw.edu FU Department of Veterans Affairs Office of Academic Affiliations; Advanced Fellowship Program in Mental Illness Research and Treatment; VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, and the VA Puget Sound Health Care System, Seattle, Washington. The views expressed in this article are those of the authors and do not represent the views of the Department of Veterans Affairs or the United States government. NR 68 TC 11 Z9 11 U1 3 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S609 EP S614 DI 10.1007/s11606-012-2291-2 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900021 PM 23807073 ER PT J AU Maguen, S Madden, E Cohen, B Bertenthal, D Neylan, T Talbot, L Grunfeld, C Seal, K AF Maguen, Shira Madden, Erin Cohen, Beth Bertenthal, Daniel Neylan, Thomas Talbot, Lisa Grunfeld, Carl Seal, Karen TI The Relationship between Body Mass Index and Mental Health Among Iraq and Afghanistan Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women's health; veteran; mental health; obesity ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY VETERANS; WOMEN VETERANS; OBESITY; DIAGNOSES; RISK; CARE; OVERWEIGHT; SAMPLE; BMI AB BACKGROUND: Obesity is a growing public health concern and is becoming an epidemic among veterans in the post-deployment period. OBJECTIVE: To explore the relationship between body mass index (BMI) and posttraumatic stress disorder (PTSD) in a large cohort of Iraq and Afghanistan veterans, and to evaluate trajectories of change in BMI over 3 years. DESIGN: Retrospective, longitudinal cohort analysis of veterans' health records PARTICIPANTS: A total of 496,722 veterans (59,790 female and 436,932 male veterans) whose height and weight were recorded at the Department of Veterans Affairs (VA) healthcare system at least once after the end of their last deployment and whose first post-deployment outpatient encounter at the VA was at least 1 year prior to the end of the study period (December 31, 2011). MAIN MEASURES: BMI, mental health diagnoses. KEY RESULTS: Seventy-five percent of Iraq and Afghanistan veterans were either overweight or obese at baseline. Four trajectories were observed: "stable overweight" represented the largest class; followed by "stable obese;" "overweight/obese gaining;" and "obese losing." During the 3-year ascertainment period, those with PTSD and depression in particular were at the greatest risk of being either obese without weight loss or overweight or obese and continuing to gain weight. Adjustment for demographics and antipsychotic medication attenuated the relationship between BMI and certain mental health diagnoses. Although BMI trajectories were similar in men and women, some gender differences were observed. For example, the risk of being in the persistently obese class in men was highest for those with PTSD, whereas for women, the risk was highest among those with depression. CONCLUSIONS: The growing number of overweight or obese returning veterans is a concerning problem for clinicians who work with these patients. Successful intervention to reduce the prevalence of obesity will require integrated efforts from primary care and mental health to treat underlying mental health causes and assist with engagement in weight loss programs. (C) Society of General Internal Medicine 2013 C1 [Maguen, Shira; Madden, Erin; Cohen, Beth; Bertenthal, Daniel; Neylan, Thomas; Talbot, Lisa; Grunfeld, Carl; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Neylan, Thomas; Talbot, Lisa; Seal, Karen] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Cohen, Beth; Grunfeld, Carl; Seal, Karen] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bertenthal, Daniel] Mental Illness Res Educ & Clin Ctr, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov FU Department of Defense; VA Health Sciences Research and Development (HSR&D) Career Development Award; National Institutes of Health [K23 HL 094765-01]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration FX This research was supported by Department of Defense Concept Award Grant (Maguen), VA Health Sciences Research and Development (HSR&D) Career Development Award (Maguen), National Institutes of Health grant K23 HL 094765-01 (Cohen), and the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. NR 33 TC 21 Z9 21 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S563 EP S570 DI 10.1007/s11606-013-2374-8 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900014 PM 23807066 ER PT J AU Mattocks, KM Sadler, A Yano, EM Krebs, EE Zephyrin, L Brandt, C Kimerling, R Sandfort, T Dichter, ME Weiss, JJ Allison, J Haskell, S AF Mattocks, Kristin M. Sadler, Anne Yano, Elizabeth M. Krebs, Erin E. Zephyrin, Laurie Brandt, Cynthia Kimerling, Rachel Sandfort, Theo Dichter, Melissa E. Weiss, Jeffrey J. Allison, Jeroan Haskell, Sally TI Sexual Victimization, Health Status, and VA Healthcare Utilization Among Lesbian and Bisexual OEF/OIF Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE lesbian; health services research; Veterans; women ID MENTAL-HEALTH; RISK-FACTORS; AFGHANISTAN; TRAUMA; FEMALE; IRAQ AB BACKGROUND: Many lesbian and bisexual (LB) women veterans may have been targets of victimization in the military based on their gender and presumed sexual orientation, and yet little is known regarding the health or mental health of LB veterans, nor the degree to which they feel comfortable receiving care in the VA. OBJECTIVE: The purpose of this study was to examine the prevalence of mental health and gender-specific conditions, VA healthcare satisfaction and trauma exposure among LB veterans receiving VA care compared with heterosexually-identified women veterans receiving. DESIGN: Prospective cohort study of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) women veterans at two large VA facilities. PARTICIPANTS: Three hundred and sixty five women veterans that completed a baseline survey. Thirty-five veterans (9.6 %) identified as gay or lesbian (4.7 %), or bisexual (4.9 %). MAIN MEASURES: Measures included sexual orientation, military sexual trauma, mental and gender-specific health diagnoses, and VA healthcare utilization and satisfaction. KEY RESULTS: LB OEF/OIF veterans were significantly more likely to have experienced both military and childhood sexual trauma than heterosexual women (MST: 31 % vs. 13 %, p<.001; childhood sexual trauma: 60 % vs. 36 %, p=.01), to be hazardous drinkers (32 % vs. 16 %, p=.03) and rate their current mental health as worse than before deployment (35 % vs. 16 %, p<.001). CONCLUSIONS: Many LB veterans have experienced sexual victimization, both within the military and as children, and struggle with substance abuse and poor mental health. Health care providers working with female Veterans should be aware of high rates of military sexual trauma and childhood abuse and refer women to appropriate VA treatment and support groups for sequelae of these experiences. Future research should focus on expanding this study to include a larger and more diverse sample of lesbian, gay, bisexual, and transgender veterans receiving care at VA facilities across the country. (C) Society of General Internal Medicine 2013 C1 [Mattocks, Kristin M.] VA Cent Western Massachusetts, Leeds, MA 01053 USA. [Mattocks, Kristin M.; Allison, Jeroan] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Sadler, Anne] Iowa City VA Hlth Care Syst, CADRE, Mental Hlth Serv Line, Iowa City, IA USA. [Sadler, Anne] Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. [Yano, Elizabeth M.] VA Greater Los Angeles HSR&D Ctr Excellence Study, Sepulveda, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Krebs, Erin E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Krebs, Erin E.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Zephyrin, Laurie] Dept Vet Affairs, Washington, DC USA. [Brandt, Cynthia; Haskell, Sally] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brandt, Cynthia; Haskell, Sally] Yale Univ, Sch Med, New Haven, CT USA. [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Sandfort, Theo] Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY USA. [Dichter, Melissa E.] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. [Weiss, Jeffrey J.] Mt Sinai Sch Med, Div Gen Internal Med, Dept Med, New York, NY USA. RP Mattocks, KM (reprint author), VA Cent Western Massachusetts Healthcare Syst, 421 North Main St, Leeds, MA 01053 USA. EM Kristin.mattocks@va.gov OI Kimerling, Rachel/0000-0003-0996-4212; Allison, Jeroan/0000-0003-4472-2112 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; VA Health Services Research & Development (HSR&D) Service Senior Research Career Scientist Award (RCS) [05-195] FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United Stated Government. Dr. Yano's time was supported by a VA Health Services Research & Development (HSR&D) Service Senior Research Career Scientist Award (RCS #05-195). NR 18 TC 17 Z9 17 U1 2 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S604 EP S608 DI 10.1007/s11606-013-2357-9 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900020 PM 23807072 ER PT J AU Rose, DE Farmer, MM Yano, EM Washington, DL AF Rose, Danielle E. Farmer, Melissa M. Yano, Elizabeth M. Washington, Donna L. TI Racial/Ethnic Differences in Cardiovascular Risk Factors Among Women Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cardiovascular disease; risk factors; race; ethnicity; women veterans ID QUALITY-OF-CARE; SMOKING; DISEASE; UPDATE; SYSTEM AB BACKGROUND: Heart disease is the leading cause of death for women in the United States, accounting for 24.5 % of all deaths among women. Earlier research has demonstrated racial/ethnic differences in prevalence of cardiovascular (CVD) risk factors. OBJECTIVE: To empirically examine the prevalence of CVD risk factors among a national sample of women Veterans by race/ethnicity, providing the first portrait of women Veterans' cardiovascular care needs. DESIGN AND PARTICIPANTS: Cross-sectional, national population-based telephone survey of 3,611 women Veterans. MEASUREMENTS: Women Veterans were queried about presence of diabetes, hypertension, obesity, tobacco use and physical activity. Four racial/ethnic categories were created: Hispanic, Non-Hispanic White (White), Non-Hispanic Black (Black), and Other. Logistic regressions were conducted for each risk factor to test for racial/ethnic differences, controlling for age (under 40 vs. 40 and over). KEY RESULTS: Racial/ethnic differences in CVD risk factors persisted after adjusting for age. Black women Veterans were more likely to report a diagnosis of diabetes (OR: 2.58, 95 % CI: 1.07, 6.21) or hypertension (OR: 2.31, 95 % CI: 1.10, 4.83) and be obese (OR: 2.06, 95 % CI: 1.05, 3.91) than White women Veterans. Hispanic women Veterans were more likely than White women Veterans to report diabetes (OR: 4.20, 95 % CI: 1.15, 15.39) and daily smoking (OR: 3.38, 95 % CI: 1.01, 11.30), but less likely to report a hypertension diagnosis (OR 0.21, 95% CI: 0.07, 0.64) or to be obese (OR: 0.39, 95 % CI: 0.18, 0.81). CONCLUSIONS: Among women Veterans, CVD risks vary by race/ethnicity. Black women Veterans consistently face higher CVD risk compared to White women Veterans, while results are mixed for Hispanic women Veterans. (C) Society of General Internal Medicine 2013 C1 [Rose, Danielle E.; Farmer, Melissa M.; Yano, Elizabeth M.; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D Ctr Excellence Study, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Rose, DE (reprint author), VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D Ctr Excellence Study, 16111 Plummer St,Mailcode 152, Sepulveda, CA 91343 USA. EM Danielle.Rose@va.gov FU Department of Veterans Affairs (VA) Women's Health Services in the Office of Patient Care Services; VA Health Services Research and Development (HSRD) Service [SDR 08-270]; VA HSR&D Senior Research Career Scientist award [RCS 05-195] FX This study was funded by the Department of Veterans Affairs (VA) Women's Health Services in the Office of Patient Care Services, and the VA Health Services Research and Development (HSR&D) Service (#SDR 08-270). Dr. Yano was supported by a VA HSR&D Senior Research Career Scientist award (#RCS 05-195). The authors gratefully acknowledge Mark Canning for project management, Julia Yosef, MA for assistance with survey fieldwork, Su Sun, MPH for assistance with data management, and Michael Mitchell, PhD, for statistical assistance. The views expressed within are solely those of the authors, and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 17 TC 7 Z9 7 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S524 EP S528 DI 10.1007/s11606-012-2309-9 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900008 PM 23807060 ER PT J AU Washington, DL Bean-Mayberry, B Hamilton, AB Cordasco, KM Yano, EM AF Washington, Donna L. Bean-Mayberry, Bevanne Hamilton, Alison B. Cordasco, Kristina M. Yano, Elizabeth M. TI Women Veterans' Healthcare Delivery Preferences and Use by Military Service Era: Findings from the National Survey of Women Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women Veterans; VA healthcare; health services need; health services utilization; health care preferences ID GENDER-DIFFERENCES; VA; ILLNESS AB BACKGROUND: The number of women Veterans (WVs) utilizing the Veterans Health Administration (VA) has doubled over the past decade, heightening the importance of understanding their healthcare delivery preferences and utilization patterns. Other studies have identified healthcare issues and behaviors of WVs in specific military service eras (e. g., Vietnam), but delivery preferences and utilization have not been examined within and across eras on a population basis. OBJECTIVE: To identify healthcare delivery preferences and healthcare use of WVs by military service era to inform program design and patient-centeredness. DESIGN AND PARTICIPANTS: Cross-sectional 2008-2009 survey of a nationally representative sample of 3,611 WVs, weighted to the population. MAIN MEASURES: Healthcare delivery preferences measured as importance of selected healthcare features; types of healthcare services and number of visits used; use of VA or non-VA; all by military service era. KEY RESULTS: Military service era differences were present in types of healthcare used, with World War II and Korea era WVs using more specialty care, and Vietnam era-to-present WVs using more women's health and mental health care. Operations Enduring Freedom, Iraqi Freedom, New Dawn (OEF/OIF/OND) WVs made more healthcare visits than WVs of earlier military eras. The greatest healthcare delivery concerns were location convenience for Vietnam and earlier WVs, and cost for Gulf War 1 and OEF/OIF/OND WVs. Co-located gynecology with general healthcare was also rated important by a sizable proportion of WVs from all military service eras. CONCLUSIONS: Our findings point to the importance of ensuring access to specialty services closer to home for WVs, which may require technology-supported care. Younger WVs' higher mental health care use reinforces the need for integration and coordination of primary care, reproductive health and mental health care. (C) Society of General Internal Medicine 2013 C1 [Washington, Donna L.; Bean-Mayberry, Bevanne; Hamilton, Alison B.; Cordasco, Kristina M.; Yano, Elizabeth M.] VA Greater Los Angeles Hlth Serv Res & Dev HSR&D, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA. [Washington, Donna L.; Bean-Mayberry, Bevanne; Cordasco, Kristina M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Cordasco, Kristina M.] RAND Corp, Santa Monica, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM Donna.washington@va.gov FU Department of Veterans Affairs (VA) Women's Health Services in the Office of Patient Care Services; VA Health Services Research and Development (HSRD) Service [SDR-08-270]; VA HSR&D Research Career Scientist award [RCS-05-195]; VA HSR&D Research Career Development Transition award [RCD 02-039] FX This study was funded by the Department of Veterans Affairs (VA) Women's Health Services in the Office of Patient Care Services, and the VA Health Services Research and Development (HSR&D) Service (#SDR-08-270). Dr. Yano is supported by a VA HSR&D Research Career Scientist award (#RCS-05-195). Dr. Bean-Mayberry was supported by a VA HSR&D Research Career Development Transition award (#RCD 02-039) during this study. The views expressed within are solely those of the authors, and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 28 TC 26 Z9 26 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S571 EP S576 DI 10.1007/s11606-012-2323-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900015 PM 23807067 ER PT J AU Yan, GW McAndrew, L D'Andrea, EA Lange, G Santos, SL Engel, CC Quigley, KS AF Yan, Grace W. McAndrew, Lisa D'Andrea, Elizabeth A. Lange, Gudrun Santos, Susan L. Engel, Charles C. Quigley, Karen S. TI Self-Reported Stressors of National Guard Women Veterans Before and After Deployment: The Relevance of Interpersonal Relationships SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women's health; veterans; survey research; quality of life ID MILITARY SEXUAL TRAUMA; COMBAT; WAR; CARE; RISK; IRAQ AB BACKGROUND: With their rapidly expanding roles in the military, women service members experience significant stressors throughout their deployment experience. However, there are few studies that examine changes in women Veterans' stressors before and after deployment. OBJECTIVE: This study examines the types of stressors women Veterans report before deployment, immediately after deployment, 3 months after deployment, and 1 year post-deployment. DESIGN: Descriptive data on reported stressors was collected at four time points of a longitudinal study (HEROES Project). Open-ended responses from the Coping Response Inventory (CRI) were coded into six possible major stressor categories for analysis. PARTICIPANTS: Seventy-nine Army National Guard and Reserve female personnel deploying to Operation Enduring Freedom (OFF)/Operation Iraqi Freedom (OIF) were surveyed prior to deployment. Of these participants, 35 women completed Phase 2, 41 completed Phase 3, and 48 completed Phase 4 of the study. KEY RESULTS: We identified six major stressor categories: (1) interpersonal (i.e., issues with family and/or friends), (2) deployment-related and military-related, (3) health concerns, (4) death of a loved one, (5) daily needs (i. e., financial/housing/transportation concerns), and (6) employment or school-related concerns. At all time points, interpersonal issues were one of the most common type of stressor for this sample. Daily needs concerns increased from 3 months post-deployment to 1 year post-deployment. CONCLUSIONS: Interpersonal concerns are commonly reported by women Veterans both before and after their combat experience, suggesting that this is a time during which interpersonal support is especially critical. We discuss implications, which include the need for a more coordinated approach to women Veterans' health care (e. g., greater community-based outreach), and the need for more and more accessible Veterans Affairs (VA) services to address the needs of female Veterans. (C) Society of General Internal Medicine 2012 C1 [Yan, Grace W.; McAndrew, Lisa; D'Andrea, Elizabeth A.; Lange, Gudrun; Santos, Susan L.] NJ War Related Illness & Injury Study Ctr, Dept Vet Affairs, E Orange, NJ USA. [McAndrew, Lisa; Lange, Gudrun] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. [D'Andrea, Elizabeth A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Santos, Susan L.] Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA. [Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Washington, DC USA. [Engel, Charles C.] Walter Reed Army Med Ctr, Deployment Hlth Clin Ctr, Bethesda, MD USA. [Quigley, Karen S.] Edith Nourse Rogers Mem Vet Adm Hosp, Dept Vet Affairs, Bedford, MA 01730 USA. [Quigley, Karen S.] Northeastern Univ, Boston, MA 02115 USA. RP Yan, GW (reprint author), NJ War Related Illness Injury Study Ctr, Dept Vet Affairs, 385 Tremont Ave,Mailstop 129, E Orange, NJ 07018 USA. EM weiyin.yan@va.gov FU Department of Veterans Affairs, Health Services Research & Development Service [IIR 02-296]; NJ War Related Illness and Injury Study Center, the NJ REAP [REA 03-021]; Deployment Health Clinical Center, Walter Reed Army Medical Center FX This study was supported by grants from the Department of Veterans Affairs, Health Services Research & Development Service (IIR 02-296 to K. Quigley); the NJ War Related Illness and Injury Study Center, the NJ REAP (REA 03-021); and the Deployment Health Clinical Center, Walter Reed Army Medical Center. NR 20 TC 5 Z9 5 U1 0 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 SU 2 BP S549 EP S555 DI 10.1007/s11606-012-2247-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 184RL UT WOS:000321910900012 PM 23807064 ER PT J AU Nedjat-Haiem, FR Carrion, IV Cribbs, K Lorenz, K AF Nedjat-Haiem, Frances R. Carrion, Iraida V. Cribbs, Kristen Lorenz, Karl TI Advocacy at the End of Life: Meeting the Needs of Vulnerable Latino Patients SO SOCIAL WORK IN HEALTH CARE LA English DT Article DE Latinos; advocacy; end of life; public sector health care system ID ADVANCED CANCER; HEALTH-CARE; SOCIAL-WORK AB This research explores health care professionals' understanding of the problems that arise in managing a terminal condition impacting the Latino population and conceptualizes the components of patient advocacy that address gaps in end-of-life care for patients and their family members. Limited research exists regarding patient advocacy from the perspectives of health care providers working with vulnerable Latino populations utilizing a public sector health care system. Forty-six semi-structured interviews were conducted with providers from different disciplines including medicine, nursing, social work, and chaplaincy. Although roles and responsibilities vary among health providers, it is imperative that all providers become aware of the need for patient advocacy. Doing so is not only in the best interest of vulnerable Latino populations but also has overarching financial benefits and positive outcomes for patients, administrators, and public health care systems. Social workers are the ideal professionals to assume leadership roles and share their knowledge of how to advocate effectively for the most vulnerable populations. C1 [Nedjat-Haiem, Frances R.; Lorenz, Karl] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL USA. [Cribbs, Kristen] Columbia Univ, Sch Publ Hlth, New York, NY USA. RP Nedjat-Haiem, FR (reprint author), VA Greater Los Angeles Healthcare Syst, VA Associated Hlth Postdoctoral Fellowship Progra, Off Acad Affiliat, HSR&D Ctr Excellence, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM nedjatha@gmail.com RI chen, zhu/K-5923-2013 OI Carrion, Iraida/0000-0003-4076-6644 NR 45 TC 4 Z9 4 U1 2 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0098-1389 J9 SOC WORK HEALTH CARE JI Soc. Work Health Care PD JUL 1 PY 2013 VL 52 IS 6 BP 558 EP 577 DI 10.1080/00981389.2013.779359 PG 20 WC Social Work SC Social Work GA 185RA UT WOS:000321986600004 PM 23865972 ER PT J AU Balevich, EC Wein, ND Flory, JD AF Balevich, Emily C. Wein, Naftali D. Flory, Janine D. TI Cigarette Smoking and Measures of Impulsivity in a College Sample SO SUBSTANCE ABUSE LA English DT Article DE Delay discounting; disinhibition; impulsivity; reward seeking; tobacco use ID IOWA GAMBLING TASK; DECISION-MAKING; FUTURE CONSEQUENCES; NICOTINE DEPENDENCE; DRUG-USE; SMOKERS; DELAY; NONSMOKERS; DISORDERS; BEHAVIOR AB .Background: An association between impulsivity and smoking has been consistently reported in the literature, but few studies have examined how distinct dimensions of impulsivity may relate differentially to smoking initiation versus persistent smoking. The aim of the current study was to examine the relationship between self-report and behavioral measures of impulsivity and smoking status in college students. Methods: Participants (N = 243) completed a self-report history of tobacco use, 2 self-report measures of impulsivity (the Barratt Impulsiveness Scale and Zuckerman Sensation-Seeking Scale), and 2 behavioral measures (the Delay Discounting Task and Iowa Gambling Task). All participants were classified as never-smokers, triers, or smokers based on their smoking history, and between-group differences on the 4 measures were examined. Results: On the self-report measures, all 3 groups differed on sensation seeking, with the never-smokers reporting the lowest levels and the smokers reporting the highest. Furthermore, the smokers reported significantly higher disinhibitory impulsivity than the triers and never-smokers. The groups did not differ on the behavioral measures. Conclusions: These results indicate that distinct dimensions of impulsivity characterize different smoking phenotypes. In particular, sensation seeking is associated with the initiation of smoking, whereas disinhibitory impulsivity is associated with the transition to more persistent and regular use of cigarettes. C1 [Balevich, Emily C.; Wein, Naftali D.] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. [Balevich, Emily C.] CUNY, Grad Ctr, Flushing, NY USA. [Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Flory, Janine D.] James J Peters Bronx VA Med Ctr, Bronx, NY USA. RP Balevich, EC (reprint author), CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. EM emily.balevich@qc.cuny.edu FU National Institutes of Health [MH K01-069979] FX This research was supported by National Institutes of Health grant MH K01-069979 (J.D.F.). NR 40 TC 9 Z9 9 U1 3 U2 15 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PD JUL 1 PY 2013 VL 34 IS 3 BP 256 EP 262 DI 10.1080/08897077.2012.763082 PG 7 WC Substance Abuse SC Substance Abuse GA 181SF UT WOS:000321688100005 PM 23844956 ER PT J AU Koulajian, K Ivovic, A Ye, KT Desai, T Shah, A Fantus, IG Ran, QT Giacca, A AF Koulajian, Khajag Ivovic, Alexander Ye, Kaitai Desai, Tejas Shah, Anu Fantus, I. George Ran, Qitao Giacca, Adria TI Overexpression of glutathione peroxidase 4 prevents beta-cell dysfunction induced by prolonged elevation of lipids in vivo SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE oxidative stress; lipid peroxide; glutathione peroxidase 4; lipotoxicity; beta-cell dysfunction; in vivo ID FREE FATTY-ACIDS; STIMULATED INSULIN-SECRETION; ENZYME GENE-EXPRESSION; RAT PANCREATIC-ISLETS; KAPPA-B ACTIVATION; OXIDATIVE STRESS; NONDIABETIC MEN; SUPEROXIDE-DISMUTASE; NADPH OXIDASE; GLUCOSE AB We have shown that oxidative stress is a mechanism of free fatty acid (FFA)-induced beta-cell dysfunction. Unsaturated fatty acids in membranes, including plasma and mitochondrial membranes, are substrates for lipid peroxidation, and lipid peroxidation products are known to cause impaired insulin secretion. Therefore, we hypothesized that mice overexpressing glutathione peroxidase-4 (GPx4), an enzyme that specifically reduces lipid peroxides, are protected from fat-induced beta-cell dysfunction. GPx4-overexpressing mice and their wild-type littermate controls were infused intravenously with saline or oleate for 48 h, after which reactive oxygen species (ROS) were imaged, using dihydrodichlorofluorescein diacetate in isolated islets, and beta-cell function was assessed ex vivo in isolated islets and in vivo during hyperglycemic clamps. Forty-eight-hour FFA elevation in wild-type mice increased ROS and the lipid peroxidation product malondialdehyde and impaired beta-cell function ex vivo in isolated islets and in vivo, as assessed by decreased disposition index. Also, islets of wild-type mice exposed to oleate for 48 h had increased ROS and lipid peroxides and decreased beta-cell function. In contrast, GPx4-overexpressing mice showed no FFA-induced increase in ROS and lipid peroxidation and were protected from the FFA-induced impairment of beta-cell function assessed in vitro, ex vivo and in vivo. These results implicate lipid peroxidation in FFA-induced beta-cell dysfunction. C1 [Koulajian, Khajag; Ivovic, Alexander; Ye, Kaitai; Desai, Tejas; Shah, Anu; Fantus, I. George; Giacca, Adria] Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada. [Shah, Anu; Fantus, I. George] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Shah, Anu; Fantus, I. George] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada. [Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Ran, Qitao] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. [Fantus, I. George; Giacca, Adria] Univ Toronto, Fac Med, Dept Med, Toronto, ON, Canada. [Fantus, I. George; Giacca, Adria] Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1L5, Canada. [Fantus, I. George; Giacca, Adria] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON, Canada. RP Giacca, A (reprint author), Univ Toronto, 1 Kings Coll Circle,Med Sci Bldg,Rm 3336, Toronto, ON, Canada. EM adria.giacca@utoronto.ca FU Canadian Institutes of Health Research [MOP-69018]; Banting and Best Diabetes Centre (University of Toronto); Ontario Graduate Scholarship; Ontario Graduate Scholarship for Science and Technology FX This work was supported by Canadian Institutes of Health Research Grants MOP-69018 (A. Giacca). K. Koulajian was supported by Scholarships from the Banting and Best Diabetes Centre (University of Toronto), an Ontario Graduate Scholarship, and an Ontario Graduate Scholarship for Science and Technology. NR 72 TC 8 Z9 8 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUL PY 2013 VL 305 IS 2 BP E254 EP E262 DI 10.1152/ajpendo.00481.2012 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 184OS UT WOS:000321902000009 PM 23695217 ER PT J AU Vargas, LA Diaz, RG Swenson, ER Perez, NG Alvarez, BV AF Vargas, Lorena A. Diaz, Romina G. Swenson, Erik R. Perez, Nestor G. Alvarez, Bernardo V. TI Inhibition of carbonic anhydrase prevents the Na+/H+ exchanger 1-dependent slow force response to rat myocardial stretch SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE NHE1 Na+/H+ exchanger; carbonic anhydrase II; papillary muscle; slow force response; cardiac hypertrophy ID INDUCED CARDIOMYOCYTE HYPERTROPHY; MYOCYTES IN-VITRO; CARDIAC-HYPERTROPHY; HEART-FAILURE; ANGIOTENSIN-II; H+ EXCHANGE; MEDIATED REGULATION; MECHANICAL STRETCH; PAPILLARY-MUSCLE; GENE-EXPRESSION AB Myocardial stretch is an established signal that leads to hypertrophy. Myocardial stretch induces a first immediate force increase followed by a slow force response (SFR), which is a consequence of an increased Ca2+ transient that follows the NHE1 Na+/H+ exchanger activation. Carbonic anhydrase II (CAII) binds to the extreme COOH terminus of NHE1 and regulates its transport activity. We aimed to test the role of CAII bound to NHE1 in the SFR. The SFR and changes in intracellular pH (pH(i)) were evaluated in rat papillary muscle bathed with CO2/HCO3- buffer and stretched from 92% to 98% of the muscle maximal force development length for 10 min in the presence of the CA inhibitor 6-ethoxzolamide (ETZ, 100 mu M). SFR control was 120 +/- 3% (n = 8) of the rapid initial phase and was fully blocked by ETZ (99 +/- 4%, n = 6). The SFR corresponded to a maximal increase in pH(i) of 0.18 +/- 0.02 pH units (n = 4), and pH(i) changes were blocked by ETZ (0.04 +/- 0.04, n = 6), as monitored by epifluorescence. NHE1/CAII physical association was examined in the SFR by coimmunoprecipitation, using muscle lysates. CAII immunoprecipitated with an anti-NHE1 antibody and the CAII immunoprecipitated protein levels increased 58 +/- 9% (n = 6) upon stretch of muscles, assessed by immunoblots. The p90(RSK) kinase inhibitor SL0101-1 (10 mu M) blocked the SFR of heart muscles after stretch 102 +/- 2% (n = 4) and reduced the binding of CAII to NHE1, suggesting that the stretch-induced phosphorylation of NHE1 increases its binding to CAII. CAII/NHE1 interaction constitutes a component of the SFR to heart muscle stretch, which potentiates NHE1-mediated H+ transport in the myocardium. C1 [Vargas, Lorena A.; Diaz, Romina G.; Perez, Nestor G.; Alvarez, Bernardo V.] Univ Nacl La Plata, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina. [Swenson, Erik R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Alvarez, BV (reprint author), Univ Nacl La Plata, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina. EM balvarez@med.unlp.edu.ar FU Agencia Nacional de Promocion Cientifica Grant (PICT) [01011, 320/08] FX This work was supported by the Agencia Nacional de Promocion Cientifica Grant (PICT 2007 No. 01011, Res. No. 320/08) to B. V. Alvarez. B. V. Alvarez and N. G. Perez are Established Investigators of the Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina). L. A. Vargas and R. G. Diaz are Fellows of CONICET. NR 61 TC 5 Z9 5 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUL PY 2013 VL 305 IS 2 BP H228 EP H237 DI 10.1152/ajpheart.00055.2013 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 184PD UT WOS:000321903500010 PM 23709596 ER PT J AU Yee, J Keysor, KJ Kim, DH AF Yee, Judy Keysor, Kathryn J. Kim, David H. TI The Time Has Arrived for National Reimbursement of Screening CT Colonography SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE CT colonography screening ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; EXTRACOLONIC FINDINGS; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; ASYMPTOMATIC ADULTS; ADENOMATOUS POLYPS; POPULATION; PREVALENCE; SURVEILLANCE; ACCURACY AB OBJECTIVE. CT colonography (CTC) has been fully validated as an accurate screening test for colorectal carcinoma and is being disseminated globally. There is an abundance of new literature addressing the prior concerns of the U. S. Preventive Services Task Force and the Centers for Medicare & Medicaid Services. Specific areas related to radiation dose, extracolonic findings, and generalizability of CTC to senior patients are discussed. CONCLUSION. The time has arrived for national reimbursement of CTC in the United States. C1 [Yee, Judy] San Francisco VA Med Ctr, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. [Yee, Judy] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Keysor, Kathryn J.] Amer Coll Radiol, Reston, VA USA. [Kim, David H.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Yee, J (reprint author), San Francisco VA Med Ctr, Dept Radiol & Biomed Imaging, 4150 Clement St, San Francisco, CA 94121 USA. EM judy.yee@ucsf.edu NR 42 TC 9 Z9 9 U1 0 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUL PY 2013 VL 201 IS 1 BP 73 EP 79 DI 10.2214/AJR.13.10656 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 169HX UT WOS:000320771900034 PM 23789660 ER PT J AU Moshiri, M Osman, S Robinson, TJ Khandelwal, S Bhargava, P Rohrmann, CA AF Moshiri, Mariam Osman, Sherif Robinson, Tracy J. Khandelwal, Saurabh Bhargava, Puneet Rohrmann, Charles A. TI Evolution of Bariatric Surgery: A Historical Perspective SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE bariatric; biliopancreatic diversion; gastric bypass; gastrojejunostomy; gastroplasty; jejunocolic ID VERTICAL BANDED GASTROPLASTY; MORBID-OBESITY; JEJUNOILEAL BYPASS; SURGICAL-TREATMENT; BILIOPANCREATIC DIVERSION; DUODENAL SWITCH; GASTRIC BYPASS; COMPLICATIONS; OPERATIONS AB OBJECTIVE. Older legacy bariatric surgical procedures, including jejunocolic bypass, jejunoileal bypass, vertical banded gastroplasty, and biliopancreatic diversion, are no longer performed. Biliopancreatic diversion with duodenal switch is still performed in select centers. Although the legacy procedures are no longer performed, there are still patients who have undergone these surgeries in the past who are currently either under continuous surveillance or are being evaluated for surgical conversion or revision because of complications or weight regain. The purpose of this article is to describe the evolutionary development of various bariatric surgical techniques and the associated surgical anatomy. Because these procedures are no longer performed, only limited imaging of legacy bariatric surgeries is available for radiologic demonstration. CONCLUSION. Although earlier bariatric surgical techniques are no longer favored, there are still patients who underwent these procedures who require imaging evaluation for clinical follow-up or surgical revision. Understanding the radiologic-surgical anatomy of these older bariatric procedures can help in the prompt and appropriate management of these patients. C1 [Moshiri, Mariam; Osman, Sherif; Robinson, Tracy J.; Bhargava, Puneet; Rohrmann, Charles A.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Khandelwal, Saurabh] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. RP Moshiri, M (reprint author), Univ Washington, Sch Med, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM Moshiri@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 27 TC 12 Z9 12 U1 0 U2 9 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUL PY 2013 VL 201 IS 1 BP W40 EP W48 DI 10.2214/AJR.12.10131 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 169HX UT WOS:000320771900005 PM 23789695 ER PT J AU Azadani, AN Chitsaz, S Mannion, A Mookhoek, A Wisneski, A Guccione, JM Hope, MD Ge, L Tseng, EE AF Azadani, Ali N. Chitsaz, Sam Mannion, Alex Mookhoek, Aart Wisneski, Andrew Guccione, Julius M. Hope, Michael D. Ge, Liang Tseng, Elaine E. TI Biomechanical Properties of Human Ascending Thoracic Aortic Aneurysms SO ANNALS OF THORACIC SURGERY LA English DT Article ID RUPTURE-RISK; MECHANICAL-PROPERTIES; WALL STRESS; ASSOCIATION; PREDICTION; DIAMETER; STRENGTH; BEHAVIOR; AGE AB Background. Surgical management of ascending thoracic aortic aneurysms (aTAAs) relies on maximum diameter, growth rate, and presence of connective tissue disorders. However, dissection and rupture do occur in patients who do not meet criteria for surgical repair. This study investigated the mechanical properties of aTAAs compared with normal human ascending aortas for eventual development of biomechanical aTAA risk models. Methods. aTAA specimens (n = 18) were obtained from patients undergoing surgical aneurysm repair, and fresh, healthy ascending aortas (n = 19) as controls were obtained from the transplant donor network. Biaxial stretch testing was performed to obtain tissue mechanical properties. Patient-specific aTAA physiologic stress was calculated based on preoperative computed tomography diameter. aTAA and ascending aorta tissue stiffness at respective physiologic stress were determined. Results. Physiologic stress of aTAA was significantly greater (241.6 +/- 59.4 kPa) than the 74 kPa for normal controls. Tissue stiffness of aTAAs was significantly greater than that of the ascending aortas at their respective physiologic stresses in the circumferential (3041.4 +/- 1673.7 vs 905.1 +/- 358.9 kPa, respectively; p < 0.001) and longitudinal (3498.2 +/- 2456.8 vs 915.3 +/- 368.9 kPa, respectively; p < 0.001) directions. Tissue stiffness of aTAAs positively correlated with aTAA diameter but did not correlate with patient age. No correlation was found between aTAA physiologic stress level and maximum aTAA diameter. Conclusions. aTAAs are much stiffer than normal ascending aortas at their respective physiologic stress, which was also significantly greater in ATAAs than ascending aortas. Patient-specific physiologic stress did not correlate with maximum aTAA diameter, and patient-specific aTAA wall stress may be a useful variable to predict adverse aTAA events. (C) 2013 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Med Ctr, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Erasmus Univ, Med Ctr, Dept Cardiothorac Surg, Rotterdam, Netherlands. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, 500 Parnassus Ave,Ste 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org RI Chitsaz, Sam/C-4586-2008 NR 23 TC 20 Z9 20 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUL PY 2013 VL 96 IS 1 BP 50 EP 58 DI 10.1016/j.athoracsur.2013.03.094 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 182KP UT WOS:000321741300019 PM 23731613 ER PT J AU Katiyar, SK Athar, M AF Katiyar, Santosh K. Athar, Mohammad TI Grape Seeds: Ripe for Cancer Chemoprevention SO CANCER PREVENTION RESEARCH LA English DT Article ID CELL LUNG-CANCER; FACTOR BINDING PROTEIN-3; PROSTATE TUMOR-GROWTH; SKH-1 HAIRLESS MICE; PROANTHOCYANIDINS INHIBIT; PANCREATIC-CANCER; MOUSE SKIN; KAPPA-B; EXTRACT; ACTIVATION AB A wide variety of phytochemicals, mostly flavonoids or polyphenolics, have been shown to possess anticarcinogenic activities. Among these are the grape seed proanthocyanidins (GSPs), which are the active ingredients of grape seed extract (GSE). Substantial in vitro and preclinical in vivo studies have shown the chemopreventive efficacy of GSPs against various forms of cancers in different tumor models. In this issue of the journal, Derry and colleagues show that administration of GSE in the diet reduces azoxymethane-induced colon carcinogenesis in an A/J mouse model. The results of this innovative and comprehensive study indicate that inhibition of azoxymethane- induced colon cancer by dietary GSE is mediated through the induction of apoptosis that is associated with alterations in microRNA (miRNA) and cytokine expression profiles as well as beta-catenin signaling. Notably, the demonstration that miRNA expression is affected by dietary GSE suggests a novel underlying mechanism for the chemopreventive action of GSE in colon cancer and, potentially, other cancers. (c) 2013 AACR. C1 [Katiyar, Santosh K.; Athar, Mohammad] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award; NIH [CA166883] FX The work reported from the author's laboratory is supported by the Veterans Administration Merit Review Award (to S.K. Katiyar) and NIH (CA166883; to S.K. Katiyar). NR 35 TC 6 Z9 8 U1 4 U2 17 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD JUL PY 2013 VL 6 IS 7 BP 617 EP 621 DI 10.1158/1940-6207.CAPR-13-0193 PG 5 WC Oncology SC Oncology GA 174YR UT WOS:000321195000001 PM 23771521 ER PT J AU Fett, N AF Fett, Nicole TI Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies SO CLINICS IN DERMATOLOGY LA English DT Article ID PULMONARY ARTERIAL-HYPERTENSION; JUVENILE LOCALIZED SCLERODERMA; PUVA BATH PHOTOCHEMOTHERAPY; LOW-DOSE METHOTREXATE; 1ST CASE SERIES; SYSTEMIC-SCLEROSIS; MYCOPHENOLATE-MOFETIL; LINEAR SCLERODERMA; UVA1 PHOTOTHERAPY; PLAQUE MORPHEA AB Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options. Published by Elsevier Inc. C1 [Fett, Nicole] Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Fett, Nicole] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Fett, N (reprint author), Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA USA. EM nmfett325@gmail.com NR 93 TC 23 Z9 23 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0738-081X J9 CLIN DERMATOL JI Clin. Dermatol. PD JUL-AUG PY 2013 VL 31 IS 4 BP 432 EP 437 DI 10.1016/j.clindermatol.2013.01.010 PG 6 WC Dermatology SC Dermatology GA 181QR UT WOS:000321684100011 PM 23806160 ER PT J AU Teitelman, AM Tennille, J Bohinski, J Jemmott, LS Jemmott, JB AF Teitelman, Anne M. Tennille, Julie Bohinski, Julia Jemmott, Loretta S. Jemmott, John B., III TI Urban Adolescent Girls' Perspectives on Multiple Partners in the Context of the Sexual Double Standard and Intimate Partner Violence SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE LA English DT Article DE adolescent; females; HIV; multiple sexual partners; partner abuse; safer sex ID GENDER-BASED VIOLENCE; DATING VIOLENCE; RELATIONSHIP POWER; RISK BEHAVIOR; HIV; PERPETRATION; PREGNANCY; HEALTH; WOMEN; TRIAL AB This article describes the influence of abusive and nonabusive relationship dynamics on the number of sex partners among urban adolescent girls. Focus groups were conducted with 64 sexually active adolescent girls ages 14 to 17 years. General coding and content analyses identified patterns, themes, and salient beliefs. More than one third (37.5%) reported having experienced physical, intimate partner violence; 32.8% had two or more recent sex partners, and 37.5% had ever had a sexually transmitted infection (STI) or HIV. Although some girls in abusive relationships feared retribution if they had more than one partner, others sought additional partners for solace or as an act of resistance. Adolescent HIV/STI prevention programs need to address the influence of gender norms such as the sexual double standard, as well as partner pressure and partner abuse on adolescent decision-making about safer sex, and also promote healthy relationships as integral to advancing HIV/STI risk reduction. Copyright (C) 2013 Association of Nurses in AIDS Care C1 [Teitelman, Anne M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Tennille, Julie] W Chester Univ, Grad Sch Social Work, W Chester, PA 19380 USA. [Bohinski, Julia] Optimal Stategix Grp Inc, Philadelphia, PA USA. [Jemmott, Loretta S.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Jemmott, John B., III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. RP Teitelman, AM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. FU National Institute of Mental Health [1K01MH080649-01A1]; University of Pennsylvania: Center for AIDS Research and Institute for Urban Research FX This research was supported by National Institute of Mental Health grant 1K01MH080649-01A1 and the University of Pennsylvania: Center for AIDS Research and Institute for Urban Research. The authors would like to express appreciation to the late Dr. Martin Fishbein for suggestions about the wording of the open-ended questions on the brief survey; Dr. Patricia Benner, Dr. Pat D'Antonio, and Annet Davis-Vogel for reading and commenting on drafts of the paper; Lynette Gueits for her role in advising on the development of the focus group guide; The Talking about Relationships Project research team members for logistical support during focus groups and for insightful discussions during the coding process; and the research study participants for the time and thoughtful comments they provided. NR 31 TC 2 Z9 2 U1 3 U2 38 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1055-3290 EI 1552-6917 J9 J ASSOC NURSE AIDS C JI J. Assoc. Nurses Aids Care PD JUL-AUG PY 2013 VL 24 IS 4 SI SI BP 308 EP 321 DI 10.1016/j.jana.2013.04.001 PG 14 WC Nursing SC Nursing GA 184AP UT WOS:000321859000004 PM 23790274 ER PT J AU Maguen, S Madden, E Lau, KM Seal, KH AF Maguen, Shira Madden, Erin Lau, Karen M. Seal, Karen H. TI Service Utilization among Iraq and Afghanistan Veterans Screening Positive for Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE brain injuries; health services; mental health; post-traumatic; stress disorders; veterans ID MULTICENTER ANALYSIS; PRIMARY-CARE; AUDIT-C; MANAGEMENT; SYMPTOMS; ETIOLOGY; VALIDITY AB We compared mental health outpatient, primary care, and emergency care service utilization among veterans screening TBI positive (S-TBI+) versus those screening TBI negative (S-TBI-) and describe associations between TBI-related symptoms and health service utilization. Our study population consisted of 1746 Iraq and Afghanistan veterans in VA care screened for TBI between April 1, 2007 and June 1, 2010. Rates of mental health outpatient, primary care, and emergency services utilization were greater for S-TBI+ veterans, compared with S-TBI- veterans, even after adjusting for mental health screen results. Irritability on the initial TBI screen was associated with increased mental health outpatient utilization rates [incidence rate ratio (IRR), 1.64; 95% confidence interval (CI), 1.18-2.3; p < 0.01]. Reports of dizziness (IRR, 1.24; 95% CI, 1.02-1.51; p < 0.05) and headaches (IRR, 1.41; 95% CI, 1.16-1.7; p < 0.001) were associated with increased primary care utilization rates. Higher utilization rates among veterans who screened positive for TBI were not better explained by screening positive for comorbid mental health problems. Knowing that certain symptoms are more strongly associated with increased utilization in certain health service domains will help to better plan for the care of returning veterans who screen positive for TBI. C1 [Maguen, Shira; Madden, Erin; Lau, Karen M.; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov FU Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program; VA Health Sciences Research and Development (HSR&D) Career Development Award FX This research was supported by the Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program (to S.M.) and a VA Health Sciences Research and Development (HSR&D) Career Development Award (to S.M.). The authors thank Gary Abrams, Tatjana Agopian-Novokovic, Daniel Bertenthal, Jeane Bosch, Julie Dinh, Don Donati, Thomas Neylan, and Richard Pham for their contributions. NR 28 TC 1 Z9 1 U1 2 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL PY 2013 VL 30 IS 13 BP 1123 EP 1128 DI 10.1089/neu.2012.2744 PG 6 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 174WB UT WOS:000321186400003 PM 23327186 ER PT J AU Nguyen, HQ Donesky, D Reinke, LF Wolpin, S Chyall, L Benditt, JO Paul, SM Carrieri-Kohlman, V AF Nguyen, Huong Q. Donesky, DorAnne Reinke, Lynn F. Wolpin, Seth Chyall, Lawrence Benditt, Joshua O. Paul, Steven M. Carrieri-Kohlman, Virginia TI Internet-Based Dyspnea Self-Management Support for Patients With Chronic Obstructive Pulmonary Disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Self-management; self-care; dyspnea; pulmonary disease; COPD; chronic disease; health behavior; health education; Internet; smartphone; cell phone ID CHRONIC RESPIRATORY QUESTIONNAIRE; QUALITY-OF-LIFE; CONTROLLED-TRIAL; PRIMARY-CARE; REHABILITATION; STATEMENT; COPD; MECHANISMS; PROGRAM AB Context. People with chronic obstructive pulmonary disease experience dyspnea with activities despite optimal medical management. Objectives. The purpose of this study was to test the efficacy of two 12-month dyspnea self-management programs (DSMPs), Internet-based (eDSMP) and face-to-face (fDSMP), compared with a general health education (GHE) control on the primary outcome of dyspnea with activities. Methods. Participants with chronic obstructive pulmonary disease were randomized to eDSMP (n = 43), fDSMP (n = 41), or GHE (n = 41). The content of the DSMPs were similar and focused on education, skills training, and coaching on dyspnea self-management strategies, including exercise, and only differed in the delivery mode. Dyspnea with activities was measured with the Chronic Respiratory Questionnaire at three, six, and 12 months. Secondary outcomes included exercise behavior and performance, health-related quality of life, self-efficacy for dyspnea management, and perception of support for exercise. The study was registered at Clinicaltrials.gov (NCT00461162). Results. There were no differences in dyspnea with activities across groups over 12 months (P = 0.48). With the exception of arm endurance (P = 0.04), exercise behavior, performance, and health-related quality of life did not differ across groups (P > 0.05). Self-efficacy for managing dyspnea improved for the DSMPs compared with GHE (P = 0.06). DSMP participants perceived high levels of support for initiating and maintaining an exercise program. Conclusion. The DSMPs did not significantly reduce dyspnea with activities compared with attention control. However, the high participant satisfaction with the DSMPs combined with positive changes in other outcomes, including self-efficacy for managing dyspnea and exercise behavior, highlight the need for additional testing of individually tailored technology-enabled interventions to optimize patient engagement and improve clinically relevant outcomes. (c) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Nguyen, Huong Q.; Wolpin, Seth; Benditt, Joshua O.] Univ Washington, Seattle, WA 98199 USA. [Reinke, Lynn F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Donesky, DorAnne; Chyall, Lawrence; Paul, Steven M.; Carrieri-Kohlman, Virginia] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Nguyen, HQ (reprint author), Univ Washington, Box 357266, Seattle, WA 98199 USA. EM hqn@u.washington.edu RI Emchi, Karma/Q-1952-2016 FU UCSF [R01 NR008938]; UW GCRCs [MO1-RR-000037, MO1 RR-00079]; National Institutes of Health [1KL2RR025015, 1 UL1 RR025014]; Oncology Nursing Society; Department of Veterans Affairs FX This work was supported in part by UCSF (R01 NR008938), UW GCRCs (MO1-RR-000037 and MO1 RR-00079), and National Institutes of Health grants 1KL2RR025015 and 1 UL1 RR025014. Dr. Reinke has funding through the Oncology Nursing Society and the Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest. NR 42 TC 26 Z9 27 U1 6 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUL PY 2013 VL 46 IS 1 BP 43 EP 55 DI 10.1016/j.jpainsymman.2012.06.015 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 182MZ UT WOS:000321748500005 PM 23073395 ER PT J AU Shahnazari, M Ceresa, C Foley, S Fong, A Zidaru, E Moody, S AF Shahnazari, Mohammad Ceresa, Carol Foley, Sharon Fong, Angela Zidaru, Elena Moody, Sandra TI Nutrition-Focused Wellness Coaching Promotes a Reduction in Body Weight in Overweight US Veterans SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Veterans; Nutrition coaching; Healthy eating; Weight loss ID CORONARY-HEART-DISEASE; FOOD-FREQUENCY QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL; OBESITY; WOMEN; CHOLESTEROL; PREVALENCE; VALIDITY; PROGRAM; RECORDS AB Diet plays a critical role in the pathogenesis of major Chronic diseases common in populations of US veterans. The role of nutrition-focused wellness coaching in improving dietary behavior and/or reducing weight in overweight and obese US veterans is not known. At the San Francisco Veterans Affairs Medical Center, US veterans aged 25 to 80 years were randomized to receive nutrition coaching on eating behaviors at baseline only (control group, n=22) or an additional eight times over the course of 6 months (intervention group, n=28) in 2010-2011. Multiple coaching contacts decreased intake of energy, fat, and carbohydrate by 31% (P <= 0.001) as evaluated by the 2005 Block food frequency questionnaire, which is composed of 111 food items. A weight loss of 5% from baseline (92.8 to 88.2 kg; P<0.01) was observed in the intervention group with mean body mass index decreasing from 30.4 to 28.9 (P<0.05). The control group showed a decrease in fat intake by 20% (P=0.01), but no statistically significant changes in intake of other nutrients or body weight (88.7 to 87.4 kg). Those in the intervention group reported diets at follow-up that were lower in cholesterol, saturated fat, sodium, sugar (P <= 0.01), calcium (P<0.05), and vitamin D (P<0.01), although when adjusted for energy (le, nutrient density) calcium intake increased and vitamin D remained unchanged. Veterans' readiness to change eating behavior for weight loss improved with nutrition coaching. This study demonstrates that intermittent nutrition coaching can be an effective strategy to promote reductions in energy intake, body weight, and body mass index in overweight US veterans. Further research is needed to determine whether nutrition coaching improves other clinical outcomes and sustains weight loss. C1 [Shahnazari, Mohammad] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Ceresa, Carol] San Francisco VA Med Ctr, Nutr & Food Serv, San Francisco, CA 94121 USA. [Foley, Sharon] Rush Univ, Chicago, IL 60612 USA. [Fong, Angela] Univ Calif San Francisco, San Francisco Med Ctr, San Francisco, CA 94143 USA. [Zidaru, Elena] Community Hlth Resource Ctr, San Francisco, CA USA. [Moody, Sandra] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. RP Ceresa, C (reprint author), San Francisco VA Med Ctr, 4150 Clement, San Francisco, CA 94121 USA. EM carol.ceresa@va.gov FU Department of Veterans Affairs, San Francisco VA Medical Center, San Francisco, CA FX The Department of Veterans Affairs, San Francisco VA Medical Center, San Francisco, CA, provided funding for this study. NR 43 TC 6 Z9 7 U1 0 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD JUL PY 2013 VL 113 IS 7 BP 928 EP 935 DI 10.1016/j.jand.2013.04.001 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 183FI UT WOS:000321799300008 PM 23706353 ER PT J AU Longo, FM Massa, SM AF Longo, Frank M. Massa, Stephen M. TI Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease SO NATURE REVIEWS DRUG DISCOVERY LA English DT Review ID NERVE GROWTH-FACTOR; TRKB AGONIST 7,8-DIHYDROXYFLAVONE; MILD COGNITIVE IMPAIRMENT; BETA-TURN PEPTIDOMIMETICS; RETINAL GANGLION-CELLS; AFFINITY NGF RECEPTOR; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; INTRACELLULAR DOMAIN AB Neurotrophins and their receptors modulate multiple signalling pathways to regulate neuronal survival and to maintain axonal and dendritic networks and synaptic plasticity. Neurotrophins have potential for the treatment of neurological diseases. However, their therapeutic application has been limited owing to their poor plasma stability, restricted nervous system penetration and, importantly, the pleiotropic actions that derive from their concomitant binding to multiple receptors. One strategy to overcome these limitations is to target individual neurotrophin receptors-such as tropomyosin receptor kinase A (TRKA), TRKB, TRKC, the p75 neurotrophin receptor or sortilin-with small-molecule ligands. Such small molecules might also modulate various aspects of these signalling pathways in ways that are distinct from the programmes triggered by native neurotrophins. By departing from conventional neurotrophin signalling, these ligands might provide novel therapeutic options for a broad range of neurological indications. C1 [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Massa, Stephen M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA. RP Longo, FM (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, 300 Pasteur Dr, Stanford, CA 94305 USA. EM longo@stanford.edu; stephen.massa@ucsf.edu FU NIA [UO1 AG032225]; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; Eastern Chapter of the North Carolina Alzheimer's Association; Koret Foundation; Taube Philanthropies; Jean Perkins Foundation; Horngren Family Alzheimer's Research Fund; Richard M. Lucas Foundation; US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Work by the authors has been supported by grants from the following bodies: NIA UO1 AG032225 (to F.M.L.); the Alzheimer's Drug Discovery Foundation (to F.M.L.); the Alzheimer's Association (to F.M.L.); the Eastern Chapter of the North Carolina Alzheimer's Association (to F.M.L.); the Koret Foundation (to F.M.L.); the Taube Philanthropies (to F.M.L.); the Jean Perkins Foundation (to F.M.L.); the Horngren Family Alzheimer's Research Fund (to F.M.L.); the Richard M. Lucas Foundation (to F.M.L.); and the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (to S.M.M). NR 217 TC 73 Z9 77 U1 8 U2 41 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 EI 1474-1784 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD JUL PY 2013 VL 12 IS 7 BP 507 EP 525 DI 10.1038/nrd4024 PG 19 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 173VU UT WOS:000321110600016 PM 23977697 ER PT J AU Hage, FG Lusa, L Dondi, M Giubbini, R Iskandrian, AE AF Hage, Fadi G. Lusa, Lara Dondi, Maurizio Giubbini, Raffaele Iskandrian, Ami E. CA IAEA Diabet Investigators TI Exercise Stress Tests for Detecting Myocardial Ischemia in Asymptomatic Patients With Diabetes Mellitus SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; PERFUSION; DIAD; RISK; OUTCOMES; ELECTROCARDIOGRAPHY; GUIDELINES; TRIAL AB The predominant cause of death in diabetes mellitus (DM) is coronary artery disease (CAD). Little is known about prevalence of silent ischemia in developing nations. We compared prevalence of silent ischemia in DM to a control group by exercise myocardial perfusion imaging (MPI) and electrocardiogram (ECG) in developing nations. The prospective multinational Ischemia Assessment with Exercise imaging in Asymptomatic Diabetes study recruited. participants at 12 sites in Asia, Africa, and Latin America. DM participants were age- and gender-matched 2:1 to non-DM individuals with >= 1 CAD risk factor. Subjects, underwent exercise tests that were interpreted in core labs in blinded fashion. The study included 392 DM and 205 control participants. Among participants with diagnostic ECGs, a similar proportion of DM and controls had ischemic ECG (15% vs 12%, p = 0.5). A significantly higher proportion of DM group had MPI abnormalities compared with controls (26% vs 14%, p <0.001). In participants with ischemia on MPI, only 17% had ischemic ECG, whereas in those without ischemia on MPI, 10% had ischemic ECG. In a multivariable model, DM was independently associated with abnormal MPI (odds ratio 2.1, 95% confidence interval 1.3-3.5, p = 0.004). Women were less likely to have ischemia by MPI than men (10% vs 30%, p <0.001) and concordance between ECG and MPI was much worse in women. In conclusion, in this large prospective study, asymptomatic DM participants had (1) more ischemia by exercise MPI than ECG, (2) more ischemia by MPI but not ECG than control group, and (3) ischemia by MPI was less in women than men. (C) 2013 Elsevier Inc. All rights reserved. C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Lusa, Lara] Univ Ljubljana, Inst Biostat & Med Informat, Fac Med, Ljubljana 61000, Slovenia. [Dondi, Maurizio] IAEA, Nucl Med Sect, Div Human Hlth, A-1400 Vienna, Austria. [Giubbini, Raffaele] Univ Brescia, I-25121 Brescia, Italy. RP Hage, FG (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA. EM fadihage@uab.edu RI Lusa, Lara/C-6692-2015 OI Lusa, Lara/0000-0002-8981-2421; Hage, Fadi/0000-0002-1397-4942 FU International Atomic Energy Agency [E1.30.31] FX This study was supported by the International Atomic Energy Agency through the Coordinated Research Project E1.30.31. NR 24 TC 5 Z9 8 U1 0 U2 7 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 1 PY 2013 VL 112 IS 1 BP 14 EP 20 DI 10.1016/j.amjcard.2013.02.047 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 181OA UT WOS:000321677200003 PM 23578350 ER PT J AU Kalapatapu, RK Delucchi, KL AF Kalapatapu, Raj K. Delucchi, Kevin L. TI APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE APOE; e4; cognitive; cigarette smoking; mild cognitive impairment; neurocognitive ID UNIFORM DATA SET; EPSILON 4 ALLELE; APOLIPOPROTEIN-E; ALZHEIMER-DISEASE; TEST-BATTERY; CESSATION; RISK; UDS; PHARMACOGENETICS; METAANALYSIS AB Background: APOE e4 genotype is known to be a risk factor for Alzheimer's disease and atherosclerosis. Recently, published evidence has shown that APOE e4 genotype may also be associated with the cessation of cigarette smoking. Objectives: The aim of this retrospective analysis was to explore whether any past smoking outcomes differed based on APOE e4 genotype in a large national dataset. Methods: Data were extracted from the National Alzheimer's Coordinating Center's longitudinal Uniform Data Set study. We limited this retrospective baseline analysis to the normal cognition (n = 2995) and mild cognitive impairment (n = 1627) groups that had APOE genotype and smoking data. Because this was an exploratory retrospective analysis, we conducted descriptive analyses on all variables based on APOE e4 genotype. We controlled for demographic, clinical, medication and neurocognitive data in the analyses. Results: In both the normal cognition group and the mild cognitive impairment group, e4 carriers and e4 non-carriers did not significantly differ on total years smoked, age when last smoked and the average # of packs/day smoked during the years they smoked. In both groups, e4 carriers and e4 non-carriers differed on various neurocognitive measures. Conclusion: These data do not support the recently published evidence of the association between APOE e4 genotype and smoking outcomes. Scientific Significance: Larger prospective clinical trials are needed to further explore the relationship between APOE genotype and smoking outcomes. C1 [Kalapatapu, Raj K.; Delucchi, Kevin L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kalapatapu, Raj K.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Opioid Replacement Treatment Clin, Bldg 1,Ground Floor,Mailstop 116F,4150 Clement St, San Francisco, CA 94121 USA. EM kalapatapu.raj.k@gmail.com FU NIA NIH HHS [U01 AG016976, K01 AG027295, UO1 AG016976]; NIDA NIH HHS [P50 DA009253, T32 DA007294, K23 DA034883, K23DA034883, P50DA009253] NR 42 TC 2 Z9 3 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD JUL PY 2013 VL 39 IS 4 BP 219 EP 226 DI 10.3109/00952990.2013.800084 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 180JT UT WOS:000321590700001 PM 23808899 ER PT J AU Scheiman, JM Dominitz, JA AF Scheiman, James M. Dominitz, Jason A. TI Growth of Ambulatory Surgical Centers, Surgery Volume, and Savings to Medicare SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID ANESTHESIA SERVICES C1 [Scheiman, James M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. RP Scheiman, JM (reprint author), 3912 Taubman Ct,Box 9362, Ann Arbor, MI 48109 USA. EM jscheima@med.umich.edu OI Dominitz, Jason/0000-0002-8070-7086 NR 4 TC 0 Z9 0 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUL PY 2013 VL 108 IS 7 BP 1175 EP 1176 DI 10.1038/ajg.2013.154 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 176LG UT WOS:000321305300022 PM 23820999 ER PT J AU Young, BA AF Young, Bessie Ann TI Health Literacy in Nephrology: Why Is It Important? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; RECEIVING CHRONIC-HEMODIALYSIS; SYMPTOM MANAGEMENT STRATEGIES; KNOWLEDGE; ASSOCIATIONS; TRIAL; TRANSPLANTATION; PREVALENCE; QUESTIONS; NUMERACY C1 [Young, Bessie Ann] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Young, Bessie Ann] Univ Washington, Seattle, WA 98195 USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst 152 E, 1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu NR 38 TC 2 Z9 3 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2013 VL 62 IS 1 BP 3 EP 6 DI 10.1053/j.ajkd.2013.04.003 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 167RZ UT WOS:000320653000004 PM 23773837 ER PT J AU Green, JA Mor, MK Shields, AM Sevick, MA Arnold, RM Palevsky, PM Fine, MJ Weisbord, SD AF Green, Jamie A. Mor, Maria K. Shields, Anne Marie Sevick, Mary Ann Arnold, Robert M. Palevsky, Paul M. Fine, Michael J. Weisbord, Steven D. TI Associations of Health Literacy With Dialysis Adherence and Health Resource Utilization in Patients Receiving Maintenance Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Health literacy; hemodialysis; outcomes ID MANAGED CARE ENROLLEES; HEART-FAILURE; HOSPITAL ADMISSION; ELDERLY PERSONS; CHRONIC DISEASE; MORTALITY; SKILLS; POPULATION; VALIDATION; KNOWLEDGE AB Background: Although limited health literacy is common in hemodialysis patients, its effects on clinical outcomes are not well understood. Study Design: Observational study. Setting & Participants: 260 maintenance hemodialysis patients enrolled in a randomized clinical trial of symptom management strategies from January 2009 through April 2011. Predictor: Limited health literacy. Outcomes: Dialysis adherence (missed and abbreviated treatments) and health resource utilization (emergency department visits and end-stage renal disease [ESRD]-related hospitalizations). Measurements: We assessed health literacy using the Rapid Estimate of Adult Literacy in Medicine (REALM) and used negative binomial regression to analyze the independent associations of limited health literacy with dialysis adherence and health resource utilization over 12-24 months. Results: 41 of 260 (16%) patients showed limited health literacy (REALM score, <= 60). There were 1,152 missed treatments, 5,127 abbreviated treatments, 552 emergency department visits, and 463 ESRD-related hospitalizations. Limited health literacy was associated independently with an increased incidence of missed dialysis treatments (missed, 0.6% vs 0.3%; adjusted incidence rate ratio [IRR], 2.14; 95% CI, 1.10-4.17), emergency department visits (annual visits, 1.7 vs 1.0; adjusted IRR, 1.37; 95% CI, 1.01-1.86), and hospitalizations related to ESRD (annual hospitalizations, 0.9 vs 0.5; adjusted IRR, 1.55; 95% CI, 1.03-2.34). Limitations: Generalizability and potential for residual confounding. Conclusions: Patients receiving maintenance hemodialysis who have limited health literacy are more likely to miss dialysis treatments, use emergency care, and be hospitalized related to their kidney disease. These findings have important clinical practice and cost implications. Am J Kidney Dis. 62(1):73-80. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Green, Jamie A.] Geisinger Med Ctr, Dept Nephrol, Danville, PA 17822 USA. [Mor, Maria K.; Shields, Anne Marie; Sevick, Mary Ann; Fine, Michael J.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann; Arnold, Robert M.; Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Arnold, Robert M.] Univ Pittsburgh, Sect Palliat Care, Pittsburgh, PA USA. [Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA USA. [Palevsky, Paul M.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Green, JA (reprint author), Geisinger Ctr Hlth Res, 100 N Acad Ave, Danville, PA 17822 USA. EM jgreen1@geisinger.edu OI Palevsky, Paul/0000-0002-7334-5400 FU US Department of Veterans Affairs Health Services Research and Development Service [HSRD IIR 07-190]; Clinical Scientist in Nephrology Fellowship Grant from the American Kidney Fund FX This study was funded by a grant from the US Department of Veterans Affairs Health Services Research and Development Service (Dr Weisbord; HSR&D IIR 07-190) and a Clinical Scientist in Nephrology Fellowship Grant from the American Kidney Fund (Dr Green). The opinions expressed in this article are those of the authors and do not represent the views of the US Department of Veterans Affairs or the US Government. Dr Green completed this study while at the University of Pittsburgh but currently is an employee of Geisinger Medical Center. NR 57 TC 18 Z9 19 U1 8 U2 27 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2013 VL 62 IS 1 BP 73 EP 80 DI 10.1053/j.ajkd.2012.12.014 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 167RZ UT WOS:000320653000016 PM 23352380 ER PT J AU Winterberg, PD Wang, YX Lin, KM Hartono, JR Nagami, GT Zhou, XJ Shelton, JM Richardson, JA Lu, CY AF Winterberg, Pamela D. Wang, Yanxia Lin, Keng-Mean Hartono, John R. Nagami, Glenn T. Zhou, Xin J. Shelton, John M. Richardson, James A. Lu, Christopher Y. TI Reactive oxygen species and IRF1 stimulate IFN alpha production by proximal tubules during ischemic AKI SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE AKI; innate immunity; type I interferon ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; GENE-EXPRESSION; HOSPITALIZED-PATIENTS; OXIDATIVE STRESS; MOUSE KIDNEY; IN-VIVO; INTERFERON AB We previously reported that expression of the transcription factor interferon regulatory factor 1 (IRF1) is an early, critical maladaptive signal expressed by renal tubules during murine ischemic acute kidney injury (AKI). We now show that IRF1 mediates signals from reactive oxygen species (ROS) generated during ischemic AKI and that these signals ultimately result in production of alpha-subtypes of type I interferons (IFN alpha s). We found that genetic knockout of the common type I IFN receptor (IFNARI(-/-)) improved kidney function and histology during AKI. There are major differences in the spatial-temporal production of the two major IFN subtypes, IFN beta and IFN alpha s: IFN beta expression peaks at 4 h, earlier than IFN alpha s, and continues at the same level at 24 h; expression of IFN alpha s also increases at 4 h but continues to increase through 24 h. The magnitude of the increase in IFN alpha s relative to baseline is much greater than that of IFN beta. We show by immunohistology and study of isolated cells that IFN beta is produced by renal leukocytes and IFN alpha s are produced by renal tubules. IRF1, IFN alpha s, and IFNARI were found on the same renal tubules during ischemic AKI. Furthermore, we found that ROS induced IFN alpha expression by renal tubules in vitro. This expression was inhibited by small interfering RNA knockdown of IRF1. Overexpression of IRF1 resulted in the production of IFN alpha s. Furthermore, we found that IFN alpha stimulated production of maladaptive proinflammatory CXCL2 by renal tubular cells. Altogether our data support the following autocrine pathway in renal tubular cells: ROS > IRF1 > IFN alpha > IFNARI > CXCL2. C1 [Winterberg, Pamela D.] Univ Texas SW Med Ctr Dallas, Div Nephrol, Dept Pediat, Dallas, TX 75390 USA. [Wang, Yanxia; Lin, Keng-Mean; Hartono, John R.; Lu, Christopher Y.] Univ Texas SW Med Ctr Dallas, Div Nephrol, Dept Internal Med, Dallas, TX 75390 USA. [Shelton, John M.; Richardson, James A.] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dept Internal Med, Dallas, TX 75390 USA. [Zhou, Xin J.; Richardson, James A.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA. [Lu, Christopher Y.] Univ Texas SW Med Ctr Dallas, Grad Sch Biomed Sci Immunol, Dallas, TX 75390 USA. [Nagami, Glenn T.] Vet Affairs Greater Los Angeles, Nephrol Sect, Los Angeles, CA USA. [Nagami, Glenn T.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Lu, CY (reprint author), UT Southwestern Med Ctr, Dept Internal Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM christopher.lu@utsouthwestern.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [RO1-DK-069633, T32-DK-07257, F32-DK-084701]; Beecherl Foundation Grant; Genzyme Nephrology Fellowship; University of Texas Southwestern O'Brien Kidney Research Core Center (National Institute of Diabetes and Digestive and Kidney Diseases) [DK-079328] FX The preceding work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant RO1-DK-069633 and Beecherl Foundation Grant (to C. Y. Lu), National Institute of Diabetes and Digestive and Kidney Diseases Grant T32-DK-07257 (to P. D. Winterberg), National Institute of Diabetes and Digestive and Kidney Diseases Grants F32-DK-084701 and T32-DK-07257 (to J. R. Hartono), a Genzyme Nephrology Fellowship (to Y. Wang), and the University of Texas Southwestern O'Brien Kidney Research Core Center (National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-079328). NR 61 TC 7 Z9 7 U1 1 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUL PY 2013 VL 305 IS 2 BP F164 EP F172 DI 10.1152/ajprenal.00487.2012 PG 9 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 183NI UT WOS:000321822400003 PM 23657854 ER PT J AU Rice, LA Smith, I Kelleher, AR Greenwald, K Hoelmer, C Boninger, ML AF Rice, Laura A. Smith, Ian Kelleher, Annmaire R. Greenwald, Karen Hoelmer, Claire Boninger, Michael L. TI Impact of the Clinical Practice Guideline for Preservation of Upper Limb Function on Transfer Skills of Persons With Acute Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Medical education; Rehabilitation; Spinal cord injuries; Wheelchairs ID WHEELCHAIR USERS SHOULDER; BEARING UPPER EXTREMITY; LONG-TERM PARAPLEGIA; PAIN; IMPLEMENTATION; INDEPENDENCE; IMPINGEMENT; PATIENT AB Objectives: To describe the development of a strict education protocol to implement the clinical practice guideline "Preservation of Upper Limb Function Following Spinal Cord Injury" into a clinical setting, and evaluate the effect of the protocol on transfer quality. Design: Randomized controlled trial. Setting: Acute Model Spinal Cord Injury Systems rehabilitation facility and community. Participants: Volunteer sample of full-time wheelchair users (N=70) with new spinal cord injuries randomized (1:1) to an intervention and standard-of-care group. Intervention: The intervention group was educated on transfer skills with a structured protocol implemented by a physical and occupational therapist who were extensively educated on the clinical practice guidelines and current transfer research. The standard-of-care group received standard therapy services. Main Outcome Measures: Comparison of transfer quality evaluated by the Transfer Assessment Instrument at 4 time points during first year after injury. Results: No significant differences were found between study groups. Secondary analysis based on type of transfer performed found that participants in the intervention group who performed assisted sitting pivot transfers performed higher-quality transfers (mean +/- SE: 9.43 +/-.55) compared with the standard-of-care group (mean +/- SE: 7.81 +/-.46) (P=.026) at 1 year after discharge. Also, participants who performed a dependent transfer had a higher average score across all 4 time points (mean +/- SE: 9.14 +/-.34) compared with the standard-of-care group (mean +/- SE: 8.09 +/-.29) (P=.019). Conclusions: For participants who perform assisted or dependent transfers, use of an evidenced-based, structured education program during acute inpatient rehabilitation has the potential to significantly improve the quality of transfers. Further follow-up testing is necessary with a larger sample size to determine the long-term effects. (C) 2013 by the American Congress of Rehabilitation Medicine C1 [Rice, Laura A.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA. [Smith, Ian; Greenwald, Karen; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Kelleher, Annmaire R.; Boninger, Michael L.] Univ Pittsburgh, Pittsburgh, PA USA. [Kelleher, Annmaire R.; Hoelmer, Claire; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Hoelmer, Claire; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Rice, LA (reprint author), Huff Hall M-C-586,1206 S 4th St, Champaign, IL 61820 USA. EM ricela@illinois.edu OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U.S. Department of Education [H133N000019/H133N060019] FX Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U.S. Department of Education (grant nos. H133N000019/H133N060019). The material presented here is solely the responsibility of the authors and does not necessarily reflect the opinions of the funding agency or the United States Department of Education. NR 29 TC 6 Z9 6 U1 0 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2013 VL 94 IS 7 BP 1230 EP 1246 DI 10.1016/j.apmr.2013.03.008 PG 17 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 182GG UT WOS:000321729100003 PM 23537608 ER PT J AU Ruhdorfer, A Dannhauer, T Wirth, W Hitzl, W Kwoh, CK Guermazi, A Hunter, DJ Benichou, O Eckstein, F AF Ruhdorfer, Anja Dannhauer, Torben Wirth, Wolfgang Hitzl, Wolfgang Kwoh, C. Kent Guermazi, Ali Hunter, David J. Benichou, Olivier Eckstein, Felix CA Osteoarthritis Initiative TI Thigh Muscle Cross-Sectional Areas and Strength in Advanced Versus Early Painful Osteoarthritis: An Exploratory Between-Knee, Within-Person Comparison in Osteoarthritis Initiative Participants SO ARTHRITIS CARE & RESEARCH LA English DT Article ID MAXIMAL ISOMETRIC STRENGTH; SPACE NARROWING DATA; QUADRICEPS WEAKNESS; CARTILAGE LOSS; ACTIVATION; WOMEN; VOLUME; MEN; ARTHROPLASTY; DISABILITY AB ObjectiveTo compare cross-sectional and longitudinal side differences in thigh muscle anatomic cross-sectional areas (ACSAs), strength, and specific strength (strength/ACSA) between knees with early versus advanced painful radiographic osteoarthritis in the same person. MethodsForty-four of 2,678 Osteoarthritis Initiative participants (31 women and 13 men) met the inclusion criteria of bilateral frequent knee pain, medial joint space narrowing (JSN) in 1 knee, and no medial (or lateral) JSN in the contralateral knee. Thigh muscle ACSAs of the quadriceps, hamstrings, adductors, and individual quadriceps heads at consistent locations were determined using magnetic resonance imaging. Isometric muscle strength was determined in extension/flexion (Good Strength Chair). Baseline quadriceps ACSAs and strength were considered primary end points, and longitudinal changes of these factors were considered secondary end points (by paired t-tests). ResultsNo significant side differences in quadriceps (or other thigh muscle) ACSAs, strength, or specific strength were observed between medial JSN knees versus knees without JSN, or between specific medial JSN knee strata and contralateral knees without JSN, either in men or women. Two-year longitudinal changes in thigh muscle ACSAs and strength were small (5.2%) and did not differ significantly between medial JSN knees and knees without JSN. ConclusionIn the context of previous findings that side differences in pain are associated with side differences in quadriceps ACSAs, the current results suggest that quadriceps (and other thigh muscle) properties are not independently associated with radiographic disease status (JSN) once knees have reached frequent pain status. Further, our longitudinal findings indicate that a more advanced radiographic stage of knee osteoarthritis is not necessarily associated with a longitudinal decline in muscle function. C1 [Ruhdorfer, Anja; Dannhauer, Torben; Wirth, Wolfgang; Hitzl, Wolfgang; Eckstein, Felix] Paracelsus Med Univ, A-5020 Salzburg, Austria. [Dannhauer, Torben; Wirth, Wolfgang; Eckstein, Felix] Chondrometrics, Ainring, Germany. [Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Guermazi, Ali] Boston Univ, Sch Med, Boston, MA 02118 USA. [Guermazi, Ali] Boston Imaging Core Lab LLC, Boston, MA USA. [Hunter, David J.] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia. [Hunter, David J.] Univ Sydney, Northern Clin Sch, Sydney, NSW 2006, Australia. [Benichou, Olivier] Eli Lilly & Co, Indianapolis, IN 46285 USA. RP Ruhdorfer, A (reprint author), Paracelsus Med Univ, Inst Anat, Strubergasse 21, A-5020 Salzburg, Austria. EM anja.ruhdorfer@pmu.ac.at RI Hitzl, Wolfgang/A-1068-2013; Wirth, Wolfgang/C-8724-2011 OI Wirth, Wolfgang/0000-0002-2297-8283 FU Osteoarthritis Initiative (OAI) [N01-AR-2-2258, N01-AR-22259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; NIH, a branch of the Department of Health and Human Services; Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer Inc.; Paracelsus Medical University Research Fund; Australian Research Council Future Fellowship; Merck Sorono; Genzyme; Novartis; AstraZeneca; Medtronic; Synthes; GSK; Sanofi-Aventis; Abbott; Pfizer FX Image and clinical data acquisition was supported by the Osteoarthritis Initiative (OAI), a public-private partnership comprising 5 contracts (N01-AR-2-2258, N01-AR-22259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners of the OAI include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. The image analysis was supported by the Paracelsus Medical University Research Fund. Dr. Hunter's work was supported by an Australian Research Council Future Fellowship.; Dr. Wirth has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Merck Sorono, and owns stock and/or stock options in Chondrometrics. Dr. Guermazi has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Genzyme, Novartis, and AstraZeneca and (more than $10,000) from Merck Sorono, and owns stock and/or stock options in Boston Imaging Core Lab LLC. Dr. Benichou owns stock and/or stock options in Eli Lilly. Dr. Eckstein has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Medtronic, Synthes, GSK, and Genzyme and (more than $10,000 each) from Merck Sorono, Sanofi-Aventis, Novartis, Abbott, and Pfizer, and owns stock and/or stock options in Chondrometrics. NR 40 TC 18 Z9 18 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUL PY 2013 VL 65 IS 7 BP 1034 EP 1042 DI 10.1002/acr.21965 PG 9 WC Rheumatology SC Rheumatology GA 174VF UT WOS:000321184000004 PM 23401316 ER PT J AU Singh, JA Kwoh, CK Richardson, D Chen, W Ibrahim, SA AF Singh, Jasvinder A. Kwoh, C. Kent Richardson, Diane Chen, Wei Ibrahim, Said A. TI Sex and Surgical Outcomes and Mortality After Primary Total Knee Arthroplasty: A Risk-Adjusted Analysis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID MYOCARDIAL-INFARCTION MORTALITY; STATES MEDICARE POPULATION; IN-HOSPITAL COMPLICATIONS; UNITED-STATES; TOTAL HIP; JOINT ARTHROPLASTY; RIGHT TOOL; APR-DRGS; REPLACEMENT; GENDER AB ObjectiveTotal knee arthroplasty (TKA) is a widely utilized and effective treatment option for end-stage knee osteoarthritis (OA). Knee OA is more prevalent among women compared to men, but there are limited data on the sex differences in surgical outcomes after primary TKA. MethodsOur sample consisted of all primary TKAs performed in Pennsylvania during the fiscal year 2002. We used International Classification of Diseases, Ninth Revision, Clinical Modification codes to identify major complications and surgical revision. We used mixed-effects logistic regression models to examine the associations between sex and all-cause mortality, readmissions, and major surgical complications. We used proportional hazards models to assess the risk of surgical revision after index arthroplasty. We adjusted for race, age, hospital teaching status, hospital procedure volume, insurance status, and risk of mortality. ResultsIn 17,994 primary TKAs, there were 46 and 220 deaths at 30 days and 1 year, respectively. Compared to women, men had higher adjusted odds of 1-year mortality (odds ratio [OR] 1.48 [95% confidence interval (95% CI) 1.13-1.94]) after primary TKA. The overall odds of most major 30-day complications did not differ by sex except for surgical wound infections, which were higher in men compared to women (OR 1.31 [95% CI 1.08-1.60]); 30-day readmission was higher in men (OR 1.25 [95% CI 1.10-1.43]). Men had significantly higher rates of revision of index knee arthroplasty at 5 years (hazard ratio 1.20 [95% CI 1.05-1.36]) compared to women. ConclusionThe higher rates of mortality, hospital readmissions, revision surgery, and wound infections in men undergoing elective primary TKA compared to women indicate there is a sex disparity in these outcomes. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Rochester, MN USA. [Kwoh, C. Kent; Richardson, Diane; Chen, Wei] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kwoh, C. Kent; Richardson, Diane; Chen, Wei] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kwoh, C. Kent; Richardson, Diane; Chen, Wei; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off, Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Arthritis Foundation, Western Pennsylvania Chapter; National Institute on Aging, National Cancer Institute; Agency for Healthcare Research and Quality Centers for Education & Research on Therapeutics; Birmingham VA Medical Center, Alabama; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24-AR-055259]; Allergan; Novartis; Regeneron; Saviant; URL; Areda; Takeda FX Supported by a pilot grant from the Arthritis Foundation, Western Pennsylvania Chapter. Dr. Singh's work was supported by the National Institute on Aging, National Cancer Institute, Agency for Healthcare Research and Quality Centers for Education & Research on Therapeutics, and Birmingham VA Medical Center, Alabama. Dr. Ibrahim's work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K24-AR-055259).; Dr. Singh has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Novartis, Regeneron, Saviant, and URL, and (more than $10,000 each) from Areda and Takeda. NR 37 TC 13 Z9 13 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUL PY 2013 VL 65 IS 7 BP 1095 EP 1102 DI 10.1002/acr.21953 PG 8 WC Rheumatology SC Rheumatology GA 174VF UT WOS:000321184000011 PM 23335560 ER PT J AU Vina, ER Cloonan, YK Ibrahim, SA Hannon, MJ Boudreau, RM Kwoh, CK AF Vina, Ernest R. Cloonan, Yona K. Ibrahim, Said A. Hannon, Michael J. Boudreau, Robert M. Kwoh, C. Kent TI Race, Sex, and Total Knee Replacement Consideration: Role of Social Support SO ARTHRITIS CARE & RESEARCH LA English DT Article ID QUALITY-OF-LIFE; OLDER-ADULTS; JOINT REPLACEMENT; AFRICAN-AMERICAN; PSYCHOSOCIAL FACTORS; DEPRESSIVE SYMPTOMS; PATIENT PREFERENCES; RACIAL-DIFFERENCES; OSTEO-ARTHRITIS; HEALTH AB ObjectiveTo determine whether there are racial differences in social support among patients with knee osteoarthritis (OA) and whether the impact of social support on patient preferences for total knee replacement (TKR) varies by race and sex. MethodsA total of 514 white and 285 African American patients with knee OA were surveyed. Logistic regression models were performed to determine if the relationship between willingness to undergo TKR and the interaction of patient race and sex was mediated by social support. ResultsCompared to whites with knee OA, African American patients were less likely to be married (P < 0.001), reported less close friends/relatives (P < 0.001), and had lower Medical Outcomes Study Social Support Scale (MOS-SSS) scores (P < 0.001). African American patients were also less willing to undergo TKR (62% versus 80%; P < 0.001) than whites. The odds of willingness to undergo TKR were less in white females compared to white males when adjusted for recruitment site, age, income, and the Western Ontario and McMaster Universities Osteoarthritis Index score (odds ratio [OR] 0.57, 95% confidence interval [95% CI] 0.34-0.96). This difference was no longer significant when further adjusted for marital status, number of close friends/relatives, and MOS-SSS score, but the effect size remained unchanged (OR 0.60, 95% CI 0.35-1.02). The odds of willingness to undergo TKR remained much less in African American females (OR 0.35, 95% CI 0.19-0.64) and African American males (OR 0.28, 95% CI 0.14-0.54) compared to white males when controlled for sociodemographic, clinical, and social support measures. ConclusionAfrican American patients reported less structural and functional social support than whites. Social support is an important determinant of preference for TKR surgery only among whites. C1 [Vina, Ernest R.; Cloonan, Yona K.; Hannon, Michael J.; Boudreau, Robert M.; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Vina, Ernest R.; Kwoh, C. Kent] Pittsburgh VA Healthcare Syst, Pittsburgh, PA USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ibrahim, Said A.] Univ Penn, Philadelphia, PA 19104 USA. RP Vina, ER (reprint author), Arthrit Res Ctr, 3347 Forbes Ave,Suite 220, Pittsburgh, PA 15213 USA. EM evina1@pitt.edu OI Boudreau, Robert/0000-0003-0162-5187; Cloonan, Yona/0000-0003-3893-3693; Vina, Ernest/0000-0001-8135-1731 FU NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-054731, AR-055259] FX Supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant P60-AR-054731). Dr. Ibrahim's work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases K24 Award (grant AR-055259). NR 52 TC 9 Z9 9 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUL PY 2013 VL 65 IS 7 BP 1103 EP 1111 DI 10.1002/acr.21925 PG 9 WC Rheumatology SC Rheumatology GA 174VF UT WOS:000321184000012 PM 23281259 ER PT J AU Green, JS Norris, DA Wisell, J AF Green, J. S. Norris, D. A. Wisell, J. TI Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID METASTATIC MELANOMA; MELANOCYTIC NEVI; RAF INHIBITORS; HALO NEVI; VEMURAFENIB; SORAFENIB; MUTATIONS; THERAPY; REGRESSION; INFILTRATE AB The discovery that some melanoma tumours harbour mutations in the BRAF gene (e.g. V600E) and the subsequent development of specific BRAF inhibitors have greatly improved the treatment of metastatic melanoma. Resistance of tumour cells to BRAF inhibitors is reduced by the addition of an MEK inhibitor; both BRAF and MEK inhibitors have been reported to produce a variety of dermatological toxic effects. Benign naevi often harbour BRAF mutations but few reports exist that document the response of naevus cells to BRAF inhibition. We report sarcoidal-type granulomatous inflammation in two patients with metastatic melanoma undergoing treatment with combination BRAF and MEK inhibitor therapy. This inflammation manifested in one patient as a nonspecific papular eruption; in the other, in association with clinical regression of multiple benign-appearing naevi during the course of therapy. The significance of sarcoidal-type inflammation occurring during treatment of metastatic melanoma with a combination of BRAF and MEK inhibitors is unclear. Its association with the clinical regression of benign-appearing naevi suggests a possible exaggerated inflammatory response to degenerating naevus cells in these lesions. C1 [Green, J. S.; Norris, D. A.; Wisell, J.] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80011 USA. [Wisell, J.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80011 USA. [Norris, D. A.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Green, JS (reprint author), Univ Colorado Denver, Dept Dermatol, Anschutz Med Campus,1665 Aurora Court,Mail Stop F, Aurora, CO 80011 USA. EM julie.green@ucdenver.edu NR 28 TC 7 Z9 7 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JUL PY 2013 VL 169 IS 1 BP 172 EP 176 DI 10.1111/bjd.12279 PG 5 WC Dermatology SC Dermatology GA 178HK UT WOS:000321436900030 PM 23413975 ER PT J AU Thomas, BA Rodriguez, RA Boyko, EJ Robinson-Cohen, C Fitzpatrick, AL O'Hare, AM AF Thomas, Bernadette A. Rodriguez, Rudolph A. Boyko, Edward J. Robinson-Cohen, Cassianne Fitzpatrick, Annette L. O'Hare, Ann M. TI Geographic Variation in Black-White Differences in End-of-Life Care for Patients with ESRD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; RACIAL-DIFFERENCES; AFRICAN-AMERICAN; UNITED-STATES; NEIGHBORHOOD POVERTY; TREATMENT INTENSITY; REGIONAL-VARIATIONS; ETHNIC DISPARITIES; ELDERLY-PATIENTS; NEPHROLOGY CARE AB Background and objectives Patterns of end-of-life care among patients with ESRD differ by race. Whether the magnitude of racial differences in end-of-life care varies across regions is not known. Design, setting, participants, & measurements This observational cohort study used data from the US Renal Data System and regional health care spending patterns from the Dartmouth Atlas of Healthcare. The cohort included 101,331 black and white patients 18 years and older who initiated chronic dialysis or received a kidney transplant between June 1, 2005, and September 31, 2008, and died before October 1, 2009. Black white differences in the odds of in-hospital death, dialysis discontinuation, and hospice referral by quintile of end-of-life expenditure index (EOL-EI) were examined. Results In adjusted analyses, the odds ratios for dialysis discontinuation for black versus white patients ranged from 0.47 (95% confidence interval=0.43 to 0.51) in the highest quintile of EOL-EI to 0.63 (95% confidence interval=0.54 to 0.74) in the lowest quintile (P for interaction<0.001). Hospice referral ranged from 0.55 (95% confidence interval:=0.50 to 0.60) in the highest quintile of EOL-EI to 0.82(95% confidence interval=0.69 to 0.96) in the lowest quintile (P for interaction<0.001). The association of race with in-hospital death also differed in magnitude across quintiles of EOL-EI, ranging from 1.21 (95% confidence interval=1.08 to 1.35) in the highest quintile of EOL-EI to 1.47 (95% confidence interval=1.27 to 1.71) in the second quintile (P for interaction<0.001). Conclusions There are pronounced black white differences in patterns of hospice referral and dialysis discontinuation among patients with ESRD that vary substantially across regions of the United States. C1 [Thomas, Bernadette A.; Rodriguez, Rudolph A.; O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Boyko, Edward J.; Robinson-Cohen, Cassianne; Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Rodriguez, Rudolph A.; O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Thomas, BA (reprint author), Univ Washington, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA. EM bthomas19@gmail.com OI Robinson-Cohen, Cassianne/0000-0003-4783-7046; Boyko, Edward/0000-0002-3695-192X FU Ruth L. Kirschstein National Research Service Award from the National Institutes of Health [F32 DK093167-01]; Beeson Career Development Award from the National Institute on Aging [K 1K23AG28980] FX We acknowledge the following grant support: Ruth L. Kirschstein National Research Service Award F32 DK093167-01 from the National Institutes of Health (to B.A.T.) and Beeson Career Development Award K 1K23AG28980 from the National Institute on Aging (to A.M.O.). NR 50 TC 11 Z9 11 U1 2 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2013 VL 8 IS 7 BP 1171 EP 1178 DI 10.2215/CJN.06780712 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 178DA UT WOS:000321423100016 PM 23580783 ER PT J AU Palomino, HL Rifkin, DE Anderson, C Criqui, MH Whooley, MA Ix, JH AF Palomino, Heather L. Rifkin, Dena E. Anderson, Cheryl Criqui, Michael H. Whooley, Mary A. Ix, Joachim H. TI 24-Hour Urine Phosphorus Excretion and Mortality and Cardiovascular Events SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CORONARY-HEART-DISEASE; NUTRITION EXAMINATION SURVEY; CHRONIC KIDNEY-DISEASE; 3RD NATIONAL-HEALTH; SERUM PHOSPHORUS; DIETARY PHOSPHORUS; MINERAL METABOLISM; RENAL-DISEASE; CALCIUM; CKD AB Background and objectives Higher morning serum phosphorus has been associated with cardiovascular disease (CVD) in patients with or without CKD. In patients with CKD and a phosphorous level >4.6 mg/dl, the Kidney Disease Improving Global Outcomes guidelines recommend dietary phosphorus restriction. However, whether phosphorus restriction influences serum phosphorus concentrations and whether dietary phosphorus is itself associated with CVD or death are uncertain. Design, setting, participants, & measurements Among 880 patients with stable CVD and normal kidney function to moderate CKD, 24-hour urine phosphorus excretion (UPE) and serum phosphorus were measured at baseline. Participants were followed for a median. of 7.4 years for CVD events and all-cause mortality. Results Mean +/- SD age was 67 +/- 11 years, estimated GFR (eGFR) was 71 +/- 22 ml/min per 1.73 m(2), and serum phosphorus was 3.7 +/- 0.6 mg/dl. Median UPE was 632 (interquartile range, 439, 853) mg/d. In models adjusted for demographic characteristics and eGFR, UPE was weakly and nonsignificantly associated with serum phosphorus (0.03 mg/dl higher phosphorus per 300 mg higher UPE; P=0.07). When adjusted for demographics, eGFR, and CVD risk factors, each 300-mg higher UPE was associated with 17% lower risk of CVD events. The association of UPE with all-cause mortality was not statistically significant (hazard ratio, 0.93; 95% confidence interval, 0.82 to 1.05). Results were similar irrespective of CKD status (P interactions > 0.87). Conclusions Among outpatients with stable CVD, the magnitude of the association of UPE with morning serum phosphorus is modest. Greater UPE is associated with lower risk for CVD events. The association was similar for all-cause mortality but was not statistically significant. C1 [Palomino, Heather L.; Rifkin, Dena E.; Anderson, Cheryl; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Sch Med, San Diego, CA 92161 USA. [Rifkin, Dena E.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Rifkin, Dena E.; Anderson, Cheryl; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Whooley, Mary A.] Univ Calif San Diego, Dept Epidemiol & Biostat, San Diego, CA 92161 USA. [Rifkin, Dena E.; Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu FU National Heart, Lung, and Blood Institute [1R01HL096851, R01 HL079235]; American Heart Association Fellow-to-Faculty Transition Award; Sandra Daugherty Foundation; National Institutes of Health [TL1TR00098]; Department of Veterans Affairs; American Federation of Aging Research; Robert Wood Johnson Foundation; Nancy Kirwan Heart Research Fund; Ischemia Research and Education Foundation FX This study was supported by grants from the National Heart, Lung, and Blood Institute (1R01HL096851) (J.H.I.), an American Heart Association Fellow-to-Faculty Transition Award (J.H.I.), and an award from the Sandra Daugherty Foundation (J.H.I.). Heather Palomino was supported by a training grant from the National Institutes of Health (TL1TR00098). The Heart and Soul Study was funded by the Department of Veterans Affairs, American Federation of Aging Research, Robert Wood Johnson Foundation, Nancy Kirwan Heart Research Fund, Ischemia Research and Education Foundation, and the National Heart, Lung, and Blood Institute (R01 HL079235). NR 32 TC 12 Z9 12 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2013 VL 8 IS 7 BP 1202 EP 1210 DI 10.2215/CJN.11181012 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 178DA UT WOS:000321423100020 PM 23539231 ER PT J AU Price, M Gros, DF Strachan, M Ruggiero, KJ Acierno, R AF Price, Matthew Gros, Daniel F. Strachan, Martha Ruggiero, Kenneth J. Acierno, Ron TI Combat Experiences, Pre-Deployment Training, and Outcome of Exposure Therapy for Post-Traumatic Stress Disorder in Operation Enduring Freedom/Operation Iraqi Freedom Veterans SO CLINICAL PSYCHOLOGY & PSYCHOTHERAPY LA English DT Article DE PTSD; OEF; OIF; Veterans; Exposure Therapy; Combat Exposure; Pre-Deployment Preparedness ID COGNITIVE-BEHAVIORAL THERAPY; CHILD SEXUAL-ABUSE; ADMINISTERED PTSD SCALE; MENTAL-HEALTH; PROLONGED EXPOSURE; TRAUMATIC EVENTS; CLINICAL-TRIALS; SUBSTANCE USE; RISK-FACTORS; SYMPTOMS AB The association between exposure to multiple potentially traumatic events (PTEs) and subsequent increased risk of post-traumatic stress disorder (PTSD) is well established. However, less is known about the relation between exposure to numerous PTEs, as is typical with military service, and treatment outcome. Furthermore, there has been little research examining military specific protective factors, such as pre-deployment preparedness, on PTSD treatment response. The current study investigated combat exposure and potential moderators of treatment outcome for exposure therapy in Operation Enduring Freedom/ Operation Iraqi Freedom (OEF/OIF) veterans with PTSD. One hundred and eleven OEF/OIF veterans diagnosed with PTSD participated in 8weeks of exposure therapy. Results indicated that increased combat exposure was associated with a reduced rate of change in PTSD symptoms but not depression symptoms. These findings were consistent across two measures of combat exposure. There was preliminary support for the moderating effect of pre-deployment preparedness on the association between combat exposure and treatment response. Together, these findings suggest that increased combat exposure is associated with poor treatment response in veterans with PTSD; however, this can be reduced by elevated pre-deployment preparedness. Copyright (C) 2012 John Wiley & Sons, Ltd. Key Practitioner Message: Increased combat exposure is associated with poorer treatment response. Pre-deployment training is associated with improved treatment response. PTSD interventions should account for the frequency of combat in military personnel. C1 [Price, Matthew; Gros, Daniel F.; Strachan, Martha; Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Price, Matthew; Gros, Daniel F.; Strachan, Martha; Ruggiero, Kenneth J.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. RP Price, M (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St,MSC 861,2nd Floor IOP S, Charleston, SC 29425 USA. EM prima@musc.edu FU NIDA NIH HHS [R01 DA030143] NR 61 TC 6 Z9 6 U1 2 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1063-3995 J9 CLIN PSYCHOL PSYCHOT JI Clin. Psychol. Psychother. PD JUL PY 2013 VL 20 IS 4 BP 277 EP 285 DI 10.1002/cpp.1768 PG 9 WC Psychology, Clinical SC Psychology GA 178GT UT WOS:000321434700001 PM 22253233 ER PT J AU Dehlinger, K Tarnowski, K House, JL Los, E Hanavan, K Bustamante, B Ahmann, AJ Ward, WK AF Dehlinger, Ky Tarnowski, Kristin House, Jody L. Los, Evan Hanavan, Kathryn Bustamante, Bryan Ahmann, Andrew J. Ward, W. Kenneth TI Can Trained Dogs Detect a Hypoglycemic Scent in Patients With Type 1 Diabetes? SO DIABETES CARE LA English DT Letter C1 [Dehlinger, Ky; Bustamante, Bryan] Portland VA Med Ctr, Vet Med Unit, Portland, OR USA. [Dehlinger, Ky] Legacy Res Inst, Dept Comparat Med, Portland, OR USA. [Los, Evan; Hanavan, Kathryn; Ward, W. Kenneth] Legacy Res Inst, Diabet Div, Portland, OR USA. [Ahmann, Andrew J.; Ward, W. Kenneth] Oregon Hlth & Sci Univ, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97201 USA. [Tarnowski, Kristin; House, Jody L.] Dogs Assisting Diabet Fdn, Forest Grove, OR USA. RP Ward, WK (reprint author), Legacy Res Inst, Diabet Div, Portland, OR USA. EM kenward503@msn.com OI Los, Evan/0000-0002-7567-0178 NR 4 TC 4 Z9 4 U1 2 U2 16 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2013 VL 36 IS 7 BP E98 EP + DI 10.2337/dc12-2342 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 178UK UT WOS:000321472700060 PM 23801820 ER PT J AU Li, G Shih, YYI Kiel, JW De La Garza, BH Du, F Duong, TQ AF Li, Guang Shih, Yen-Yu Ian Kiel, Jeffrey W. De La Garza, Bryan H. Du, Fang Duong, Timothy Q. TI MRI study of cerebral, retinal and choroidal blood flow responses to acute hypertension SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE cASL MRI; retina; choroid; blood pressure; blood flow; baroregulation; autoregulation ID FUNCTIONAL MRI; PARASYMPATHETIC NERVES; INTRAOCULAR-PRESSURE; ARTERIAL-PRESSURE; MOUSE MODEL; IN-VIVO; AUTOREGULATION; DIFFUSION; BRAIN; RAT AB Blood flow (BF) in many tissues is stable during significant fluctuations in systemic arterial blood pressure or perfusion pressure under normal conditions. The regulatory mechanisms responsible for this non-passive BF behavior include both local and neural control mechanisms. This study evaluated cerebral BF (CBF), retinal BF (RBF) and choroidal BF (ChBF) responses to acute blood pressure increases in rats using magnetic resonance imaging (MRI). A transient increase in blood pressure inside the MRI scanner was achieved by mechanically inflating a balloon catheter to occlude the descending aorta near the diaphragm. We verified the rat model of mechanical occlusion and MRI approach by first measuring blood-flow regulatory responses to changing BP in the brain under normoxia and hypercapnia where the phenomenon is well documented. Retinal and choroidal blood-flow responses to transient increased arterial pressure were then investigated. In response to an acute increase in blood pressure, RBF exhibited autoregulatory behavior and ChBF exhibited baroregulation similar to that seen in the cerebral circulation. This approach may prove useful to investigate retinal and choroidal vascular dysregulation in rat models of retinal diseases with suspected vascular etiology. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 OI Shih, Yen-Yu Ian/0000-0001-6529-911X FU NIH/NEI [R01 EY014211, EY018855, EY009702]; Department of Veterans Affairs; San Antonio Life Science Institute; American Heart Association [10POST4290091]; CTSA/RII imaging supplement awards [CTSA-004A, CTSA-008A]; San Antonio Area Foundation FX This work was supported in part by the NIH/NEI (R01 EY014211, EY018855 and EY009702), MERIT Award from the Department of Veterans Affairs, and San Antonio Life Science Institute to TQD and American Heart Association (10POST4290091), CTSA/RII imaging supplement awards (CTSA-004A and CTSA-008A), and San Antonio Area Foundation to YYIS. NR 41 TC 6 Z9 6 U1 0 U2 8 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 EI 1096-0007 J9 EXP EYE RES JI Exp. Eye Res. PD JUL PY 2013 VL 112 BP 118 EP 124 DI 10.1016/j.exer.2013.04.003 PG 7 WC Ophthalmology SC Ophthalmology GA 180OS UT WOS:000321605100014 PM 23623996 ER PT J AU Wine, TM Duvvuri, U Maurer, SH Mehta, DK AF Wine, Todd M. Duvvuri, Umamaheswar Maurer, Scott H. Mehta, Deepak K. TI Pediatric transoral robotic surgery for oropharyngeal malignancy: A case report SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article DE Pediatric TORS; Oropharyngeal malignancy; Robot; Head and neck sarcoma; Nonrhabdomyosarcoma ID QUALITY-OF-LIFE; SQUAMOUS-CELL CARCINOMA; LASER MICROSURGERY TLM; SOFT-TISSUE SARCOMAS; PROGNOSTIC-FACTORS; ADJUVANT THERAPY; NECK-CANCER; HEAD; CHEMOTHERAPY; RADIOTHERAPY AB The treatment of oropharyngeal malignancy is associated with numerous functional morbidities. Transoral robotic surgery has been used with increased frequency in adult oropharyngeal malignancy. The benefits include decreased surgical morbidity and improved functional outcomes. Use of transoral robotic has been limited in children. This case represents our experience with a 17-month old child who was diagnosed with a high-grade undifferentiated sarcoma of the soft palate. She was able to be successfully treated with transoral robotic surgery as a part of her multimodal therapy, representing the first case of transoral robotic surgery for an oropharyngeal malignancy in a young child. (c) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Wine, Todd M.; Duvvuri, Umamaheswar; Mehta, Deepak K.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Wine, Todd M.; Mehta, Deepak K.] UPMC, Childrens Hosp Pittsburgh, Div Pediat Otolaryngol, Pittsburgh, PA USA. [Maurer, Scott H.] Univ Pittsburgh, Sch Med, Div Pediat Hematol & Oncol, Pittsburgh, PA 15260 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh HealthCare Syst, Pittsburgh, PA USA. RP Mehta, DK (reprint author), 4401 Penn Ave Fac Pavil,7th Floor, Pittsburgh, PA 15224 USA. EM Deepak.mehta@chp.edu NR 28 TC 5 Z9 5 U1 2 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD JUL PY 2013 VL 77 IS 7 BP 1222 EP 1226 DI 10.1016/j.ijporl.2013.04.024 PG 5 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA 179QB UT WOS:000321535300036 PM 23680523 ER PT J AU Corson, K Denneson, LM Bair, MJ Helmer, DA Goulet, JL Dobscha, SK AF Corson, Kathryn Denneson, Lauren M. Bair, Matthew J. Helmer, Drew A. Goulet, Joseph L. Dobscha, Steven K. TI Prevalence and correlates of suicidal ideation among Operation Enduring Freedom and Operation Iraqi Freedom veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Depression; Veterans; Primary health care; Mental health; Screening ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; POLYTRAUMA CLINICAL TRIAD; RISK-FACTORS; COMBAT VETERANS; FOLLOW-UP; AFFAIRS; CARE; AFGHANISTAN AB Background: We sought to determine the prevalence and correlates of suicidal ideation (SI) among Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans following the Department of Veterans Affairs' (VA) 2007 implementation of required brief SI assessments for veterans who screen positive for depression and post-traumatic stress disorder. Methods: We retrospectively identified OEF/OIF veterans screened for depression using the Patient Health Questionnaire (PHQ-2) between April 2008 and September 2009 at three geographically-distinct VA Medical Centers' primary care or mental health clinics. Veteran responses to a two-item risk assessment tool (VA Pocket Card) or PHQ-9 9th item, administered following a positive depression screen (PHQ-2 > 3), were determined using manual chart review. Generalized estimating equations were used to calculate adjusted odds ratios for demographic and clinical correlates of positive SI assessments. Results: Of 1340 OEF/OIF veterans with positive depression screens, 32.4% reported SI. In multivariate models, odds of SI were lower for non-Hispanic white veterans (AOR=0.68) and greater for those with PHQ-2 >= 5 (AOR=1.87), depression (AOR=1.45), bipolar disorder/schizophrenia (AOR=2.84), and 2 or >= 3 diagnoses (AORs=1.59 and 2.49, respectively). Limitations: Study findings may not be generalizable to non-veteran patient populations and the study does not address the reliability and validity of tools employed for brief suicidal ideation assessment. Conclusions: SI is common among OEF/OIF veterans who receive VA care, perhaps more so among non-white veterans. Targeting veterans with higher PHQ-2 scores for SI assessment should be considered to reduce patient and administrative burden. Published by Elsevier B.V. C1 [Corson, Kathryn; Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, Portland, OR 97207 USA. [Bair, Matthew J.] Indiana Univ, Dept Med, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. [Helmer, Drew A.] Univ Med & Dent New Jersey, Sch Med, Vet Affairs New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, Newark, NJ USA. [Goulet, Joseph L.] Yale Univ, Sch Med, Dept Psychiat, West Haven Vet Affairs Med Ctr, New Haven, CT USA. [Dobscha, Steven K.] Portland VA Med Ctr, Portland, OR USA. RP Corson, K (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, POB 1034 P3 DEP PC, Portland, OR 97207 USA. EM kathryn.corson@va.gov OI Goulet, Joseph/0000-0002-0842-804X FU Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project [DHI-08-096] FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project DHI-08-096. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. The funding source had no role in study design; data collection, analysis, or interpretation; or in writing of the manuscript and submission process. NR 71 TC 14 Z9 14 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUL PY 2013 VL 149 IS 1-3 BP 291 EP 298 DI 10.1016/j.jad.2013.01.043 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 166XJ UT WOS:000320593000038 PM 23531358 ER PT J AU Xie, AL Teodorescu, M Pegelow, DF Teodorescu, MC Gong, YS Fedie, JE Dempsey, JA AF Xie, Ailiang Teodorescu, Mihaela Pegelow, David F. Teodorescu, Mihai C. Gong, Yuansheng Fedie, Jessica E. Dempsey, Jerome A. TI Effects of stabilizing or increasing respiratory motor outputs on obstructive sleep apnea SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE isocapnia; hypercapnia; hyperoxia ID CHEYNE-STOKES RESPIRATION; POSITIVE AIRWAY PRESSURE; CONGESTIVE-HEART-FAILURE; TOTAL PULMONARY RESISTANCE; CARBON-DIOXIDE; NREM SLEEP; LOOP GAIN; MECHANICAL VENTILATION; CO2 STIMULATION; MUSCLE-ACTIVITY AB To determine how the obstructive sleep apnea (OSA) patient's pathophysiological traits predict the success of the treatment aimed at stabilization or increase in respiratory motor outputs, we studied 26 newly diagnosed OSA patients [apnea-hypopnea index (AHI) 42 +/- 5 events/h with 92% of apneas obstructive] who were treated with O-2 supplementation, an isocapnic rebreathing system in which CO2 was added only during hyperpnea to prevent transient hypocapnia, and a continuous rebreathing system. We also measured each patient's controller gain below eupnea [change in minute volume/change in end-tidal PCO2 (Delta(V)over dotE/Delta PETCO2)], CO2 reserve (eupnea-apnea threshold PETCO2), and plant gain (Delta PETCO2 /Delta(V)over dotE), as well as passive upper airway closing pressure (Pcrit). With isocapnic rebreathing, 14/26 reduced their AHI to 31 +/- 6% of control (P < 0.01) (responder); 12/26 did not show significant change (nonresponder). The responders vs. nonresponders had a greater controller gain (6.5 +/- 1.7 vs. 2.1 +/- 0.2 l.min(-1).mmHg(-1), P < 0.01) and a smaller CO2 reserve (1.9 +/- 0.3 vs. 4.3 +/- 0.4 mmHg, P < 0.01) with no differences in Pcrit (-0.1 +/- 1.2 vs. 0.2 +/- 0.9 cmH(2)O, P > 0.05). Hypercapnic rebreathing (+4.2 +/- 1 mmHg PETCO2) reduced AHI to 15 +/- 4% of control (P < 0.001) in 17/21 subjects with a wide range of CO2 reserve. Hyperoxia (SaO(2) similar to 95-98%) reduced AHI to 36 +/- 11% of control in 7/19 OSA patients tested. We concluded that stabilizing central respiratory motor output via prevention of transient hypocapnia prevents most OSA in selected patients with a high chemosensitivity and a collapsible upper airway, whereas increasing respiratory motor output via moderate hypercapnia eliminates OSA in most patients with a wider range of chemosensitivity and CO2 reserve. Reducing chemosensitivity via hyperoxia had a limited and unpredictable effect on OSA. C1 [Xie, Ailiang; Teodorescu, Mihaela; Pegelow, David F.; Teodorescu, Mihai C.; Gong, Yuansheng; Fedie, Jessica E.; Dempsey, Jerome A.] William S Middleton Mem Vet Affairs Hosp, James B Skatrud Lab Pulm & Sleep Med, Madison, WI USA. [Teodorescu, Mihaela] Univ Wisconsin, Dept Med, Madison, WI USA. [Xie, Ailiang; Pegelow, David F.; Fedie, Jessica E.; Dempsey, Jerome A.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Teodorescu, Mihaela; Teodorescu, Mihai C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Xie, AL (reprint author), VA Hosp, James B Skatrud Lab Pulm & Sleep Med, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@wisc.edu FU National Heart, Lung, and Blood Institute [1RC-1-HL-099724-01, HL-15469] FX This work was supported by National Heart, Lung, and Blood Institute Grants 1RC-1-HL-099724-01 and HL-15469. NR 79 TC 18 Z9 19 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JUL PY 2013 VL 115 IS 1 BP 22 EP 33 DI 10.1152/japplphysiol.00064.2013 PG 12 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 174ZW UT WOS:000321199200003 PM 23599393 ER PT J AU Liu, CY Krishnan, AP Yan, LR Smith, RX Kilroy, E Alger, JR Ringman, JM Wang, DJJ AF Liu, Collin Y. Krishnan, Anitha P. Yan, Lirong Smith, Robert X. Kilroy, Emily Alger, Jeffery R. Ringman, John M. Wang, Danny J. J. TI Complexity and synchronicity of resting state blood oxygenation level-dependent (BOLD) functional MRI in normal aging and cognitive decline SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE resting state BOLD fMRI; approximate entropy (ApEn); complexity; aging; familial Alzheimer's disease (fAD); default mode network (DMN) ID APPROXIMATE ENTROPY; ALZHEIMERS-DISEASE; BRAIN ACTIVITY; FRACTAL DYNAMICS; FMRI; FREQUENCY; CLINICIAN; HORMONE; NETWORK; SYSTEM AB Purpose: To explore the use of approximate entropy (ApEn) as an index of the complexity and the synchronicity of resting state blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) in normal aging and cognitive decline associated with familial Alzheimer's disease (fAD). Materials and Methods: Resting state BOLD fMRI data were acquired at 3T from two independent cohorts of subjects consisting of healthy young (age 23 +/- 2 years, n = 8) and aged volunteers (age 66 +/- 3 years, n = 8), as well as 22 fAD associated subjects (14 mutation carriers, age 41.2 +/- 15.8 years; and eight nonmutation carrying family members, age 28.8 +/- 5.9 years). Mean ApEn values were compared between the two age groups and correlated with cognitive performance in the fAD group. Cross-ApEn (C-ApEn) was further calculated to assess the asynchrony between precuneus and the rest of the brain. Results: Complexity of brain activity measured by mean ApEn in gray and white matter decreased with normal aging. In the fAD group, cognitive impairment was associated with decreased mean ApEn in gray matter as well as decreased regional ApEn in right precuneus, right lateral parietal regions, left precentral gyrus, and right paracentral gyrus. A pattern of asynchrony between BOLD fMRI series emerged from C-ApEn analysis, with significant regional anti-correlation with cross-correlation coefficient of functional connectivity analysis. Conclusion: ApEn and C-ApEn may be useful for assessing the complexity and synchronicity of brain activity in normal aging and cognitive decline associated with neuro-degenerative diseases. C1 [Liu, Collin Y.; Yan, Lirong; Smith, Robert X.; Kilroy, Emily; Alger, Jeffery R.; Ringman, John M.; Wang, Danny J. J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Liu, Collin Y.] Greater Los Angeles Vet Adm Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Liu, Collin Y.; Krishnan, Anitha P.] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Liu, Collin Y.] Univ So Calif, Dept Radiol, Los Angeles, CA USA. [Ringman, John M.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA. RP Wang, DJJ (reprint author), Univ Calif Los Angeles, Dept Neurol, 660 Charles E Young Dr South, Los Angeles, CA 90095 USA. EM jwang71@gmail.com FU National Institutes of Health (NIH) [R01-MH080892, P50-AG016570, U01-AG032438]; Easton Consortium for Alzheimer's Disease Drug and Biomarker Discovery FX Contract grant sponsor: National Institutes of Health (NIH); Contract grant numbers: R01-MH080892, P50-AG016570, U01-AG032438, Easton Consortium for Alzheimer's Disease Drug and Biomarker Discovery. NR 40 TC 18 Z9 18 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JUL PY 2013 VL 38 IS 1 BP 36 EP 45 DI 10.1002/jmri.23961 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 180SA UT WOS:000321614600005 PM 23225622 ER PT J AU Ersek, M Smith, D Cannuscio, C Richardson, DM Moore, D AF Ersek, Mary Smith, Dawn Cannuscio, Carolyn Richardson, Diane M. Moore, Denise TI A Nationwide Study Comparing End-of-Life Care for Men and Women Veterans SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID QUALITY IMPROVEMENT; GENDER-DIFFERENCES; FAMILY ASSESSMENT; PALLIATIVE CARE; AFFAIRS; PERCEPTIONS; CANCER; PAIN AB Background: The quality of end-of-life (EOL) care at Veterans Affairs Medical Centers (VAMC) has improved. To date, however, the quality and outcomes of end-of-life care delivered to women veterans have not been examined. Objective: The goal of this study was to evaluate gender differences in the quality of EOL care received by patients in VAMCs nationwide. Design: The study was conducted via retrospective medical chart review and telephone survey with next of kin of recently deceased inpatients. Setting/subjects: The chart review included records for all patients who died in acute and long-term care units in 145 VAMCs nationwide (n = 36,618). For the survey, the documented next of kin were invited to respond on behalf of the deceased veteran; a total of 25,638 next of kin completed the survey. Measurements: Chart review measures included five indicators of optimal end-of-life care. Bereaved family survey items included one global and nine specific items (e. g., bereavement care, pain management) describing care in the last month of life. Results: Receipt of optimal end-of-life care did not differ significantly between women and men with respect to frequency of discussion of treatment goals with a family member, receipt of palliative consult, bereavement contact, and chaplain contact with a family member. Family members of women were more likely than those of men to report that the overall care provided to the veteran had been "excellent" (adjusted proportions: 63% versus 56%; odds ratio (OR) = 1.33; 95% confidence interval (CI) 1.10-1.61; p = 0.003). Conclusions: In this nationwide study of all inpatient deaths in VAMCs, women received comparable and on some metrics better quality EOL care than that received by male patients. C1 [Ersek, Mary; Smith, Dawn; Richardson, Diane M.; Moore, Denise] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, PROMISE Ctr, Philadelphia, PA 19104 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. RP Ersek, M (reprint author), Philadelphia VAMC, PROMISE Ctr, 3900 Woodland Ave,ANNEX Bldg, Philadelphia, PA 19104 USA. EM ersekm@nursing.upenn.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United Stated Government. The authors thank Melissa Dichter, MSW, PhD, for her thoughtful review of the manuscript prior to its submission. NR 31 TC 9 Z9 9 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JUL PY 2013 VL 16 IS 7 BP 734 EP 740 DI 10.1089/jpm.2012.0537 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 169GV UT WOS:000320768900009 PM 23676096 ER PT J AU Lonergan, MH Olivera-Figueroa, LA Pitman, RK Brunet, A AF Lonergan, Michelle H. Olivera-Figueroa, Lening A. Pitman, Roger K. Brunet, Alain TI Propranolol's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE LA English DT Review ID BETA-ADRENERGIC-BLOCKADE; POSTTRAUMATIC-STRESS-DISORDER; NORADRENERGIC MODULATION; PROTEIN-SYNTHESIS; YOUNG MEN; RETRIEVAL; TRAUMA; FEAR; REACTIVATION; AMYGDALA AB Background: Considering the pivotal role of negative emotional experiences in the development and persistence of mental disorders, interfering with the consolidation/reconsolidation of such experiences would open the door to a novel treatment approach in psychiatry. We conducted a meta-analysis on the experimental evidence regarding the capacity of the beta-blocker propranolol to block the consolidation/reconsolidation of emotional memories in healthy adults. Methods: Selected studies consisted of randomized, double-blind experiments assessing long-term memory for emotional material in healthy adults and involved at least 1 propranolol and 1 placebo condition. We searched PsycInfo, PubMed, Web of Science, Cochrane Central, PILOTS, Google Scholar and clinicaltrials.org for eligible studies from the period 1995-2012. Ten consolidation (n = 259) and 8 reconsolidation (n = 308) experiments met the inclusion criteria. We calculated effect sizes (Hedges g) using a random effects model. Results: Compared with placebo, propranolol given before memory consolidation reduced subsequent recall for negatively valenced stories, pictures and word lists (Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74). Propranolol before reconsolidation also reduced subsequent recall for negatively valenced emotional words and the expression of cue-elicited fear responses (Hedges g = 0.56, 95% CI 0.13-1.00). Limitations: Limitations include the moderate number of studies examining the influence of propranolol on emotional memory consolidation and reconsolidation in healthy adults and the fact that most samples consisted entirely of young adults, which may limit the ecological validity of results. Conclusion: Propranolol shows promise in reducing subsequent memory for new or recalled emotional material in healthy adults. However, future studies will need to investigate whether more powerful idiosyncratic emotional memories can also be weakened and whether this weakening can bring about long-lasting symptomatic relief in clinical populations, such as patients with posttraumatic stress or other event-related disorders. C1 [Lonergan, Michelle H.; Brunet, Alain] McGill Univ, Dept Psychiat, Montreal, PQ, Canada. [Lonergan, Michelle H.; Brunet, Alain] Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada. [Olivera-Figueroa, Lening A.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Olivera-Figueroa, Lening A.] US Dept Vet Affairs, West Haven, CT 06516 USA. [Pitman, Roger K.] Harvard Univ, Sch Med, Dept Psychiat, Charlestown, MA USA. RP Brunet, A (reprint author), Douglas Mental Hlth Univ Inst, 6875 Blvd LaSalle, Montreal, PQ H4H 1R3, Canada. EM alain.brunet@mcgill.ca OI Olivera-Figueroa, Lening/0000-0001-6325-9819 FU Fonds de Recherche du Quebec - Sante; Canadian Institutes of Health Research; Fernand-Seguin Research Centre FX A. Brunet holds a salary award from the Fonds de Recherche du Quebec - Sante. M. H. Lonergan holds a student award from the Canadian Institutes of Health Research. L. A. Olivera-Figueroa holds a postdoctoral fellowship from the Fernand-Seguin Research Centre. NR 60 TC 41 Z9 42 U1 1 U2 37 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 1180-4882 J9 J PSYCHIATR NEUROSCI JI J. Psychiatry Neurosci. PD JUL PY 2013 VL 38 IS 4 BP 222 EP 231 DI 10.1503/jpn.120111 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 180CR UT WOS:000321571000007 PM 23182304 ER PT J AU Cooper, RA AF Cooper, Rory A. TI Technology, trends, and the future for people with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Editorial Material C1 [Cooper, Rory A.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA 15260 USA. [Cooper, Rory A.] US Dept Vet Affairs, Philadelphia, PA USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2013 VL 36 IS 4 BP 257 EP 257 DI 10.1179/1079026813Z.000000000197 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 180DU UT WOS:000321574200001 PM 23820141 ER PT J AU Collinger, JL Foldes, S Bruns, TM Wodlinger, B Gaunt, R Weber, DJ AF Collinger, Jennifer L. Foldes, Stephen Bruns, Tim M. Wodlinger, Brian Gaunt, Robert Weber, Douglas J. TI Neuroprosthetic technology for individuals with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE Spinal cord injuries; Assistive technology; Neural interface; Neuroprosthesis; Brain-computer interface; Electrical stimulation; Epidural stimulation; Central pattern generators; Neurogenic bladder; Paraplegia; Tetraplegia; Rehabilitation ID FUNCTIONAL ELECTRICAL-STIMULATION; SILICON MICROELECTRODE ARRAYS; PUDENDAL NERVE-STIMULATION; BRAIN-COMPUTER INTERFACES; INTRASPINAL MICROSTIMULATION; INTRACORTICAL MICROSTIMULATION; NEUROMUSCULAR STIMULATION; BLADDER CONTRACTIONS; MICRO STIMULATION; SACRAL NEUROMODULATION AB Context: Spinal cord injury (SCI) results in a loss of function and sensation below the level of the lesion. Neuroprosthetic technology has been developed to help restore motor and autonomic functions as well as to provide sensory feedback. Findings: This paper provides an overview of neuroprosthetic technology that aims to address the priorities for functional restoration as defined by individuals with SCI. We describe neuroprostheses that are in various stages of preclinical development, clinical testing, and commercialization including functional electrical stimulators, epidural and intraspinal microstimulation, bladder neuroprosthesis, and cortical stimulation for restoring sensation. We also discuss neural recording technologies that may provide command or feedback signals for neuroprosthetic devices. Conclusion/clinical relevance: Neuroprostheses have begun to address the priorities of individuals with SCI, although there remains room for improvement. In addition to continued technological improvements, closing the loop between the technology and the user may help provide intuitive device control with high levels of performance. C1 [Collinger, Jennifer L.; Foldes, Stephen; Weber, Douglas J.] Dept Vet Affairs, Pittsburgh, PA USA. [Collinger, Jennifer L.; Foldes, Stephen; Bruns, Tim M.; Wodlinger, Brian; Gaunt, Robert; Weber, Douglas J.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Collinger, Jennifer L.; Gaunt, Robert; Weber, Douglas J.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Foldes, Stephen; Wodlinger, Brian; Weber, Douglas J.] Ctr Neural Basis Cognit, Pittsburgh, PA USA. RP Collinger, JL (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM collingr@pitt.edu OI Gaunt, Robert/0000-0001-6202-5818; Bruns, Tim/0000-0003-1692-0541 FU Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs [B6789C, B7143R, RX720]; Defense Advanced Research Projects Agency (DARPA) [N66001-10-C-4056]; National Institutes of Health, National Institute of Neurological Disorders and Stroke [F32NS074565]; UPMC Rehabilitation Institute FX This material is based on work supported by the Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs (Grants #B6789C, B7143R, and RX720), the Defense Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics program contract number N66001-10-C-4056, the National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant #F32NS074565, and the UPMC Rehabilitation Institute. The views expressed herein are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs, Department of Defense, National Institutes of Health, National Institute of Neurological Disorders and Stroke, or the United States government. NR 178 TC 15 Z9 17 U1 1 U2 42 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2013 VL 36 IS 4 BP 258 EP 272 DI 10.1179/2045772313Y.0000000128 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA 180DU UT WOS:000321574200002 PM 23820142 ER PT J AU Fineberg, DB Asselin, P Harel, NY Agranova-Breyter, I Kornfeld, SD Bauman, WA Spungen, AM AF Fineberg, Drew B. Asselin, Pierre Harel, Noam Y. Agranova-Breyter, Irina Kornfeld, Stephen D. Bauman, William A. Spungen, Ann M. TI Vertical ground reaction force-based analysis of powered exoskeleton-assisted walking in persons with motor-complete paraplegia SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injury; Paraplegia; Rehabilitation; ReWalk (TM); Assistive technology; Robotic-assisted exoskeletal device; Vertical ground reaction force; Mechanical loading; F-scan (TM) tekscan; Fourier series ID SPINAL-CORD-INJURY; RECIPROCATING GAIT ORTHOSIS AB Objective: To use vertical ground reaction force (vGRF) to show the magnitude and pattern of mechanical loading in persons with spinal cord injury (SCI) during powered exoskeleton-assisted walking. Research design: A cross-sectional study was performed to analyze vGRF during powered exoskeleton-assisted walking (ReWalk (TM): Argo Medical Technologies, Inc, Marlborough, MA, USA) compared with vGRF of able-bodied gait. Setting: Veterans Affairs Medical Center. Participants: Six persons with thoracic motor-complete SCI (T1-T11 AIS A/B) and three age-, height-, weight- and gender-matched able-bodied volunteers participated. Interventions: SCI participants were trained to ambulate over ground using a ReWalk (TM). vGRF was recorded using the F-Scan (TM) system (TekScan, Boston, MA, USA). Outcome measures: Peak stance average (PSA) was computed from vGRF and normalized across all participants by percent body weight. Peak vGRF was determined for heel strike, mid-stance, and toe-off. Relative linear impulse and harmonic analysis provided quantitative support for analysis of powered exoskeletal gait. Results: Participants with motor-complete SCI, ambulating independently with a ReWalk (TM), demonstrated mechanical loading magnitudes and patterns similar to able-bodied gait. Harmonic analysis of PSA profile by Fourier transform contrasted frequency of stance phase gait components between able-bodied and powered exoskeleton-assisted walking. Conclusion: Powered exoskeleton-assisted walking in persons with motor-complete SCI generated vGRF similar in magnitude and pattern to that of able-bodied walking. This suggests the potential for powered exoskeleton-assisted walking to provide a mechanism for mechanical loading to the lower extremities. vGRF profile can be used to examine both magnitude of loading and gait mechanics of powered exoskeleton-assisted walking among participants of different weight, gait speed, and level of assist. C1 [Fineberg, Drew B.; Asselin, Pierre; Harel, Noam Y.; Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, VA Rehabil Res & Dev, Bronx, NY USA. [Harel, Noam Y.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Harel, Noam Y.; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Agranova-Breyter, Irina] James J Peters VA Med Ctr, Rehabil Med Serv, Bronx, NY USA. [Kornfeld, Stephen D.] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY USA. [Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Spungen, AM (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ann.spungen@va.gov FU Rehabilitation Medicine Service, Spinal Cord Injury Service, Prosthetics and Orthotics Service James J. Peters Veterans Affairs Medical Center, Department of Neurology; Mount Sinai School of Medicine; Department of Veterans Affairs Rehabilitation Research and Development Service [B9212-C] FX We thank our participants and volunteers for their hard work and commitment. This work was supported by the Rehabilitation Medicine Service, Spinal Cord Injury Service, Prosthetics and Orthotics Service James J. Peters Veterans Affairs Medical Center, Department of Neurology, Mount Sinai School of Medicine, and the Department of Veterans Affairs Rehabilitation Research and Development Service (B9212-C). We would like to acknowledge Argo Medical Technologies, Inc. for loaning two ReWalk units and Aetrex Worldwide, Inc. for donating orthopedic shoes for this project. NR 15 TC 27 Z9 28 U1 6 U2 41 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2013 VL 36 IS 4 BP 313 EP 321 DI 10.1179/2045772313Y.0000000126 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 180DU UT WOS:000321574200007 PM 23820147 ER PT J AU Mahajan, HP Dicianno, BE Cooper, RA Ding, D AF Mahajan, Harshal P. Dicianno, Brad E. Cooper, Rory A. Ding, Dan TI Assessment of wheelchair driving performance in a virtual reality-based simulator SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Wheelchair; Assistive technology; Virtual reality; Driving simulator; User-computer interface; Multiple sclerosis; Cerebral palsy; Muscular dystrophy; Spinal cord injury ID TRAUMATIC BRAIN-INJURY; POWERED WHEELCHAIR; JOYSTICK; REHABILITATION; ENVIRONMENTS; ENHANCEMENT; RELIABILITY; EXPERIENCE; VALIDITY; MOBILITY AB Objective: To develop a virtual reality (VR)-based simulator that can assist clinicians in performing standardized wheelchair driving assessments. Design: A completely within-subjects repeated measures design. Methods: Participants drove their wheelchairs along a virtual driving circuit modeled after the Power Mobility Road Test (PMRT) and in a hallway with decreasing width. The virtual simulator was displayed on computer screen and VR screens and participants interacted with it using a set of instrumented rollers and a wheelchair joystick. Driving performances of participants were estimated and compared using quantitative metrics from the simulator. Qualitative ratings from two experienced clinicians were used to estimate intra- and inter-rater reliability. Results: Ten regular wheelchair users (seven men, three women; mean age +/- SD, 39.5 +/- 15.39 years) participated. The virtual PMRT scores from the two clinicians show high inter-rater reliability (78-90%) and high intra-rater reliability (71-90%) for all test conditions. More research is required to explore user preferences and effectiveness of the two control methods (rollers and mathematical model) and the display screens. Conclusions: The virtual driving simulator seems to be a promising tool for wheelchair driving assessment that clinicians can use to supplement their real-world evaluations. C1 [Mahajan, Harshal P.; Dicianno, Brad E.; Cooper, Rory A.; Ding, Dan] VA Pittsburgh HealthCare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. [Mahajan, Harshal P.; Cooper, Rory A.; Ding, Dan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. RP Dicianno, BE (reprint author), VA Pittsburgh HealthCare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu FU Department of Veteran Affairs Research and Development Merit Review Award [A6035R] FX This study is supported by the Department of Veteran Affairs Research and Development Merit Review Award (Grant #A6035R) and with resources and facilities by the Human Engineering Research Laboratories, VA Pittsburgh HealthCare System. The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated. NR 47 TC 4 Z9 4 U1 2 U2 17 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2013 VL 36 IS 4 BP 322 EP 332 DI 10.1179/2045772313Y.0000000130 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 180DU UT WOS:000321574200008 PM 23820148 ER PT J AU Garcia-Mendez, Y Pearlman, JL Boninger, ML Cooper, RA AF Garcia-Mendez, Yasmin Pearlman, Jonathan L. Boninger, Michael L. Cooper, Rory A. TI Health risks of vibration exposure to wheelchair users in the community SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Wheelchair; Manual; Vibration exposure; Wheelchair design; Paraplegia; Tetraplegia; Low back pain; Spinal disorders; Wheelchair sports; Veterans ID WHOLE-BODY VIBRATION; LOW-BACK-PAIN; MANUAL WHEELCHAIRS; SEAT CUSHIONS; SIDEWALK SURFACES; SUSPENSION; PROPULSION; INDIVIDUALS; SUPPORTS AB Objective: The purpose of this study was to evaluate whole-body vibration (WBV) exposure to wheelchair (WC) users in their communities and to determine the effect of WC frame type (folding, rigid, and suspension) in reducing WBV transmitted to the person. Design: An observational case-control study of the WBV exposure levels among WC users. Participants: Thirty-seven WC users, with no pressure sores, 18 years old or older and able to perform independent transfers. Main outcome measures: WC users were monitored for 2 weeks to collect WBV exposure, as well as activity levels, by using custom vibration and activity data-loggers. Vibration levels were evaluated using ISO 2631-1 methods. Results: All WC users who participated in this study were continuously exposed to WBV levels at the seat that were within and above the health caution zone specified by ISO 2631-1 during their day-to-day activities (0.83 +/- 0.17 m/second(2), weighted root-mean-squared acceleration, for 13.07 +/- 3.85 hours duration of exposure). WCs with suspension did not attenuate vibration transmitted to WC users (V = 0.180, F(8, 56) = 0.692, P = 0.697). Conclusions: WBV exposure to WC users exceeds international standards. Suspension systems need to be improved to reduce vibrations transmitted to the users. C1 [Garcia-Mendez, Yasmin; Pearlman, Jonathan L.; Boninger, Michael L.; Cooper, Rory A.] VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. [Garcia-Mendez, Yasmin; Pearlman, Jonathan L.; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Pearlman, Jonathan L.; Boninger, Michael L.; Cooper, Rory A.] Ctr Excellence WCs & Related Technol, VA Rehabil Res & Dev Serv, Pittsburgh, PA USA. [Garcia-Mendez, Yasmin] Univ Autonoma Estado Mexico, Fac Med, Dept Phys Therapy, Mexico City, DF, Mexico. RP Pearlman, JL (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, 6425 Penn Ave Suite 400, Pittsburgh, PA 15206 USA. EM jlp46@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136; Boninger, Michael/0000-0001-6966-919X FU Veterans Affairs Healthcare Network: VISN 4 Competitive Pilot Project [02778, B6673M]; Associated Rehabilitation Engineering (WaRE) VA center of excellence [B6789C]; Mexican Foundation for Education, Technology and Science (FUNED) [120701793-8]; Mexican National Council of Science and Technology (CONACyT) [212007] FX This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Healthcare Network: VISN 4 Competitive Pilot Project Fund #02778, Career Development Award grant #B6673M, WC and Associated Rehabilitation Engineering (WaRE) VA center of excellence grant #B6789C, the Mexican Foundation for Education, Technology and Science (FUNED) scholarship register #120701793-8, and the Mexican National Council of Science and Technology (CONACyT) scholarship register #212007. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. Thanks are extended to the Human Engineering Research Labs shop staff, clinical coordinators, students, and participants. NR 29 TC 2 Z9 2 U1 0 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2013 VL 36 IS 4 BP 365 EP 375 DI 10.1179/2045772313Y.0000000124 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 180DU UT WOS:000321574200012 PM 23820152 ER PT J AU Hollis, BW Marshall, DT Savage, SJ Garrett-Mayer, E Kindy, MS Gattoni-Celli, S AF Hollis, Bruce W. Marshall, David T. Savage, Stephen J. Garrett-Mayer, Elizabeth Kindy, Mark S. Gattoni-Celli, Sebastiano TI Vitamin D-3 supplementation, low-risk prostate cancer, and health disparities SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 15th Vitamin D Workshop CY JUN 20-22, 2012 CL Houston, TX DE Vitamin D; Prostate cancer; Biopsy; Health disparities ID 1,25-DIHYDROXYVITAMIN D-3; CONSERVATIVE MANAGEMENT; AFRICAN-AMERICAN; WHITE MEN; GROWTH; CELLS; IDENTIFICATION; EXPRESSION; GENE; PREVALENCE AB Vitamin D promotes the differentiation of prostate cancer cells, raising the possibility that vitamin D deficiency over time may contribute to the progression from subclinical prostate cancer to clinical disease. Since low-risk prostate cancers are monitored over time in an effort to determine which progress into clinically important, more aggressive cancers, they provide an excellent model in which to study, over an extended period of time, the effects of enhancing vitamin D status and related changes in tumor progression. This is particularly relevant to African-American men, who exhibit a high prevalence of vitamin D deficiency as well as higher incidence of prostate cancer and higher mortality rates from prostate cancer than Caucasians. Our research team has recently completed an open-label clinical trial aimed at assessing the safety and potential efficacy of vitamin D-3 supplementation at 4000 international units (IU) per day for one year in subjects diagnosed with early stage, low-risk prostate cancer. The results of this clinical study suggest that supplementation with vitamin D-3 at 4000 IU per day may benefit patients with early stage, low-risk prostate cancer on active surveillance, because of the improved outcome (a decreased number of positive cores at repeat biopsy) in more than half of the subjects enrolled in the trial. We also observed that, after one year of supplementation, there was no difference in circulating levels of vitamin D between African-American and Caucasian subjects who completed the study. These clinical results also suggest that robust and sustained vitamin D-3 supplementation can reduce prostate cancer-related health disparities in African-American men and that these health disparities are at least in part the result of widespread hypovitaminosis D within the African-American population. This article is part of a Special Issue entitled 'Vitamin D Workshop'. C1 [Hollis, Bruce W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Marshall, David T.; Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Savage, Stephen J.] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. [Garrett-Mayer, Elizabeth] Med Univ S Carolina, Dept Med Biostat, Charleston, SC 29425 USA. [Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Savage, Stephen J.; Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Gattoni-Celli, S (reprint author), Strom Thurmond Biomed Res Bldg,Room 338C,114 Doug, Charleston, SC 29403 USA. EM gattonis@musc.edu FU Gateway for Cancer Research; Health Services Research and Development Program of the Department of Veterans Affairs; South Carolina Clinical and Translational Research Institute,; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313] FX These studies were supported in part by grants from the Gateway for Cancer Research, the Health Services Research and Development Program of the Department of Veterans Affairs, the South Carolina Clinical and Translational Research Institute, and the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313). The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. We thank Drs. Leander Cannick, Jason Zauls, Kyle Russo, and Lewis Cooper (MUSC Department of Radiation Oncology) for helping with the recruitment of eligible subjects. NR 45 TC 9 Z9 9 U1 0 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD JUL PY 2013 VL 136 SI SI BP 233 EP 237 DI 10.1016/j.jsbmb.2012.11.012 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 177WJ UT WOS:000321405800049 PM 23220550 ER PT J AU Bikle, DD Elalieh, H Welsh, J Oh, D Cleaver, J Teichert, A AF Bikle, Daniel D. Elalieh, Hashem Welsh, JoEllen Oh, Dennis Cleaver, James Teichert, Arnaud TI Protective role of vitamin D signaling in skin cancer formation SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article; Proceedings Paper CT 15th Vitamin D Workshop CY JUN 20-22, 2012 CL Houston, TX DE Vitamin D receptor; 1,25-Dihydroxyvitamin D; Keratinocyte; UVR; DNA damage repair; Sonic hedgehog ID BASAL-CELL CARCINOMA; TRANSCRIPTION-COUPLED REPAIR; PRIMARY HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR GENE; D-RECEPTOR; DNA-REPAIR; EXCISION-REPAIR; SONIC HEDGEHOG; ULTRAVIOLET-RADIATION; INDUCED TUMORIGENESIS AB Vitamin D sufficiency is associated with protection against malignancy in a number of tissues clinically, and a strong body of evidence from animal and cell culture studies supports this protective role. Cancers in the skin differ, however, in that higher serum levels of 25OHD are associated with increased basal cell carcinomas (BCC), the most common form of epidermal malignancy. This result may be interpreted as indicating the role of UVR (spectrum 280-320) in producing vitamin D in the skin as well as causing those DNA mutations and proliferative changes that lead to epidermal malignancies. Recent animal studies have shown that mice lacking the vitamin D receptor (VDR) are predisposed to developing skin tumors either from chemical carcinogens such as 7,12-dimethylbenzanthracene (DMBA) or chronic UVR exposure. Such studies suggest that vitamin D production and subsequent signaling through the VDR in the skin may have evolved in part as a protective mechanism against UVR induced epidermal cancer formation. In this manuscript we provide evidence indicating that vitamin D signaling protects the skin from cancer formation by controlling keratinocyte proliferation and differentiation, facilitating DNA repair, and suppressing activation of the hedgehog (Hh) pathway following UVR exposure. This article is part of a Special Issue entitled 'Vitamin D Workshop'. Published by Elsevier Ltd. C1 [Bikle, Daniel D.; Elalieh, Hashem; Teichert, Arnaud] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Bikle, Daniel D.; Elalieh, Hashem; Oh, Dennis; Cleaver, James; Teichert, Arnaud] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Welsh, JoEllen] SUNY Albany, GenNYsis Ctr Excellence Canc Genom, Rensselaer, NY USA. [Bikle, Daniel D.; Oh, Dennis; Cleaver, James] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. RP Bikle, DD (reprint author), San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. EM daniel.bikle@ucsf.edu FU NIH [RO1 AR050023, DOD CA110338]; VA Merit Reviews; University of California Cancer Coordinating Committee grants FX The authors acknowledge the administrative support of Teresa Tong and Victoria Lee, the technical support of Sally Pennypacker, Stephanie Demetriou, and Katherine Ona-Vu, and the funding support from NIH RO1 AR050023 (DDB), DOD CA110338 (DDB), VA Merit Reviews (DDB and DHO), and the University of California Cancer Coordinating Committee grants (DHO, JEC). NR 68 TC 15 Z9 16 U1 0 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD JUL PY 2013 VL 136 SI SI BP 271 EP 279 DI 10.1016/j.jsbmb.2012.09.021 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 177WJ UT WOS:000321405800055 PM 23059470 ER PT J AU Potter, JS Marino, EN Hillhouse, MP Nielsen, S Wiest, K Canamar, CP Martin, JA Ang, A Baker, R Saxon, AJ Ling, W AF Potter, Jennifer S. Marino, Elise N. Hillhouse, Maureen P. Nielsen, Suzanne Wiest, Katharina Canamar, Catherine P. Martin, Judith A. Ang, Alfonso Baker, Rachael Saxon, Andrew J. Ling, Walter TI Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; INJECTION-DRUG USERS; SPECIFICATION TESTS; RANDOMIZED-TRIAL; DEPENDENCE; TRANSITION; HEALTH AB Objective: The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. Method: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results: Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions: Findings indicate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users. C1 [Potter, Jennifer S.; Marino, Elise N.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hillhouse, Maureen P.; Ang, Alfonso; Ling, Walter] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA USA. [Nielsen, Suzanne] Univ Sydney, Discipline Addict Med, Sydney, NSW 2006, Australia. [Wiest, Katharina; Baker, Rachael] CODA Inc, Portland, OR USA. [Canamar, Catherine P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Judith A.] City & Cty San Francisco, Dept Publ Hlth, Community Behav Hlth Serv, San Francisco, CA USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Potter, JS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7526 Louis Pasteur,MC7733, San Antonio, TX 78229 USA. EM PotterJS@uthscsa.edu RI Nielsen, Suzanne/C-3256-2015; Potter, Jennifer/C-6720-2008 OI Nielsen, Suzanne/0000-0001-5341-1055; Potter, Jennifer/0000-0002-7250-4422 FU National Institute on Drug Abuse Clinical Trials Network [U10 DA020024, U10 DA13045, 5 U10 DA013714-08, U10 DA13036, K23 DA02297] FX This research was supported by National Institute on Drug Abuse Clinical Trials Network Grants U10 DA020024 (to Madhukar H. Trivedi), U10 DA13045 (to Walter Ling), 5 U10 DA013714-08 (to Dennis Donovan), U10 DA13036 (to Dennis McCarty), and K23 DA02297 (to Jennifer S. Potter). NR 27 TC 32 Z9 32 U1 5 U2 19 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD JUL PY 2013 VL 74 IS 4 BP 605 EP 613 PG 9 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 175LC UT WOS:000321231200013 PM 23739025 ER PT J AU Mckay, JR Van Horn, D Ivey, M Drapkin, ML Rennert, L Lynch, KG AF McKay, James R. Van Horn, Deborah Ivey, Megan Drapkin, Michelle L. Rennert, Lior Lynch, Kevin G. TI Enhanced Continuing Care Provided in Parallel to Intensive Outpatient Treatment Does Not Improve Outcomes for Patients With Cocaine Dependence SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID RECOVERY MANAGEMENT CHECKUPS; ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSE PATIENTS; DRINKING BEHAVIOR; 24-MONTH OUTCOMES; USE DISORDERS; SELF-REPORTS; ALCOHOL; RELIABILITY; VALIDITY AB Objective: This study tested whether the addition of an enhanced continuing care (ECC) intervention that combined in-person and telephone sessions and began in the first week of treatment improved outcomes for cocaine-dependent patients entering an intensive outpatient program (IOP). Method: Participants (N = 152) were randomized to IOP treatment as usual (TAU) or IOP plus 12 months of ECC. ECC included cognitive-behavioral therapy elements to increase coping skills, as well as monetary incentives for attendance. It was provided by counselors situated at a separate clinical research facility who did not provide IOP. The primary outcomes measured were (a) cocaine urine toxicology and (b) good clinical outcome, as indicated by abstinence from all drugs and from heavy alcohol use. Secondary outcomes were frequency of abstinent days, cocaine use days, and heavy drinking days. Follow-ups were conducted at 3, 6, 9, and 12 months after baseline. Results: Patients in ECC completed a mean of 18 sessions. Contrary to the hypotheses, patients in TAU had better scores on both the cocaine urine toxicology and the good clinical outcome measures than those in ECC, as indicated by significant Group x Time interactions (cocaine urine toxicology, p=.0025; abstinence composite, p=.017). These results were not moderated by substance use before or early in treatment or by IOP attendance. Results with the secondary outcomes also did not favor ECC over TAU. Conclusions: Continuing care that is not well integrated with the primary treatment program may interfere in some way with the therapeutic process, particularly when it is implemented shortly after intake. C1 [McKay, James R.; Van Horn, Deborah; Ivey, Megan; Drapkin, Michelle L.; Rennert, Lior; Lynch, Kevin G.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [McKay, James R.; Drapkin, Michelle L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Mckay, JR (reprint author), Univ Penn, Ctr Continuum Care Addict, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM Mckay_j@mail.trc.upenn.edu FU National Institute on Drug Abuse [RC1 DA029062, K24 DA029062]; Medical Research Service; Substance Use Disorder Quality Enhancement Research Initiative (SUD-QUERI) of the Department of Veterans Affairs FX This research was supported by National Institute on Drug Abuse Grants RC1 DA029062 and K24 DA029062. Additional support was provided by the Medical Research Service and the Substance Use Disorder Quality Enhancement Research Initiative (SUD-QUERI) of the Department of Veterans Affairs. NR 32 TC 4 Z9 4 U1 1 U2 2 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD JUL PY 2013 VL 74 IS 4 BP 642 EP 651 PG 10 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 175LC UT WOS:000321231200018 PM 23739030 ER PT J AU Bekelman, JE Suneja, G Guzzo, T Pollack, CE Armstrong, K Epstein, AJ AF Bekelman, Justin E. Suneja, Gita Guzzo, Thomas Pollack, Craig Evan Armstrong, Katrina Epstein, Andrew J. TI Effect of Practice Integration Between Urologists and Radiation Oncologists on Prostate Cancer Treatment Patterns SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; physician's practice patterns; radiotherapy, intensity-modulated; delivery of health care, integrated ID THERAPY; COST; CARE; TECHNOLOGIES; RADIOTHERAPY AB Purpose: National attention has focused on whether urology-radiation oncology practice integration, known as integrated prostate cancer centers, contributes to the use of intensity modulated radiation therapy, a common and expensive prostate cancer treatment. Materials and Methods: We examined prostate cancer treatment patterns before and after conversion of a urology practice to an integrated prostate cancer center in July 2006. Using the SEER (Statistics, Epidemiology and End Results)-Medicare database, we identified patients 65 years old or older in 1 statewide registry diagnosed with nonmetastatic prostate cancer between 2004 and 2007. We classified patients into 3 groups, including 1-those seen by integrated prostate cancer center physicians (exposure group), 2-those living in the same hospital referral region who were not seen by integrated prostate cancer center physicians (hospital referral region control group) and 3-those living elsewhere in the state (state control group). We compared changes in treatment among the 3 groups, adjusting for patient, clinical and socioeconomic factors. Results: Compared with the 8.1 ppt increase in adjusted intensity modulated radiation therapy use in the state control group, the use of this therapy increased 20.3 ppts (95% CI 13.4, 27.1) in the integrated prostate cancer center group and 19.2 ppts (95% CI 9.6, 28.9) in the hospital referral region control group. Androgen deprivation therapy, for which Medicare reimbursement decreased sharply, similarly decreased in integrated prostate cancer center and hospital referral region controls. Prostatectomy decreased significantly in the integrated prostate cancer center group. Conclusions: Coincident with the conversion of a urology group practice to an integrated prostate cancer center, we observed an increase in intensity modulated radiation therapy and a decrease in androgen deprivation therapy in patients seen by integrated prostate cancer center physicians and those seen in the surrounding health care market that were not observed in the remainder of the state. C1 [Bekelman, Justin E.; Suneja, Gita] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Guzzo, Thomas] Univ Penn, Perelman Sch Med, Dept Surg, Div Urol, Philadelphia, PA 19104 USA. [Armstrong, Katrina; Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Bekelman, Justin E.; Guzzo, Thomas; Armstrong, Katrina; Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Bekelman, Justin E.; Pollack, Craig Evan; Armstrong, Katrina; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Pollack, Craig Evan] Johns Hopkins Sch Med, Dept Gen Internal Med, Baltimore, MD USA. RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Dept Radiat Oncol, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bekelman@uphs.upenn.edu FU National Cancer Institute [K07-CA163616] FX Supported by National Cancer Institute K07-CA163616 (JEB). NR 25 TC 16 Z9 16 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUL PY 2013 VL 190 IS 1 BP 97 EP 101 DI 10.1016/j.juro.2013.01.103 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 178GH UT WOS:000321432900027 PM 23399652 ER PT J AU Bardeleben, C Sharma, S Reeve, JR Bassilian, S Frost, P Hoang, B Shi, YJ Lichtenstein, A AF Bardeleben, Carolyne Sharma, Sanjai Reeve, Joseph R. Bassilian, Sara Frost, Patrick Hoang, Bao Shi, Yijiang Lichtenstein, Alan TI Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-beta-Riboside-Induced Apoptosis in Multiple Myeloma Cells SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID ACTIVATED PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHOSPHONACETYL-L-ASPARTATE; LYMPHOID-CELLS; AICA-RIBOSIDE; OROTIC-ACID; AMPK; ADENOSINE; INHIBITION; DEXAMETHASONE AB To investigate the mechanism by which 5-aminoimidazole-4-carboxamide-1-beta-riboside (AICAr) induces apoptosis in multiple myeloma cells, we conducted an unbiased metabolomics screen. AICAr had selective effects on nucleotide metabolism, resulting in an increase in purine metabolites and a decrease in pyrimidine metabolites. The most striking abnormality was a 26-fold increase in orotate associated with a decrease in uridine monophosphate (UMP) levels, indicating an inhibition of UMP synthetase (UMPS), the last enzyme in the de novo pyrimidine biosynthetic pathway, which produces UMP from orotate and 5-phosphoribosyl-alpha-pyrophosphate (PRPP). As all pyrimidine nucleotides can be synthesized from UMP, this suggested that the decrease in UMP would lead to pyrimidine starvation as a possible cause of AICAr-induced apoptosis. Exogenous pyrimidines uridine, cytidine, and thymidine, but not purines adenosine or guanosine, rescued multiple myeloma cells from AICAr-induced apoptosis, supporting this notion. In contrast, exogenous uridine had no protective effect on apoptosis resulting from bortezomib, melphalan, or metformin. Rescue resulting from thymidine add-back indicated apoptosis was induced by limiting DNA synthesis rather than RNA synthesis. DNA replicative stress was identified by associated H2A. X phosphorylation in AICAr-treated cells, which was also prevented by uridine add-back. Although phosphorylation of AICAr by adenosine kinase was required to induce multiple myeloma cell death, apoptosis was not associated with AMP-activated kinase activation or mTORC1 inhibition. A possible explanation for inhibition of UMP synthase activity by AICAr was a depression in cellular levels of PRPP, a substrate of UMP synthase. These data identify pyrimidine biosynthesis as a potential molecular target for future therapeutics in multiple myeloma cells. (C) 2013 AACR. C1 [Bardeleben, Carolyne; Sharma, Sanjai; Frost, Patrick; Hoang, Bao; Shi, Yijiang; Lichtenstein, Alan] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Div Hematology Oncol, Los Angeles, CA USA. [Lichtenstein, Alan] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Reeve, Joseph R.; Bassilian, Sara] Univ Calif Los Angeles, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Lichtenstein, A (reprint author), Greater Los Angeles VA Healthcare Ctr, Div Hematol Oncol, 111H,VA West Med Ctr,11301 Wilshire BLVD, Los Angeles, CA 90073 USA. EM alan.lichtenstein@med.va.gov FU NIH [CA132778, CA111448, CA168491]; Research funds of the Multiple Myeloma Research Foundation; Research Funds of the Veteran's Administration; NIH Center Grant; CURE: Digestive Diseases Research Center [DK-41301]; Peptidomic, RIA and Proteomic Core FX This work was supported in part by NIH grants CA132778, CA111448, CA168491, Research funds of the Multiple Myeloma Research Foundation and Research Funds of the Veteran's Administration to A. Lichtenstein and in part by NIH Center Grant, CURE: Digestive Diseases Research Center DK-41301 Peptidomic, RIA and Proteomic Core (J.R. Reeve). NR 48 TC 4 Z9 4 U1 2 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JUL PY 2013 VL 12 IS 7 BP 1310 EP 1321 DI 10.1158/1535-7163.MCT-12-1042 PG 12 WC Oncology SC Oncology GA 179BQ UT WOS:000321492700016 PM 23585020 ER PT J AU Carvill, GL Heavin, SB Yendle, SC McMahon, JM O'Roak, BJ Cook, J Khan, A Dorschner, MO Weaver, M Calvert, S Malone, S Wallace, G Stanley, T Bye, AME Bleasel, A Howell, KB Kivity, S Mackay, MT Rodriguez-Casero, V Webster, R Korczyn, A Afawi, Z Zelnick, N Lerman-Sagie, T Lev, D Moller, RS Gill, D Andrade, DM Freeman, JL Sadleir, LG Shendure, J Berkovic, SF Scheffer, IE Mefford, HC AF Carvill, Gemma L. Heavin, Sinead B. Yendle, Simone C. McMahon, Jacinta M. O'Roak, Brian J. Cook, Joseph Khan, Adiba Dorschner, Michael O. Weaver, Molly Calvert, Sophie Malone, Stephen Wallace, Geoffrey Stanley, Thorsten Bye, Ann M. E. Bleasel, Andrew Howell, Katherine B. Kivity, Sara Mackay, Mark T. Rodriguez-Casero, Victoria Webster, Richard Korczyn, Amos Afawi, Zaid Zelnick, Nathanel Lerman-Sagie, Tally Lev, Dorit Moller, Rikke S. Gill, Deepak Andrade, Danielle M. Freeman, Jeremy L. Sadleir, Lynette G. Shendure, Jay Berkovic, Samuel F. Scheffer, Ingrid E. Mefford, Heather C. TI Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1 SO NATURE GENETICS LA English DT Article ID AUTISM SPECTRUM DISORDERS; INTELLECTUAL DISABILITY; SODIUM-CHANNEL; MENTAL-RETARDATION; GENE SCN2A; MICRODELETION; SEIZURES; EPILEPSIES; PHENOTYPE; DELETIONS AB Epileptic encephalopathies are a devastating group of epilepsies with poor prognosis, of which the majority are of unknown etiology. We perform targeted massively parallel resequencing of 19 known and 46 candidate genes for epileptic encephalopathy in 500 affected individuals (cases) to identify new genes involved and to investigate the phenotypic spectrum associated with mutations in known genes. Overall, we identified pathogenic mutations in 10% of our cohort. Six of the 46 candidate genes had 1 or more pathogenic variants, collectively accounting for 3% of our cohort. We show that de novo CHD2 and SYNGAP1 mutations are new causes of epileptic encephalopathies, accounting for 1.2% and 1% of cases, respectively. We also expand the phenotypic spectra explained by SCN1A, SCN2A and SCN8A mutations. To our knowledge, this is the largest cohort of cases with epileptic encephalopathies to undergo targeted resequencing. Implementation of this rapid and efficient method will change diagnosis and understanding of the molecular etiologies of these disorders. C1 [Carvill, Gemma L.; Cook, Joseph; Khan, Adiba; Mefford, Heather C.] Univ Washington, Div Med Genet, Dept Pediat, Seattle, WA 98195 USA. [Heavin, Sinead B.; Yendle, Simone C.; McMahon, Jacinta M.; Berkovic, Samuel F.; Scheffer, Ingrid E.] Univ Melbourne, Austin Hlth, Dept Med, Epilepsy Res Ctr, Melbourne, Vic, Australia. [O'Roak, Brian J.; Shendure, Jay] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Dorschner, Michael O.; Weaver, Molly] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dorschner, Michael O.; Weaver, Molly] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Calvert, Sophie; Malone, Stephen; Wallace, Geoffrey] Royal Childrens Hosp, Neurosci Childrens Hlth Queensland, Brisbane, Qld, Australia. [Calvert, Sophie; Malone, Stephen; Wallace, Geoffrey] Univ Queensland, Mater Childrens Hosp, Neurosci Childrens Hlth Queensland, Brisbane, Qld 4101, Australia. [Stanley, Thorsten; Sadleir, Lynette G.] Univ Otago, Sch Med & Hlth Sci, Dept Paediat, Wellington, New Zealand. [Bye, Ann M. E.] Univ New S Wales, Dept Paediat Neurol, Sydney Childrens Hosp, Sydney, NSW, Australia. [Bleasel, Andrew] Univ Sydney, Westmead Hosp, Dept Neurol, Sydney, NSW 2006, Australia. [Howell, Katherine B.; Mackay, Mark T.; Freeman, Jeremy L.; Scheffer, Ingrid E.] Royal Childrens Hosp, Dept Neurol, Melbourne, Vic, Australia. [Kivity, Sara] Schneider Childrens Med Ctr Israel, Epilepsy Unit, Petah Tiqwa, Israel. [Mackay, Mark T.; Freeman, Jeremy L.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Mackay, Mark T.; Scheffer, Ingrid E.] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic, Australia. [Rodriguez-Casero, Victoria] Monash Med Ctr, Melbourne, Vic, Australia. [Webster, Richard; Gill, Deepak] Childrens Hosp Westmead, TY Nelson Dept Neurol, Sydney, NSW, Australia. [Korczyn, Amos] Tel Aviv Univ, Dept Neurol, IL-69978 Tel Aviv, Israel. [Afawi, Zaid] Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel. [Zelnick, Nathanel] Technion Israel Inst Technol, Fac Med, Carmel Med Ctr, Dept Pediat, Haifa, Israel. [Lerman-Sagie, Tally; Lev, Dorit] Wolfson Med Ctr, Metab Neurogenet Serv, Holon, Israel. [Lerman-Sagie, Tally; Moller, Rikke S.] Danish Epilepsy Ctr, Dianalund, Denmark. [Andrade, Danielle M.] Univ Toronto, Toronto Western Hosp, Dept Med, Div Neurol,Krembil Neurosci Program, Toronto, ON M5T 2S8, Canada. [Scheffer, Ingrid E.] Florey Inst, Melbourne, Vic, Australia. RP Mefford, HC (reprint author), Univ Washington, Div Med Genet, Dept Pediat, Seattle, WA 98195 USA. EM scheffer@unimelb.edu.au; hmefford@uw.edu RI Wallace, Geoff/H-1252-2013; Scheffer, Ingrid/G-1668-2013; Korczyn, Amos/C-3461-2017 OI Wallace, Geoff/0000-0001-9306-3542; Scheffer, Ingrid/0000-0002-2311-2174; Korczyn, Amos/0000-0003-0125-2579; McMahon, Jacinta/0000-0001-8891-0049; Berkovic, Samuel/0000-0003-4580-841X; O'Roak, Brian/0000-0002-4141-0095; Shendure, Jay/0000-0002-1516-1865 FU US National Institutes of Health (NIH; National Institute of Neurological Disorders and Stroke (NINDS)) [1R01NS069605]; Burroughs Wellcome Fund Career Award for Medical Scientists; National Health and Medical Research Council of Australia [628952, 1006110]; Health Research Council of New Zealand FX We thank the individuals with epileptic encephalopathies and their families for participating in our research. H. C. M. is supported by a grant from the US National Institutes of Health (NIH; National Institute of Neurological Disorders and Stroke (NINDS) 1R01NS069605) and is a recipient of a Burroughs Wellcome Fund Career Award for Medical Scientists. This work was supported by the National Health and Medical Research Council of Australia (program grant 628952 to S. F. B. and I. E. S., practitioner fellowship 1006110 to I. E. S.) and a Health Research Council of New Zealand project grant to L.G.S. NR 37 TC 192 Z9 198 U1 2 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JUL PY 2013 VL 45 IS 7 BP 825 EP U158 DI 10.1038/ng.2646 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 172LQ UT WOS:000321005200021 PM 23708187 ER PT J AU Lafata, JE Morris, HL Dobie, E Heisler, M Werner, RM Dumenci, L AF Lafata, Jennifer Elston Morris, Heather L. Dobie, Elizabeth Heisler, Michele Werner, Rachel M. Dumenci, Levent TI Patient-reported use of collaborative goal setting and glycemic control among patients with diabetes SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Diabetes; Collaborative goal setting; Glycemic control; Perceived competency; Patient-clinician communication ID COMPLEX DECISION-MAKING; CHRONIC CARE MODEL; QUALITY-OF-LIFE; SELF-MANAGEMENT; ACTIVATION INTERVENTION; PHYSICIAN COMMUNICATION; METABOLIC CONTROL; HEALTH; PERFORMANCE; STANDARDS AB Objective: Little is known about how patient-clinician communication leads to better outcomes. Among patients with diabetes, we describe patient-reported use of collaborative goal setting and evaluate whether perceived competency and physician trust mediate the association between collaborative goal setting and glycemic control. Methods: Data from a patient survey administered in 2008 to a cohort of insured patients aged 18+ years with diabetes who initiated oral mono-therapy between 2000 and 2005 were joined with pharmaceutical claims data for the prior 12 months and laboratory data for the prior and subsequent 12 months (N = 1065). A structural equation model (SEM) was used to test mediation models controlling for baseline HbA1c. Results: The hypothesized mediation model was supported. Patient-reported use of more collaborative goal setting was associated with greater perceived self-management competency and increased level of trust in the physician (p < 0.05). In turn, both greater perceived competence and increased trust were associated with increased control (p < 0.05). Conclusions: Findings indicate that engaging patients in collaborative goal setting during clinical encounters has potential to foster a trusting patient-clinician relationship as well as enhance patient perceived competence, thereby improving clinical control. Practice implications: Fostering collaborative goal setting may yield payoffs in improved clinical outcomes among patients with diabetes. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Lafata, Jennifer Elston; Morris, Heather L.; Dumenci, Levent] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23284 USA. [Dobie, Elizabeth] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Heisler, Michele] Univ Michigan, Ann Arbor, MI 48109 USA. [Werner, Rachel M.] Univ Penn, Dept Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Lafata, JE (reprint author), 830 E Main Floor,9th Floor,POB 980149, Richmond, VA 23298 USA. EM jelstonlafat@vcu.edu RI Heisler, Michele/B-5774-2015 OI Heisler, Michele/0000-0002-6889-2063 FU Sanofi-Aventis FX The database used was developed under a contract from Sanofi-Aventis. NR 34 TC 6 Z9 6 U1 2 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD JUL PY 2013 VL 92 IS 1 BP 94 EP 99 DI 10.1016/j.pec.2013.01.016 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 178YQ UT WOS:000321483700014 PM 23433777 ER PT J AU Shahim, P Darin, N Andreasson, U Blennow, K Jennions, E Lundgren, J Mansson, JE Naess, K Tornhage, CJ Zetterberg, H Mattsson, N AF Shahim, Pashtun Darin, Niklas Andreasson, Ulf Blennow, Kaj Jennions, Elizabeth Lundgren, Johan Mansson, Jan-Eric Naess, Karin Tornhage, Carl-Johan Zetterberg, Henrik Mattsson, Nildas TI Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study SO PEDIATRIC NEUROLOGY LA English DT Article ID FIBRILLARY ACIDIC PROTEIN; ALZHEIMERS-DISEASE; NEUROFILAMENT PROTEIN; STATUS EPILEPTICUS; TAU-PROTEIN; MARKERS; NEUROBORRELIOSIS; HYDROCEPHALUS; MENINGITIS; ASTROCYTES AB BACKGROUND: Cerebrospinal fluid (CSF) biomarkers reflecting neuronal and astroglial injury, such as total tau (T-tau), glial flbrillary acidic protein (GFAP), and neurofilament light (NFL), have been extensively investigated in neurologic diseases in adults, but no large study has investigated these biomarkers in children. METHODS: This study presents a detailed evaluation of CFS T-tau, GFAP, NFL, and CSF:albumin ratio in a large cohort of pediatric patients. This is a retrospective multicenter study on pediatric patients aged <16 years (n = 607), where neuronal injury biomarkers T-tau, GFAP, NFL, and CSF albumin ratio were analyzed during 2000-2010 at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden. The patients were grouped into eight categories: epilepsy, infectious and inflammatory central nervous system disorders, progressive encephalopathy, static encephalopathy, tumors, movement disorders, miscellaneous disorders, and a control group. RESULTS: T-tau, GFAP, and NFL were increased in progressive encephalopathy (P < 0.001), epilepsy (P < 0.001), and infectious and inflammatory central nervous system disorders (P < 0.001) compared with controls. T-tau was the biomarker with the highest diagnostic accuracy with the area under the curve of 0.83 (95% confidence interval (CI), 0.77-0.90; P < 0.0001) for progressive encephalopathy followed by epilepsy 0.80 (95% CI, 0.75-0.87; P < 0.0001). The combination of all four biomarkers further improved the area under the curve for the progressive encephalopathy 0.87 (95% CI, 0.77-0.89; P < 0.0001), followed by epilepsy 0.81 (95% CI, 0.74-0.80; P = 0.030). The combination of the biomarkers also separated progressive from static encephalopathy 0.88 (95% CI, 0.83-0.93; P < 0.0001). CONCLUSIONS: CSF T-tau, GFAP, and NFL are differently altered across different neurologic diseases in children. Importantly, the biomarker pattern distinguishes between progressive and static neurologic disorders. (c) 2013 Elsevier Inc. All rights reserved. C1 [Shahim, Pashtun; Andreasson, Ulf; Blennow, Kaj; Mansson, Jan-Eric; Zetterberg, Henrik; Mattsson, Nildas] Sahlgrenska Univ Hosp Molndal, Inst Neurosci & Physiol, Dept Neurochem, Clin Neurochem Lab, S-43180 Molndal, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, London, England. [Darin, Niklas] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Inst Clin Sci, Dept Pediat, Ostra, Sweden. [Jennions, Elizabeth] Sodra Alvborgs Hosp, Boras, Sweden. [Lundgren, Johan] Skane Univ Hosp, Dept Clin Sci, Pediat Unit, Lund, Sweden. [Naess, Karin] Karolinska Univ Hosp, Ctr Inherited Metab Dis, Stockholm, Sweden. [Naess, Karin] Karolinska Inst, Dept Lab Med, Stockholm, Sweden. [Tornhage, Carl-Johan] Skaraborgs Hosp, Dept Pediat, Skovde, Sweden. [Mattsson, Nildas] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA. RP Shahim, P (reprint author), Sahlgrenska Univ Hosp Molndal, Clin Neurochem Lab, S-43180 Molndal, Sweden. EM pashtun.shahim@neuro.gu.se FU Swedish Research Council; Alzheimer's Association; Swedish Brain Power; Swedish State Support for Clinical Research; Sahlgrenska University Hospital; Sahlgrenska Academy; Lundbeck Foundation; Stiftelsen Psykiatriska Forskningsfonden; Stiftelsen Gamla Tjanarinnor; Uppsala Universitets Medicinska Fakultet stiftelse for psykiatrisk och neurologisk forskning; Swedish Brain Fund; Goteborgs lakaresallskap; Thureus stiftelse; Pfannenstills stiftelse; Demensfonden, Sweden FX The authors' work is supported by grants from the Swedish Research Council, Alzheimer's Association, Swedish Brain Power, Swedish State Support for Clinical Research, Sahlgrenska University Hospital, Sahlgrenska Academy, the Lundbeck Foundation, Stiftelsen Psykiatriska Forskningsfonden, Stiftelsen Gamla Tjanarinnor, Uppsala Universitets Medicinska Fakultet stiftelse for psykiatrisk och neurologisk forskning, the Swedish Brain Fund, Goteborgs lakaresallskap, Thureus stiftelse, Pfannenstills stiftelse, and Demensfonden, Sweden. NR 37 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0887-8994 J9 PEDIATR NEUROL JI Pediatr. Neurol. PD JUL PY 2013 VL 49 IS 1 BP 31 EP 39 DI 10.1016/j.pediatrneurol.2013.02.015 PG 9 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 183IR UT WOS:000321808700007 PM 23827424 ER PT J AU Blackard, JT Kong, L Huber, AK Tomer, Y AF Blackard, Jason T. Kong, Ling Huber, Amanda K. Tomer, Yaron TI Hepatitis C Virus Infection of a Thyroid Cell Line: Implications for Pathogenesis of Hepatitis C Virus and Thyroiditis SO THYROID LA English DT Article ID INTERFERON-ALPHA THERAPY; BLOOD MONONUCLEAR-CELLS; HCV CHRONIC HEPATITIS; HUMAN HEPATOMA-CELLS; HUMAN HEPATOCYTES; IN-VITRO; EXTRAHEPATIC REPLICATION; ANTIVIRAL ACTION; WHOLE-BLOOD; INTERLEUKIN-8 AB Background: Autoimmune and non-autoimmune thyroiditis frequently occur in persons with hepatitis C virus (HCV) infection. Treatment with interferon alpha (IFN alpha) is also associated with significant risk for the development of thyroiditis. To explore HCV-thyroid interactions at a cellular level, we evaluated whether a human thyroid cell line (ML1) could be infected productively with HCV in vitro. Methods and Results: ML1 cells showed robust surface expression of the major HCV receptor CD81. Using a highly sensitive, strand-specific reverse transcription polymerase chain reaction assay, positive-sense and negative-sense HCV RNA were detected in ML1 cell lysates at days 3, 7, and 14 postinfection with HCV. HCV core protein was expressed at high levels in ML1 supernatants at days 1, 3, 5, 7, and 14 postinfection. The nonstructural protein NS5A was also detected in ML1 cell lysates by Western blotting. HCV entry into ML1 cells was shown to be dependent on the HCV entry factors CD81 and SR-B1/CLA1, while IFN alpha inhibited HCV replication in ML1 cells in a dose-dependent manner. Supernatants from HCV-infected ML1 cells were able to infect fresh ML1 cells productively, suggesting that infectious virions could be transferred from infected to naive thyroid cells in vivo. Additionally, HCV infection of ML1 cells led to increased expression of the proinflammatory cytokine IL-8. Conclusions: For the first time, we have demonstrated that HCV can infect human thyroid cells in vitro. These findings strongly suggest that HCV infection of thyrocytes may play a role in the association between chronic HCV infection and thyroid autoimmunity. Furthermore, the thyroid may serve as an extrahepatic reservoir for HCV viral replication, thus contributing to the persistence of viral infection and to the development of thyroid autoimmunity. C1 [Blackard, Jason T.; Kong, Ling] Univ Cincinnati, Coll Med, Div Digest Dis, Dept Internal Med, Cincinnati, OH 45267 USA. [Huber, Amanda K.; Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA. RP Blackard, JT (reprint author), Univ Cincinnati, Coll Med, Div Digest Dis, Dept Internal Med, ML 0595,231 Albert Sabin Way, Cincinnati, OH 45267 USA. EM jason.blackard@uc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; VA Biomedical Laboratory Research and Development Merit Award; NIDDK [DK61659, DK67555, DK073681] FX This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and by the VA Biomedical Laboratory Research and Development Merit Award and by grants DK61659, DK67555, and DK073681 from NIDDK (to Y.T.). The authors would like to thank Ms. Eleanor Powell for her critical evaluation of this manuscript. NR 51 TC 26 Z9 29 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD JUL PY 2013 VL 23 IS 7 BP 863 EP 870 DI 10.1089/thy.2012.0507 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 179XF UT WOS:000321554900013 PM 23259732 ER PT J AU Pennington, DL Durazzo, TC Schmidt, TP Mon, A Abe, C Meyerhoff, DJ AF Pennington, David L. Durazzo, Timothy C. Schmidt, Thomas P. Mon, Anderson Abe, Christoph Meyerhoff, Dieter J. TI The Effects of Chronic Cigarette Smoking on Cognitive Recovery During Early Abstinence from Alcohol SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol Dependence; Cigarette Smoking; Cognition; Treatment; Former Smoking ID NEUROCOGNITIVE FUNCTION; DEPENDENT INDIVIDUALS; NICOTINE DEPENDENCE; MAJOR DEPRESSION; DRINKING HISTORY; USE DISORDERS; CONSUMPTION; PERFORMANCE; DEFICITS; CONSEQUENCES AB Background Alcohol use disorders are related to neurocognitive abnormalities during early abstinence in those seeking treatment for alcohol dependence (ALC). Considerable evidence indicates that chronic cigarette smoking is associated with multiple neurocognitive deficiencies. However, very little is known about the effects of chronic smoking on neurocognitive recovery during early abstinence from alcohol. We evaluated whether cigarette smoking interferes with cognitive improvement during early abstinence from alcohol, a period thought important for maintaining long-term sobriety. Methods Neurocognitive functions previously shown to be adversely affected by both alcohol use disorders and chronic cigarette smoking were evaluated. We assessed 35 smoking ALC (sALC) and 34 nonsmoking ALC (nsALC) at approximately 1 and 5weeks of monitored abstinence. Results Although neither group was clinically impaired, both cross-sectional and longitudinal deficiencies were observed in sALC versus nsALC in processing speed, working memory, and auditory-verbal learning and memory. Lifetime alcohol consumption, medical, and psychiatric comorbidities did not predict neurocognitive performance or improvement across assessments. Within sALC, greater drinking and smoking severities were synergistically (more than additively) related to less improvement on visuospatial learning and memory. Former smoking status in the nsALC-mediated group differences in auditory-verbal delayed recall. Conclusions Chronic cigarette smoking appears to negatively impact neurocognition during early abstinence from alcohol. Although the cognitive deficiencies observed in this cohort were not in a clinical range of impairment, they should be considered to enhance treatment efficacy. Our findings lend support to integrating smoking cessation as well as the individual assessment of cognition into early ALC treatment. Additionally, there is a need to elucidate the effects of current and former smoking status in future reports of neurocognition. C1 [Pennington, David L.; Durazzo, Timothy C.; Schmidt, Thomas P.; Mon, Anderson; Abe, Christoph; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Pennington, David L.; Durazzo, Timothy C.; Schmidt, Thomas P.; Mon, Anderson; Abe, Christoph; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Pennington, DL (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM david.pennington@ucsf.edu OI Abe, Christoph/0000-0002-1680-8480 FU National Institutes of Health [AA10788, DA24136] FX This work was supported by grants from the National Institutes of Health (AA10788 to DJM; DA24136 to TCD) administered by the Northern California Institute for Research and Education, and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen, and Drs. Peter Banys and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital (which routinely offers smoking cessation with substance abuse treatment), and Dr. David Pating, Karen Moise, and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 54 TC 11 Z9 12 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUL PY 2013 VL 37 IS 7 BP 1220 EP 1227 DI 10.1111/acer.12089 PG 8 WC Substance Abuse SC Substance Abuse GA 175TR UT WOS:000321256800019 PM 23432133 ER PT J AU Ahmad, FS Metlay, JP Barg, FK Henderson, RR Werner, RM AF Ahmad, Faraz S. Metlay, Joshua P. Barg, Frances K. Henderson, Rebecca R. Werner, Rachel M. TI Identifying Hospital Organizational Strategies to Reduce Readmissions SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE readmissions; quality; qualitative methods; care transitions ID MYOCARDIAL-INFARCTION; 30-DAY READMISSIONS; QUALITY; PROGRAM AB With looming financial penalties for institutions with high readmission rates, hospital administrators are under pressure to implement strategies to reduce readmissions despite limited evidence of effective strategies. The objectives of this study were to understand the process of developing readmission reduction strategies and to identify and categorize the range of strategies being implemented. The authors designed a qualitative study using semistructured interviews with 12 hospital administrators at 6 different hospitals. The following 6 categories of strategies were identified: (a) tracking readmissions, (b) using prediction tools, (c) implementing disease-specific or generic readmission reduction programs, (d) adopting electronic health record-based strategies to improve transitions, (e) recruiting frontline staff for program leadership, and (f) coordinating with primary care providers. The results highlight the myriad approaches to readmission reduction and the complexity of developing effective strategies. C1 [Ahmad, Faraz S.; Metlay, Joshua P.; Barg, Frances K.; Henderson, Rebecca R.; Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Ahmad, FS (reprint author), Hosp Univ Penn, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA. EM Faraz.Ahmad@uphs.upenn.edu FU Center for Healthcare Improvement & Patient Safety in the Department of Medicine at the Perelman School of Medicine of the University of Pennsylvania FX The authors received the following financial support for the research, authorship, and/or publication of this article: This study was funded by Center for Healthcare Improvement & Patient Safety in the Department of Medicine at the Perelman School of Medicine of the University of Pennsylvania. NR 20 TC 6 Z9 6 U1 2 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD JUL PY 2013 VL 28 IS 4 BP 278 EP 285 DI 10.1177/1062860612464999 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 176XM UT WOS:000321340100001 PM 23118202 ER PT J AU Ellett, JD Rosoff, JS Prasad, SM AF Ellett, Justin D. Rosoff, James S. Prasad, Sandip M. TI Long-term differences in urinary, bowel and sexual function among men treated with surgery versus radiation for prostate cancer SO ASIAN JOURNAL OF ANDROLOGY LA English DT Editorial Material ID ACTIVE SURVEILLANCE; OUTCOMES C1 [Ellett, Justin D.; Rosoff, James S.; Prasad, Sandip M.] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. [Prasad, Sandip M.] Ralph H Johnson VA Med Ctr, Urol Sect, Charleston, SC 29401 USA. RP Prasad, SM (reprint author), Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. EM prasads@musc.edu NR 10 TC 1 Z9 1 U1 1 U2 6 PU ACTA PHARMACOLOGICA SINICA PI SHANGHAI PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA SN 1008-682X J9 ASIAN J ANDROL JI Asian J. Androl. PD JUL PY 2013 VL 15 IS 4 BP 443 EP 444 DI 10.1038/aja.2013.39 PG 2 WC Andrology; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 174XE UT WOS:000321190000003 PM 23665759 ER PT J AU Ansbaugh, N Shannon, J Mori, M Farris, PE Garzotto, M AF Ansbaugh, Nathan Shannon, Jackilen Mori, Motomi Farris, Paige E. Garzotto, Mark TI Agent Orange as a risk factor for high-grade prostate cancer SO CANCER LA English DT Article DE prostatic neoplasms; urology; Agent Orange; risk factors; veterans ID VIETNAM-WAR; VETERANS; MORTALITY; EXPOSURE AB BACKGROUND Agent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high-grade PCa (HGPCa) (Gleason score 7) on biopsy in a US Veteran cohort. METHODS Risk factors included clinicodemographic and laboratory data from veterans who were referred for an initial prostate biopsy. Outcomes were defined as the presence versus the absence of PCa, HGPCa, or low-grade PCa (LGPCa) (Gleason score 6) in biopsy specimens. Risk among AOe veterans relative to unexposed veterans was estimated using multivariate logistic regression. Separate models were used to determine whether AOe was associated with an increased risk of PCa, HGPCa, or LGPCa. RESULTS Of 2720 veterans who underwent biopsy, PCa was diagnosed in 896 veterans (32.9%), and 459 veterans (16.9%) had HGPCa. AOe was associated with a 52% increase in the overall risk of detecting PCa (adjusted odds ratio, 1.52; 95% confidence interval, 1.07-2.13). AOe did not confer an increase in the risk of LGPCa (adjusted odds ratio, 1.24; 95% confidence interval, 0.81-1.91), although a 75% increase in the risk of HGPCa was observed (adjusted odds ratio, 1.75; 95% confidence interval, 1.12-2.74). AOe was associated with a 2.1-fold increase (95% confidence interval, 1.22-3.62; P < .01) in the risk of detecting PCa with a Gleason score 8. CONCLUSIONS The current results indicated that an increased risk of PCa associated with AOe is driven by an increased risk of HGPCa in men who undergo an initial prostate biopsy. These findings may aid in improved PCa screening for Vietnam-era veterans. Cancer 2013;119:2399-2404. (c) 2013 American Cancer Society. C1 [Ansbaugh, Nathan; Shannon, Jackilen] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Shannon, Jackilen; Farris, Paige E.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA. [Shannon, Jackilen; Garzotto, Mark] Portland VA Med Ctr, Div Urol, Portland, OR USA. [Shannon, Jackilen; Mori, Motomi; Garzotto, Mark] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Garzotto, Mark] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA. [Garzotto, Mark] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA. RP Garzotto, M (reprint author), 3710 SW US Vet Hosp Rd P3GU, Portland, OR 97239 USA. EM mark.garzotto@va.gov FU NCI NIH HHS [P30 CA069533] NR 13 TC 8 Z9 9 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD JUL 1 PY 2013 VL 119 IS 13 BP 2399 EP 2404 DI 10.1002/cncr.27941 PG 6 WC Oncology SC Oncology GA 165FT UT WOS:000320469400009 PM 23670242 ER PT J AU Musuuza, JS Sherman, ME Knudsen, KJ Sweeney, HA Tyler, CV Koroukian, SM AF Musuuza, Jackson S. Sherman, Marion E. Knudsen, Kraig J. Sweeney, Helen Anne Tyler, Carl V. Koroukian, Siran M. TI Analyzing excess mortality from cancer among individuals with mental illness SO CANCER LA English DT Article DE mental illness; excess mortality; all-cancer mortality; site-specific cancer mortality ID OHIO MEDICAID POPULATION; RENAL-CELL CARCINOMA; CIGARETTE-SMOKING; BREAST-CANCER; UNITED-STATES; LUNG-CANCER; FOLLOW-UP; DISORDERS; RISK; SCHIZOPHRENIA AB BACKGROUND The objective was to compare patterns of site-specific cancer mortality in a population of individuals with and without mental illness. METHODS This was a cross-sectional, population-based study using a linked data set comprised of death certificate data for the state of Ohio for the years 2004-2007 and data from the publicly funded mental health system in Ohio. Decedents with mental illness were those identified concomitantly in both data sets. We used age-adjusted standardized mortality ratios (SMRs) in race- and sex-specific person-year strata to estimate excess deaths for each of the anatomic cancer sites. RESULTS Overall, there was excess mortality from cancer associated with having mental illness in all the race/sex strata: SMR, 2.16 (95% CI, 1.85-2.50) for black men; 2.63 (2.31-2.98) for black women; 3.89 (3.61-4.19) for nonblack men; and 3.34 (3.13-3.57) for nonblack women. In all the race/sex strata except for black women, the highest SMR was observed for laryngeal cancer, 3.94 (1.45-8.75) in black men and 6.51 (3.86-10.35) and 6.87 (3.01-13.60) in nonblack men and women, respectively. The next highest SMRs were noted for hepatobiliary cancer and cancer of the urinary tract in all race/sex strata, except for black men. CONCLUSIONS Compared with the general population in Ohio, individuals with mental illness experienced excess mortality from most cancers, possibly explained by a higher prevalence of smoking, substance abuse, and chronic hepatitis B or C infections in individuals with mental illness. Excess mortality could also reflect late-stage diagnosis and receipt of inadequate treatment. Cancer 2013;119:2469-2476. (c) 2013 American Cancer Society. C1 [Musuuza, Jackson S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Sherman, Marion E.] Joint Ambulatory Care Ctr, US Dept Vet Affairs, Pensacola, FL USA. [Knudsen, Kraig J.; Sweeney, Helen Anne] Ohio Dept Mental Hlth, Columbus, OH USA. [Tyler, Carl V.] Cleveland Clin, Cleveland, OH 44106 USA. [Tyler, Carl V.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Koroukian, Siran M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Sch Med, Cleveland, OH 44106 USA. RP Koroukian, SM (reprint author), Case Western Reserve Univ, Dept Epidemiol & Biostat, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA. EM skoroukian@case.edu FU Ohio Department of Mental Health; Clinical and Translational Science Collaborative of Cleveland from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1TR000439]; NIH Roadmap for Medical Research FX Drs. Siran M. Koroukian and Jackson Musuuza were supported by a grant from the Ohio Department of Mental Health. Dr. Siran M. Koroukian is also supported by the Clinical and Translational Science Collaborative of Cleveland, UL1TR000439, from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 45 TC 8 Z9 8 U1 1 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD JUL 1 PY 2013 VL 119 IS 13 BP 2469 EP 2476 DI 10.1002/cncr.28091 PG 8 WC Oncology SC Oncology GA 165FT UT WOS:000320469400018 PM 23585241 ER PT J AU Reiter, RJ Tan, DX Manchester, LC Korkmaz, A Fuentes-Broto, L Hardman, WE Rosales-Corral, SA Qi, WB AF Reiter, Russel J. Tan, Dun-Xian Manchester, Lucien C. Korkmaz, Ahmet Fuentes-Broto, Lorena Hardman, W. Elaine Rosales-Corral, Sergio A. Qi, Wenbo TI A Walnut-Enriched Diet Reduces the Growth of LNCaP Human Prostate Cancer Xenografts in Nude Mice SO CANCER INVESTIGATION LA English DT Article DE LNCaP cells; Prostate cancer; Walnuts; F-2-isoprostanes ID N-3 FATTY-ACIDS; BREAST-CANCER; GAMMA-TOCOPHEROL; VITAMIN-E; IN-VIVO; ENDOTHELIAL FUNCTION; CELL-PROLIFERATION; LIPID-PEROXIDATION; MEDITERRANEAN DIET; ELLAGIC ACID AB It was investigated whether a standard mouse diet (AIN-76A) supplemented with walnuts reduced the establishment and growth of LNCaP human prostate cancer cells in nude (nu/nu) mice. The walnut-enriched diet reduced the number of tumors and the growth of the LNCaP xenografts; 3 of 16 (18.7%) of the walnut-fed mice developed tumors; conversely, 14 of 32 mice (44.0%) of the control diet-fed animals developed tumors. Similarly, the xenografts in the walnut-fed animals grew more slowly than those in the control diet mice. The final average tumor size in the walnut-diet animals was roughly one-fourth the average size of the prostate tumors in the mice that ate the control diet. C1 [Reiter, Russel J.; Tan, Dun-Xian; Manchester, Lucien C.; Korkmaz, Ahmet; Fuentes-Broto, Lorena; Rosales-Corral, Sergio A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Hardman, W. Elaine] Marshall Univ, Sch Med, Dept Biochem & Microbiol, Huntington, WV USA. [Qi, Wenbo] Vet Adm Hosp, San Antonio, TX USA. RP Reiter, RJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM reiter@uthscsa.edu RI Fuentes-Broto, Lorena/D-2773-2009 OI Fuentes-Broto, Lorena/0000-0003-2656-6750 FU American Institute for Cancer Research [09A073] FX This work was supported by a grant from the American Institute for Cancer Research (grant #09A073). NR 66 TC 13 Z9 14 U1 0 U2 18 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PD JUL PY 2013 VL 31 IS 6 BP 365 EP 373 DI 10.3109/07357907.2013.800095 PG 9 WC Oncology SC Oncology GA 170PZ UT WOS:000320866800001 PM 23758186 ER PT J AU Yomogida, K Chou, YK Chu, CQ AF Yomogida, Kentaro Chou, Yuan K. Chu, Cong-Qiu TI Superantigens induce IL-17 production from polarized Th1 clones SO CYTOKINE LA English DT Article DE Superantigen; Th1; Th17; MOG(35-55) ID MYELIN BASIC-PROTEIN; BACTERIAL SUPERANTIGENS; T-CELLS; DIFFERENTIATION; SPECIFICITY; ACTIVATION; DISEASES AB Differentiation of naive CD4(+) T cells has been considered to be an irreversible event and, in particular, the plasticity is believed to be completely lost in Th1 subset in vitro after multiple stimulations. However, here we demonstrate that highly polarized myelin oligodendrocyte glycoprotein (MOG)- and herpes simples virus-specific Th1 clones were still capable of producing IL-17 upon superantigen stimulation. Anti-MHC class-II and anti-TCR alpha beta chains partially blocked superantigen-induced IL-17 production. These findings suggest that fully differentiated Th1 cells still have capability to produce cytokines of other Th subsets and production of IL-17 by MOG-specific Th1 cells may have implication in initiation and/or exacerbation of neurological autoimmune diseases. Published by Elsevier Ltd. C1 Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Chu, CQ (reprint author), 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA. EM chuc@ohsu.edu FU NIH [AR055254]; Portland VA Medical Center FX This work was supported by a grant from NIH to CQC (AR055254) and Portland VA Medical Center. NR 14 TC 3 Z9 3 U1 0 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD JUL PY 2013 VL 63 IS 1 BP 6 EP 9 DI 10.1016/j.cyto.2013.04.015 PG 4 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 172CG UT WOS:000320977000002 PM 23664273 ER PT J AU Rhodes, CJ White, MF Leahy, JL Kahn, SE AF Rhodes, Christopher J. White, Morris F. Leahy, John L. Kahn, Steven E. TI Direct Autocrine Action of Insulin on beta-Cells: Does It Make Physiological Sense? SO DIABETES LA English DT Article ID PREPROINSULIN MESSENGER-RNA; PROINSULIN BIOSYNTHESIS; IRS-2 EXPRESSION; FEEDBACK INHIBITION; PANCREATIC INSULIN; DIABETES-MELLITUS; PORTAL-VEIN; GLUCOSE; RECEPTOR; SECRETION AB In recent years there has been a growing interest in the possibility of a direct autocrine effect of insulin on the pancreatic beta-cell. Indeed, there have been numerous intriguing articles and several eloquent reviews written on the subject (1-3); however, the concept is still controversial. Although many in vitro experiments, a few transgenic mouse studies, and some human investigations would be supportive of the notion, there exist different insights, other studies, and circumstantial evidence that question the concept. Therefore, the idea of autocrine action of insulin remains a conundrum. Here we outline a series of thoughts, insights, and alternative interpretations of the available experimental evidence. We ask, how convincing are these, and what are the confusing issues? We agree that there is a clear contribution of certain downstream elements in the insulin signaling pathway for beta-cell function and survival, but the question of whether insulin itself is actually the physiologically relevant ligand that triggers this signal transduction remains unsettled. C1 [Rhodes, Christopher J.] Univ Chicago, Dept Med, Kovler Diabet Ctr, Chicago, IL 60637 USA. [White, Morris F.] Harvard Univ, Sch Med, Dept Med, Div Endocrinol,Boston Childrens Hosp, Boston, MA USA. [Leahy, John L.] Univ Vermont, Dept Med, Div Endocrinol Diabet & Metab, Colchester, VT USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Rhodes, CJ (reprint author), Univ Chicago, Dept Med, Kovler Diabet Ctr, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM cjrhodes@uchicago.edu FU National Institutes of Health [DK-055267, DK-050610, DK-075998, DK-017047, DK-056818, DK-038712]; Department of Veterans Affairs FX This work was supported by National Institutes of Health grants DK-055267 (C.J.R.), DK-050610 (C.J.R.), DK-075998 (S.E.K.), DK-017047 (S.E.K.), DK-056818 (J.L.L.), and DK-038712 (M.F.W.) and the Department of Veterans Affairs (S.E.K.). NR 64 TC 27 Z9 28 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JUL PY 2013 VL 62 IS 7 BP 2157 EP 2163 DI 10.2337/db13-0246 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 173KA UT WOS:000321077200001 PM 23801714 ER PT J AU Kahn, SE AF Kahn, Steven E. TI Incretin Therapy and Islet Pathology: A Time for Caution SO DIABETES LA English DT Editorial Material ID GLUCAGON-LIKE PEPTIDE-1; GASTRIC BYPASS-SURGERY; BETA-CELL APOPTOSIS; ACUTE-PANCREATITIS; GLP-1 ANALOG; RISK; GLUCOSE; HYPERPLASIA; SECRETION; HUMANS C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU BLRD VA [I01 BX001060]; NIDDK NIH HHS [P30 DK017047] NR 25 TC 40 Z9 40 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JUL PY 2013 VL 62 IS 7 BP 2178 EP 2180 DI 10.2337/db13-0520 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 173KA UT WOS:000321077200005 PM 23596147 ER PT J AU Rosenstock, J Marx, N Kahn, SE Zinman, B Kastelein, JJ Lachin, JM Bluhmki, E Patel, S Johansen, OE Woerle, HJ AF Rosenstock, Julio Marx, Nikolaus Kahn, Steven E. Zinman, Bernard Kastelein, John J. Lachin, John M. Bluhmki, Erich Patel, Sanjay Johansen, Odd-Erik Woerle, Hans-Juergen TI Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial SO DIABETES & VASCULAR DISEASE RESEARCH LA English DT Review DE Type 2 diabetes mellitus; cardiovascular disease; oral glucose-lowering agent; dipeptidyl peptidase-4 inhibitor; sulphonylurea ID BLOOD-GLUCOSE CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; CORONARY-ARTERY-DISEASE; ALL-CAUSE MORTALITY; MYOCARDIAL-INFARCTION; EUROPEAN-ASSOCIATION; VASCULAR COMPLICATIONS; GLYCEMIC CONTROL; HEART-DISEASE; MELLITUS AB Sulphonylureas (SUs) are widely used glucose-lowering agents in type 2 diabetes mellitus (T2DM) with apparent declining efficacy over time. Concerns have been raised from observational retrospective studies on the cardiovascular (CV) safety of SUs but there are few long-term data on CV outcomes from randomized controlled trials (RCTs) involving the use of this class of agents. Most of the observational studies and registry data are conflicting and vary with study population and methodology used for analyses. To address the SU controversy, we reviewed the recently published literature (until end of the year 2011) to evaluate the impact of SUs on CV outcomes in modern, longer-term (>= 72 weeks) RCTs where they were compared in a head-to-head fashion versus an active comparator or were used as part of a treatment strategy. We identified 15 trials and found no report of an increase in the incidence of CV events with the use of SUs. However, the available data are limited, and, most importantly, there was no adequately powered formal head-to-head CV outcome trial designed to address CV safety. Since SUs are still being advocated as second-line therapy added-on to metformin, as one of several classes, and in certain circumstances first-line therapy in T2DM management, definitive data from a dedicated RCT addressing the CV safety question with SUs would be informative. Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) is such a trial, ongoing since November 2010, and is currently the largest head-to-head CV outcome trial that involves a comparison of a SU (glimepiride) with a dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin) and will provide a unique perspective with respect to CV outcomes with these two commonly used agents. C1 [Rosenstock, Julio] Med City, Dallas Diabet & Endocrine Ctr, Dallas, TX USA. [Marx, Nikolaus] Univ Hosp Aachen, Dept Internal Med 1, D-52074 Aachen, Germany. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Dept Med, Seattle, WA USA. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Zinman, Bernard] Univ Toronto, Div Endocrinol, Toronto, ON, Canada. [Kastelein, John J.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Bluhmki, Erich] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany. [Patel, Sanjay] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England. [Johansen, Odd-Erik; Woerle, Hans-Juergen] Boehringer Ingelheim KG, Ingelheim, Germany. RP Marx, N (reprint author), Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany. EM nmarx@ukaachen.de RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002 FU Boehringer Ingelheim FX This study was supported financially by Boehringer Ingelheim. NR 62 TC 70 Z9 72 U1 2 U2 15 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1479-1641 J9 DIABETES VASC DIS RE JI Diabetes Vasc. Dis. Res. PD JUL PY 2013 VL 10 IS 4 BP 289 EP 301 DI 10.1177/1479164112475102 PG 13 WC Endocrinology & Metabolism; Peripheral Vascular Disease SC Endocrinology & Metabolism; Cardiovascular System & Cardiology GA 165RX UT WOS:000320502300001 PM 23449634 ER PT J AU Penzes, P Buonanno, A Passafaro, M Sala, C Sweet, RA AF Penzes, Peter Buonanno, Andres Passafaro, Maria Sala, Carlo Sweet, Robert A. TI Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders SO JOURNAL OF NEUROCHEMISTRY LA English DT Review DE Alzheimer's disease; autism; dendritic spine; dopamine; ErbB4; GABAergic interneuron ID LINKED MENTAL-RETARDATION; AUTISM SPECTRUM DISORDER; CENTRAL-NERVOUS-SYSTEM; PARVALBUMIN-POSITIVE INTERNEURONS; HIPPOCAMPAL GAMMA OSCILLATIONS; DENDRITIC SPINE MORPHOGENESIS; GLUTAMIC-ACID DECARBOXYLASE; 22Q13.3 DELETION SYNDROME; INCREASED FAMILIAL RISK; EARLY-ONSET PSYCHOSIS AB Psychiatric and neurodegenerative disorders, including intellectual disability, autism spectrum disorders (ASD), schizophrenia (SZ), and Alzheimer's disease, pose an immense burden to society. Symptoms of these disorders become manifest at different stages of life: early childhood, adolescence, and late adulthood, respectively. Progress has been made in recent years toward understanding the genetic substrates, cellular mechanisms, brain circuits, and endophenotypes of these disorders. Multiple lines of evidence implicate excitatory and inhibitory synaptic circuits in the cortex and hippocampus as key cellular substrates of pathogenesis in these disorders. Excitatory/inhibitory balance - modulated largely by dopamine - critically regulates cortical network function, neural network activity (i.e. gamma oscillations) and behaviors associated with psychiatric disorders. Understanding the molecular underpinnings of synaptic pathology and neuronal network activity may thus provide essential insight into the pathogenesis of these disorders and can reveal novel drug targets to treat them. Here, we discuss recent genetic, neuropathological, and molecular studies that implicate alterations in excitatory and inhibitory synaptic circuits in the pathogenesis of psychiatric disorders across the lifespan. C1 [Penzes, Peter] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Buonanno, Andres] Eunice Shriver Kennedy NICHD, Mol Neurobiol Sect, NIH, Program Dev Neurobiol, Bethesda, MD USA. [Passafaro, Maria; Sala, Carlo] Univ Milan, CNR Inst Neurosci, Milan, Italy. [Passafaro, Maria; Sala, Carlo] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy. [Passafaro, Maria] CNR, Inst Neurosci, Dulbecco Telethon Inst, I-20133 Milan, Italy. [Sala, Carlo] Neurol Inst, Milan, Italy. [Sala, Carlo] Fdn Carlo Besta, Milan, Italy. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. RP Penzes, P (reprint author), Northwestern Univ, Dept Physiol, Feinberg Sch Med, 303 E,Chicago Ave, Chicago, IL 60611 USA. EM p-penzes@northwestern.edu RI Penzes, Peter/L-3987-2016; Sala, Carlo/A-2493-2009 OI Penzes, Peter/0000-0001-5449-1640; Sala, Carlo/0000-0003-0662-9523 FU NIH [MH071316, MH097216, MH071533, AG027224]; Eunice Shriver Kennedy National Institute of Child Health and Human Development Intramural Research Program; Veterans Health Administration [BX000452]; Comitato Telethon Fondazione Onlus [GGP09196, GGP11095, GGP12097, GGP11116B]; Fondazione CARI-PLO project [2009.264]; Italian Institute of Technology, Seed Grant, Ministry of Health in the frame of ERA-NET NEURON and PNR-CNR Aging Program FX This study was supported by NIH grants MH071316 and MH097216 to P. P., Eunice Shriver Kennedy National Institute of Child Health and Human Development Intramural Research Program to A. B., Veterans Health Administration Grant BX000452 and NIH Grants MH071533 and AG027224 to R. A. S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, the National Institutes of Health, or the United States government. We thank Ruoqi Gao for assistance with editing the manuscript. This study was financially supported by Comitato Telethon Fondazione Onlus, grant n. GGP09196 and GGP11095 (to CS), n. GGP12097 and GGP11116B (to MP) Fondazione CARI-PLO project number 2009.264, Italian Institute of Technology, Seed Grant, Ministry of Health in the frame of ERA-NET NEURON and PNR-CNR Aging Program 2012-2014 (to CS). The authors declare no conflicts of interest. NR 217 TC 40 Z9 41 U1 5 U2 29 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD JUL PY 2013 VL 126 IS 2 BP 165 EP 182 DI 10.1111/jnc.12261 PG 18 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 175DY UT WOS:000321211700004 PM 23574039 ER PT J AU Liu, X Hirano, AA Sun, XP Brecha, NC Barnes, S AF Liu, Xue Hirano, Arlene A. Sun, Xiaoping Brecha, Nicholas C. Barnes, Steven TI Calcium channels in rat horizontal cells regulate feedback inhibition of photoreceptors through an unconventional GABA- and pH-sensitive mechanism SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID TIGER SALAMANDER RETINA; OUTER PLEXIFORM LAYER; CONE PHOTORECEPTORS; ROD PHOTORECEPTORS; MOUSE RETINA; INTRACELLULAR CALCIUM; TRANSMITTER RELEASE; VERTEBRATE RETINA; PLASMA-MEMBRANE; GOLDFISH RETINA AB Horizontal cells send inhibitory feedback to photoreceptors, helping form antagonistic receptive fields in the retina, but the neurotransmitter and the mechanisms underlying this signalling are not known. Since the proteins responsible for conventional Ca2+-dependent release of GABAergic synaptic vesicles are present in mammalian horizontal cells, we investigated this conventional mechanism as the means by which horizontal cells inhibit photoreceptors. Using Ca2+ imaging in rat retinal slices, we confirm that horizontal cell depolarization with kainate inhibits and horizontal cell hyperpolarization with NBQX disinhibits the Ca2+ signals produced by pH-sensitive activation of voltage-gated calcium channels (Ca channels) in photoreceptors. We show that while 100 mu M Co2+ reduces photoreceptor Ca2+ signals, it disinhibits them at 10 mu M, an effect reminiscent of earlier studies where low [Co2+] eliminated feedback. The low [Co2+] disinhibition is pH sensitive. We localized L-, N- and P/Q-type Ca channels in rat horizontal cells, and showed that both the N-type Ca channel blocker omega-conotoxin GVIA and the P/Q-type Ca channel blocker omega-agatoxin IVA increased Ca2+ signals in photoreceptors in a pH-sensitive manner. Pronounced actions of GABAergic agents on feedback signals to photoreceptors were observed, and are pH sensitive, but are inconsistent with direct inhibition by GABA of photoreceptor [Ca2+]. Patch-clamp studies revealed that GABA activates a conductance having high bicarbonate permeability in isolated horizontal cells, suggesting that the commonality of pH sensitivity throughout the results could arise from a GABA autofeedback action in horizontal cells. This could change cleft pH with concomitant inhibitory influences on photoreceptor Ca channels. C1 [Liu, Xue; Hirano, Arlene A.; Sun, Xiaoping; Brecha, Nicholas C.; Barnes, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Liu, Xue; Hirano, Arlene A.; Sun, Xiaoping; Brecha, Nicholas C.; Barnes, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Hirano, Arlene A.; Brecha, Nicholas C.; Barnes, Steven] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada. RP Barnes, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM sbarnes@dal.ca FU National Eye Institute [EY15573]; UCLA Oppenheimer Seed Grant; Plum Foundation; Canadian Institutes of Health Research [MOP-10968]; National Science and Engineering Research Council; Veterans Administration Senior Career Scientist Award FX Support for this work was provided by grants from the National Eye Institute (EY15573 to N.C.B.), a UCLA Oppenheimer Seed Grant (A. A. H.), the Plum Foundation (S. B. and N.C.B.), the Canadian Institutes of Health Research (MOP-10968 to S. B.), the National Science and Engineering Research Council (Discovery Award to S. B.), and a Veterans Administration Senior Career Scientist Award (N.C.B.). NR 70 TC 20 Z9 20 U1 0 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD JUL 1 PY 2013 VL 591 IS 13 BP 3309 EP 3324 DI 10.1113/jphysiol.2012.248179 PG 16 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 174XV UT WOS:000321192000019 PM 23613534 ER PT J AU Singh, H Spitzmueller, C Petersen, NJ Sawhney, MK Smith, MW Murphy, DR Espadas, D Laxmisan, A Sittig, DF AF Singh, Hardeep Spitzmueller, Christiane Petersen, Nancy J. Sawhney, Mona K. Smith, Michael W. Murphy, Daniel R. Espadas, Donna Laxmisan, Archana Sittig, Dean F. TI Primary care practitioners' views on test result management in EHR-enabled health systems: a national survey SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID ELECTRONIC MEDICAL-RECORD; PHYSICIAN ORDER ENTRY; FOLLOW-UP; INFORMATION-TECHNOLOGY; RESPONSE RATES; DIAGNOSTIC ERROR; NOTIFICATION; COMMUNICATION; QUESTIONNAIRES; IMPLEMENTATION AB Context Failure to notify patients of test results is common even when electronic health records (EHRs) are used to report results to practitioners. We sought to understand the broad range of social and technical factors that affect test result management in an integrated EHR-based health system. Methods Between June and November 2010, we conducted a cross-sectional, web-based survey of all primary care practitioners (PCPs) within the Department of Veterans Affairs nationwide. Survey development was guided by a socio-technical model describing multiple inter-related dimensions of EHR use. Findings Of 5001 PCPs invited, 2590 (51.8%) responded. 55.5% believed that the EHRs did not have convenient features for notifying patients of test results. Over a third (37.9%) reported having staff support needed for notifying patients of test results. Many relied on the patient's next visit to notify them for normal (46.1%) and abnormal results (20.1%). Only 45.7% reported receiving adequate training on using the EHR notification system and 35.1% reported having an assigned contact for technical assistance with the EHR; most received help from colleagues (60.4%). A majority (85.6%) stayed after hours or came in on weekends to address notifications; less than a third reported receiving protected time (30.1%). PCPs strongly endorsed several new features to improve test result management, including better tracking and visualization of result notifications. Conclusions Despite an advanced EHR, both social and technical challenges exist in ensuring notification of test results to practitioners and patients. Current EHR technology requires significant improvement in order to avoid similar challenges elsewhere. C1 [Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.; Smith, Michael W.; Murphy, Daniel R.; Espadas, Donna; Laxmisan, Archana] Baylor Coll Med, Dept Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.; Smith, Michael W.; Murphy, Daniel R.; Espadas, Donna; Laxmisan, Archana] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Spitzmueller, Christiane] Univ Houston, Dept Psychol, Houston, TX USA. [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), Baylor Coll Med, Dept Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr 152,Sect Hl, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU Department of Veterans Affairs National Center for Patient Safety; Houston VA HSR&D Center of Excellence [HFP90-020]; National Library of Medicine [R01 LM006942]; Office of the National Coordinator for Health Information Technology (ONC) [10510592] FX The research reported here was supported by the Department of Veterans Affairs National Center for Patient Safety and in part by the Houston VA HSR&D Center of Excellence (HFP90-020), the National Library of Medicine (R01 LM006942), and the Office of the National Coordinator for Health Information Technology (ONC #10510592). NR 60 TC 15 Z9 15 U1 2 U2 12 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JUL PY 2013 VL 20 IS 4 BP 727 EP 735 DI 10.1136/amiajnl-2012-001267 PG 9 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 161CJ UT WOS:000320168600019 PM 23268489 ER PT J AU Zlatar, ZZ Towler, S McGregor, KM Dzierzewski, JM Bauer, A Phan, S Cohen, M Marsiske, M Manini, TM Crosson, B AF Zlatar, Zvinka Z. Towler, Stephen McGregor, Keith M. Dzierzewski, Joseph M. Bauer, Andrew Phan, Stephanie Cohen, Matthew Marsiske, Michael Manini, Todd M. Crosson, Bruce TI Functional Language Networks in Sedentary and Physically Active Older Adults SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Cognitive aging; Physical activity; Functional magnetic resonance imaging; Semantic fluency; Attention network; Transcranial magnetic stimulation ID AGE-DIFFERENCES; BRAIN ACTIVITY; FITNESS; OPTIMIZATION; REGISTRATION; COGNITION; TMS/FMRI; IMAGES; CORTEX; MEMORY AB Functional magnetic resonance imaging (fMRI) studies have identified consistent age-related changes during various cognitive tasks, such that older individuals display more positive and less negative task-related activity than young adults. Recently, evidence shows that chronic physical exercise may alter aging-related changes in brain activity; however, the effect of exercise has not been studied for the neural substrates of language function. Additionally, the potential mechanisms by which aging alters neural recruitment remain understudied. To address these points, the present study enrolled elderly adults who were either sedentary or physically active to characterize the neural correlates of language function during semantic fluency between these groups in comparison to a young adult sample. Participants underwent fMRI during semantic fluency and transcranial magnetic stimulation to collect the ipsilateral silent period, a measure of interhemispheric inhibition. Results indicated that sedentary older adults displayed reductions in negative task-related activity compared to the active old group in areas of the attention network. Longer interhemispheric inhibition was associated with more negative task-related activity in the right and left posterior perisylvian cortex, suggesting that sedentary aging may result in losses in task facilitatory cortical inhibition. However, these losses may be mitigated by regular engagement in physical exercise. C1 [Zlatar, Zvinka Z.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Towler, Stephen; McGregor, Keith M.; Crosson, Bruce] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Towler, Stephen; Crosson, Bruce] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [McGregor, Keith M.; Crosson, Bruce] Atlanta Vet Affairs Med Ctr, RR&D Ctr Excellence, Decatur, GA USA. [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bauer, Andrew; Phan, Stephanie] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. [Cohen, Matthew; Marsiske, Michael] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Manini, Todd M.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. RP Zlatar, ZZ (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr MC 0664, La Jolla, CA 92093 USA. EM zzlatar@ucsd.edu RI Crosson, Bruce/L-3128-2013; Meijer, Anna/K-5118-2016 OI Marsiske, Michael/0000-0001-5973-2116; McGregor, Keith/0000-0003-3654-351X FU National Institutes on Aging (NIA) [P30 AG028740-03, T32 AG020499-08, F31 AG 032802 01A1]; Department of Veteran Affairs Office of Academic Affairs Predoctoral Fellowship; VA Rehabilitation R&D Center of Excellence [F2182C]; Senior Research Career Scientist awards [B6364L] FX This work was supported by the National Institutes on Aging (NIA) through awards: P30 AG028740-03 (ZZ), T32 AG020499-08 (ZZ), F31 AG 032802 01A1 (JD); the Department of Veteran Affairs Office of Academic Affairs Predoctoral Fellowship (KMM); the VA Rehabilitation R&D Center of Excellence F2182C (BC); and Senior Research Career Scientist awards B6364L (BC). The authors gratefully acknowledge the assistance of staff and participants. The authors report no actual or potential conflicts of interest. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 40 TC 8 Z9 8 U1 0 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD JUL PY 2013 VL 19 IS 6 BP 625 EP 634 DI 10.1017/S1355617713000246 PG 10 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 170QY UT WOS:000320869700001 PM 23458438 ER PT J AU Jin, YM Liu, RJ Xie, JY Xiong, HB He, JCJ Chen, N AF Jin, Yuanmeng Liu, Ruijie Xie, Jingyuan Xiong, Huabao He, John Cijiang Chen, Nan TI Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model SO LABORATORY INVESTIGATION LA English DT Article DE fibrosis; inflammation; interleukin-10; kidney; unilateral ureteral obstruction ID NF-KAPPA-B; RENAL-DISEASE; IN-VIVO; IL-10; CELLS; GENE; EXPRESSION; MICE; PANCREATITIS; MACROPHAGES AB Interleukin-10 functions as a general immunosuppressive cytokine, which also negatively regulates inflammatory responses through complex mechanisms. Recent studies suggested that IL-10 may also inhibit fibrosis in various diseased models. However, the role of IL-10 in renal fibrosis has not been demonstrated. Here, we investigated the effects of IL-10 in the development of renal tubulointerstitial fibrosis by creating the unilateral ureteral obstruction (UUO) model in IL-10 knockout (-/-) mice. We performed sham or unilateral ureteral obstruction surgery in 8-week-old IL-10 -/- male mice and age and sex-matched wild type littermates. Mice were killed at 7 days or 14 days post surgery and renal tissues were obtained for RNA, protein, and immunohistochemical analysis. Our results found IL-10 deficiency resulted in enhanced renal fibrosis demonstrated by more severe tubular injury and collagen deposition and higher expression of pro-fibrotic genes (including alpha-SMA, MMP-2, fibronectin, FSP-1 and vimentin). Our results also found IL-10-/- UUO mice developed more severe renal inflammation with a significant increase in inflammatory cells infiltration, and upregulation of inflammatory chemokines (MCP-1 and RANTES), and cytokines (TNF-alpha, IL-6, IL-8, and M-CSF). Further study revealed that enhanced renal inflammation and fibrosis was associated with significantly increased activation of both TGF-beta/Smad3 and NF-kappa B signaling pathways. In summary, our study provides the direct evidence that IL-10 is an endogenous cytokine that has a key role in protecting against development of renal inflammation and fibrosis. Enhancement of IL-10 expression could be a potential anti-fibrosis therapy for patients with chronic kidney diseases. C1 [Jin, Yuanmeng; Xie, Jingyuan; Chen, Nan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Nephrol, Shanghai 200030, Peoples R China. [Liu, Ruijie; He, John Cijiang] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. [Liu, Ruijie; He, John Cijiang] James J Peters Vet Adm Med Ctr, New York, NY USA. [Xiong, Huabao] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA. RP He, JCJ (reprint author), Mt Sinai Sch Med, Div Nephrol, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu; chen-nan@medmail.com.cn FU National Basic Research Program of China 973 [2012CB517600, 2012CB517604]; National key technology R&D Program (12-5) [2011BAI10B00, 2011BAI10B06]; National Natural Science Foundation of China [81070568, 81000295, 81200526] FX This work is the result of a collaborative effort between the Nephrology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China and the Nephrology Division of Mount Sinai Hospital, New York, USA. This work is supported by National Basic Research Program of China 973, program No. 2012CB517600 (No.2012CB517604), National key technology R&D Program (12-5), program NO. 2011BAI10B00 (2011BAI10B06), National Natural Science Foundation of China (No. 81070568), National Natural Science Foundation of China (No. 81000295) and National Natural Science Foundation of China (No. 81200526). NR 42 TC 16 Z9 17 U1 1 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JUL PY 2013 VL 93 IS 7 BP 801 EP 811 DI 10.1038/labinvest.2013.64 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 172XD UT WOS:000321039100006 PM 23628901 ER PT J AU Leung, AC Asch, DA Lozada, KN Saynisch, OB Asch, JM Becker, N Griffis, HM Shofer, F Hershey, JC Hill, S Branas, CC Nichol, G Becker, LB Merchant, RM AF Leung, Alison C. Asch, David A. Lozada, Kirkland N. Saynisch, Olivia B. Asch, Jeremy M. Becker, Nora Griffis, Heather M. Shofer, Frances Hershey, John C. Hill, Shawndra Branas, Charles C. Nichol, Graham Becker, Lance B. Merchant, Raina M. TI Where are lifesaving automated external defibrillators located and how hard is it to find them in a large urban city? SO RESUSCITATION LA English DT Article DE AED; Cardiac arrest; CPR; Sudden death; Surveying ID AMERICAN-HEART-ASSOCIATION; PUBLIC-ACCESS DEFIBRILLATION; HOSPITAL CARDIAC-ARREST; IMPROVING SURVIVAL; CARE COMMITTEE; LOCATIONS; MODEL AB Objectives: Automated external defibrillators (AEDs) are lifesaving, but little is known about where they are located or how to find them. We sought to locate AEDs in high employment areas of Philadelphia and characterize the process of door-to-door surveying to identify these devices. Methods: Block groups representing approximately the top 3rd of total primary jobs in Philadelphia were identified using the US Census Local Employment Dynamics database. All buildings within these block groups were surveyed during regular working hours over six weeks during July-August 2011. Buildings were characterized as publically accessible or inaccessible. For accessible buildings, address, location type, and AED presence were collected. Total devices, location description and prior use were gathered in locations with AEDs. Process information (total people contacted, survey duration) was collected for all buildings. Results: Of 1420 buildings in 17 block groups, 949 (67%) were accessible, but most 834 (88%) did not have an AED. 283 AEDs were reported in 115 buildings (12%). 81 (29%) were validated through visualization and 68 (24%) through photo because employees often refused access. In buildings with AEDs, several employees (median 2; range 1-8) were contacted to ascertain information, which required several minutes (mean 4; range 1-55). Conclusions: Door-to-door surveying is a feasible, but time-consuming method for identifying AEDs in high employment areas. Few buildings reported having AEDs and few permitted visualization, which raises concerns about AED access. To improve cardiac arrest outcomes, efforts are needed to improve the availability of AEDs, awareness of their location and access to them. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Asch, David A.; Merchant, Raina M.] Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Branas, Charles C.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Nichol, Graham] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA. RP Merchant, RM (reprint author), Univ Penn, 423 Guardian St,1022 Blockley Hall, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU NIH, Physio-Control Seattle, Washington [10714038]; NIH, Zoll Medical, Boston, MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; Resuscitation Outcomes Consortium [NIH U01 HL077863-05]; Asmund S. Laerdal Foundation for Acute Medicine; NHLBI [R21 HL093641-01A1, R01 HL089554-03]; Medtronic Foundation; [200211UCT-110607]; [1RC2HL101759-01] FX Merchant: Grant/research support: NIH, K23 Grant 10714038, Pilot funding: Physio-Control Seattle, Washington; Zoll Medical, Boston, MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington.; Nichol: Institutional grant/research support: Resuscitation Outcomes Consortium (NIH U01 HL077863-05) 2004-2015; Co-PI, Evaluation of Video Self-Instruction in Compressions-Only CPR (Asmund S. Laerdal Foundation for Acute Medicine) 2007-2010; PI, Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI R21 HL093641-01A1) 2009-2011; PI, Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI R01 HL089554-03) 2007-2012; Co-I, Resynchronization/Defibrillation for Advanced Heart Failure Trial (RAFT) (200211UCT-110607) 2003-2010; Co-I, Novel Methods of Measuring Health Disparities (1RC2HL101759-01) 2009-2011; Co-I, Cascade Cardiac Resuscitation System (Medtronic Foundation) 2010-2015; PI, Research Collaborator: Gambro Renal Inc., Lakewood, CO, Sotera Wireless, San Diego, CA, Lifebridge Medizintechnik AG, Ampfing, Germany, Other: Chair, AHA Executive Database Steering Committee; Chair, Mission: Lifeline EMS Task Force, Co-Chair, AHA Resuscitation Science Symposium Planning Committee; Member, AHA Advanced Cardiac Life Support Subcommittee; Member, AHA Epidemiology and Statistics Committee; Member, Pacific Mountain Affiliate Board of Directors, American Heart Association, Received travel reimbursement, AHA.; Becker (L): Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA. Institutional grant/research support: Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington. NR 24 TC 13 Z9 13 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD JUL PY 2013 VL 84 IS 7 BP 910 EP 914 DI 10.1016/j.resuscitation.2013.01.010 PG 5 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 172IX UT WOS:000320997000016 PM 23357702 ER PT J AU Bergman, J Lorenz, KA Acquah-Asare, S Scales, CD Ryan, G Saigal, CS Bennett, CJ Litwin, MS AF Bergman, Jonathan Lorenz, Karl A. Acquah-Asare, Sadie Scales, Charles D. Ryan, Gery Saigal, Christopher S. Bennett, Carol J. Litwin, Mark S. TI Urologist Attitudes Toward End-of-life Care SO UROLOGY LA English DT Article ID CENTERED MEDICAL HOME; PALLIATIVE CARE; QUALITY; HEALTH; CANCER; COMMUNICATION; ASSOCIATIONS; PRIORITIES; PROVIDERS; SUPPORT AB OBJECTIVE To examine urology trainees' views about the quality and current practices of end-of-life care and to explore strategies for improving integration and quality of care. METHODS We conducted semi-structured interviews with 20 trainees from 4 institutions in different regions of the United States. Open-ended questions allowed participants to express themselves independently, and follow-up discussions explored their perception of current end-of-life practices, as well as avenues for future integration and improvement. We analyzed transcripts using a multistage, cutting-and-sorting technique in an inductive approach based on grounded theory analysis. RESULTS Clinicians agreed that their patients do not currently receive ideal care and were interested in joining a team geared towards improving care at the end of life. They expressed a preference for a multidisciplinary team, although the precise role each wanted to play within the team varied. Better identification of depression, pain, and patient-centered goals to allow value-congruent care were high in priorities for improvement. Trainees cited the lack of an educational curriculum on end-of-life care as a barrier to improving care and expressed a desire for formal education on this topic. CONCLUSION Urology trainees believe that end-of-life care can be improved and are interested in participating as part of a multidisciplinary team to better care for these individuals. There was consensus that end-of-life care should be formally taught to all intern and resident physicians and care at the end of life should be integrated to pursue value-congruent care for each patient. UROLOGY 82: 48-52, 2013. (C) 2013 Elsevier Inc. C1 [Bergman, Jonathan] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM jbergman@mednet.ucla.edu NR 30 TC 2 Z9 2 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JUL PY 2013 VL 82 IS 1 BP 48 EP 52 DI 10.1016/j.urology.2013.01.040 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 172WK UT WOS:000321036200017 PM 23676360 ER PT J AU Prasad, SM Bennett, CL AF Prasad, Sandip M. Bennett, Charles L. TI Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era EDITORIAL COMMENT SO UROLOGY LA English DT Editorial Material C1 [Prasad, Sandip M.] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. [Prasad, Sandip M.] Med Univ S Carolina, Ralph Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. [Bennett, Charles L.] South Carolina Coll Pharm, Charleston, SC USA. [Bennett, Charles L.] Wm Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA. [Bennett, Charles L.] Hollings Canc Ctr, Charleston, SC USA. [Bennett, Charles L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Bennett, Charles L.] Univ S Carolina, Charleston, SC USA. RP Prasad, SM (reprint author), Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JUL PY 2013 VL 82 IS 1 BP 66 EP 66 DI 10.1016/j.urology.2013.01.073 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 172WK UT WOS:000321036200022 PM 23706256 ER PT J AU Liu, DP Zhou, XH AF Liu, Danping Zhou, Xiao-Hua TI ROC Analysis in Biomarker Combination with Covariate Adjustment SO ACADEMIC RADIOLOGY LA English DT Article DE Biomarker combination; covariate adjustment; AUC; covariate standardization ID OPERATING CHARACTERISTIC CURVE; REGRESSION; ACCURACY; MARKERS; AREA AB Rational and Objectives: Receiver operating characteristic (ROC) analysis is often used to find the optimal combination of biomarkers. When the subject level covariates affect the magnitude and/or accuracy of the biomarkers, the combination rule should take into account of the covariate adjustment. The authors propose two new biomarker combination methods that make use of the covariate information. Materials and Methods: The first method is to maximize the area under the covariate-adjusted ROC curve (AAUC). To overborne the limitations of the AAUC measure, the authors further proposed the area under covariate-standardized ROC curve (SAUC), which is an extension of the covariate-specific ROC curve. With a series of simulation studies, the proposed optimal AAUC and SAUC methods are compared with the optimal AUC method that ignores the covariates. The biomarker combination methods are illustrated by an example from Alzheimer's disease research. Results: The simulation results indicate that the optimal AAUC combination performs well in the current study population. The optimal SAUC method is flexible to choose any reference populations, and allows the results to be generalized to different populations. Conclusions: The proposed optimal AAUC and SAUC approaches successfully address the covariate adjustment problem in estimating the optimal marker combination. The optimal SAUC method is preferred-for practical use, because the biomarker combination rule can be easily evaluated for different population of interest. C1 [Liu, Danping] NICHD, Biostat & Bioinformat Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Liu, DP (reprint author), NICHD, Biostat & Bioinformat Branch, Div Epidemiol Stat & Prevent Res, NIH, 6100 Execut Blvd, Bethesda, MD 20892 USA. EM danping.liu@nih.gov FU National Institute of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH/NIA [U01AG016976] FX D.L.'s research is supported by the Intramural Research Program of the National Institute of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This work was supported in part by NIH/NIA grant U01AG016976. NR 16 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 EI 1878-4046 J9 ACAD RADIOL JI Acad. Radiol. PD JUL PY 2013 VL 20 IS 7 BP 874 EP 882 DI 10.1016/j.acra.2013.03.009 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 168YT UT WOS:000320744600011 PM 23747153 ER PT J AU Karlin, BE Walser, RD Yesavage, J Zhang, A Trockel, M Taylor, CB AF Karlin, Bradley E. Walser, Robyn D. Yesavage, Jerome Zhang, Aimee Trockel, Mickey Taylor, C. Barr TI Effectiveness of acceptance and commitment therapy for depression: Comparison among older and younger veterans SO AGING & MENTAL HEALTH LA English DT Article DE acceptance and commitment therapy; depression; older adults; geriatrics; veterans; effectiveness ID WORKING ALLIANCE INVENTORY; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; CHRONIC PAIN PATIENTS; MENTAL-HEALTH-CARE; PSYCHOMETRIC PROPERTIES; STRESS REDUCTION; ADULTS; METAANALYSIS; MOOD AB Objectives: Limited data exist on outcomes of older adults receiving psychotherapy for depression in real-world settings. Acceptance and Commitment Therapy for depression (ACT-D) offers potential utility for older individuals who may experience issues of loss, reduced control, and other life changes. The present article examines and compares outcomes of older and younger Veterans receiving ACT-D nationally in the U.S. Department of Veterans Affairs health care system. Method: Patient outcomes were assessed using the Beck Depression Inventory-Second Edition and the World Health Organization Quality of Life-BREF. Therapeutic alliance was assessed using the Working Alliance Inventory-Short Revised. Results: Six hundred fifty-five Veterans aged 18-64 and 76 Veterans aged 65+ received ACT-D. Seventy-eight percent of older and 67% of younger patients completed all sessions or finished early. Mean depression scores declined from 28.4 (SD = 11.4) to 17.5 (SD = 12.0) in the older group and 30.3 (SD = 10.6) to 19.1 (SD = 14.3) in the younger group. Within-group effect sizes were d = .95 and d = 1.06 for the two age groups, respectively. Quality of life and therapeutic alliance also increased during treatment. Conclusion: The findings suggest that ACT-D is an effective and acceptable treatment for older Veterans treated in routine clinical settings, including those with high levels of depression. C1 [Karlin, Bradley E.] Mental Hlth Serv, US Dept Vet Affairs, Cent Off, Washington, DC USA. [Karlin, Bradley E.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Walser, Robyn D.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Yesavage, Jerome; Zhang, Aimee; Trockel, Mickey; Taylor, C. Barr] Stanford Univ, Med Ctr, Dept Psychiat, Palo Alto, CA 94304 USA. [Yesavage, Jerome; Zhang, Aimee; Trockel, Mickey; Taylor, C. Barr] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Dept Psychiat, Palo Alto, CA USA. RP Karlin, BE (reprint author), Mental Hlth Serv, US Dept Vet Affairs, Cent Off, Washington, DC USA. EM bradley.karlin2@va.gov FU Mental Health Services, U.S. Department of Veterans Affairs Central Office FX This project was supported by Mental Health Services, U.S. Department of Veterans Affairs Central Office. NR 62 TC 12 Z9 13 U1 3 U2 29 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PD JUL 1 PY 2013 VL 17 IS 5 BP 555 EP 563 DI 10.1080/13607863.2013.789002 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 171GN UT WOS:000320913300005 PM 23607328 ER PT J AU VanKirk, KK Horner, MD Turner, TH Dismuke, CE Muzzy, W AF VanKirk, Kathryn K. Horner, Michael David Turner, Travis H. Dismuke, Clara E. Muzzy, Wendy TI CE Hospital Service Utilization is Reduced Following Neuropsychological Evaluation in a Sample of US Veterans SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Health care utilization; Neuropsychological assessment; Clinical neuropsychology; Health outcomes; Cost-effectiveness ID COGNITIVE REHABILITATION; CLINICAL NEUROPSYCHOLOGY; HEALTH; ALZHEIMERS; OUTCOMES; UTILITY; COST AB The aim of this study was to evaluate the objective value of neuropsychological evaluation (NPE) through reduction in Emergency Room (ER) visits and hospitalizations. Retrospective analysis examined trends in ER visits and hospitalizations in 440 U.S. veterans who completed NPE between the years of 2003 and 2010. Within-subjects comparisons showed significant decreases in incidence of hospitalization and length of hospitalization in the year after evaluation compared to the year prior. Mean number of hospitalizations declined from 0.31 (SD = 0.64) pre-NPE to 0.22 (SD = 0.59) post-NPE; there were a total of 41 fewer hospitalizations in the year following NPE. Mean length of hospitalization decreased from 1.9 days (SD = 5.6) pre-NPE to 1.06 days (SD = 3.9) post-NPE; there were a total of 368 fewer days of hospitalization post-NPE. This reduction was not attributable to age or time. Incidence of ER visits also decreased from pre-NPE (M = 0.74, SD = 1.3) to post-evaluation (M = 0.69, SD = 1.3), though this was not significant. These findings provide preliminary evidence of the clinical and potential economic value of neuropsychological services within a medical setting. Follow-up studies should examine individual and exam-specific factors that may contribute to reduced utilization. C1 [VanKirk, Kathryn K.; Horner, Michael David; Turner, Travis H.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [VanKirk, Kathryn K.; Horner, Michael David; Turner, Travis H.; Muzzy, Wendy] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29401 USA. [Dismuke, Clara E.] Med Univ S Carolina, Dept Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Muzzy, Wendy] Charleston Res Inst, Charleston, SC USA. RP VanKirk, KK (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. NR 26 TC 4 Z9 4 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD JUL 1 PY 2013 VL 27 IS 5 BP 750 EP 761 DI 10.1080/13854046.2013.783122 PG 12 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 170OR UT WOS:000320863200001 PM 23548168 ER PT J AU Hsieh, YH Lin, HJ Hsieh, JJ Tseng, KC Tseng, CW Hung, TH Leung, FW AF Hsieh, Yu-Hsi Lin, Hwai-Jeng Hsieh, Jin-Jian Tseng, Kuo-Chih Tseng, Chih-Wei Hung, Tsung-Hsing Leung, Felix W. TI Meperidine as the single sedative agent during esophagogastroduodenoscopy, a double-blind, randomized, controlled study SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE esophagogastroduodenoscopy; meperidine; minimal sedation ID UPPER GASTROINTESTINAL ENDOSCOPY; UNSEDATED ESOPHAGOGASTRODUODENOSCOPY; PHARYNGEAL ANESTHESIA; CONSCIOUS SEDATION; CONTROLLED-TRIAL; LIDOCAINE SPRAY; GI ENDOSCOPY; MIDAZOLAM; GASTROSCOPY; COMBINATION AB Background and Aim In Taiwan, unsedated esophagogastroduodenoscopy (EGD) is widely used, but it is uncomfortable for some patients. While meperidine has been adopted in colonoscopy, its use in EGD has not received extensive attention. This was a prospective study to investigate the use of meperidine as a single sedative agent during EGD. Methods One hundred and forty patients were randomized to receive either 25-mg meperidine (n=70) or placebo (n=70) by intramuscular injection before EGD. The primary outcome was patient discomfort scores. The secondary outcomes included patient, endoscopist, and EGD-related variables. Results Patients in the meperidine group reported less discomfort during esophageal intubation (median score of 2.0 and interquartile range [IQR] of 0-4.0 vs median score of 4.8 and IQR of 1.7-7.0, respectively; P<0.001) and during the procedure (median score of 1.0 [IQR 0-3.1] vs 3.5 [IQR 0-5.6], P=0.001) than patients in the placebo group. The endoscopist found patients in the meperidine group had better tolerance during esophageal intubation (median score of 1.0 [IQR 0-2.0] vs 2.0 [IQR 1.0-3.0], P=0.021) and during the procedure (median score of 0 [IQR 0-1.0] vs 1.0 [IQR 0-3.0], P<0.001). After the procedure more patients in the meperidine group (71.4% vs 35.7%, P<0.001) experienced self-limited dizziness that prolonged recovery by approximate to 3.7min. Conclusions After receiving meperidine injection, patients had better tolerance and less discomfort during diagnostic EGD (NCT01547520). C1 [Hsieh, Yu-Hsi; Tseng, Kuo-Chih; Tseng, Chih-Wei; Hung, Tsung-Hsing] Buddhist Dalin Tzu Chi Gen Hosp, Div Gastroenterol, Dept Med, Dalin 622, Chia Yi, Taiwan. [Hsieh, Jin-Jian] Natl Chung Cheng Univ, Dept Math, Chiayi, Taiwan. [Hsieh, Yu-Hsi; Tseng, Kuo-Chih; Tseng, Chih-Wei; Hung, Tsung-Hsing] Buddhist Tzu Chi Univ, Sch Med, Hwalien, Taiwan. [Lin, Hwai-Jeng] Taipei Med Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan. [Lin, Hwai-Jeng] Taipei Med Univ, Sch Med, Taipei, Taiwan. [Leung, Felix W.] Sepulveda Ambulatory Care Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, North Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Hsieh, YH (reprint author), Buddhist Dalin Tzu Chi Gen Hosp, Div Gastroenterol, Dept Med, 2 Min Sheng Rd, Dalin 622, Chia Yi, Taiwan. EM hsieh.yuhsi@msa.hinet.net OI Tseng, Chih-Wei/0000-0002-6951-4646 FU Buddhist Dalin Tzu Chi General Hospital FX This study was supported by research funds from Buddhist Dalin Tzu Chi General Hospital. NR 23 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD JUL PY 2013 VL 28 IS 7 BP 1167 EP 1173 DI 10.1111/jgh.12183 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168RC UT WOS:000320722200017 PM 23431993 ER PT J AU Jarcho, JM Feier, NA Bert, A Labus, JA Lee, M Stains, J Ebrat, B Groman, SM Tillisch, K Brody, AL London, ED Mandelkern, MA Mayer, EA AF Jarcho, Johanna M. Feier, Natasha A. Bert, Alberto Labus, Jennifer A. Lee, Maunoo Stains, Jean Ebrat, Bahar Groman, Stephanie M. Tillisch, Kirsten Brody, Arthur L. London, Edythe D. Mandelkern, Mark A. Mayer, Emeran A. TI Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain SO PAIN LA English DT Article DE PET; NK-1 receptor; Irritable bowel syndrome; Inflammatory bowel disease; Somatic pain; Quality of life ID IRRITABLE-BOWEL-SYNDROME; POSITRON-EMISSION-TOMOGRAPHY; QUALITY-OF-LIFE; SUBSTANCE-P; NK1 RECEPTOR; SPINAL-CORD; HUMAN BRAIN; INFLAMMATORY PAIN; PLACEBO ANALGESIA; PERSISTENT PAIN AB Central sensitization and dysregulation of peripheral substance P and neurokinin-1 receptor (NK-1R) signaling are associated with chronic abdominal pain in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Although positron emission tomography (PET) has demonstrated that patients with injury-related chronic pain have diminished NK-1R availability in the brain, it is unknown whether these deficits are present in IBD and IBS patients, who have etiologically distinct forms of non-injury-related chronic pain. This study's aim was to determine if patients with IBD or IBS exhibit deficits in brain expression of NK-1Rs relative to healthy controls (HCs), the extent to which expression patterns differ across patient populations, and if these patterns differentially relate to clinical parameters. PET with [F-18] SPA-RQ was used to measure NK-1R availability by quantifying binding potential (BP) in the 3 groups. Exploratory correlation analyses were performed to detect associations between NK-1R BP and physical symptoms. Compared to HCs, IBD patients had NK-1R BP deficits across a widespread network of cortical and subcortical regions. IBS patients had similar, but less pronounced deficits. BP in a subset of these regions was robustly related to discrete clinical parameters in each patient population. Widespread deficits in NK-1R BP occur in IBD and, to a lesser extent, IBS; however, discrete clinical parameters relate to NK-1R BP in each patient population. This suggests that potential pharmacological interventions that target NK-1R signaling may be most effective for treating distinct symptoms in IBD and IBS. (C) 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Jarcho, Johanna M.] NIMH, Sect Dev & Affect Neurosci, Bethesda, MD 20892 USA. [Jarcho, Johanna M.; Feier, Natasha A.; Labus, Jennifer A.; Lee, Maunoo; Stains, Jean; Ebrat, Bahar; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA 90095 USA. [Feier, Natasha A.] McGill Univ, Fac Dent, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada. [Bert, Alberto] SpA, Med Imaging Lab Im3D, Turin, Italy. [Groman, Stephanie M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Brody, Arthur L.; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Brody, Arthur L.; London, Edythe D.; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu OI Bert, Alberto/0000-0001-8391-7508; Jarcho, Johanna/0000-0001-9075-6968 FU National Institutes of Health [F31-DA021951, T32-MH017140, F31-DA028812, NIH AT00268]; Tobacco-Related Disease Research Program [19XT-0135]; Department of Veterans Affairs, Office of Research and Development (Merit Review Award) FX This work was supported in part by National Institutes of Health Grants F31-DA021951, T32-MH017140 (J.M.J.), F31-DA028812 (S.M.G.), NIH AT00268 (E.A.M.), and endowments from the Marjorie Greene Family Trust and National Institute on Drug Abuse (A.L.B. [R01 DA20872]), the Tobacco-Related Disease Research Program (A.L.B. [19XT-0135]), the Department of Veterans Affairs, Office of Research and Development (Merit Review Award [A.L.B.]), and the Thomas P. and Katherine K. Pike Chair in Addiction Studies (E.D.L.). NR 85 TC 12 Z9 12 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JUL PY 2013 VL 154 IS 7 BP 987 EP 996 DI 10.1016/j.pain.2013.02.026 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 166XD UT WOS:000320592200007 PM 23582152 ER PT J AU Gehrman, P Seelig, AD Jacobson, IG Boyko, EJ Hooper, TI Gackstetter, GD Ulmer, CS Smith, TC AF Gehrman, Philip Seelig, Amber D. Jacobson, Isabel G. Boyko, Edward J. Hooper, Tomoko I. Gackstetter, Gary D. Ulmer, Christi S. Smith, Tyler C. CA Millennium Cohort Study Team TI Predeployment Sleep Duration and Insomnia Symptoms as Risk Factors for New-Onset Mental Health Disorders Following Military Deployment SO SLEEP LA English DT Article DE Stress disorders; post-traumatic; anxiety; depression; sleep ID POSTTRAUMATIC-STRESS-DISORDER; PENN STATE COHORT; MILLENNIUM COHORT; PSYCHIATRIC-DISORDERS; LONGITUDINAL ASSESSMENT; VIETNAM VETERANS; YOUNG-ADULTS; PRIMARY-CARE; PRIME-MD; DEPRESSION AB Study Objectives: To evaluate predeployment sleep duration and insomnia symptoms in relation to the development of mental health symptoms. Design: Longitudinal cohort study. Setting: The Millennium Cohort Study survey is administered via a secure website or US mail. Participants: Data were from 15,204 participants who completed their first deployment between the submissions of 2 consecutive Millennium Cohort questionnaires (2001-2008). Interventions: N/A. Measurements and Results: Using self-reported data from the Millennium Cohort Study we evaluated the association of predeployment sleep duration and insomnia symptoms on the development of new-onset mental disorders among deployers. Multivariable logistic regression was used to estimate the odds of developing posttraumatic stress disorder (PTSD), depression, and anxiety, while adjusting for relevant covariates including combat-related trauma. The study outcomes were assessed using validated instruments, including the PTSD checklist-civilian version, and the PRIME-MD Patient Health Questionnaire. We identified 522 people with new-onset PTSD, 151 with anxiety, and 303 with depression following deployment. In adjusted models, combat-related trauma and predeployment insomnia symptoms were significantly associated with higher odds of developing posttraumatic stress disorder, depression, and anxiety postdeployment. Conclusions: Sleep characteristics, especially insomnia symptoms, are related to the development of mental disorders following military deployments. Assessment of insomnia symptoms predeployment may help to better identify those at highest risk for subsequent adverse mental health outcomes. C1 [Gehrman, Philip] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Seelig, Amber D.; Jacobson, Isabel G.; Smith, Tyler C.] Naval Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Hooper, Tomoko I.] Univ Hlth Sci, Uniformed Serv, Dept Prevent Med & Biometr, Bethesda, MD USA. [Ulmer, Christi S.] Durham VA, Durham, NC USA. [Ulmer, Christi S.] Duke Univ, Med Ctr, Durham, NC USA. [Smith, Tyler C.] Natl Univ Technol, Sch Hlth & Human Serv, Dept Community Hlth, San Diego, CA USA. [Smith, Tyler C.] Hlth Sci Ctr, San Diego, CA USA. RP Seelig, AD (reprint author), Naval Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM amber.seelig@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X FU Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland; Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland; VA Puget Sound Health Care System; VA Career Development Award [CDA 09-218]; Department of Defense [60002] FX The authors thank the Millennium Cohort Study participants, without whom these analyses would not be possible. We thank Scott Seggerman from the Management Information Division, US Defense Manpower Data Center, Seaside, California; Michelle LeWark from the Naval Health Research Center; and all the professionals from the US Army Medical Research and Materiel Command, especially those from the Military Operational Medicine Research Program, Fort Detrick, Maryland. We appreciate the support of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland.; The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland. VA Puget Sound Health Care System provided support for Dr. Boyko's involvement in this research. Dr. Ulmer was supported by a VA Career Development Award (CDA 09-218). The funding organization had no role in the design and conduct of the study; collection, analysis, or preparation of data; or preparation, review, or approval of the manuscript.; This article represents report 12-03, supported by the Department of Defense, under work unit number 60002. The views expressed in this work are those of the authors, and do not reflect the official policy or position of the Department of the Navy, Department of the Army, Department of the Air Force, Department of Veterans Affairs, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. Human subjects participated in this study after giving their free and informed consent. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research. NR 67 TC 37 Z9 39 U1 2 U2 15 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD JUL 1 PY 2013 VL 36 IS 7 BP 1009 EP 1018 DI 10.5665/sleep.2798 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 172XG UT WOS:000321039500010 ER PT J AU Khazim, K Giustarini, D Rossi, R Verkaik, D Cornell, JE Cunningham, SED Mohammad, M Trochta, K Lorenzo, C Folli, F Bansal, S Fanti, P AF Khazim, Khaled Giustarini, Daniela Rossi, Ranieri Verkaik, Darlene Cornell, John E. Cunningham, Sue E. D. Mohammad, Maryam Trochta, Kara Lorenzo, Carlos Folli, Franco Bansal, Shweta Fanti, Paolo TI Glutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients SO TRANSLATIONAL RESEARCH LA English DT Article ID CHROMATOGRAPHY-MASS SPECTROMETRY; CHRONIC KIDNEY-DISEASE; OXIDATIVE STRESS; LIQUID-CHROMATOGRAPHY; RESPIRATORY BURST; CATION CHANNELS; S-THIOLATION; HUMAN PLASMA; BLOOD; ERYTHROCYTES AB Glutathione (GSH), the most abundant intracellular low molecular mass thiol, protects cells from oxidative damage and regulates their function. Available information is inconsistent regarding levels of GSH and its disulfide (GSSG) in maintenance hemodialysis patients (HD). In addition, very limited data are available in HD about the relationship of GSH and GSSG with other measures of thiol metabolism and with the clinical profile. We tested the hypothesis that erythrocyte GSH/GSSG redox potential (Eh) is lower in HD than in healthy controls (C), and that Eh correlates with posttranslational thiolation of hemoglobin (Hb) and with standard clinical parameters in HD. In cross-sectional comparison of 33 stable HD and 21 C, we found a net loss of reducing capacity in HD as indicated by low erythrocyte GSH/GSSG Eh (-257 +/- 5.5 vs -270 +/- 5.6 mV, P = 0.002). Glutathionylated Hb (HbSSG) was 46% higher in HD than C (19.3 +/- 4.80 vs 13.2 +/- 2.79 pmol/mg Hb; P = 0.001) and cysteinylated Hb (HbSSCy) was >3-fold higher in HD than C (38.3 (29.0-63.3) vs 11.5 (9.6-17.2) pmol/mg Hb; P = 0.001). In multiple regression analysis of the HD cases, statistically significant associations were found between the GSH/GSSG Et, and the blood urea nitrogen (P = 0.001), creatinine (P = 0.015) and normalized protein catabolic rate (P = 0.05), after adjusting for age, race/ethnicity, and etiology of end-stage renal disease. In conclusion, accurate and precise analysis of GSH, GSSG, and mixed disulfides reveals loss of erythrocyte GSH/GSSG Eh, rise of both HbSSG and HbSSCy, and correlation of these thiols with measures of uremia and dietary protein intake. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, Sch Med, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Sch Hlth Profess, Program Dietet & Nutr, San Antonio, TX 78229 USA. Audie L Murphy Vet Mem Hosp, San Antonio, TX USA. Western Galilee Hosp, Div Nephrol, Nahariyya, Israel. Univ Siena, Lab Pharmacol & Toxicol, Dept Life Sci, I-53100 Siena, Italy. RP Fanti, P (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol MC 7882, San Antonio, TX 78229 USA. EM fanti@uthscsa.edu OI Giustarini, Daniela/0000-0003-4929-5316; folli, franco/0000-0001-9824-5222 FU NIH-NCCAM [AT004490]; VA [1I01CX000264] FX This work was supported by grants (to P.F.) from NIH-NCCAM (#AT004490) and from the VA (Merit Review #1I01CX000264). NR 45 TC 8 Z9 8 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 J9 TRANSL RES JI Transl. Res. PD JUL PY 2013 VL 162 IS 1 BP 16 EP 25 DI 10.1016/j.trsl.2012.12.014 PG 10 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 173OU UT WOS:000321089600002 PM 23333585 ER PT J AU Li, XB Hartwell, KJ Borckardt, J Prisciandaro, JJ Saladin, ME Morgan, PS Johnson, KA LeMatty, T Brady, KT George, MS AF Li, Xingbao Hartwell, Karen J. Borckardt, Jeffery Prisciandaro, James J. Saladin, Michael E. Morgan, Paul S. Johnson, Kevin A. LeMatty, Todd Brady, Kathleen T. George, Mark S. TI Volitional reduction of anterior cingulate cortex activity produces decreased cue craving in smoking cessation: a preliminary real-time fMRI study SO ADDICTION BIOLOGY LA English DT Article DE anterior cingulate cortex; cue-induced craving; neurofeedback; nicotine dependence; real-time fMRI; smoking cessation ID RESTING TOBACCO SMOKERS; NICOTINE DEPENDENCE; BRAIN ACTIVATION; DRUG-ADDICTION; FRONTAL GYRUS; ABSTINENCE; TASK; NEUROFEEDBACK; EXPECTANCY; RESPONSES AB Numerous research groups are now using analysis of blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI) results and relaying back information about regional activity in their brains to participants in the scanner in real time'. In this study, we explored the feasibility of self-regulation of frontal cortical activation using real-time fMRI (rtfMRI) neurofeedback in nicotine-dependent cigarette smokers during exposure to smoking cues. Ten cigarette smokers were shown smoking-related visual cues in a 3 Tesla MRI scanner to induce their nicotine craving. Participants were instructed to modify their craving using rtfMRI feedback with two different approaches. In a reduce craving' paradigm, participants were instructed to reduce' their craving, and decrease the anterior cingulate cortex (ACC) activity. In a separate increase resistance' paradigm, participants were asked to increase their resistance to craving and to increase middle prefrontal cortex (mPFC) activity. We found that participants were able to significantly reduce the BOLD signal in the ACC during the reduce craving' task (P=0.028). There was a significant correlation between decreased ACC activation and reduced craving ratings during the reduce craving' session (P=0.011). In contrast, there was no modulation of the BOLD signal in mPFC during the increase resistance' session. These preliminary results suggest that some smokers may be able to use neurofeedback via rtfMRI to voluntarily regulate ACC activation and temporarily reduce smoking cue-induced craving. Further research is needed to determine the optimal parameters of neurofeedback rtfMRI, and whether it might eventually become a therapeutic tool for nicotine dependence. C1 [Li, Xingbao; Hartwell, Karen J.; Borckardt, Jeffery; Prisciandaro, James J.; Saladin, Michael E.; LeMatty, Todd; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Hartwell, Karen J.; Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Dept Psychiat, Charleston, SC USA. [Morgan, Paul S.] Univ Nottingham, Dept Acad Radiol, Nottingham NG7 2RD, England. [Johnson, Kevin A.] Standford Univ, Syst Neurosci & Pain Lab, Dept Anesthesiol, Palo Alto, CA USA. RP Li, XB (reprint author), MUSC IOP, Dept Psychiat, 502 N,67 President St, Charleston, SC 29425 USA. EM lixi@musc.edu OI Morgan, Paul/0000-0002-5870-1446 FU National Institute of Health [5R21DA026085]; Brainsway; Cyberonics; Force Protection; GlaxoSmithKline; Jazz Pharmaceuticals; MECTA; Neurospace; PureTech Ventures FX This study is supported by National Institute of Health Grant no. 5R21DA026085 (KTB, MSG).; Mark George has served as a paid consultant to or received research support from Brainsway, Cyberonics, Force Protection, GlaxoSmithKline, Jazz Pharmaceuticals, MECTA, Neurospace, and PureTech Ventures and as an unpaid consultant to Brainsonix, Brainsway, Cephos, MECTA, NeoSync, and Neuronetics. The Medical University of South Carolina has two patent applications in Dr. George's name on combining TMS with MRI imaging. NR 46 TC 44 Z9 46 U1 2 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 J9 ADDICT BIOL JI Addict. Biol. PD JUL PY 2013 VL 18 IS 4 BP 739 EP 748 DI 10.1111/j.1369-1600.2012.00449.x PG 10 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA 169IW UT WOS:000320774700016 PM 22458676 ER PT J AU Smith, K James, JA Harley, JB AF Smith, Kenneth James, Judith A. Harley, John B. TI Editorial for Lindop et al. "Long-term Ro60 humoral autoimmunity in primary Sjogren's syndrome is maintained by rapid clonal turnover" SO CLINICAL IMMUNOLOGY LA English DT Editorial Material ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIBODY; CELLS C1 [Smith, Kenneth] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [James, Judith A.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, CAGE, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Harley, JB (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Rheumatol, Cincinnati, OH 45229 USA. EM Ken-Smith@omrf.org; Judith-James@omrf.org; John.Harley@cchmc.org NR 18 TC 2 Z9 2 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD JUL PY 2013 VL 148 IS 1 BP 110 EP 112 DI 10.1016/j.clim.2013.04.015 PG 3 WC Immunology SC Immunology GA 164RN UT WOS:000320427300013 PM 23685220 ER PT J AU Suzuki, E Williams, S Sato, S Gilkeson, G Watson, DK Zhang, XK AF Suzuki, Eiji Williams, Sarah Sato, Shuzo Gilkeson, Gary Watson, Dennis K. Zhang, Xian K. TI The transcription factor Fli-1 regulates monocyte, macrophage and dendritic cell development in mice SO IMMUNOLOGY LA English DT Article DE dendritic cells; Fli-1 transcription factor; Fms-related tyrosine kinase 3 ligand; macrophages; monocytes ID GENE-TARGETED MICE; MARGINAL ZONE; FLT3 LIGAND; ETS FAMILY; IN-VIVO; EXPRESSION; MEGAKARYOPOIESIS; DIFFERENTIATION; PROLIFERATION; HOMEOSTASIS AB Fli-1 belongs to the Ets transcription factor family and is expressed in haematopoietic cells, including most of the cells that are active in immunity. The mononuclear phagocytes, i.e. monocytes, macrophages and dendritic cells, originate in haematopoietic stem cells and play an important role in immunity. To assess the role of Fli-1 in mononuclear phagocyte development in vivo, we generated mice that express a truncated Fli-1 protein, lacking the C-terminal transcriptional activation domain (Fli-1CTA). Fli-1CTA/CTA mice had significantly increased populations of haematopoietic stem cells and common dendritic cell precursors in bone marrow compared with wild-type littermates. Significantly increased classical dendritic cells, plasmacytoid dendritic cells, and macrophage populations were found in spleens from Fli-1CTA/CTA mice compared with wild-type littermates. Fli-1CTA/CTA mice also had increased pre-classical dendritic cell and monocyte populations in peripheral blood mononuclear cells. Furthermore, bone marrow reconstitution studies demonstrated that expression of Fli-1 in both haematopoietic cells and stromal cells affected mononuclear phagocyte development in mice. Expression of Fms-like tyrosine kinase 3 ligand (Flt3L), a haematopoietic growth factor, in multipotent progenitors was statistically significantly increased from Fli-1CTA/CTA mice compared with wild-type littermates. Fli-1 protein binds directly to the promoter region of the Flt3L gene. Hence, Fli-1 plays an important role in the mononuclear phagocyte development, and the C-terminal transcriptional activation domain of Fli-1 negatively modulates mononuclear phagocyte development. C1 [Suzuki, Eiji; Sato, Shuzo; Gilkeson, Gary; Zhang, Xian K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Williams, Sarah; Gilkeson, Gary; Zhang, Xian K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Zhang, XK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St MSC637,Suite 912, Charleston, SC 29425 USA. EM zhangjo@musc.edu FU National Institutes of Health [AR056670]; Medical Research Service, Department of Veterans Affairs FX This study was supported in part by National Institutes of Health grants (AR056670 to X.K.Z.) and the Medical Research Service, Department of Veterans Affairs (to G. G. and X.K.Z.). We thank Dr Mara Lennard-Richard at the Medical University of South Carolina for critical reading of the manuscript. NR 39 TC 6 Z9 6 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD JUL PY 2013 VL 139 IS 3 BP 318 EP 327 DI 10.1111/imm.12070 PG 10 WC Immunology SC Immunology GA 164EU UT WOS:000320392500007 PM 23320737 ER PT J AU Dismuke, CE Egede, LE AF Dismuke, Clara E. Egede, Leonard E. TI Medicare Part D Prescription Drug Program: Benefits, Unintended Consequences and Impact on Health Disparities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID COVERAGE GAP; BENEFICIARIES; ADHERENCE C1 [Dismuke, Clara E.; Egede, Leonard E.] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699] NR 9 TC 2 Z9 2 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 IS 7 BP 860 EP 861 DI 10.1007/s11606-013-2423-3 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 165TU UT WOS:000320508100002 PM 23539284 ER PT J AU Washington, DL Davis, TD Der-Martirosian, C Yano, EM AF Washington, Donna L. Davis, Teri D. Der-Martirosian, Claudia Yano, Elizabeth M. TI PTSD Risk and Mental Health Care Engagement in a Multi-War Era Community Sample of Women Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE post-traumatic stress disorder; women; veterans; mental health services; utilization; Veterans hospitals ID POSTTRAUMATIC-STRESS-DISORDER; SHORT SCREENING SCALE; FEMALE VETERANS; SERVICE USE; VA; IRAQ; COMORBIDITY; AFGHANISTAN; PREVALENCE; POPULATION AB Post-traumatic stress disorder (PTSD) is common in women veterans (WVs), and associated with significant co-morbidity. Effective treatment is available; however, PTSD is often unrecognized. Identify PTSD prevalence and mental healthcare (MHC) use in a representative national WV sample. Cross-sectional, population-based 2008-2009 national survey of 3,611 WVs, weighted to the population. We screened for PTSD using a validated instrument, and also assessed demographic characteristics, health characteristics, and MHC use in the prior 12 months. Among those screening positive, we conducted multivariate logistic regression to identify independent predictors of MHC use. Overall, 13.0 % (95 % confidence interval [CI] 9.8-16.2) of WVs screened PTSD-positive. Veterans Health Administration (VA) healthcare was used by 31.1 % of PTSD-positives and 11.4 % of PTSD-negatives (p < 0.001). Among those screening positive, 48.7 % (95 % CI 35.9-61.6) used MHC services (66.3 % of VA-users, 40.8 % of VA-nonusers; p < 0.001). Having a diagnosis of depression (OR = 8.6; 95 % CI 1.5-48.9) and VA healthcare use (OR = 2.7; 95 % CI 1.1-7.0) predicted MHC use, whereas lacking a regular provider for health care (OR = 0.2; 95 % CI 0.1-0.4) and household income below the federal poverty level (OR = 0.2; 95 % CI 0.1-0.5) predicted nonuse. More than one in eight WVs screened positive for PTSD. Though a majority of VA-users received MHC, low income predicted nonuse. Only a minority of VA-nonusers received MHC. The majority of WVs use non-VA healthcare providers, who may be unaware of their veteran status and PTSD risk. VA outreach to educate VA-nonusers and their healthcare providers about WVs' PTSD risk and available evidence-based VA treatment options is one approach to extend the reach of VA MHC. Research to characterize barriers to VA MHC use for VA-nonusers and low income VA-users is warranted to better understand low service utilization, and to inform program development to engage more WVs in needed MHC. C1 [Washington, Donna L.; Davis, Teri D.; Der-Martirosian, Claudia; Yano, Elizabeth M.] VA Greater Los Angeles Hlth Serv Res & Dev HSR&D, Sepulveda, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM Donna.washington@va.gov FU Department of Veterans Affairs, Women's Health Services in the Office of Patient Care Services; Health Services Research and Development (HSRD) Service [IAE-06-083, SDR-08-270]; VA HSR&D Senior Research Career Scientist award [RCS-05-195] FX This study was funded by the Department of Veterans Affairs, Women's Health Services in the Office of Patient Care Services and the Health Services Research and Development (HSR&D) Service (#IAE-06-083 and #SDR-08-270). Dr. Yano is supported by a VA HSR&D Senior Research Career Scientist award (#RCS-05-195). The views expressed within are solely those of the authors, and do not necessarily represent the views of the Department of Veterans Affairs. NR 35 TC 18 Z9 18 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 IS 7 BP 894 EP 900 DI 10.1007/s11606-012-2303-2 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 165TU UT WOS:000320508100013 PM 23435765 ER PT J AU Tilstra, SA Kraemer, KL Rubio, DM McNeil, MA AF Tilstra, Sarah A. Kraemer, Kevin L. Rubio, Doris M. McNeil, Melissa A. TI Evaluation of VA Women's Health Fellowships: Developing Leaders in Academic Women's Health SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE VA women's health; fellowship; academic productivity; female leadership; women in academic medicine ID GENERAL INTERNAL-MEDICINE; EDITORIAL-BOARDS; CAREER; PHYSICIANS; PROGRAM; FACULTY; PRODUCTIVITY; VETERANS; IMPACT AB The Department of Veterans Affairs (VA) instituted the VA Women's Health Fellowship (VAWHF) Program in 1994, to accommodate the health needs of increasing numbers of female veterans and to develop academic leaders in women's health. Despite the longevity of the program, it has never been formally evaluated. To describe the training environments of VAWHFs and career outcomes of female graduates. Cross-sectional web-based surveys of current program directors (2010-2011) and VAWHF graduates (1995-2011). Responses were received from six of seven program directors (86 %) and 42 of 74 graduates (57 %). The mean age of graduates was 41.2 years, and mean time since graduation was 8.5 years. Of the graduates, 97 % were female, 74 % trained in internal medicine, and 64 % obtained an advanced degree. Those with an advanced degree were more likely than those without an advanced degree to pursue an academic career (82 % vs. 60 %; P < 0.01). Of the female graduates, 76 % practice clinical women's health and spend up to 66 % of their time devoted to women's health issues. Thirty percent have held a VA faculty position. Seventy-nine percent remain in academics, with 39 % in the tenure stream. Overall, 94 % had given national presentations, 88 % had received grant funding, 79 % had published in peer-reviewed journals, 64 % had developed or evaluated curricula, 51 % had received awards for teaching or research, and 49 % had held major leadership positions. At 11 or more years after graduation, 33 % of the female graduates in academics had been promoted to the rank of associate professor and 33 % to the rank of full professor. The VAWHF Program has been successful in training academic leaders in women's health. Finding ways to retain graduates in the VA system would ensure continued clinical, educational, and research success for the VA women veteran's healthcare program. C1 [Tilstra, Sarah A.; McNeil, Melissa A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Tilstra, Sarah A.; Kraemer, Kevin L.; Rubio, Doris M.; McNeil, Melissa A.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA. [Kraemer, Kevin L.; Rubio, Doris M.; McNeil, Melissa A.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. RP Tilstra, SA (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, Dept Med, 200 Lothrop St,MUH W933, Pittsburgh, PA 15213 USA. EM tilstrasa@upmc.edu FU NCATS NIH HHS [UL1 TR000005] NR 27 TC 5 Z9 5 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2013 VL 28 IS 7 BP 901 EP 907 DI 10.1007/s11606-012-2306-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 165TU UT WOS:000320508100014 PM 23435766 ER PT J AU Bloomfield, GS Yi, SS Astor, BC Kramer, H Shea, S Shlipak, MG Post, WS AF Bloomfield, G. S. Yi, S. S. Astor, B. C. Kramer, H. Shea, S. Shlipak, M. G. Post, W. S. TI Blood pressure and chronic kidney disease progression in a multi-racial cohort: the Multi-Ethnic Study of Atherosclerosis SO JOURNAL OF HUMAN HYPERTENSION LA English DT Article DE blood pressure; glomerular filtration rate; renal disease; cystatin C; creatinine; ethnicity ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; CHRONIC RENAL-DISEASE; FUNCTION DECLINE; HYPERTENSION; CREATININE; ADULTS; TRIAL; RISK; METAANALYSIS AB The relationship between blood pressure (BP) and kidney function among individuals with chronic kidney disease (CKD) remains controversial. This study evaluated the association between BP and estimated glomerular filtration rate (eGFR) decline among adults with nondiabetic stage 3 CKD. The Multi-Ethnic Study of Atherosclerosis participants with an eGFR 30-59 ml min(-1) per 1.73 m(2) at baseline without diabetes were included. Participants were followed over a 5-year period. Kidney function change was determined by annualizing the change in eGFR using cystatin C, creatinine and a combined equation. Risk factors for progression of CKD (defined as a decrease in annualized eGFR > 2.5 ml min(-1) per 1.73 m(2)) were identified using univariate analyses and sequential logistic regression models. There were 220 participants with stage 3 CKD at baseline using cystatin C, 483 participants using creatinine and 381 participants using the combined equation. The median (interquartile range) age of the sample was 74 (68-79) years. The incidence of progression of CKD was 16.8% using cystatin C and 8.9% using creatinine (P = 0.002). Systolic BP > 140 mm Hg or diastolic BP > 90 mm Hg was significantly associated with progression using a cystatin C-based (odds ratio (OR), 2.49; 95% confidence interval (CI), 1.12-5.52) or the combined equation (OR, 2.07; 95% CI, 1.16-3.69), but not when using creatinine after adjustment for covariates. In conclusion, with the inclusion of cystatin C in the eGFR assessment hypertension was an important predictor of CKD progression in a multi-ethnic cohort with stage 3 CKD. C1 [Bloomfield, G. S.] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA. [Bloomfield, G. S.] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Yi, S. S.; Astor, B. C.; Post, W. S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Astor, B. C.] Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Astor, B. C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Kramer, H.] Loyola Med Ctr, Dept Prevent Med, Maywood, IL USA. [Shea, S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Shea, S.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. [Shlipak, M. G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, M. G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Post, W. S.] Johns Hopkins Sch Med, Dept Med, Div Cardiol, Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. RP Post, WS (reprint author), Johns Hopkins Univ, Dept Med, Div Cardiol, Carnegie 568,600 N Wolfe St, Baltimore, MD 21287 USA. EM wpost@jhmi.edu OI Kramer, Holly/0000-0002-6374-837X; Bloomfield, Gerald/0000-0002-7176-1611; Yi, Stella/0000-0002-9943-2609 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169, K01 TW008407-02, R01 DK066488-01] FX We thank the other investigators, the staff and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute, K01 TW008407-02 (to GSB) and R01 DK066488-01 (to MGS). NR 32 TC 5 Z9 6 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9240 J9 J HUM HYPERTENS JI J. Hum. Hypertens. PD JUL PY 2013 VL 27 IS 7 BP 421 EP 426 DI 10.1038/jhh.2013.1 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 162EP UT WOS:000320248400005 PM 23407373 ER PT J AU Rani, CSS Soto-Pina, A Iacovitti, L Strong, R AF Rani, C. S. Sheela Soto-Pina, Alexandra Iacovitti, Lorraine Strong, Randy TI Evolutionary conservation of an atypical glucocorticoid-responsive element in the human tyrosine hydroxylase gene SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE AP-1; glucocorticoid receptor; glucocorticoid response element; tyrosine hydroxylase ID TRANSCRIPTIONAL REGULATION; DNA-BINDING; CYCLIC-AMP; IN-VIVO; RECEPTOR; PROMOTER; AP-1; EXPRESSION; REPRESSION; SEQUENCES AB The human tyrosine hydroxylase (hTH) gene has a 42bp evolutionarily conserved region designated (CR) II at -7.24kb, which bears 93% homology to the region we earlier identified as containing the glucocorticoid response element, a 7bp activator protein-1 (AP-1)-like motif in the rat TH gene. We cloned this hTH-CRII region upstream of minimal basal hTH promoter in luciferase (Luc) reporter vector, and tested glucocorticoid responsiveness in human cell lines. Dexamethasone (Dex) stimulated Luc activity of hTH-CRII in HeLa cells, while mifepristone, a glucocorticoid receptor (GR) antagonist, prevented Dex stimulation. Deletion of the 7bp 5-TGACTAA at -7243bp completely abolished the Dex-stimulated Luc activity of hTH-CRII construct. The AP-1 agonist, tetradeconoyl-12,13-phorbol acetate (TPA), also stimulated hTH promoter activity, and Dex and TPA together further accentuated this response. Chromatin immunoprecipitation assays revealed the presence of both GR and AP-1 proteins, especially Jun family members, at this hTH promoter site. Dex did not stimulate hTH promoter activity in a catecholaminergic cell line, which had low endogenous GR levels, but did activate the response when GR was expressed exogenously. Thus, our studies have clearly identified a glucocorticoid-responsive element in a 7bp AP-1-like motif in the promoter region at -7.24kb of the human TH gene. C1 [Rani, C. S. Sheela; Soto-Pina, Alexandra; Strong, Randy] UTHSCSA, Dept Pharmacol, San Antonio, TX 78229 USA. [Rani, C. S. Sheela; Soto-Pina, Alexandra; Strong, Randy] UTHSCSA, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Iacovitti, Lorraine] Thomas Jefferson Univ, Dept Neurosci, Farber Inst Neurosci, Philadelphia, PA 19107 USA. [Strong, Randy] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Rani, CSS (reprint author), UTHSCSA, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kadapakkam@uthscsa.edu OI Soto Pina, Alexandra Estela/0000-0002-3289-5510 FU Department of Veterans Affairs [VA 1 I01 BX001641]; Department of Defense [W81XWH-08-02-0118] FX We are grateful to Dr. N. Elango for his helpful suggestions in cloning of the hTH constructs. We thank Dr. John Cidlowski, NIEHS, Research Triangle Park, NC, for his gift of the pCMV5-hGR expression vector. This study was supported in part by grants from the Merit Review Medical Research Program of the Department of Veterans Affairs (VA 1 I01 BX001641; RS) and by the Department of Defense Congressionally Directed Medical Research Program (W81XWH-08-02-0118; RS). The authors have no conflict of interest to declare. NR 36 TC 2 Z9 4 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD JUL PY 2013 VL 126 IS 1 BP 19 EP 28 DI 10.1111/jnc.12294 PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 168RG UT WOS:000320722700003 ER PT J AU Berg, AT Caplan, R Baca, CB Vickrey, BG AF Berg, Anne T. Caplan, Rochelle Baca, Christine B. Vickrey, Barbara G. TI Adaptive behavior and later school achievement in children with early-onset epilepsy SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Article ID LONG-TERM PROGNOSIS; CRYPTOGENIC EPILEPSY; DISABILITY; EDUCATION; SEIZURE AB Aim To determine whether early measures of adaptive behavior are predictive of later school difficulties and achievement in otherwise neurotypical (unimpaired) children with onset of epilepsy during the preschool years. Method In a prospective cohort study, parents completed the Vineland Adaptive Behavior Scales (VABS) for children who were aged 5years or less at epilepsy diagnosis. Eight to 9 years later, the children were assessed using the Wechsler Intelligence Scales for Children (WISC), the Wide Range Achievement Test (WRAT), and the Child Behavior Checklist (CBCL). Associations of VABS scores with later WRAT and CBCL scores were tested. Results A total of 108 neurotypical children (64 males, 44 females; mean age at testing 11y 11mo, SD 2y) were studied. After adjustment for IQ and other factors, there was an increase of 0.15 points (95% confidence interval [CI] 0.03-0.27 points; p=0.03) and 0.14 points (95% CI 0.0-0.28 points; p=0.05) in WRAT reading and spelling scores for each 1-point increment in the VABS communication score. Corresponding numbers for the VABS socialization score were 0.20 (95% CI 0.08-0.32; p=0.005) and 0.17 (95% CI 0.05-0.29; p=0.005). Conclusion In neurotypical preschool children with epilepsy, early social and communication scores predict later school performance. These findings raise questions about opportunities for early identification and intervention for children at greatest risk. C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA. [Caplan, Rochelle] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Baca, Christine B.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Berg, AT (reprint author), Lurie Childrens Hosp, Epilepsy Ctr, 225 East Chicago Ave,Box 29, Chicago, IL 60611 USA. EM atberg@luriechildrens.org FU NINDS [R37-NS31146]; Pediatric Epilepsy Research Foundation; National Institutes of Health (NIA, NINDS); US Veterans Administration Health Services Research and Development Service; American Heart Association; [NINDS-R37-NS31146]; [NINDS R37 NS31146] FX Dr Berg has received speaker honoraria and travel support from BIAL pharmaceuticals and the Medical University of South Carolina, and travel support from the International League Against Epilepsy. She serves on the editorial boards of Epilepsy & Behavior and Neurology, and is supported by funding from the NINDS (grant R37-NS31146) and the Pediatric Epilepsy Research Foundation. Dr Caplan receives support from grant NINDS-R37-NS31146. She serves on the editorial boards of Epilepsy & Behavior, Epilepsy Currents, and Journal of Pediatric Epilepsy. Dr Baca receives support from grant NINDS-R37-NS31146. Dr Vickrey receives support from grant NINDS R37 NS31146. She serves on scientific advisory boards for the Sports Concussion Institute, American Heart Association, and the National Institutes of Health. She also serves on the editorial boards of Neurorehabilitation and Neural Repair and Circulation: Cardiovascular Quality and Outcomes, and is a section editor for Stroke; receives research support from the National Institutes of Health (NIA, NINDS), the US Veterans Administration Health Services Research and Development Service, the American Heart Association; and is a consultant to EMD Serono Canada and to Imperial Clinical Research Services, Inc. NR 25 TC 6 Z9 6 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD JUL PY 2013 VL 55 IS 7 BP 661 EP 667 DI 10.1111/dmcn.12143 PG 7 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 160HO UT WOS:000320109900018 PM 23534842 ER PT J AU Adeyemo, O Doi, H Reddy, KR Kaplan, DE AF Adeyemo, O. Doi, H. Reddy, K. Rajender Kaplan, D. E. CA SyNCH Trial Investigators TI Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE hepatitis C; interferon-gamma; interferon-stimulated gene; lymphocyte; silymarin; T-cell ID ANTIOXIDANT FLAVONOID MIXTURE; INTERFERON THERAPY; GENE-EXPRESSION; LIVER-DISEASE; MILK THISTLE; PHYSIOLOGICAL-RESPONSES; INTRAVENOUS SILIBININ; COMBINATION THERAPY; ANTIVIRAL THERAPY; IMMUNE-RESPONSE AB Silymarin displays anti-inflammatory effects on T lymphocytes in vitro. The immunomodulatory properties of oral silymarin in vivo in humans with chronic hepatitis C have not previously been characterized. We hypothesized that silymarin would suppress T-cell proliferation and pro-inflammatory cytokine production of virus- and non-virus-specific T cells while increasing anti-inflammatory IL-10 production in vivo. Patients from one site of the SyNCH-HCV double-masked, placebo-controlled study of oral silymarin in prior interferon nonresponders with chronic hepatitis C provided blood samples at baseline and treatment week 20. Mononuclear cells were stimulated with recombinant HCV proteins and controls in 3H-thymidine proliferation assays, IFN ELISPOT and IL-10 ELISPOT. The frequency of CD4+CD25hi and CD4+foxp3+ regulatory T cells, serum cytokine levels, serum IP-10 and lymphocyte interferon-stimulated gene expression were also quantified at baseline and week 20. Thirty-two patients were recruited (10; placebo, 11; 420mg three times a day, 11; 700mg three times a day). Serum ALT and HCV RNA titres did not change in any group. HCV-specific CD4+ T-cell proliferation and the frequency of IFN- and IL-10-producing T cells were not significantly changed in silymarin-treated subjects. However, C.albicans-induced T-cell IFN and phytohaemagglutinin-induced T-cell proliferation were suppressed by silymarin therapy. A trend towards augmentation of interferon-induced ISG15 expression was present in the high-dose silymarin group. While no effect on HCV-specific T cells was identified, these data confirm that high-dose oral silymarin exerts modest nonspecific immunomodulatory effects in vivo. The impact of this anti-inflammatory effect on long-term liver health in chronic hepatitis C merits future clinical investigation. C1 [Adeyemo, O.; Doi, H.; Reddy, K. Rajender; Kaplan, D. E.] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA. [Kaplan, D. E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA. RP Adeyemo, O (reprint author), Philadelphia VA Med Ctr, Res Bldg 21,A402A,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM dakaplan@mail.med.upenn.edu OI Kaplan, David E./0000-0002-3839-336X FU National Institutes of Health (NIH), National Center for Complementary and Alternative Medicine [AT003573, AT003571, AT003566, AT003560, AT003574]; NIDDK; NIH CTSA Division of Research Resources (University of Pennsylvania) [UL1 RR024134]; Research Career Development Award from the Veterans Health Administration (DEK); University of Pennsylvania (DEK); Center for Molecular Studies in Digestive and Liver Disease (NIH/NIDDK) [P30-DK050306] FX This research was supported with cooperative agreements to the SyNCH Study Group from the National Institutes of Health (NIH), National Center for Complementary and Alternative Medicine: AT003573, AT003571, AT003566, AT003560 and AT003574 with co-funding from the NIDDK, and with support from the NIH CTSA Division of Research Resources (University of Pennsylvania UL1 RR024134). In addition, Rottapharmvertical barMadaus (Monza, Italy and Cologne, Germany) provided both the silymarin and placebo for the trial. Other support was received from a Research Career Development Award from the Veterans Health Administration (DEK), academic development funds from the University of Pennsylvania (DEK) and Center for Molecular Studies in Digestive and Liver Disease (NIH/NIDDK P30-DK050306, DEK, KRR). The authors would like to thank Amina Wirjosemito for sample acquisition. The authors would also like to thank the patients who contributed samples. The content of this article does not reflect the views of the VA or of the US Government. NR 38 TC 4 Z9 4 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JUL PY 2013 VL 20 IS 7 BP 453 EP 462 DI 10.1111/jvh.12050 PG 10 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 157GL UT WOS:000319884000002 PM 23730838 ER PT J AU Brody, AL Mukhin, AG Shulenberger, S Mamoun, MS Kozman, M Phuong, J Neary, M Luu, T Mandelkern, MA AF Brody, Arthur L. Mukhin, Alexey G. Shulenberger, Stephanie Mamoun, Michael S. Kozman, Maggie Phuong, Jonathan Neary, Meaghan Trinh Luu Mandelkern, Mark A. TI Treatment for Tobacco Dependence: Effect on Brain Nicotinic Acetylcholine Receptor Density SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE tobacco dependence; nicotine; nicotinic acetylcholine receptor; bupropion; cognitive-behavioral therapy; positron emission tomography ID PREDICTING SMOKING-CESSATION; SELF-EFFICACY; WITHDRAWAL SYMPTOMS; CLINICAL-TRIALS; QUIT ATTEMPT; ABSTINENCE; RELAPSE; BUPROPION; SMOKERS; LAPSE AB Cigarette smoking leads to upregulation of brain nicotinic acetylcholine receptors (nAChRs), including the common alpha(4)beta(2)* nAChR subtype. Although a substantial percentage of smokers receive treatment for tobacco dependence with counseling and/or medication, the effect of a standard course of these treatments on nAChR upregulation has not yet been reported. In the present study, 48 otherwise healthy smokers underwent positron emission tomography (PET) scanning with the radiotracer 2-FA (for labeling alpha(4)beta(2)* nAChRs) before and after treatment with either cognitive-behavioral therapy, bupropion HCl, or pill placebo. Specific binding volume of distribution (VS/fP), a measure proportional to a4b2* nAChR density, was determined for regions known to have nAChR upregulation with smoking (prefrontal cortex, brainstem, and cerebellum). In the overall study sample, significant decreases in VS/fP were found for the prefrontal cortex, brainstem, and cerebellum of -20 (+/- 35), -25 (+/- 36), and -25 (+/- 31)%, respectively, which represented movement of VS/fP values toward values found in non-smokers (mean 58.2% normalization of receptor levels). Participants who quit smoking had significantly greater reductions in VS/fP across regions than non-quitters, and correlations were found between reductions in cigarettes per day and decreases in VS/fP for brainstem and cerebellum, but there was no between-group effect of treatment type. Thus, smoking reduction and cessation with commonly used treatments (and pill placebo) lead to decreased alpha(4)beta(2)* nAChR densities across brain regions. Study findings could prove useful in the treatment of smokers by providing encouragement with the knowledge that decreased smoking leads to normalization of specific brain receptors. C1 [Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Brody, Arthur L.; Shulenberger, Stephanie; Mamoun, Michael S.; Kozman, Maggie; Phuong, Jonathan; Neary, Meaghan; Trinh Luu; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Mukhin, Alexey G.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU National Institute on Drug Abuse [R01 DA20872]; Tobacco-Related Disease Research Program [19XT-0135]; Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; Pfizer, Inc.; Phillip Morris, Inc. FX This study was supported by the National Institute on Drug Abuse (ALB (R01 DA20872)), the Tobacco-Related Disease Research Program (ALB (19XT-0135)), and the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412 (ALB)). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.; ALB and MAM were previously co-investigators on a grant funded by Pfizer, Inc. that was unrelated to this study. AGM is a co-investigator on a grant from Phillip Morris, Inc. for research unrelated to this study. All the other authors report no biomedical financial disclosures or potential conflicts of interest. NR 71 TC 11 Z9 11 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JUL PY 2013 VL 38 IS 8 BP 1548 EP 1556 DI 10.1038/npp.2013.53 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 163WJ UT WOS:000320368200016 PM 23429692 ER PT J AU Valente, AJ Yoshida, T Clark, RA Delafontaine, P Siebenlist, U Chandrasekar, B AF Valente, Anthony J. Yoshida, Tadashi Clark, Robert A. Delafontaine, Patrice Siebenlist, Ulrich Chandrasekar, Bysani TI Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE AOPPs; TRAF3IP2; Oxidative stress; Cell death; Myocardial injury; Free radicals ID GLYCATION END-PRODUCTS; NF-KAPPA-B; ACUTE CORONARY SYNDROMES; C-REACTIVE PROTEIN; NADPH OXIDASE; OXIDIZED LDL; ARTERY-DISEASE; NOX FAMILY; CIKS ACT1; APOPTOSIS AB Advanced oxidation protein products (AOPPs) are formed during chronic oxidative stress as a result of reactions between plasma proteins and chlorinated oxidants. Their levels are elevated during various cardiovascular diseases. Because elevated AOPPs serve as independent risk factors for ischemic heart disease, and cardiomyocyte death is a hallmark of ischemic heart disease, we hypothesized that AOPPs will induce cardiomyocyte death. AOPP-modified mouse serum albumin (AOPP-MSA) induced significant death of neonatal mouse cardiomyocytes that was attenuated by knockdown of the receptor for advanced glycation end products, but not CD36. Notably, TRAF3-interacting protein 2 (TRAF3IP2; also known as CIKS or Act1) knockdown blunted AOPP-induced apoptosis. AOPP-MSA stimulated Nox2/Rac1-dependent superoxide generation, TRAF3IP2 expression, and TRAF3IP2-dependent JNK activation. The superoxide anion generating xanthine/xanthine oxidase system and hydrogen peroxide both induced TRAF3IP2 expression. Further, AOPP-MSA induced mitochondrial Bax translocation and release of cytochrome c into cytoplasm. Moreover, AOPP-MSA suppressed antiapoptotic Bcl-2 and Bcl-xL expression. These effects were reversed by TRAF3IP2 knockdown or forced expression of mutant JNK. Similar to its effects in neonatal cardiomyocytes, AOPP-MSA induced adult cardiomyocyte death in part via TRAF3IP2. These results demonstrate for the first time that AOPPs induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK activation in vitro and suggest that AOPPs may contribute to myocardial injury in vivo. Thus TRAF3IP2 may represent a potential therapeutic target in ischemic heart disease. (C) 2013 Elsevier Inc. All rights reserved. C1 [Valente, Anthony J.; Clark, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Valente, Anthony J.; Clark, Robert A.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Yoshida, Tadashi; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. [Siebenlist, Ulrich] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA. [Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA. RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave, New Orleans, LA 70112 USA. EM bchandra@tulane.edu OI Delafontaine, Patrice/0000-0003-3744-3617; Yoshida, Tadashi/0000-0002-4544-1497 FU Department of Veterans Affairs Research Career Scientist Award; VA Office of Research and Development Biomedical Laboratory Research and Development Service Award [11O1BX000246]; NHLBI/NIH [HL-86787]; NHLBI [HL-70241, HL-80682] FX B.C. is a recipient of the Department of Veterans Affairs Research Career Scientist Award and is supported by VA Office of Research and Development Biomedical Laboratory Research and Development Service Award 11O1BX000246 and NHLBI/NIH Grant HL-86787. The contents of this report do not represent the views of the Department of Veterans Affairs or the U.S. government. PD is supported by NHLBI Grants HL-70241 and HL-80682. NR 49 TC 23 Z9 25 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUL PY 2013 VL 60 BP 125 EP 135 DI 10.1016/j.freeradbiomed.2013.02.012 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 151UU UT WOS:000319486500016 PM 23453926 ER PT J AU Zhang, YQ Ikeno, Y Bokov, A Gelfond, J Jaramillo, C Zhang, HM Liu, YH Qi, WB Hubbard, G Richardson, A Van Remmen, H AF Zhang, Yiqiang Ikeno, Yuji Bokov, Alex Gelfond, Jon Jaramillo, Carlos Zhang, Hong-Mei Liu, Yuhong Qi, Wenbo Hubbard, Gene Richardson, Arlan Van Remmen, Holly TI Dietary restriction attenuates the accelerated aging phenotype of Sod1(-/-) mice SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Dietary restriction; Aging oxidative stress; Cu/ZnSOD; Free radicals ID FATAL NEOPLASTIC DISEASES; DISMUTASE-DEFICIENT MICE; CALORIC RESTRICTION; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; MUSCLE ATROPHY; LIFE-SPAN; DELAYED OCCURRENCE; SHORT-TERM; AGE AB Dietary restriction is a powerful aging intervention that extends the life span of diverse biological species ranging from yeast to invertebrates to mammals, and it has been argued that the antiaging action of dietary restriction occurs through reduced oxidative stress/damage. Using Sod1(-/-) mice, which have previously been shown to have increased levels of oxidative stress associated with a shorter life span and a high incidence of neoplasia, we were able to test directly the ability of dietary restriction to reverse an aging phenotype due to increased oxidative stress/damage. We found that dietary restriction increased the life span of Sod1(-/-) mice 30%, returning it to that of wild-type, control mice fed ad libitum. Oxidative damage in Sod1(-/-) mice was markedly reduced by dietary restriction, as indicated by a reduction in liver and brain F-2-isoprostanes, a marker of lipid peroxidation. Analysis of end of life pathology showed that dietary restriction significantly reduced the overall incidence of pathological lesions in the Sod1(-/-) mice fed the dietary-restricted diet compared to Sod1(-/-) mice fed ad libitum, including the incidence of lymphoma (27 vs 5%) and overall liver pathology. In addition to reduced incidence of overall and liver-specific pathology, the burden and severity of both neoplastic and nonneoplastic lesions was also significantly reduced in the Sod1(-/-) mice fed the dietary-restricted diet. These data demonstrate that dietary restriction can significantly attenuate the accelerated aging phenotype observed in Sod1(-/-) mice that arises from increased oxidative stress/damage. (C) 2013 Elsevier Inc. All rights reserved. C1 [Zhang, Yiqiang; Ikeno, Yuji; Bokov, Alex; Jaramillo, Carlos; Liu, Yuhong; Qi, Wenbo; Hubbard, Gene; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging studies, San Antonio, TX 78229 USA. [Ikeno, Yuji; Hubbard, Gene] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ikeno, Yuji; Richardson, Arlan; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Educ Clin & Res Ctr, San Antonio, TX 78229 USA. [Bokov, Alex; Gelfond, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Zhang, Hong-Mei] Fourth Mil Med Univ, Dept Clin Oncol, Xijing Hosp, Xian 710032, Peoples R China. [Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging studies, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu FU NIH [P01AG020591]; American Federation for Aging Research FX This study was supported by a NIH grant to H.V.R. and A.R. (P01AG020591) and a Julie Martin Mid-career grant from the American Federation for Aging Research (H.V.R.). NR 43 TC 6 Z9 6 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUL PY 2013 VL 60 BP 300 EP 306 DI 10.1016/j.freeradbiomed.2013.02.026 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 151UU UT WOS:000319486500033 PM 23459073 ER PT J AU Antebi, B Cheng, XG Harris, JN Gower, LB Chen, XD Ling, J AF Antebi, Ben Cheng, Xingguo Harris, Jeffrey N. Gower, Laurie B. Chen, Xiao-Dong Ling, Jian TI Biomimetic Collagen-Hydroxyapatite Composite Fabricated via a Novel Perfusion-Flow Mineralization Technique SO TISSUE ENGINEERING PART C-METHODS LA English DT Article ID APATITE FORMATION; IN-VITRO; BONE; SCAFFOLDS; BIOMINERALIZATION; MATRIX; REGENERATION; MECHANISM; REPAIR; CELLS AB Prevalent three-dimensional scaffolds for bone tissue engineering are mineralized collagen-hydroxyapatite (Col/HA) composites. Conventional mineralization techniques are either to coat collagen scaffold surfaces with minerals or to simply mix collagen and mineral nanoparticles together. These conventional in vitro collagen mineralization methods are different from the in vivo bone formation process and often result in scaffolds that are not suitable for bone tissue engineering. In this study, a unique perfusion-flow (i.e., dynamic) in conjunction with a previously described polymer-induced liquid-precursor (PILP) method was used to fabricate a porous Col/HA composite. The dynamic flow emulated the physiological extracellular fluid flow containing the mineralization ions, while the PILP method facilitated the deposition of the HA crystals within the collagen fibrils (i.e., intrafibrillar mineralization). By utilizing a dynamic PILP technique to mimic the in vivo bone formation process, the resultant Col/HA composite has a similar structure and compositions like human trabecular bone. A comparison of the dynamic and static mineralization methods revealed that the novel dynamic technique facilitates more efficient and homogenous mineral deposition throughout the Col/HA composite. The dynamic intrafibrillar mineralization method generated stiff Col/HA composites with excellent surface property for cell attachment and growth. The human mesenchymal stem cells cultured on the Col/HA composites quickly remodeled the scaffolds and resulted in constructs with an extensive cell-derived extracellular matrix network. C1 [Antebi, Ben; Cheng, Xingguo; Harris, Jeffrey N.; Ling, Jian] SW Res Inst, Dept Microencapsulat & Nanomat, San Antonio, TX 78238 USA. [Antebi, Ben; Ling, Jian] Univ Texas Hlth Sci Ctr San Antonio, Univ Texas San Antonio, Biomed Engn Program, San Antonio, TX 78229 USA. [Gower, Laurie B.] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA. [Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Chen, Xiao-Dong] South Texas Vet Hlth Care Syst, Audie L Murphy Div Hosp, San Antonio, TX USA. RP Ling, J (reprint author), SW Res Inst, Dept Microencapsulat & Nanomat, 6220 Culebra Rd, San Antonio, TX 78238 USA. EM jling@swri.org RI Gower, Laurie/A-5947-2008 OI Gower, Laurie/0000-0003-2927-5406 FU National Heart, Lung, and Blood Institute [1R21 HL102775-01] FX This work was supported by the National Heart, Lung, and Blood Institute: 1R21 HL102775-01. NR 38 TC 22 Z9 23 U1 4 U2 66 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3384 J9 TISSUE ENG PART C-ME JI Tissue Eng. Part C-Methods PD JUL PY 2013 VL 19 IS 7 BP 487 EP 496 DI 10.1089/ten.tec.2012.0452 PG 10 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 150PY UT WOS:000319404500001 PM 23157544 ER PT J AU Puntil, C York, J Limandri, B Greene, P Arauz, E Hobbs, D AF Puntil, Cheryl York, Janet Limandri, Barbara Greene, Pamela Arauz, Eric Hobbs, Deborah TI Competency-Based Training for PMH Nurse Generalists: Inpatient Intervention and Prevention of Suicide SO JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION LA English DT Article DE suicide prevention; self-directed violence (SDV); psychiatric nursing; inpatient intervention; competencies; consumer perspective ID CONTROLLED-TRIAL; ATTEMPTERS; EDUCATION; PROGRAMS; VETERANS AB Suicide is the tenth leading cause of death in the United States. Approximately 90,000 psychiatric mental health (PMH) nurse generalists work in hospitals in the United States, mostly on inpatient psychiatric units where the most acutely suicidal patients are hospitalized. Although competencies have been developed for mental health clinicians in assessing and managing suicide risk, there are no standard competencies for PMH nurse generalists. Widely accepted nursing practices do not meet suicide-specific standards of care or evidence-based criteria. Although both the Commission on Collegiate Nursing Education Essentials for Baccalaureate Education and the Quality and Safety Education for Nurses competencies stress the necessity for comprehensive assessment, safe clinical practices, patient-centered care, evidence-based interventions, and interprofessional communication and collaboration, there are no specific requirements for suicide prevention training in educational and clinical programs. The American Psychiatric Nurses Association has an opportunity to provide leadership in developing, implementing, and evaluating competency-based training for nurses and partner with the national effort to increase the competencies in suicide prevention in the behavioral health workforce. C1 [Puntil, Cheryl] Univ Calif Los Angeles, Resnick Neuropsychiat Hosp, Los Angeles, CA 90095 USA. [York, Janet] Ralph H Johnson VAMC, Charleston, SC USA. [Limandri, Barbara] Linfield Coll, Mcminnville, OR USA. [Greene, Pamela] Menninger Clin, Houston, TX USA. [Arauz, Eric] Arauz Inspirat Enterprises LLC, East Brunswick, NJ USA. [Hobbs, Deborah] Amer Psychiat Nurses Assoc, Falls Church, VA USA. RP Puntil, C (reprint author), Univ Calif Los Angeles, Resnick Neuropsychiat Hosp, 195 Med Plaza, Los Angeles, CA 90095 USA. EM cpuntil@mednet.ucla.edu NR 42 TC 9 Z9 9 U1 3 U2 16 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3903 EI 1532-5725 J9 J AM PSYCHIAT NURSES JI J. Am. Psych. Nurses Assoc. PD JUL-AUG PY 2013 VL 19 IS 4 BP 205 EP 210 DI 10.1177/1078390313496275 PG 6 WC Nursing; Psychiatry SC Nursing; Psychiatry GA AJ5KK UT WOS:000337720900007 PM 23950543 ER PT J AU Dransfield, MT Lettis, S Barnhart, F Crim, C Calverley, PMA AF Dransfield, Mark T. Lettis, Sally Barnhart, Frank Crim, Courtney Calverley, Peter M. A. TI Fluticasone furoate and vilanterol for COPD Reply SO LANCET RESPIRATORY MEDICINE LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; PROPIONATE/SALMETEROL 250/50; EXACERBATIONS; SALMETEROL C1 [Dransfield, Mark T.] Univ Alabama Birmingham, AB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Barnhart, Frank; Crim, Courtney] GlaxoSmithKline, Res Triangle Pk, NC USA. [Lettis, Sally] GlaxoSmithKline, London, England. [Calverley, Peter M. A.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. RP Dransfield, MT (reprint author), Univ Alabama Birmingham, AB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD JUL PY 2013 VL 1 IS 5 BP E21 EP E22 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AQ3JS UT WOS:000342689300002 PM 24429207 ER PT J AU Thomas, CP Garnick, DW Horgan, CM Miller, K Harris, AHS Rosen, MM AF Thomas, Cindy Parks Garnick, Deborah W. Horgan, Constance M. Miller, Kay Harris, Alex H. S. Rosen, Melissa M. TI Establishing the feasibility of measuring performance in use of addiction pharmacotherapy SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Performance measurement; Pharmacotherapy; Addiction medication; Veterans health; Medicaid ID ALCOHOL-DEPENDENT PATIENTS; SUBSTANCE-ABUSE TREATMENT; RANDOMIZED CONTROLLED TRIAL/; USE DISORDERS; HEALTH-CARE; MEDICATION COMPLIANCE; COST-EFFECTIVENESS; OPIOID DEPENDENCE; MEASURING QUALITY; MENTAL-HEALTH AB This paper presents the rationale and feasibility of standardized performance measures for use of pharmacotherapy in the treatment of substance use disorders (SUD), an evidence-based practice and critical component of treatment that is often underused. These measures have been developed and specified by the Washington Circle, to measure treatment of alcohol and opioid dependence with FDA-approved prescription medications for use in office-based general health and addiction specialty care. Measures were pilot tested in private health plans, the Veterans Health Administration (VHA), and Medicaid. Testing revealed that use of standardized measures using administrative data for overall use and initiation of SUD pharmacotherapy is feasible and practical. Prevalence of diagnoses and use of pharmacotherapy vary widely across health systems. Pharmacotherapy is generally used in a limited portion of those for whom it might be indicated. An important methodological point is that results are sensitive to specifications, so that standardization is critical to measuring performance across systems. (c) 2013 Elsevier Inc. All rights reserved. C1 [Thomas, Cindy Parks; Garnick, Deborah W.; Horgan, Constance M.; Rosen, Melissa M.] Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA 02454 USA. [Harris, Alex H. S.] US Dept Vet Affairs, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Miller, Kay] Truven Hlth Analyt, Santa Barbara, CA 93111 USA. RP Thomas, CP (reprint author), Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA 02454 USA. EM cthomas@brandeis.edu RI Thomas, Cindy/L-3204-2015; Garnick, Deborah/I-9009-2012 OI Thomas, Cindy/0000-0001-5855-1196; FU NIDA NIH HHS [R01 DA029316] NR 72 TC 10 Z9 10 U1 0 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUL PY 2013 VL 45 IS 1 BP 11 EP 18 DI 10.1016/j.jsat.2013.01.004 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 141VU UT WOS:000318755400002 PM 23490233 ER PT J AU Hagedorn, HJ Noorbaloochi, S Simon, AB Bangerter, A Stitzer, ML Stetler, CB Kivlahan, D AF Hagedorn, Hildi J. Noorbaloochi, Siamak Simon, Alisha Baines Bangerter, Ann Stitzer, Maxine L. Stetler, Cheryl B. Kivlahan, Daniel TI Rewarding early abstinence in Veterans Health Administration addiction clinics SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Alcohol dependence; Stimulant dependence; Contingency management; Substance use disorders treatment; Effectiveness ID SUBSTANCE USE DISORDERS; COST CONTINGENCY MANAGEMENT; COCAINE ABSTINENCE; REINFORCEMENT THERAPY; RANDOMIZED-TRIAL; MAINTAINED PATIENTS; METHADONE PATIENTS; FOLLOW-UP; INCENTIVES; DEPENDENCE AB This study investigates the addition of a contingency management (CM) intervention to Veterans Health Administration substance use disorders treatment on during- and post-treatment outcomes for Veterans diagnosed with alcohol dependence only (n = 191) or stimulant dependence (n = 139). Participants were randomly assigned to 8 weeks of usual care or usual care plus CM. Follow-up assessments occurred at 2, 6 and 12 months. In the alcohol dependent subgroup, CM participants submitted significantly more negative samples (13 versus 11 samples, Cohen's d = 0.54), were retained significantly longer (7 versus 6 weeks, d = 0.47), achieved significantly longer median durations of abstinence (16 versus 9 consecutive visits; median difference = 7, 95% CI = 4-8), and submitted significantly more negative samples at follow-ups (unstandardized effect size = 0.669, se = 0.2483) compared to usual care participants. Intervention effects were nonsignificant for the stimulant dependent subgroup. The study provides support for the effectiveness of CM interventions for alcohol dependent patients. Published by Elsevier Inc. C1 [Hagedorn, Hildi J.] Minneapolis VA Healthcare Syst, Vet Hlth Adm Subst Use Disorder Qual Enhancement, Minneapolis, MN 55417 USA. [Hagedorn, Hildi J.; Noorbaloochi, Siamak; Simon, Alisha Baines; Bangerter, Ann] Minneapolis VA Healthcare Syst, Vet Hlth Adm Hlth Serv Res & Dev Ctr Excellence, Minneapolis, MN 55417 USA. [Hagedorn, Hildi J.; Noorbaloochi, Siamak] Univ Minnesota, Minneapolis, MN 55455 USA. [Stitzer, Maxine L.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA. [Stetler, Cheryl B.] Boston Univ, Sch Hlth & Independent Consultant, Dept Hlth Serv, Amherst, MA 01002 USA. [Kivlahan, Daniel] VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Kivlahan, Daniel] Univ Washington, Sch Med, Seattle, WA 98185 USA. RP Hagedorn, HJ (reprint author), Minneapolis VA Healthcare Syst, 1 Vet Dr, Minneapolis, MN 55417 USA. EM hildi.hagedorn@va.gov NR 30 TC 5 Z9 5 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUL PY 2013 VL 45 IS 1 BP 109 EP 117 DI 10.1016/j.jsat.2013.01.006 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 141VU UT WOS:000318755400014 PM 23453480 ER PT J AU Das, F Ghosh-Choudhury, N Bera, A Kasinath, BS Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Bera, Amit Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI TGF-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID INITIATION-FACTOR 4E; PROTEIN-KINASE; MESSENGER-RNA; TRANSLATION INITIATION; AKT KINASE; BETA; EXPRESSION; DISEASE; GROWTH; TUMORIGENESIS AB Transforming growth factor (TGF)-induced canonical signal transduction is involved in glomerular mesangial cell hypertrophy; however, the role played by the noncanonical TGF signaling remains largely unexplored. TGF time-dependently stimulated eIF4E phosphorylation at Ser-209 concomitant with enhanced phosphorylation of Erk1/2 (extracellular signal regulated kinase1/2) and MEK (mitogen-activated and extracellular signal-regulated kinase kinase) in mesangial cells. Inhibition of Erk1/2 by MEK inhibitor or by expression of dominant negative Erk2 blocked eIF4E phosphorylation, resulting in attenuation of TGF-induced protein synthesis and mesangial cell hypertrophy. Expression of constitutively active (CA) MEK was sufficient to induce protein synthesis and hypertrophy similar to those induced by TGF. Pharmacological or dominant negative inhibition of phosphatidylinositol (PI) 3 kinase decreased MEK/Erk1/2 phosphorylation leading to suppression of eIF4E phosphorylation. Inducible phosphorylation of eIF4E at Ser-209 is mediated by Mnk-1 (mitogen-activated protein kinase signal-integrating kinase-1). Both PI 3 kinase and Erk1/2 promoted phosphorylation of Mnk-1 in response to TGF. Dominant negative Mnk-1 significantly inhibited TGF-stimulated protein synthesis and hypertrophy. Interestingly, inhibition of mTORC1 activity, which blocks dissociation of eIF4E-4EBP-1 complex, decreased TGF-stimulated phosphorylation of eIF4E without any effect on Mnk-1 phosphorylation. Furthermore, mutant eIF4E S209D, which mimics phosphorylated eIF4E, promoted protein synthesis and hypertrophy similar to TGF. These results were confirmed using phosphorylation deficient mutant of eIF4E. Together our results highlight a significant role of dissociation of 4EBP-1-eIF4E complex for Mnk-1-mediated phosphorylation of eIF4E. Moreover, we conclude that TGF-induced noncanonical signaling circuit involving PI 3 kinase-dependent Mnk-1-mediated phosphorylation of eIF4E at Ser-209 is required to facilitate mesangial cell hypertrophy. J. Cell. Physiol. 228: 16171626, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Das, Falguni; Bera, Amit; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIH [RO1 DK50190, RO1 AR52425, RO1 DK077295, RC2A 036613]; VA Merit Review grants; VA Senior Research Career Scientist Award; VA Research Service FX Contract grant sponsor: NIH;; Contract grant numbers: RO1 DK50190, RO1 AR52425, RO1 DK077295, RC2A 036613.; Contract grant sponsor: VA Merit Review grants.; Contract grant sponsor: VA Senior Research Career Scientist Award.; Contract grant sponsor: VA Research Service. NR 29 TC 9 Z9 9 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JUL PY 2013 VL 228 IS 7 BP 1617 EP 1626 DI 10.1002/jcp.24327 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 113PX UT WOS:000316681100029 PM 23359369 ER PT J AU Wilson, PC Lee, MH Appleton, KM El-Shewy, HM Morinelli, TA Peterson, YK Luttrell, LM Jaffa, AA AF Wilson, Parker C. Lee, Mi-Hye Appleton, Kathryn M. El-Shewy, Hesham M. Morinelli, Thomas A. Peterson, Yuri K. Luttrell, Louis M. Jaffa, Ayad A. TI The Arrestin-selective Angiotensin AT(1) Receptor Agonist [Sar(1),Ile(4),Ile(8)]-AngII Negatively Regulates Bradykinin B-2 Receptor Signaling via AT(1)-B-2 Receptor Heterodimers SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID KALLIKREIN-KININ SYSTEM; OXIDE-GENERATING VASODILATORS; VASCULAR SMOOTH-MUSCLE; G-PROTEIN; BETA-ARRESTIN; NITRIC-OXIDE; IN-VIVO; DIABETIC-NEPHROPATHY; HEART-FAILURE; BIASED LIGAND AB The renin-angiotensin and kallikrein-kinin systems are key regulators of vascular tone and inflammation. Angiotensin II, the principal effector of the renin-angiotensin system, promotes vasoconstriction by activating angiotensin AT(1) receptors. The opposing effects of the kallikrein-kinin system are mediated by bradykinin acting on B-1 and B-2 bradykinin receptors. The renin-angiotensin and kallikrein-kinin systems engage in cross-talk at multiple levels, including the formation of AT(1)-B-2 receptor heterodimers. In primary vascular smooth muscle cells, we find that the arrestin pathway-selective AT(1) agonist, [Sar(1),Ile(4),Ile(8)]-AngII, but not the neutral AT(1) antagonist, losartan, inhibits endogenous B-2 receptor signaling. In a transfected HEK293 cell model that recapitulates this effect, we find that the actions of [Sar(1), Ile(4), Ile(8)]-AngII require the AT(1) receptor and result from arrestin-dependent co-internalization of AT(1)-B-2 heterodimers. BRET50 measurements indicate that AT(1) and B-2 receptors efficiently heterodimerize. In cells expressing both receptors, pretreatment with [Sar(1),Ile(4),Ile(8)]-AngII blunts B-2 receptor activation of G(q/11)-dependent intracellular calcium influx and G(i/o)-dependent inhibition of adenylyl cyclase. In contrast, [Sar(1),Ile(4),Ile(8)]-AngII has no effect on B-2 receptor ligand affinity or bradykinin-induced arrestin3 recruitment. Both radioligand binding assays and quantitative microscopy-based analysis demonstrate that [Sar(1),Ile(4),Ile(8)]-AngII promotes internalization of AT(1)-B-2 heterodimers. Thus, [Sar(1),Ile(4),Ile(8)]-AngII exerts lateral allosteric modulation of B-2 receptor signaling by binding to the orthosteric ligand binding site of the AT(1) receptor and promoting co-sequestration of AT(1)-B-2 heterodimers. Given the opposing roles of the renin-angiotensin and kallikrein-kinin systems in vivo, the distinct properties of arrestin pathway-selective and neutral AT(1) receptor ligands may translate into different pharmacologic actions. C1 [Wilson, Parker C.; Lee, Mi-Hye; El-Shewy, Hesham M.; Morinelli, Thomas A.; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Coll Med, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Coll Med, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Appleton, Kathryn M.; Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. [Jaffa, Ayad A.] Amer Univ Beirut, Dept Biochem, Beirut 11072020, Lebanon. [Jaffa, Ayad A.] Amer Univ Beirut, Dept Mol Genet, Beirut 11072020, Lebanon. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 816CSB,MSC624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU National Institutes of Health [R01 HL087986, HL077192, R01 DK55524, F30 DK083208]; National Center for Research Resources [S10 RR027777]; Research Service of the Ralph H. Johnson Veterans Affairs Medical Center FX This work was supported, in whole or in part, by National Institutes of Health Grants R01 HL087986 and HL077192 (to A. A. J.), R01 DK55524 (to L. M. L.), and F30 DK083208 (to P. C. W.) and National Center for Research Resources Grant S10 RR027777 (to T. A. M. and L. M. L.). This work was also supported by the Research Service of the Ralph H. Johnson Veterans Affairs Medical Center. NR 56 TC 15 Z9 15 U1 0 U2 10 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 28 PY 2013 VL 288 IS 26 BP 18872 EP 18884 DI 10.1074/jbc.M113.472381 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 176WB UT WOS:000321335800025 PM 23661707 ER PT J AU Prasad, R Katiyar, SK AF Prasad, Ram Katiyar, Santosh K. TI Grape seed proanthocyanidins inhibit migration potential of pancreatic cancer cells by promoting mesenchymal-to-epithelial transition and targeting NF-kappa B SO CANCER LETTERS LA English DT Article DE NF-kappa B; Epithelial-to-mesenchymal transition; Pancreatic cancer cells; Cancer cell migration; Grape seed proanthocyanidins ID REPRESSES E-CADHERIN; BREAST-CANCER; TUMOR PROGRESSION; EXPRESSION; TRANSCRIPTION; INFLAMMATION; SNAIL; SLUG; METASTASIS; ALPHA AB Here we explore the effect of grape seed proanthocyanidins (GSPs) on pancreatic cancer cell migration and the molecular mechanisms underlying these effects. Treatment of human pancreatic cancer cell lines Miapaca-2, PANC-1 and AsPC-1 with GSPs resulted in inhibition of cell migration (19-82%, P < 0.01-0.001), which was associated with decreased phosphorylation of ERK1/2 and inactivation of NF-kappa B. Treatment of cells with UO126, an inhibitor of MEK, and caffeic acid phenethyl ester, an inhibitor of NE-kappa B, also inhibited the migration of cells (40-80%, P < 0.01-0.001). Inhibition of cell migration by GSPs was associated with reversal of the epithelial-to-mesenchymal transition. This was associated with upregulation of E-cadherin and desmoglein-2 and down-regulation of fibronectin, N-cadherin and vimentin. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Sch Publ Hlth, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award FX This work was supported partially by the funds from the Veterans Administration Merit Review Award (SKK). Grateful thanks to Dr. Fiona Hunter for editorial assistance. The content of this article does not necessarily reflect the views or policies of the funding sources, and also the funders had no role in study design, data analysis and preparation of the manuscript. NR 35 TC 7 Z9 11 U1 1 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 J9 CANCER LETT JI Cancer Lett. PD JUN 28 PY 2013 VL 334 IS 1 SI SI BP 118 EP 126 DI 10.1016/j.canlet.2012.08.003 PG 9 WC Oncology SC Oncology GA 164MF UT WOS:000320413500018 PM 22902508 ER PT J AU Smith, AK White, DB Arnold, RM AF Smith, Alexander K. White, Douglas B. Arnold, Robert M. TI Uncertainty - The Other Side of Prognosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [White, Douglas B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. FU NIA NIH HHS [K23 AG040772] NR 5 TC 35 Z9 36 U1 1 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 27 PY 2013 VL 368 IS 26 BP 2448 EP 2450 DI 10.1056/NEJMp1303295 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 171KQ UT WOS:000320926900004 PM 23802514 ER PT J AU Nayak, BK Feliers, D Sudarshan, S Friedrichs, WE Day, RT New, DD Fitzgerald, JP Eid, A DeNapoli, T Parekh, DJ Gorin, Y Block, K AF Nayak, B. K. Feliers, D. Sudarshan, S. Friedrichs, W. E. Day, R. T. New, D. D. Fitzgerald, J. P. Eid, A. DeNapoli, T. Parekh, D. J. Gorin, Y. Block, K. TI Stabilization of HIF-2 alpha through redox regulation of mTORC2 activation and initiation of mRNA translation SO ONCOGENE LA English DT Article DE mTOR; Nox oxidase; Rictor; p22(phox); HIF-2 alpha; renal cancer ID TUMOR-SUPPRESSOR PROTEIN; CANCER; PHOSPHORYLATION; EXPRESSION; CARCINOMA; COMPLEX; EIF4E; AKT; TRANSFORMATION; CONTRIBUTES AB Hypoxia inducible factor-2 alpha (HIF-2 alpha) has a critical role in renal tumorigenesis. HIF-2 alpha is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation. Mammalian target of rapamycin (mTOR) functions in two distinct complexes: Raptor-associated mTORC1 and Rictor-associated mTORC2. Rictor-associated mTORC2 complex has been linked to maintaining HIF-2 alpha protein in the absence of VHL; however, the mechanisms remain to be elucidated. Although Raptor-associated mTORC1 is a known key upstream regulator of mRNA translation, initiation and elongation, the role of mTORC2 in regulating mRNA translation is not clear. Complex assembly of the mRNA cap protein, eukaryotic translation initiation factor 4 (eIF4)E, with activators (eIF4 gamma (eIF4G)) and inhibitors (eIF4E-binding protein 1 (4E-BP1)) are rate-limiting determinants of mRNA translation. Our laboratory has previously demonstrated that reactive oxygen species, mediated by p22(phox)-based Nox oxidases, are enhanced in VHL-deficient cells and have a role in the activation of Akt on S473, a site phosphorylated by the mTORC2 complex. In this study, we examined the role of Rictor-dependent regulation of HIF-2 alpha through eIF4E-dependent mRNA translation and examined the effects of p22(phox)-based Nox oxidases on TORC2 regulation. We demonstrate for the first time that mTORC2 complex stability and activation is redox sensitive, and further defined a novel role for p22(phox)-based Nox oxidases in eIF4E-dependent mRNA translation through mTORC2. Furthermore, we provide the first evidence that silencing of p22(phox) reduces HIF-2 alpha-dependent gene targeting in vitro and tumor formation in vivo. The clinical relevance of these studies is demonstrated. C1 [Nayak, B. K.; Feliers, D.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Eid, A.; Gorin, Y.; Block, K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Sudarshan, S.; Fitzgerald, J. P.; Parekh, D. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [DeNapoli, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Block, K.] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA. RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM block@uthscsa.edu FU Veterans Administration; NIH [R01 NCI CA131272, K08 CA138774]; Voelcker Fund Young Investigator Award; Cancer Center Support Grant, National Cancer Institute [5 P30 CA054174-18] FX We acknowledge Dr Goutam Gosh-Choudhury for the HRE responsive element, Cynthia Galindo for technical contributions and Dr Hanna E. Abboud for helpful discussions and critical reading of the manuscript. This study was supported by the Veterans Administration Career Development Award and NIH R01 NCI CA131272 (KB), and NIH K08 CA138774 and Voelcker Fund Young Investigator Award (SS). This study was also supported in part by the Cancer Center Support Grant, National Cancer Institute, 5 P30 CA054174-18 (DJP). NR 28 TC 18 Z9 19 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD JUN 27 PY 2013 VL 32 IS 26 BP 3147 EP 3155 DI 10.1038/onc.2012.333 PG 9 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 172LL UT WOS:000321004600005 PM 22869144 ER PT J AU Liu, H Rose, ME Miller, TM Li, WJ Shinde, SN Pickrell, AM Poloyac, SM Graham, SH Hickey, RW AF Liu, Hao Rose, Marie E. Miller, Tricia M. Li, Wenjin Shinde, Sunita N. Pickrell, Alicia M. Poloyac, Samuel M. Graham, Steven H. Hickey, Robert W. TI COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest SO BRAIN RESEARCH LA English DT Article DE Prostaglandin; Cyclopentenone; Hypoxic-ischemia; Cardiac arrest; Cyclooxygenase ID CEREBRAL-ISCHEMIA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); BRAIN-INJURY; PPAR-GAMMA; CYCLOOXYGENASE-2; INHIBITION; ELECTROPHILE; MECHANISMS; RAT AB Background: Cyclopentenone prostaglandins have been identified as potential neurotoxic agents in the setting of hypoxia-ischemia. Cyclooxygenase-2 (COX-2), the upstream enzyme responsible for prostaglandin production is upregulated following hypoxic-ischemic brain injury. However, the temporal production and concentration of cyclopentenone prostaglandins has not been described following global brain ischemia. Methods Global brain ischemia was induced in rats by asphyxial cardiac arrest (ACA) followed by resuscitation. Rats were sacrificed between 24 h and 7 days following resuscitation and their brains removed. Western blot, immunohistochemistry, and mass spectroscopy were performed. A cohort of rats was pretreated with the COX-2 inhibitor SC58125. Results COX-2 is induced in hippocampus at 24 h following ACA. Multiple prostaglandins, including cyclopentenone prostaglandin species, are increased in hippocampus as 24 h following ACA. Prostaglandin and cyclopentenone prostaglandin concentrations are returned to baseline at 3 and 7 days post-ischemia. The COX-2 inhibitor SC58125 completely abrogates the post-ischemic increase in prostaglandins and cyclopentenone prostaglandins. Conclusions Prostaglandins, including cyclopentenone prostaglandins, are increased in ischemic brain, peak at 24 h and can be attenuated by the COX-2 inhibitor SC58125. These data establish the presence of potentially neurotoxic cyclopentenone prostaglandins in post-ischemic brains, thus identifying a target and therapeutic window for neuroprotective therapies. (C) 2013 Elsevier B.V. All rights reserved. C1 [Liu, Hao; Rose, Marie E.; Li, Wenjin; Graham, Steven H.] VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr GR H 00, Pittsburgh, PA USA. [Liu, Hao; Rose, Marie E.; Li, Wenjin; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA. [Shinde, Sunita N.; Pickrell, Alicia M.; Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA. RP Hickey, RW (reprint author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA. EM Robert.hickey@chp.edu FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1 RR024153-05]; NIH Roadmap for Medical Research; [R21HD058846]; [R01NS37459] FX We would like to thank Li Wang, MS for her help with statistical support. Supported by R21HD058846 (RWH), R01NS37459 (SHG). Statistical support was provided by the Clinical Translational Science Institute of the University of Pittsburgh: Grant number 5UL1 RR024153-05 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 27 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JUN 26 PY 2013 VL 1519 BP 71 EP 77 DI 10.1016/j.brainres.2013.04.029 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 178US UT WOS:000321473500008 PM 23624225 ER PT J AU Woodell, A Coughlin, B Kunchithapautham, K Casey, S Williamson, T Ferrell, WD Atkinson, C Jones, BW Rohrer, B AF Woodell, Alex Coughlin, Beth Kunchithapautham, Kannan Casey, Sarah Williamson, Tucker Ferrell, W. Drew Atkinson, Carl Jones, Bryan W. Rohrer, Baerbel TI Alternative Complement Pathway Deficiency Ameliorates Chronic Smoke-Induced Functional and Morphological Ocular Injury SO PLOS ONE LA English DT Article ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM; CAUSES OXIDATIVE DAMAGE; MACULAR DEGENERATION; CIGARETTE-SMOKE; BRUCHS MEMBRANE; FACTOR-B; CHOROIDAL NEOVASCULARIZATION; MITOCHONDRIAL DYSFUNCTION AB Background: Age-related macular degeneration (AMD), a complex disease involving genetic variants and environmental insults, is among the leading causes of blindness in Western populations. Genetic and histologic evidence implicate the complement system in AMD pathogenesis; and smoking is the major environmental risk factor associated with increased disease risk. Although previous studies have demonstrated that cigarette smoke exposure (CE) causes retinal pigment epithelium (RPE) defects in mice, and smoking leads to complement activation in patients, it is unknown whether complement activation is causative in the development of CE pathology; and if so, which complement pathway is required. Methods: Mice were exposed to cigarette smoke or clean, filtered air for 6 months. The effects of CE were analyzed in wildtype (WT) mice or mice without a functional complement alternative pathway (AP; CFB-/-) using molecular, histological, electrophysiological, and behavioral outcomes. Results: CE in WT mice exhibited a significant reduction in function of both rods and cones as determined by electroretinography and contrast sensitivity measurements, concomitant with a thinning of the nuclear layers as measured by SD-OCT imaging and histology. Gene expression analyses suggested that alterations in both photoreceptors and RPE/choroid might contribute to the observed loss of function, and visualization of complement C3d deposition implies the RPE/Bruch's membrane (BrM) complex as the target of AP activity. RPE/BrM alterations include an increase in mitochondrial size concomitant with an apical shift in mitochondrial distribution within the RPE and a thickening of BrM. CFB-/- mice were protected from developing these CE-mediated alterations. Conclusions: Taken together, these findings provide clear evidence that ocular pathology generated in CE mice is dependent on complement activation and requires the AP. Identifying animal models with RPE/BrM damage and verifying which aspects of pathology are dependent upon complement activation is essential for developing novel complement-based treatment approaches for the treatment of AMD. C1 [Woodell, Alex; Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA. [Coughlin, Beth; Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Casey, Sarah; Williamson, Tucker; Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Ferrell, W. Drew; Jones, Bryan W.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA. EM rohrer@musc.edu OI Jones, Bryan/0000-0001-5527-6643 FU Department for Veterans Affairs [RX000444]; Research to Prevent Blindness (RPB), New York, NY; Foundation Fighting Blindness, Columbia, MD; NIH NHLBI [RO1 091944]; NIH [C06RR015455] FX This work was supported in part by a Department for Veterans Affairs merit award RX000444 (BR), unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New York, NY and Foundation Fighting Blindness, Columbia, MD, and NIH NHLBI RO1 091944 (CA). Animal studies were conducted in a facility constructed with support from the NIH (C06RR015455). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 93 TC 9 Z9 9 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 25 PY 2013 VL 8 IS 6 AR e67894 DI 10.1371/journal.pone.0067894 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 175IB UT WOS:000321223000122 PM 23825688 ER PT J AU Stickrath, C Noble, M Prochazka, A Anderson, M Griffiths, M Manheim, J Sillau, S Aagaard, E AF Stickrath, Chad Noble, Melissa Prochazka, Allan Anderson, Mel Griffiths, Megan Manheim, Jonathan Sillau, Stefan Aagaard, Eva TI Attending Rounds in the Current Era What Is and Is Not Happening SO JAMA INTERNAL MEDICINE LA English DT Article ID DUTY-HOUR REGULATIONS; INTERNAL-MEDICINE; EDUCATION; BEDSIDE; FACULTY; MODEL AB Importance: General medicine rounds by attending physicians provide the foundation for patient care and education in teaching hospitals. However, the detailed activities of these rounds in the current era are not well characterized. Objective: To describe the characteristics of attending rounds for internal medicine inpatients in a large teaching hospital system. Design: A cross-sectional observational study of attending rounds in internal medicine. Rounds were observed directly by research assistants. Setting: Four teaching hospitals associated with a large public medical school. Participants: Fifty-six attending physicians and 279 trainees treating 807 general medicine inpatients. Main Outcomes and Measures: Duration and location of rounds, composition of teams, and frequency of 19 potential activities during rounds. Results: We observed 90 days of rounds. A typical rounding day consisted of 1 attending with 3 trainees visiting a median of 9 (range, 2-18 [SD, 2.9]) patients for a median of 2.0 hours (range, 25-241 [SD, 2.7] minutes). On rounds, teams most frequently discussed the patient care plan (96.7% of patients), reviewed diagnostic studies (90.7%), communicated with patients (73.4%), and discussed the medication list (68.8%). Teams infrequently discussed invasive lines or tubes (9.3%) or nursing notes (6.2%) and rarely communicated with nurses (12.0%) or taught physical examination skills (14.6%), evidence-based medicine topics (7.2%), or learner-identified topics (3.2%). Many commonly performed activities occurred infrequently at the bedside. Conclusions and Relevance: Most activities on attending rounds do not take place at the bedside. The teams discuss patient care plans and test results most of the time but fail to include many items that may be of significant value, including specific aspects of patient care, interprofessional communication, and learner-centered education. Future studies are needed to further assess the implications of these observations. C1 [Stickrath, Chad; Prochazka, Allan; Anderson, Mel; Manheim, Jonathan; Sillau, Stefan; Aagaard, Eva] Univ Colorado, Sch Med, Dept Med, Denver, CO 80220 USA. [Stickrath, Chad; Prochazka, Allan; Anderson, Mel] Denver Vet Affairs Med Ctr, Med Serv, Denver, CO USA. [Noble, Melissa; Griffiths, Megan] Univ Colorado, Sch Med, Denver, CO 80220 USA. RP Stickrath, C (reprint author), Univ Colorado, Sch Med, Med Serv, Denver VA Med Ctr, 1055 Clermont St,Box 111, Denver, CO 80220 USA. EM Chad.stickrath@va.gov FU University of Colorado Academy of Medical Educators Rymer Family Endowment Grant FX This study was supported by the University of Colorado Academy of Medical Educators Rymer Family Endowment Grant. NR 20 TC 25 Z9 25 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 24 PY 2013 VL 173 IS 12 BP 1084 EP 1089 DI 10.1001/jamainternmed.2013.6041 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 170OE UT WOS:000320861700012 PM 23649040 ER PT J AU Lee, BY Sonnenberg, A AF Lee, Brent Y. Sonnenberg, Amnon TI Time Trends of Mortality From Colorectal Cancer in the United States: A Birth-Cohort Analysis SO JAMA INTERNAL MEDICINE LA English DT Letter ID HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; RISK; METAANALYSIS C1 [Lee, Brent Y.; Sonnenberg, Amnon] Portland VA Med Ctr, Div Gastroenterol & Hepatol, Portland, OR USA. [Lee, Brent Y.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 6 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 24 PY 2013 VL 173 IS 12 BP 1148 EP 1150 DI 10.1001/jamainternmed.2013.656 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 170OE UT WOS:000320861700029 PM 23700085 ER PT J AU Ishida, JH McCulloch, CE Dudley, RA Grimes, BA Johansen, KL AF Ishida, Julie H. McCulloch, Charles E. Dudley, R. Adams Grimes, Barbara A. Johansen, Kirsten L. TI Dialysis Facility Profit Status and Compliance With a Black Box Warning SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Ishida, Julie H.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. [Dudley, R. Adams] Univ Calif San Francisco, Dept Med, Div Pulm Dis & Crit Care Med, San Francisco, CA 94143 USA. [McCulloch, Charles E.; Dudley, R. Adams; Grimes, Barbara A.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA. RP Ishida, JH (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, 521 Parnassus Ave,Clin Sci C443,Box 0532, San Francisco, CA 94143 USA. EM julie.ishida@ucsf.edu FU NIDDK NIH HHS [K24 DK085153, T32 DK007219, K24DK085153, N01-DK-7-0005] NR 6 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 24 PY 2013 VL 173 IS 12 BP 1152 EP 1153 DI 10.1001/jamainternmed.2013.979 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 170OE UT WOS:000320861700031 PM 23699967 ER PT J AU Lewinsohn, DM Swarbrick, GM Cansler, ME Null, MD Rajaraman, V Frieder, MM Sherman, DR McWeeney, S Lewinsohn, DA AF Lewinsohn, David M. Swarbrick, Gwendolyn M. Cansler, Meghan E. Null, Megan D. Rajaraman, Veena Frieder, Marisa M. Sherman, David R. McWeeney, Shannon Lewinsohn, Deborah A. TI Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library SO PLOS ONE LA English DT Article ID PROTECTIVE IMMUNITY; DENDRITIC CELLS; INFECTED-CELLS; HIV-INFECTION; HLA-B; LYMPHOCYTES; VACCINES; ANTIGEN; MICE; VACCINATION AB Identification of CD8(+) T cell antigens/epitopes expressed by human pathogens with large genomes is especially challenging, yet necessary for vaccine development. Immunity to tuberculosis, a leading cause of mortality worldwide, requires CD8(+) T cell immunity, yet the repertoire of CD8 antigens/epitopes remains undefined. We used integrated computational and proteomic approaches to screen 10% of the Mycobacterium tuberculosis (Mtb) proteome for CD8 Mtb antigens. We designed a weighting schema based upon a Multiple Attribute Decision Making: framework to select 10% of the Mtb proteome with a high probability of containing CD8(+) T cell epitopes. We created a synthetic peptide library consisting of 15-mers overlapping by 11 aa. Using the interferon-gamma ELISPOT assay and Mtb-infected dendritic cells as antigen presenting cells, we screened Mtb-specific CD8(+) T cell clones restricted by classical MHC class I molecules (MHC class Ia molecules), that were isolated from Mtb-infected humans, against this library. Three novel CD8 antigens were unambiguously identified: the EsxJ family (Rv1038c, Rv1197, Rv3620c, Rv2347c, Rv1792), PE9 (Rv1088), and PE_PGRS42 (Rv2487c). The epitopes are B5701-restricted EsxJ(24-34), B3905-restricted PE9(53-67), and B3514-restricted PE_PGRS42(48-56), respectively. The utility of peptide libraries in identifying unknown epitopes recognized by classically restricted CD8(+) T cells was confirmed, which can be applied to other intracellular pathogens with large size genomes. In addition, we identified three novel Mtb epitopes/antigens that may be evaluated for inclusion in vaccines and/or diagnostics for tuberculosis. C1 [Lewinsohn, David M.; Frieder, Marisa M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Lewinsohn, David M.; Rajaraman, Veena; Frieder, Marisa M.] Portland VA Med Ctr, Portland, OR USA. [Swarbrick, Gwendolyn M.; Cansler, Meghan E.; Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Rajaraman, Veena; McWeeney, Shannon] Oregon Hlth & Sci Univ, Oregon Canc Inst, Portland, OR 97201 USA. [Sherman, David R.] Seattle Biomed Res Inst, Seattle, WA 98109 USA. RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. EM lewinsde@ohsu.edu RI ; Lewinsohn, David/I-4936-2013 OI McWeeney, Shannon/0000-0001-8333-6607; Lewinsohn, David/0000-0001-9906-9494 FU VA Merit Review Grant; Portland VA Medical Center, US National Institutes of Health [HHSN266200400081C (NO1-A1-400081), R01AI48090] FX This work was supported by a VA Merit Review Grant and the Portland VA Medical Center, US National Institutes of Health HHSN266200400081C (NO1-A1-400081), and R01AI48090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 13 Z9 14 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 21 PY 2013 VL 8 IS 6 AR e67016 DI 10.1371/journal.pone.0067016 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 170JP UT WOS:000320846500117 PM 23805289 ER PT J AU Liu, XH Wu, Y Yao, S Levine, AC Kirschenbaum, A Collier, L Bauman, WA Cardozo, CP AF Liu, Xin-Hua Wu, Yong Yao, Shen Levine, Alice C. Kirschenbaum, Alexander Collier, Lauren Bauman, William A. Cardozo, Christopher P. TI Androgens Up-regulate Transcription of the Notch Inhibitor Numb in C2C12 Myoblasts via Wnt/beta-Catenin Signaling to T Cell Factor Elements in the Numb Promoter SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-CATENIN; MYOGENIC DIFFERENTIATION; SKELETAL-MUSCLE; POSTNATAL MYOGENESIS; WNT; ACTIVATION; RECEPTOR; FATE; TESTOSTERONE; PATHWAY AB Androgen signaling via the androgen receptor is a key pathway that contributes to development, cell fate decisions, and differentiation, including that of myogenic progenitors. Androgens and synthetic steroids have well established anabolic actions on skeletal muscle. Wnt and Notch signaling pathways are also essential to myogenic cell fate decisions during development and tissue repair. However, the interactions among these pathways are largely unknown. Androgenic regulation of Wnt signaling has been reported. Nandrolone, an anabolic steroid, has been shown to inhibit Notch signaling and up-regulate Numb, a Notch inhibitor. To elucidate the mechanisms of interaction between nandrolone and Wnt/Notch signaling, we investigated the effects of nandrolone on Numb expression and Wnt signaling and determined the roles of Wnt signaling in nandrolone-induced Numb expression in C2C12 myoblasts. Nandrolone increased Numb mRNA and protein levels and T cell factor (Tcf) transcriptional activity via inhibition of glycogen synthase kinase 3 beta. Up-regulation of Numb expression by nandrolone was blocked by the Wnt inhibitors, sFRP1 and DKK1, whereas Wnt3a increased Numbm RNA and protein expression. In addition, we observed that the proximal promoter of the Numb gene had functional Tcf binding elements to which beta-catenin was recruited in a manner enhanced by both nandrolone and Wnt3a. Moreover, site-directed mutagenesis indicated that the Tcf binding sites in the Numb promoter are required for the nandrolone-induced Numb transcriptional activation in this cell line. These results reveal a novel molecular mechanism underlying up-regulation of Numb transcription with a critical role for increased canonical Wnt signaling. In addition, the data identify Numb as a novel target gene of the Wnt signaling pathway by which Wnts would be able to inhibit Notch signaling. C1 [Liu, Xin-Hua; Wu, Yong; Collier, Lauren; Bauman, William A.; Cardozo, Christopher P.] James J Peter Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA. [Yao, Shen; Levine, Alice C.; Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Kirschenbaum, Alexander] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peter Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, F7756R, F6997R] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service Grants B4162C, F7756R, and F6997R. NR 47 TC 7 Z9 7 U1 1 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 21 PY 2013 VL 288 IS 25 BP 17990 EP 17998 DI 10.1074/jbc.M113.478487 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 168QZ UT WOS:000320721900006 PM 23649620 ER PT J AU Buck, TM Plavchak, L Roy, A Donnelly, BF Kashlan, OB Kleyman, TR Subramanya, AR Brodsky, JL AF Buck, Teresa M. Plavchak, Lindsay Roy, Ankita Donnelly, Bridget F. Kashlan, Ossama B. Kleyman, Thomas R. Subramanya, Arohan R. Brodsky, Jeffrey L. TI The Lhs1/GRP170 Chaperones Facilitate the Endoplasmic Reticulum-associated Degradation of the Epithelial Sodium Channel SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ER-ASSOCIATED DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-EXCHANGE FACTOR; HEAT-SHOCK PROTEINS; NA+ CHANNEL; MOLECULAR CHAPERONES; MISFOLDED GLYCOPROTEINS; HSP70 CHAPERONES; QUALITY-CONTROL; MECHANISTICALLY DISTINCT AB The epithelial sodium channel, ENaC, plays a critical role in maintaining salt and water homeostasis, and not surprisingly defects in ENaC function are associated with disease. Like many other membrane-spanning proteins, this trimeric protein complex folds and assembles inefficiently in the endoplasmic reticulum (ER), which results in a substantial percentage of the channel being targeted for ER-associated degradation (ERAD). Because the spectrum of factors that facilitates the degradation of ENaC is incomplete, we developed yeast expression systems for each ENaC subunit. We discovered that a conserved Hsp70-like chaperone, Lhs1, is required for maximal turnover of the ENaC alpha subunit. By expressing Lhs1 ATP binding mutants, we also found that the nucleotide exchange properties of this chaperone are dispensable for ENaC degradation. Consistent with the precipitation of an Lhs1-alpha ENaC complex, Lhs1 holdase activity was instead most likely required to support the ERAD of alpha ENaC. Moreover, a complex containing the mammalian Lhs1 homolog GRP170 and alpha ENaC co-precipitated, and GRP170 also facilitated ENaC degradation in human, HEK293 cells, and in a Xenopus oocyte expression system. In both yeast and higher cell types, the effect of Lhs1 on the ERAD of alpha ENaC was selective for the unglycosylated form of the protein. These data establish the first evidence that Lhs1/Grp170 chaperones can act as mediators of ERAD substrate selection. C1 [Buck, Teresa M.; Plavchak, Lindsay; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA. [Roy, Ankita; Donnelly, Bridget F.; Kashlan, Ossama B.; Kleyman, Thomas R.; Subramanya, Arohan R.] Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. RP Brodsky, JL (reprint author), Univ Pittsburgh, Dept Biol Sci, A320 Langley Hall,4249 5th Ave, Pittsburgh, PA 15260 USA. EM jbrodsky@pitt.edu FU National Institutes of Health [K01DK090195, DK65161, GM75061, DK79307]; United States Department of Veterans Affairs; University of Pittsburgh George O'Brien Kidney Research Center; American Heart Association [10BGIA3890010] FX This work was supported, in whole or in part, by National Institutes of Health Grants K01DK090195 (to T. M. B.), DK65161 (to T. K.), GM75061 (to J. L. B.), and DK79307 (to the University of Pittsburgh George O'Brien Kidney Research Center).; Supported by a Mid-level Career Development Award from the United States Department of Veterans Affairs, pilot funds from the University of Pittsburgh George O'Brien Kidney Research Center, and by James A. Shaver Fund of the American Heart Association Grant 10BGIA3890010. NR 116 TC 17 Z9 17 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 21 PY 2013 VL 288 IS 25 BP 18366 EP 18380 DI 10.1074/jbc.M113.469882 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 168QZ UT WOS:000320721900040 PM 23645669 ER PT J AU Tobwala, S Zhang, XS Zheng, YY Wang, HJ Banks, WA Ercal, N AF Tobwala, Shakila Zhang, Xinsheng Zheng, Youyou Wang, Hsiu-Jen Banks, William A. Ercal, Nuran TI Disruption of the integrity and function of brain microvascular endothelial cells in culture by exposure to diesel engine exhaust particles SO TOXICOLOGY LETTERS LA English DT Article DE Diesel engine exhaust; Diesel exhaust particles; Oxidative stress; Reactive oxygen species; Glutathione ID PARTICULATE AIR-POLLUTION; TERT-BUTYL HYDROPEROXIDE; OXIDATIVE STRESS; IN-VITRO; GLUTATHIONE METABOLISM; DOPAMINERGIC-NEURONS; ULTRAFINE PARTICLES; LIPID-PEROXIDATION; BARRIER; DAMAGE AB Diesel exhaust particles (DEPs), a by-product of diesel engine exhaust (DEE), are known to produce pro-oxidative and pro-inflammatory effects, thereby leading to oxidative stress-induced damage. Given the key role of DEPs in inducing oxidative stress, we investigated the role of DEPs in disrupting the integrity and function of immortalized human brain microvascular endothelial cells (HBMVEC). To study this, HBMVEC cells were exposed to media containing three different concentrations of DEPs or plain media for 24 h. Those exposed to DEPs showed significantly higher oxidative stress than the untreated group, as indicated by the glutathione (GSH) and malondialdehyde (MDA) levels, and the glutathione peroxidase and glutathione reductase activities. DEPs also induced oxidative stress-related disruption of the HBMVEC cells monolayer, as measured by trans-epithelial electrical resistance. Taken together, these data suggest that DEPs induce cell death and disrupt the function and integrity of HBMVEC cells, indicating a potential role of DEPs in neurotoxicities. (c) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Tobwala, Shakila; Zhang, Xinsheng; Zheng, Youyou; Wang, Hsiu-Jen; Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO 65409 USA. [Banks, William A.] Univ Washington, Sch Med, GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Ercal, N (reprint author), Missouri Univ Sci & Technol, Dept Chem, 400 West 11th St,142 Schrenk Hall, Rolla, MO 65409 USA. EM nercal@mst.edu FU NIDA, NIH [1 R15DA023409-01A2] FX Dr. Ercal was supported by 1 R15DA023409-01A2 from the NIDA, NIH and the contents of this paper are solely the responsibility of the authors and do not necessarily represent official views of the NIDA or NIH. The authors appreciate the editorial efforts of Barbara Harris. NR 58 TC 9 Z9 9 U1 1 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-4274 J9 TOXICOL LETT JI Toxicol. Lett. PD JUN 20 PY 2013 VL 220 IS 1 BP 1 EP 7 DI 10.1016/j.toxlet.2013.03.023 PG 7 WC Toxicology SC Toxicology GA 151GS UT WOS:000319449300001 PM 23542817 ER PT J AU Yehia, BR Kangovi, S Frank, I AF Yehia, Baligh R. Kangovi, Shreya Frank, Ian TI Patients in transition: avoiding detours on the road to HIV treatment success SO AIDS LA English DT Article DE behavioral model; care transitions; health outcomes; HIV; quality of care ID HEALTH-CARE TRANSITION; ANTIRETROVIRAL THERAPY; YOUTH; PERSPECTIVES; PREVENTION; RELEASE; SYSTEM; ADULTS; PRISON C1 [Yehia, Baligh R.; Kangovi, Shreya; Frank, Ian] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Yehia, BR (reprint author), Univ Penn, Perelman Sch Med, 1309 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM byehia@upenn.edu FU Penn Center for AIDS Research [P30 AI 045008]; National Institutes of Health [K23-MH097647-01A1] FX This work was support, in part, by the Penn Center for AIDS Research, P30 AI 045008. B.R.Y. was supported by the National Institutes of Health (K23-MH097647-01A1). NR 20 TC 11 Z9 11 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUN 19 PY 2013 VL 27 IS 10 BP 1529 EP 1533 DI 10.1097/QAD.0b013e328360104e PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 250HG UT WOS:000326840700001 PM 23435297 ER PT J AU Konadhode, RR Pelluru, D Blanco-Centurion, C Zayachkivsky, A Liu, M Uhde, T Glen, WB van den Pol, AN Mulholland, PJ Shiromani, PJ AF Konadhode, Roda Rani Pelluru, Dheeraj Blanco-Centurion, Carlos Zayachkivsky, Andrew Liu, Meng Uhde, Thomas Glen, W. Bailey, Jr. van den Pol, Anthony N. Mulholland, Patrick J. Shiromani, Priyattam J. TI Optogenetic Stimulation of MCH Neurons Increases Sleep SO JOURNAL OF NEUROSCIENCE LA English DT Article ID MELANIN-CONCENTRATING HORMONE; LOCUS-COERULEUS; OREXIN NEURONS; RAT; MICE; HYPOTHALAMUS; HYPOCRETIN; NUCLEUS; BRAIN; GENE AB Melanin concentrating hormone (MCH) is a cyclic neuropeptide present in the hypothalamus of all vertebrates. MCH is implicated in a number of behaviors but direct evidence is lacking. To selectively stimulate the MCH neurons the gene for the light-sensitive cation channel, channelrhodopsin-2, was inserted into the MCH neurons of wild-type mice. Three weeks later MCH neurons were stimulated for 1 min every 5 min for 24 h. A 10 Hz stimulation at the start of the night hastened sleep onset, reduced length of wake bouts by 50%, increased total time in non-REM and REM sleep at night, and increased sleep intensity during the day cycle. Sleep induction at a circadian time when all of the arousal neurons are active indicates that MCH stimulation can powerfully counteract the combined wake-promoting signal of the arousal neurons. This could be potentially useful in treatment of insomnia. C1 [Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Konadhode, Roda Rani; Pelluru, Dheeraj; Blanco-Centurion, Carlos; Liu, Meng; Uhde, Thomas; Mulholland, Patrick J.; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Glen, W. Bailey, Jr.; Mulholland, Patrick J.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Zayachkivsky, Andrew; van den Pol, Anthony N.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA. RP Shiromani, PJ (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Psychiat, 114 Doughty St,MSC404 STB 404, Charleston, SC 29425 USA. EM shiroman@musc.edu FU NIH [AA017922, MH055772, NS052287, NS079940, NS48476]; Medical Research Service of the Department of Veterans Affairs FX This work was supported by NIH grants AA017922, MH055772, NS052287, NS079940, and NS48476 and the Medical Research Service of the Department of Veterans Affairs. We thank Dr. Mahesh Thakkar for helpful comments during the writing of this manuscript, and Sundaravadivel Balasubramanian for assistance with the confocal microscope. NR 23 TC 73 Z9 75 U1 0 U2 16 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 19 PY 2013 VL 33 IS 25 BP 10257 EP 10263 DI 10.1523/JNEUROSCI.1225-13.2013 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 166YF UT WOS:000320596400008 PM 23785141 ER PT J AU Kullgren, JT Duey, KA Werner, RM AF Kullgren, Jeffrey T. Duey, Katia A. Werner, Rachel M. TI A Census of State Health Care Price Transparency Websites SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Kullgren, Jeffrey T.] Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Duey, Katia A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48105 USA. EM jkullgre@med.umich.edu NR 6 TC 10 Z9 10 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 19 PY 2013 VL 309 IS 23 BP 2437 EP 2438 DI 10.1001/jama.2013.6557 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 165SW UT WOS:000320505100019 PM 23780454 ER PT J AU Thompson, GR Kontoyiannis, DP Patterson, TF AF Thompson, George R., III Kontoyiannis, Dimitrios P. Patterson, Thomas F. TI Real-world Experience in the Midst of an Exserohilum Meningitis Outbreak SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID FUNGAL-INFECTIONS C1 [Thompson, George R., III] Univ Calif Davis, Div Infect Dis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Control, Houston, TX 77030 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Employee Hlth, Houston, TX 77030 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Room 5-035R,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM patterson@uthscsa.edu NR 8 TC 2 Z9 2 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 19 PY 2013 VL 309 IS 23 BP 2493 EP 2495 DI 10.1001/jama.2013.6294 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 165SW UT WOS:000320505100032 PM 23780464 ER PT J AU Fu, RW Selph, S McDonagh, M Peterson, K Tiwari, A Chou, R Helfand, M AF Fu, Rongwei Selph, Shelley McDonagh, Marian Peterson, Kimberly Tiwari, Arpita Chou, Roger Helfand, Mark TI Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine Fusion A Systematic Review and Meta-analysis SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID LUMBAR INTERBODY FUSION; ANTERIOR CERVICAL DISKECTOMY; OFF-LABEL USE; RADIOGRAPHIC OUTCOMES; RETROGRADE EJACULATION; INTEGRATED ANALYSIS; RHBMP-2; SURGERY; AUTOGRAFT; ALLOGRAFT AB Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is used as a bone graft substitute in spinal fusion, which unites (fuses) bones in the spine. The accuracy and completeness of journal publications of industry-sponsored trials on the effectiveness and harms of rhBMP-2 has been called into question. Purpose: To independently assess the effectiveness and harms of rhBMP-2 in spinal fusion and reporting bias in industry-sponsored journal publications. Data Sources: Individual-patient data (IPD) from 17 industry-sponsored studies; related internal documents; and searches of MEDLINE (1996 to August 2012), other databases, and reference lists. Study Selection: Randomized, controlled trials (RCTs) and cohort studies of rhBMP-2 versus any control and uncontrolled studies of harms. Data Extraction: Effectiveness outcomes in IPD were recalculated using consistent definitions. Study characteristics and results were abstracted by 1 investigator and confirmed by another. Two investigators independently assessed quality using predefined criteria. Data Synthesis: Thirteen RCTs and 31 cohort studies were included. For lumbar spine fusion, rhBMP-2 and iliac crest bone graft were similar in overall success, fusion, and other effectiveness measures and in risk for any adverse event, although rates were high across interventions (77% to 93% at 24 months from surgery). For anterior lumbar interbody fusion, rhBMP-2 was associated with nonsignificantly increased risk for retrograde ejaculation and urogenital problems. For anterior cervical spine fusion, rhBMP-2 was associated with increased risk for wound complications and dysphagia. At 24 months, the cancer risk was increased with rhBMP-2 (risk ratio, 3.45 [95% CI, 1.98 to 6.00]), but event rates were low and cancer was heterogeneous. Early journal publications misrepresented the effectiveness and harms through selective reporting, duplicate publication, and underreporting. Limitations: Outcome assessment was not blinded, and ascertainment of harms in trials was poor. No trials were truly independent of industry sponsorship. Conclusion: In spinal fusion, rhBMP-2 has no proven clinical advantage over bone graft and may be associated with important harms, making it difficult to identify clear indications for rhBMP-2. Earlier disclosure of all relevant data would have better informed clinicians and the public than the initial published trial reports did. C1 [Fu, Rongwei] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. Oregon State Univ, Corvallis, OR 97331 USA. RP Fu, RW (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code CSB669, Portland, OR 97239 USA. EM fur@ohsu.edu FU Yale University; Medtronic; Oregon Health & Science University FX Yale University and Medtronic.; By a research subcontract to Oregon Health & Science University under a sponsored research agreement between Yale University and Medtronic. NR 82 TC 152 Z9 153 U1 1 U2 20 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 18 PY 2013 VL 158 IS 12 BP 890 EP + DI 10.7326/0003-4819-158-12-201306180-00006 PG 23 WC Medicine, General & Internal SC General & Internal Medicine GA 167PW UT WOS:000320645000017 PM 23778906 ER PT J AU Clark, D McGiffin, DC Dell'Italia, LJ Ahmed, MI AF Clark, Donald, III McGiffin, David C. Dell'Italia, Louis J. Ahmed, Mustafa I. TI Submassive Pulmonary Embolism: Where's the Tipping Point? SO CIRCULATION LA English DT Article DE pulmonary embolism ID RIGHT-VENTRICULAR DYSFUNCTION; VENOUS THROMBOEMBOLISM; SURGICAL-TREATMENT; CONSECUTIVE PATIENTS; PROGNOSTIC VALUE; RISK-FACTORS; RIGHT HEART; EMBOLECTOMY; MANAGEMENT; HYPERTENSION C1 [Clark, Donald, III; Dell'Italia, Louis J.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. [McGiffin, David C.] Univ Alabama Birmingham, Div Cardiothorac Surg, Dept Surg, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Ahmed, MI (reprint author), Univ Alabama Birmingham, Div Cardiol, Dept Med, 434 BMR2,901 19th St South, Birmingham, AL 35294 USA. EM mahmed@uab.edu FU NIDDK NIH HHS [P30 DK079626] NR 36 TC 0 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUN 18 PY 2013 VL 127 IS 24 BP 2458 EP 2464 DI 10.1161/CIRCULATIONAHA.112.000859 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 168IM UT WOS:000320699100025 PM 23775195 ER PT J AU Zurowski, M McDonald, WM Fox, S Marsh, L AF Zurowski, Mateusz McDonald, William M. Fox, Susan Marsh, Laura TI Psychiatric comorbidities in dystonia: Emerging concepts SO MOVEMENT DISORDERS LA English DT Review DE dystonia; psychiatry; depression; anxiety; social phobia ID QUALITY-OF-LIFE; PRIMARY FOCAL DYSTONIA; IDIOPATHIC CERVICAL DYSTONIA; SPASMODIC TORTICOLLIS; GENERALIZED DYSTONIA; ANXIETY DISORDERS; MUTATION CARRIERS; DEPRESSION; MANAGEMENT; RECOGNITION AB Psychiatric disorders are highly prevalent in patients with dystonia and have a profound effect on quality of life. Patients with dystonia frequently meet criteria for anxiety disorders, especially social phobia, and major depressive disorder. Deficits in emotional processing have also been demonstrated in some dystonia populations. Onset of psychiatric disturbances in patients with dystonia often precedes onset of motor symptoms, suggesting that the pathophysiology of dystonia itself contributes to the genesis of psychiatric disturbances. This article examines the hypothesis that mood and anxiety disorders are intrinsic to the neurobiology of dystonia, citing the available literature, which is derived mostly from research on focal isolated dystonias. Limitations of studies are identified, and the role of emotional reactivity, especially in the context of pain secondary to dystonia, is recognized. Available evidence underscores the need to develop dystonia assessment tools that incorporate psychiatric measures. Such tools would allow for a better understanding of the full spectrum of dystonia presentations and facilitate research on the treatment of dystonia as well as the treatment of psychiatric illnesses in the context of dystonia. This article, solicited for a special Movement Disorders issue on novel research findings and emerging concepts in dystonia, addresses the following issues: (1) To what extent are psychiatric disturbances related to the pathophysiology of dystonia? (2) What is the impact of psychiatric disturbances on outcome measures of current assessment tools for dystonia? (3) How do psychiatric comorbidities influence the treatment of dystonia? Answers to these questions will lead to an increased appreciation of psychiatric disorders in dystonia, a better understanding of brain physiology, more nuanced research questions pertaining to this population, better clinical scales that can be used to further patient management and research, and improved patient outcomes. (C) 2013 Movement Disorder Society C1 [Zurowski, Mateusz] Univ Toronto, Dept Psychiat, Univ Hlth Network, Toronto, ON, Canada. [McDonald, William M.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Fox, Susan] Univ Toronto, Div Neurol, Univ Hlth Network, Toronto, ON, Canada. [Marsh, Laura] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Zurowski, M (reprint author), Univ Hlth Network, Dept Psychiat, Toronto Western Hosp, 7 Main,399 Bathurst St, Toronto, ON M5T 2S8, Canada. EM mateusz.zurowski@uhn.ca RI zurowski, mateusz/D-1536-2010 OI zurowski, mateusz/0000-0002-6407-4629 FU Dystonia Coalition [U54 NS065701, NS065701] FX This work was supported by the Dystonia Coalition U54 NS065701 (to Mateusz Zurowski) and by Dystonia Coalition grant NS065701 (William M. McDonald). NR 45 TC 13 Z9 13 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN 15 PY 2013 VL 28 IS 7 BP 914 EP 920 DI 10.1002/mds.25501 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 188ZH UT WOS:000322235700009 PM 23893448 ER PT J AU Singh, JA AF Singh, J. A. TI Intraarticular botulinum toxin reduced joint pain in patients with painful total knee or shoulder arthroplasty SO TOXICON LA English DT Meeting Abstract CT 7th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins (TOXINS) CY OCT 02-05, 2011 CL Santa Fe, NM C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA. EM jasvinder.md@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0041-0101 J9 TOXICON JI Toxicon PD JUN 15 PY 2013 VL 68 BP 121 EP 121 DI 10.1016/j.toxicon.2012.07.164 PG 1 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 159VN UT WOS:000320075500152 ER PT J AU Littman, AJ Thompson, ML Boyko, EJ Arterburn, DE AF Littman, Alyson J. Thompson, Mary Lou Boyko, Edward J. Arterburn, David E. TI USE OF BODY WEIGHTS FROM ELECTRONIC MEDICAL RECORDS: OPPORTUNITIES AND CHALLENGES. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Littman, Alyson J.; Thompson, Mary Lou; Boyko, Edward J.; Arterburn, David E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S72 EP S72 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300287 ER PT J AU Winston, C Lucero-Obusan, C Schirmer, P Holodniy, M AF Winston, Carla Lucero-Obusan, Cynthia Schirmer, Patricia Holodniy, Mark TI PREDICTING INFLUENZA ADMISSIONS AMONG VETERANS FROM TELEPHONE TRIAGE SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Winston, Carla; Lucero-Obusan, Cynthia; Schirmer, Patricia; Holodniy, Mark] US Dept Vet Affairs, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S111 EP S111 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300439 ER PT J AU Wharton, W Gleason, CE Miller, VM Asthana, S AF Wharton, Whitney Gleason, Carey E. Miller, Virginia M. Asthana, Sanjay TI Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog) SO BRAIN RESEARCH LA English DT Article DE Hormone therapy; Clinical trial; KEEPS; Estrogen; Alzheimer's disease; Cognition; Menopause ID CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; HEALTH INITIATIVE MEMORY; ORAL MICRONIZED PROGESTERONE; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; PLUS PROGESTIN; ALZHEIMER-DISEASE; CACHE COUNTY AB This manuscript describes the study design and rationalle for the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective ancillary study (KEEPS Cog). KEEPS is a multicenter, randomized, double-blinded, placebo-controlled trial, designed to test the hypothesis that low-dose hormone therapy (HT) initiated in recently postmenopausal women will reduce the progression of subclinical atherosclerosis as measured by carotid artery intima-media thickness (CIMT) and coronary artery calcification (CAC) over four years. The KEEPS Cog ancillary study was designed to assess potential estrogenic treatment effects on cognition and mood. We present the KEEPS trial in the context of issues raised by the Women's Health Initiative (WHI) and the Women's Health Initiative Memory Study (WHIMS). Here we also describe the most recent results and ongoing HT-related research studies designed to address similar issues. This article is part of a Special Issue entitled Hormone Therapy. (C) 2013 Published by Elsevier B.V. C1 [Wharton, Whitney; Gleason, Carey E.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Gleason, Carey E.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Wharton, Whitney; Gleason, Carey E.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr ADRC, Madison, WI 53792 USA. [Miller, Virginia M.] Mayo Clin, Rochester, MN 55905 USA. RP Wharton, W (reprint author), Univ Wisconsin, Dept Med & Publ Hlth, 2500 Overlook Terrace,VA Hosp GRECC D4243, Madison, WI 53705 USA. EM wlwharto@medicine.wisc.edu FU NIA NIH HHS [P50 AG033514] NR 32 TC 22 Z9 23 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JUN 13 PY 2013 VL 1514 SI SI BP 12 EP 17 DI 10.1016/j.brainres.2013.04.011 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 180KV UT WOS:000321595000003 PM 23603409 ER PT J AU Bartsch, P Swenson, ER AF Baertsch, Peter Swenson, Erik R. TI Acute High-Altitude Illnesses SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ACUTE MOUNTAIN-SICKNESS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; PULMONARY-EDEMA; CEREBRAL EDEMA; EXERCISE PERFORMANCE; NORMOBARIC HYPOXIA; DOUBLE-BLIND; PREVENTION; DEXAMETHASONE AB A 45-year-old healthy man wishes to climb Mount Kilimanjaro (5895 m) in a 5-day period, starting at 1800 m. The results of a recent exercise stress test were normal; he runs 10 km 4 or 5 times per week and finished a marathon in less than 4 hours last year. He wants to know how he can prevent becoming ill at high altitude and whether training or sleeping under normobaric hypoxic conditions in the weeks before the ascent would be helpful. What would you advise? C1 [Baertsch, Peter] Univ Clin, Dept Internal Med, Div Sports Med 7, D-69120 Heidelberg, Germany. [Swenson, Erik R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. RP Bartsch, P (reprint author), Univ Clin, Dept Internal Med, Div Sports Med 7, Neuenheimer Feld 410, D-69120 Heidelberg, Germany. EM peter.bartsch@med.uni-heidelberg.de FU Merck Sharp Dohme; Bayer HealthCare; Linde Group FX Dr. Bartsch reports receiving lecture fees from Merck Sharp & Dohme and Bayer HealthCare and payment to his institution for meeting expenses from the Linde Group. No other potential conflict of interest relevant to this article was reported. NR 50 TC 92 Z9 94 U1 6 U2 44 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 13 PY 2013 VL 368 IS 24 BP 2294 EP 2302 DI 10.1056/NEJMcp1214870 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 161YN UT WOS:000320230500005 PM 23758234 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Editorial Material ID THERAPY; RISK; MALIGNANCIES; METAANALYSIS; ABATACEPT; EFFICACY; AGENTS C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg & Med Acute care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Ctr Surg & Med Acute care Res & Transit C SMART, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 NR 15 TC 2 Z9 2 U1 0 U2 0 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD JUN 11 PY 2013 VL 185 IS 9 BP 793 EP 795 DI 10.1503/cmaj.121607 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 180YQ UT WOS:000321635600036 PM 23460636 ER PT J AU Sun, L Zhu, LL Lu, P Yuen, T Li, JH Ma, RS Baliram, R Moonga, SS Liu, P Zallone, A New, MI Davies, TF Zaidi, M AF Sun, Li Zhu, Ling-Ling Lu, Ping Yuen, Tony Li, Jianhua Ma, Risheng Baliram, Ramkumari Moonga, Surinder S. Liu, Peng Zallone, Alberta New, Maria I. Davies, Terry F. Zaidi, Mone TI Genetic confirmation for a central role for TNF alpha in the direct action of thyroid stimulating hormone on the skeleton SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE bone metabolism; thyroid disease; bone density ID MARROW STROMAL CELLS; BONE LOSS; OSTEOCLAST PRECURSORS; THYROTROPIN RECEPTOR; POSTMENOPAUSAL WOMEN; TRANSGENIC MICE; IN-VIVO; TSH; EXPRESSION; OXYTOCIN AB Clinical data showing correlations between low thyroid-stimulating hormone (TSH) levels and high bone turnover markers, low bone mineral density, and an increased risk of osteoporosis-related fractures are buttressed by mouse genetic and pharmacological studies identifying a direct action of TSH on the skeleton. Here we show that the skeletal actions of TSH deficiency are mediated, in part, through TNF alpha. Compound mouse mutants generated by genetically deleting the Tnf alpha gene on a Tshr(-/-) (homozygote) or Tshr(+/-) (heterozygote) background resulted in full rescue of the osteoporosis, low bone formation, and hyperresorption that accompany TSH deficiency. Studies using ex vivo bone marrow cell cultures showed that TSH inhibits and stimulates TNF alpha production from macrophages and osteoblasts, respectively. TNF alpha, in turn, stimulates osteoclastogenesis but also enhances the production in bone marrow of a variant TSH beta. This locally produced TSH suppresses osteoclast formation in a negative feedback loop. We speculate that TNF alpha elevations due to low TSH signaling in human hyperthyroidism contribute to the bone loss that has traditionally been attributed solely to high thyroid hormone levels. C1 [Sun, Li; Zhu, Ling-Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA. [Sun, Li; Zhu, Ling-Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Yuen, Tony; New, Maria I.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. [Ma, Risheng; Baliram, Ramkumari; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Thyroid Res Unit, Bronx, NY 10468 USA. [Zallone, Alberta] Univ Bari, Dept Human Anat & Histol, I-70124 Bari, Italy. RP New, MI (reprint author), Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA. EM maria.new@mssm.edu; mone.zaidi@mssm.edu FU National Institutes of Health [DK80459, AG23176, AG40132]; Department of Veterans Affairs; Maria I. New Children's Hormone Research Foundation; Chinese University of Hong Kong FX We thank Dr. Jay Cao for help with microtomography measurements. This work was supported by National Institutes of Health Grants DK80459 (to L. S., T. F. D., and M.Z.), AG23176 (to M.Z.), and AG40132 (to M.Z.). T. F. D. acknowledges support from the Department of Veterans Affairs (Veterans Affairs Merit Award). M.I.N. is supported by the Maria I. New Children's Hormone Research Foundation and the Chinese University of Hong Kong. NR 38 TC 8 Z9 10 U1 0 U2 4 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUN 11 PY 2013 VL 110 IS 24 BP 9891 EP 9896 DI 10.1073/pnas.1308336110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 171LM UT WOS:000320930100068 PM 23716650 ER PT J AU Yao, JK Dougherty, GG Reddy, RD Matson, WR Kaddurah-Daouk, R Keshavan, MS AF Yao, Jeffrey K. Dougherty, George G. Reddy, Ravinder D. Matson, Wayne R. Kaddurah-Daouk, Rima Keshavan, Matcheri S. TI Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Article DE schizophrenia; first-episode psychosis; neuroleptic-naive; oxidative stress; purine catabolism; monoamine neurotransmitters ID SERUM URIC-ACID; NEUROLOGIC EXAMINATION ABNORMALITIES; MULTIPLE-SCLEROSIS PATIENTS; NEUROLEPTIC-NAIVE PATIENTS; REDOX-ACTIVE COMPOUNDS; SEROTONERGIC RESPONSIVITY; LIQUID-CHROMATOGRAPHY; PLASMA ANTIOXIDANTS; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE AB Schizophrenia (SZ) is a biochemically complex disorder characterized by widespread defects in multiple metabolic pathways whose dynamic interactions, until recently, have been difficult to examine. Rather, evidence for these alterations has been collected piecemeal, limiting the potential to inform our understanding of the interactions amongst relevant biochemical pathways. We herein review perturbations in purine and neurotransmitter metabolism observed in early SZ using a metabolomic approach. Purine catabolism is an underappreciated, but important component of the homeostatic response of mitochondria to oxidant stress. We have observed a homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with SZ (FENNS). Precursor and product relationships within purine pathways are tightly correlated. Although some of these correlations persist across disease or medication status, others appear to be lost among FENNS suggesting that steady formation of the antioxidant uric acid (UA) via purine catabolism is altered early in the course of illness. As is the case for within-pathway correlations, there are also significant cross-pathway correlations between respective purine and tryptophan (TRP) pathway metabolites. By contrast, purine metabolites show significant cross-pathway correlation only with tyrosine, and not with its metabolites. Furthermore, several purine metabolites (UA, guanosine, or xanthine) are each significantly correlated with 5-hydroxyindoleacetic acid (5-HIAA) in healthy controls, but not in FENNS at baseline or 4-week after antipsychotic treatment. Taken together, the above findings suggest that purine catabolism strongly associates with the TRP pathways leading to serotonin (5-hydroxytryptamine, 5-HT) and kynurenine metabolites. The lack of a significant correlation between purine metabolites and 5-HIAA, suggests alterations in key 5-HT pathways that may both be modified by and contribute to oxidative stress via purine catabolism in FENNS. C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15206 USA. [Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Keshavan, Matcheri S.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA. [Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Med Res Serv, 7180 Highland Dr,151U-H, Pittsburgh, PA 15206 USA. EM jkyao@pitt.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory RD; VA Pittsburgh Healthcare System [MH58141, MH64118, MH45203, MH 45156, R24 GM078233, c UL1 RR024153, M01 RR00056]; Metabolomics Research Network; Stanley Medical Research Institute; NARSAD FX This review is based upon work supported in part by the grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory R&D [Merit Reviews (Jeffrey K. Yao) and Senior Research Career Scientist Award (Jeffrey K. Yao)], VA Pittsburgh Healthcare System (Jeffrey K. Yao, George G. Dougherty, Ravinder D. Reddy), National Institute of Health [MH58141 (Jeffrey K. Yao), MH64118 (Ravinder D. Reddy), MH45203 and MH 45156 (Matcheri S. Keshavan), R24 GM078233 (Rima Kaddurah-Daouk), c UL1 RR024153 and NIH/NCRR/GCRC Grant M01 RR00056], Metabolomics Research Network (Rima Kaddurah-Daouk); Stanley Medical Research Institute (Rima Kaddurah-Daouk), and NARSAD (Rima Kaddurah-Daouk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 99 TC 10 Z9 10 U1 1 U2 14 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD JUN 11 PY 2013 VL 7 AR 90 DI 10.3389/fncel.2013.00090 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 170JM UT WOS:000320846200001 PM 23781173 ER PT J AU Flood, KL MacLennan, PA McGrew, D Green, D Dodd, C Brown, CJ AF Flood, Kellie L. MacLennan, Paul A. McGrew, Deborah Green, Darlene Dodd, Cindy Brown, Cynthia J. TI Effects of an Acute Care for Elders Unit on Costs and 30-Day Readmissions SO JAMA INTERNAL MEDICINE LA English DT Article ID HOSPITALIZED OLDER PATIENTS; ONCOLOGY-ACUTE CARE; FUNCTIONAL DECLINE; CONTROLLED TRIAL; HEALTH-CARE; HIGH-RISK; OUTCOMES; ADULTS; INTERVENTION; MOBILITY AB Importance: Providing high-quality care while containing cost is essential for the economic stability of our health care system. The United States is experiencing a rapidly growing elderly population. The Acute Care for Elders (ACE) unit interdisciplinary team model of care has been shown to improve outcomes in hospitalized older adults. The University of Alabama at Birmingham ACE unit incorporates evidence-based care processes. We hypothesized that the ACE model would also reduce costs. Objective: To examine variable direct costs from an interdisciplinary ACE compared with a multidisciplinary usual care (UC) unit. Design: Retrospective cohort study. Setting: Tertiary care academic medical center. Participants: Hospitalists' patients aged 70 years or older spending the entirety of their hospitalization in either the ACE or UC unit in fiscal year 2010. Main Outcome Measures: Using administrative data, we analyzed variable direct costs for ACE and UC patients. We also conducted a subset analysis restricted to the 25 most common diagnosis related groups (DRGs) shared by ACE and UC patients. Generalized linear regression was used to estimate cost ratios and 95% confidence intervals adjusted for age, sex, comorbidity score, and case mix index (CMI). Results: A total of 818 hospitalists' patients met inclusion criteria: 428 from the ACE and 390 from the UC unit. For this study group (all DRGs), the mean (SD) variable direct cost per patient was $2109 ($1870) for ACE and $2480 ($2113) for UC (P=.009). Adjusted cost ratios revealed significant cost savings for patients with low (0.82; 95% CI, 0.72-0.94) or moderate (0.74; 95% CI, 0.620.89) CMI scores; care was cost neutral for patients with high CMI scores (1.13; 95% CI, 0.93-1.37). Significantly fewer ACE patients than UC patients were readmitted within 30 days of discharge (7.9% vs 12.8%; P=.02). Subset analysis of the 25 most common DRGs revealed a significantly reduced mean (SD) variable direct cost per patient for ACE compared with UC patients ($1693 [$1063] vs $2138 [$1431]; P<.001); cost ratios for total (0.78; 95% CI, 0.70-0.87) and daily (0.89; 95% CI, 0.85-0.94) variable direct costs remained significant after adjustment. Conclusions and Relevance: The ACE unit team model reduces costs and 30-day readmissions. In an era when improving care processes while reducing costs is a vital objective for the Medicare program and our nation as a whole, the ACE model meets these goals. C1 [Flood, Kellie L.; Brown, Cynthia J.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [MacLennan, Paul A.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [McGrew, Deborah; Green, Darlene; Dodd, Cindy] Univ Alabama Birmingham, Birmingham Hosp, Birmingham, AL 35294 USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Flood, KL (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, 1720 2nd Ave S,CH-19,Room 219, Birmingham, AL 35294 USA. EM kflood@uabmc.edu NR 33 TC 22 Z9 23 U1 2 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 10 PY 2013 VL 173 IS 11 BP 981 EP 987 DI 10.1001/jamainternmed.2013.524 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 159MT UT WOS:000320050200010 PM 23609002 ER PT J AU Hung, WW Ross, JS Farber, J Siu, AL AF Hung, William W. Ross, Joseph S. Farber, Jeffrey Siu, Albert L. TI Evaluation of the Mobile Acute Care of the Elderly (MACE) Service SO JAMA INTERNAL MEDICINE LA English DT Article ID HOSPITALIZED OLDER PATIENTS; UNITED-STATES; MULTICOMPONENT INTERVENTION; FUNCTIONAL OUTCOMES; MEDICAL UNIT; SYSTEM; VALIDATION; COMMUNITY; DELIRIUM; SCORES AB Importance: Older adults are particularly vulnerable to adverse events during hospitalization for acute medical problems. The Mobile Acute Care of the Elderly (MACE) service is a novel model of care delivered by an interdisciplinary team, designed to deliver specialized care to hospitalized older adults to improve patient outcomes. Objective: To evaluate the impact of the MACE service when compared with general medical service (usual care). Design: Prospective, matched cohort study. Setting: The Mount Sinai Hospital, an urban tertiary acute care hospital. Participants: Patients aged 75 years or older admitted because of an acute illness to either the MACE service or usual care. Patients were matched for age, diagnosis, and ability to ambulate independently. Exposures: Admission to the MACE service when compared with admission to usual care. Main Outcome Measures: Patient outcomes included incidence of adverse events, including falls, pressure ulcers, restraint use, and catheter-associated urinary tract infections, along with length of stay, rehospitalization within 30 days, functional status at 30 days, and patient satisfaction during care transitions, measured with the 3-item Care Transition Measure. Results: A total of 173 matched pairs of patients were recruited. The mean (SD) age was 85.2 (5.3) and 84.7 (5.4) years in the MACE and usual-care groups, respectively. After adjustment for confounders, patients in the MACE group were less likely to experience adverse events (9.5% vs 17.0%; adjusted odds ratio, 0.11; 95% CI, 0.01-0.88; P=.04) and had shorter hospital stays (0.8 days, 95% CI, 0.7-0.9; P=.001) than patients receiving usual care. Patients in the MACE group were not less likely to have a lower rate of rehospitalization within 30 days than those in the usual-care group (odds ratio, 0.91; 95% CI, 0.39-2.10; P=.83). Functional status did not differ between the 2 groups. Care Transition Measure scores were 7.4 points (95% CI, 2.9-11.9; P=.001) higher in the MACE group. Conclusions and Relevance: Admission to the MACE service was associated with lower rates of adverse events, shorter hospital stays, and better satisfaction. This model has the potential to improve care outcomes among hospitalized older adults. C1 [Hung, William W.; Farber, Jeffrey; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Bronx, NY USA. [Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ Clin Ctr, Bronx, NY USA. [Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Hung, WW (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,POB 1070, New York, NY 10029 USA. EM william.hung@mssm.edu FU Medtronic, Inc; National Institute on Aging [K08 AG032886]; American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; John A. Hartford Center of Excellence; Claude D. Pepper Older Americans Independence Center at Mount Sinai School of Medicine [P30-AG028741]; Centers for Medicare & Medicaid Services; Pew Charitable Trusts FX Dr Ross reports that he is a member of a scientific advisory board for FAIR Health, Inc, and receives grant funding from Medtronic, Inc, to develop methods of clinical trial data sharing, from the Centers for Medicare & Medicaid Services to develop and maintain performance measures used for public reporting, and from the Pew Charitable Trusts to examine regulatory issues at the US Food and Drug Administration. Dr Ross is supported by the National Institute on Aging (grant K08 AG032886) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program.; Support for this project was provided by the John A. Hartford Center of Excellence and in part by the Claude D. Pepper Older Americans Independence Center at Mount Sinai School of Medicine (grant P30-AG028741). NR 28 TC 9 Z9 9 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 10 PY 2013 VL 173 IS 11 BP 990 EP 996 DI 10.1001/jamainternmed.2013.478 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 159MT UT WOS:000320050200012 PM 23608775 ER PT J AU Linos, E Parvataneni, R Stuart, SE Boscardin, WJ Landefeld, CS Chren, MM AF Linos, Eleni Parvataneni, Rupa Stuart, Sarah E. Boscardin, W. John Landefeld, C. Seth Chren, Mary-Margaret TI Treatment of Nonfatal Conditions at the End of Life Nonmelanoma Skin Cancer SO JAMA INTERNAL MEDICINE LA English DT Article ID MOHS MICROGRAPHIC SURGERY; BASAL-CELL CARCINOMA; UNITED-STATES; CARE; COHORT AB Importance: Nonmelanoma skin cancer (NMSC) is the most common cancer and predominantly affects older patients. Because NMSCs do not typically affect survival or short-term quality of life, the decision about whether and how to treat patients with limited life expectancy (LLE) is challenging, especially for asymptomatic tumors. Objective: To compare treatment patterns and clinical outcomes of patients with NMSC with and without LLE. Design, Setting, and Participants: A prospective cohort study of 1536 consecutive patients diagnosed with NMSC at 2 dermatology clinics: a university-based private practice and a Veterans Affairs Medical Center in San Francisco, California. Patients were recruited in 1999 through 2000 and followed up for a median of 9 years. A total of 1360 patients with 1739 tumors (90%) were included in the final analysis. Limited life expectancy was defined as patients either 85 years or older at the time of diagnosis or patients with multiple comorbidities (Charlson Comorbidity Index of >= 3). Treatment options included no treatment, destruction, or 2 types of surgery-elliptical excision or Mohs surgery. Main Outcomes and Measures: Treatment type. Results: Most NMSCs (69%) were treated surgically, regardless of patient life expectancy. The choice of surgery was not influenced by patient prognosis in univariate or multivariable models adjusted for tumor and patient characteristics. Many patients with LLE (43%) died within 5 years, none of NMSC. Tumor recurrence was rare (3.7% at 5 years [95% CI, 2.6%-4.7%]) in all patients. Although serious complications were unusual, approximately 20% of patients with LLE reported complications of therapy, compared with 15% of other patients. Conclusions and Relevance: Most NMSCs are treated surgically, regardless of the patient's life expectancy. Given the very low tumor recurrence rates and high mortality from causes unrelated to NMSC in patients with LLE, clinicians should consider whether these patients would prefer less invasive treatment strategies. C1 [Linos, Eleni; Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA. RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Room N421,Mail Code Box 0808, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu RI Linos, Eleni/C-4392-2014 OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU National Center for Research Resources [KL2RR024130]; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health [R01 AR 054983, K24 AR052667]; American Skin Association; Dermatology Foundation FX This study was supported in part by Award KL2RR024130 from the National Center for Research Resources (Dr Linos), by grants R01 AR 054983 and K24 AR052667 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (Dr Chren), and by a Career Development Award from the American Skin Association and Dermatology Foundation (Dr Linos). NR 23 TC 17 Z9 17 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN 10 PY 2013 VL 173 IS 11 BP 1006 EP 1012 DI 10.1001/jamainternmed.2013.639 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 159MT UT WOS:000320050200016 PM 23699934 ER PT J AU McDavid, A Crane, PK Newton, KM Crosslin, DR McCormick, W Weston, N Ehrlich, K Hart, E Harrison, R Kukull, WA Rottscheit, C Peissig, P Stefanski, E McCarty, CA Zuvich, RL Ritchie, MD Haines, JL Denny, JC Schellenberg, GD de Andrade, M Kullo, I Li, RL Mirel, D Crenshaw, A Bowen, JD Li, G Tsuang, D McCurry, S Teri, L Larson, EB Jarvik, GP Carlson, CS AF McDavid, Andrew Crane, Paul K. Newton, Katherine M. Crosslin, David R. McCormick, Wayne Weston, Noah Ehrlich, Kelly Hart, Eugene Harrison, Robert Kukull, Walter A. Rottscheit, Carla Peissig, Peggy Stefanski, Elisha McCarty, Catherine A. Zuvich, Rebecca Lynn Ritchie, Marylyn D. Haines, Jonathan L. Denny, Joshua C. Schellenberg, Gerard D. de Andrade, Mariza Kullo, Iftikhar Li, Rongling Mirel, Daniel Crenshaw, Andrew Bowen, James D. Li, Ge Tsuang, Debby McCurry, Susan Teri, Linda Larson, Eric B. Jarvik, Gail P. Carlson, Chris S. TI Enhancing the Power of Genetic Association Studies through the Use of Silver Standard Cases Derived from Electronic Medical Records SO PLOS ONE LA English DT Article ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; CATEGORICAL-DATA; COMMON VARIANTS; MISCLASSIFICATION; DIAGNOSIS; CRITERIA; LINKAGE; CD2AP AB The feasibility of using imperfectly phenotyped "silver standard" samples identified from electronic medical record diagnoses is considered in genetic association studies when these samples might be combined with an existing set of samples phenotyped with a gold standard technique. An analytic expression is derived for the power of a chi-square test of independence using either research-quality case/control samples alone, or augmented with silver standard data. The subset of the parameter space where inclusion of silver standard samples increases statistical power is identified. A case study of dementia subjects identified from electronic medical records from the Electronic Medical Records and Genomics (eMERGE) network, combined with subjects from two studies specifically targeting dementia, verifies these results. C1 [McDavid, Andrew; Carlson, Chris S.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Crane, Paul K.; McCormick, Wayne; Larson, Eric B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Newton, Katherine M.; Weston, Noah; Ehrlich, Kelly; Hart, Eugene; Harrison, Robert; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Crosslin, David R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Kukull, Walter A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Rottscheit, Carla; Peissig, Peggy] Marshfield Clin Res Fdn, Biomed Informat Res Ctr, Marshfield, WI USA. [Stefanski, Elisha] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. [McCarty, Catherine A.] Essentia Inst Rural Hlth, Duluth, MN USA. [Zuvich, Rebecca Lynn; Haines, Jonathan L.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA. [Ritchie, Marylyn D.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA. [Denny, Joshua C.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA. [de Andrade, Mariza] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA. [Kullo, Iftikhar] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [Li, Rongling] NHGRI, NIH, Bethesda, MD 20892 USA. [Mirel, Daniel; Crenshaw, Andrew] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Bowen, James D.] Swedish Med Ctr, Dept Neurol, Seattle, WA USA. [Li, Ge; Tsuang, Debby] Univ Washington, Dept Psychiat, Sch Med, Seattle, WA 98195 USA. [Tsuang, Debby] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [McCurry, Susan; Teri, Linda] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA. RP McDavid, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. EM amcdavid@fhcrc.org RI Crane, Paul/C-8623-2014; Jarvik, Gail/N-6476-2014; Tsuang, Debby/L-7234-2016 OI Jarvik, Gail/0000-0002-6710-8708; Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014; Crane, Paul/0000-0003-4278-7465; McDavid, Andrew/0000-0002-6581-1213 FU National Institutes of Health (NIH) [HG004610, AG06781, U01HG004438] FX This study was funded by National Institutes of Health (NIH) award HG004610, AG06781 (Group Health Cooperative) and U01HG004438. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 7 Z9 7 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 10 PY 2013 VL 8 IS 6 AR e63481 DI 10.1371/journal.pone.0063481 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 164VY UT WOS:000320440500003 PM 23762230 ER PT J AU Adams, SV Ahnen, DJ Baron, JA Campbell, PT Gallinger, S Grady, WM LeMarchand, L Lindor, NM Potter, JD Newcomb, PA AF Adams, Scott V. Ahnen, Dennis J. Baron, John A. Campbell, Peter T. Gallinger, Steven Grady, William M. LeMarchand, Loic Lindor, Noralane M. Potter, John D. Newcomb, Polly A. TI Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Colorectal cancer; Inflammatory bowel disease; Outcomes research; Cancer survival; Inflammation ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POPULATION-BASED DANISH; C-REACTIVE PROTEIN; ULCERATIVE-COLITIS; CROHNS-DISEASE; MICROSATELLITE INSTABILITY; 5-AMINOSALICYLATE USE; INTESTINAL CANCER; RISK; PROGNOSIS AB AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC. METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD- associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined. RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records. CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC. (C) 2013 Baishideng. All rights reserved. C1 [Adams, Scott V.; Grady, William M.; Potter, John D.; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Ahnen, Dennis J.] Denver VA Med Ctr, Dept Med, Denver, CO 80045 USA. [Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver, CO 80045 USA. [Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA. [Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Dept Intramural Res, Atlanta, GA 30303 USA. [Gallinger, Steven] Univ Toronto, Div Gen Surg, Toronto, ON M5G 2C4, Canada. [LeMarchand, Loic] Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA. [Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ 85259 USA. RP Adams, SV (reprint author), Fred Hutchinson Canc Res Ctr, M3-B232,POB 19024, Seattle, WA 98109 USA. EM sadams@fhcrc.org RI Gallinger, Steven/E-4575-2013 OI Potter, John/0000-0001-5439-1500 FU The American Society of Preventive Oncology/Prevent Cancer Foundation/American Society for Clinical Oncology Cancer Prevention Research Fellowship; Australasian Colorectal Cancer Family Registry [U01 CA097735]; Familial Colorectal Neoplasia Collaborative Group [U01 CA074799]; Mayo Clinic Cooperative Family Registry for Colon Cancer Studies [U01 CA074800]; Ontario Registry for Studies of Familial Colorectal Cancer [U01 CA074783]; Seattle Colorectal Cancer Family Registry [U01 CA074794]; University of Hawaii Colorectal Cancer Family Registry [U01 CA074806]; University of California, Irvine Informatics Center [U01 CA078296] FX Supported by The American Society of Preventive Oncology/Prevent Cancer Foundation/American Society for Clinical Oncology Cancer Prevention Research Fellowship to SVA; the Australasian Colorectal Cancer Family Registry, No. U01 CA097735; the Familial Colorectal Neoplasia Collaborative Group, No. U01 CA074799; the Mayo Clinic Cooperative Family Registry for Colon Cancer Studies, No. U01 CA074800; the Ontario Registry for Studies of Familial Colorectal Cancer, No. U01 CA074783; the Seattle Colorectal Cancer Family Registry, No. U01 CA074794; the University of Hawaii Colorectal Cancer Family Registry, No. U01 CA074806; and the University of California, Irvine Informatics Center, No. U01 CA078296 NR 45 TC 7 Z9 7 U1 0 U2 6 PU BAISHIDENG PUBL GRP CO LTD PI WANCHAI PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG 100025, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JUN 7 PY 2013 VL 19 IS 21 BP 3241 EP 3248 DI 10.3748/wjg.v19.i21.3241 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 163YQ UT WOS:000320375000007 PM 23745025 ER PT J AU Zhang, Y Schuff, N Camacho, M Chao, LL Fletcher, TP Yaffe, K Woolley, SC Madison, C Rosen, HJ Miller, BL Weiner, MW AF Zhang, Yu Schuff, Norbert Camacho, Monica Chao, Linda L. Fletcher, Thomas P. Yaffe, Kristine Woolley, Susan C. Madison, Catherine Rosen, Howard J. Miller, Bruce L. Weiner, Michael W. TI MRI Markers for Mild Cognitive Impairment: Comparisons between White Matter Integrity and Gray Matter Volume Measurements SO PLOS ONE LA English DT Article ID MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; POSTERIOR CINGULATE; ENTORHINAL CORTEX; ABNORMAL INTEGRITY; DIAGNOSTIC UTILITY; STRUCTURAL MRI; FIBER TRACTS; DIFFUSION AB The aim of the study was to evaluate the value of assessing white matter integrity using diffusion tensor imaging (DTI) for classification of mild cognitive impairment (MCI) and prediction of cognitive impairments in comparison to brain atrophy measurements using structural MRI. Fifty-one patients with MCI and 66 cognitive normal controls (CN) underwent DTI and T1-weighted structural MRI. DTI measures included fractional anisotropy (FA) and radial diffusivity (DR) from 20 predetermined regions-of-interest (ROIs) in the commissural, limbic and association tracts, which are thought to be involved in Alzheimer's disease; measures of regional gray matter (GM) volume included 21 ROIs in medial temporal lobe, parietal cortex, and subcortical regions. Significant group differences between MCI and CN were detected by each MRI modality: In particular, reduced FA was found in splenium, left isthmus cingulum and fornix; increased DR was found in splenium, left isthmus cingulum and bilateral uncinate fasciculi; reduced GM volume was found in bilateral hippocampi, left entorhinal cortex, right amygdala and bilateral thalamus; and thinner cortex was found in the left entorhinal cortex. Group classifications based on FA or DR was significant and better than classifications based on GM volume. Using either DR or FA together with GM volume improved classification accuracy. Furthermore, all three measures, FA, DR and GM volume were similarly accurate in predicting cognitive performance in MCI patients. Taken together, the results imply that DTI measures are as accurate as measures of GM volume in detecting brain alterations that are associated with cognitive impairment. Furthermore, a combination of DTI and structural MRI measurements improves classification accuracy. C1 [Zhang, Yu; Schuff, Norbert; Camacho, Monica; Chao, Linda L.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Zhang, Yu; Schuff, Norbert; Camacho, Monica; Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Fletcher, Thomas P.] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Dept Psychiat Neurol & Epidemiol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Woolley, Susan C.; Madison, Catherine] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USA. [Rosen, Howard J.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Zhang, Y (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. EM Yu.Zhang@ucsf.edu FU National Institutes of Health/National Institute on Aging [P01AG19724, P01AG12435]; NIH/National Center for Research Resources [P41RR023953] FX This research was supported in part by National Institutes of Health/National Institute on Aging grants P01AG19724, P01AG12435 and grant from NIH/National Center for Research Resources P41RR023953, which were administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 79 TC 22 Z9 23 U1 1 U2 19 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 6 PY 2013 VL 8 IS 6 AR e66367 DI 10.1371/journal.pone.0066367 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 173SK UT WOS:000321099000132 PM 23762488 ER PT J AU Hoo, GWS AF Hoo, Guy W. Soo TI In Prone Ventilation, One Good Turn Deserves Another SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; FAILURE C1 [Hoo, Guy W. Soo] Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect 111Q, Los Angeles, CA USA. [Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Hoo, GWS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect 111Q, Los Angeles, CA USA. NR 10 TC 3 Z9 3 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 6 PY 2013 VL 368 IS 23 BP 2227 EP 2228 DI 10.1056/NEJMe1304349 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 158DN UT WOS:000319948900012 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Ipsilateral lower extremity joint involvement increases the risk of poor pain and function outcomes after hip or knee arthroplasty SO BMC MEDICINE LA English DT Article DE Arthroplasty; Ipsilateral; Joint replacement; Outcomes; Risk factors; Total hip replacement; Total knee replacement ID CLINICAL RATING SYSTEM; REPLACEMENT; PREDICTORS; TRENDS AB Background: Poor pain and function outcomes are undesirable after an elective surgery such as total hip or knee arthroplasty (THA/TKA). Recent studies have indicated that the presence of contralateral joint influences outcomes of THA/TKA, however the impact of ipsilateral knee/hip involvement on THA/TKA outcomes has not been explored. The objective of this study was to assess the association of ipsilateral knee/hip joint involvement on short-term and medium-term pain and function outcomes after THA/TKA. Methods: In this retrospective study of prospectively collected data, we used the data from the Mayo Clinic Total Joint Registry to assess the association of ipsilateral knee or hip joint involvement with moderate to severe pain and moderate to severe activity limitation at 2-year and 5-year follow-up after primary and revision THA and TKA using multivariable-adjusted logistic regression analyses. Results: At 2 years, 3,823 primary THA, 4,701 primary TKA, 1,218 revision THA and 725 revision TKA procedures were studied. After adjusting for multiple covariates, ipsilateral knee pain was significantly associated with outcomes after primary THA (all P values <0.01): (1) moderate to severe pain: at 2 years, odds ratio (OR), 2.3 (95% confidence interval (CI) 1.5 to 3.6); at 5 years, OR 1.8 (95% CI 1.1 to 2.7); (2) moderate to severe activity limitation: at 2 years, OR 3.1 (95% CI 2.3 to 4.3); at 5 years, OR 3.6 (95% CI 2.6 to 5.0). Ipsilateral hip pain was significantly associated with outcomes after primary TKA (all P values <0.01): (1) moderate to severe pain: at 2 years, OR 3.3 (95% CI 2.3 to 4.7); at 5 years, OR 1.8 (95% CI 1.1 to 2.7); (2) moderate to severe activity limitation: at 2 years, OR 3.6 (95% CI 2.6 to 4.9); at 5 years, OR 2.2 (95% CI 1.6 to 3.2). Similar associations were noted for revision THA and TKA patients. Conclusions: To the best of our knowledge, this is the first study showing that the presence of ipsilateral joint involvement after THA or TKA is strongly associated with poor pain and function outcomes. A potential way to improve outcomes is to address ipsilateral lower extremity joint involvement. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Aging and National Cancer Institute FX This study was supported by research funds from the Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Aging and National Cancer Institute. The funding agencies played no role in the design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. This study was presented as an oral abstract presentation at the 2012 American College of Rheumatology Annual meeting in Washington, DC in November 2012. NR 22 TC 7 Z9 7 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD JUN 5 PY 2013 VL 11 AR 144 DI 10.1186/1741-7015-11-144 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 163GF UT WOS:000320323300001 PM 23738845 ER PT J AU Harms, AS Cao, SW Rowse, AL Thome, AD Li, XR Mangieri, LR Cron, RQ Shacka, JJ Raman, C Standaert, DG AF Harms, Ashley S. Cao, Shuwen Rowse, Amber L. Thome, Aaron D. Li, Xinru Mangieri, Leandra R. Cron, Randy Q. Shacka, John J. Raman, Chander Standaert, David G. TI MHCII Is Required for alpha-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneratione SO JOURNAL OF NEUROSCIENCE LA English DT Article ID PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; MOUSE MODEL; CEREBROSPINAL-FLUID; BRAIN; GAMMA; CHAIN; INTERLEUKIN-1-BETA; INFLAMMATION; EXPRESSION AB Accumulation of alpha-synuclein (alpha-syn) in the brain is a core feature of Parkinson disease (PD) and leads to microglial activation, production of inflammatory cytokines and chemokines, T-cell infiltration, and neurodegeneration. Here, we have used both an in vivo mouse model induced by viral overexpression of alpha-syn as well as in vitro systems to study the role of the MHCII complex in alpha-syn-induced neuroinflammation and neurodegeneration. We find that in vivo, expression of full-length human alpha-syncauses striking induction of MHCII expression by microglia, while knock-out of MHCII prevents alpha-syn-induced microglial activation, antigen presentation, IgG deposition, and the degeneration of dopaminergic neurons. In vitro, treatment of microglia with aggregated alpha-syn leads to activation of antigen processing and presentation of antigen sufficient to drive CD4 T-cell proliferation and to trigger cytokine release. These results indicate a central role for microglial MHCII in the activation of both the innate and adaptive immune responses to alpha-syn in PD and suggest that the MHCII signaling complex may be a target of neuroprotective therapies for the disease. C1 [Harms, Ashley S.; Cao, Shuwen; Thome, Aaron D.; Li, Xinru; Standaert, David G.] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL 35294 USA. [Rowse, Amber L.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Mangieri, Leandra R.; Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Cron, Randy Q.] Childrens Hosp Alabama, Dept Pediat, Div Rheumatol, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Raman, Chander] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. RP Standaert, DG (reprint author), Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, 1719 6th Ave South,CIRC 516, Birmingham, AL 35294 USA. EM dstandaert@uab.edu RI Cao, Shuwen/E-1924-2016 FU RJG Foundation; University of Alabama (UAB) Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center (CAMAC) Comprehensive Flow Cytometry Core (NIH) [P30 AR48311]; UAB Animal Resources Program (NIH) [G20 RR025858, G20 RR022807-01]; NIH [T32 AR007450-30] FX The work from these studies is generously supported by the RJG Foundation, the University of Alabama (UAB) Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center (CAMAC) Comprehensive Flow Cytometry Core (NIH Grant P30 AR48311), the UAB Animal Resources Program (NIH Grants G20 RR025858 and G20 RR022807-01), and NIH Grant T32 AR007450-30. We thank Dr. Chad Steele for his help with the multiplex ELISA assay at University of Alabama at Birmingham. NR 39 TC 56 Z9 58 U1 3 U2 20 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 5 PY 2013 VL 33 IS 23 BP 9592 EP 9600 DI 10.1523/JNEUROSCI.5610-12.2013 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 158IS UT WOS:000319963300003 PM 23739956 ER PT J AU Seal, KH Stein, MB AF Seal, Karen H. Stein, Murray B. TI Preventing the Pain of PTSD SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; MORPHINE; OPIOIDS; FEAR; IRAQ AB A selective opioid receptor agonist prevents fear memory consolidation in the amygdala in a mouse model of posttraumatic stress disorder (Andero et al.). C1 [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA 92103 USA. RP Stein, MB (reprint author), Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. EM mstein@ucsd.edu NR 10 TC 2 Z9 2 U1 1 U2 5 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JUN 5 PY 2013 VL 5 IS 188 AR 188fs22 DI 10.1126/scitranslmed.3006635 PG 3 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 158LK UT WOS:000319972300002 PM 23740896 ER PT J AU Maggard-Gibbons, M Maglione, M Livhits, M Ewing, B Maher, AR Hu, JH Li, ZP Shekelle, PG AF Maggard-Gibbons, Melinda Maglione, Margaret Livhits, Masha Ewing, Brett Maher, Alicia Ruelaz Hu, Jianhui Li, Zhaoping Shekelle, Paul G. TI Bariatric Surgery for Weight Loss and Glycemic Control in Nonmorbidly Obese Adults With Diabetes A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID Y GASTRIC BYPASS; BODY-MASS INDEX; RANDOMIZED-CONTROLLED-TRIAL; LIFE-STYLE INTERVENTIONS; BMI LESS-THAN-35 KG/M(2); LONG-TERM EFFECTIVENESS; GLUCAGON-LIKE PEPTIDE-1; 10-YEAR FOLLOW-UP; THAN 35 KG/M(2); SLEEVE GASTRECTOMY AB Importance Bariatric surgery is beneficial in persons with a body mass index (BMI) of 35 or greater with obesity-related comorbidities. There is interest in using these procedures in persons with lower BMI and diabetes. Objective To assess the association between bariatric surgery vs nonsurgical treatments and weight loss and glycemic control among patients with diabetes or impaired glucose tolerance and BMI of 30 to 35. Evidence Review PubMed, EMBASE, and Cochrane Library databases were searched from January 1985 through September 2012. Of 1291 screened articles, we included 32 surgical studies, 11 systematic reviews on nonsurgical treatments, and 11 large nonsurgical studies published after those reviews. Weight loss, metabolic outcomes, and adverse events were abstracted by 2 independent reviewers. Findings Three randomized clinical trials (RCTs) (N=290; including 1 trial of 150 patients with type 2 diabetes and mean BMI of 37, 1 trial of 80 patients without diabetes [38% with metabolic syndrome] and BMI of 30 to 35, and 1 trial of 60 patients with diabetes and BMI of 30 to 40 [13 patients with BMI <35]) found that surgery was associated with greater weight loss (range, 14.4-24 kg) and glycemic control (range, 0.9-1.43 point improvements in hemoglobin A(1c) levels) during 1 to 2 years of follow-up than nonsurgical treatment. Indirect comparisons of evidence from observational studies of bariatric procedures (n approximate to 600 patients) and meta-analyses of nonsurgical therapies (containing more than 300 RCTs) support this finding at 1 or 2 years of follow-up. However, there are no robust surgical data beyond 5 years of follow-up on outcomes of diabetes, glucose control, or macrovascular and microvascular outcomes. In contrast, some RCT data of nonsurgical therapies show benefits at 10 years of follow-up or more. Surgeon-reported adverse events were low (eg, hospital deaths of 0.3%-1.0%), but data were from select centers and surgeons. Long-term adverse events are unknown. Conclusions and Relevance Current evidence suggests that, when compared with nonsurgical treatments, bariatric surgical procedures in patients with a BMI of 30 to 35 and diabetes are associated with greater short-term weight loss and better intermediate glucose outcomes. Evidence is insufficient to reach conclusions about the appropriate use of bariatric surgery in this population until more data are available about long-term outcomes and complications of surgery. C1 [Maggard-Gibbons, Melinda; Maglione, Margaret; Ewing, Brett; Maher, Alicia Ruelaz; Hu, Jianhui; Shekelle, Paul G.] Rand Hlth, Santa Monica, CA USA. [Maggard-Gibbons, Melinda; Livhits, Masha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Maggard-Gibbons, Melinda; Livhits, Masha; Li, Zhaoping; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Maggard-Gibbons, Melinda] Olive View UCLA Med Ctr, Dept Surg, Sylmar, CA 91342 USA. [Maher, Alicia Ruelaz] Akasha Ctr Integrat Med, Santa Monica, CA USA. RP Maggard-Gibbons, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, CHS 72-215,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mmaggard@mednet.ucla.edu FU AHRQ [290-2007-10062I]; US Department of Health and Human Services FX This project was funded under the contract 290-2007-10062I from the AHRQ and US Department of Health and Human Services. NR 84 TC 97 Z9 99 U1 2 U2 34 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 5 PY 2013 VL 309 IS 21 BP 2250 EP 2261 DI 10.1001/jama.2013.4851 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 156YC UT WOS:000319859200029 PM 23736734 ER PT J AU Hsu, JC Li, YM Marcus, GM Hsue, PY Scherzer, R Grunfeld, C Shlipak, MG AF Hsu, Jonathan C. Li, Yongmei Marcus, Gregory M. Hsue, Priscilla Y. Scherzer, Rebecca Grunfeld, Carl Shlipak, Michael G. TI Atrial Fibrillation and Atrial Flutter in Human Immunodeficiency Virus-Infected Persons Incidence, Risk Factors, and Association With Markers of HIV Disease Severity SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE arrhythmia; atrial fibrillation; epidemiology; HIV infection; risk factors ID ANTIRETROVIRAL THERAPY ERA; CARDIOVASCULAR EVENTS; KIDNEY-FUNCTION; LIFETIME RISK; HEART; INFLAMMATION; PREVALENCE; VETERANS; COHORT; ATHEROSCLEROSIS AB Objectives The purpose of this study was to investigate the associations of traditional risk factors and longitudinal measures of human immunodeficiency virus (HIV) disease severity with risk of incident atrial fibrillation (AF) in a contemporary cohort of HIV-infected individuals. Background Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhythmia, AF, has not been adequately studied in this population. Methods We studied a national sample of 30,533 HIV-infected veterans followed in the Veterans Affairs HIV Clinical Case Registry from 1996 to 2011. We examined the independent associations of demographic characteristics, time-updated comorbidities, and time-updated clinical measurements including CD4(+) cell count and viral load with the outcome of incident AF using proportional hazards regression for multivariable analysis. Results Over a median follow-up of 6.8 years, 780 (2.6%) patients developed AF. After multivariable adjustment for traditional risk factors, a lower CD4(+) cell count (<200 compared with >350 cells/mm(3); hazard ratio [HR]: 1.4; 95% confidence interval [CI]: 1.1 to 1.8; p = 0.018) and higher viral load (>100,000 compared with <500 copies/ml; HR: 1.7; 95% CI: 1.2 to 2.4; p = 0.002) were independently associated with increased risk of incident AF. Additional risk factors independently associated with risk of AF included older age, White race, coronary artery disease, congestive heart failure, alcoholism, proteinuria, reduced kidney function, and hypothyroidism. Conclusions In a large HIV-infected cohort, markers of HIV disease severity represented by low CD4(+) cell count and high viral load, assessed by multiple time-updated measures, were independently associated with development of AF. (C) 2013 by the American College of Cardiology Foundation C1 [Hsu, Jonathan C.; Marcus, Gregory M.] Univ Calif San Francisco, Sect Cardiac Electrophysiol, Div Cardiol, Dept Med, San Francisco, CA 94143 USA. [Li, Yongmei; Scherzer, Rebecca; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Li, Yongmei; Scherzer, Rebecca; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hsue, Priscilla Y.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. RP Hsu, JC (reprint author), Univ Calif San Francisco, Sect Cardiac Electrophysiol, Div Cardiol, Dept Med, 500 Parnassus Ave,MUE 434,Box 1354, San Francisco, CA 94143 USA. EM jonhsumd@gmail.com OI Hsu, Jonathan/0000-0002-1523-573X FU National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30-AI027763]; St. Jude Medical; Baylis; Medical, Gilead; SentreHeart Inc; Tobira FX This research was supported by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research, P30-AI027763. Dr. Marcus receives speaker's fees from St. Jude Medical; is a consultant for InCarda; and receives research support from Baylis; Medical, Gilead, and SentreHeart Inc. Dr. Hsue is an advisor for Gilead and Pfizer; and has received research support from Tobira. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 33 TC 22 Z9 22 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 4 PY 2013 VL 61 IS 22 BP 2288 EP 2295 DI 10.1016/j.jacc.2013.03.022 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 166ZV UT WOS:000320600700010 PM 23563125 ER PT J AU Zhao, LB Lu, YT Li, FQ Wu, K Hou, S Yu, JH Shen, QL Wu, DX Song, M OuYang, WH Luo, Z Lee, T Fang, XH Shao, C Xu, X Garcia, MA Chung, LWK Rettig, M Tseng, HR Posadas, EM AF Zhao, Libo Lu, Yi-Tsung Li, Fuqiang Wu, Kui Hou, Shuang Yu, Juehua Shen, Qinglin Wu, Dongxia Song, Min OuYang, Wei-Han Luo, Zheng Lee, Tom Fang, Xiaohong Shao, Chen Xu, Xun Garcia, Mitch A. Chung, Leland W. K. Rettig, Matthew Tseng, Hsian-Rong Posadas, Edwin M. TI High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing SO ADVANCED MATERIALS LA English DT Article DE electrospun nanomaterials; microfluidics; circulating tumor cell; whole exome sequencing; prostate cancer ID CANCER PATIENTS; BREAST-CANCER; CAPTURE; PROGRESSION; ENRICHMENT; BLOOD C1 [Zhao, Libo; Fang, Xiaohong] Chinese Acad Sci, Key Lab Mol Nanostruct & Nanotechnol, Inst Chem, Beijing 100190, Peoples R China. [Lu, Yi-Tsung; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urol Oncol Program, Los Angeles, CA 90048 USA. [Lu, Yi-Tsung; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA. [Zhao, Libo; Hou, Shuang; Yu, Juehua; Shen, Qinglin; Wu, Dongxia; Song, Min; Luo, Zheng; Lee, Tom; Tseng, Hsian-Rong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, CIMI, CNSI, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA USA. [Li, Fuqiang; Wu, Kui; Xu, Xun] BGI ShenZhen, Shenzhen 518083, Peoples R China. [OuYang, Wei-Han; Garcia, Mitch A.] CytoLumina Technol Corp, Walnut, CA 91789 USA. [Shao, Chen] Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Peoples R China. RP Xu, X (reprint author), BGI ShenZhen, 2nd F,Bldg 11, Shenzhen 518083, Peoples R China. EM xuxun@genomics.cn; mgarcia@cytolumina.com; Leland.Chung@cshs.org; MRettig@mednet.ucla.edu; HRTseng@mednet.ucla.edu; Edwin.Posadas@csmc.edu RI Tseng, Hsian-Rong/G-2222-2010; Zhao, Libo/G-2421-2010 FU NIH/NCI [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422]; PCF Young Investigator Award; Prostate Cancer Foundation (PCF) FX The research endeavors at UCLA were supported by a Creativity Award from Prostate Cancer Foundation (PCF), and research grants (R21 CA151159 and R33 CA157396) from NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program. The research endeavors at Cedars Sinai Medical Center were supported by DoD Idea Award (W81XWH-11-1-0422) and PCF Young Investigator Award. NR 26 TC 60 Z9 61 U1 14 U2 162 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 0935-9648 J9 ADV MATER JI Adv. Mater. PD JUN 4 PY 2013 VL 25 IS 21 BP 2897 EP 2902 DI 10.1002/adma.201205237 PG 6 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 157MG UT WOS:000319899700002 PM 23529932 ER PT J AU Hamilton, RT Bhattacharya, A Walsh, ME Shi, Y Wei, R Zhang, YQ Rodriguez, KA Buffenstein, R Chaudhuri, AR Van Remmen, H AF Hamilton, Ryan T. Bhattacharya, Arunabh Walsh, Michael E. Shi, Yun Wei, Rochelle Zhang, Yiqiang Rodriguez, Karl A. Buffenstein, Rochelle Chaudhuri, Asish R. Van Remmen, Holly TI Elevated Protein Carbonylation, and Misfolding in Sciatic Nerve from db/db and Sod1(-/-) Mice: Plausible Link between Oxidative Stress and Demyelination SO PLOS ONE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; PERIPHERAL MYELIN PROTEIN-22; ALDOSE REDUCTASE INHIBITION; ALZHEIMERS-DISEASE BRAIN; DIABETIC-NEUROPATHY; LIPID-PEROXIDATION; SKELETAL-MUSCLE; CONDUCTION-VELOCITY; NITROSATIVE STRESS; ADVANCED GLYCATION AB Diabetic peripheral polyneuropathy is associated with decrements in motor/sensory neuron myelination, nerve conduction and muscle function; however, the mechanisms of reduced myelination in diabetes are poorly understood. Chronic elevation of oxidative stress may be one of the potential determinants for demyelination as lipids and proteins are important structural constituents of myelin and highly susceptible to oxidation. The goal of the current study was to determine whether there is a link between protein oxidation/misfolding and demyelination. We chose two distinct models to test our hypothesis: 1) the leptin receptor deficient mouse (dbdb) model of diabetic polyneuropathy and 2) superoxide dismutase 1 knockout (Sod1 2/2) mouse model of in vivo oxidative stress. Both experimental models displayed a significant decrement in nerve conduction, increase in tail distal motor latency as well as reduced myelin thickness and fiber/axon diameter. Further biochemical studies demonstrated that oxidative stress is likely to be a potential key player in the demyelination process as both models exhibited significant elevation in protein carbonylation and alterations in protein conformation. Since peripheral myelin protein 22 (PMP22) is a key component of myelin sheath and has been found mutated and aggregated in several peripheral neuropathies, we predicted that an increase in carbonylation and aggregation of PMP22 may be associated with demyelination in dbdb mice. Indeed, PMP22 was found to be carbonylated and aggregated in sciatic nerves of dbdb mice. Sequence-driven hydropathy plot analysis and in vitro oxidation-induced aggregation of purified PMP22 protein supported the premise for oxidation-dependent aggregation of PMP22 in dbdb mice. Collectively, these data strongly suggest for the first time that oxidation-mediated protein misfolding and aggregation of key myelin proteins may be linked to demyelination and reduced nerve conduction in peripheral neuropathies. C1 [Hamilton, Ryan T.; Bhattacharya, Arunabh; Walsh, Michael E.; Shi, Yun; Zhang, Yiqiang; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Rodriguez, Karl A.; Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hamilton, Ryan T.; Bhattacharya, Arunabh; Shi, Yun; Wei, Rochelle; Zhang, Yiqiang; Rodriguez, Karl A.; Buffenstein, Rochelle; Chaudhuri, Asish R.; Van Remmen, Holly] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Chaudhuri, Asish R.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM chaudhuria@uthscsa.edu; vanremmen@uthscsa.edu FU National Service Research Award; Program project at the National Institute of Aging [AG20591]; University of Michigan Grant; Go Grant at the National institute of Aging project [RCA2AG036613]; Glenn Award (Research in Biological Mechanisms of Aging); Ellison Medical Foundation [AGSS-178006]; Glenn Foundation for Medical Research FX Funding provided by T32 AG021890-08 (NIA) National Service Research Award to Postdoctoral Fellow Training Grant on the Biology of Aging to Steven N. Austad for trainees (RTH, KAR) AG20591 Program project at the National Institute of Aging (HV) (Project 2: Does Superoxide-Induced Mitochondrial Dysfunction Lead to Muscle Atrophy?) University of Michigan Grant (Subcontract), RCA2AG036613 Go Grant at the National institute of Aging project 8 (WW and HV) (Effect of rapa on removal of protein by the autophagic and/or proteasomal pathways) under (AR) (Can rapamycin retard aging?), Glenn Award (Research in Biological Mechanisms of Aging) (http://glennfoundation.org/), AGSS-178006 (RB is PI) Ellison Medical Foundation (Genomic Stability in the Naked Mole-Rat: A Role for Cancer Resistance and Extended Longevity) (http://www.ellisonfoundation.org/), and Glenn Foundation for Medical Research (RB is PI). (Comparative biological mechanisms of aging, insights from the longest lived rodent, the naked mole-rat) (http://glennfoundation.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 17 Z9 17 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 4 PY 2013 VL 8 IS 6 AR e65725 DI 10.1371/journal.pone.0065725 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 158IE UT WOS:000319961900075 PM 23750273 ER PT J AU Rehman, H Krishnasamy, Y Haque, K Thurman, RG Lemasters, JJ Schnellmann, RG Zhong, Z AF Rehman, Hasibur Krishnasamy, Yasodha Haque, Khujista Thurman, Ronald G. Lemasters, John J. Schnellmann, Rick G. Zhong, Zhi TI Green Tea Polyphenols Stimulate Mitochondrial Biogenesis and Improve Renal Function after Chronic Cyclosporin A Treatment in Rats SO PLOS ONE LA English DT Article ID PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; PROXIMAL TUBULE CELLS; HUMAN SKELETAL-MUSCLE; ACUTE KIDNEY INJURY; MAMMALIAN-CELLS; DIETARY GLYCINE; PROTEIN-KINASE; PERMEABILITY TRANSITION; METABOLIC REGULATOR AB Our previous studies showed that an extract from Camellia sinenesis (green tea), which contains several polyphenols, attenuates nephrotoxicity caused by cyclosporine A (CsA). Since polyphenols are stimulators of mitochondrial biogenesis (MB), this study investigated whether stimulation of MB plays a role in green tea polyphenol protection against CsA renal toxicity. Rats were fed a powdered diet containing green tea polyphenolic extract (0.1%) starting 3 days prior to CsA treatment (25 mg/kg, i.g. daily for 3 weeks). CsA alone decreased renal nuclear DNA-encoded oxidative phosphorylation (OXPHOS) protein ATP synthase-beta (AS-beta) by 42%, mitochondrial DNA (mtDNA)-encoded OXPHOS protein NADH dehydrogenase-3 (ND3) by 87% and their associated mRNAs. Mitochondrial DNA copy number was also decreased by 78% by CsA. Immunohistochemical analysis showed decreased cytochrome c oxidase subunit IV (COX-IV), an OXPHOS protein, in tubular cells. Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1 alpha, the master regulator of MB, and mitochondrial transcription factor-A (Tfam), the transcription factor that regulates mtDNA replication and transcription, were 42% and 90% lower, respectively, in the kidneys of CsA-treated than in untreated rats. These results indicate suppression of MB by chronic CsA treatment. Green tea polyphenols alone and following CsA increased AS-beta, ND3, COX-IV, mtDNA copy number, PGC-1 alpha mRNA and protein, decreased acetylated PGC-1 alpha, and increased Tfam mRNA and protein. In association with suppressed MB, CsA increased serum creatinine, caused loss of brush border and dilatation of proximal tubules, tubular atrophy, vacuolization, apoptosis, calcification, and increased neutrophil gelatinase-associated lipocalin expression, leukocyte infiltration, and renal fibrosis. Green tea polyphenols markedly attenuated CsA-induced renal injury and improved renal function. Together, these results demonstrate that green tea polyphenols attenuate CsA-induced kidney injury, at least in part, through the stimulation of MB. C1 [Rehman, Hasibur; Krishnasamy, Yasodha; Haque, Khujista; Lemasters, John J.; Schnellmann, Rick G.; Zhong, Zhi] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Lemasters, John J.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Lemasters, John J.; Schnellmann, Rick G.; Zhong, Zhi] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Thurman, Ronald G.; Zhong, Zhi] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. EM zhong@musc.edu FU National Institutes of Health [DK70844, DK37034, GM 084147]; South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling [P20 GM103542] FX This study was supported, in part, by Grants DK70844, DK37034, and GM 084147 from the National Institutes of Health and South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling [P20 GM103542]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 97 TC 13 Z9 13 U1 1 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 3 PY 2013 VL 8 IS 6 AR e65029 DI 10.1371/journal.pone.0065029 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 157CD UT WOS:000319872300044 ER PT J AU Basu, P Shah, NJ Farhat, S Siriki, R Mittimanj, K Rahaman, M Atluri, S AF Basu, P. Shah, N. J. Farhat, S. Siriki, R. Mittimanj, K. Rahaman, M. Atluri, S. TI EFFECT OF N ACETYLCYSTEINE (NAC) IN HYPOXIA INDUCED LIVER INJURY (HILI)-A RANDOMIZED PLACEBO CONTROL CLINICAL TRIAL SO GUT LA English DT Meeting Abstract CT Annual General Meeting of the British-Society-of-Gastroenterology CY JUN 24-27, 2013 CL Glasgow, SCOTLAND SP British Soc Gastroenterol C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA. [Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA. [Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD JUN PY 2013 VL 62 SU 1 BP A184 EP A184 DI 10.1136/gutjnl-2013-304907.418 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA6SF UT WOS:000331227600312 ER PT J AU Basu, P Shah, NJ Farhat, S Siriki, R Mittimanj, K Rahaman, M Atluri, S AF Basu, P. Shah, N. J. Farhat, S. Siriki, R. Mittimanj, K. Rahaman, M. Atluri, S. TI ROMIPLOSTIM'S EFFECT TO OPTIMIZE SVR WITH TELAPRAVIR, RIBAVIRIN, AND PEG INTERFERON-ALFA 2A IN THROMBOCYTOPENIC CIRRHOTICS WITH CHRONIC HEPATITIS C. A PLACEBO CONTROLLED PROSPECTIVE CLINICAL TRIAL: RESTRAINT C TRIAL SO GUT LA English DT Meeting Abstract CT Annual General Meeting of the British-Society-of-Gastroenterology CY JUN 24-27, 2013 CL Glasgow, SCOTLAND SP British Soc Gastroenterol C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA. [Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD JUN PY 2013 VL 62 SU 1 BP A183 EP A183 DI 10.1136/gutjnl-2013-304907.416 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA6SF UT WOS:000331227600310 ER PT J AU Basu, P Shah, NJ Farhat, S Siriki, R Mittimanj, K Rahaman, M Atluri, S AF Basu, P. Shah, N. J. Farhat, S. Siriki, R. Mittimanj, K. Rahaman, M. Atluri, S. TI TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT) SO GUT LA English DT Meeting Abstract CT Annual General Meeting of the British-Society-of-Gastroenterology CY JUN 24-27, 2013 CL Glasgow, SCOTLAND SP British Soc Gastroenterol C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA. [Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD JUN PY 2013 VL 62 SU 1 BP A182 EP A182 DI 10.1136/gutjnl-2013-304907.414 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA6SF UT WOS:000331227600308 ER PT J AU Basu, P Shah, NJ Farhat, S Siriki, R Mittimanj, K Atluri, S Rahaman, M AF Basu, P. Shah, N. J. Farhat, S. Siriki, R. Mittimanj, K. Atluri, S. Rahaman, M. TI CURCUMIN, ANTI-OXIDANT, AND PIOGLITAZONE THERAPY WITH INCLUSION OF VITAMIN E IN NON ALCOHOLIC FATTY LIVER DISEASE-A RANDOMIZED OPEN LABEL PLACEBO CONTROLLED CLINICAL PROSPECTIVE TRIAL (CAPTIVE) SO GUT LA English DT Meeting Abstract CT Annual General Meeting of the British-Society-of-Gastroenterology CY JUN 24-27, 2013 CL Glasgow, SCOTLAND SP British Soc Gastroenterol C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA. [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA. [Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD JUN PY 2013 VL 62 SU 1 BP A23 EP A23 DI 10.1136/gutjnl-2013-304907.052 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA6SF UT WOS:000331227600047 ER PT J AU Ahluwalia, S Bekelman, D Prendergast, TJ Huynh, AK Lorenz, K AF Ahluwalia, Sangeeta Bekelman, David Prendergast, Thomas J. Huynh, Alexis K. Lorenz, Karl TI CROSSING BOUNDARIES: WHAT IS NEEDED TO REALIZE A COMPREHENSIVE MODEL OF ADVANCE CARE PLANNING? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Ahluwalia, Sangeeta; Huynh, Alexis K.; Lorenz, Karl] Vet Adm Greater Los Angeles, Los Angeles, CA USA. [Ahluwalia, Sangeeta] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Bekelman, David] VA Denver, Denver, CO USA. [Bekelman, David] Univ Colorado, Denver, CO 80202 USA. [Prendergast, Thomas J.] VA Portland, Portland, OR USA. [Lorenz, Karl] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S56 EP S57 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300133 ER PT J AU Arreola-Owen, OA Warde, CM Gomez, AG AF Arreola-Owen, Olivia A. Warde, Carole M. Gomez, Arthur G. TI A PILOT PRIMARY CARE RESIDENCY TRACK: EDUCATION AND LEADERSHIP IN PATIENT-ALIGNED CARE TEAMS (ELPACT) SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Arreola-Owen, Olivia A.] Cedars Sinai Internal Med Residency, Los Angeles, CA USA. [Warde, Carole M.; Gomez, Arthur G.] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S452 EP S452 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302389 ER PT J AU Bachhuber, M Patel, S O'Brien, B AF Bachhuber, Melissa Patel, Shalini O'Brien, Bridget TI A HOME VISIT CURRICULUM TO FOSTER INTERPROFESSIONAL LEARNING AND IMPROVE CARE COORDINATION FOR HIGH-RISK PATIENTS IN TRAINEE PRIMARY CARE CONTINUITY CLINICS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Bachhuber, Melissa; Patel, Shalini; O'Brien, Bridget] UCSF, San Francisco, CA USA. [Bachhuber, Melissa; Patel, Shalini; O'Brien, Bridget] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S451 EP S451 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302386 ER PT J AU Barocas, J Brennan, M Crnich, C Hess, T Sethi, A Sosman, JM AF Barocas, Joshua Brennan, Meghan Crnich, Christopher Hess, Timothy Sethi, Ajay Sosman, James M. TI SELF-AUDIT INCREASES CLINICIAN-DRIVEN UNIVERSAL HIV SCREENING AMONG INTERNAL MEDICINE RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Barocas, Joshua; Brennan, Meghan; Crnich, Christopher; Hess, Timothy; Sethi, Ajay; Sosman, James M.] Univ Wisconsin, Madison, WI USA. [Brennan, Meghan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S178 EP S178 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301183 ER PT J AU Bekelman, D Nowels, CT Main, D Heidenreich, P Hattler, B Lorenz, K Meek, P McBryde, C Hooker, S AF Bekelman, David Nowels, Carolyn T. Main, Debbi Heidenreich, Paul Hattler, Brack Lorenz, Karl Meek, Paula McBryde, Connor Hooker, Stephanie TI PILOT CLINICAL TRIAL OF A COLLABORATIVE CARE INTERVENTION TO IMPROVE SYMPTOMS AND QUALITY OF LIFE IN CHRONIC HEART FAILURE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Bekelman, David; Hattler, Brack; McBryde, Connor] VA Eastern Colorado Heath Care Syst, Denver, CO USA. [Bekelman, David; Nowels, Carolyn T.; Hattler, Brack; McBryde, Connor] Univ Colorado, Sch Med, Aurora, CO USA. [Main, Debbi; Hooker, Stephanie] Univ Colorado, Denver, CO 80202 USA. [Meek, Paula] Univ Colorado, Coll Nursing, Aurora, CO USA. [Heidenreich, Paul] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Lorenz, Karl] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S149 EP S149 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301113 ER PT J AU Bokhour, BG Solomon, J Laws, MB Gifford, AL Goetz, MB AF Bokhour, Barbara G. Solomon, Jeffrey Laws, Michael B. Gifford, Allen L. Goetz, Matthew B. TI THE IMPACT OF AN HIV ADHERENCE INFORMATICS INTERVENTION ON PATIENT-PROVIDER COMMUNICATION ABOUT ART ADHERENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Bokhour, Barbara G.; Solomon, Jeffrey; Gifford, Allen L.] ENRM Vet Affairs Med Ctr, Bedford, MA USA. [Bokhour, Barbara G.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Goetz, Matthew B.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Brown Univ, Providence, RI 02912 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S217 EP S217 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301274 ER PT J AU Bradley, K Rubinsky, AD Au, D Bryson, CL Achtmeyer, C Williams, E Lapham, G Chavez, L Kivlahan, D AF Bradley, Katharine Rubinsky, Anna D. Au, David Bryson, Christopher L. Achtmeyer, Carol Williams, Emily Lapham, Gwendolyn Chavez, Laura Kivlahan, Daniel TI VALIDATING ALCOHOL SCREENING SCORES AS PATIENT-REPORTED OUTCOME MEASURES - RESULTS OF THE MONITOR STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Bradley, Katharine; Rubinsky, Anna D.; Au, David; Bryson, Christopher L.; Achtmeyer, Carol; Williams, Emily; Lapham, Gwendolyn; Chavez, Laura] VA Puget Sound, Seattle, WA USA. [Bradley, Katharine] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Au, David; Bryson, Christopher L.; Williams, Emily] Univ Washington, Seattle, WA 98195 USA. [Kivlahan, Daniel] Vet Hlth Adm, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S236 EP S236 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301317 ER PT J AU Brown, RT Ahalt, C Steinman, MA Williams, B AF Brown, Rebecca T. Ahalt, Cyrus Steinman, Michael A. Williams, Brie TI HANDS ON THE HOOD, GRANDPA: ASSESSING THE NEED FOR GERIATRICS HEALTH TRAINING AMONG POLICE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Brown, Rebecca T.; Ahalt, Cyrus; Steinman, Michael A.; Williams, Brie] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S84 EP S84 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300199 ER PT J AU Burke, R Guo, RX Misky, GJ AF Burke, Robert Guo, Ruixin Misky, Gregory J. TI IDENTIFYING KEYS TO SUCCESS FOR REDUCING READMISSIONS: USING THE IDEAL TRANSITION IN CARE FRAMEWORK SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Burke, Robert] Denver VA Med Ctr, Denver, CO USA. [Burke, Robert; Guo, Ruixin; Misky, Gregory J.] Univ Colorado, Sch Med, Denver, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S94 EP S94 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300225 ER PT J AU Burke, R Whitfield, E Prochazka, AV AF Burke, Robert Whitfield, Emily Prochazka, Allan V. TI EFFECT OF A HOSPITALIST-RUN POST-DISCHARGE CLINIC ON ADVERSE POST-DISCHARGE OUTCOMES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Burke, Robert; Whitfield, Emily; Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA. [Burke, Robert; Prochazka, Allan V.] Univ Colorado, Sch Med, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S69 EP S69 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300162 ER PT J AU Chang, E Chung, B Gilmore, J Tang, LQ Morgan, A Wells, KB AF Chang, Evelyn Chung, Bowen Gilmore, James Tang, Lingqi Morgan, Anna Wells, Kenneth B. TI COMORBID DEPRESSION AND SUBSTANCE ABUSE IN SAFETY-NET CLIENTS OF HEALTH AND COMMUNITY-BASED AGENCIES IN LOS ANGELES: CLINICAL NEEDS AND SERVICE USE PATTERNS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Chang, Evelyn] VA Greater Los Angeles, Los Angeles, CA USA. [Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA. [Chung, Bowen; Tang, Lingqi; Wells, Kenneth B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Gilmore, James] Behav Hlth Serv Inc, Los Angeles, CA USA. [Morgan, Anna] Harbor UCLA, Torrance, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S48 EP S49 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300115 ER PT J AU Chang, E Wells, KB Young, AS Stockdale, SE Fickel, J Johnson, M Jou, K Rubenstein, LV AF Chang, Evelyn Wells, Kenneth B. Young, Alexander S. Stockdale, Susan E. Fickel, Jacqueline Johnson, Megan Jou, Kevin Rubenstein, Lisa V. TI ACHIEVING COMMUNICATION BETWEEN PRIMARY CARE AND MENTAL HEALTH: WHY IS IT SO DIFFICULT, EVEN IN THE VA? A QUALITY IMPROVEMENT APPROACH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Chang, Evelyn] VA Greater Los Angeles, Los Angeles, CA USA. [Young, Alexander S.; Stockdale, Susan E.; Fickel, Jacqueline; Johnson, Megan; Jou, Kevin; Rubenstein, Lisa V.] VA Greater Los Angeles, North Hills, CA USA. [Wells, Kenneth B.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S17 EP S17 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300039 ER PT J AU Cohen, B Shi, Y Neylan, T Seal, KH AF Cohen, Beth Shi, Ying Neylan, Thomas Seal, Karen H. TI OFF-LABEL ANTIPSYCHOTIC PRESCRIPTIONS IN IRAQ AND AFGHANISTAN VETERANS WITH POSTTRAUMATIC STRESS DISORDER IN VA HEALTHCARE, 2001-2011 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Cohen, Beth; Shi, Ying; Neylan, Thomas; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Beth; Neylan, Thomas; Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S131 EP S132 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301072 ER PT J AU Cohen, B Neylan, T Bertenthal, D Yaffe, K AF Cohen, Beth Neylan, Thomas Bertenthal, Daniel Yaffe, Kristine TI ASSOCIATION OF POSTTRAUMATIC STRESS DISORDER AND INCIDENT CEREBROVASCULAR DISEASE IN A VETERANS ADMINISTRATION POPULATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Cohen, Beth; Neylan, Thomas; Bertenthal, Daniel; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Beth; Neylan, Thomas; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S28 EP S28 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300066 ER PT J AU Darby, A Ahalt, C Cenzer, IS Sudore, RL Williams, B AF Darby, Anna Ahalt, Cyrus Cenzer, Irena Stijacic Sudore, Rebecca L. Williams, Brie TI EVALUATING A MODIFIED INFORMED CONSENT FOR OLDER ADULTS IN CORRECTIONAL RESEARCH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Darby, Anna] Mt Sinai Sch Med, New York, NY USA. [Ahalt, Cyrus; Cenzer, Irena Stijacic; Sudore, Rebecca L.; Williams, Brie] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cenzer, Irena Stijacic; Sudore, Rebecca L.; Williams, Brie] San Francisco VA Med Ctr, San Francisco, CA USA. RI Darby, Alistair/I-6485-2012 OI Darby, Alistair/0000-0002-3786-6209 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S74 EP S74 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300174 ER PT J AU Edelman, EJ Gordon, KS Lo Re, V Skanderson, M Fiellin, DA Justice, AC AF Edelman, E. J. Gordon, Kirsha S. Lo Re, Vincent Skanderson, Melissa Fiellin, David A. Justice, Amy C. TI ACETAMINOPHEN RECEIPT AMONG HIV-INFECTED PATIENTS WITH ADVANCED HEPATIC FIBROSIS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Edelman, E. J.; Fiellin, David A.; Justice, Amy C.] Yale Univ, New Haven, CT USA. [Gordon, Kirsha S.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Lo Re, Vincent] Univ Penn, Philadelphia, PA 19104 USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RI Lo Re, Vincent/N-7817-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S16 EP S17 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300038 ER PT J AU Eng, JA Hatoun, J Liu, C Blum-Smith, L Shea, S Suen, W AF Eng, Jessica A. Hatoun, Jonathan Liu, Constance Blum-Smith, Laura Shea, Sandra Suen, Winnie TI RESIDENT ATTITUDES, KNOWLEDGE AND BEHAVIORS REGARDING AN ELECTRONIC INCIDENT REPORTING SYSTEM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Eng, Jessica A.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hatoun, Jonathan; Liu, Constance; Suen, Winnie] Boston Med Ctr, Boston, MA USA. [Hatoun, Jonathan] Boston Childrens Hosp, Boston, MA USA. [Blum-Smith, Laura; Shea, Sandra] Comm Interns & Residents, New York, NY USA. [Suen, Winnie] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S171 EP S171 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301166 ER PT J AU Eng, JA Hunter, CJ Cantino, LB Yuan, C Lai, S Kalmar, E Boscardin, CK Handley, MA Gonzales, R Ackerman, S AF Eng, Jessica A. Hunter, Cecily J. Cantino, Laura B. Yuan, Caterina Lai, Sunny Kalmar, Evie Boscardin, Christy K. Handley, Margaret A. Gonzales, Ralph Ackerman, Sara TI LET'S TALK! PATIENT ATTITUDES ABOUT TELEPHONE-BASED ALTERNATIVES TO FOLLOW-UP OFFICE VISITS WITH SPECIALISTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Eng, Jessica A.; Hunter, Cecily J.; Cantino, Laura B.; Yuan, Caterina; Lai, Sunny; Kalmar, Evie; Boscardin, Christy K.; Handley, Margaret A.; Gonzales, Ralph] UCSF Sch Med, San Francisco, CA USA. [Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ackerman, Sara] UCSF Sch Nursing, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S114 EP S115 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301034 ER PT J AU Flickinger, TE Saha, S Moore, RD Beach, MC AF Flickinger, Tabor E. Saha, Somnath Moore, Richard D. Beach, Mary Catherine TI HIGHER QUALITY COMMUNICATION AND RELATIONSHIPS ARE ASSOCIATED WITH IMPROVED PATIENT ENGAGEMENT IN HIV CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Flickinger, Tabor E.; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S88 EP S88 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300210 ER PT J AU Fu, S Roth, C Battaglia, C Nelson, D Farmer, M Do, T Goldstein, M Kavathekar, R Widome, R Hagedorne, H Zillich, A AF Fu, Steven Roth, Craig Battaglia, Catherine Nelson, David Farmer, Melissa Do, Tam Goldstein, Michael Kavathekar, Rahul Widome, Rachel Hagedorne, Hildi Zillich, Alan TI A RANDOMIZED TRIAL OF TWO APPROACHES TO TRAINING VETERANS AFFAIRS (VA) MEDICAL HOME HEALTHCARE PROVIDERS ON MOTIVATIONAL INTERVIEWING FOR TOBACCO CESSATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Fu, Steven; Roth, Craig; Nelson, David; Do, Tam; Kavathekar, Rahul; Widome, Rachel; Hagedorne, Hildi] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Zillich, Alan] Roudebush VA Med Ctr, Indianapolis, IN USA. [Battaglia, Catherine] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Farmer, Melissa] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Goldstein, Michael] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S7 EP S8 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300017 ER PT J AU Gopalan, A Tahirovic, E Moss, H Troxel, AB Zhu, JS Volpp, KG AF Gopalan, Anjali Tahirovic, Emin Moss, Haley Troxel, Andrea B. Zhu, Jingsan Volpp, Kevin G. TI A RANDOMIZED, CONTROLLED TRIAL OF ALTERNATIVE FORMS OF FEEDBACK ON GLYCEMIC CONTROL IN PATIENTS WITH POORLY CONTROLLED DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Gopalan, Anjali; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Tahirovic, Emin; Moss, Haley; Troxel, Andrea B.; Zhu, Jingsan; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gopalan, Anjali] Robert Wood Johnson Clin Scholars Program, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S13 EP S13 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300030 ER PT J AU Hebert, P Liu, CF Wong, E Hernandez, S Batten, A Lo, S Lemon, J AF Hebert, Paul Liu, Chuan-Fen Wong, Edwin Hernandez, Susan Batten, Adam Lo, Sophie Lemon, Jackie TI NATIONAL EVALUATION OF THE EFFECTS ON HEALTHCARE UTILIZATION AND COSTS OF THE VA PATIENT CENTERED MEDICAL HOME INITIATIVE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Hebert, Paul; Liu, Chuan-Fen; Wong, Edwin; Hernandez, Susan; Batten, Adam; Lo, Sophie; Lemon, Jackie] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S124 EP S124 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301057 ER PT J AU Ho, M Aron, D Sales, AE Au, D Helfrich, C Fagan, K Lambert-Kerzner, A Lowery, J Battaglia, C Pogach, L Graham, GD Ellington, V Kirsh, S AF Ho, Michael Aron, David Sales, Anne E. Au, David Helfrich, Christian Fagan, Katherine Lambert-Kerzner, Anne Lowery, Julie Battaglia, Catherine Pogach, Leonard Graham, Glenn D. Ellington, Vaness Kirsh, Susan TI THE VA'S SPECIALTY CARE TRANSFORMATIONAL INITIATIVES TO IMPROVE ACCESS AND DELIVERY OF SPECIALTY CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Ho, Michael; Fagan, Katherine; Lambert-Kerzner, Anne; Battaglia, Catherine] Eastern Colorado Hlth Care Syst, Denver, CO USA. [Sales, Anne E.; Lowery, Julie] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Pogach, Leonard; Graham, Glenn D.; Ellington, Vaness] Washington DC VA Med Ctr, Washington, DC USA. [Aron, David; Kirsh, Susan] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Au, David; Helfrich, Christian] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S447 EP S448 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302379 ER PT J AU Jarvie, JL Regan, MC Cohen, B AF Jarvie, Jennifer L. Regan, Mathilda C. Cohen, Beth TI PROSPECTIVE ASSOCIATION OF PHYSICAL ACTIVITY AND MARKERS OF INFLAMMATION AND INSULIN RESISTANCE IN OUTPATIENTS WITH CORONARY HEART DISEASE: DATA FROM THE HEART AND SOUL STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Jarvie, Jennifer L.; Cohen, Beth] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Regan, Mathilda C.; Cohen, Beth] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S160 EP S161 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301140 ER PT J AU Jubelt, LE Graham, J Maeng, DD Metlay, J Epstein, A AF Jubelt, Lindsay E. Graham, Jove Maeng, Daniel D. Metlay, Joshua Epstein, Andrew TI CASE MANAGEMENT PERFORMANCE IN A MEDICAL HOME AND ASSOCIATIONS WITH PATIENT SATISFACTION AND HEALTHCARE UTILIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Jubelt, Lindsay E.; Metlay, Joshua; Epstein, Andrew] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Jubelt, Lindsay E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Graham, Jove] Geisinger Ctr Hlth Res, Danville, PA USA. [Maeng, Daniel D.] Geisinger Hlth Syst, Danville, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S40 EP S41 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300096 ER PT J AU Justice, AC Tate, JP Brown, ST Gibert, C Rodriguez-Barradas, M Rimland, D Akgun, KM Bryant, K AF Justice, Amy C. Tate, Janet P. Brown, Sheldon T. Gibert, Cynthia Rodriguez-Barradas, Maria Rimland, David Akguen, Kathleen M. Bryant, Kendall TI CAN THE VETERANS AGING COHORT STUDY INDEX IMPROVE CLINICAL JUDGMENT FOR BOTH HIV INFECTED AND UNINFECTED VETERANS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Justice, Amy C.; Tate, Janet P.; Akguen, Kathleen M.] Yale Univ, West Haven, CT USA. [Justice, Amy C.; Tate, Janet P.; Akguen, Kathleen M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, New York, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA. [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rimland, David] Emory Sch Med, Atlanta, GA USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Bryant, Kendall] NIAAA, Bethesda, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S39 EP S39 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300093 ER PT J AU Kaminetzky, CP Keedy, JR Evans, GA Poppe, AP Wipf, JE AF Kaminetzky, Catherine P. Keedy, Jacqueline R. Evans, Ginger A. Poppe, Anne P. Wipf, Joyce E. TI INTERPROFESSIONAL PANEL MANAGEMENT: TEACHING RESIDENTS DATA-DRIVEN LONGITUDINAL AND CONTINUOUS CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kaminetzky, Catherine P.; Keedy, Jacqueline R.; Evans, Ginger A.; Poppe, Anne P.; Wipf, Joyce E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kaminetzky, Catherine P.; Keedy, Jacqueline R.; Evans, Ginger A.; Poppe, Anne P.; Wipf, Joyce E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S469 EP S470 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302429 ER PT J AU Kangovi, S Grande, D Mitra, N Sellman, J White, ML McCollum, S Shannon, R Long, JA AF Kangovi, Shreya Grande, David Mitra, Nandita Sellman, Jeffrey White, Mary L. McCollum, Sharon Shannon, Richard Long, Judith A. TI A RANDOMIZED CONTROLLED TRIAL OF A COMMUNITY HEALTH WORKER POST-HOSPITAL CARE TRANSITIONS INTERVENTION FOR LOW SOCIOECONOMIC STATUS PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kangovi, Shreya; Sellman, Jeffrey; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Grande, David; Shannon, Richard; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Grande, David; Mitra, Nandita] Univ Penn, Philadelphia, PA 19104 USA. [Kangovi, Shreya; White, Mary L.; McCollum, Sharon] Spectrum Hlth Serv Inc, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S11 EP S12 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300026 ER PT J AU Kertesz, S Kim, TW Gordon, A Young, AS Pollio, DE Jones, RN Holt, CL Austin, EL Roth, D AF Kertesz, Stefan Kim, Theresa W. Gordon, Adam Young, Alexander S. Pollio, David E. Jones, Richard N. Holt, Cheryl L. Austin, Erika L. Roth, David TI COMPARING HOMELESS PERSONS' CARE EXPERIENCES IN TAILORED VERSUS NON-TAILORED PRIMARY CARE SETTINGS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kertesz, Stefan; Austin, Erika L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan; Austin, Erika L.] U Alabama Birmingham, Birmingham, AL USA. [Kim, Theresa W.] Boston Univ, Boston, MA 02215 USA. [Gordon, Adam] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Gordon, Adam] U Pittsburgh, Pittsburgh, PA USA. [Pollio, David E.] U Alabama, Tuscaloosa, AL USA. [Young, Alexander S.] VA Greater Los Angeles, Los Angeles, CA USA. [Holt, Cheryl L.] U Maryland, Baltimore, MD USA. [Roth, David] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Jones, Richard N.] Hebrew SeniorLife, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S49 EP S50 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300117 ER PT J AU Kolehmainen, CJ Brennan, M Filut, A Isaac, C Carnes, M AF Kolehmainen, Christine J. Brennan, Meghan Filut, Amarette Isaac, Carol Carnes, Molly TI GENDER AND LEADERSHIP IN CARDIOPULMONARY RESUSCITATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kolehmainen, Christine J.; Brennan, Meghan; Filut, Amarette; Isaac, Carol; Carnes, Molly] Univ Wisconsin, Madison, WI USA. [Kolehmainen, Christine J.; Brennan, Meghan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S81 EP S81 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300191 ER PT J AU Krug, MF Davidson, HL Wander, PL Wipf, JE AF Krug, Michael F. Davidson, Heather L. Wander, P. L. Wipf, Joyce E. TI THE EFFECTS OF A DECADE OF PROGRESSIVE DUTY HOUR LIMITATIONS AT A MULTI-HOSPITAL INTERNAL MEDICINE RESIDENCY PROGRAM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Krug, Michael F.; Davidson, Heather L.; Wander, P. L.; Wipf, Joyce E.] Univ Washington, Seattle, WA 98195 USA. [Davidson, Heather L.; Wipf, Joyce E.] VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S201 EP S202 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301237 ER PT J AU Kullgren, JT Troxel, AB Loewenstein, G Norton, L Gatto, D Tao, YY Zhu, JS Schofield, H Shea, JA Asch, DA Pellathy, T Driggers, J Volpp, KG AF Kullgren, Jeffrey T. Troxel, Andrea B. Loewenstein, George Norton, Laurie Gatto, Dana Tao, Yuanyuan Zhu, Jingsan Schofield, Heather Shea, Judy A. Asch, David A. Pellathy, Thomas Driggers, Jay Volpp, Kevin G. TI A MIXED-METHODS RANDOMIZED CONTROLLED TRIAL OF EMPLOYER MATCHING OF DEPOSIT CONTRACTS TO PROMOTE WEIGHT LOSS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kullgren, Jeffrey T.] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. [Kullgren, Jeffrey T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Troxel, Andrea B.; Norton, Laurie; Gatto, Dana; Tao, Yuanyuan; Zhu, Jingsan; Shea, Judy A.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Schofield, Heather] Harvard Univ, Cambridge, MA 02138 USA. [Asch, David A.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Pellathy, Thomas] McKinsey & Co Inc, Pittsburgh, PA USA. [Driggers, Jay] Horizon Healthcare Innovat, Newark, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S5 EP S5 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300011 ER PT J AU Kullgren, JT Duey, KA Werner, RM AF Kullgren, Jeffrey T. Duey, Katia A. Werner, Rachel M. TI A CENSUS OF STATE-BASED CONSUMER HEALTH CARE PRICE WEBSITES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Kullgren, Jeffrey T.] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. [Kullgren, Jeffrey T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Duey, Katia A.; Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S4 EP S4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300008 ER PT J AU Lee, JS Nsa, W Hausmann, LR Trivedi, AN Bratzler, DW Auden, D Goodrich, K Larbi, FM Fine, MJ AF Lee, Jonathan S. Nsa, Wato Hausmann, Leslie R. Trivedi, Amal N. Bratzler, Dale W. Auden, Dana Goodrich, Kate Larbi, Fiona M. Fine, Michael J. TI NATIONAL TRENDS IN PROCESSES AND OUTCOMES OF CARE FOR ELDERLY PATIENTS HOSPITALIZED FOR PNEUMONIA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Lee, Jonathan S.; Hausmann, Leslie R.; Fine, Michael J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Nsa, Wato; Auden, Dana] Oklahoma Fdn Med Qual, Oklahoma City, OK USA. [Hausmann, Leslie R.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S126 EP S127 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301062 ER PT J AU Lee, JS Nsa, W Hausmann, LR Trivedi, AN Bratzler, DW Auden, D Goodrich, K Larbi, FM Fine, MJ AF Lee, Jonathan S. Nsa, Wato Hausmann, Leslie R. Trivedi, Amal N. Bratzler, Dale W. Auden, Dana Goodrich, Kate Larbi, Fiona M. Fine, Michael J. TI ASSOCIATIONS BETWEEN PROCESSES OF CARE AND MORTALITY IN A NATIONAL COHORT OF ELDERLY PATIENTS HOSPITALIZED FOR PNEUMONIA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Lee, Jonathan S.; Hausmann, Leslie R.; Fine, Michael J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Nsa, Wato; Auden, Dana] Univ Pittsburgh, Med Ctr, Oklahoma City, OK USA. [Hausmann, Leslie R.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S28 EP S28 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300067 ER PT J AU Makam, AN Boscardin, WJ Miao, YH Steinman, M AF Makam, Anil N. Boscardin, W. John Miao, Yinghui Steinman, Michael TI THE RISK OF THIAZIDE-INDUCED ADVERSE EFFECTS IN OLDER ADULTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Makam, Anil N.; Boscardin, W. John; Miao, Yinghui; Steinman, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Boscardin, W. John; Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S209 EP S209 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301257 ER PT J AU Mann, EA Kinsosian, B Miller, RK Mary-Ann, H Hammond, J Feinberg, A AF Mann, Elizabeth A. Kinsosian, Bruce Miller, Rachel K. Mary-Ann, Haggerty Hammond, James Feinberg, Ariel TI HOSPITAL AT HOME AS AN INTERAGENCY COLLABORATIVE AT THE PHILADELPHIA VA MEDICAL CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Mann, Elizabeth A.; Kinsosian, Bruce; Miller, Rachel K.] Univ Penn, Philadelphia, PA 19104 USA. [Kinsosian, Bruce; Miller, Rachel K.; Mary-Ann, Haggerty; Hammond, James; Feinberg, Ariel] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S437 EP S437 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302357 ER PT J AU Nasir, S Bates, JT AF Nasir, Saifullah Bates, Jeffrey T. TI CLOPIDOGREL HYPERSENSITIVITY REACTION AFTER PLACEMENT OF A DRUG-ELUTING STENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Nasir, Saifullah; Bates, Jeffrey T.] Baylor Coll Med, Houston, TX 77030 USA. [Nasir, Saifullah; Bates, Jeffrey T.] Houston VAMC, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S309 EP S309 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302030 ER PT J AU Neugarten, C Saha, S Roter, D Korthuis, PT Cohn, JA Sharp, VL Moore, RD Beach, MC AF Neugarten, Carter Saha, Somnath Roter, Deborah Korthuis, Philip T. Cohn, Jonathan A. Sharp, Victoria L. Moore, Richard D. Beach, Mary Catherine TI AT EASE AND DIS-EASE: PATIENT REQUESTS FOR REASSURANCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Neugarten, Carter; Roter, Deborah; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, Philip T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sharp, Victoria L.] St Lukes Roosevelt, New York, NY USA. [Cohn, Jonathan A.] Wayne State Univ, Detroit, MI USA. RI Roter, Debra/N-8830-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S30 EP S30 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300071 ER PT J AU Ong, M Wells, KB Jones, L Chung, B Dixon, E Tang, LQ Gilmore, J Sherbourne, C Ngo, VK Stockdale, SE Ramos, E Belin, TR Miranda, J AF Ong, Michael Wells, Kenneth B. Jones, Loretta Chung, Bowen Dixon, Elizabeth Tang, Lingqi Gilmore, James Sherbourne, Cathy Ngo, Victoria K. Stockdale, Susan E. Ramos, Esmeralda Belin, Thomas R. Miranda, Jeanne TI COMMUNITY-PARTNERED CLUSTER-RANDOMIZED COMPARATIVE EFFECTIVENESS TRIAL OF COMMUNITY ENGAGEMENT AND PLANNING OR PROGRAM TECHNICAL ASSISTANCE TO ADDRESS DEPRESSION DISPARITIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Wells, Kenneth B.; Chung, Bowen; Sherbourne, Cathy; Ngo, Victoria K.] RAND Corp, Santa Monica, CA USA. [Ong, Michael; Wells, Kenneth B.; Tang, Lingqi; Stockdale, Susan E.; Ramos, Esmeralda; Belin, Thomas R.; Miranda, Jeanne] Univ Calif Los Angeles, Los Angeles, CA USA. [Jones, Loretta] Hlth African Amer Families II, Los Angeles, CA USA. [Jones, Loretta] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA. [Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Dixon, Elizabeth] QueensCare Hlth & Faith Partnership, Los Angeles, CA USA. [Gilmore, James] Behav Hlth Serv, Gardena, CA USA. [Stockdale, Susan E.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S47 EP S47 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300112 ER PT J AU Ong, M Miranda, J Jones, L Chung, B Dixon, E Tang, LQ Gilmore, J Sherbourne, C Ngo, VK Stockdale, SE Ramos, E Belin, TR Wells, KB AF Ong, Michael Miranda, Jeanne Jones, Loretta Chung, Bowen Dixon, Elizabeth Tang, Lingqi Gilmore, James Sherbourne, Cathy Ngo, Victoria K. Stockdale, Susan E. Ramos, Esmeralda Belin, Thomas R. Wells, Kenneth B. TI COMMUNITY-PARTNERED EVALUATION OF DEPRESSION SERVICES FOR CLIENTS OF COMMUNITY-BASED AGENCIES IN UNDER-RESOURCED COMMUNITIES IN LOS ANGELES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Ong, Michael; Miranda, Jeanne; Tang, Lingqi; Ramos, Esmeralda; Belin, Thomas R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Jones, Loretta] Hlth African Amer Families II, Los Angeles, CA USA. [Jones, Loretta] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA. [Chung, Bowen; Sherbourne, Cathy; Ngo, Victoria K.; Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA. [Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Dixon, Elizabeth] QueensCare Hlth & Faith Partnership, Los Angeles, CA USA. [Gilmore, James] Behav Hlth Serv, Gardena, CA USA. [Stockdale, Susan E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S48 EP S48 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300113 ER PT J AU Redmond, N Litaker, MS Conner, M Kertesz, S AF Redmond, Nicole Litaker, Mark S. Conner, Michael Kertesz, Stefan TI DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF VETERANS WITH A HISTORY OF INCARCERATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Redmond, Nicole; Litaker, Mark S.; Kertesz, Stefan] Univ Alabama Birmingham, Birmingham, AL USA. [Litaker, Mark S.; Conner, Michael; Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S58 EP S59 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300137 ER PT J AU Seal, KH Samuelson, K McCamish, N Koenig, CJ Bertenthal, D Tarasovsky, G Choucroun, G AF Seal, Karen H. Samuelson, Kristin McCamish, Nicole Koenig, Christopher J. Bertenthal, Daniel Tarasovsky, Gary Choucroun, Gerard TI OUTCOMES OF A NEW WEB-BASED PTSD TRAINING FOR PRIMARY CARE PROVIDERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Seal, Karen H.; Samuelson, Kristin; McCamish, Nicole; Koenig, Christopher J.; Bertenthal, Daniel; Tarasovsky, Gary; Choucroun, Gerard] San Francisco VA Med Ctr, San Francisco, CA USA. [Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Samuelson, Kristin] Alliant Int Univ, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S473 EP S474 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302439 ER PT J AU Silverman, JB Compton, N AF Silverman, Julie B. Compton, Nicholas TI AN UNCOMMON CAUSE OF DYSASTHESIA AND PRURITUS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Silverman, Julie B.; Compton, Nicholas] VA Puget Sound, Seattle, WA USA. [Silverman, Julie B.; Compton, Nicholas] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S286 EP S286 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301443 ER PT J AU Sudore, RL Knight, SJ Stewart, AL McMahan, RD Feuz, M Miao, YH Barnes, DE AF Sudore, Rebecca L. Knight, Sara J. Stewart, Anita L. McMahan, Ryan D. Feuz, Mariko Miao, Yinghui Barnes, Deborah E. TI A NOVEL WEBSITE TO PREPARE DIVERSE OLDER ADULTS FOR DECISION MAKING AND ADVANCE CARE PLANNING: A PILOT STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Sudore, Rebecca L.; Stewart, Anita L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui; Barnes, Deborah E.] UCSF, San Francisco, CA USA. [Sudore, Rebecca L.; Knight, Sara J.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Sara J.] Vet Hlth Adm, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S6 EP S6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300013 ER PT J AU Sugiyama, T Zingmond, D Lorenz, K Diamant, A O'Malley, K Citko, J Gonzalez, V Wenger, N AF Sugiyama, Takehiro Zingmond, David Lorenz, Karl Diamant, Allison O'Malley, Kate Citko, Judy Gonzalez, Victor Wenger, Neil TI IMPLICATIONS OF POVERTY, HOSPITAL TYPE, AND A GRASSROOTS COMMUNITY INTERVENTION ON DISSEMINATION OF PHYSICIAN ORDERS FOR LIFE SUSTAINING TREATMENT IN CALIFORNIA HOSPITALS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Sugiyama, Takehiro; Zingmond, David; Diamant, Allison; Gonzalez, Victor; Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA USA. [Sugiyama, Takehiro] Univ Tokyo, Tokyo, Japan. [Lorenz, Karl] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [O'Malley, Kate] Calif HealthCare Fdn, Oakland, CA USA. [Citko, Judy] Coalit Compassionate Care Calif, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S104 EP S104 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301009 ER PT J AU Takahashi, TA Berger, DB Wipf, JE Shannon, SE Zierler, BK AF Takahashi, Traci A. Berger, Douglas B. Wipf, Joyce E. Shannon, Sarah E. Zierler, Brenda K. TI "MEET YOUR COLLEAGUES": ENHANCING THE APPEAL OF EDUCATION IN COLLABORATIVE CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Takahashi, Traci A.; Berger, Douglas B.; Wipf, Joyce E.] VA Puget Sound, Seattle, WA USA. [Takahashi, Traci A.; Berger, Douglas B.; Wipf, Joyce E.; Shannon, Sarah E.; Zierler, Brenda K.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S488 EP S488 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302473 ER PT J AU Talamantes, E Moreno, G Guerrero, LR Mangione, C Morales, L AF Talamantes, Efrain Moreno, Gerardo Guerrero, Lourdes R. Mangione, Carol Morales, Leo TI HABLAMOS JUNTOS (TOGETHER WE SPEAK): A BRIEF PATIENT-REPORTED MEASURE OF THE QUALITY OF INTERPRETERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Talamantes, Efrain; Moreno, Gerardo; Guerrero, Lourdes R.; Mangione, Carol] Univ Calif Los Angeles, Los Angeles, CA USA. [Talamantes, Efrain] US Dept Vet Affairs, Los Angeles, CA USA. [Morales, Leo] Univ Washington, Seattle, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S83 EP S83 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300197 ER PT J AU Trivedi, AN Nsa, W Hausmann, LR Lee, JS Ma, A Bratzler, DW Goodrich, K Larbi, FM Fine, MJ AF Trivedi, Amal N. Nsa, Wato Hausmann, Leslie R. Lee, Jonathan S. Ma, Allen Bratzler, Dale W. Goodrich, Kate Larbi, Fiona M. Fine, Michael J. TI TRENDS IN THE QUALITY OF CARE AND RACIAL/ETHNIC DISPARITIES IN US HOSPITALS, 2005-2010 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Trivedi, Amal N.] Providence VA Med Ctr, Providence, RI USA. [Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Nsa, Wato; Ma, Allen; Bratzler, Dale W.] Oklahoma Fdn Med Qual, Oklahoma City, OK USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hausmann, Leslie R.; Lee, Jonathan S.; Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare Serv, Baltimore, MD USA. [Hausmann, Leslie R.; Lee, Jonathan S.; Goodrich, Kate; Larbi, Fiona M.] Ctr Medicaid Serv, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S228 EP S228 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301298 ER PT J AU Trivedi, R Kivlahan, D McCarthy, J Post, EP Saxon, AJ Pomerantz, A Sun, H Piette, JD Fihn, SD Nelson, KM AF Trivedi, Ranak Kivlahan, Dan McCarthy, John Post, Edward P. Saxon, Andrew J. Pomerantz, Andrew Sun, Haili Piette, John D. Fihn, Stephan D. Nelson, Karin M. TI BURDEN OF MENTAL ILLNESS AMONG VA PRIMARY CARE PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Trivedi, Ranak; Saxon, Andrew J.; Sun, Haili; Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Trivedi, Ranak; Saxon, Andrew J.; Fihn, Stephan D.; Nelson, Karin M.] Univ Washington, Seattle, WA 98195 USA. [McCarthy, John; Post, Edward P.; Piette, John D.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [McCarthy, John; Post, Edward P.; Piette, John D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Kivlahan, Dan; Pomerantz, Andrew] VA Off Mental Hlth Serv, White River, VT USA. [Pomerantz, Andrew] Dartmouth Coll, Hanover, NH 03755 USA. [Fihn, Stephan D.] VA Off Analyt & Business Intelligence, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S37 EP S38 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300089 ER PT J AU Turner, BJ Finley, E Garza, DR Vale, S Simmonds, MJ Pugh, MJ AF Turner, Barbara J. Finley, Erin Garza, Diandrea R. Vale, Shruthi Simmonds, Maureen J. Pugh, Mary Jo TI THEMES FROM FOCUS GROUPS OF VETERANS WITH CHRONIC NON-CANCER PAIN ON HIGH DOSE OPIOID ANALGESICS: LOVE/HATE OF OPIOIDS AND CHALLENGES WITH ALTERNATIVE PAIN CARE STRATEGIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Turner, Barbara J.; Finley, Erin; Garza, Diandrea R.; Vale, Shruthi; Simmonds, Maureen J.; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Finley, Erin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S221 EP S222 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301284 ER PT J AU Varkey, AB Manwell, LB Ibrahim, SA Brown, R Laiteerapong, N Schwartz, MD Williams, E Burgess, D Wiltshire, J Montague, E Poplau, S Linzer, M AF Varkey, Anita B. Manwell, Linda Baier Ibrahim, Said A. Brown, Roger Laiteerapong, Neda Schwartz, Mark D. Williams, Eric Burgess, Diana Wiltshire, Jacqueline Montague, Enid Poplau, Sara Linzer, Mark TI IMPACT OF WORK CONDITIONS ON ERRORS AND QUALITY: A COMPARISON OF PRIMARY CARE CLINICS SERVING LARGE PROPORTIONS OF MINORITY PATIENTS TO THOSE THAT DO NOT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Varkey, Anita B.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Manwell, Linda Baier; Brown, Roger] Univ Wisconsin, Madison, WI USA. [Ibrahim, Said A.] VA Philadelphia Med Ctr, Philadelphia, PA USA. [Ibrahim, Said A.] Perelman Univ Penn, Sch Med, Philadelphia, PA USA. [Laiteerapong, Neda] Univ Chicago, Chicago, IL 60637 USA. [Schwartz, Mark D.] NYU, Sch Med, New York, NY USA. [Schwartz, Mark D.] VA New York Harbor Hlth Care Syst, New York, NY USA. [Williams, Eric] Univ Alabama, Tuscaloosa, AL USA. [Burgess, Diana] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Burgess, Diana] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Wiltshire, Jacqueline] Univ S Florida, Tampa, FL USA. [Montague, Enid] Northwestern Univ, Chicago, IL 60611 USA. [Poplau, Sara; Linzer, Mark] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. RI Burgess, Diana/A-1946-2016; Williams, Eric/G-9837-2017 OI Williams, Eric/0000-0001-6297-4837 NR 0 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S100 EP S100 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300238 ER PT J AU Wang, EA McGinnis, KA Akgun, KM Edelman, J Justice, AC Rimland, D Wang, KR Fiellin, DA AF Wang, Emily A. McGinnis, Kathleen A. Akguen, Kathleen M. Edelman, Jennifer Justice, Amy C. Rimland, David Wang, Karen Fiellin, David A. TI INCARCERATION IS ASSOCIATED WITH WORSE HEALTH OUTCOMES AND ANTIRETROVIRAL ADHERENCE AMONG HIV-INFECTED PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Wang, Emily A.; Akguen, Kathleen M.; Edelman, Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, New Haven, CT USA. [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Justice, Amy C.; Wang, Karen] VA CT Healthcare Syst, West Haven, CT USA. [Rimland, David] Atlanta VAMC, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S107 EP S108 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301017 ER PT J AU Wang, ES Conde, M Simon, B Leykum, L AF Wang, Emily S. Conde, Michelle Simon, Bret Leykum, Luci TI KNOWLEDGE AND PERCEPTIONS OF NON-PHYSICIAN PRIMARY CARE TEAM MEMBERS REGARDING END OF YEAR PCP TRANSITIONS IN A RESIDENT CONTINUITY CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Wang, Emily S.; Conde, Michelle; Leykum, Luci] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wang, Emily S.; Conde, Michelle; Simon, Bret; Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S112 EP S112 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301028 ER PT J AU Warde, CM Pearson, M AF Warde, Carole M. Pearson, Marjorie TI A CURRICULUM TO IMPROVE AND TEACH PRIMARY CARE TEAM FUNCTION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Warde, Carole M.] Greater Los Angeles VA Hlth Syst, North Hills, CA USA. [Pearson, Marjorie] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S450 EP S451 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939302385 ER PT J AU Young, EA Stratton, KA Brin, M AF Young, Eric A. Stratton, Kristin A. Brin, Michael TI DECLINE IN INTERNAL MEDICINE RESIDENTS' ACLS EXPERIENCE IN THE MODERN TRAINING ERA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Young, Eric A.; Stratton, Kristin A.; Brin, Michael] Denver VA Med Ctr, Denver, CO USA. [Young, Eric A.; Stratton, Kristin A.] Univ Colorado Denver, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S57 EP S58 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939300135 ER PT J AU Zulman, D Yoon, J Cohen, DM Wagner, TH Ritchie, C Asch, S AF Zulman, Donna Yoon, Jean Cohen, Danielle M. Wagner, Todd H. Ritchie, Christine Asch, Steven TI MULTIMORBIDITY AND HEALTH CARE UTILIZATION AMONG HIGH-COST PATIENTS: IMPLICATIONS FOR CARE COORDINATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Zulman, Donna; Yoon, Jean; Cohen, Danielle M.; Wagner, Todd H.; Asch, Steven] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Zulman, Donna; Cohen, Danielle M.; Wagner, Todd H.; Asch, Steven] Stanford Univ, Stanford, CA 94305 USA. [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S123 EP S124 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301055 ER EF